Effects O
of O
docosahexaenoic B
acid I
and O
methylmercury B
on O
child O
' O
s O
brain O
development O
due O
to O
consumption O
of O
fish O
by O
Finnish O
mother O
during O
pregnancy O
: O
a O
probabilistic O
modeling O
approach O
. O

Fish O
contains O
both O
beneficial O
substances O
e O
. O
g O
. O
docosahexaenoic B
acids I
but O
also O
harmful O
compounds O
e O
. O
g O
. O
methylmercury B
. O

Endothelial O
nitric B
oxide I
synthase O
genotypes O
and O
haplotypes O
modify O
the O
responses O
to O
sildenafil B
in O
patients O
with O
erectile O
dysfunction O
. O

Although O
genetic O
polymorphisms O
in O
the O
endothelial O
nitric B
oxide I
synthase O
( O
eNOS O
) O
gene O
may O
impair O
endogenous O
NO B
formation O
, O
there O
is O
little O
information O
about O
how O
eNOS O
polymorphisms O
and O
haplotypes O
affect O
the O
responses O
to O
sildenafil B
. O

On O
the O
benefit O
of O
magnetic O
magnesium B
nanocarrier O
in O
cardiovascular O
toxicity O
of O
aluminum B
phosphide I
. O

The O
present O
study O
was O
designed O
to O
determine O
the O
effect O
of O
a O
new O
( B
25 I
) I
Mg I
( I
2 I
+ I
) I
- O
carrying O
nanoparticle O
( O
( B
25 I
) I
MgPMC16 I
) O
on O
energy O
depletion O
, O
oxidative O
stress O
, O
and O
electrocardiographic O
( O
ECG O
) O
parameters O
on O
heart O
tissue O
of O
the O
rats O
poisoned O
by O
aluminum B
phosphide I
( O
AlP B
) O
. O

Sodium B
bicarbonate I
( O
Bicarb B
; O
2 O
mEq O
/ O
kg O
, O
iv O
) O
was O
used O
as O
the O
standard O
therapy O
. O

In O
order O
to O
study O
the O
mechanism O
of O
the O
histone O
deacetylase O
( O
HDAC O
) O
inhibitors O
valproic B
acid I
( O
VPA B
) O
and O
suberoylanilide B
hydroxamic I
acid I
( O
SAHA B
) O
in O
breast O
cancer O
, O
we O
generated O
and O
validated O
genomic O
profiles O
of O
drug O
response O
using O
a O
series O
of O
breast O
cancer O
cell O
lines O
sensitive O
to O
each O
drug O
. O

The O
main O
isolated O
compounds O
were O
triterpenes B
( O
alpha B
- I
amyrin I
, O
beta B
- I
amyrin I
, O
lupeol B
, O
betulin B
, O
betulinic B
acid I
, O
uvaol B
, O
erythrodiol B
and O
oleanolic B
acid I
) O
and O
phenolic B
acid I
derivatives O
from O
4 B
- I
hydroxybenzoic I
acid I
( O
gallic B
and I
protocatechuic I
acids I
and O
isocorilagin B
) O
. O

The O
main O
isolated O
compounds O
were O
triterpenes B
( O
alpha B
- I
amyrin I
, O
beta B
- I
amyrin I
, O
lupeol B
, O
betulin B
, O
betulinic B
acid I
, O
uvaol B
, O
erythrodiol B
and O
oleanolic B
acid I
) O
and O
phenolic B
acid I
derivatives O
from O
4 B
- I
hydroxybenzoic I
acid I
( O
gallic B
and I
protocatechuic I
acids I
and O
isocorilagin B
) O
. O

The O
main O
isolated O
compounds O
were O
triterpenes B
( O
alpha B
- I
amyrin I
, O
beta B
- I
amyrin I
, O
lupeol B
, O
betulin B
, O
betulinic B
acid I
, O
uvaol B
, O
erythrodiol B
and O
oleanolic B
acid I
) O
and O
phenolic B
acid I
derivatives O
from O
4 B
- I
hydroxybenzoic I
acid I
( O
gallic B
and I
protocatechuic I
acids I
and O
isocorilagin B
) O
. O

In O
the O
germination O
assays O
, O
high O
inhibitory O
allelopathic O
effects O
of O
the O
extracts O
and O
isocorilagin B
were O
observed O
and O
2 B
, I
2 I
- I
diphenyl I
- I
1 I
- I
picrylhydrazyl I
radical O
scavenging O
activity O
of O
isocorilagin B
was O
higher O
than O
those O
of O
the O
standards O
used O
( O
Trolox B
and O
butylated B
hydroxyanisole I
) O
. O

Impact O
of O
aqueous O
doash O
extract O
on O
urinary O
mutagenicity O
in O
rats O
exposed O
to O
heterocyclic B
amines I
. O

The O
2 B
- I
amino I
- I
3 I
- I
methylimidazo I
[ I
4 I
, I
5 I
- I
f I
] I
quinoline I
( O
IQ O
) O
and O
2 B
- I
amino I
- I
1 I
- I
methyl I
- I
6 I
- I
phenylimidazo I
[ I
4 I
, I
5 I
- I
b I
] I
pyridine I
( O
PhIP B
) O
are O
the O
most O
abundant O
of O
the O
heterocyclic B
amine I
carcinogens O
present O
in O
cooked O
food O
. O

In O
the O
present O
study O
, O
the O
potential O
of O
doash O
tea O
to O
influence O
carcinogen O
metabolism O
was O
investigated O
indirectly O
using O
heterocyclic B
amines I
as O
model O
mutagens O
, O
IQ O
and O
PhIP B
. O

The O
selected O
dosage O
was O
5 O
mg O
/ O
kg O
for O
both O
heterocyclic B
amines I
. O

Results O
obtained O
revealed O
that O
rats O
treated O
with O
doash O
tea O
and O
given O
a O
single O
dose O
of O
the O
heterocyclic B
amines I
, O
whether O
for O
1 O
day O
( O
short O
- O
term O
) O
or O
for O
1 O
month O
( O
long O
term O
) O
, O
showed O
a O
statistically O
significant O
decrease O
in O
their O
excretion O
of O
indirect O
mutagens O
( O
IQ O
or O
PhIP B
) O
. O

Accumulation O
profiles O
of O
fatty B
acids I
and O
alpha B
- I
tocopherol I
were O
analysed O
at O
three O
ripening O
stages O
in O
the O
seed O
oils O
of O
Primula O
and O
Echium O
species O
. O

Increased O
levels O
of O
ALA B
and O
oleic B
acid I
, O
and O
decrease O
in O
linoleic B
and I
palmitic I
acids I
at O
late O
ripening O
stages O
of O
Primula O
sibthorpii O
, O
and O
slightly O
fluctuations O
of O
all O
examined O
fatty B
acids I
in O
Echium O
italicum O
were O
observed O
. O

Increased O
levels O
of O
ALA B
and O
oleic B
acid I
, O
and O
decrease O
in O
linoleic B
and I
palmitic I
acids I
at O
late O
ripening O
stages O
of O
Primula O
sibthorpii O
, O
and O
slightly O
fluctuations O
of O
all O
examined O
fatty B
acids I
in O
Echium O
italicum O
were O
observed O
. O

Considerable O
amounts O
of O
alpha B
- I
tocopherol I
( O
27 O
. O
4 O
mg O
/ O
100 O
g O
) O
, O
linoleic B
acid I
( O
42 O
. O
76 O
% O
) O
and O
ALA B
( O
25 O
. O
46 O
% O
) O
and O
GLA B
( O
4 O
. O
11 O
% O
) O
were O
detected O
in O
Ribes O
alpinum O
. O

Protective O
effect O
of O
vitamin B
E I
and O
epicatechin B
against O
nicotine B
- O
induced O
oxidative O
stress O
in O
rats O
. O

Vitamin B
E I
is O
a O
major O
lipid O
- O
soluble O
antioxidant O
vitamin O
and O
free O
radical O
scavenger O
, O
presents O
as O
an O
integral O
component O
of O
cellular O
membranes O
and O
has O
important O
biological O
functions O
. O

The O
primary O
mechanism O
by O
which O
vitamin B
E I
is O
proposed O
to O
prevent O
cancer O
is O
through O
their O
antioxidant O
properties O
. O

The O
goal O
of O
this O
study O
is O
to O
evaluate O
the O
effect O
of O
epicatechin B
alone O
or O
combined O
with O
vitamin B
E I
in O
inhibiting O
the O
oxidative O
stress O
induced O
by O
nicotine B
in O
rats O
. O

The O
combined O
treatment O
( O
epicatechin B
+ O
Vit B
E I
) O
group O
showed O
a O
potential O
reduction O
of O
these O
parameters O
more O
than O
individual O
treatment O
. O

In O
conclusion O
, O
these O
results O
suggested O
that O
the O
supplementation O
of O
diet O
with O
epicatechin B
and O
vitamin B
E I
provided O
antioxidant O
defense O
with O
strong O
chemopreventive O
activity O
against O
nicotine B
- O
induced O
carcinogenesis O
. O

Moreover O
, O
increase O
in O
histone O
acetylation O
by O
trichostatin B
A I
could O
also O
significantly O
enhance O
the O
protection O
effect O
of O
QU O
at O
10 O
or O
20 O
micro O
M O
but O
not O
at O
higher O
concentrations O
. O

Cadmium B
concentration O
was O
determined O
by O
graphite B
furnace O
atomic O
absorption O
spectrophotometry O
in O
91 O
shrimp O
samples O
after O
nitric B
acid I
/ O
perchloric B
acid I
digestion O
. O

Cadmium B
concentration O
was O
determined O
by O
graphite B
furnace O
atomic O
absorption O
spectrophotometry O
in O
91 O
shrimp O
samples O
after O
nitric B
acid I
/ O
perchloric B
acid I
digestion O
. O

Selective O
separation O
of O
patchouli B
alcohol I
from O
the O
essential O
oil O
of O
Cablin O
potchouli O
by O
inclusion O
crystalline O
method O
. O

In O
this O
article O
, O
we O
have O
focused O
on O
the O
application O
of O
non O
- O
traditional O
separation O
approach O
, O
the O
host O
- O
guest O
inclusion O
method O
, O
into O
the O
separation O
of O
the O
active O
component O
patchouli B
alcohol I
from O
the O
essential O
oil O
of O
Cablin O
potchouli O
Herb O
. O

The O
host O
molecule O
1 B
, I
1 I
, I
6 I
, I
6 I
- I
tetraphenylhexa I
- I
2 I
, I
4 I
- I
diyne I
- I
1 I
, I
6 I
- I
diol I
( O
A O
) O
was O
used O
to O
selectively O
recognise O
the O
guest O
molecule O
patchouli B
alcohol I
( O
B O
) O
in O
the O
essential O
oil O
of O
Pogostemon O
cablin O
( O
Blanco O
) O
Benth O
through O
two O
strong O
hydrogen B
bonding O
. O

The O
separation O
effect O
was O
examined O
by O
gas O
chromatography O
for O
the O
whole O
essential O
oil O
and O
the O
inclusion O
compound O
, O
showing O
that O
the O
inclusion O
crystalline O
method O
is O
simple O
, O
rapid O
and O
effective O
for O
the O
separation O
of O
patchouli B
alcohol I
from O
the O
essential O
oil O
of O
C O
. O
potchouli O
Herb O
. O

In O
this O
experiment O
, O
a O
total O
of O
100 O
male O
albino O
rats O
of O
Spargue O
Dawley O
strain O
were O
divided O
into O
10 O
groups O
: O
G O
( O
1 O
) O
was O
fed O
basal O
diet O
and O
served O
as O
control O
, O
G O
( O
2 O
) O
: O
basal O
diet O
+ O
Brilliant B
blue I
( O
blue O
dye O
, O
No O
. O
2 O
, O
124 O
mg O
/ O
kg O
diet O
) O
, O
G O
( O
3 O
) O
: O
basal O
diet O
+ O
carmoisine B
( O
red O
dye O
, O
No O
. O
3 O
, O
70 O
mg O
/ O
kg O
diet O
) O
, O
G O
( O
4 O
) O
: O
basal O
diet O
+ O
tartrazine B
( O
yellow O
dye O
, O
FD O
& O
C O
yellow O
No O
. O
5 O
, O
75 O
mg O
/ O
kg O
diet O
) O
, O
G O
( O

5 O
) O
: O
basal O
diet O
+ O
trans B
- I
anethole I
( O
4 O
. O
5 O
g O
/ O
kg O
diet O
) O
G O
( O
6 O
) O
: O
basal O
diet O
+ O
propylene B
glycol I
( O
0 O
. O
25 O
g O
/ O
kg O
diet O
) O
, O
G O
( O
7 O
) O
: O
basal O
diet O
+ O
vanillin B
( O
1 O
. O
25 O
g O
/ O
kg O
diet O
) O
, O
G O
( O
8 O
) O
: O
basal O
diet O
+ O
Brilliant B
blue I
+ O
propylene B
glycol I
, O
G O
( O
9 O
) O
: O
basal O
diet O
+ O
carmoisine B
+ O
trans B
- I
anethole I
, O
G O
( O
10 O
) O
: O
basal O
diet O
+ O
tartrazine B
+ O
vanillin B
for O
42 O
successive O
days O

5 O
) O
: O
basal O
diet O
+ O
trans B
- I
anethole I
( O
4 O
. O
5 O
g O
/ O
kg O
diet O
) O
G O
( O
6 O
) O
: O
basal O
diet O
+ O
propylene B
glycol I
( O
0 O
. O
25 O
g O
/ O
kg O
diet O
) O
, O
G O
( O
7 O
) O
: O
basal O
diet O
+ O
vanillin B
( O
1 O
. O
25 O
g O
/ O
kg O
diet O
) O
, O
G O
( O
8 O
) O
: O
basal O
diet O
+ O
Brilliant B
blue I
+ O
propylene B
glycol I
, O
G O
( O
9 O
) O
: O
basal O
diet O
+ O
carmoisine B
+ O
trans B
- I
anethole I
, O
G O
( O
10 O
) O
: O
basal O
diet O
+ O
tartrazine B
+ O
vanillin B
for O
42 O
successive O
days O

5 O
) O
: O
basal O
diet O
+ O
trans B
- I
anethole I
( O
4 O
. O
5 O
g O
/ O
kg O
diet O
) O
G O
( O
6 O
) O
: O
basal O
diet O
+ O
propylene B
glycol I
( O
0 O
. O
25 O
g O
/ O
kg O
diet O
) O
, O
G O
( O
7 O
) O
: O
basal O
diet O
+ O
vanillin B
( O
1 O
. O
25 O
g O
/ O
kg O
diet O
) O
, O
G O
( O
8 O
) O
: O
basal O
diet O
+ O
Brilliant B
blue I
+ O
propylene B
glycol I
, O
G O
( O
9 O
) O
: O
basal O
diet O
+ O
carmoisine B
+ O
trans B
- I
anethole I
, O
G O
( O
10 O
) O
: O
basal O
diet O
+ O
tartrazine B
+ O
vanillin B
for O
42 O
successive O
days O

The O
isolated O
compounds O
were O
identified O
by O
spectroscopic O
analyses O
as O
( B
22E I
, I
24R I
) I
- I
6 I
beta I
- I
methoxyergosta I
- I
7 I
, I
22 I
- I
diene I
- I
3 I
beta I
, I
5 I
alpha I
- I
diol I
( O
1 O
) O
, O
2 B
' I
, I
3 I
' I
- I
diacetoxy I
- I
3 I
, I
4 I
, I
5 I
' I
, I
6 I
' I
, I
4 I
' I
' I
- I
pentahydroxy I
- I
p I
- I
terphenyl I
( O
2 O
) O
, O
cerebroside B
B I
( O
3 O
) O
, O
ergosta B
- I
7 I
, I
22 I
- I
dien I
- I
3 I
beta I
- I
ol I
( O
4 O
) O
, O
ergosterol B
peroxide I
( O
5 O

The O
isolated O
compounds O
were O
identified O
by O
spectroscopic O
analyses O
as O
( B
22E I
, I
24R I
) I
- I
6 I
beta I
- I
methoxyergosta I
- I
7 I
, I
22 I
- I
diene I
- I
3 I
beta I
, I
5 I
alpha I
- I
diol I
( O
1 O
) O
, O
2 B
' I
, I
3 I
' I
- I
diacetoxy I
- I
3 I
, I
4 I
, I
5 I
' I
, I
6 I
' I
, I
4 I
' I
' I
- I
pentahydroxy I
- I
p I
- I
terphenyl I
( O
2 O
) O
, O
cerebroside B
B I
( O
3 O
) O
, O
ergosta B
- I
7 I
, I
22 I
- I
dien I
- I
3 I
beta I
- I
ol I
( O
4 O
) O
, O
ergosterol B
peroxide I
( O
5 O

) O
, O
( B
22E I
, I
24R I
) I
- I
3 I
beta I
- I
hydroxy I
- I
ergosta I
- I
5 I
, I
22 I
- I
dien I
- I
7 I
- I
one I
( O
6 O
) O
, O
benzoic B
acid I
( O
7 O
) O
, O
methyl B
p I
- I
hydroxybenzoate I
( O
8 O
) O
and O
3 B
, I
4 I
- I
dihydroxybenzoic I
acid I
( O
9 O
) O
. O

4 B
- I
Thujanol I
( O
sabinene B
hydrate I
) O
, O
a O
bicyclic B
monoterpene I
alcohol I
, O
is O
found O
in O
the O
essential O
oils O
of O
many O
aromatic O
and O
medicinal O
plants O
and O
is O
widely O
used O
as O
a O
fragrance O
and O
flavouring O
agent O
in O
many O
different O
products O
. O

The O
aim O
of O
this O
study O
was O
to O
evaluate O
the O
protective O
effects O
of O
4 B
- I
thujanol I
against O
the O
genotoxic O
effects O
induced O
by O
mitomycin B
C I
( O
MMC B
) O
and O
cyclophosphamide B
( O
CP O
) O
in O
human O
lymphocytes O
, O
using O
the O
chromosome O
aberrations O
, O
sister O
chromatid O
exchanges O
, O
and O
micronucleus O
tests O
, O
in O
the O
absence O
and O
in O
the O
presence O
of O
S9 O
mix O
, O
respectively O
. O

Chlorogenic B
acid I
, O
rutin B
and O
hyperoside B
content O
in O
Fragaria O
vesca O
, O
F O
. O
viridis O
and O
F O
. O
moschata O
in O
Lithuania O
. O

The O
main O
objective O
of O
this O
study O
was O
to O
establish O
the O
variation O
pattern O
in O
the O
content O
of O
chlorogenic B
acid I
, O
rutin B
and O
hyperoside B
in O
leaves O
and O
fruits O
of O
the O
native O
Lithuanian O
species O
. O

F O
. O
vesca O
fruits O
had O
the O
highest O
rutin B
( O
1 O
. O
38 O
+ O
/ O
- O
0 O
. O
19 O
mg O
g O
( O
- O
1 O
) O
DM O
) O
, O
hyperoside B
( O
0 O
. O
69 O
+ O
/ O
- O
0 O
. O
10 O
mg O
g O
( O
- O
1 O
) O
DM O
) O
and O
chlorogenic B
acid I
( O
2 O
. O
25 O
+ O
/ O
- O
0 O
. O
34 O
mg O
g O
( O
- O
1 O
) O
DM O
) O
content O
, O
followed O
by O
F O
. O
viridis O
and O
F O
. O
moschata O
. O

Bromotheoynic B
acid I
, O
a O
brominated B
acetylenic I
acid I
from O
the O
marine O
sponge O
Theonella O
swinhoei O
. O

A O
new O
brominated B
C I
( I
17 I
) I
acetylenic I
acid I
( O
1 O
) O
designated O
as O
bromotheoynic B
acid I
has O
been O
isolated O
from O
the O
marine O
sponge O
Theonella O
swinhoei O
, O
collected O
off O
the O
coast O
of O
Tanegashima O
, O
Kagoshima O
Prefecture O
, O
Japan O
. O

Bromotheoynic B
acid I
( O
1 O
) O
inhibited O
maturation O
of O
starfish O
oocytes O
and O
cell O
division O
of O
fertilised O
starfish O
eggs O
. O

Bromotheoynic B
acid I
( O
1 O
) O
also O
inhibited O
proliferation O
of O
human O
leukaemia O
U937 O
and O
HL60 O
cells O
, O
human O
lung O
cancer O
A549 O
and O
H1299 O
cells O
, O
and O
human O
embryonic O
kidney O
293 O
( O
HEK293 O
) O
cells O
. O

In O
continuation O
of O
our O
search O
for O
bioactive O
secondary O
metabolites O
from O
terrestrial O
Bacillus O
spp O
. O
, O
a O
new O
microbial O
diketopiperazine B
, O
cis B
- I
cyclo I
- I
( I
His I
, I
Leu I
) I
( O
1 O
) O
was O
isolated O
from O
the O
ethyl B
acetate I
extract O
of O
a O
strain O
B O
. O
subtilis O
B38 O
, O
together O
with O
cis B
- I
cyclo I
- I
( I
Phe I
, I
Phe I
) I
( O
2 O
) O
, O
tryptophane B
( O
3 O
) O
, O
cis B
- I
cyclo I
- I
( I
Leu I
, I
Tyr I
) I
( O
4 O
) O
, O
cis B
- I
cyclo I
- I
( I

alpha B
- I
Thujone I
( O
36 O
. O
35 O
% O
) O
, O
beta B
- I
thujone I
( O
9 O
. O
37 O
% O
) O
, O
germacrene B
D I
( O
6 O
. O
32 O
% O
) O
, O
4 B
- I
terpineol I
( O
6 O
. O
31 O
% O
) O
, O
beta B
- I
caryophyllene I
( O
5 O
. O
43 O
% O
) O
, O
camphene B
( O
5 O
. O
47 O
% O
) O
and O
borneol B
( O
4 O
. O
12 O
% O
) O
were O
identified O
as O
the O
major O
constituents O
. O

Optimized O
batch O
was O
coated O
in O
a O
bottom O
- O
spray O
fluidized O
bed O
processor O
( O
FBP O
) O
with O
an O
inner O
coat O
of O
sustained O
release O
polymer O
Eudragit B
NE30D I
and O
an O
outer O
coat O
of O
pH O
- O
sensitive O
polymer O
Eudragit B
FS30D I
. O

Optimized O
batch O
was O
coated O
in O
a O
bottom O
- O
spray O
fluidized O
bed O
processor O
( O
FBP O
) O
with O
an O
inner O
coat O
of O
sustained O
release O
polymer O
Eudragit B
NE30D I
and O
an O
outer O
coat O
of O
pH O
- O
sensitive O
polymer O
Eudragit B
FS30D I
. O

gugglsterol B
I I
, O
( B
E I
) I
- I
guggulsterone I
and O
( B
Z I
) I
- I
guggulsterone I
. O

Many O
common O
constituents O
were O
found O
in O
both O
species O
, O
including O
shikimic B
acid I
, O
5 B
- I
O I
- I
caffeoylshikimic I
acid I
, O
trans B
- I
resveratrol I
, O
taxifolin B
, O
astilbin B
and O
its O
three O
stereoisomers O
, O
engeletin B
and O
isoengeletin B
. O

However O
, O
syringic B
acid I
was O
found O
only O
in O
RSG O
, O
while O
chlorogenic B
acid I
was O
found O
only O
in O
RSC O
. O

However O
, O
syringic B
acid I
was O
found O
only O
in O
RSG O
, O
while O
chlorogenic B
acid I
was O
found O
only O
in O
RSC O
. O

The O
molecular O
mechanism O
is O
predominantly O
based O
on O
an O
increased O
expression O
of O
the O
endothelial O
and O
inducible O
nitric B
oxide I
( O
NO B
) O
synthase O
with O
a O
consecutive O
rapid O
supply O
of O
NO B
as O
well O
as O
an O
increased O
content O
of O
vascular O
endothelial O
growth O
factor O
( O
VEGF O
) O
in O
the O
wound O
. O

Actions O
of O
Xanthurenic B
acid I
, O
a O
putative O
endogenous O
Group O
II O
metabotropic O
glutamate B
receptor O
agonist O
, O
on O
sensory O
transmission O
in O
the O
thalamus O
. O

Xanthurenic B
acid I
( O
XA O
) O
, O
a O
molecule O
arising O
from O
tryptophan B
metabolism O
by O
transamination O
of O
3 B
- I
hydroxykynurenine I
, O
has O
recently O
been O
identified O
as O
an O
endogenous O
Group O
II O
( O
mGlu2 O
and O
mGlu3 O
) O
metabotropic O
glutamate B
( O
mGlu O
) O
receptor O
ligand O
in O
vitro O
. O

Sol O
- O
flame O
synthesis O
: O
a O
general O
strategy O
to O
decorate O
nanowires O
with O
metal B
oxide I
/ O
noble O
metal O
nanoparticles O
. O

Moreover O
, O
the O
sol O
- O
flame O
method O
is O
simple O
and O
general O
, O
with O
which O
we O
have O
successfully O
decorated O
various O
NWs O
with O
binary O
/ O
ternary O
metal B
oxide I
and O
even O
noble O
metal O
NPs O
. O

The O
antiinflammatory O
activity O
was O
evaluated O
using O
the O
mouse O
models O
of O
acute O
ear O
inflammation O
induced O
by O
croton O
oil O
, O
arachidonic B
acid I
, O
phenol B
or O
histamine B
, O
and O
chronic O
inflammation O
induced O
by O
croton O
oil O
. O

The O
topical O
application O
of O
EOLS O
or O
thymol B
at O
a O
dose O
of O
2 O
mg O
/ O
ear O
significantly O
reduced O
( O
p O
< O
0 O
. O
001 O
) O
ear O
edema O
induced O
with O
arachidonic B
acid I
by O
45 O
. O
1 O
% O
and O
47 O
. O
4 O
% O
and O
reduced O
ear O
edema O
induced O
with O
phenol B
by O
33 O
. O
2 O
% O
( O
p O
< O
0 O
. O
05 O
) O
and O
54 O
. O
7 O
% O
( O
p O
< O
0 O
. O
01 O
) O
in O
acute O
ear O
edema O
. O

The O
second O
series O
of O
peptides O
derives O
from O
the O
endogenous O
protein O
kinase O
C O
( O
PKC O
) O
inhibitor O
PKI55 O
, O
a O
55 O
- O
amino B
acid I
protein O
, O
whose O
synthesis O
is O
induced O
by O
PKC O
activation O
, O
so O
that O
a O
feedback O
loop O
of O
inhibition O
is O
established O
. O

In O
vitro O
experiments O
showed O
that O
PKI55 O
inhibits O
recombinant O
PKC O
isoforms O
alpha O
, O
beta O
1 O
, O
beta O
2 O
, O
gamma O
, O
delta O
, O
zeta O
, O
; O
to O
identify O
the O
minimal O
amino B
acid I
sequence O
of O
PKI55 O
protein O
maintaining O
the O
inhibitory O
effects O
on O
PKC O
, O
peptides O
derived O
from O
both O
C B
- O
and O
N B
- O
terminal O
sequences O
have O
been O
synthesized O
. O

A O
new O
triterpenoid B
, O
2 B
alpha I
, I
24 I
- I
diacetoxy I
- I
3 I
beta I
- I
hydroxyolean I
- I
12 I
- I
en I
- I
28 I
- I
oic I
acid I
( O
1 O
) O
, O
was O
characterised O
from O
the O
rhizomes O
of O
Nelumbo O
nucifera O
Gaertn O
by O
spectroscopic O
and O
chemical O
methods O
along O
with O
four O
known O
compounds O
, O
hyptatic B
acid I
- I
A I
( O
2 B
alpha I
, I
3 I
beta I
, I
24 I
- I
trihydroxyolean I
- I
12 I
- I
en I
- I
28 I
- I
oic I
acid I
) O
( O
2 O
) O
, O
maslinic B
acid I
( O
2 B
alpha I
, I
3 I
beta I
- I

Vasodilatory O
effects O
of O
cinnamic B
acid I
via O
the O
nitric B
oxide I
- O
cGMP B
- O
PKG O
pathway O
in O
rat O
thoracic O
aorta O
. O

Vasodilatory O
effects O
of O
cinnamic B
acid I
via O
the O
nitric B
oxide I
- O
cGMP B
- O
PKG O
pathway O
in O
rat O
thoracic O
aorta O
. O

Cinnamic B
acid I
( O
CA O
) O
and O
its O
derivatives O
have O
a O
broad O
therapeutic O
spectrum O
that O
includes O
antimicrobial O
, O
antifungal O
, O
and O
antitumoral O
activities O
. O

Pretreatment O
of O
the O
endothelium O
- O
intact O
aortic O
strips O
with O
N B
( I
G I
) I
- I
nitro I
- I
l I
- I
arginine I
methyl I
ester I
( O
10 O
( O
- O
4 O
) O
M O
) O
, O
1 B
H I
- I
[ I
1 I
, I
2 I
, I
4 I
] I
- I
oxadiazolole I
- I
[ I
4 I
, I
3 I
- I
a I
] I
quinoxalin I
- I
10 I
- I
one I
, O
( O
10 O
( O
- O
6 O
) O
M O
) O
and O
methylene B
blue I
( O
10 O
( O
- O
5 O
) O
M O
) O
inhibited O
CA O
- O
induced O
vasorelaxation O
. O

CA O
also O
increased O
the O
phosphorylation O
of O
endothelial O
nitric B
oxide I
synthase O
and O
nitric B
oxide I
generation O
in O
a O
concentration O
- O
dependent O
manner O
in O
HUVECs O
. O

CA O
also O
increased O
the O
phosphorylation O
of O
endothelial O
nitric B
oxide I
synthase O
and O
nitric B
oxide I
generation O
in O
a O
concentration O
- O
dependent O
manner O
in O
HUVECs O
. O

These O
findings O
suggest O
that O
CA O
exerts O
an O
endothelium O
- O
dependent O
vasodilation O
effect O
via O
the O
nitric B
oxide I
- O
cGMP B
- O
PKG O
- O
mediated O
pathway O
in O
rat O
thoracic O
aorta O
. O

The O
synergistic O
apoptotic O
interaction O
of O
panaxadiol B
and O
epigallocatechin B
gallate I
in O
human O
colorectal O
cancer O
cells O
. O

Epigallocatechin B
gallate I
( O
EGCG B
) O
, O
a O
major O
catechin B
in O
green O
tea O
, O
is O
a O
strong O
botanical O
antioxidant O
. O

Extract O
of O
guava O
leaf O
( O
GvEx O
) O
consists O
of O
carbohydrate B
and O
polyphenols B
, O
which O
are O
Gvpp O
, O
quercetin B
, O
and O
ellagic B
acid I
. O

A O
new O
phenylethanoid B
glucoside I
from O
Plantago O
depressa O
Willd O
. O

Chemical O
research O
of O
Plantago O
depressa O
Willd O
. O
led O
to O
one O
new O
phenylethanoid B
glucoside I
with O
alpha B
- I
L I
- I
rhamnosyl I
( I
1 I
- I
- I
> I
2 I
) I
- I
beta I
- I
D I
- I
glucose I
structure O
, O
together O
with O
four O
known O
compounds O
. O

The O
main O
component O
of O
essential O
oil O
was O
ethyl B
homovanillate I
( O
11 O
. O
79 O
% O
) O
in O
buds O
and O
drimenol B
( O
29 O
. O
42 O
% O
) O
in O
roots O
. O

A O
new O
triterpenoid B
saponin I
from O
Glinus O
oppositifolius O
with O
alpha O
- O
glucosidase O
inhibitory O
activity O
. O

Evaluation O
of O
alpha O
- O
glucosidase O
inhibitory O
activity O
led O
to O
the O
isolation O
of O
six O
triterpene B
saponins I
from O
the O
aerial O
parts O
of O
Glinus O
oppositifolius O
including O
one O
new O
and O
five O
known O
constituents O
. O

The O
structure O
of O
the O
new O
saponin B
, O
glinoside B
C I
( O
1 O
) O
, O
was O
established O
as O
16 B
- I
O I
- I
( I
beta I
- I
D I
- I
glucopyranosyl I
) I
- I
3 I
beta I
, I
12 I
beta I
, I
16 I
beta I
, I
21 I
alpha I
, I
22 I
- I
pentahydroxy I
hopane I
by O
extensive O
use O
of O
1 O
- O
D O
, O
2 O
- O
D O
NMR O
and O
mass O
spectral O
techniques O
. O

The O
other O
constituents O
identified O
were O
3 B
- I
O I
- I
( I
beta I
- I
D I
- I
xylopyranosyl I
) I
- I
spergulagenin I
A I
( O
2 O
) O
, O
spergulacin B
( O
3 O
) O
, O
spergulin B
A I
( O
4 O
) O
, O
spergulacin B
A I
( O
5 O
) O
and O
spergulin B
B I
( O
6 O
) O
. O

The O
other O
constituents O
identified O
were O
3 B
- I
O I
- I
( I
beta I
- I
D I
- I
xylopyranosyl I
) I
- I
spergulagenin I
A I
( O
2 O
) O
, O
spergulacin B
( O
3 O
) O
, O
spergulin B
A I
( O
4 O
) O
, O
spergulacin B
A I
( O
5 O
) O
and O
spergulin B
B I
( O
6 O
) O
. O

The O
other O
constituents O
identified O
were O
3 B
- I
O I
- I
( I
beta I
- I
D I
- I
xylopyranosyl I
) I
- I
spergulagenin I
A I
( O
2 O
) O
, O
spergulacin B
( O
3 O
) O
, O
spergulin B
A I
( O
4 O
) O
, O
spergulacin B
A I
( O
5 O
) O
and O
spergulin B
B I
( O
6 O
) O
. O

A O
central O
composite O
design O
was O
applied O
for O
optimization O
of O
the O
formulation O
parameters O
and O
for O
studying O
the O
effects O
of O
three O
independent O
variables O
: O
PLGA B
concentration O
, O
polyvinyl B
alcohol I
( O
PVA B
) O
concentration O
and O
organic O
solvent O
removal O
rate O
on O
the O
particle O
size O
and O
the O
entrapment O
efficiency O
( O
response O
variables O
) O
. O

The O
role O
of O
diallyl B
sulfides I
and O
dipropyl B
sulfides I
in O
the O
in O
vitro O
antimicrobial O
activity O
of O
the O
essential O
oil O
of O
garlic O
, O
Allium O
sativum O
L O
. O
, O
and O
Leek O
, O
Allium O
porrum O
L O
. O

The O
role O
of O
diallyl B
sulfides I
and O
dipropyl B
sulfides I
in O
the O
in O
vitro O
antimicrobial O
activity O
of O
the O
essential O
oil O
of O
garlic O
, O
Allium O
sativum O
L O
. O
, O
and O
Leek O
, O
Allium O
porrum O
L O
. O

The O
main O
constituents O
of O
the O
garlic O
EO O
were O
diallyl B
monosulfide I
, O
diallyl B
disulfide I
( O
DADS B
) O
, O
diallyl B
trisulfide I
, O
and O
diallyl B
tetrasulfide I
. O

The O
main O
constituents O
of O
the O
garlic O
EO O
were O
diallyl B
monosulfide I
, O
diallyl B
disulfide I
( O
DADS B
) O
, O
diallyl B
trisulfide I
, O
and O
diallyl B
tetrasulfide I
. O

The O
main O
constituents O
of O
the O
garlic O
EO O
were O
diallyl B
monosulfide I
, O
diallyl B
disulfide I
( O
DADS B
) O
, O
diallyl B
trisulfide I
, O
and O
diallyl B
tetrasulfide I
. O

The O
main O
constituents O
of O
the O
garlic O
EO O
were O
diallyl B
monosulfide I
, O
diallyl B
disulfide I
( O
DADS B
) O
, O
diallyl B
trisulfide I
, O
and O
diallyl B
tetrasulfide I
. O

The O
EO O
of O
A O
. O
porrum O
was O
characterized O
by O
the O
presence O
of O
dipropyl B
disulfide I
( O
DPDS B
) O
, O
dipropyl B
trisulfide I
, O
and O
dipropyl B
tetrasulfide I
. O

The O
EO O
of O
A O
. O
porrum O
was O
characterized O
by O
the O
presence O
of O
dipropyl B
disulfide I
( O
DPDS B
) O
, O
dipropyl B
trisulfide I
, O
and O
dipropyl B
tetrasulfide I
. O

The O
EO O
of O
A O
. O
porrum O
was O
characterized O
by O
the O
presence O
of O
dipropyl B
disulfide I
( O
DPDS B
) O
, O
dipropyl B
trisulfide I
, O
and O
dipropyl B
tetrasulfide I
. O

A O
new O
flavonol B
triglycoside I
, O
myricetin B
- I
3 I
- I
O I
- I
[ I
beta I
- I
xylopyranosyl I
- I
( I
1 I
- I
2 I
) I
- I
alpha I
- I
rhamnopyranoside I
] I
- I
4 I
' I
- I
O I
- I
alpha I
- I
rhamnopyranoside I
, O
named O
as O
bayarin B
( O
1 O
) O
, O
was O
isolated O
from O
the O
aerial O
parts O
of O
Zizyphus O
incurva O
Roxb O
. O

Anxiolytic O
- O
but O
not O
antidepressant O
- O
like O
activity O
of O
Lu B
AF21934 I
, O
a O
novel O
, O
selective O
positive O
allosteric O
modulator O
of O
the O
mGlu O
4 O
receptor O
. O

Herein O
, O
we O
report O
the O
pharmacological O
actions O
of O
Lu B
AF21934 I
, O
a O
novel O
, O
selective O
, O
and O
brain O
- O
penetrant O
positive O
allosteric O
modulator O
( O
PAM O
) O
of O
the O
mGlu O
( O
4 O
) O
receptor O
in O
the O
stress O
- O
induced O
hyperthermia O
( O
SIH O
) O
, O
four O
- O
plate O
, O
marble O
- O
burying O
and O
Vogel O
' O
s O
conflict O
tests O
. O

The O
anti O
- O
hyperthermic O
effect O
of O
Lu B
AF21934 I
( O
5 O
mg O
/ O
kg O
) O
in O
the O
SIH O
test O
was O
inhibited O
by O
the O
benzodiazepine B
receptor O
antagonist O
flumazenil B
( O
10 O
mg O
/ O
kg O
) O
and O
was O
not O
serotonin B
- O
dependent O
, O
as O
it O
persisted O
in O
serotonin B
- O
deficient O
mice O
and O
upon O
blockade O
of O
either O
5 B
- I
HT I
( O
1A O
) O
receptors O
by O
WAY100635 B
, O
or O
5 B
- I
HT I
( O
2A O
/ O
2C O
) O
receptors O
by O
ritanserin B
. O

These O
results O
suggest O
that O
the O
GABAergic O
system O
, O
but O
not O
the O
serotonergic O
system O
, O
is O
involved O
in O
the O
mechanism O
of O
the O
anxiolytic O
- O
like O
phenotype O
of O
Lu B
AF21934 I
in O
rodents O
. O

Lu B
AF21934 I
did O
not O
produce O
antidepressant O
- O
like O
effects O
in O
the O
tail O
suspension O
test O
( O
TST O
) O
in O
mice O
; O
however O
, O
it O
decreased O
the O
basal O
locomotor O
activity O
of O
mice O
that O
were O
not O
habituated O
to O
activity O
cages O
. O

Four O
chemotypes O
were O
identified O
: O
piperitone B
oxide I
, O
piperitenone B
oxide I
, O
piperitone B
- O
menthone B
and O
pulegone B
. O

Four O
chemotypes O
were O
identified O
: O
piperitone B
oxide I
, O
piperitenone B
oxide I
, O
piperitone B
- O
menthone B
and O
pulegone B
. O

In O
this O
study O
, O
we O
screened O
308 O
extracts O
from O
102 O
species O
for O
cytostatic O
and O
cytotoxic O
activity O
against O
a O
panel O
of O
six O
tumor O
cell O
lines O
using O
a O
24 O
- O
h O
sulphorhodamine B
B I
assay O
. O

Two O
new O
phenolic B
glycosides I
from O
Inula O
cappa O
DC O
. O

Two O
new O
phenolic B
glycosides I
were O
isolated O
from O
the O
ethanol B
extract O
of O
the O
roots O
of O
Inula O
cappa O
DC O
. O

Both O
enzymes O
efficiently O
hydrolyzed O
diisopropylfluoropho B
, O
sarin B
, O
soman B
, O
tabun B
and O
cyclosarin B
, O
but O
were O
much O
less O
efficient O
at O
hydrolyzing O
paraoxon B
and O
methyl B
paraoxon I
. O

Theoretical O
study O
of O
the O
pH O
- O
dependent O
antioxidant O
properties O
of O
vitamin B
C I
. O

Vitamin B
C I
is O
known O
to O
be O
one O
of O
these O
molecules O
. O

In O
this O
study O
we O
have O
analyzed O
the O
reactivity O
of O
vitamin B
C I
toward O
the O
[ O
Formula O
: O
see O
text O
] O
and O
[ O
Formula O
: O
see O
text O
] O
ROS O
species O
, O
in O
all O
acidic O
, O
neutral O
and O
basic O
media O
. O

In O
all O
three O
media O
, O
vitamin B
C I
reactions O
with O
two O
hydroxyl B
radicals O
show O
a O
wide O
variety O
of O
possible O
products O
. O

We O
examined O
the O
molecular O
evolution O
of O
two O
unlinked O
P O
/ O
A O
polymorphisms O
that O
underlie O
a O
well O
- O
documented O
adaptive O
polymorphism O
for O
cyanogenesis O
( O
hydrogen B
cyanide I
release O
with O
tissue O
damage O
) O
in O
white O
clover O
. O

Using O
a O
sample O
of O
65 O
plants O
, O
we O
investigated O
the O
molecular O
evolution O
of O
sequences O
flanking O
the O
two O
underlying O
cyanogenesis O
genes O
: O
Ac O
/ O
ac O
( O
controlling O
the O
presence O
/ O
absence O
of O
cyanogenic B
glucosides I
) O
and O
Li O
/ O
li O
( O
controlling O
the O
presence O
/ O
absence O
of O
their O
hydrolysing O
enzyme O
, O
linamarase O
) O
. O

A O
comparison O
between O
the O
temperatures O
within O
imploding O
acoustic O
cavitation O
bubbles O
and O
the O
extent O
of O
sonoluminescence O
( O
SL O
) O
quenching O
by O
C O
( O
1 O
) O
- O
C O
( O
5 O
) O
aliphatic B
alcohols I
in O
1 B
- I
ethyl I
- I
3 I
- I
methylimidazolium I
ethylsulfate I
( O
[ B
EMIM I
] I
[ I
EtSO I
( I
4 I
) I
] I
, O
a O
well O
known O
imidazolium B
based O
room O
temperature O
ionic O
liquid O
( O
RTIL O
) O
) O
, O
has O
been O
made O
at O
an O
ultrasound O
frequency O
of O
213 O
kHz O
. O

Both O
the O
extent O
of O
the O
reduction O
in O
the O
bubble O
temperatures O
and O
the O
SL O
quenching O
were O
much O
smaller O
than O
those O
obtained O
in O
comparable O
aqueous O
solutions O
containing O
aliphatic B
alcohols I
. O

Pinosylvin B
Induces O
Cell O
Survival O
, O
Migration O
and O
Anti O
- O
Adhesiveness O
of O
Endothelial O
Cells O
via O
Nitric B
Oxide I
Production O
. O

Moreover O
, O
pinosylvin B
was O
shown O
to O
activate O
endothelial O
nitric B
oxide I
synthetase O
( O
eNOS O
) O
. O

Bioactivity O
of O
Diosmetin B
Glycosides I
Isolated O
from O
the O
Epicarp O
of O
Date O
Fruits O
, O
Phoenix O
dactylifera O
, O
on O
the O
Biochemical O
Profile O
of O
Alloxan B
Diabetic O
Male O
Rats O
. O

Human O
neuronal O
coenzyme B
Q10 I
deficiency O
results O
in O
global O
loss O
of O
mitochondrial O
respiratory O
chain O
activity O
, O
increased O
mitochondrial O
oxidative O
stress O
and O
reversal O
of O
ATP B
synthase O
activity O
: O
implications O
for O
pathogenesis O
and O
treatment O
. O

A O
phytochemical O
investigation O
of O
a O
herb O
tea O
made O
from O
Thamnolia O
vermicularis O
led O
to O
the O
isolation O
of O
three O
new O
beta B
- I
orcinol I
- O
type O
depsides B
( O
1 O
, O
2 O
and O
3 O
) O
, O
along O
with O
seven O
known O
compounds O
hypothamnolic B
acid I
( O
4 O
) O
, O
3 B
' I
- I
methylevenic I
acid I
( O
5 O
) O
, O
baeomycesic B
acid I
( O
6 O
) O
, O
squamatic B
acid I
( O
7 O
) O
, O
methyl B
3 I
' I
- I
methyllecanorate I
( O
8 O
) O
, O
barbatinic B
acid I
( O
9 O
) O
and O
atranorin B
( O
10 O
) O
. O

A O
phytochemical O
investigation O
of O
a O
herb O
tea O
made O
from O
Thamnolia O
vermicularis O
led O
to O
the O
isolation O
of O
three O
new O
beta B
- I
orcinol I
- O
type O
depsides B
( O
1 O
, O
2 O
and O
3 O
) O
, O
along O
with O
seven O
known O
compounds O
hypothamnolic B
acid I
( O
4 O
) O
, O
3 B
' I
- I
methylevenic I
acid I
( O
5 O
) O
, O
baeomycesic B
acid I
( O
6 O
) O
, O
squamatic B
acid I
( O
7 O
) O
, O
methyl B
3 I
' I
- I
methyllecanorate I
( O
8 O
) O
, O
barbatinic B
acid I
( O
9 O
) O
and O
atranorin B
( O
10 O
) O
. O

A O
phytochemical O
investigation O
of O
a O
herb O
tea O
made O
from O
Thamnolia O
vermicularis O
led O
to O
the O
isolation O
of O
three O
new O
beta B
- I
orcinol I
- O
type O
depsides B
( O
1 O
, O
2 O
and O
3 O
) O
, O
along O
with O
seven O
known O
compounds O
hypothamnolic B
acid I
( O
4 O
) O
, O
3 B
' I
- I
methylevenic I
acid I
( O
5 O
) O
, O
baeomycesic B
acid I
( O
6 O
) O
, O
squamatic B
acid I
( O
7 O
) O
, O
methyl B
3 I
' I
- I
methyllecanorate I
( O
8 O
) O
, O
barbatinic B
acid I
( O
9 O
) O
and O
atranorin B
( O
10 O
) O
. O

A O
phytochemical O
investigation O
of O
a O
herb O
tea O
made O
from O
Thamnolia O
vermicularis O
led O
to O
the O
isolation O
of O
three O
new O
beta B
- I
orcinol I
- O
type O
depsides B
( O
1 O
, O
2 O
and O
3 O
) O
, O
along O
with O
seven O
known O
compounds O
hypothamnolic B
acid I
( O
4 O
) O
, O
3 B
' I
- I
methylevenic I
acid I
( O
5 O
) O
, O
baeomycesic B
acid I
( O
6 O
) O
, O
squamatic B
acid I
( O
7 O
) O
, O
methyl B
3 I
' I
- I
methyllecanorate I
( O
8 O
) O
, O
barbatinic B
acid I
( O
9 O
) O
and O
atranorin B
( O
10 O
) O
. O

In O
this O
study O
, O
silibinin B
, O
a O
plant O
flavonolignan B
extracted O
from O
milk O
thistle O
with O
potent O
antioxidant O
activity O
, O
was O
evaluated O
for O
its O
effects O
in O
( O
a O
) O
preventing O
hydrogen B
peroxide I
( O
H2O2 B
) O
- O
induced O
cellular O
damage O
and O
( O
b O
) O
blocking O
the O
phenylephrine B
- O
induced O
hypertrophic O
response O
. O

The O
major O
metabolites O
detected O
in O
rat O
hepatocytes O
were O
hydroxybenzoic B
acid I
and O
in O
human O
hepatocytes O
were O
hydroxybenzoic B
acid I
and O
hydroxyhippuric B
acid I
. O

The O
major O
metabolites O
detected O
in O
rat O
hepatocytes O
were O
hydroxybenzoic B
acid I
and O
in O
human O
hepatocytes O
were O
hydroxybenzoic B
acid I
and O
hydroxyhippuric B
acid I
. O

The O
major O
metabolites O
detected O
in O
rat O
hepatocytes O
were O
hydroxybenzoic B
acid I
and O
in O
human O
hepatocytes O
were O
hydroxybenzoic B
acid I
and O
hydroxyhippuric B
acid I
. O

Metabolites O
detected O
in O
urine O
included O
those O
previously O
reported O
, O
BPB B
- I
glucuronide I
, O
BPB B
- I
sulfate I
, O
hydroxybenzoic B
acid I
and O
hydroxyhippuric B
acid I
, O
but O
also O
novel O
metabolites O
arising O
from O
ring O
hydroxylation O
followed O
by O
glucuronidation O
and O
sulfation O
. O

Metabolites O
detected O
in O
urine O
included O
those O
previously O
reported O
, O
BPB B
- I
glucuronide I
, O
BPB B
- I
sulfate I
, O
hydroxybenzoic B
acid I
and O
hydroxyhippuric B
acid I
, O
but O
also O
novel O
metabolites O
arising O
from O
ring O
hydroxylation O
followed O
by O
glucuronidation O
and O
sulfation O
. O

Combined O
effects O
of O
treatment O
with O
vitamin B
C I
, O
vitamin B
E I
and O
selenium B
on O
the O
skin O
of O
diabetic O
rats O
. O

Combined O
effects O
of O
treatment O
with O
vitamin B
C I
, O
vitamin B
E I
and O
selenium B
on O
the O
skin O
of O
diabetic O
rats O
. O

The O
aim O
of O
this O
study O
was O
to O
investigate O
the O
effects O
of O
vitamin B
C I
, O
vitamin B
E I
and O
selenium B
( O
Se B
) O
on O
the O
skin O
tissue O
of O
streptozotocin B
- O
induced O
diabetic O
rats O
. O

The O
aim O
of O
this O
study O
was O
to O
investigate O
the O
effects O
of O
vitamin B
C I
, O
vitamin B
E I
and O
selenium B
( O
Se B
) O
on O
the O
skin O
tissue O
of O
streptozotocin B
- O
induced O
diabetic O
rats O
. O

Vitamin B
C I
( O
250 O
mg O
/ O
kg O
) O
, O
vitamin B
E I
( O
250 O
mg O
/ O
kg O
) O
and O
Se B
( O
0 O
. O
2 O
mg O
/ O
kg O
) O
were O
given O
by O
gavage O
technique O
to O
rats O
of O
one O
diabetic O
and O
one O
control O
group O
for O
30 O
days O
. O

Vitamin B
C I
( O
250 O
mg O
/ O
kg O
) O
, O
vitamin B
E I
( O
250 O
mg O
/ O
kg O
) O
and O
Se B
( O
0 O
. O
2 O
mg O
/ O
kg O
) O
were O
given O
by O
gavage O
technique O
to O
rats O
of O
one O
diabetic O
and O
one O
control O
group O
for O
30 O
days O
. O

Treatment O
with O
vitamin B
C I
, O
vitamin B
E I
and O
Se B
reversed O
these O
effects O
. O

Treatment O
with O
vitamin B
C I
, O
vitamin B
E I
and O
Se B
reversed O
these O
effects O
. O

The O
present O
study O
showed O
that O
vitamin B
C I
, O
vitamin B
E I
and O
Se B
exerted O
antioxidant O
effects O
and O
consequently O
may O
prevent O
skin O
damage O
caused O
by O
streptozotocin B
- O
induced O
diabetes O
. O

The O
present O
study O
showed O
that O
vitamin B
C I
, O
vitamin B
E I
and O
Se B
exerted O
antioxidant O
effects O
and O
consequently O
may O
prevent O
skin O
damage O
caused O
by O
streptozotocin B
- O
induced O
diabetes O
. O

Absorption O
of O
TAK B
- I
491 I
, O
a O
new O
angiotensin B
II I
receptor O
antagonist O
, O
in O
animals O
. O

However O
, O
medoxomil B
alcohol I
wasn O
' O
t O
detected O
during O
the O
hydrolysis O
of O
TAK B
- I
491 I
. O

These O
metabolic O
features O
of O
TAK B
- I
491 I
were O
similar O
to O
olmesartan B
medoxomil I
, O
suggesting O
the O
hydrolytic O
pathway O
and O
enzymes O
for O
TAK B
- I
491 I
when O
catalyzing O
to O
TAK B
- I
536 I
would O
be O
the O
same O
as O
olmesartan B
medoxomil I
. O

These O
metabolic O
features O
of O
TAK B
- I
491 I
were O
similar O
to O
olmesartan B
medoxomil I
, O
suggesting O
the O
hydrolytic O
pathway O
and O
enzymes O
for O
TAK B
- I
491 I
when O
catalyzing O
to O
TAK B
- I
536 I
would O
be O
the O
same O
as O
olmesartan B
medoxomil I
. O

Gelucires O
are O
polyethylene B
glycol I
( O
PEG B
) O
glycerides O
composed O
of O
mono B
- I
, I
di I
- I
and I
triglycerides I
and O
mono O
- O
and O
diesters O
of O
PEG B
. O

The O
results O
confirmed O
that O
surface O
coating O
of O
TiO B
( I
2 I
) I
nanoparticles O
could O
reduce O
such O
toxicity O
after O
photoactivation O
, O
by O
hindering O
adsorption O
of O
biomolecules O
and O
generation O
of O
hydroxyl B
radical O
( O
. B
OH I
) O
during O
photoactivation O
. O

Vitamin B
D I
is O
a O
potent O
stimulator O
of O
monocyte O
innate O
immunity O
, O
and O
this O
effect O
is O
mediated O
via O
intracrine O
conversion O
of O
25 B
- I
hydroxyvitamin I
D I
( O
25OHD B
) O
to O
1 B
, I
25 I
- I
dihydroxyvitamin I
D I
( O
1 B
, I
25 I
( I
OH I
) I
( I
2 I
) I
D I
) O
. O

In O
the O
kidney O
, O
synthesis O
of O
1 B
, I
25 I
( I
OH I
) I
( I
2 I
) I
D I
is O
suppressed O
by O
fibroblast O
growth O
factor O
23 O
( O
FGF23 O
) O
, O
via O
transcriptional O
suppression O
of O
the O
vitamin B
D I
- O
activating O
enzyme O
1 O
alpha O
- O
hydroxylase O
( O
CYP27B1 O
) O
. O

Elevated O
expression O
of O
FGF23 O
may O
therefore O
play O
a O
crucial O
role O
in O
defining O
immune O
responses O
to O
vitamin B
D I
and O
this O
, O
in O
turn O
, O
may O
be O
a O
key O
determinant O
of O
infection O
in O
patients O
with O
chronic O
kidney O
disease O
( O
CKD O
) O
. O

A O
proposed O
mechanism O
for O
the O
reaction O
indicates O
that O
the O
ethyl B
side O
of O
the O
ester O
is O
eliminated O
as O
ethylene B
through O
a O
concerted O
six O
- O
membered O
cyclic O
transition O
state O
, O
and O
the O
unstable O
intermediate O
glycidic B
acid I
decarboxylates O
rapidly O
to O
give O
the O
corresponding O
aldehyde B
. O

Two O
possible O
pathways O
for O
glycidic B
acid I
decarboxylation O
were O
studied O
: O
one O
via O
a O
five O
- O
membered O
cyclic O
transition O
state O
, O
and O
the O
other O
via O
a O
four O
- O
membered O
cyclic O
transition O
state O
. O

Emergency O
Do O
Not O
Consume O
/ O
do O
Not O
Use O
concentrations O
for O
potassium B
permanganate I
in O
drinking O
water O
. O

Potassium B
permanganate I
( O
KMnO B
( I
4 I
) I
) O
is O
used O
to O
control O
iron O
concentrations O
and O
to O
reduce O
the O
levels O
of O
nuisance O
materials O
that O
affect O
odor O
or O
taste O
of O
finished O
drinking O
water O
. O

CBDP B
is O
produced O
in O
vivo O
from O
ortho O
- O
containing O
isomers O
of O
tricresyl B
phosphate I
( O
TCP B
) O
, O
a O
component O
of O
jet O
engine O
lubricants O
and O
hydraulic O
fluids O
. O

Male O
Wistar O
rats O
were O
exposed O
orally O
to O
manganese B
chloride I
( O
20 O
mg O
/ O
mL O
) O
for O
30 O
days O
followed O
by O
intraperitoneal O
cotreatment O
with O
silymarin O
( O
100 O
mg O
/ O
kg O
) O
. O

This O
metal O
reduced O
the O
activities O
of O
superoxide B
dismutase O
, O
catalase O
and O
glutathione B
peroxidase O
and O
nonenzymatic O
antioxidant O
levels O
such O
as O
reduced O
glutathione B
, O
total O
sulfhydryl B
groups O
and O
vitamin B
C I
. O

A O
marked O
increase O
was O
observed O
in O
both O
the O
cell O
lines O
in O
the O
nitrate B
plus O
nitrite B
concentration O
, O
protein O
carbonyls B
and O
thiobarbituric B
acid I
reactive O
substances O
( O
TBARS O
) O
. O

High O
levels O
of O
arachidonic B
acid I
and O
peroxisome O
proliferator O
- O
activated O
receptor O
- O
alpha O
in O
breast O
cancer O
tissues O
are O
associated O
with O
promoting O
cancer O
cell O
proliferation O
. O

Fatty B
acids I
are O
endogenous O
ligands O
of O
peroxisome O
proliferator O
- O
activated O
receptor O
- O
alpha O
( O
PPAR O
alpha O
) O
, O
which O
is O
linked O
to O
the O
regulation O
of O
fatty B
acid I
uptake O
, O
lipid O
metabolism O
and O
breast O
cancer O
cell O
growth O
. O

Fatty B
acids I
are O
endogenous O
ligands O
of O
peroxisome O
proliferator O
- O
activated O
receptor O
- O
alpha O
( O
PPAR O
alpha O
) O
, O
which O
is O
linked O
to O
the O
regulation O
of O
fatty B
acid I
uptake O
, O
lipid O
metabolism O
and O
breast O
cancer O
cell O
growth O
. O

This O
study O
was O
designed O
to O
screen O
candidate O
fatty B
acids I
from O
breast O
cancer O
tissue O
and O
to O
investigate O
the O
effects O
of O
these O
candidate O
fatty B
acids I
on O
PPAR O
alpha O
expression O
, O
cell O
growth O
and O
cell O
cycle O
progression O
in O
breast O
cancer O
cell O
lines O
. O

This O
study O
was O
designed O
to O
screen O
candidate O
fatty B
acids I
from O
breast O
cancer O
tissue O
and O
to O
investigate O
the O
effects O
of O
these O
candidate O
fatty B
acids I
on O
PPAR O
alpha O
expression O
, O
cell O
growth O
and O
cell O
cycle O
progression O
in O
breast O
cancer O
cell O
lines O
. O

One O
breast O
cancer O
tissue O
and O
one O
reference O
tissue O
were O
each O
taken O
from O
30 O
individual O
breasts O
to O
examine O
for O
fatty B
acid I
composition O
and O
PPAR O
alpha O
expression O
. O

We O
found O
that O
arachidonic B
acid I
( O
AA O
) O
and O
PPAR O
alpha O
were O
highly O
expressed O
in O
the O
breast O
cancer O
tissues O
. O

Vitamin B
E I
deficiency O
impairs O
the O
somatostatinergic O
receptor O
- O
effector O
system O
and O
leads O
to O
phosphotyrosine B
phosphatase O
overactivation O
and O
cell O
death O
in O
the O
rat O
hippocampus O
. O

Vitamin B
E I
plays O
an O
essential O
role O
in O
maintaining O
the O
structure O
and O
function O
of O
the O
nervous O
system O
, O
and O
its O
deficiency O
, O
commonly O
associated O
with O
fat O
malabsorption O
diseases O
, O
may O
reduce O
neuronal O
survival O
. O

To O
gain O
a O
better O
understanding O
of O
the O
molecular O
actions O
of O
tocopherols B
and O
examine O
the O
link O
among O
vitamin B
E I
, O
somatostatin B
and O
neuronal O
survival O
, O
we O
have O
investigated O
the O
effects O
of O
a O
deficiency O
and O
subsequent O
administration O
of O
tocopherol B
on O
the O
somatostatin B
signaling O
pathway O
and O
neuronal O
survival O
in O
the O
rat O
hippocampus O
. O

Nevertheless O
, O
vitamin B
E I
deficiency O
impaired O
the O
ability O
of O
the O
somatostatin B
receptors O
to O
couple O
to O
the O
effectors O
adenylyl B
cyclase O
and O
phosphotyrosine B
phosphatase O
by O
diminishing O
Gi O
protein O
functionality O
. O

Furthermore O
, O
vitamin B
E I
deficiency O
significantly O
increased O
phosphotyrosine B
phosphatase O
activity O
and O
PTP O
eta O
expression O
, O
as O
well O
as O
PKC O
delta O
activation O
, O
and O
decreased O
extracellular O
- O
signal O
- O
regulated O
kinase O
phosphorylation O
. O

Altogether O
, O
our O
results O
prove O
the O
importance O
of O
vitamin B
E I
homeostasis O
in O
the O
somatostatin B
receptor O
- O
effector O
system O
and O
suggest O
a O
possible O
mechanism O
by O
which O
this O
vitamin O
may O
regulate O
the O
neuronal O
cell O
survival O
in O
the O
adult O
hippocampus O
. O

Avobenzone B
presented O
a O
pronounced O
phototoxicity O
and O
vitamin B
A I
presented O
a O
tendency O
to O
a O
weak O
phototoxic O
potential O
. O

However O
, O
despite O
the O
four O
formulations O
studied O
did O
not O
present O
any O
acute O
phototoxicity O
potential O
, O
the O
combination O
2 O
containing O
octyl B
methoxycinnamate I
( O
OMC B
) O
, O
avobenzone B
( O
AVB B
) O
and O
4 B
- I
methylbenzilidene I
camphor I
( O
MBC B
) O
presented O
an O
indication O
of O
phototoxicity O
that O
should O
be O
better O
investigated O
in O
terms O
of O
the O
frequency O
of O
photoallergic O
or O
chronic O
phototoxicity O
in O
humans O
, O
once O
these O
tests O
are O
scientifically O
validated O
only O
to O
detect O
phototoxic O
potential O
with O
the O
aim O
of O
preventing O
phototoxic O
reactions O
in O
the O
general O
population O
, O
and O
positive O
results O

Group O
II O
metabotropic O
glutamate B
receptor O
type O
2 O
allosteric O
potentiators O
prevent O
sodium B
lactate I
- O
induced O
panic O
- O
like O
response O
in O
panic O
- O
vulnerable O
rats O
. O

Rats O
with O
chronic O
inhibition O
of O
GABA B
synthesis O
by O
infusion O
of O
l B
- I
allyglycine I
, O
a O
glutamic B
acid I
decarboxylase O
inhibitor O
, O
into O
their O
dorsomedial O
/ O
perifornical O
hypothalamus O
are O
anxious O
and O
exhibit O
panic O
- O
like O
cardio O
- O
respiratory O
responses O
to O
treatment O
with O
intravenous O
( O
i O
. O
v O
. O
) O
sodium B
lactate I
( O
NaLac B
) O
infusions O
, O
in O
a O
manner O
similar O
to O
what O
occurs O
in O
patients O
with O
panic O
disorder O
. O

Rats O
with O
chronic O
inhibition O
of O
GABA B
synthesis O
by O
infusion O
of O
l B
- I
allyglycine I
, O
a O
glutamic B
acid I
decarboxylase O
inhibitor O
, O
into O
their O
dorsomedial O
/ O
perifornical O
hypothalamus O
are O
anxious O
and O
exhibit O
panic O
- O
like O
cardio O
- O
respiratory O
responses O
to O
treatment O
with O
intravenous O
( O
i O
. O
v O
. O
) O
sodium B
lactate I
( O
NaLac B
) O
infusions O
, O
in O
a O
manner O
similar O
to O
what O
occurs O
in O
patients O
with O
panic O
disorder O
. O

High O
multivitamin O
intake O
( O
HV O
) O
during O
pregnancy O
increases O
body O
fat O
and O
weight O
and O
alters O
glucose B
and O
fatty B
acid I
metabolism O
in O
Wistar O
rat O
offspring O
. O

This O
study O
investigated O
the O
expression O
of O
peroxisome O
- O
proliferator O
activated O
receptors O
( O
PPARs O
) O
genes O
involved O
in O
regulation O
of O
glucose B
and O
fatty B
acid I
metabolism O
in O
their O
tissues O
. O

Lead O
- O
induced O
ER O
calcium B
release O
and O
inhibitory O
effects O
of O
methionine B
choline I
in O
cultured O
rat O
hippocampal O
neurons O
. O

In O
this O
study O
, O
laser O
scanning O
confocal O
microscopy O
was O
used O
to O
examine O
the O
effects O
of O
Pb B
( I
2 I
+ I
) I
on O
intracellular O
and O
endoplasmic O
reticulum O
free O
calcium B
concentration O
( O
[ O
Ca B
( I
2 I
+ I
) I
] O
( O
i O
) O
and O
[ O
Ca B
( I
2 I
+ I
) I
] O
( O
ER O
) O
) O
in O
cultured O
neonatal O
rat O
hippocampal O
neurons O
and O
their O
possible O
antagonism O
by O
methionine B
choline I
; O
understanding O
these O
effects O
would O
help O
explain O
the O
lead O
- O
induced O
cognitive O
and O
learning O
dysfunction O
and O
explore O
efficient O
safety O
and O
relief O
strategies O
. O

The O
addition O
of O
10 O
, O
20 O
, O
or O
40 O
mmol O
/ O
L O
methionine B
choline I
simultaneously O
with O
addition O
of O
10 O
mu O
mol O
/ O
L O
Pb B
( I
2 I
+ I
) I
decreased O
[ O
Ca B
( I
2 I
+ I
) I
] O
( O
i O
) O
in O
Ca B
( I
2 I
+ I
) I
- O
free O
culture O
medium O
by O
39 O
. O
0 O
% O
, O
66 O
. O
0 O
% O
, O
and O
61 O
. O
6 O
% O
, O
respectively O
, O
in O
a O
concentration O
- O
dependant O
manner O
in O
a O
certain O
dose O
range O
. O

Our O
results O
suggest O
that O
Pb B
( I
2 I
+ I
) I
induces O
ER O
calcium B
release O
to O
increase O
the O
resting O
[ O
Ca B
( I
2 I
+ I
) I
] O
( O
i O
) O
; O
and O
methionine B
choline I
inhibit O
this O
increase O
in O
[ O
Ca B
( I
2 I
+ I
) I
] O
( O
i O
) O
. O

Synthesis O
of O
NaP B
zeolite I
at O
room O
temperature O
and O
short O
crystallization O
time O
by O
sonochemical O
method O
. O

NaP B
zeolite I
nano O
crystals O
were O
synthesized O
by O
sonochemical O
method O
at O
room O
temperature O
with O
crystallization O
time O
of O
3h O
. O

NaP B
zeolites I
are O
directly O
formed O
by O
ultrasonic O
treatment O
without O
the O
application O
of O
autogenous O
pressure O
and O
also O
hydrothermal O
treatment O
. O

Amino B
acid I
sequence O
of O
the O
ligand O
- O
binding O
domain O
of O
the O
aryl B
hydrocarbon I
receptor O
1 O
predicts O
sensitivity O
of O
wild O
birds O
to O
effects O
of O
dioxin B
- O
like O
compounds O
. O

Amino B
acid I
sequence O
of O
the O
ligand O
- O
binding O
domain O
of O
the O
aryl B
hydrocarbon I
receptor O
1 O
predicts O
sensitivity O
of O
wild O
birds O
to O
effects O
of O
dioxin B
- O
like O
compounds O
. O

The O
sensitivity O
of O
avian O
species O
to O
the O
toxic O
effects O
of O
dioxin B
- O
like O
compounds O
( O
DLCs O
) O
varies O
up O
to O
1000 O
- O
fold O
among O
species O
, O
and O
this O
variability O
has O
been O
associated O
with O
interspecies O
differences O
in O
aryl B
hydrocarbon I
receptor O
1 O
ligand O
- O
binding O
domain O
( O
AHR1 O
LBD O
) O
sequence O
. O

In O
the O
present O
study O
, O
the O
AHR1 O
LBD O
sequences O
of O
86 O
avian O
species O
were O
studied O
, O
and O
differences O
at O
amino B
acid I
sites O
256 O
, O
257 O
, O
297 O
, O
324 O
, O
337 O
, O
and O
380 O
were O
identified O
. O

Site O
- O
directed O
mutagenesis O
, O
the O
LRG O
assay O
, O
and O
homology O
modeling O
highlighted O
the O
importance O
of O
each O
amino B
acid I
site O
in O
AHR1 O
sensitivity O
to O
2 B
, I
3 I
, I
7 I
, I
8 I
- I
tetrachlorodibenzo I
- I
p I
- I
dioxin I
and O
other O
DLCs O
. O

The O
results O
of O
the O
study O
revealed O
that O
( O
1 O
) O
only O
amino B
acids I
at O
sites O
324 O
and O
380 O
affect O
the O
sensitivity O
of O
AHR1 O
expression O
constructs O
of O
the O
86 O
avian O
species O
to O
DLCs O
and O
( O
2 O
) O
in O
vitro O
luciferase O
activity O
of O
AHR1 O
constructs O
containing O
only O
the O
LBD O
of O
the O
species O
of O
interest O
is O
significantly O
correlated O
( O
r O
( O
2 O
) O
= O
0 O
. O
93 O
, O
p O
< O
0 O
. O
0001 O
) O
with O
in O
ovo O
toxicity O
data O
for O
those O
species O
. O

These O
results O
indicate O
promise O
for O
the O
use O
of O
AHR1 O
LBD O
amino B
acid I
sequences O
independently O
, O
or O
combined O
with O
the O
LRG O
assay O
, O
to O
predict O
avian O
species O
sensitivity O
to O
DLCs O
. O

By O
applying O
modern O
proteomic O
technologies O
together O
with O
a O
target O
peptide O
containing O
all O
amino B
acids I
, O
the O
assay O
permits O
the O
profiling O
of O
all O
amino B
acid I
specific O
allergen O
- O
peptide O
interactions O
. O

By O
applying O
modern O
proteomic O
technologies O
together O
with O
a O
target O
peptide O
containing O
all O
amino B
acids I
, O
the O
assay O
permits O
the O
profiling O
of O
all O
amino B
acid I
specific O
allergen O
- O
peptide O
interactions O
. O

Additionally O
, O
more O
specific O
mechanisms O
exist O
where O
xenobiotics O
act O
as O
ligands O
, O
including O
the O
aryl B
hydrocarbon I
receptor O
, O
metal O
- O
responsive O
transcription O
factor O
- O
1 O
and O
the O
nuclear O
receptor O
family O
of O
transcription O
factors O
. O

The O
current O
study O
examined O
the O
hypothesis O
that O
the O
nature O
of O
the O
BE O
itself O
would O
be O
a O
critical O
determinant O
of O
outcome O
in O
mice O
that O
had O
been O
continually O
exposed O
to O
0 O
or O
100 O
ppm O
Pb B
acetate I
in O
drinking O
water O
alone O
or O
in O
combination O
with O
prenatal O
restraint O
stress O
. O

Brain O
monoamines B
and O
amino B
acids I
differed O
significantly O
in O
relation O
to O
BE O
, O
even O
in O
control O
animals O
, O
as O
did O
the O
trajectory O
of O
effects O
of O
Pb B
+ O
/ O
- O
PS O
, O
particularly O
in O
frontal O
cortex O
, O
hippocampus O
( O
both O
genders O
) O
, O
and O
midbrain O
( O
males O
) O
. O

Lyral B
and O
lilial B
: O
( O
a O
) O
decreased O
the O
viability O
of O
HaCat O
cells O
with O
a O
50 O
% O
cell O
death O
at O
100 O
and O
60 O
nM O
respectively O
; O
( O
b O
) O
decreased O
significantly O
in O
a O
dose O
dependant O
manner O
the O
intracellular O
ATP B
level O
following O
12 O
- O
h O
of O
treatment O
; O
( O
c O
) O
inhibited O
complexes O
I O
and O
II O
of O
electron O
transport O
chain O
in O
liver O
sub O
- O
mitochondrial O
particles O
; O
and O
( O
d O
) O
increased O
reactive O
oxygen B
species O
generation O
that O
was O
reversed O
by O
N B
- I
acetyl I
cysteine I
and O
trolox B
and O
the O
natural O
antioxidant O
lipoic B
acid I
, O
without O
influencing O
the O
level O
of O
free O

Lipoic B
acid I
protected O
HaCat O
cells O
against O
the O
decrease O
in O
viability O
induced O
by O
either O
compound O
. O

Dehydrogenation O
of O
lyral B
and O
lilial B
produce O
alpha B
, I
beta I
- I
unsaturated I
aldehydes I
, O
that O
reacts O
with O
lipoic B
acid I
requiring O
proteins O
resulting O
in O
their O
inhibition O
. O

The O
peptide O
sequence O
synthesized O
was O
in O
the O
reverse O
order O
of O
the O
human O
peptide O
with O
the O
stable O
isotope O
- O
labels O
in O
the O
amino B
acid I
arginine B
( O
( B
13 I
) I
C6 I
( I
15 I
) I
N4 I
) O
resulting O
in O
an O
increase O
in O
the O
mass O
of O
the O
SIL O
peptide O
of O
10 O
amu O
, O
from O
1753 O
to O
1763 O
. O

A O
dose O
response O
study O
to O
assess O
effects O
after O
dietary O
administration O
of O
diisononyl B
phthalate I
( O
DINP B
) O
in O
gestation O
and O
lactation O
on O
male O
rat O
sexual O
development O
. O

Male O
rat O
sexual O
development O
was O
evaluated O
after O
dietary O
administration O
of O
0 O
, O
760 O
, O
3800 O
, O
11 O
, O
400 O
ppm O
diisononyl B
phthalate I
( O
DiNP B
) O
and O
7600 O
ppm O
dibutyl B
phthalate I
( O
DBP B
) O
from O
gestation O
day O
( O
GD O
) O
12 O
to O
postnatal O
day O
( O
PND O
) O
14 O
. O

Male O
rat O
sexual O
development O
was O
evaluated O
after O
dietary O
administration O
of O
0 O
, O
760 O
, O
3800 O
, O
11 O
, O
400 O
ppm O
diisononyl B
phthalate I
( O
DiNP B
) O
and O
7600 O
ppm O
dibutyl B
phthalate I
( O
DBP B
) O
from O
gestation O
day O
( O
GD O
) O
12 O
to O
postnatal O
day O
( O
PND O
) O
14 O
. O

Treatment O
options O
for O
DUB O
are O
: O
combined O
oral O
contraceptives O
( O
COCs O
) O
, O
progestogens B
, O
non O
steroidal O
anti O
inflammatory O
drugs O
( O
NSAIDs O
) O
, O
tranexamic B
acid I
( O
anti O
- O
fibrinolytic O
) O
, O
GnRH B
analogues O
, O
Danazol B
and O
Levonorgestrel B
releasing O
intra O
uterine O
system O
( O
LNG O
IUS O
) O
. O

Bile B
acid I
accumulation O
in O
liver O
and O
serum O
was O
markedly O
diminished O
in O
A O
( O
1 O
) O
AR O
( O
- O
/ O
- O
) O
mice O
compared O
with O
wild O
- O
type O
( O
WT O
) O
mice O
. O

However O
, O
biliary O
and O
urinary O
outputs O
of O
bile B
acids I
were O
significantly O
enhanced O
in O
A O
( O
1 O
) O
AR O
( O
- O
/ O
- O
) O
mice O
. O

In O
the O
liver O
, O
mRNA O
expression O
of O
genes O
related O
to O
bile B
acid I
transport O
( O
Bsep O
and O
Mdr2 O
) O
and O
hydroxylation O
( O
Cyp3a11 O
) O
was O
increased O
in O
A O
( O
1 O
) O
AR O
( O
- O
/ O
- O
) O
mice O
. O

Methamphetamine B
- O
induced O
nitric B
oxide I
promotes O
vesicular O
transport O
in O
blood O
- O
brain O
barrier O
endothelial O
cells O
. O

The O
BMVEC O
response O
to O
METH B
also O
involved O
rapid O
activation O
of O
endothelial O
nitric B
oxide I
synthase O
and O
its O
inhibition O
abrogated O
METH B
- O
induced O
permeability O
and O
lymphocyte O
migration O
, O
indicating O
that O
nitric B
oxide I
was O
a O
key O
mediator O
of O
BBB O
disruption O
in O
response O
to O
METH B
. O

The O
BMVEC O
response O
to O
METH B
also O
involved O
rapid O
activation O
of O
endothelial O
nitric B
oxide I
synthase O
and O
its O
inhibition O
abrogated O
METH B
- O
induced O
permeability O
and O
lymphocyte O
migration O
, O
indicating O
that O
nitric B
oxide I
was O
a O
key O
mediator O
of O
BBB O
disruption O
in O
response O
to O
METH B
. O

This O
study O
underlines O
the O
key O
role O
of O
nitric B
oxide I
in O
BBB O
function O
and O
describes O
a O
novel O
mechanism O
of O
drug O
- O
induced O
fluid O
- O
phase O
transcytosis O
at O
the O
BBB O
. O

A O
directed O
library O
of O
thirty O
uncharged O
oximes B
that O
contain O
tertiary B
amine I
or O
imidazole B
protonable O
functional O
groups O
that O
should O
cross O
the O
BBB O
as O
unionized O
species O
was O
tested O
as O
tabun B
- O
hAChE O
conjugate O
reactivators O
along O
with O
three O
reference O
oximes B
: O
DAM B
( O
diacetylmonoxime B
) O
, O
MINA B
( O
monoisonitrosoaceton B
) O
, O
and O
2 B
- I
PAM I
. O

Cd B
- O
stimulated O
Trx1 O
nuclear O
translocation O
and O
NF O
- O
kappa O
B O
activation O
were O
inhibited O
by O
cytochalasin B
D I
, O
an O
inhibitor O
of O
actin O
polymerization O
, O
suggesting O
that O
actin O
regulates O
Trx1 O
nuclear O
translocation O
and O
NF O
- O
kappa O
B O
activation O
by O
Cd B
. O

Six O
compounds O
were O
identified O
: O
a O
new O
flavonoid B
, O
3 B
' I
- I
hydroxy I
- I
isoscutellarein I
7 I
- I
O I
- I
[ I
6 I
' I
' I
' I
acetyl I
- I
beta I
- I
D I
- I
glucopyranosyl I
- I
( I
1 I
- I
- I
> I
2 I
) I
- I
beta I
- I
D I
- I
glucopyranoside I
] I
; O
three O
iridoid B
glucosides I
: O
harpagide B
, O
acetyl B
harpagide I
and O
for O
the O
first O
time O
in O
this O
species O
, O
8 B
- I
epi I
- I
loganin I
; O
two O
known O
acetylated B
flavonoid I
glycosides I
: O
3 B
' I
- I
hydroxy I
- I
4 I

Six O
compounds O
were O
identified O
: O
a O
new O
flavonoid B
, O
3 B
' I
- I
hydroxy I
- I
isoscutellarein I
7 I
- I
O I
- I
[ I
6 I
' I
' I
' I
acetyl I
- I
beta I
- I
D I
- I
glucopyranosyl I
- I
( I
1 I
- I
- I
> I
2 I
) I
- I
beta I
- I
D I
- I
glucopyranoside I
] I
; O
three O
iridoid B
glucosides I
: O
harpagide B
, O
acetyl B
harpagide I
and O
for O
the O
first O
time O
in O
this O
species O
, O
8 B
- I
epi I
- I
loganin I
; O
two O
known O
acetylated B
flavonoid I
glycosides I
: O
3 B
' I
- I
hydroxy I
- I
4 I

Identification O
of O
various O
antioxidant O
agents O
, O
such O
as O
thiol B
molecules O
( O
glutathione B
and O
mucolytic O
drugs O
, O
such O
as O
N B
- I
acetyl I
- I
Lcysteine I
, O
N B
- I
acystelyn I
, O
erdosteine B
, O
fudosteine B
, O
ergothioneine B
, O
and O
carbocysteine B
lysine I
salt O
) O
, O
dietary O
natural O
productderived O
polyphenols B
and O
other O
compounds O
( O
curcumin B
, O
resveratrol B
, O
green O
tea O
catechins B
, O
quercetin B
sulforaphane I
, O
lycopene B
, O

Identification O
of O
various O
antioxidant O
agents O
, O
such O
as O
thiol B
molecules O
( O
glutathione B
and O
mucolytic O
drugs O
, O
such O
as O
N B
- I
acetyl I
- I
Lcysteine I
, O
N B
- I
acystelyn I
, O
erdosteine B
, O
fudosteine B
, O
ergothioneine B
, O
and O
carbocysteine B
lysine I
salt O
) O
, O
dietary O
natural O
productderived O
polyphenols B
and O
other O
compounds O
( O
curcumin B
, O
resveratrol B
, O
green O
tea O
catechins B
, O
quercetin B
sulforaphane I
, O
lycopene B
, O

This O
includes O
specific O
spin O
traps O
like O
alpha B
- I
phenyl I
- I
N I
- I
tert I
- I
butyl I
nitrone I
, O
a O
catalytic O
antioxidant O
( O
ECSOD O
mimetic O
) O
, O
porphyrins B
( O
AEOL B
10150 I
and O
AEOL B
10113 I
) O
, O
and O
a O
superoxide B
dismutase O
mimetic O
M40419 B
, O
lipid O
peroxidation O
and O
protein O
carbonylation O
blockers O
/ O
inhibitors O
, O
such O
as O
edaravone B
and O
lazaroids B
/ O
tirilazad B
, O
myeloperoxidase O
inhibitors O
, O
as O
well O
as O
specialized O
pro O
- O
resolving O

This O
includes O
specific O
spin O
traps O
like O
alpha B
- I
phenyl I
- I
N I
- I
tert I
- I
butyl I
nitrone I
, O
a O
catalytic O
antioxidant O
( O
ECSOD O
mimetic O
) O
, O
porphyrins B
( O
AEOL B
10150 I
and O
AEOL B
10113 I
) O
, O
and O
a O
superoxide B
dismutase O
mimetic O
M40419 B
, O
lipid O
peroxidation O
and O
protein O
carbonylation O
blockers O
/ O
inhibitors O
, O
such O
as O
edaravone B
and O
lazaroids B
/ O
tirilazad B
, O
myeloperoxidase O
inhibitors O
, O
as O
well O
as O
specialized O
pro O
- O
resolving O

mediators O
/ O
inflammatory O
resolving O
lipid O
mediators O
, O
omega B
- I
3 I
fatty I
acids I
, O
vitamin B
D I
, O
and O
hydrogen B
sulfide I
. O

mediators O
/ O
inflammatory O
resolving O
lipid O
mediators O
, O
omega B
- I
3 I
fatty I
acids I
, O
vitamin B
D I
, O
and O
hydrogen B
sulfide I
. O

Activity O
- O
guided O
fractionation O
of O
seeds O
of O
Solanum O
indicum O
for O
anti O
- O
HBV O
activity O
led O
to O
the O
isolation O
of O
two O
novel O
coumarinolignoid B
alkaloids I
( O
indicumines B
A I
- I
B I
, O
1 O
- O
2 O
) O
and O
two O
new O
coumarinolignoids B
( O
indicumines B
C I
- I
D I
, O
3 O
- O
4 O
) O
, O
together O
with O
four O
known O
coumarins B
( O
5 O
- O
8 O
) O
. O

The O
two O
novel O
coumarinolignoid B
alkaloids I
shows O
anti O
- O
HBV O
activities O
through O
specifically O
inhibiting O
the O
secretion O
of O
HBsAg O
in O
HepG2 O
. O
2 O
. O
15 O
. O

Leukotriene B
D4 I
induces O
cognitive O
impairment O
through O
enhancement O
of O
CysLT O
1 O
R O
- O
mediated O
amyloid O
- O
beta O
generation O
in O
mice O
. O

In O
the O
present O
study O
, O
we O
examined O
neuroinflammation O
, O
amyloidogenesis O
, O
and O
memory O
performance O
following O
intracerebral O
infusions O
of O
leukotriene B
D4 I
( O
LTD4 B
) O
in O
mice O
. O

LTD4 B
also O
induced O
expression O
of O
cysteinyl B
leukotriene I
receptor O
1 O
( O
CysLT O
( O
1 O
) O
R O
) O
and O
NF O
- O
kappa O
B O
p65 O
in O
the O
hippocampus O
and O
cortex O
. O

Juvenile B
hormone I
levels O
reflect O
social O
opportunities O
in O
the O
facultatively O
eusocial O
sweat O
bee O
Megalopta O
genalis O
( O
Hymenoptera O
: O
Halictidae O
) O
. O

Using O
females O
that O
varied O
in O
social O
, O
reproductive O
, O
and O
ecological O
context O
, O
we O
measured O
juvenile B
hormone I
( O
JH O
) O
, O
a O
major O
regulator O
of O
colony O
caste O
dynamics O
in O
other O
eusocial O
species O
. O

Targeted O
disruption O
of O
inducible O
nitric B
oxide I
synthase O
protects O
against O
aging O
, O
S B
- O
nitrosation O
, O
and O
insulin O
resistance O
in O
muscle O
of O
male O
mice O
. O

Here O
, O
we O
explored O
the O
role O
of O
inducible O
nitric B
oxide I
synthase O
( O
iNOS O
) O
in O
the O
S B
- O
nitrosation O
of O
proteins O
involved O
in O
the O
early O
steps O
of O
the O
insulin O
- O
signaling O
pathway O
and O
insulin O
resistance O
in O
the O
skeletal O
muscle O
of O
aged O
mice O
. O

Ornithine B
( O
Orn B
) O
plays O
a O
main O
role O
in O
the O
biosynthesis O
of O
many O
amino B
acids I
, O
nicotinic B
alkaloids I
, O
and O
polyamines B
in O
tobacco O
. O

Ornithine B
( O
Orn B
) O
plays O
a O
main O
role O
in O
the O
biosynthesis O
of O
many O
amino B
acids I
, O
nicotinic B
alkaloids I
, O
and O
polyamines B
in O
tobacco O
. O

Analysis O
of O
primary O
adipocytes O
isolated O
from O
Retn O
( O
- O
/ O
- O
) O
, O
Retn O
( O
+ O
/ O
- O
) O
, O
and O
Retn O
( O
+ O
/ O
+ O
) O
mice O
found O
that O
GIP O
stimulated O
the O
PKB O
/ O
LKB1 O
/ O
AMPK O
/ O
LPL O
pathway O
and O
fatty B
acid I
uptake O
only O
in O
Retn O
( O
+ O
/ O
+ O
) O
adipocytes O
, O
suggesting O
that O
GIP O
signaling O
and O
/ O
or O
GIP O
responsiveness O
were O
compromised O
in O
Retn O
( O
+ O
/ O
- O
) O
and O
Retn O
( O
- O
/ O
- O
) O
adipocytes O
. O

In O
this O
study O
, O
we O
developed O
oral O
in O
situ O
gelling O
formulations O
composed O
of O
pluronic B
( O
Plu B
) O
and O
polyacrylic B
acid I
( O
PAA B
) O
for O
the O
delivery O
of O
an O
anticancer O
drug O
, O
epirubicin B
( O
Epi B
) O
. O

While O
most O
high O
and O
medium O
oxidation O
state O
( O
O O
. O
S O
. O
> O
= O
3 O
) O
metal B
and I
non I
- I
metal I
fluorides I
and O
oxide B
fluorides B
are O
strong O
Lewis B
acids I
, O
exploration O
of O
their O
coordination O
chemistry O
with O
neutral O
ligands O
has O
been O
limited O
and O
mostly O
non O
- O
systematic O
. O

Expression O
of O
quinone B
reductase O
, O
glutathione B
reductase O
and O
methionine B
sulfoxide I
reductase O
A O
proteins O
were O
significantly O
up O
- O
regulated O
by O
quercetin B
, O
suggesting O
their O
involvement O
in O
the O
cytoprotective O
activity O
of O
quercetin B
. O

However O
, O
expressions O
of O
only O
glutathione B
reductase O
and O
methionine B
sulfoxide I
reductase O
A O
proteins O
were O
significantly O
up O
- O
regulated O
by O
the O
kernel O
extract O
, O
again O
suggesting O
their O
involvement O
in O
the O
cytoprotective O
activity O
of O
bambangan O
kernel O
extract O
. O

The O
LC O
- O
MS O
/ O
MS O
technique O
was O
applied O
to O
the O
stability O
study O
of O
several O
flavonoids B
and O
phenolic B
acids I
in O
honey O
samples O
during O
the O
ultrasonic O
extraction O
( O
USE O
) O
and O
microwave O
- O
assisted O
extraction O
( O
MAE O
) O
. O

Phenolic B
compounds O
from O
the O
standard O
mixture O
were O
stable O
under O
ultrasounds O
action O
with O
the O
mean O
recovery O
of O
( O
90 O
. O
4 O
% O
+ O
/ O
- O
7 O
. O
1 O
% O
) O
, O
but O
during O
microwave O
- O
assisted O
extraction O
the O
benzoic B
acid I
derivatives O
and O
aglycones O
of O
flavonoids B
showed O
lower O
recovery O
( O
70 O
- O
80 O
% O
) O
. O

In O
honey O
matrix O
, O
the O
phenolic B
acids I
and O
the O
glycosides O
exhibited O
the O
high O
stability O
for O
MAE O
and O
USE O
treatments O
. O

Application O
of O
the O
USE O
conditions O
provided O
higher O
and O
/ O
or O
similar O
extraction O
yields O
for O
phenolic B
acids I
than O
usually O
applied O
shaking O
with O
solvent O
. O

Phenolic B
acids I
and O
glycosides O
such O
as O
quercetrin B
, O
rutin B
and O
hesperidin B
appeared O
to O
be O
stable O
under O
such O
conditions O
. O

A O
novel O
one O
- O
step O
microbial O
transformation O
of O
betulin B
to O
betulinic B
acid I
catalysed O
by O
Cunninghamella O
blakesleeana O
. O

Betulinic B
acid I
and O
its O
derivatives O
are O
potential O
bioactive O
compounds O
present O
in O
nature O
. O

This O
study O
investigated O
the O
biotransformation O
of O
betulin B
to O
betulinic B
acid I
by O
Cunninghamella O
blakesleeana O
cells O
. O

LC O
- O
MS O
analysis O
demonstrated O
that O
betulin B
could O
be O
transformed O
into O
at O
least O
five O
products O
from O
cultured O
C O
. O
blakesleeana O
cells O
, O
among O
which O
betulinic B
acid I
was O
the O
most O
important O
. O

For O
the O
quantitative O
estimation O
of O
triterpenic B
acids I
in O
the O
crude O
extracts O
an O
NMR O
based O
methodology O
was O
used O
and O
compared O
with O
the O
HPLC O
measurements O
, O
both O
applied O
for O
the O
first O
time O
, O
for O
the O
case O
of O
betulinic B
acid I
. O

For O
the O
quantitative O
estimation O
of O
triterpenic B
acids I
in O
the O
crude O
extracts O
an O
NMR O
based O
methodology O
was O
used O
and O
compared O
with O
the O
HPLC O
measurements O
, O
both O
applied O
for O
the O
first O
time O
, O
for O
the O
case O
of O
betulinic B
acid I
. O

Decrease O
of O
RINm5F O
viability O
was O
mediated O
by O
nitric B
oxide I
( O
NO B
) O
- O
induced O
apoptosis O
. O

The O
rosemary O
extract O
developed O
more O
pronounced O
antioxidant O
, O
cytotoxic O
and O
immunomodifying O
activities O
, O
probably O
due O
to O
the O
presence O
of O
betulinic B
acid I
and O
a O
higher O
concentration O
of O
carnosic B
acid I
in O
its O
phytochemical O
profile O
. O

The O
rosemary O
extract O
developed O
more O
pronounced O
antioxidant O
, O
cytotoxic O
and O
immunomodifying O
activities O
, O
probably O
due O
to O
the O
presence O
of O
betulinic B
acid I
and O
a O
higher O
concentration O
of O
carnosic B
acid I
in O
its O
phytochemical O
profile O
. O

Phenylalanine B
ammonia I
lyase O
( O
PAL O
) O
enzyme O
activity O
and O
antioxidant O
properties O
of O
some O
cyanobacteria O
isolates O
. O

HPLC O
analysis O
revealed O
gallic B
acid I
, O
trans B
- I
cinnamic I
acid I
, O
p B
- I
coumaric I
acid I
, O
and O
ferulic B
acid I
as O
the O
main O
compounds O
. O

HPLC O
analysis O
revealed O
gallic B
acid I
, O
trans B
- I
cinnamic I
acid I
, O
p B
- I
coumaric I
acid I
, O
and O
ferulic B
acid I
as O
the O
main O
compounds O
. O

Twenty O
four O
hours O
after O
MIPEF O
treatments O
, O
an O
increase O
was O
observed O
in O
hydroxycinnamic B
acids I
and O
flavanones B
, O
whereas O
flavonols B
, O
coumaric B
and I
ferulic I
acid I
- I
O I
- I
glucoside I
were O
not O
affected O
. O

Amino B
acid I
composition O
, O
antinutrients O
and O
allergens O
in O
the O
peanut O
protein O
fraction O
obtained O
by O
an O
aqueous O
enzymatic O
process O
. O

The O
aqueous O
fraction O
( O
AF O
) O
obtained O
by O
EAE O
had O
a O
better O
essential O
amino B
acid I
profile O
than O
the O
residues O
obtained O
by O
solvent O
extraction O
( O
Rs O
) O
and O
cold O
pressing O
( O
Rc O
) O
. O

Dimethyl B
sulphide I
, O
1 B
- I
penten I
- I
3 I
- I
ol I
, O
1 B
- I
hexen I
- I
3 I
- I
ol I
and O
1 B
- I
octen I
- I
3 I
- I
ol I
increased O
during O
storage O
, O
whereas O
pentanal B
, O
hexanal B
, O
heptanal B
, O
octanal B
and O
3 B
- I
undecen I
- I
2 I
- I
one I
decreased O
. O

In O
the O
mussel O
liquor O
, O
dimethyl B
sulphide I
was O
undetectable O
pre O
- O
storage O
, O
becoming O
detectable O
after O
2 O
days O
, O
and O
a O
large O
increase O
was O
noted O
after O
6 O
days O
. O

The O
contents O
of O
carvacrol B
and O
fumaric B
acid I
in O
the O
methanolic O
- O
water O
extracts O
were O
1119 O
and O
1966mg O
/ O
l O
respectively O
. O

The O
hypocholesterolemic O
effects O
of O
two O
low O
calorie O
structured O
lipids O
( O
SL1 O
and O
SL2 O
) O
containing O
essential O
fatty B
acids I
, O
prepared O
by O
lipase O
catalysed O
interesterification O
of O
ethyl B
behenate I
respectively O
with O
sunflower O
and O
soybean O
oils O
were O
studied O
in O
rats O
and O
rabbits O
. O

The O
hypocholesterolemic O
effects O
of O
two O
low O
calorie O
structured O
lipids O
( O
SL1 O
and O
SL2 O
) O
containing O
essential O
fatty B
acids I
, O
prepared O
by O
lipase O
catalysed O
interesterification O
of O
ethyl B
behenate I
respectively O
with O
sunflower O
and O
soybean O
oils O
were O
studied O
in O
rats O
and O
rabbits O
. O

However O
, O
the O
structured O
lipids O
beneficially O
lowered O
serum O
and O
liver O
lipids O
, O
particularly O
cholesterol B
, O
LDL O
cholesterol B
, O
triglycerides B
and O
also O
maintains O
the O
essential O
fatty B
acid I
status O
in O
serum O
and O
liver O
. O

The O
presence O
of O
lysine B
and O
the O
major O
component O
lauric B
acid I
derivative O
, O
as O
indicated O
by O
electrospray O
ionisation O
- O
mass O
spectrometry O
( O
ESI O
- O
MS O
) O
direct O
infusion O
and O
nuclear O
magnetic O
resonance O
( O
NMR O
) O
spectroscopy O
, O
may O
have O
contributed O
to O
the O
antibacterial O
effect O
of O
purified O
PKC O
fraction O
. O

This O
study O
suggests O
that O
the O
antibacterial O
PKC O
compound O
may O
be O
not O
a O
pure O
peptide O
but O
instead O
a O
peptide O
- O
containing O
compound O
high O
in O
lauric B
acid I
derivative O
. O

Effects O
of O
vitamin B
D I
on O
antigen O
- O
specific O
and O
non O
- O
antigen O
- O
specific O
immune O
modulation O
: O
relevance O
for O
type O
1 O
diabetes O
. O

Vitamin B
D I
is O
a O
fat O
- O
soluble O
precursor O
of O
the O
circulating O
25 B
- I
hydroxyvitamin I
D I
3 I
( O
25 B
( I
OH I
) I
D I
3 I
) O
which O
can O
be O
converted O
by O
the O
1 O
alpha O
- O
hydroxylase O
( O
1 O
alpha O
( O
OH O
) O
ase O
) O
enzyme O
into O
the O
bioactive O
hormonal O
metabolite O
1 B
, I
25 I
- I
dihydroxyvitamin I
D I
3 I
( O
1 B
, I
25 I
( I
OH I
) I
2 I
D I
3 I
) O
, O
generally O
known O
to O
promote O
bone O
mineralization O
through O
its O
ability O
to O
enhance O
calcium B
absorption O
from O
the O
gut O
. O

Importantly O
, O
in O
humans O
, O
vitamin B
D I
is O
mainly O
derived O
from O
endogenous O
production O
of O
vitamin B
D I
3 I
from O
ultraviolet O
( O
UV O
) O
radiation O
exposure O
to O
the O
skin O
while O
a O
small O
part O
( O
< O
10 O
% O
) O
is O
obtained O
via O
dietary O
intake O
of O
dairy O
products O
and O
fatty O
fish O
( O
1 O
) O
. O

Taking O
these O
factors O
into O
account O
, O
geographic O
distribution O
and O
seasonality O
, O
skin O
pigmentation O
, O
age O
, O
and O
lifestyle O
may O
predispose O
certain O
populations O
to O
be O
at O
a O
higher O
risk O
of O
developing O
vitamin B
D I
insufficiency O
or O
deficiency O
( O
2 O
) O
. O

The O
first O
valid O
reports O
correlating O
the O
importance O
of O
an O
adequate O
vitamin B
D I
status O
to O
optimal O
human O
health O
originate O
from O
the O
early O
part O
of O
the O
20th O
century O
, O
when O
vitamin B
D I
was O
described O
to O
prevent O
and O
treat O
the O
bone O
disease O
rickets O
. O

The O
first O
valid O
reports O
correlating O
the O
importance O
of O
an O
adequate O
vitamin B
D I
status O
to O
optimal O
human O
health O
originate O
from O
the O
early O
part O
of O
the O
20th O
century O
, O
when O
vitamin B
D I
was O
described O
to O
prevent O
and O
treat O
the O
bone O
disease O
rickets O
. O

Since O
then O
, O
the O
findings O
that O
vitamin B
D I
receptors O
( O
VDR O
) O
are O
present O
in O
many O
body O
tissues O
and O
that O
vitamin B
D I
metabolizing O
enzymes O
can O
be O
found O
in O
various O
cells O
outside O
the O
kidney O
, O
including O
the O
intestine O
, O
prostate O
, O
immune O
cells O
, O
and O
within O
the O
skin O
itself O
( O
reviewed O
in O
reference O
3 O
) O
, O
have O
revolutionized O
the O
vitamin B
D I
business O
. O

Since O
then O
, O
the O
findings O
that O
vitamin B
D I
receptors O
( O
VDR O
) O
are O
present O
in O
many O
body O
tissues O
and O
that O
vitamin B
D I
metabolizing O
enzymes O
can O
be O
found O
in O
various O
cells O
outside O
the O
kidney O
, O
including O
the O
intestine O
, O
prostate O
, O
immune O
cells O
, O
and O
within O
the O
skin O
itself O
( O
reviewed O
in O
reference O
3 O
) O
, O
have O
revolutionized O
the O
vitamin B
D I
business O
. O

Since O
then O
, O
the O
findings O
that O
vitamin B
D I
receptors O
( O
VDR O
) O
are O
present O
in O
many O
body O
tissues O
and O
that O
vitamin B
D I
metabolizing O
enzymes O
can O
be O
found O
in O
various O
cells O
outside O
the O
kidney O
, O
including O
the O
intestine O
, O
prostate O
, O
immune O
cells O
, O
and O
within O
the O
skin O
itself O
( O
reviewed O
in O
reference O
3 O
) O
, O
have O
revolutionized O
the O
vitamin B
D I
business O
. O

In O
this O
review O
, O
we O
will O
mainly O
focus O
on O
vitamin B
D I
as O
a O
component O
of O
immune O
regulation O
and O
on O
the O
role O
of O
vitamin B
D I
in O
antigen O
- O
specific O
and O
non O
- O
specific O
therapies O
with O
potential O
relevance O
for O
type O
1 O
diabetes O
( O
T1D O
) O
. O

In O
this O
review O
, O
we O
will O
mainly O
focus O
on O
vitamin B
D I
as O
a O
component O
of O
immune O
regulation O
and O
on O
the O
role O
of O
vitamin B
D I
in O
antigen O
- O
specific O
and O
non O
- O
specific O
therapies O
with O
potential O
relevance O
for O
type O
1 O
diabetes O
( O
T1D O
) O
. O

Developmental O
effects O
of O
prenatal O
di B
- I
n I
- I
hexyl I
phthalate I
and O
dicyclohexyl B
phthalate I
exposure O
on O
reproductive O
tract O
of O
male O
rats O
: O
Postnatal O
outcomes O
. O

The O
present O
study O
is O
to O
investigate O
the O
effects O
of O
in O
utero O
di B
- I
n I
- I
hexyl I
phthalate I
( O
DHP B
) O
and O
dicyclohexyl B
phthalate I
exposure O
( O
DCHP B
) O
on O
the O
development O
of O
male O
reproductive O
tract O
at O
prepubertal O
, O
pubertal O
and O
adult O
stages O
. O

The O
organometallic O
chemistry O
of O
cycloheptatrienyl B
zirconium I
complexes O
. O

This O
tutorial O
review O
summarizes O
the O
organometallic O
chemistry O
derived O
from O
the O
half O
- O
sandwich O
complex O
[ O
( B
eta I
( I
7 I
) I
- I
C I
( I
7 I
) I
H I
( I
7 I
) I
) I
ZrCl I
( I
tmeda I
) I
] O
, O
which O
was O
used O
as O
an O
efficient O
and O
versatile O
starting O
material O
for O
the O
incorporation O
of O
monoanionic O
ligands O
into O
the O
cycloheptatrienyl B
zirconium I
coordination O
sphere O
by O
conventional O
salt O
metathesis O
reactions O
. O

Metabolites O
M2 O
and O
M5 O
were O
the O
alcohol B
and O
carboxylic B
acid I
species O
3 B
- I
hydroxypropyl I
- I
phosphinic I
acid I
and O
3 B
- I
hydroxyphosphonoyl I
- I
propanoic I
acid I
, O
respectively O
, O
both O
of O
which O
had O
lost O
the O
fluorine B
atom O
present O
in O
the O
parent O
compound O
. O

M3 O
was O
the O
corresponding O
carboxylic B
acid I
species O
retaining O
the O
fluorine B
atom O
, O
( B
2R I
) I
- I
2 I
- I
fluoro I
- I
3 I
- I
hydroxyphosphonoyl I
- I
propanoic I
acid I
. O

Prenatal O
exposure O
to O
polychlorinated B
biphenyls I
and O
dioxins B
from O
the O
maternal O
diet O
may O
be O
associated O
with O
immunosuppressive O
effects O
that O
persist O
into O
early O
childhood O
. O

We O
investigated O
whether O
prenatal O
exposure O
from O
the O
maternal O
diet O
to O
the O
toxicants O
polychlorinated B
biphenyls I
( O
PCBs B
) O
and O
dioxins B
is O
associated O
with O
the O
development O
of O
immune O
- O
related O
diseases O
in O
childhood O
. O

PC12 O
cell O
apoptosis O
induced O
by O
DBDCT B
was O
confirmed O
by O
annexin O
V O
/ O
propidium B
iodide I
staining O
, O
and O
characterized O
by O
cleavage O
of O
caspase O
- O
9 O
and O
caspase O
- O
3 O
proteins O
. O

Songaricalarins B
A I
- I
E I
, O
cytotoxic O
oplopane B
sesquiterpenes I
from O
Ligularia O
songarica O
. O

Amino B
acid I
residues O
at O
the O
N O
- O
and O
C O
- O
termini O
are O
essential O
for O
the O
folding O
of O
active O
human O
butyrylcholinesteras O
polypeptide O
. O

Sex O
and O
dose O
- O
dependent O
effects O
of O
developmental O
exposure O
to O
bisphenol B
A I
on O
anxiety O
and O
spatial O
learning O
in O
deer O
mice O
( O
Peromyscus O
maniculatus O
bairdii O
) O
offspring O
. O

Bisphenol B
A I
( O
BPA B
) O
is O
a O
widely O
produced O
, O
endocrine O
disrupting O
compound O
that O
is O
pervasive O
in O
the O
environment O
. O

Here O
, O
dams O
during O
gestation O
and O
lactation O
were O
fed O
with O
a O
phytoestrogen O
- O
free O
control O
diet O
, O
the O
same O
diet O
supplemented O
with O
either O
ethinyl B
estradiol I
( O
0 O
. O
1 O
ppb O
) O
, O
or O
one O
of O
the O
three O
doses O
of O
BPA B
( O
50 O
mg O
, O
5 O
mg O
, O
50 O
mu O
g O
/ O
kg O
feed O
weight O
) O
. O

Relative O
to O
controls O
, O
males O
exposed O
to O
the O
two O
upper O
but O
not O
the O
lowest O
dose O
of O
BPA B
demonstrated O
similar O
impairments O
in O
spatial O
learning O
, O
increased O
anxiety O
and O
reduced O
exploratory O
behaviors O
as O
ethinyl B
estradiol I
- O
exposed O
males O
, O
while O
females O
exposed O
to O
ethinyl B
estradiol I
, O
but O
not O
to O
BPA B
, O
consistently O
exhibited O
masculinized O
spatial O
abilities O
. O

Relative O
to O
controls O
, O
males O
exposed O
to O
the O
two O
upper O
but O
not O
the O
lowest O
dose O
of O
BPA B
demonstrated O
similar O
impairments O
in O
spatial O
learning O
, O
increased O
anxiety O
and O
reduced O
exploratory O
behaviors O
as O
ethinyl B
estradiol I
- O
exposed O
males O
, O
while O
females O
exposed O
to O
ethinyl B
estradiol I
, O
but O
not O
to O
BPA B
, O
consistently O
exhibited O
masculinized O
spatial O
abilities O
. O

These O
fabricated O
nanosized O
devices O
have O
typical O
dimensions O
of O
300 O
nm O
( O
diameter O
) O
by O
4 O
. O
5 O
mu O
m O
( O
length O
) O
, O
and O
they O
are O
able O
to O
move O
in O
a O
hydrogen B
peroxide I
fuel O
solution O
with O
velocities O
up O
to O
approximately O
40 O
body O
lengths O
per O
second O
. O

Induction O
of O
miR O
- O
21 O
was O
inhibited O
by O
the O
estrogen B
receptor O
antagonist O
fulvestrant B
, O
by O
androgen B
receptor O
antagonist O
bicalutamide B
, O
by O
actinomycin B
D I
and O
cycloheximide B
, O
and O
by O
inhibitors O
of O
the O
mitogen O
- O
activated O
protein O
kinases O
and O
phosphoinositide B
3 O
- O
kinase O
pathways O
. O

Protein O
expression O
of O
Ugt1a6 O
also O
decreased O
and O
corresponded O
with O
reduced O
in O
vitro O
glucuronidation O
of O
bisphenol B
A I
in O
S9 O
fractions O
from O
livers O
of O
pregnant O
mice O
. O

The O
human O
ether B
- O
a O
- O
go O
- O
go O
- O
related O
gene O
( O
hERG O
) O
is O
a O
K B
+ I
channel O
protein O
mainly O
expressed O
in O
the O
heart O
and O
the O
nervous O
systems O
and O
its O
blockade O
by O
non O
- O
cardiovascular O
acting O
drugs O
resulted O
in O
tachycardia O
and O
sudden O
death O
. O

The O
quinolizidine B
alkaloids I
( O
natural O
products O
) O
such O
as O
oxymatrine B
, O
sophoridine B
, O
sophocarpine B
and O
matrine B
carry O
the O
common O
molecular O
structure O
of O
O B
= I
C I
= I
N I
- I
C I
- I
C I
- I
C I
- I
N I
that O
possessed O
positive O
ionotropic O
effect O
and O
hERG O
blocking O
activity O
. O

Acehytisine B
hydrochloride I
( O
previously O
named O
Guangfu B
base I
A I
) O
was O
isolated O
from O
the O
root O
of O
Aconitum O
coreanum O
( O
Levl O
. O
) O
, O
is O
an O
anti O
- O
arrhythmic O
drug O
in O
phase O
IV O
clinical O
trial O
. O

The O
isoquinoline B
alkaloid I
, O
neferine B
( O
Nef B
) O
induces O
a O
concentration O
- O
dependent O
decrease O
in O
current O
amplitude O
( O
IC50 O
of O
7 O
. O
419 O
MM O
) O
. O

Cells O
were O
exposed O
to O
contact O
allergens O
( O
2 B
- I
bromo I
- I
2 I
- I
bromomethyl I
glutaronitrile I
, O
cinnamaldehyde B
, O
citral B
, O
diethylmaleate B
, O
dinitrochlorobenzene B
, O
glyoxal B
, O
2 B
- I
mercaptobenzothiazol I
, O
nickel B
sulfate I
, O
4 B
- I
nitrobenzylbromide I
, O
oxazolone B
, O
penicillin B
G I
, O
resorcinol B
, O
tetramethylthiuram B
disulfide I
) O
, O
to O
pre O
- O
pro O
- O
haptens O
( O

Cells O
were O
exposed O
to O
contact O
allergens O
( O
2 B
- I
bromo I
- I
2 I
- I
bromomethyl I
glutaronitrile I
, O
cinnamaldehyde B
, O
citral B
, O
diethylmaleate B
, O
dinitrochlorobenzene B
, O
glyoxal B
, O
2 B
- I
mercaptobenzothiazol I
, O
nickel B
sulfate I
, O
4 B
- I
nitrobenzylbromide I
, O
oxazolone B
, O
penicillin B
G I
, O
resorcinol B
, O
tetramethylthiuram B
disulfide I
) O
, O
to O
pre O
- O
pro O
- O
haptens O
( O

Cells O
were O
exposed O
to O
contact O
allergens O
( O
2 B
- I
bromo I
- I
2 I
- I
bromomethyl I
glutaronitrile I
, O
cinnamaldehyde B
, O
citral B
, O
diethylmaleate B
, O
dinitrochlorobenzene B
, O
glyoxal B
, O
2 B
- I
mercaptobenzothiazol I
, O
nickel B
sulfate I
, O
4 B
- I
nitrobenzylbromide I
, O
oxazolone B
, O
penicillin B
G I
, O
resorcinol B
, O
tetramethylthiuram B
disulfide I
) O
, O
to O
pre O
- O
pro O
- O
haptens O
( O

cinnamyl B
alcohol I
, O
eugenol B
, O
isoeugenol B
, O
p B
- I
phenylediamine I
) O
, O
to O
respiratory O
allergens O
( O
ammonium B
hexachloroplatinate I
, O
diphenylmethane B
diisocyanate I
, O
glutaraldehyde B
, O
hexamethylenediisocy B
, O
maleic B
anhydride I
, O
trimellitic B
anhydride I
) O
and O
to O
irritants O
( O
benzaldehyde B
, O
cholorobenzene B
, O
diethylphtalate B
, O
hydrobenzoic B
acid I
, O
lactic B
acid I
, O
octanoic B
acid I
, O

cinnamyl B
alcohol I
, O
eugenol B
, O
isoeugenol B
, O
p B
- I
phenylediamine I
) O
, O
to O
respiratory O
allergens O
( O
ammonium B
hexachloroplatinate I
, O
diphenylmethane B
diisocyanate I
, O
glutaraldehyde B
, O
hexamethylenediisocy B
, O
maleic B
anhydride I
, O
trimellitic B
anhydride I
) O
and O
to O
irritants O
( O
benzaldehyde B
, O
cholorobenzene B
, O
diethylphtalate B
, O
hydrobenzoic B
acid I
, O
lactic B
acid I
, O
octanoic B
acid I
, O

cinnamyl B
alcohol I
, O
eugenol B
, O
isoeugenol B
, O
p B
- I
phenylediamine I
) O
, O
to O
respiratory O
allergens O
( O
ammonium B
hexachloroplatinate I
, O
diphenylmethane B
diisocyanate I
, O
glutaraldehyde B
, O
hexamethylenediisocy B
, O
maleic B
anhydride I
, O
trimellitic B
anhydride I
) O
and O
to O
irritants O
( O
benzaldehyde B
, O
cholorobenzene B
, O
diethylphtalate B
, O
hydrobenzoic B
acid I
, O
lactic B
acid I
, O
octanoic B
acid I
, O

cinnamyl B
alcohol I
, O
eugenol B
, O
isoeugenol B
, O
p B
- I
phenylediamine I
) O
, O
to O
respiratory O
allergens O
( O
ammonium B
hexachloroplatinate I
, O
diphenylmethane B
diisocyanate I
, O
glutaraldehyde B
, O
hexamethylenediisocy B
, O
maleic B
anhydride I
, O
trimellitic B
anhydride I
) O
and O
to O
irritants O
( O
benzaldehyde B
, O
cholorobenzene B
, O
diethylphtalate B
, O
hydrobenzoic B
acid I
, O
lactic B
acid I
, O
octanoic B
acid I
, O

cinnamyl B
alcohol I
, O
eugenol B
, O
isoeugenol B
, O
p B
- I
phenylediamine I
) O
, O
to O
respiratory O
allergens O
( O
ammonium B
hexachloroplatinate I
, O
diphenylmethane B
diisocyanate I
, O
glutaraldehyde B
, O
hexamethylenediisocy B
, O
maleic B
anhydride I
, O
trimellitic B
anhydride I
) O
and O
to O
irritants O
( O
benzaldehyde B
, O
cholorobenzene B
, O
diethylphtalate B
, O
hydrobenzoic B
acid I
, O
lactic B
acid I
, O
octanoic B
acid I
, O

cinnamyl B
alcohol I
, O
eugenol B
, O
isoeugenol B
, O
p B
- I
phenylediamine I
) O
, O
to O
respiratory O
allergens O
( O
ammonium B
hexachloroplatinate I
, O
diphenylmethane B
diisocyanate I
, O
glutaraldehyde B
, O
hexamethylenediisocy B
, O
maleic B
anhydride I
, O
trimellitic B
anhydride I
) O
and O
to O
irritants O
( O
benzaldehyde B
, O
cholorobenzene B
, O
diethylphtalate B
, O
hydrobenzoic B
acid I
, O
lactic B
acid I
, O
octanoic B
acid I
, O

cinnamyl B
alcohol I
, O
eugenol B
, O
isoeugenol B
, O
p B
- I
phenylediamine I
) O
, O
to O
respiratory O
allergens O
( O
ammonium B
hexachloroplatinate I
, O
diphenylmethane B
diisocyanate I
, O
glutaraldehyde B
, O
hexamethylenediisocy B
, O
maleic B
anhydride I
, O
trimellitic B
anhydride I
) O
and O
to O
irritants O
( O
benzaldehyde B
, O
cholorobenzene B
, O
diethylphtalate B
, O
hydrobenzoic B
acid I
, O
lactic B
acid I
, O
octanoic B
acid I
, O

cinnamyl B
alcohol I
, O
eugenol B
, O
isoeugenol B
, O
p B
- I
phenylediamine I
) O
, O
to O
respiratory O
allergens O
( O
ammonium B
hexachloroplatinate I
, O
diphenylmethane B
diisocyanate I
, O
glutaraldehyde B
, O
hexamethylenediisocy B
, O
maleic B
anhydride I
, O
trimellitic B
anhydride I
) O
and O
to O
irritants O
( O
benzaldehyde B
, O
cholorobenzene B
, O
diethylphtalate B
, O
hydrobenzoic B
acid I
, O
lactic B
acid I
, O
octanoic B
acid I
, O

phenol B
, O
salicylic B
acid I
, O
sodium B
lauryl I
sulphate I
, O
sulfamic B
acid I
) O
. O

phenol B
, O
salicylic B
acid I
, O
sodium B
lauryl I
sulphate I
, O
sulfamic B
acid I
) O
. O

At O
not O
- O
cytotoxic O
concentrations O
( O
cell O
viability O
higher O
of O
80 O
% O
, O
as O
assessed O
by O
MTT B
reduction O
assay O
) O
, O
all O
contact O
sensitizers O
, O
including O
pre O
- O
pro O
- O
haptens O
, O
induced O
a O
dose O
- O
related O
increase O
in O
IL O
- O
18 O
, O
whereas O
both O
irritants O
, O
with O
the O
exception O
of O
sulfamic B
acid I
, O
and O
respiratory O
allergens O
failed O
. O

Assay O
of O
vtg O
, O
ERs O
and O
PPARs O
as O
endpoint O
for O
the O
rapid O
in O
vitro O
screening O
of O
the O
harmful O
effect O
of O
Di B
- I
( I
2 I
- I
ethylhexyl I
) I
- I
phthalate I
( O
DEHP B
) O
and O
phthalic B
acid I
( O
PA O
) O
in O
zebrafish O
primary O
hepatocyte O
cultures O
. O

Considering O
that O
, O
at O
date O
data O
available O
dealing O
with O
the O
adverse O
outcome O
of O
Di B
- I
( I
2 I
- I
ethylhexyl I
) I
- I
phthalate I
( O
DEHP B
) O
on O
the O
reproduction O
of O
several O
species O
are O
still O
contrasting O
, O
in O
this O
study O
, O
the O
effects O
induced O
by O
DEHP B
( O
0 O
. O
05 O
, O
0 O
. O
1 O
, O
1 O
, O
10 O
and O
100 O
nM O
) O
and O
its O
active O
metabolite O
, O
phthalic B
acid I
( O
PA O
) O
( O
0 O
. O
01 O
, O
0 O
. O
1 O
, O
1 O
and O
10 O
mu O
M O
) O
, O
were O
analyzed O
in O
zebrafish O
, O
Danio O
rerio O
, O
primary O
hepatocyte O
cultures O
, O
using O
target O
molecules O

Vitamin B
D I
is O
an O
important O
regulator O
of O
bone O
health O
. O

Previous O
studies O
examining O
the O
association O
between O
vitamin B
D I
deficiency O
and O
osteoporotic O
fractures O
have O
reported O
conflicting O
results O
. O

The O
relationship O
between O
vitamin B
D I
status O
and O
risk O
of O
vertebral O
fractures O
in O
diabetic O
patients O
is O
unknown O
. O

However O
, O
there O
was O
no O
significant O
association O
between O
vitamin B
D I
status O
and O
the O
prevalence O
of O
vertebral O
fractures O
in O
women O
( O
14 O
. O
4 O
% O
vs O
. O
19 O
. O
2 O
% O
vs O
. O
26 O
. O
6 O
% O
, O
p O
for O
trend O
= O
0 O
. O
111 O
) O
. O

The O
potentiation O
of O
heteromeric O
KARs O
by O
mGlu1 O
activation O
was O
attenuated O
by O
GDP O
beta O
S O
, O
blocked O
by O
an O
inhibitor O
of O
phospholipase O
C O
or O
the O
calcium B
chelator O
1 B
, I
2 I
- I
bis I
( I
o I
- I
aminophenoxy I
) I
ethane I
- I
N I
, I
N I
, I
N I
' I
, I
N I
' I
- I
tetraacetic I
acid I
( O
BAPTA B
) O
, O
prolonged O
by O
the O
phosphatase O
inhibitor O
okadaic B
acid I
, O
but O
unaffected O
by O
the O
tyrosine B
kinase O
inhibitor O
lavendustin B
A I
. O

The O
potentiation O
of O
heteromeric O
KARs O
by O
mGlu1 O
activation O
was O
attenuated O
by O
GDP O
beta O
S O
, O
blocked O
by O
an O
inhibitor O
of O
phospholipase O
C O
or O
the O
calcium B
chelator O
1 B
, I
2 I
- I
bis I
( I
o I
- I
aminophenoxy I
) I
ethane I
- I
N I
, I
N I
, I
N I
' I
, I
N I
' I
- I
tetraacetic I
acid I
( O
BAPTA B
) O
, O
prolonged O
by O
the O
phosphatase O
inhibitor O
okadaic B
acid I
, O
but O
unaffected O
by O
the O
tyrosine B
kinase O
inhibitor O
lavendustin B
A I
. O

Cell O
treatment O
with O
the O
nuclear O
export O
inhibitor O
leptomycin B
B I
did O
not O
prevent O
AM251 B
- O
induced O
destabilization O
of O
ERR O
alpha O
protein O
, O
whereas O
proteasome O
inhibition O
with O
MG132 B
stabilized O
and O
maintained O
its O
DNA O
- O
binding O
function O
, O
indicative O
of O
ERR O
alpha O
being O
a O
target O
of O
nuclear O
proteasomal O
complexes O
. O

AM251 B
induced O
SUMO O
- O
2 O
, O
3 O
incorporation O
in O
ERR O
alpha O
in O
conjunction O
with O
increased O
protein O
kinase O
C O
activity O
, O
whose O
activation O
by O
phorbol B
ester I
also O
promoted O
ERR O
alpha O
protein O
loss O
. O

To O
test O
whether O
Metformin B
directly O
affects O
ghrelin O
cells O
, O
rat O
primary O
stomach O
cells O
were O
treated O
with O
Metformin B
and O
the O
levels O
of O
ghrelin O
secretion O
, O
proghrelin O
gene O
expression O
and O
activation O
of O
adenosine B
monophosphate I
- O
activated O
protein O
kinase O
( O
AMPK O
) O
were O
examined O
. O

Metformin B
significantly O
reduced O
ghrelin O
secretion O
and O
proghrelin O
mRNA O
production O
and O
both O
these O
effects O
were O
blocked O
by O
co O
- O
incubation O
with O
the O
AMPK O
inhibitor O
compound B
C I
. O

Voluntary O
exercise O
does O
not O
ameliorate O
spatial O
learning O
and O
memory O
deficits O
induced O
by O
chronic O
administration O
of O
nandrolone B
decanoate I
in O
rats O
. O

Chronic O
exposure O
to O
the O
anabolic O
androgenic O
steroids B
( O
AAS O
) O
nandrolone B
decanoate I
( O
ND O
) O
in O
supra O
- O
physiological O
doses O
is O
associated O
with O
learning O
and O
memory O
impairments O
. O

Perfluorooctane B
sulfonate I
( O
PFOS B
) O
affects O
hormone O
receptor O
activity O
, O
steroidogenesis O
, O
and O
expression O
of O
endocrine O
- O
related O
genes O
in O
vitro O
and O
in O
vivo O
. O

Perfluorooctane B
sulfonate I
( O
PFOS B
) O
is O
a O
widespread O
and O
persistent O
chemical O
in O
the O
environment O
. O

Reporter O
gene O
assays O
were O
used O
to O
detect O
receptor O
- O
mediated O
( O
anti O
- O
) O
estrogenic O
, O
( O
anti O
- O
) O
androgenic O
, O
and O
( O
anti O
- O
) O
thyroid B
hormone I
activities O
. O

The O
results O
indicate O
that O
PFOS B
can O
act O
as O
an O
estrogen B
receptor O
agonist O
and O
thyroid B
hormone I
receptor O
antagonist O
. O

Bis B
( I
12 I
) I
- I
hupyridone I
( O
B12H B
) O
, O
derived O
from O
the O
Chinese O
medicinal O
component O
huperzine B
A I
, O
was O
originally O
designed O
as O
a O
novel O
acetylcholinesterase O
( O
AChE O
) O
inhibitor O
. O

Fetal O
muscle O
- O
type O
nicotinic O
acetylcholine B
receptor O
activation O
in O
TE O
- O
671 O
cells O
and O
inhibition O
of O
fetal O
movement O
in O
a O
day O
40 O
pregnant O
goat O
model O
by O
optical O
isomers O
of O
the O
piperidine B
alkaloid I
coniine B
. O

Coniine B
is O
an O
optically O
active O
toxic O
piperidine B
alkaloid I
and O
nicotinic O
acetylcholine B
receptor O
( O
nAChR O
) O
agonist O
found O
in O
poison O
hemlock O
( O
Conium O
maculatum O
L O
. O
) O
. O

The O
pyridine B
alkaloid I
nicotine B
did O
not O
inhibit O
fetal O
movement O
in O
a O
day O
40 O
pregnant O
goat O
model O
, O
suggesting O
agonist O
specificity O
for O
the O
inhibition O
of O
fetal O
movement O
. O

These O
results O
provide O
pharmacological O
evidence O
that O
the O
piperidine B
alkaloid I
coniine B
is O
acting O
at O
fetal O
muscle O
- O
type O
nAChR O
in O
a O
concentration O
- O
dependent O
manner O
. O

UV O
- O
B O
radiation O
led O
to O
the O
inhibition O
in O
the O
activities O
of O
the O
key O
enzymes O
( O
nitrate B
reductase O
, O
glutamine B
synthetase O
, O
glutamate B
synthase O
) O
in O
the O
nitrogen B
assimilation O
, O
the O
decrease O
in O
the O
contents O
of O
nitrate B
and O
soluble O
proteins O
, O
as O
well O
as O
the O
increase O
in O
the O
content O
of O
amino B
acid I
in O
soybean O
seedlings O
. O

The O
pretreatment O
with O
20 O
mg O
L O
( O
- O
1 O
) O
La B
( I
III I
) I
could O
alleviate O
the O
effects O
of O
UV O
- O
B O
radiation O
on O
the O
activities O
of O
nitrate B
reductase O
, O
glutamine B
synthetase O
, O
glutamate B
synthase O
, O
and O
glutamate B
dehydrogenase O
, O
promoting O
amino B
acid I
conversion O
and O
protein O
synthesis O
in O
soybean O
seedlings O
. O

2 B
- I
Bromopalmitate I
( O
2 B
- I
BP I
) O
, O
a O
known O
inhibitor O
of O
protein O
palmitoylation O
, O
markedly O
attenuated O
cytokine O
- O
induced O
, O
Nox2 O
- O
mediated O
reactive O
oxygen B
species O
( O
ROS O
) O
generation O
and O
inducible O
nitric B
oxide I
synthase O
( O
iNOS O
) O
- O
mediated O
nitric B
oxide I
( O
NO B
) O
generation O
. O

2 B
- I
Bromopalmitate I
( O
2 B
- I
BP I
) O
, O
a O
known O
inhibitor O
of O
protein O
palmitoylation O
, O
markedly O
attenuated O
cytokine O
- O
induced O
, O
Nox2 O
- O
mediated O
reactive O
oxygen B
species O
( O
ROS O
) O
generation O
and O
inducible O
nitric B
oxide I
synthase O
( O
iNOS O
) O
- O
mediated O
nitric B
oxide I
( O
NO B
) O
generation O
. O

Single O
molecule O
conductance O
measurements O
on O
alkanedithiols B
and O
alkoxydithiols B
( O
dithiolated B
oligoethers I
) O
were O
performed O
using O
the O
STM O
- O
controlled O
break O
junction O
method O
in O
order O
to O
ascertain O
how O
the O
oxygen B
heteroatoms O
in O
saturated O
linear O
chains O
impact O
the O
molecular O
conductance O
. O

Efficacy O
of O
asiatic B
acid I
, O
a O
pentacyclic B
triterpene I
on O
attenuating O
the O
key O
enzymes O
activities O
of O
carbohydrate B
metabolism O
in O
streptozotocin B
- O
induced O
diabetic O
rats O
. O

Efficacy O
of O
asiatic B
acid I
, O
a O
pentacyclic B
triterpene I
on O
attenuating O
the O
key O
enzymes O
activities O
of O
carbohydrate B
metabolism O
in O
streptozotocin B
- O
induced O
diabetic O
rats O
. O

Asiatic B
acid I
( O
AA O
) O
, O
a O
triterpenoid B
derivative O
of O
Centella O
asiatica O
, O
has O
shown O
significant O
biological O
effects O
of O
antioxidant O
and O
anti O
- O
inflammatory O
activities O
. O

In O
vitro O
metabolism O
, O
permeation O
, O
and O
brain O
availability O
of O
six O
major O
boswellic B
acids I
from O
Boswellia O
serrata O
gum O
resins O
. O

Therefore O
pharmacokinetic O
and O
pharmacodynamic O
studies O
focused O
mainly O
on O
these O
two O
boswellic B
acids I
( O
BAs O
) O
. O

However O
, O
other O
BAs O
, O
like O
beta B
- I
boswellic I
acid I
( O
beta B
BA I
) O
, O
might O
also O
contribute O
to O
the O
anti O
- O
inflammatory O
actions O
of O
BSE O
. O

Here O
, O
we O
determined O
the O
metabolic O
stability O
, O
permeability O
and O
brain O
availability O
of O
six O
major O
BAs O
, O
that O
is O
, O
KBA B
, O
AKBA B
, O
beta B
BA I
, O
3 B
- I
acetyl I
- I
beta I
- I
boswellic I
acid I
( O
A B
beta I
BA I
) O
, O
alpha B
- I
boswellic I
acid I
( O
alpha B
BA I
) O
, O
and O
3 B
- I
acetyl I
- I
alpha I
- I
boswellic I
acid I
( O
A B
alpha I
BA I
) O
. O

Here O
, O
we O
determined O
the O
metabolic O
stability O
, O
permeability O
and O
brain O
availability O
of O
six O
major O
BAs O
, O
that O
is O
, O
KBA B
, O
AKBA B
, O
beta B
BA I
, O
3 B
- I
acetyl I
- I
beta I
- I
boswellic I
acid I
( O
A B
beta I
BA I
) O
, O
alpha B
- I
boswellic I
acid I
( O
alpha B
BA I
) O
, O
and O
3 B
- I
acetyl I
- I
alpha I
- I
boswellic I
acid I
( O
A B
alpha I
BA I
) O
. O

In O
contrast O
to O
A B
alpha I
- I
and I
A I
beta I
BA I
, O
beta B
BA I
and O
alpha B
BA I
were O
intensively O
metabolized O
after O
incubation O
with O
human O
and O
rat O
liver O
microsomes O
. O

In O
contrast O
to O
A B
alpha I
- I
and I
A I
beta I
BA I
, O
beta B
BA I
and O
alpha B
BA I
were O
intensively O
metabolized O
after O
incubation O
with O
human O
and O
rat O
liver O
microsomes O
. O

Finally O
, O
the O
availability O
of O
all O
six O
major O
BAs O
could O
be O
confirmed O
in O
rat O
brain O
8h O
after O
oral O
administration O
of O
240mg O
/ O
kg O
BSE O
to O
rats O
showing O
mean O
concentrations O
of O
11 O
. O
6ng O
/ O
g O
for O
KBA B
, O
37 O
. O
5ng O
/ O
g O
for O
AKBA B
, O
485 O
. O
1ng O
/ O
g O
for O
alpha B
BA I
, O
1066 O
. O
6ng O
/ O
g O
for O
beta B
BA I
, O
43 O
. O
0ng O
/ O
g O
for O
A B
alpha I
BA I
and O
163 O
. O
7ng O
/ O
g O
for O
A B
beta I
BA I
. O

Finally O
, O
the O
availability O
of O
all O
six O
major O
BAs O
could O
be O
confirmed O
in O
rat O
brain O
8h O
after O
oral O
administration O
of O
240mg O
/ O
kg O
BSE O
to O
rats O
showing O
mean O
concentrations O
of O
11 O
. O
6ng O
/ O
g O
for O
KBA B
, O
37 O
. O
5ng O
/ O
g O
for O
AKBA B
, O
485 O
. O
1ng O
/ O
g O
for O
alpha B
BA I
, O
1066 O
. O
6ng O
/ O
g O
for O
beta B
BA I
, O
43 O
. O
0ng O
/ O
g O
for O
A B
alpha I
BA I
and O
163 O
. O
7ng O
/ O
g O
for O
A B
beta I
BA I
. O

Local O
infusion O
of O
100 O
mM O
potassium B
chloride I
into O
the O
mPFC O
also O
stimulated O
greater O
serotonin B
efflux O
in O
adult O
rats O
. O

Arsenic B
trioxide I
- O
induced O
hERG O
K B
( I
+ I
) I
channel O
deficiency O
can O
be O
rescued O
by O
matrine B
and O
oxymatrine B
through O
up O
- O
regulating O
transcription O
factor O
Sp1 O
expression O
. O

Arsenic B
trioxide I
( O
As B
( I
2 I
) I
O I
( I
3 I
) I
) O
, O
which O
is O
used O
to O
treat O
acute O
promyelocytic O
leukemia O
, O
can O
cause O
LQTS O
type O
2 O
( O
LQT2 O
) O
by O
reducing O
the O
hERG O
current O
through O
the O
diversion O
of O
hERG O
trafficking O
to O
the O
cytoplasmic O
membrane O
. O

Interorgan O
metabolism O
of O
ornithine B
phenylacetate I
( O
OP O
) O
- O
- O
a O
novel O
strategy O
for O
treatment O
of O
hyperammonemia O
. O

[ B
2 I
, I
5 I
- I
( I
15 I
) I
N I
] I
Ornithine I
or O
( B
15 I
) I
NH I
( I
4 I
) I
( I
+ I
) I
were O
administered O
intravenously O
and O
the O
incorporation O
of O
( B
15 I
) I
N I
in O
amino B
acids I
as O
well O
as O
the O
content O
of O
the O
amino B
acids I
were O
subsequently O
determined O
in O
plasma O
, O
skeletal O
muscle O
, O
liver O
and O
kidney O
. O

[ B
2 I
, I
5 I
- I
( I
15 I
) I
N I
] I
Ornithine I
or O
( B
15 I
) I
NH I
( I
4 I
) I
( I
+ I
) I
were O
administered O
intravenously O
and O
the O
incorporation O
of O
( B
15 I
) I
N I
in O
amino B
acids I
as O
well O
as O
the O
content O
of O
the O
amino B
acids I
were O
subsequently O
determined O
in O
plasma O
, O
skeletal O
muscle O
, O
liver O
and O
kidney O
. O

To O
this O
end O
, O
protein O
lysates O
of O
human O
podocytes O
were O
treated O
with O
or O
without O
hydrogen B
peroxide I
( O
250 O
mu O
M O
) O
. O

Chloroacetic B
acid I
induced O
neuronal O
cells O
death O
through O
oxidative O
stress O
- O
mediated O
p38 O
- O
MAPK O
activation O
pathway O
regulated O
mitochondria O
- O
dependent O
apoptotic O
signals O
. O

Chloroacetic B
acid I
( O
CA O
) O
, O
a O
toxic O
chlorinated O
analog O
of O
acetic B
acid I
, O
is O
widely O
used O
in O
chemical O
industries O
as O
an O
herbicide O
, O
detergent O
, O
and O
disinfectant O
, O
and O
chemical O
intermediates O
that O
are O
formed O
during O
the O
synthesis O
of O
various O
products O
. O

Chloroacetic B
acid I
( O
CA O
) O
, O
a O
toxic O
chlorinated O
analog O
of O
acetic B
acid I
, O
is O
widely O
used O
in O
chemical O
industries O
as O
an O
herbicide O
, O
detergent O
, O
and O
disinfectant O
, O
and O
chemical O
intermediates O
that O
are O
formed O
during O
the O
synthesis O
of O
various O
products O
. O

Active O
self O
- O
healing O
encapsulation O
of O
two O
antigens O
, O
ovalbumin O
and O
tetanus O
toxoid O
( O
TT O
) O
, O
in O
PLGA B
microspheres O
was O
adjusted O
by O
preparing O
blank O
microspheres O
containing O
different O
vaccine O
adjuvants O
( O
aluminum B
hydroxide I
( O
Al B
( I
OH I
) I
3 I
) O
or O
calcium B
phosphate I
) O
. O

Active O
self O
- O
healing O
encapsulation O
of O
two O
antigens O
, O
ovalbumin O
and O
tetanus O
toxoid O
( O
TT O
) O
, O
in O
PLGA B
microspheres O
was O
adjusted O
by O
preparing O
blank O
microspheres O
containing O
different O
vaccine O
adjuvants O
( O
aluminum B
hydroxide I
( O
Al B
( I
OH I
) I
3 I
) O
or O
calcium B
phosphate I
) O
. O

Effects O
of O
Korean O
red O
ginseng O
extracts O
on O
neural O
tube O
defects O
and O
impairment O
of O
social O
interaction O
induced O
by O
prenatal O
exposure O
to O
valproic B
acid I
. O

Using O
the O
prenatal O
valproic B
acid I
( O
VPA B
) O
- O
injection O
model O
of O
autism O
spectrum O
disorder O
( O
ASD O
) O
in O
rats O
, O
which O
produces O
social O
impairrment O
and O
altered O
seizure O
susceptibility O
as O
in O
human O
ASD O
patients O
as O
well O
as O
mild O
neural O
tube O
defects O
like O
crooked O
tail O
phenotype O
, O
we O
examined O
whether O
chronic O
administration O
of O
red O
ginseng O
extract O
may O
rescue O
the O
social O
impairment O
and O
crooked O
tail O
phenotype O
in O
prenatally O
VPA B
- O
exposed O
rat O
offspring O
. O

Rat O
aortic O
VSMC O
were O
treated O
with O
1 O
- O
100 O
micro O
M O
of O
either O
sodium B
arsenate I
( O
As B
( I
V I
) I
) O
, O
sodium B
arsenite I
( O
As B
( I
III I
) I
) O
, O
monomethylarsonic B
acid I
, O
or O
dimethylarsinic B
acid I
. O

Rat O
aortic O
VSMC O
were O
treated O
with O
1 O
- O
100 O
micro O
M O
of O
either O
sodium B
arsenate I
( O
As B
( I
V I
) I
) O
, O
sodium B
arsenite I
( O
As B
( I
III I
) I
) O
, O
monomethylarsonic B
acid I
, O
or O
dimethylarsinic B
acid I
. O

Rat O
aortic O
VSMC O
were O
treated O
with O
1 O
- O
100 O
micro O
M O
of O
either O
sodium B
arsenate I
( O
As B
( I
V I
) I
) O
, O
sodium B
arsenite I
( O
As B
( I
III I
) I
) O
, O
monomethylarsonic B
acid I
, O
or O
dimethylarsinic B
acid I
. O

Rat O
aortic O
VSMC O
were O
treated O
with O
1 O
- O
100 O
micro O
M O
of O
either O
sodium B
arsenate I
( O
As B
( I
V I
) I
) O
, O
sodium B
arsenite I
( O
As B
( I
III I
) I
) O
, O
monomethylarsonic B
acid I
, O
or O
dimethylarsinic B
acid I
. O

Enantioselective O
hydrolysis O
of O
oral O
racemic B
methylphenidate I
( O
dl B
- I
MPH I
) O
by O
carboxylesterase O
1 O
( O
CES1 O
) O
limits O
the O
absolute O
bioavailability O
of O
the O
pharmacologically O
active O
d B
- I
MPH I
isomer O
to O
approximately O
30 O
% O
and O
that O
of O
the O
inactive O
l B
- I
MPH I
to O
only O
1 O
- O
2 O
% O
. O

Effects O
of O
bisphenol B
A I
on O
growth O
and O
nitrogen B
nutrition O
of O
roots O
of O
soybean O
seedlings O
. O

Bisphenol B
A I
( O
BPA B
) O
is O
an O
environmental O
endocrine O
disruptor O
that O
seriously O
threatens O
ecological O
systems O
. O

Cell O
apoptosis O
induced O
by O
TSN B
was O
confirmed O
by O
Annexin O
V O
- O
FITC B
/ O
propidium B
iodide I
staining O
. O

Nano O
- O
titanium B
dioxide I
induces O
genotoxicity O
and O
apoptosis O
in O
human O
lung O
cancer O
cell O
line O
, O
A549 O
. O

The O
increased O
inhaled O
application O
of O
titanium B
dioxide I
nanoparticles O
( O
TiO B
( I
2 I
) I
NPs O
) O
increases O
the O
potential O
pulmonary O
health O
risks O
. O

Platycodin B
D I
attenuates O
bile O
duct O
ligation O
- O
induced O
hepatic O
injury O
and O
fibrosis O
in O
mice O
. O

Platycodin B
D I
( O
PD O
) O
is O
the O
major O
triterpene B
saponin I
in O
the O
root O
of O
Platycodon O
grandiflorum O
. O

Platycodin B
D I
( O
PD O
) O
is O
the O
major O
triterpene B
saponin I
in O
the O
root O
of O
Platycodon O
grandiflorum O
. O

PD O
treatment O
attenuated O
oxidative O
stress O
, O
as O
evidenced O
by O
an O
increase O
in O
anti O
- O
oxidative O
enzyme O
levels O
glutathione B
and O
superoxide B
dismutase O
together O
with O
a O
decrease O
in O
lipid O
peroxidation O
and O
oxidative O
stress O
indices O
levels O
of O
malondialdehyde B
and O
nitric B
oxide I
. O

In O
addition O
, O
nuclear O
factor O
- O
kappa O
B O
and O
inducible O
nitric B
oxide I
synthase O
levels O
significantly O
decreased O
after O
PD O
treatment O
, O
as O
did O
the O
levels O
of O
hepatocyte O
apoptosis O
. O

In O
NTERA O
cells O
treated O
with O
the O
histone O
deacetylase O
inhibitors O
SAHA B
and O
valproic B
acid I
, O
a O
significant O
increase O
in O
NIS O
mRNA O
( O
about O
60 O
- O
and O
30 O
- O
fold O
vs O
control O
, O
P O
< O
0 O
. O
001 O
and O
P O
< O
0 O
. O
01 O
respectively O
) O
and O
protein O
levels O
, O
resulting O
in O
enhanced O
ability O
to O
uptake O
radioiodine B
, O
was O
observed O
. O

Mapping O
of O
Saccharomyces O
cerevisiae O
metabolites O
in O
fermenting O
wheat O
straight O
- O
dough O
reveals O
succinic B
acid I
as O
pH O
- O
determining O
factor O
. O

Ethanol B
and O
carbon B
dioxide I
concentrations O
reached O
up O
to O
60 O
mmol O
/ O
100g O
flour O
. O

Interestingly O
, O
high O
levels O
of O
glycerol B
( O
up O
to O
10 O
mmol O
/ O
100g O
flour O
) O
and O
succinic B
acid I
( O
up O
to O
1 O
. O
6 O
mmol O
/ O
100g O
flour O
) O
were O
produced O
during O
dough O
fermentation O
. O

Further O
tests O
showed O
that O
, O
contrary O
to O
current O
belief O
, O
the O
pH O
decrease O
in O
fermenting O
dough O
is O
primarily O
caused O
by O
the O
production O
of O
succinic B
acid I
by O
the O
yeast O
instead O
of O
carbon B
dioxide I
dissolution O
or O
bacterial O
organic O
acids O
. O

Further O
tests O
showed O
that O
, O
contrary O
to O
current O
belief O
, O
the O
pH O
decrease O
in O
fermenting O
dough O
is O
primarily O
caused O
by O
the O
production O
of O
succinic B
acid I
by O
the O
yeast O
instead O
of O
carbon B
dioxide I
dissolution O
or O
bacterial O
organic O
acids O
. O

A O
two O
- O
phase O
solvent O
system O
consisted O
of O
n B
- I
hexane I
- O
ethyl B
acetate I
- O
methanol B
- O
water O
( O
35 O
: O
100 O
: O
35 O
: O
100 O
, O
v O
/ O
v O
/ O
v O
/ O
v O
) O
was O
applied O
. O

The O
upper O
detergent O
- O
poor O
phase O
extract O
was O
subsequently O
fractionated O
by O
40 O
- O
80 O
% O
ammonium B
sulfate I
and O
chromatographed O
on O
HiTrap O
Phenyl B
Sepharose O
and O
Superdex O
200 O
HR O
10 O
/ O
30 O
. O

Among O
the O
chemical O
inhibitors O
tested O
, O
l B
- I
cysteine I
showed O
the O
best O
inhibitory O
effect O
, O
with O
an O
IC O
( O
50 O
) O
of O
1 O
. O
3 O
+ O
/ O
- O
0 O
. O
002 O
mM O
followed O
by O
ascorbic B
acid I
( O
1 O
. O
5 O
+ O
/ O
- O
0 O
. O
06 O
mM O
) O
, O
glutathione B
( O
1 O
. O
5 O
+ O
/ O
- O
0 O
. O
07 O
mM O
) O
, O
EDTA B
( O
100 O
+ O
/ O
- O
0 O
. O
02 O
mM O
) O
and O
citric B
acid I
( O
186 O
+ O
/ O
- O
0 O
. O
16 O
mM O
) O
. O

Among O
the O
chemical O
inhibitors O
tested O
, O
l B
- I
cysteine I
showed O
the O
best O
inhibitory O
effect O
, O
with O
an O
IC O
( O
50 O
) O
of O
1 O
. O
3 O
+ O
/ O
- O
0 O
. O
002 O
mM O
followed O
by O
ascorbic B
acid I
( O
1 O
. O
5 O
+ O
/ O
- O
0 O
. O
06 O
mM O
) O
, O
glutathione B
( O
1 O
. O
5 O
+ O
/ O
- O
0 O
. O
07 O
mM O
) O
, O
EDTA B
( O
100 O
+ O
/ O
- O
0 O
. O
02 O
mM O
) O
and O
citric B
acid I
( O
186 O
+ O
/ O
- O
0 O
. O
16 O
mM O
) O
. O

Toona O
sinensis O
and O
its O
major O
bioactive O
compound O
gallic B
acid I
inhibit O
LPS O
- O
induced O
inflammation O
in O
nuclear O
factor O
- O
kappa O
B O
transgenic O
mice O
as O
evaluated O
by O
in O
vivo O
bioluminescence O
imaging O
. O

In O
the O
present O
study O
, O
we O
investigated O
the O
anti O
- O
inflammatory O
effects O
of O
a O
nutritious O
vegetable O
Toona O
sinensis O
( O
leaf O
extracts O
, O
TS O
) O
and O
its O
major O
bioactive O
compound O
gallic B
acid I
( O
GA O
) O
by O
analysing O
LPS O
- O
induced O
NF O
- O
kappa O
B O
activation O
in O
transgenic O
mice O
, O
using O
bioluminescence O
imaging O
. O

Ciprofloxacin B
( O
CIP B
) O
, O
danofloxacin B
( O
DAN B
) O
, O
enrofloxacin B
( O
ENR B
) O
, O
sarafloxacin B
( O
SAR B
) O
, O
oxolinic B
acid I
( O
OXO B
) O
, O
nalidixic B
acid I
( O
NAL B
) O
and O
flumequine B
( O
FLU B
) O
were O
separated O
on O
a O
Perfectsil O
ODS O
- O
2 O
120 O
( O
250 O
mm O
x O
4 O
mm O
, O
5 O
mu O
m O
) O
column O
by O
gradient O
elution O
with O
a O
mobile O
phase O
consisting O
of O
0 O
. O
1 O
% O
trifluoroacetic B
acid I
( O
pH O
= O
1 O
) O

Ciprofloxacin B
( O
CIP B
) O
, O
danofloxacin B
( O
DAN B
) O
, O
enrofloxacin B
( O
ENR B
) O
, O
sarafloxacin B
( O
SAR B
) O
, O
oxolinic B
acid I
( O
OXO B
) O
, O
nalidixic B
acid I
( O
NAL B
) O
and O
flumequine B
( O
FLU B
) O
were O
separated O
on O
a O
Perfectsil O
ODS O
- O
2 O
120 O
( O
250 O
mm O
x O
4 O
mm O
, O
5 O
mu O
m O
) O
column O
by O
gradient O
elution O
with O
a O
mobile O
phase O
consisting O
of O
0 O
. O
1 O
% O
trifluoroacetic B
acid I
( O
pH O
= O
1 O
) O

Ciprofloxacin B
( O
CIP B
) O
, O
danofloxacin B
( O
DAN B
) O
, O
enrofloxacin B
( O
ENR B
) O
, O
sarafloxacin B
( O
SAR B
) O
, O
oxolinic B
acid I
( O
OXO B
) O
, O
nalidixic B
acid I
( O
NAL B
) O
and O
flumequine B
( O
FLU B
) O
were O
separated O
on O
a O
Perfectsil O
ODS O
- O
2 O
120 O
( O
250 O
mm O
x O
4 O
mm O
, O
5 O
mu O
m O
) O
column O
by O
gradient O
elution O
with O
a O
mobile O
phase O
consisting O
of O
0 O
. O
1 O
% O
trifluoroacetic B
acid I
( O
pH O
= O
1 O
) O

Quantitative O
determination O
of O
fatty B
acid I
chain O
composition O
in O
pork O
meat O
products O
by O
high O
resolution O
1H B
NMR O
spectroscopy O
. O

High O
resolution O
( B
1 I
) I
H I
NMR O
spectroscopy O
was O
proposed O
for O
the O
determination O
of O
the O
fatty B
acid I
chain O
profile O
of O
lipids O
in O
pork O
meat O
products O
during O
ripening O
. O

Quantitative O
NMR O
analysis O
provided O
the O
fatty B
acid I
chain O
profiles O
of O
total O
lipid O
extracts O
. O

In O
this O
work O
, O
phytochemical O
investigation O
of O
litchi O
pericarp O
methanol B
extracts O
led O
to O
the O
isolation O
of O
a O
novel O
phenolic B
, O
2 B
- I
( I
2 I
- I
hydroxyl I
- I
5 I
- I
( I
methoxycarbonyl I
) I
phenoxy I
) I
benzoic I
acid I
, O
together O
with O
kaempferol B
, O
isolariciresinol B
, O
stigmasterol B
, O
butylated B
hydroxytoluene I
, O
3 B
, I
4 I
- I
dihydroxyl I
benzoate I
, O
methyl B
shikimate I
and O
ethyl B
shikimate I
. O

In O
this O
work O
, O
phytochemical O
investigation O
of O
litchi O
pericarp O
methanol B
extracts O
led O
to O
the O
isolation O
of O
a O
novel O
phenolic B
, O
2 B
- I
( I
2 I
- I
hydroxyl I
- I
5 I
- I
( I
methoxycarbonyl I
) I
phenoxy I
) I
benzoic I
acid I
, O
together O
with O
kaempferol B
, O
isolariciresinol B
, O
stigmasterol B
, O
butylated B
hydroxytoluene I
, O
3 B
, I
4 I
- I
dihydroxyl I
benzoate I
, O
methyl B
shikimate I
and O
ethyl B
shikimate I
. O

In O
this O
work O
, O
phytochemical O
investigation O
of O
litchi O
pericarp O
methanol B
extracts O
led O
to O
the O
isolation O
of O
a O
novel O
phenolic B
, O
2 B
- I
( I
2 I
- I
hydroxyl I
- I
5 I
- I
( I
methoxycarbonyl I
) I
phenoxy I
) I
benzoic I
acid I
, O
together O
with O
kaempferol B
, O
isolariciresinol B
, O
stigmasterol B
, O
butylated B
hydroxytoluene I
, O
3 B
, I
4 I
- I
dihydroxyl I
benzoate I
, O
methyl B
shikimate I
and O
ethyl B
shikimate I
. O

Antioxidant O
activities O
of O
the O
eight O
compounds O
were O
determined O
by O
a O
DPPH B
radical O
scavenging O
assay O
and O
the O
results O
showed O
that O
2 B
- I
( I
2 I
- I
hydroxy I
- I
5 I
- I
( I
methoxycarbonyl I
) I
phenoxy I
) I
benzoic I
acid I
, O
kaempferol B
, O
isolariciresinol B
, O
butylated B
hydroxytoluene I
and O
3 B
, I
4 I
- I
dihydroxy I
benzoate I
exhibited O
good O
antioxidant O
activities O
. O

An O
interesting O
finding O
was O
that O
butylated B
hydroxytoluene I
was O
detected O
as O
a O
natural O
antioxidant O
in O
this O
work O
, O
which O
was O
usually O
taken O
as O
a O
synthesized O
antioxidant O
. O

Solvent O
choice O
was O
the O
most O
important O
factor O
in O
the O
extraction O
of O
resveratrols B
, O
and O
mixed O
methanol B
and O
ethyl B
acetate I
[ O
50 O
: O
50 O
( O
v O
/ O
v O
) O
] O
had O
much O
higher O
extraction O
efficiency O
than O
the O
other O
five O
solvents O
tested O
. O

For O
extracting O
resveratrols B
, O
1g O
of O
berry O
skins O
or O
leaf O
tissue O
extracted O
in O
10 O
mL O
methanol B
and O
ethyl B
acetate I
[ O
50 O
: O
50 O
( O
v O
/ O
v O
) O
] O
for O
24h O
at O
25 O
degrees O
C O
in O
darkness O
was O
the O
optimized O
extraction O
condition O
. O

C O
. O
nobile O
proved O
to O
be O
an O
equilibrated O
valuable O
herb O
rich O
in O
carbohydrates B
and O
proteins O
, O
and O
poor O
in O
fat O
, O
providing O
tocopherols B
, O
carotenoids O
and O
essential O
fatty B
acids I
( O
C18 O
: O
2n6 O
and O
C18 O
: O
3n3 O
) O
. O

Moreover O
, O
the O
herb O
and O
its O
infusion O
are O
a O
source O
of O
phenolic B
compounds O
( O
flavonoids B
such O
as O
flavonols B
and O
flavones B
, O
phenolic B
acids I
and O
derivatives O
) O
and O
organic O
acids O
( O
oxalic B
, I
quinic I
, I
malic I
, I
citric I
and I
fumaric I
acids I
) O
that O
showed O
antioxidant O
and O
antitumour O
activities O
, O
without O
hepatotoxicity O
. O

The O
K O
( O
i O
) O
for O
sulphanilamide B
was O
determined O
to O
be O
3 O
. O
57 O
. O
10 O
( O
- O
5 O
) O
M O
and O
sulphanilamide B
showed O
competitive O
inhibition O
, O
which O
makes O
it O
a O
suitable O
ligand O
for O
constructing O
a O
Sepharose B
4B I
- O
L B
- I
tyrosine I
affinity O
matrix O
. O

The O
affinity O
matrix O
was O
synthesised O
by O
coupling O
sulphanilamide B
as O
the O
ligand O
and O
L B
- I
tyrosine I
as O
the O
spacer O
arm O
to O
a O
cyanogen B
bromide I
( O
CNBr B
) O
- O
activated O
- O
Sepharose B
4B I
matrix O
. O

The O
affinity O
matrix O
was O
synthesised O
by O
coupling O
sulphanilamide B
as O
the O
ligand O
and O
L B
- I
tyrosine I
as O
the O
spacer O
arm O
to O
a O
cyanogen B
bromide I
( O
CNBr B
) O
- O
activated O
- O
Sepharose B
4B I
matrix O
. O

Otherwise O
, O
the O
plant O
methanol B
extract O
contained O
the O
highest O
amounts O
of O
both O
phenolic B
acids I
( O
3 O
. O
99 O
g O
/ O
100g O
dw O
) O
and O
flavonoids B
( O
2 O
. O
59 O
g O
/ O
100g O
dw O
) O
. O

Many O
major O
components O
( O
> O
50 O
) O
of O
beeswax O
, O
odd O
and O
even O
hydrocarbons B
, O
oleofin B
, O
palmitate B
, O
oleate B
and O
hydroxypalmitate B
monoesters I
were O
detected O
, O
and O
for O
the O
first O
time O
palmitate B
and I
oleate I
monoesters I
esterified O
with O
1 B
- I
octadecanol I
and O
1 B
- I
eicosanol I
are O
reported O
to O
be O
present O
in O
beeswax O
. O

The O
protein O
hydrolysate O
contained O
a O
high O
amount O
of O
essential O
amino B
acids I
( O
48 O
. O
22 O
% O
) O
and O
had O
arginine B
and O
lysine B
as O
the O
dominant O
amino B
acids I
. O

The O
protein O
hydrolysate O
contained O
a O
high O
amount O
of O
essential O
amino B
acids I
( O
48 O
. O
22 O
% O
) O
and O
had O
arginine B
and O
lysine B
as O
the O
dominant O
amino B
acids I
. O

Simultaneous O
separation O
and O
purification O
of O
total O
polyphenols B
, O
chlorogenic B
acid I
and O
phlorizin B
from O
thinned O
young O
apples O
. O

Chlorogenic B
acid I
and O
phlorizin B
were O
selectively O
purified O
using O
X O
- O
5 O
and O
polyamide B
resins O
. O

The O
contents O
of O
chlorogenic B
acid I
and O
phlorizin B
were O
15 O
. O
20 O
% O
and O
97 O
. O
52 O
% O
with O
recovery O
yields O
of O
89 O
. O
16 O
% O
and O
64 O
. O
95 O
% O
, O
respectively O
. O

[ B
+ I
] I
- I
Hup I
A I
block O
the O
N B
- I
methyl I
- I
d I
- I
aspartate I
( O
NMDA B
) O
- O
induced O
seizure O
in O
rats O
, O
reduce O
excitatory O
amino B
acid I
induced O
neurotoxicity O
and O
also O
prevent O
soman O
induced O
toxicity O
with O
minimum O
performance O
decrement O
. O

Unique O
combinations O
of O
two O
stereo O
- O
isomers O
of O
Hup B
A I
may O
provide O
an O
excellent O
pre O
/ O
post O
- O
treatment O
drug O
for O
the O
nerve O
agent O
induced O
seizure O
/ O
status O
epilepticus O
. O

Helenalin B
, O
a O
sesquiterpene B
lactone I
, O
exhibits O
anti O
- O
inflammatory O
and O
anti O
- O
tumor O
activities O
. O

The O
aim O
of O
the O
present O
study O
is O
to O
synthesize O
Pluronic B
F127 I
- I
polyethylenimine I
- I
folate I
( O
PF127 B
- I
PEI I
- I
FA I
) O
copolymer O
, O
construct O
a O
mixed O
micelle O
system O
with O
PF127 B
- I
PEI I
- I
FA I
copolymer O
and O
Pluronic B
P123 I
( O
PP123 B
) O
and O
to O
evaluate O
the O
potential O
of O
these O
mixed O
micelles O
as O
an O
oral O
drug O
delivery O
system O
for O
paclitaxel B
( O
PTX B
) O
. O

Chromatographic O
analysis O
revealed O
that O
ethion B
was O
degraded O
into O
ethion B
monooxon I
, O
ethion B
dioxon I
, O
O B
, I
O I
- I
diethyl I
phosphorothioate I
, O
O B
- I
ethyl I
phosphorothioate I
and O
one O
unknown O
compound O
. O

Chromatographic O
analysis O
revealed O
that O
ethion B
was O
degraded O
into O
ethion B
monooxon I
, O
ethion B
dioxon I
, O
O B
, I
O I
- I
diethyl I
phosphorothioate I
, O
O B
- I
ethyl I
phosphorothioate I
and O
one O
unknown O
compound O
. O

Synthesis O
and O
antitumor O
activity O
of O
N B
- I
sulfonyl I
- I
3 I
, I
7 I
- I
dioxo I
- I
5 I
beta I
- I
cholan I
- I
24 I
- I
amides I
, O
ursodeoxycholic B
acid I
derivatives O
. O

A O
series O
of O
N B
- I
sulfonyl I
- I
3 I
, I
7 I
- I
dioxo I
- I
5 I
beta I
- I
cholan I
- I
24 I
- I
amides I
, O
ursodeoxycholic B
acid I
derivatives O
, O
have O
been O
designed O
and O
synthesized O
in O
nine O
steps O
starting O
from O
ursodeoxycholic B
acid I
. O

A O
series O
of O
N B
- I
sulfonyl I
- I
3 I
, I
7 I
- I
dioxo I
- I
5 I
beta I
- I
cholan I
- I
24 I
- I
amides I
, O
ursodeoxycholic B
acid I
derivatives O
, O
have O
been O
designed O
and O
synthesized O
in O
nine O
steps O
starting O
from O
ursodeoxycholic B
acid I
. O

Precipitation O
of O
Ibuprofen B
Sodium I
using O
compressed O
carbon B
dioxide I
as O
antisolvent O
. O

Precipitation O
of O
Ibuprofen B
Sodium I
using O
compressed O
carbon B
dioxide I
as O
antisolvent O
. O

Precipitation O
with O
compressed O
antisolvent O
( O
PCA O
) O
process O
was O
used O
to O
produce O
fine O
particles O
of O
Ibuprofen B
Sodium I
with O
the O
ultimate O
goal O
of O
obtaining O
controlled O
particle O
size O
and O
size O
distribution O
of O
this O
non O
- O
steroidal O
anti O
- O
inflammatory O
drug O
. O

The O
influence O
of O
process O
parameters O
on O
the O
Ibuprofen B
Sodium I
crystallinity O
was O
investigated O
using O
X O
- O
ray O
diffraction O
( O
XRD O
) O
. O

The O
results O
showed O
an O
improvement O
of O
the O
PCA O
processed O
Ibuprofen B
Sodium I
' O
' O
in O
vitro O
' O
' O
drug O
activity O
. O

Our O
study O
showed O
that O
infusion O
of O
Ang B
- I
( I
1 I
- I
7 I
) I
for O
4 O
weeks O
significantly O
reduced O
the O
expression O
of O
Angiotensin B
II I
and O
Angiotensin B
II I
type O
1 O
receptors O
in O
SHR O
brain O
. O

Our O
study O
showed O
that O
infusion O
of O
Ang B
- I
( I
1 I
- I
7 I
) I
for O
4 O
weeks O
significantly O
reduced O
the O
expression O
of O
Angiotensin B
II I
and O
Angiotensin B
II I
type O
1 O
receptors O
in O
SHR O
brain O
. O

Additionally O
, O
it O
decreased O
the O
levels O
of O
malondialdehyde B
and O
elevated O
total O
superoxide B
dismutase O
activity O
, O
which O
was O
accompanied O
by O
reductions O
of O
NADPH B
oxidase O
subunit O
gp91 O
( O
phox O
) O
and O
inducible O
nitric B
oxide I
synthase O
in O
the O
brain O
of O
SHR O
. O

With O
trypan B
blue I
- O
exclusion O
assay O
, O
we O
observed O
that O
glucosamine B
( O
10 O
, O
20 O
, O
50 O
mM O
) O
caused O
a O
decrease O
in O
cell O
number O
at O
24 O
and O
48 O
h O
; O
with O
a O
flow O
cytometric O
analysis O
, O
we O
also O
noted O
an O
enhanced O
cell O
accumulation O
within O
the O
G O
( O
0 O
) O
/ O
G O
( O
1 O
) O
phase O
at O
24 O
h O
and O
induction O
of O
late O
apoptosis O
at O
24 O
and O
48 O
h O
by O
glucosamine B
( O
10 O
, O
20 O
, O
50 O
mM O
) O
in O
A549 O
cells O
and O
HBECs O
. O

In O
vitro O
and O
in O
vivo O
evaluation O
of O
an O
in O
situ O
gel O
forming O
system O
for O
the O
delivery O
of O
PEGylated B
octreotide I
. O

The O
objective O
of O
this O
study O
was O
to O
develop O
a O
controlled O
delivery O
system O
for O
PEGylated B
octreotide I
using O
a O
Poloxamer B
based O
in O
situ O
gel O
forming O
polymer O
. O

PEGylated B
octreotide I
kept O
its O
full O
biological O
activity O
and O
higher O
serum O
half O
- O
life O
compared O
to O
the O
original O
octreotide B
. O

The O
designed O
drug O
delivery O
system O
contained O
low O
concentration O
of O
Poloxamer B
407 I
( O
P407 B
) O
( O
< O
0 O
. O
16 O
% O
) O
with O
polyvinyl B
alcohol I
( O
PVA B
) O
as O
a O
polymeric O
additive O
. O

The O
designed O
drug O
delivery O
system O
contained O
low O
concentration O
of O
Poloxamer B
407 I
( O
P407 B
) O
( O
< O
0 O
. O
16 O
% O
) O
with O
polyvinyl B
alcohol I
( O
PVA B
) O
as O
a O
polymeric O
additive O
. O

The O
effect O
of O
formulation O
additives O
such O
as O
buffering O
agents O
on O
rheological O
behavior O
demonstrated O
that O
sodium B
bicarbonate I
and O
lactic B
acid I
have O
opposite O
effect O
on O
sol O
- O
gel O
transition O
temperature O
of O
the O
system O
. O

The O
effect O
of O
formulation O
additives O
such O
as O
buffering O
agents O
on O
rheological O
behavior O
demonstrated O
that O
sodium B
bicarbonate I
and O
lactic B
acid I
have O
opposite O
effect O
on O
sol O
- O
gel O
transition O
temperature O
of O
the O
system O
. O

The O
in O
vitro O
release O
profiles O
of O
octreotide B
and O
PEGylated B
octreotide I
from O
the O
selected O
P407 B
/ O
PVA B
formulations O
were O
measured O
using O
a O
membrane O
- O
less O
device O
. O

PEGylated B
octreotide I
showed O
slower O
release O
rate O
from O
the O
gel O
system O
with O
different O
release O
kinetic O
compared O
to O
octreotide B
. O

In O
animal O
studies O
, O
a O
sustained O
release O
rate O
was O
achieved O
with O
both O
PEGylated B
and I
non I
- I
PEGylated I
octreotide I
, O
but O
longer O
delivery O
was O
observed O
for O
PEGylated B
octreotide I
. O

Tissue O
histopathological O
studies O
confirmed O
the O
biocompatibility O
of O
the O
delivery O
system O
for O
PEGylated B
octreotide I
, O
supporting O
the O
suitability O
of O
P407 B
/ O
PVA B
mixture O
as O
an O
injectable O
drug O
delivery O
system O
. O

The O
total O
effects O
of O
increasing O
PEGylated O
peptide O
half O
- O
life O
and O
prolonged O
release O
from O
thermoresponsive O
gel O
system O
offer O
the O
potential O
for O
sustained O
delivery O
of O
PEGylated B
octreotide I
. O

LARGE2 O
generates O
the O
same O
xylose B
- O
and O
glucuronic B
acid I
- O
containing O
glycan O
structures O
as O
LARGE O
. O

It O
is O
a O
bifunctional O
glycosyltransferase O
using O
uridine B
diphosphate I
( O
UDP B
) O
- O
xylose B
( O
Xyl B
) O
and O
UDP B
- O
glucuronic B
acid I
( O
GlcA B
) O
as O
donor O
sugars B
to O
produce O
a O
xyloglucuronan O
with O
alternating O
Xyl B
and O
GlcA B
residues O
. O

It O
is O
a O
bifunctional O
glycosyltransferase O
using O
uridine B
diphosphate I
( O
UDP B
) O
- O
xylose B
( O
Xyl B
) O
and O
UDP B
- O
glucuronic B
acid I
( O
GlcA B
) O
as O
donor O
sugars B
to O
produce O
a O
xyloglucuronan O
with O
alternating O
Xyl B
and O
GlcA B
residues O
. O

Reversible O
and O
cyclical O
transformations O
between O
solid O
and O
hollow O
nanostructures O
in O
confined O
reactions O
of O
manganese B
oxide I
and O
silica B
within O
nanosized O
spheres O
. O

More O
interestingly O
, O
when O
catalytically O
active O
Pt B
nanocrystals O
were O
introduced O
into O
the O
manganese B
oxide I
/ O
silica B
system O
, O
the O
Mn B
( I
3 I
) I
O I
( I
4 I
) I
was O
readily O
reduced O
to O
the O
chemically O
reactive O
MnO B
, O
even O
at O
low O
temperature O
, O
which O
enabled O
reconversion O
of O
the O
solid O
nanospheres O
with O
a O
Mn B
( I
3 I
) I
O I
( I
4 I
) I
core O
to O
hollow O
nanostructures O
during O
reductive O
annealing O
. O

In O
this O
study O
, O
polydatin B
showed O
inhibitory O
activities O
on O
xanthine B
oxidase O
to O
repress O
the O
level O
of O
serum O
uric B
acid I
in O
vivo O
and O
in O
vitro O
. O

The O
nephroprotective O
activities O
of O
polydatin B
was O
not O
only O
due O
to O
the O
effects O
on O
remarkably O
attenuating O
the O
oxidative O
stress O
induced O
by O
uric B
acid I
, O
but O
also O
on O
markedly O
suppressing O
the O
oxidative O
stress O
- O
related O
inflammatory O
cascade O
, O
including O
decreasing O
the O
expressions O
of O
NF O
- O
kappa O
B O
p65 O
, O
COX O
- O
2 O
and O
iNOS O
proteins O
and O
inhibiting O
the O
productions O
of O
TNF O
- O
alpha O
, O
PGE O
( O
2 O
) O
and O
IL O
- O
1 O
beta O
. O

Furthermore O
, O
despite O
elevated O
glucose B
concentrations O
, O
carriers O
of O
GCK O
mutations O
showed O
lower O
levels O
of O
free O
fatty B
acids I
and O
triglycerides B
than O
healthy O
control O
subjects O
. O

Elevated O
levels O
of O
fatty B
acids I
are O
known O
to O
associate O
with O
beta O
- O
cell O
dysfunction O
, O
insulin O
resistance O
, O
and O
increased O
incidence O
of O
late O
complications O
. O

In O
this O
study O
, O
we O
have O
examined O
the O
dose O
- O
response O
relationship O
for O
the O
formation O
of O
the O
above O
four O
products O
arising O
in O
calf O
thymus O
DNA O
exposed O
to O
gamma O
irradiation O
, O
photoactivated O
rose B
bengal I
, O
and O
two O
sources O
of O
peroxynitrite B
. O

This O
is O
the O
first O
study O
to O
demonstrate O
sonoelectrocatalytic O
disinfection O
using O
titanium B
dioxide I
( O
TiO B
( I
2 I
) I
) O
as O
an O
anode O
for O
effective O
inactivation O
of O
Escherichia O
coli O
. O

In O
this O
study O
we O
evaluated O
the O
expression O
of O
NK O
( O
1 O
) O
and O
NK O
( O
2 O
) O
receptors O
( O
NK O
- O
1R O
and O
NK O
- O
2R O
) O
, O
as O
well O
as O
the O
effects O
of O
substance B
P I
( O
SP O
) O
and O
neurokinin B
A I
( O
NKA B
) O
, O
in O
monocytes O
isolated O
from O
15 O
healthy O
subjects O
and O
15 O
patients O
with O
recurrent O
major O
depressive O
disorder O
( O
RMDD O
) O
, O
under O
stable O
antidepressant O
therapy O
. O

In O
this O
study O
we O
evaluated O
the O
expression O
of O
NK O
( O
1 O
) O
and O
NK O
( O
2 O
) O
receptors O
( O
NK O
- O
1R O
and O
NK O
- O
2R O
) O
, O
as O
well O
as O
the O
effects O
of O
substance B
P I
( O
SP O
) O
and O
neurokinin B
A I
( O
NKA B
) O
, O
in O
monocytes O
isolated O
from O
15 O
healthy O
subjects O
and O
15 O
patients O
with O
recurrent O
major O
depressive O
disorder O
( O
RMDD O
) O
, O
under O
stable O
antidepressant O
therapy O
. O

In O
a O
previous O
study O
using O
isolated O
rat O
liver O
mitochondria O
, O
we O
observed O
that O
ABA B
inhibited O
the O
activity O
of O
adenine B
nucleotide I
translocator O
and O
FoF1 O
- O
ATPase O
. O

Different O
NSAIDs O
( O
flufenamic B
acid I
, O
meclofenamic B
acid I
, O
diclofenac B
, O
indomethacin B
, O
nimesulide B
, O
flurbiprofen B
, O
meloxicam B
, O
phenylbutazone B
, O
piroxicam B
, O
ketoprofen B
and O
aspirin B
) O
caused O
variable O
increase O
in O
neutrophil O
intracellular O
ROS O
concentration O
, O
which O
was O
inversely O
proportional O
to O
the O
change O
produced O
in O
L O
- O
selectin O
surface O
expression O
. O

Different O
NSAIDs O
( O
flufenamic B
acid I
, O
meclofenamic B
acid I
, O
diclofenac B
, O
indomethacin B
, O
nimesulide B
, O
flurbiprofen B
, O
meloxicam B
, O
phenylbutazone B
, O
piroxicam B
, O
ketoprofen B
and O
aspirin B
) O
caused O
variable O
increase O
in O
neutrophil O
intracellular O
ROS O
concentration O
, O
which O
was O
inversely O
proportional O
to O
the O
change O
produced O
in O
L O
- O
selectin O
surface O
expression O
. O

Interestingly O
, O
diclofenac B
and O
flufenamic B
acid I
but O
not O
piroxicam B
significantly O
increased O
the O
extracellular O
superoxide B
anion O
production O
by O
neutrophils O
, O
and O
inhibition O
of O
nicotinamide B
adenine I
dinucleotide I
phosphate I
( O
NADPH B
) O
- O
oxidase O
activity O
with O
diphenyleneiodonium B
prevented O
the O
down O
- O
regulation O
of O
L O
- O
selectin O
by O
diclofenac B
. O

Under O
the O
drug O
screening O
process O
of O
synthetic O
diphenylpyrazole B
derivatives O
, O
we O
discovered O
compound O
yuwen02f1 B
possesses O
anti O
- O
inflammatory O
effects O
in O
decreasing O
the O
release O
of O
pro O
- O
inflammatory O
cytokines O
including O
TNF O
alpha O
and O
IL O
- O
6 O
, O
nitric B
oxide I
, O
reactive O
oxygen B
species O
( O
ROS O
) O
as O
well O
as O
inhibiting O
migration O
of O
LPS O
- O
stimulated O
phagocytes O
. O

In O
this O
work O
, O
the O
metabolism O
of O
four O
frequently O
prescribed O
inhaled O
GCs O
, O
triamcinolone B
acetonide I
, O
flunisolide B
, O
budesonide B
, O
and O
fluticasone B
propionate I
, O
by O
the O
CYP3A O
family O
of O
enzymes O
was O
studied O
to O
identify O
differences O
in O
their O
rates O
of O
clearance O
and O
to O
identify O
their O
metabolites O
. O

In O
this O
work O
, O
the O
metabolism O
of O
four O
frequently O
prescribed O
inhaled O
GCs O
, O
triamcinolone B
acetonide I
, O
flunisolide B
, O
budesonide B
, O
and O
fluticasone B
propionate I
, O
by O
the O
CYP3A O
family O
of O
enzymes O
was O
studied O
to O
identify O
differences O
in O
their O
rates O
of O
clearance O
and O
to O
identify O
their O
metabolites O
. O

CYP3A5 O
, O
which O
is O
particularly O
relevant O
to O
GC O
metabolism O
in O
the O
lungs O
, O
was O
also O
shown O
to O
efficiently O
metabolize O
triamcinolone B
acetonide I
, O
budesonide B
, O
and O
fluticasone B
propionate I
. O

CYP3A5 O
, O
which O
is O
particularly O
relevant O
to O
GC O
metabolism O
in O
the O
lungs O
, O
was O
also O
shown O
to O
efficiently O
metabolize O
triamcinolone B
acetonide I
, O
budesonide B
, O
and O
fluticasone B
propionate I
. O

Common O
metabolites O
included O
6 O
beta O
- O
hydroxylation O
and O
Delta O
( O
6 O
) O
- O
dehydrogenation O
for O
triamcinolone B
acetonide I
, O
budesonide B
, O
and O
flunisolide B
. O

Metabolism O
also O
occurred O
on O
the O
D O
- O
ring O
substituents O
, O
including O
the O
21 B
- I
carboxy I
metabolites O
for O
triamcinolone B
acetonide I
and O
flunisolide B
. O

We O
recently O
showed O
that O
the O
hydrophobic O
anion O
dipicrylamine B
( O
DPA B
) O
negatively O
regulates O
GABA B
( O
A O
) O
receptor O
function O
by O
a O
mechanism O
indistinguishable O
from O
that O
of O
sulfated B
neurosteroids I
. O

Surprisingly O
, O
similar O
to O
cationic O
channel O
blockers O
but O
unlike O
sulfated B
neurosteroids I
, O
DPA B
antagonism O
was O
voltage O
dependent O
. O

Endometrial O
cancer O
is O
associated O
with O
enhanced O
cell O
proliferation O
due O
to O
high O
concentrations O
of O
estrogens B
, O
and O
decreased O
cell O
differentiation O
due O
to O
low O
levels O
of O
progesterone B
and O
retinoic B
acid I
. O

Nitric B
oxide I
synthase O
/ O
nitric B
oxide I
( O
NOS O
/ O
NO B
) O
system O
in O
the O
RVLM O
modulates O
cardiovascular O
activities O
. O

Nitric B
oxide I
synthase O
/ O
nitric B
oxide I
( O
NOS O
/ O
NO B
) O
system O
in O
the O
RVLM O
modulates O
cardiovascular O
activities O
. O

The O
double O
- O
staining O
immunohistochemical O
evidence O
showed O
that O
OX1R O
immunoreactive O
( O
OX1R O
- O
IR O
) O
cells O
and O
neuronal O
nitric B
oxide I
synthase O
( O
nNOS O
) O
or O
inducible O
nitric B
oxide I
synthase O
( O
iNOS O
) O
immunoreactive O
( O
IR O
) O
cells O
were O
co O
- O
localizated O
in O
the O
RVLM O
. O

The O
double O
- O
staining O
immunohistochemical O
evidence O
showed O
that O
OX1R O
immunoreactive O
( O
OX1R O
- O
IR O
) O
cells O
and O
neuronal O
nitric B
oxide I
synthase O
( O
nNOS O
) O
or O
inducible O
nitric B
oxide I
synthase O
( O
iNOS O
) O
immunoreactive O
( O
IR O
) O
cells O
were O
co O
- O
localizated O
in O
the O
RVLM O
. O

Microinjection O
into O
the O
RVLM O
of O
both O
control O
and O
SIHR O
groups O
of O
7 O
- O
Ni O
( O
0 O
. O
05 O
pmol O
/ O
100 O
nl O
, O
nNOS O
inhibitor O
) O
or O
Methylene B
Blue I
[ O
100 O
pmol O
/ O
100 O
nl O
, O
an O
inhibitor O
of O
soluble O
guanylate B
cyclase O
( O
sGC O
) O
] O
suppressed O
the O
OXA O
- O
induced O
increase O
of O
SBP O
and O
HR O
, O
whereas O
microinjection O
of O
AG O
( O
1 O
, O
10 O
, O
100 O
pmol O
/ O
100 O
nl O
) O
had O
no O
obvious O
effects O
on O
the O
OXA O
- O
induced O
increase O
of O
SBP O
and O
HR O
. O

Hydrogen B
sulfide I
increases O
nitric B
oxide I
production O
with O
calcium B
- O
dependent O
activation O
of O
endothelial O
nitric B
oxide I
synthase O
in O
endothelial O
cells O
. O

Hydrogen B
sulfide I
increases O
nitric B
oxide I
production O
with O
calcium B
- O
dependent O
activation O
of O
endothelial O
nitric B
oxide I
synthase O
in O
endothelial O
cells O
. O

Hydrogen B
sulfide I
increases O
nitric B
oxide I
production O
with O
calcium B
- O
dependent O
activation O
of O
endothelial O
nitric B
oxide I
synthase O
in O
endothelial O
cells O
. O

Hydrogen B
sulfide I
( O
H B
( I
2 I
) I
S I
) O
was O
recently O
discovered O
to O
be O
synthesized O
in O
mammalian O
tissues O
by O
several O
different O
enzymes O
. O

However O
, O
intracellular O
mechanisms O
of O
the O
H B
( I
2 I
) I
S I
- O
induced O
vasodilation O
and O
its O
interactions O
with O
other O
endothelium O
- O
derived O
relaxing O
factors O
, O
such O
as O
nitric B
oxide I
( O
NO B
) O
, O
remain O
unclear O
. O

The O
NaHS B
- O
induced O
NO B
production O
was O
partially O
blocked O
by O
inhibitors O
of O
ryanodine B
receptor O
( O
dantrolene B
) O
or O
inositol B
1 I
, I
4 I
, I
5 I
- I
triphosphate I
receptor O
( O
xestospongin B
C I
) O
. O

NaHS B
significantly O
increased O
intracellular O
calcium B
concentrations O
, O
and O
this O
effect O
was O
attenuated O
by O
dantrolene B
or O
xestospongin B
C I
. O

In O
this O
work O
, O
we O
have O
developed O
and O
evaluated O
a O
new O
targeted O
lipopolyplex O
( O
LPP O
) O
, O
by O
combining O
polyethylenimine B
( O
PEI B
) O
, O
1 B
, I
2 I
- I
dioleoyl I
- I
3 I
- I
( I
trimethylammonium I
) I
propane I
( O
DOTAP B
) O
/ O
Chol O
liposomes O
, O
the O
plasmids O
pCMVLuc O
/ O
pCMVIL O
- O
12 O
, O
and O
the O
ligand O
folic B
acid I
( O
FA O
) O
, O
able O
to O
transfect O
HeLa O
and O
B16 O
- O
F10 O
cells O
in O
the O
presence O
of O
very O
high O
concentration O
of O
serum O
( O
60 O
% O
FBS O
) O
. O

The O
combination O
of O
folic B
acid I
with O
lipopolyplexes O
also O
enhanced O
significantly O
the O
transfection O
activity O
of O
the O
therapeutic O
gene O
interleukin O
- O
12 O
( O
IL O
- O
12 O
) O
, O
without O
any O
significant O
cytotoxicity O
. O

Ferulic B
acid I
modulates O
fluoride B
- O
induced O
oxidative O
hepatotoxicity O
in O
male O
Wistar O
rats O
. O

The O
present O
study O
is O
aimed O
to O
evaluate O
the O
protective O
effect O
of O
ferulic B
acid I
( O
FA O
) O
on O
fluoride B
- O
induced O
oxidative O
hepatotoxicity O
in O
male O
Wistar O
rats O
. O

Hepatic O
damage O
were O
assessed O
using O
status O
of O
pathophysiological O
markers O
like O
serum O
marker O
enzymes O
like O
aspartate B
transaminase O
, O
alanine B
transaminase O
, O
alkaline O
phosphatase O
, O
acid O
phosphatase O
, O
gamma B
glutamyl I
transferase O
, O
lactate B
dehydrogenase O
, O
bilirubin B
, O
lipid O
profile O
, O
total O
protein O
content O
levels O
, O
and O
histopathological O
studies O
. O

Treatment O
with O
FA O
significantly O
reduced O
the O
degree O
of O
histological O
aberrations O
and O
rescued O
lipid O
peroxidation O
, O
as O
observed O
from O
reduced O
levels O
of O
lipid O
hydroperoxides B
, O
nitric B
oxide I
, O
restored O
levels O
of O
enzymic O
and O
non O
- O
enzymic O
antioxidants O
, O
and O
total O
protein O
content O
, O
with O
a O
concomitant O
decline O
in O
the O
levels O
of O
marker O
enzymes O
and O
lipid O
profile O
in O
fluoride B
- O
induced O
rats O
. O

These O
results O
suggest O
that O
ferulic B
acid I
has O
the O
ability O
to O
protect O
fluoride B
- O
induced O
hepatic O
damage O
. O

Obtusilactone B
B I
from O
Machilus O
Thunbergii O
targets O
barrier O
- O
to O
- O
autointegration O
factor O
to O
treat O
cancer O
. O

Obtusilactone B
B I
is O
a O
butanolide B
derivative O
purified O
from O
Machilus O
thunbergii O
. O

In O
this O
study O
, O
we O
show O
that O
obtusilactone B
B I
functions O
as O
a O
small O
- O
molecule O
inhibitor O
that O
causes O
abnormal O
nuclear O
envelope O
dynamics O
and O
inhibits O
growth O
by O
suppressing O
vaccinia O
- O
related O
kinase O
1 O
( O
VRK1 O
) O
- O
mediated O
phosphorylation O
of O
barrier O
- O
to O
- O
autointegration O
factor O
( O
BAF O
) O
. O

Specific O
binding O
of O
obtusilactone B
B I
to O
BAF O
suppressed O
VRK1 O
- O
mediated O
BAF O
phosphorylation O
and O
the O
subsequent O
dissociation O
of O
the O
nuclear O
envelope O
from O
DNA O
that O
allows O
cells O
to O
progress O
through O
the O
cell O
cycle O
. O

Obtusilactone B
B I
potently O
induced O
tumor O
cell O
death O
in O
vitro O
, O
indicating O
that O
specific O
targeting O
of O
BAF O
to O
block O
cell O
cycle O
progression O
can O
be O
an O
effective O
anticancer O
strategy O
. O

The O
cytotoxic O
antimetabolites O
, O
5 B
- I
flurouracil I
and O
mitomycin B
C I
both O
prolong O
success O
but O
with O
the O
increased O
risk O
of O
blinding O
complications O
. O

This O
antioxidant O
regenerating O
system O
, O
continuously O
quenched O
in O
situ O
produced O
. B
NO I
, O
O B
( I
2 I
) I
( I
. I
- I
) I
and O
OH B
. I
radicals O
and O
the O
produced O
oxidized O
phenolic B
antioxidants O
were O
regenerated O
back O
to O
their O
original O
parent O
compounds O
by O
CDH O
using O
cellobiose B
as O
electron O
donor O
. O

This O
antioxidant O
regenerating O
system O
, O
continuously O
quenched O
in O
situ O
produced O
. B
NO I
, O
O B
( I
2 I
) I
( I
. I
- I
) I
and O
OH B
. I
radicals O
and O
the O
produced O
oxidized O
phenolic B
antioxidants O
were O
regenerated O
back O
to O
their O
original O
parent O
compounds O
by O
CDH O
using O
cellobiose B
as O
electron O
donor O
. O

This O
is O
because O
methoxylated B
phenolic I
antioxidants O
like O
sinapic B
acid I
, O
ferulic B
acid I
; O
2 B
, I
6 I
- I
dimethoxyphenol I
readily O
donate O
their O
electrons O
to O
these O
radicals O
( O
DPPH B
, O
TEAC O
, O
etc O
. O
) O
, O
thereby O
greatly O
influencing O
the O
total O
antioxidant O
values O
although O
this O
study O
showed O
that O
they O
are O
not O
at O
all O
effective O
in O
quenching O
O B
( I
2 I
) I
( I
. I
- I
) I
radicals O
and O
again O
are O
not O
the O
most O
effective O
quenchers O
of O
NO B
and O
OH B
radicals O
as O
demonstrated O
during O
this O
study O
. O

This O
is O
because O
methoxylated B
phenolic I
antioxidants O
like O
sinapic B
acid I
, O
ferulic B
acid I
; O
2 B
, I
6 I
- I
dimethoxyphenol I
readily O
donate O
their O
electrons O
to O
these O
radicals O
( O
DPPH B
, O
TEAC O
, O
etc O
. O
) O
, O
thereby O
greatly O
influencing O
the O
total O
antioxidant O
values O
although O
this O
study O
showed O
that O
they O
are O
not O
at O
all O
effective O
in O
quenching O
O B
( I
2 I
) I
( I
. I
- I
) I
radicals O
and O
again O
are O
not O
the O
most O
effective O
quenchers O
of O
NO B
and O
OH B
radicals O
as O
demonstrated O
during O
this O
study O
. O

This O
is O
because O
methoxylated B
phenolic I
antioxidants O
like O
sinapic B
acid I
, O
ferulic B
acid I
; O
2 B
, I
6 I
- I
dimethoxyphenol I
readily O
donate O
their O
electrons O
to O
these O
radicals O
( O
DPPH B
, O
TEAC O
, O
etc O
. O
) O
, O
thereby O
greatly O
influencing O
the O
total O
antioxidant O
values O
although O
this O
study O
showed O
that O
they O
are O
not O
at O
all O
effective O
in O
quenching O
O B
( I
2 I
) I
( I
. I
- I
) I
radicals O
and O
again O
are O
not O
the O
most O
effective O
quenchers O
of O
NO B
and O
OH B
radicals O
as O
demonstrated O
during O
this O
study O
. O

Combination O
treatment O
with O
progesterone B
and O
vitamin B
D I
hormone O
is O
more O
effective O
than O
monotherapy O
in O
ischemic O
stroke O
: O
The O
role O
of O
BDNF O
/ O
TrkB O
/ O
Erk1 O
/ O
2 O
signaling O
in O
neuroprotection O
. O

We O
investigated O
whether O
combinatorial O
post O
- O
injury O
treatment O
with O
progesterone B
( O
P4 O
) O
and O
vitamin B
D I
hormone O
( O
VDH O
) O
would O
reduce O
ischemic O
injury O
more O
effectively O
than O
P4 O
alone O
in O
an O
oxygen B
glucose B
deprivation O
( O
OGD O
) O
model O
in O
primary O
cortical O
neurons O
and O
in O
a O
transient O
middle O
cerebral O
artery O
occlusion O
( O
tMCAO O
) O
model O
in O
rats O
. O

Animals O
were O
randomly O
divided O
into O
four O
groups O
: O
those O
administered O
1 O
% O
Tween B
80 I
( O
control O
) O
, O
those O
administered O
artemether B
( O
4 O
mg O
/ O
kg O
body O
weight O
) O
, O
those O
administered O
lumefantrine B
( O
24 O
mg O
/ O
kg O
body O
weight O
) O
, O
and O
those O
coadministered O
artemether B
( O
4 O
mg O
/ O
kg O
body O
weight O
) O
and O
lumefantrine B
( O
24 O
mg O
/ O
kg O
body O
weight O
) O
. O

In O
order O
to O
investigate O
possible O
fibril O
remodeling O
mechanisms O
using O
this O
approach O
, O
we O
performed O
comparative O
studies O
on O
the O
structural O
features O
of O
the O
different O
amyloid O
- O
beta O
( O
A O
beta O
) O
aggregates O
remodeled O
from O
A O
beta O
fibrils O
by O
three O
biocompatible O
small O
molecules O
: O
methylene B
blue I
; O
brilliant B
blue I
G I
; O
and O
erythrosine B
B I
. O

In O
order O
to O
investigate O
possible O
fibril O
remodeling O
mechanisms O
using O
this O
approach O
, O
we O
performed O
comparative O
studies O
on O
the O
structural O
features O
of O
the O
different O
amyloid O
- O
beta O
( O
A O
beta O
) O
aggregates O
remodeled O
from O
A O
beta O
fibrils O
by O
three O
biocompatible O
small O
molecules O
: O
methylene B
blue I
; O
brilliant B
blue I
G I
; O
and O
erythrosine B
B I
. O

Combined O
with O
circular O
dichroism O
( O
CD O
) O
, O
immuno O
- O
blotting O
, O
transmission O
electron O
microscopy O
( O
TEM O
) O
, O
and O
atomic O
force O
microscopy O
( O
AFM O
) O
results O
, O
it O
was O
found O
that O
brilliant B
blue I
G I
- O
and O
erythrosine B
B I
- O
treatment O
generate O
fragmented O
A O
beta O
fibrils O
and O
protofibrils O
, O
respectively O
. O

In O
contrast O
, O
incubation O
of O
the O
A O
beta O
fibrils O
with O
methylene B
blue I
perturbs O
fibrillar O
structure O
, O
leading O
to O
amorphous O
A O
beta O
aggregates O
. O

A O
novel O
permeation O
enhancer O
: O
N B
- I
succinyl I
chitosan O
on O
the O
intranasal O
absorption O
of O
isosorbide B
dinitrate I
in O
rats O
. O

The O
purpose O
of O
this O
paper O
is O
to O
study O
the O
potential O
of O
N B
- I
succinyl I
chitosan O
as O
a O
novel O
permeation O
enhancer O
for O
the O
intranasal O
absorption O
of O
isosorbide B
dinitrate I
( O
ISDN B
) O
. O

The O
Amphibian O
Metamorphosis O
Assay O
( O
AMA O
) O
, O
developed O
for O
Xenopus O
laevis O
, O
is O
designed O
to O
identify O
chemicals O
that O
disrupt O
thyroid B
hormone I
( O
TH O
) O
- O
mediated O
biological O
processes O
. O

Testing O
our O
double O
mutants O
against O
racemic B
sarin I
, O
we O
observed O
reduced O
values O
of O
KM O
for O
H115W O
/ O
F347W O
that O
modestly O
improved O
catalytic O
efficiency O
over O
wild O
type O
and O
H115W O
. O

Here O
, O
we O
elucidated O
the O
molecular O
identity O
of O
the O
F O
gene O
product O
by O
positional O
cloning O
, O
as O
SCRB15 O
, O
a O
paralog O
of O
Cameo2 O
with O
26 O
% O
amino B
acid I
identity O
. O

A O
central O
issue O
for O
copper B
oxides I
is O
the O
nature O
of O
the O
insulating O
ground O
state O
at O
low O
carrier O
densities O
and O
the O
emergence O
of O
high O
- O
temperature O
superconductivity O
from O
that O
state O
with O
doping O
. O

The O
effect O
of O
C B
- O
vacancy O
on O
hydrogen B
storage O
and O
characterization O
of O
H2 B
modes O
on O
Ti B
functionalized O
C60 B
fullerene I
a O
first O
principles O
study O
. O

The O
aforementioned O
peptides O
were O
much O
less O
efficacious O
at O
mFpr2 O
, O
which O
responded O
better O
to O
the O
synthetic O
hexapeptide B
WKYMVm O
, O
the O
synthetic O
agonists O
Quin B
- I
C1 I
( O
a O
substituted O
quinazolinone B
) O
, O
and O
compound O
43 O
( O
a O
nitrosylated B
pyrazolone I
derivative O
) O
. O

Ilexpublesnins B
C I
- I
M I
, O
eleven O
new O
triterpene B
saponins I
from O
the O
roots O
of O
Ilex O
pubescens O
. O

Eleven O
new O
triterpene B
saponins I
, O
ilexpublesnins B
C I
- I
M I
( O
1 O
- O
11 O
) O
, O
along O
with O
ten O
known O
analogues O
were O
isolated O
from O
the O
roots O
of O
Ilex O
pubescens O
. O

Compounds O
1 O
, O
2 O
, O
10 O
, O
and O
11 O
contain O
a O
24 O
- O
aldehyde B
, O
which O
is O
rare O
for O
triterpene B
saponins I
from O
Ilex O
. O

Two O
- O
stage O
metal O
- O
catalyst O
- O
free O
growth O
of O
high O
- O
quality O
polycrystalline O
graphene B
films O
on O
silicon B
nitride I
substrates O
. O

By O
using O
two O
- O
stage O
, O
metal O
- O
catalyst O
- O
free O
chemical O
vapor O
deposition O
( O
CVD O
) O
, O
it O
is O
demonstrated O
that O
high O
- O
quality O
polycrystalline O
graphene B
films O
can O
directly O
grow O
on O
silicon B
nitride I
substrates O
. O

Podophyllum O
species O
are O
sources O
of O
( B
- I
) I
- I
podophyllotoxin I
, O
an O
aryltetralin B
lignan I
used O
for O
semi O
- O
synthesis O
of O
various O
powerful O
and O
extensively O
employed O
cancer O
- O
treating O
drugs O
. O

Multiple O
geochemical O
markers O
, O
including O
aliphatic B
hydrocarbons I
( O
n B
- I
alkanes I
) O
, O
linear B
alkylbenzenes I
( O
LABs B
) O
, O
and O
polycyclic B
aromatic I
hydrocarbons I
( O
PAHs B
) O
, O
were O
employed O
to O
relate O
sediment O
organic O
chemical O
pollution O
in O
the O
coastal O
zone O
off O
South O
China O
to O
socioeconomic O
development O
there O
. O

Multiple O
geochemical O
markers O
, O
including O
aliphatic B
hydrocarbons I
( O
n B
- I
alkanes I
) O
, O
linear B
alkylbenzenes I
( O
LABs B
) O
, O
and O
polycyclic B
aromatic I
hydrocarbons I
( O
PAHs B
) O
, O
were O
employed O
to O
relate O
sediment O
organic O
chemical O
pollution O
in O
the O
coastal O
zone O
off O
South O
China O
to O
socioeconomic O
development O
there O
. O

The O
spectra O
are O
dominated O
by O
residues O
in O
collagen O
environments O
, O
as O
determined O
from O
chemical O
shift O
analysis O
, O
and O
a O
complete O
two O
- O
dimensional O
assignment O
( O
including O
minor O
amino B
acids I
) O
was O
possible O
. O

A O
new O
ganoderic B
acid I
from O
Ganoderma O
lucidum O
mycelia O
and O
its O
stability O
. O

A O
new O
ganoderic B
acid I
( O
GA O
) O
, O
3 B
alpha I
, I
22 I
beta I
- I
diacetoxy I
- I
7 I
alpha I
- I
hydroxyl I
- I
5 I
alpha I
- I
lanost I
- I
8 I
, I
24E I
- I
dien I
- I
26 I
- I
oic I
acid I
( O
1 O
) O
, O
together O
with O
four O
known O
compounds O
GA B
- I
Mk I
( O
2 O
) O
, O
- O
Mc O
( O
3 O
) O
, O
- O
S O
( O
4 O
) O
and O
- O
Mf O
( O
5 O
) O
, O
was O
isolated O
and O
characterized O
from O
Ganoderma O
lucidum O
mycelia O
. O

Cinobufagin B
, O
a O
major O
component O
of O
cinobufacini O
( O
huachansu O
) O
, O
is O
an O
important O
cardenolidal B
steroid I
. O

These O
findings O
correlated O
with O
increased O
chondrogenesis O
and O
mineral O
formation O
within O
the O
callus O
site O
at O
2 O
weeks O
postfracture O
, O
as O
demonstrated O
by O
increased O
safranin B
O I
and O
von O
Kossa O
staining O
, O
respectively O
. O

Two O
stretches O
of O
basic O
amino B
acids I
( O
basic O
motifs O
) O
are O
present O
in O
p17 O
N B
and O
C B
termini O
. O

1H B
NMR O
spectra O
of O
ethane B
- I
1 I
, I
2 I
- I
diol I
and O
other O
vicinal B
diols I
in O
benzene B
: O
GIAO O
/ O
DFT O
shift O
calculations O
. O

The O
cyclic B
CoA I
esters I
were O
identified O
in O
rat O
livers O
perfused O
with O
levulinate B
and O
in O
livers O
and O
brains O
from O
rats O
gavaged O
with O
calcium B
levulinate I
+ O
/ O
- O
ethanol B
. O

Chemotherapy O
of O
leishmaniasis O
part O
X O
: O
synthesis O
and O
bioevaluation O
of O
novel O
terpenyl B
heterocycles I
. O

Triazoyl B
- I
phenyl I
linker O
system O
enhancing O
the O
aqueous O
solubility O
of O
a O
molecular O
probe O
and O
its O
efficiency O
in O
affinity O
labeling O
of O
a O
target O
protein O
for O
jasmonate B
glucoside I
. O

We O
previously O
reported O
the O
synthesis O
of O
a O
jasmonate B
glucoside I
probe O
with O
a O
highly O
rigid O
linker O
consisting O
of O
a O
triazoyl B
- I
phenyl I
( O
TAzP B
) O
moiety O
, O
and O
this O
probe O
demonstrated O
effective O
target O
tagging O
. O

Synthesis O
and O
anti O
- O
tumor O
evaluation O
of O
novel O
25 B
- I
hydroxyprotopanaxadi I
analogs O
incorporating O
natural O
amino B
acids I
. O

The O
results O
showed O
that O
combining O
an O
ester B
group O
combined O
with O
the O
presence O
of O
an O
amino B
acid I
moiety O
led O
to O
a O
10 O
- O
fold O
improved O
anti O
- O
tumor O
activity O
. O

Aspidin B
PB I
, O
a O
phloroglucinol B
derivative O
, O
induces O
apoptosis O
in O
human O
hepatocarcinoma O
HepG2 O
cells O
by O
modulating O
PI3K O
/ O
Akt O
/ O
GSK3 O
beta O
pathway O
. O

Aspidin B
PB I
, O
a O
phloroglucinol B
derivative O
isolated O
from O
Dryopteris O
fragrans O
( O
L O
. O
) O
Schott O
, O
has O
been O
previously O
reported O
to O
exert O
high O
biological O
activities O
. O

In O
the O
present O
study O
, O
we O
analyzed O
the O
apoptotic O
mechanisms O
of O
aspidin B
PB I
on O
human O
hepatoma O
cell O
line O
, O
HepG2 O
. O

Initially O
, O
aspidin B
PB I
was O
shown O
to O
inhibit O
the O
growth O
of O
HepG2 O
cells O
in O
a O
time O
and O
dose O
- O
dependent O
manner O
. O

After O
treatment O
with O
aspidin B
PB I
for O
72 O
h O
, O
48 O
h O
and O
24 O
h O
using O
MTT B
assay O
, O
the O
IC O
( O
50 O
) O
values O
were O
10 O
. O
59 O
mu O
M O
, O
20 O
. O
86 O
mu O
M O
and O
46 O
. O
59 O
mu O
M O
, O
respectively O
. O

Aspidin B
PB I
was O
capable O
to O
induce O
apoptosis O
, O
as O
measured O
by O
mitochondrial O
membrane O
potential O
( O
Delta O
Psi O
m O
) O
, O
acridine B
orange I
( O
AO O
) O
staining O
and O
propidium B
iodide I
( O
PI O
) O
/ O
annexin O
V O
- O
FITC B
double O
staining O
. O

Aspidin B
PB I
was O
capable O
to O
induce O
apoptosis O
, O
as O
measured O
by O
mitochondrial O
membrane O
potential O
( O
Delta O
Psi O
m O
) O
, O
acridine B
orange I
( O
AO O
) O
staining O
and O
propidium B
iodide I
( O
PI O
) O
/ O
annexin O
V O
- O
FITC B
double O
staining O
. O

Aspidin B
PB I
was O
capable O
to O
induce O
apoptosis O
, O
as O
measured O
by O
mitochondrial O
membrane O
potential O
( O
Delta O
Psi O
m O
) O
, O
acridine B
orange I
( O
AO O
) O
staining O
and O
propidium B
iodide I
( O
PI O
) O
/ O
annexin O
V O
- O
FITC B
double O
staining O
. O

To O
further O
explore O
the O
signaling O
pathway O
of O
aspidin B
PB I
- O
mediated O
apoptosis O
, O
we O
examined O
PI3K O
/ O
Akt O
related O
proteins O
. O

Western O
blot O
analysis O
revealed O
that O
aspidin B
PB I
inhibited O
PI3K O
expression O
, O
phosphorylation O
of O
Ser473 B
Akt O
and O
Ser9 B
GSK3 O
beta O
followed O
by O
up O
- O
regulation O
of O
nonsteroidal O
anti O
- O
inflammatory O
drugs O
activated O
gene O
- O
1 O
( O
NAG O
- O
1 O
) O
expression O
. O

Similarly O
, O
the O
effects O
of O
aspidin B
PB I
on O
PI3K O
, O
Akt O
, O
GSK3 O
beta O
, O
NAG O
- O
1 O
expression O
were O
abolished O
by O
treatment O
with O
the O
PI3K O
inhibitor O
, O
wortmannin B
. O

Taken O
together O
, O
our O
data O
suggested O
that O
the O
PI3K O
/ O
Akt O
/ O
GSK3 O
beta O
signal O
pathway O
may O
represent O
one O
of O
the O
major O
mechanisms O
of O
the O
effects O
of O
aspidin B
PB I
on O
human O
hepatocarcinoma O
cells O
. O

Moreover O
, O
adding O
okadaic B
acid I
, O
a O
PP2A O
inhibitor O
, O
abolished O
the O
effects O
of O
erlotinib B
on O
apoptosis O
in O
Hep3B O
cells O
; O
and O
forskolin B
, O
a O
PP2A O
agonist O
enhanced O
the O
effect O
of O
erlotinib B
in O
resistant O
HA59T O
cells O
. O

In O
RAEC O
exposed O
to O
high O
glucose B
( O
30 O
mM O
) O
for O
48 O
h O
, O
pre O
- O
treatment O
with O
boldine B
reduced O
the O
elevated O
ROS O
and O
nitrotyrosine B
formation O
, O
and O
preserved O
nitric B
oxide I
( O
NO B
) O
production O
. O

Spermatozoa O
were O
exposed O
ex O
vivo O
to O
an O
alkylating O
agent O
( O
methyl B
methanesulfonate I
) O
before O
in O
vitro O
fertilization O
and O
DNA O
damage O
was O
assessed O
by O
the O
alkaline O
comet O
assay O
. O

known O
dihydrochalcone B
dimer O
( O
9 O
) O
, O
three O
known O
aromatic B
esters I
( O
10 O
- O
12 O
) O
, O
and O
one O
known O
aromatic B
amide I
( O
13 O
) O
, O
were O
isolated O
from O
the O
leaves O
of O
Melodorum O
siamensis O
. O

known O
dihydrochalcone B
dimer O
( O
9 O
) O
, O
three O
known O
aromatic B
esters I
( O
10 O
- O
12 O
) O
, O
and O
one O
known O
aromatic B
amide I
( O
13 O
) O
, O
were O
isolated O
from O
the O
leaves O
of O
Melodorum O
siamensis O
. O

Facile O
and O
clean O
release O
of O
vertical O
Si B
nanowires O
by O
wet O
chemical O
etching O
based O
on O
alkali B
hydroxides I
. O

By O
exploiting O
the O
unique O
chemistry O
involved O
for O
the O
fabrication O
of O
vertical O
arrays O
of O
SiNWs O
in O
metal O
- O
assisted O
chemical O
etching O
( O
MaCE O
) O
based O
either O
on O
HF B
/ O
AgNO3 B
or O
HF B
/ O
H2O2 B
chemistries O
, O
wet O
etching O
with O
alkali B
hydroxides I
such O
as O
NaOH B
or O
KOH B
preferentially O
attacks O
the O
bottom O
part O
of O
the O
vertical O
SiNWs O
. O

A O
protective O
layer O
of O
Si B
oxide B
is O
found O
to O
exist O
on O
the O
outer O
wall O
of O
the O
SiNWs O
and O
to O
play O
the O
key O
role O
of O
etch O
mask O
during O
the O
release O
- O
etching O
by O
alkali B
hydroxides I
. O

Enantioanalysis O
of O
pipecolic B
acid I
with O
stochastic O
and O
potentiometric O
microsensors O
. O

Stochastic O
and O
potentiometric O
microsensors O
based O
on O
porphyrins B
and O
polymeric O
surfactants O
such O
as O
polysodium B
N I
- I
undecanoyl I
- I
L I
- I
leucylvanilate I
and O
polysodium B
N I
- I
undecanoyl I
- I
L I
- I
vanilate I
were O
developed O
for O
enantioselective O
assay O
of O
pipecolic B
acid I
. O

The O
response O
characteristics O
of O
the O
microsensors O
were O
determined O
for O
the O
enantiomers O
of O
pipecolic B
acid I
. O

The O
response O
characteristics O
, O
selectivity O
, O
and O
enantioselectivity O
studies O
proved O
that O
the O
proposed O
microsensors O
can O
be O
used O
for O
clinical O
enantioanalysis O
of O
pipecolic B
acid I
in O
biological O
fluids O
, O
e O
. O
g O
. O
, O
urine O
and O
whole O
blood O
. O

For O
each O
of O
four O
proteins O
, O
three O
independently O
determined O
X O
- O
ray O
structures O
of O
differing O
crystallographic O
resolution O
were O
used O
to O
predict O
exchange O
for O
the O
static O
solvent O
- O
exposed O
amide B
hydrogens I
. O

Combination O
of O
these O
results O
with O
the O
directly O
measured O
rate O
constant O
for O
the O
reaction O
of O
the O
laser O
- O
flash O
photolytically O
generated O
1 B
- I
( I
4 I
- I
chlorophenyl I
) I
- I
3 I
- I
phenylallyl I
cation O
with O
water O
provided O
a O
complete O
mechanistic O
scheme O
for O
allyl B
carboxylate I
solvolysis O
. O

Furthermore O
, O
beta B
- I
cryptoxanthin I
induced O
an O
accumulation O
of O
cells O
in O
the O
G1 O
/ O
G0 O
phase O
of O
the O
cell O
cycle O
( O
as O
detected O
by O
flow O
cytometry O
) O
, O
which O
was O
in O
accordance O
with O
an O
increased O
expression O
of O
p21 O
and O
down O
regulations O
of O
cyclin O
D1 O
and O
cyclin O
E O
, O
detected O
by O
Western O
blot O
analysis O
, O
and O
beta B
- I
cryptoxanthin I
increased O
the O
mRNA O
levels O
of O
retinoic B
acid I
receptor O
beta O
( O
RAR O
beta O
) O
with O
the O
treatment O
at O
10 O
mu O
M O
for O
24 O
h O
. O

Edible O
and O
non O
- O
edible O
olive O
oils O
discrimination O
by O
the O
application O
of O
a O
sensory O
olfactory O
system O
based O
on O
tin B
dioxide I
sensors O
. O

The O
multisensor O
, O
developed O
at O
laboratory O
, O
is O
composed O
by O
14 O
sensing O
elements O
of O
tin B
dioxide I
thin O
layers O
( O
doped O
with O
Cr B
and O
In B
, O
and O
undoped O
) O
deposited O
by O
the O
reactive O
sputtering O
technique O
. O

The O
free O
, O
bound O
and O
total O
phenolic O
contents O
were O
66 O
. O
17 O
- O
226 O
. O
03 O
, O
11 O
. O
18 O
- O
40 O
. O
54 O
, O
and O
101 O
. O
51 O
- O
259 O
. O
18 O
mg O
of O
gallic B
acid I
equivalents O
/ O
100 O
g O
, O
respectively O
. O

Six O
individual O
phenolics B
( O
gallic B
acid I
, O
chlorogenic B
acid I
, O
( B
+ I
) I
- I
catechin I
, O
caffeic B
acid I
, O
( B
- I
) I
- I
epicatechin I
, O
and O
rutin B
) O
were O
detected O
in O
litchi O
pulp O
by O
HPLC O
. O

Six O
individual O
phenolics B
( O
gallic B
acid I
, O
chlorogenic B
acid I
, O
( B
+ I
) I
- I
catechin I
, O
caffeic B
acid I
, O
( B
- I
) I
- I
epicatechin I
, O
and O
rutin B
) O
were O
detected O
in O
litchi O
pulp O
by O
HPLC O
. O

Six O
individual O
phenolics B
( O
gallic B
acid I
, O
chlorogenic B
acid I
, O
( B
+ I
) I
- I
catechin I
, O
caffeic B
acid I
, O
( B
- I
) I
- I
epicatechin I
, O
and O
rutin B
) O
were O
detected O
in O
litchi O
pulp O
by O
HPLC O
. O

The O
production O
of O
TNF O
- O
alpha O
, O
IL O
- O
1 O
beta O
and O
nitric B
oxide I
also O
increased O
. O

Correlations O
between O
the O
dietary O
fibre O
components O
, O
associated O
bioactive O
components O
( O
e O
. O
g O
. O
tocols B
, O
sterols B
, O
phenolic B
acids I
and O
folates B
) O
and O
agronomic O
properties O
previously O
determined O
on O
the O
same O
samples O
were O
found O
with O
multivariate O
analysis O
( O
PCA O
) O
. O

Ampicillin B
( O
AMP B
) O
, O
penicillin B
G I
( O
PG O
) O
, O
penicillin B
V I
( O
PV O
) O
, O
oxacillin B
( O
OXA B
) O
, O
cloxacillin B
( O
CLO B
) O
, O
dicloxacillin B
( O
DICLO B
) O
, O
thiamphenicol B
( O
TAP B
) O
, O
florfenicol B
( O
FFC B
) O
and O
chloramphenicol B
( O
CAP B
) O
were O
separated O
on O
an O
Inertsil O
, O
C O
( O
8 O
) O
( O
250 O
x O
4 O
mm O
, O
5 O
mu O
m O
) O
column O
by O
gradient O
elution O
with O
a O
mobile O
phase O
consisting O
of O

Ampicillin B
( O
AMP B
) O
, O
penicillin B
G I
( O
PG O
) O
, O
penicillin B
V I
( O
PV O
) O
, O
oxacillin B
( O
OXA B
) O
, O
cloxacillin B
( O
CLO B
) O
, O
dicloxacillin B
( O
DICLO B
) O
, O
thiamphenicol B
( O
TAP B
) O
, O
florfenicol B
( O
FFC B
) O
and O
chloramphenicol B
( O
CAP B
) O
were O
separated O
on O
an O
Inertsil O
, O
C O
( O
8 O
) O
( O
250 O
x O
4 O
mm O
, O
5 O
mu O
m O
) O
column O
by O
gradient O
elution O
with O
a O
mobile O
phase O
consisting O
of O

ammonium B
acetate I
0 O
. O
05 O
M O
and O
acetonitrile B
at O
25 O
degrees O
C O
. O

Metabolite O
profiling O
of O
ginsenoside B
Re I
in O
rat O
urine O
and O
faeces O
after O
oral O
administration O
. O

Following O
oral O
administration O
of O
ginsenoside B
Re I
, O
the O
compound O
and O
its O
metabolites O
were O
identified O
and O
quantified O
in O
rat O
urine O
and O
faeces O
by O
liquid O
chromatography O
coupled O
with O
triple O
quadrupole O
mass O
spectrometry O
( O
LC O
- O
MS O
/ O
MS O
) O
. O

Ginsenoside B
Re I
( O
200 O
mg O
/ O
kg O
) O
was O
orally O
administered O
to O
rats O
by O
gastric O
intubation O
, O
and O
urine O
and O
faeces O
samples O
were O
then O
collected O
during O
the O
next O
24 O
h O
using O
metabolic O
cages O
. O

The O
precursor O
- O
product O
ion O
pairs O
used O
for O
LC O
- O
MS O
/ O
MS O
analysis O
were O
: O
m O
/ O
z O
945 O
- O
- O
> O
475 O
for O
ginsenoside B
Re I
, O
799 O
- O
- O
> O
637 O
for O
ginsenoside B
Rg1 I
, O
783 O
- O
- O
> O
475 O
for O
ginsenoside B
Rg2 I
, O
637 O
- O
- O
> O
475 O
for O
ginsenosides B
Rh1 I
and I
F1 I
, O
475 O
- O
- O
> O
391 O
for O
protopanaxatriol B
, O
and O
779 O
- O
- O
> O
641 O
for O
digoxin B
( O
internal O
standard O
) O
. O

The O
precursor O
- O
product O
ion O
pairs O
used O
for O
LC O
- O
MS O
/ O
MS O
analysis O
were O
: O
m O
/ O
z O
945 O
- O
- O
> O
475 O
for O
ginsenoside B
Re I
, O
799 O
- O
- O
> O
637 O
for O
ginsenoside B
Rg1 I
, O
783 O
- O
- O
> O
475 O
for O
ginsenoside B
Rg2 I
, O
637 O
- O
- O
> O
475 O
for O
ginsenosides B
Rh1 I
and I
F1 I
, O
475 O
- O
- O
> O
391 O
for O
protopanaxatriol B
, O
and O
779 O
- O
- O
> O
641 O
for O
digoxin B
( O
internal O
standard O
) O
. O

The O
precursor O
- O
product O
ion O
pairs O
used O
for O
LC O
- O
MS O
/ O
MS O
analysis O
were O
: O
m O
/ O
z O
945 O
- O
- O
> O
475 O
for O
ginsenoside B
Re I
, O
799 O
- O
- O
> O
637 O
for O
ginsenoside B
Rg1 I
, O
783 O
- O
- O
> O
475 O
for O
ginsenoside B
Rg2 I
, O
637 O
- O
- O
> O
475 O
for O
ginsenosides B
Rh1 I
and I
F1 I
, O
475 O
- O
- O
> O
391 O
for O
protopanaxatriol B
, O
and O
779 O
- O
- O
> O
641 O
for O
digoxin B
( O
internal O
standard O
) O
. O

Greater O
amounts O
of O
ginsenoside B
metabolites O
were O
detected O
in O
the O
faeces O
samples O
; O
biotransformation O
to O
ginsenoside B
Rg1 I
was O
predominant O
but O
further O
deglycosylated O
metabolites O
including O
ginsenoside B
F1 I
and O
protopanaxatriol B
were O
additionally O
detected O
. O

Greater O
amounts O
of O
ginsenoside B
metabolites O
were O
detected O
in O
the O
faeces O
samples O
; O
biotransformation O
to O
ginsenoside B
Rg1 I
was O
predominant O
but O
further O
deglycosylated O
metabolites O
including O
ginsenoside B
F1 I
and O
protopanaxatriol B
were O
additionally O
detected O
. O

1 B
, I
3 I
, I
6 I
, I
6 I
' I
- I
tetra I
- I
feruloyl I
sucrose I
named O
taroside O
was O
a O
new O
phenlypropanoid B
glycoside I
, O
together O
with O
3 B
, I
6 I
- I
di I
- I
p I
- I
coumaroyl I
- I
1 I
, I
6 I
' I
- I
di I
- I
feruloyl I
sucrose I
, O
1 B
, I
6 I
, I
6 I
' I
- I
tri I
- I
feruloyl I
- I
3 I
- I
p I
- I
coumaroyl I
sucrose I
, O
N B
- I
trans I
- I
feruloyltyramine I
and O
quercetin B
- I
3 I
- I
O I
- I
[ I
beta I
- I
D I
- I
xyloxyl I
- I

The O
main O
anthocyanins B
were O
3 B
- I
sophoroside I
- I
5 I
- I
glucoside I
derivatives O
from O
cyanidin B
and O
peonidin B
, O
acylated O
with O
p B
- I
hydroxybenzoic I
acid I
, O
ferulic B
acid I
, O
or O
caffeic B
acid I
. O

The O
main O
anthocyanins B
were O
3 B
- I
sophoroside I
- I
5 I
- I
glucoside I
derivatives O
from O
cyanidin B
and O
peonidin B
, O
acylated O
with O
p B
- I
hydroxybenzoic I
acid I
, O
ferulic B
acid I
, O
or O
caffeic B
acid I
. O

Dextrans O
and O
glucooligosaccharide O
( O
GLOS O
) O
are O
produced O
by O
lactic B
acid I
bacteria O
( O
LAB O
) O
during O
sourdough O
fermentation O
. O

Detection O
of O
pyrrolizidine B
alkaloids I
in O
commercial O
honey O
using O
liquid O
chromatography O
- O
ion O
trap O
mass O
spectrometry O
. O

Pyrrolizidine B
alkaloids I
( O
PAs O
) O
are O
known O
secondary O
plant O
metabolites O
which O
can O
cause O
hepatotoxicity O
in O
both O
humans O
and O
livestock O
. O

Renal O
cancer O
was O
initiated O
by O
single O
intraperitoneal O
( O
i O
. O
p O
. O
) O
injection O
of O
N B
- I
nitrosodiethylamine I
( O
DEN B
200 O
mg O
/ O
kg O
BW O
body O
weight O
) O
and O
promoted O
by O
twice O
weekly O
administration O
of O
ferric B
nitrilotriacetate I
( O
Fe B
- I
NTA I
) O
9 O
mg O
Fe B
/ O
kg O
BW O
for O
16 O
wk O
. O

To O
ascertain O
the O
molecular O
mechanism O
implicated O
in O
the O
antitumor O
promoting O
activity O
of O
chrysin B
, O
its O
effect O
was O
investigated O
on O
markers O
of O
tumor O
promotion O
and O
inflammation O
: O
ornithine B
decarboxylase O
( O
ODC O
) O
activity O
, O
proliferating O
cell O
nuclear O
antigen O
( O
PCNA O
) O
, O
inducible O
nitric B
oxide I
synthase O
( O
iNOS O
) O
and O
cyclo O
- O
oxygenase O
- O
2 O
( O
COX O
- O
2 O
) O
expression O
, O
and O
on O
levels O
of O
proinflammatory O
cytokines O
interleukin O
- O
6 O
( O
IL O
- O
6 O
) O
, O
tumor O
necrosis O
factor O
- O
alpha O
( O

To O
clarify O
the O
cause O
of O
age O
differences O
on O
selenite B
cataract O
formation O
in O
rats O
, O
mRNA O
expression O
of O
GPx1 O
, O
MsrA O
and O
MsrB1 O
, O
as O
well O
as O
GPx O
activity O
in O
Wistar O
rat O
lens O
at O
different O
ages O
were O
assayed O
, O
level O
of O
lipid O
peroxidation O
, O
extent O
of O
lens O
damage O
induced O
by O
sodium B
selenite I
and O
barricade O
function O
of O
blood O
- O
retinal O
barrier O
( O
BRB O
) O
were O
investigated O
. O

The O
results O
showed O
that O
mRNA O
expressions O
and O
activity O
of O
antioxidant O
enzymes O
in O
neonatal O
rat O
lens O
before O
eyelid O
opening O
were O
the O
highest O
and O
then O
decreased O
with O
age O
, O
and O
revealed O
by O
transmission O
electron O
microscopy O
( O
TEM O
) O
using O
lanthanum B
hydroxide I
as O
tracer O
that O
higher O
selenite B
content O
entering O
eyes O
injured O
lens O
and O
resulted O
in O
cataract O
formation O
for O
immature O
BRB O
before O
eyelid O
opening O
, O
moreover O
, O
a O
little O
selenite B
content O
entering O
eyes O
was O
not O
enough O
to O
induce O
cataract O
formation O
after O
eyelid O
opening O
because O
of O
mature O
BRB O
. O

Cucurbitacins B
I I
and I
D I
showed O
a O
very O
strong O
cytotoxicity O
, O
which O
was O
higher O
than O
that O
of O
cytochalasin B
D I
, O
used O
as O
a O
drug O
reference O
. O

Almost O
100 O
% O
of O
the O
cells O
were O
apoptotic O
as O
observed O
by O
DNA O
fragmentation O
( O
TUNEL O
assay O
) O
after O
12 O
h O
with O
cucurbitacins B
I I
and I
D I
( O
1 O
mu O
M O
) O
and O
cucurbitacin B
E I
( O
10 O
mu O
M O
) O
. O

In O
terms O
of O
IC O
( O
50 O
) O
values O
, O
cucurbitacins B
I I
and I
E I
presented O
a O
higher O
toxicity O
compared O
to O
that O
of O
cucurbitacin B
D I
( O
MTT B
assay O
) O
. O

Cucurbitacin B
E I
was O
readily O
hydrolyzed O
by O
human O
hepatic O
microsomes O
, O
leading O
to O
cucurbitacin B
I I
( O
K O
( O
m O
) O
22 O
mu O
M O
, O
V O
( O
max O
) O
571 O
nmol O
/ O
mg O
proteins O
/ O
min O
) O
. O

Cucurbitacin B
E I
was O
readily O
hydrolyzed O
by O
human O
hepatic O
microsomes O
, O
leading O
to O
cucurbitacin B
I I
( O
K O
( O
m O
) O
22 O
mu O
M O
, O
V O
( O
max O
) O
571 O
nmol O
/ O
mg O
proteins O
/ O
min O
) O
. O

In O
terms O
of O
V O
( O
max O
) O
/ O
K O
( O
m O
) O
, O
the O
cucurbitacin B
E I
was O
the O
best O
substrate O
of O
UDP B
- O
glucuronosyltransfer O
. O

The O
seeds O
of O
two O
local O
wheat O
cultivars O
( O
Kohistan O
- O
97 O
and O
Pasban O
- O
90 O
) O
were O
soaked O
in O
distilled O
water O
or O
sodium B
selenate I
solutions O
of O
25 O
, O
50 O
, O
75 O
, O
and O
100 O
mu O
M O
for O
1 O
/ O
2 O
or O
1 O
h O
at O
25 O
degrees O
C O
and O
later O
re O
- O
dried O
to O
their O
original O
moisture O
levels O
before O
sowing O
. O

One O
- O
hour O
priming O
at O
75 O
mu O
M O
increased O
the O
total O
sugar B
content O
and O
total O
free O
amino B
acids I
in O
both O
wheat O
cultivars O
. O

Bisphenol B
A I
inhibits O
voltage O
- O
activated O
Ca B
( I
2 I
+ I
) I
channels O
in O
vitro O
: O
mechanisms O
and O
structural O
requirements O
. O

Bisphenol B
A I
( O
BPA B
) O
, O
a O
high O
volume O
production O
chemical O
compound O
attracts O
growing O
attention O
as O
a O
health O
- O
relevant O
xenobiotic O
in O
humans O
. O

A O
corresponding O
increase O
in O
the O
level O
of O
intact O
TG O
monomer O
and O
the O
extent O
of O
TG B
ester I
hydrolysis O
was O
observed O
in O
all O
samples O
with O
enhanced O
levels O
of O
sitosterol B
. O

Geographical O
provenance O
of O
palm O
oil O
by O
fatty B
acid I
and O
volatile O
compound O
fingerprinting O
techniques O
. O

In O
this O
study O
the O
application O
of O
fatty B
acid I
and O
volatile O
organic O
compound O
fingerprinting O
in O
combination O
with O
chemometrics O
have O
been O
applied O
to O
verify O
the O
geographical O
origin O
of O
crude O
palm O
oil O
( O
continental O
scale O
) O
. O

The O
fatty B
acid I
fingerprinting O
model O
revealed O
three O
misclassified O
samples O
. O

The O
verification O
of O
the O
geographical O
origin O
of O
crude O
palm O
oil O
is O
feasible O
by O
fatty B
acid I
and O
volatile O
compound O
fingerprinting O
. O

The O
results O
showed O
that O
tigecycline B
significantly O
attenuated O
the O
expression O
and O
the O
release O
of O
nuclear O
factor O
- O
kappa O
beta O
( O
NF O
- O
kappa O
B O
) O
, O
tumor O
necrosis O
factor O
- O
alpha O
( O
TNF O
- O
alpha O
) O
and O
interleukin O
- O
1beta O
( O
IL O
- O
1 O
beta O
) O
, O
as O
well O
as O
nitric B
oxide I
( O
NO B
) O
levels O
in O
LPS O
- O
induced O
PC12 O
cells O
. O

Bradykinetic O
alcohol B
dehydrogenases O
make O
yeast O
fitter O
for O
growth O
in O
the O
presence O
of O
allyl B
alcohol I
. O

Previous O
studies O
showed O
that O
fitter O
yeast O
( O
Saccharomyces O
cerevisiae O
) O
that O
can O
grow O
by O
fermenting O
glucose B
in O
the O
presence O
of O
allyl B
alcohol I
, O
which O
is O
oxidized O
by O
alcohol B
dehydrogenase O
I O
( O
ADH1 O
) O
to O
toxic O
acrolein B
, O
had O
mutations O
in O
the O
ADH1 O
gene O
that O
led O
to O
decreased O
ADH O
activity O
. O

These O
yeast O
may O
grow O
more O
slowly O
due O
to O
slower O
reduction O
of O
acetaldehyde B
and O
a O
higher O
NADH B
/ O
NAD B
( I
+ I
) I
ratio O
, O
which O
should O
decrease O
the O
oxidation O
of O
allyl B
alcohol I
. O

Growth O
on O
YPD O
plus O
10mM O
allyl B
alcohol I
was O
inversely O
correlated O
with O
catalytic O
efficiency O
. O

Determination O
of O
aflatoxins B
, O
deoxynivalenol B
, O
ochratoxin B
A I
and O
zearalenone B
in O
wheat O
and O
oat O
based O
bran O
supplements O
sold O
in O
the O
Spanish O
market O
. O

The O
aflatoxins B
( O
AFs O
) O
, O
deoxynivalenol B
( O
DON B
) O
, O
ochratoxin B
A I
( O
OTA B
) O
and O
zearalenone B
( O
ZEA B
) O
are O
mycotoxins O
produced O
by O
fungal O
species O
which O
can O
contaminate O
, O
alone O
or O
simultaneously O
, O
cereal O
- O
based O
raw O
materials O
. O

The O
mRNA O
expression O
of O
lipid O
metabolism O
associated O
genes O
such O
as O
peroxisome O
proliferator O
- O
activated O
receptors O
( O
PPARs O
) O
, O
androgen B
receptor O
, O
acetyl B
- I
CoA I
carboxylase O
1 O
, O
fatty B
acid I
synthesis O
, O
fatty B
acid I
bing O
protein O
4 O
, O
liver O
X O
receptor O
alpha O
( O
LXR O
alpha O
) O
and O
stearoyl B
- I
CoA I
desaturase O
were O
up O
- O
regulated O
by O
PBZ B
exposure O
. O

The O
mRNA O
expression O
of O
lipid O
metabolism O
associated O
genes O
such O
as O
peroxisome O
proliferator O
- O
activated O
receptors O
( O
PPARs O
) O
, O
androgen B
receptor O
, O
acetyl B
- I
CoA I
carboxylase O
1 O
, O
fatty B
acid I
synthesis O
, O
fatty B
acid I
bing O
protein O
4 O
, O
liver O
X O
receptor O
alpha O
( O
LXR O
alpha O
) O
and O
stearoyl B
- I
CoA I
desaturase O
were O
up O
- O
regulated O
by O
PBZ B
exposure O
. O

Moreover O
, O
the O
as O
- O
prepared O
SnS B
( I
2 I
) I
/ O
TiO B
( I
2 I
) I
hierarchical O
nanostructures O
as O
nanoheterojunction O
photocatalysts O
exhibited O
excellent O
UV O
and O
visible O
light O
photocatalytic O
activities O
for O
the O
degradation O
of O
organic O
dyes O
( O
rhodamine B
B I
and O
methyl B
orange I
) O
and O
phenols B
( O
4 B
- I
nitrophenol I
) O
, O
remarkably O
superior O
to O
the O
TiO B
( I
2 I
) I
nanofibers O
and O
the O
SnS B
( I
2 I
) I
nanosheets O
, O
mainly O
owing O
to O
the O
photoinduced O
interfacial O
charge O
transfer O
based O
on O
the O

Moreover O
, O
the O
as O
- O
prepared O
SnS B
( I
2 I
) I
/ O
TiO B
( I
2 I
) I
hierarchical O
nanostructures O
as O
nanoheterojunction O
photocatalysts O
exhibited O
excellent O
UV O
and O
visible O
light O
photocatalytic O
activities O
for O
the O
degradation O
of O
organic O
dyes O
( O
rhodamine B
B I
and O
methyl B
orange I
) O
and O
phenols B
( O
4 B
- I
nitrophenol I
) O
, O
remarkably O
superior O
to O
the O
TiO B
( I
2 I
) I
nanofibers O
and O
the O
SnS B
( I
2 I
) I
nanosheets O
, O
mainly O
owing O
to O
the O
photoinduced O
interfacial O
charge O
transfer O
based O
on O
the O

1 O
. O
In O
this O
article O
, O
metabolites O
of O
ginkgolic B
acid I
( O
GA O
) O
( O
15 O
: O
1 O
) O
in O
rats O
plasma O
, O
bile O
, O
urine O
and O
faeces O
after O
oral O
administration O
have O
been O
investigated O
for O
the O
first O
time O
by O
high O
- O
performance O
liquid O
chromatography O
coupled O
to O
tandem O
mass O
spectrometry O
( O
HPLC O
- O
MS O
/ O
MS O
) O
with O
the O
aid O
of O
on O
- O
line O
hydrogen B
/ O
deuterium B
( O
H B
/ O
D B
) O
exchange O
technique O
and O
beta O
- O
glucuronidase O
hydrolysis O
experiments O
. O

In O
addition O
, O
we O
identified O
a O
single O
amino B
acid I
in O
YopK O
that O
is O
essential O
for O
translocation O
rate O
regulation O
but O
is O
dispensable O
for O
maintaining O
fidelity O
of O
translocation O
. O

Doxorubicin B
hydrochloride I
( O
DOX B
) O
was O
applied O
as O
a O
model O
drug O
, O
and O
the O
behavior O
of O
drug O
storage O
/ O
release O
was O
investigated O
. O

By O
using O
extremely O
rough O
, O
chemically O
etched O
microstructured O
aluminium B
foils O
, O
anodization O
in O
phosphoric B
acid I
under O
very O
harsh O
conditions O
, O
e O
. O
g O
. O
, O
10 O
wt O
% O
phosphoric B
acid I
and O
room O
temperature O
, O
can O
be O
repeatedly O
accomplished O
without O
suffering O
from O
breakdown O
. O

By O
using O
extremely O
rough O
, O
chemically O
etched O
microstructured O
aluminium B
foils O
, O
anodization O
in O
phosphoric B
acid I
under O
very O
harsh O
conditions O
, O
e O
. O
g O
. O
, O
10 O
wt O
% O
phosphoric B
acid I
and O
room O
temperature O
, O
can O
be O
repeatedly O
accomplished O
without O
suffering O
from O
breakdown O
. O

Catechol B
- O
initiated O
polyethers B
: O
multifunctional O
hydrophilic O
ligands O
for O
PEGylation O
and O
functionalization O
of O
metal B
oxide I
nanoparticles O
. O

Tunable O
polymers O
with O
polydispersities O
< O
1 O
. O
25 O
and O
molecular O
weights O
in O
the O
range O
500 O
- O
7700 O
g O
mol O
( O
- O
1 O
) O
containing O
a O
catechol B
moiety O
for O
conjugation O
to O
metal B
oxide I
nanoparticles O
were O
prepared O
. O

CA O
- O
OH B
was O
used O
both O
for O
homopolymerization O
of O
ethylene B
oxide I
( O
EO O
) O
as O
well O
as O
copolymerization O
with O
functional O
epoxides B
N B
, I
N I
- I
diallyl I
glycidyl I
amine I
( O
DAGA B
) O
, O
releasing O
primary B
amino I
groups O
and O
ethylene B
glycol I
vinyl I
glycidyl I
ether I
( O
EVGE B
) O
, O
exhibiting O
a O
double O
bond O
for O
click O
- O
type O
reactions O
, O
to O
generate O
CA O
- O
PEG B
and O
CA O
- O
PEG B
- O
PGA B
/ O
PEVGE B
. O

CA O
- O
OH B
was O
used O
both O
for O
homopolymerization O
of O
ethylene B
oxide I
( O
EO O
) O
as O
well O
as O
copolymerization O
with O
functional O
epoxides B
N B
, I
N I
- I
diallyl I
glycidyl I
amine I
( O
DAGA B
) O
, O
releasing O
primary B
amino I
groups O
and O
ethylene B
glycol I
vinyl I
glycidyl I
ether I
( O
EVGE B
) O
, O
exhibiting O
a O
double O
bond O
for O
click O
- O
type O
reactions O
, O
to O
generate O
CA O
- O
PEG B
and O
CA O
- O
PEG B
- O
PGA B
/ O
PEVGE B
. O

Furthermore O
, O
addressability O
of O
the O
functional O
groups O
has O
been O
proven O
, O
for O
example O
, O
by O
coupling O
with O
fluoresceine B
isothiocyanate I
( O
FITC B
) O
, O
to O
allow O
for O
optical O
monitoring O
of O
the O
nanoparticle O
fate O
in O
biological O
systems O
. O

Novel O
therapeutic O
targets O
as O
different O
as O
epidermal O
stem O
cells O
, O
cellular O
senescence O
, O
epigenetic O
enzymes O
involved O
in O
carcinogenesis O
, O
epidermal O
growth O
factor O
and O
aryl B
hydrocarbon I
receptors O
, O
and O
metabolic O
CYP1 O
subfamily O
enzymes O
are O
highlighted O
. O

1 B
- I
Nitrosocyclohexyl I
acetate I
( O
NCA B
) O
, O
a O
new O
HNO B
donor O
, O
in O
contrast O
to O
the O
classic O
HNO B
donors O
Angeli B
' I
s I
salt I
and O
isopropylamine B
NONOate I
, O
predominantly O
releases O
HNO B
and O
has O
a O
longer O
half O
- O
life O
. O

The O
concentration O
- O
response O
was O
markedly O
decreased O
in O
the O
presence O
of O
excess O
GSH B
; O
the O
nitric B
oxide I
scavenger O
2 B
- I
( I
4 I
- I
carboxyphenyl I
) I
- I
4 I
, I
4 I
, I
5 I
, I
5 I
- I
tetramethylimidazoli I
- I
1 I
- I
oxyl I
- I
3 I
- I
oxide I
had O
no O
effect O
. O

It O
was O
found O
that O
tea O
polyphenols B
( O
TP O
) O
, O
tea O
polysaccharides O
( O
TPS O
) O
, O
caffeine B
( O
Caf B
) O
, O
protein O
( O
Pro O
) O
, O
amino B
acids I
( O
AA O
) O
were O
accumulated O
in O
several O
fractions O
after O
solvent O
extraction O
despite O
not O
being O
separated O
completely O
. O

Meanwhile O
, O
95 O
% O
ethanol B
precipitate O
( O
EP O
) O
and O
ethyl B
acetate I
fraction O
( O
EF O
) O
possessed O
remarkable O
antioxidant O
activity O
and O
potent O
inhibitory O
effects O
against O
alpha O
- O
glycosidase O
in O
vitro O
. O

New O
targeted O
therapies O
include O
5 B
- I
HT I
( O
1F O
) O
receptor O
agonists O
, O
calcitonin O
gene O
- O
related O
peptide O
( O
CGRP O
) O
antagonists O
, O
nitric B
oxide I
synthetase O
inhibitors O
, O
and O
ion O
channel O
antagonists O
. O

The O
NMDA B
receptor O
subunits O
NR1 O
and O
NR2B O
and O
the O
related O
protein O
kinase O
calcium B
/ O
calmodulin O
- O
dependent O
protein O
kinase O
( O
CaMK O
) O
- O
IV O
and O
the O
transcription O
factor O
cyclic B
AMP I
responsive O
element O
binding O
protein O
( O
CREB O
) O
- O
1 O
mRNA O
levels O
were O
reduced O
in O
the O
PND O
50 O
mice O
. O

Long O
- O
term O
therapy O
with O
certain O
drugs O
, O
especially O
cytochrome O
P450 O
( O
P450 O
; O
CYP O
) O
- O
inducing O
agents O
, O
confers O
an O
increased O
risk O
of O
osteomalacia O
that O
is O
attributed O
to O
vitamin B
D I
deficiency O
. O

Human O
CYP24A1 O
, O
CYP3A4 O
, O
and O
CYP27B1 O
catalyze O
the O
inactivation O
and O
activation O
of O
vitamin B
D I
and O
have O
been O
implicated O
in O
the O
adverse O
drug O
response O
. O

Single O
- O
walled O
carbon B
nanotubes O
( O
SWNTs O
) O
wrapped O
with O
different O
types O
of O
lipids O
and O
polyethylene B
glycol I
( O
PEG B
) O
- O
grafted O
lipids O
were O
simulated O
with O
lipid O
bilayers O
. O

Radiosynthesis O
and O
evaluation O
of O
[ O
( B
1 I
) I
( I
1 I
) I
C I
- I
carbonyl I
] O
- O
labeled O
carbamates B
as O
fatty B
acid I
amide B
hydrolase O
radiotracers O
for O
positron O
emission O
tomography O
. O

Fatty B
acid I
amide B
hydrolase O
( O
FAAH O
) O
plays O
a O
key O
role O
in O
regulating O
the O
tone O
of O
the O
endocannabinoid O
system O
. O

Foams O
stabilized O
by O
multilamellar O
polyglycerol B
ester I
self O
- O
assemblies O
. O

The O
aim O
of O
the O
current O
study O
was O
to O
investigate O
the O
self O
- O
assemblies O
of O
the O
nonionic O
surfactant O
polyglycerol B
ester I
( O
PGE B
) O
in O
bulk O
solutions O
, O
at O
the O
interface O
and O
within O
foams O
, O
using O
a O
combined O
approach O
of O
small O
- O
angle O
neutron O
scattering O
, O
neutron O
reflectivity O
, O
and O
electron O
microscopy O
. O

Amplified O
fluorescent O
sensing O
of O
DNA O
using O
graphene B
oxide I
and O
a O
conjugated O
cationic O
polymer O
. O

We O
explore O
the O
interactions O
between O
a O
fluorescein B
( O
FAM B
) O
- O
labeled O
single O
- O
stranded O
DNA O
( O
P O
) O
, O
graphene B
oxide I
( O
GO O
) O
, O
and O
a O
cationic O
conjugated O
polymer O
, O
poly B
[ I
( I
9 I
, I
9 I
- I
bis I
( I
6 I
' I
- I
N I
, I
N I
, I
N I
- I
trimethylammonium I
) I
hexyl I
) I
- I
fluorenylene I
phenylene I
dibromide I
] I
( O
PFP B
) O
. O

This O
was O
done O
by O
introduction O
of O
a O
heteroatom O
( O
N B
or O
O B
) O
in O
alpha O
- O
position O
to O
the O
phosphonate B
and O
using O
the O
resultant O
OH B
and O
NH B
2 I
groups O
as O
a O
handle O
for O
appending O
a O
variety O
of O
substituents O
by O
means O
of O
several O
functional O
groups O
such O
as O
ether B
, O
amide B
, O
urea B
, O
and O
1 B
, I
4 I
- I
triazole I
. O

A O
self O
- O
assembled O
nanogel O
, O
derived O
from O
an O
acid O
- O
labile O
cholesteryl B
- O
modified O
pullulan O
( O
acL O
- O
CHP O
) O
, O
was O
prepared O
by O
grafting O
vinyl B
ether I
- O
cholesterol B
substituents O
onto O
a O
100 O
kD O
pullulan O
main O
chain O
polymer O
backbone O
. O

The O
synergistic O
activity O
was O
observed O
at O
ceftazidime B
plus O
either O
apigenin B
or O
naringenin B
combinations O
with O
FIC O
indixes O
between O
< O
0 O
. O
01 O
and O
< O
0 O
. O
27 O
against O
these O
strains O
, O
whereas O
ceftazidime B
plus O
clavulanic B
acid I
or O
quercetin B
did O
not O
exhibit O
synergy O
. O

The O
results O
for O
outer O
membrane O
( O
OM O
) O
permeabilization O
in O
both O
nitrocefin B
( O
NCF B
) O
assay O
and O
crystal B
violet I
uptake O
showed O
that O
the O
combination O
of O
ceftazidime B
plus O
apigenin B
significantly O
altered O
OM O
permeabilisation O
of O
CREC O
compared O
to O
control O
or O
single O
treatment O
of O
these O
agents O
. O

Microsomal O
prostaglandin B
E I
synthase O
- O
1 O
( O
mPGES O
- O
1 O
) O
is O
an O
inducible O
prostaglandin B
E I
synthase O
that O
catalyzes O
the O
conversion O
of O
prostaglandin B
PGH B
( I
2 I
) I
to O
PGE B
( I
2 I
) I
and O
represents O
a O
novel O
target O
for O
therapeutic O
treatment O
of O
inflammatory O
disorders O
. O

Microsomal O
prostaglandin B
E I
synthase O
- O
1 O
( O
mPGES O
- O
1 O
) O
is O
an O
inducible O
prostaglandin B
E I
synthase O
that O
catalyzes O
the O
conversion O
of O
prostaglandin B
PGH B
( I
2 I
) I
to O
PGE B
( I
2 I
) I
and O
represents O
a O
novel O
target O
for O
therapeutic O
treatment O
of O
inflammatory O
disorders O
. O

These O
strains O
, O
defective O
in O
dCTP B
deaminase O
and O
nucleoside B
diphosphate I
kinase O
, O
respectively O
, O
are O
characterized O
by O
both O
disturbances O
of O
dNTP B
pools O
and O
a O
mutator O
phenotype O
. O
ndk O
strains O
have O
been O
studied O
before O
, O
but O
were O
included O
in O
this O
study O
, O
as O
controversies O
exist O
regarding O
the O
source O
of O
its O
mutator O
phenotype O
. O

Indeed O
, O
we O
found O
that O
achyrofuran B
was O
not O
bacteriolytic O
by O
itself O
although O
it O
greatly O
compromised O
membrane O
impermeability O
as O
determined O
by O
increased O
SYTOX B
Green I
uptake O
. O

Discovery O
of O
alkenylboronic B
acids I
as O
neuroprotective O
agents O
affecting O
multiple O
biological O
targets O
involved O
in O
Alzheimer O
' O
s O
disease O
. O

Alkenylboronic B
acids I
have O
shown O
important O
biological O
activities O
that O
contribute O
to O
neuroprotection O
. O

We O
have O
determined O
their O
influence O
on O
the O
beta O
- O
amyloid O
( O
beta O
A O
) O
aggregation O
process O
, O
beta O
- O
secretase O
and O
acethylcholinesteras O
activities O
on O
cell O
- O
free O
systems O
, O
on O
the O
redox O
and O
lipid O
peroxidation O
status O
, O
and O
on O
the O
vulnerability O
to O
apoptotic O
death O
in O
an O
APPswe O
neuroblastoma O
cell O
line O
, O
before O
and O
after O
hydrogen B
peroxide I
treatment O
. O

In O
order O
to O
ascertain O
the O
degree O
of O
conservation O
of O
these O
residues O
among O
AMADHs O
and O
to O
evaluate O
their O
possible O
relevance O
in O
determining O
the O
aminoaldehyde B
specificity O
, O
we O
compared O
the O
known O
amino B
acid I
sequences O
of O
every O
ALDH O
family O
that O
have O
at O
least O
one O
member O
with O
known O
crystal O
structure O
, O
as O
well O
as O
the O
electrostatic O
potential O
surface O
of O
the O
aldehyde B
binding O
sites O
of O
these O
structures O
. O

Micelles O
of O
zinc B
protoporphyrin I
conjugated O
to O
N B
- I
( I
2 I
- I
hydroxypropyl I
) I
methacrylamide I
( O
HPMA B
) O
copolymer O
for O
imaging O
and O
light O
- O
induced O
antitumor O
effects O
in O
vivo O
. O

We O
synthesized O
N B
- I
( I
2 I
- I
hydroxypropyl I
) I
methacrylamide I
polymer O
conjugated O
with O
zinc B
protoporphyrin I
( O
HPMA B
- O
ZnPP B
) O
and O
evaluated O
its O
application O
for O
tumor O
detection O
by O
imaging O
and O
treatment O
by O
light O
exposure O
using O
in O
mouse O
sarcoma O
model O
. O

With O
hydrophilic O
active O
compounds O
, O
like O
Triptorelin B
acetate I
, O
the O
lipophilic O
polymer O
was O
formulated O
in O
form O
of O
parenterally O
injectable O
suspensions O
. O

Water O
analyses O
revealed O
aluminum B
, O
iron B
and O
zinc B
as O
well O
as O
organochlorine B
( O
aldrin B
/ O
dieldrin B
, O
endosulfan B
, O
heptachlor B
/ O
heptachlor B
epoxide I
and O
metolachlor B
) O
contamination O
at O
all O
of O
the O
sites O
, O
with O
the O
exception O
of O
FU10 O
. O

Copper B
, O
chrome B
, O
iron B
and O
zinc B
were O
detected O
in O
the O
gills O
of O
both O
species O
, O
and O
aldrin B
/ O
dieldrin B
, O
endosulfan B
and O
heptachlor B
/ O
heptachlor B
epoxide I
were O
detected O
in O
the O
gills O
of O
fish O
from O
all O
of O
the O
sites O
, O
with O
the O
exception O
of O
FU10 O
. O

Retinoic B
acid I
biosynthesis O
catalyzed O
by O
retinal B
dehydrogenases O
relies O
on O
a O
rate O
- O
limiting O
conformational O
transition O
associated O
with O
substrate O
recognition O
. O

Retinoic B
acid I
( O
RA O
) O
, O
a O
metabolite O
of O
vitamin B
A I
, O
exerts O
pleiotropic O
effects O
throughout O
life O
in O
vertebrate O
organisms O
. O

Retinoic B
acid I
( O
RA O
) O
, O
a O
metabolite O
of O
vitamin B
A I
, O
exerts O
pleiotropic O
effects O
throughout O
life O
in O
vertebrate O
organisms O
. O

The O
last O
step O
of O
retinoic B
acid I
biosynthesis O
is O
irreversibly O
catalyzed O
by O
the O
NAD B
- O
dependent O
retinal B
dehydrogenases O
( O
RALDH O
) O
, O
which O
are O
members O
of O
the O
aldehyde B
dehydrogenase O
( O
ALDH O
) O
superfamily O
. O

The O
in O
vitro O
inflammatory O
state O
showed O
cell O
barrier O
dysfunction O
and O
overproduction O
of O
IL O
- O
8 O
, O
nitric B
oxide I
( O
NO B
) O
and O
reactive O
oxygen B
species O
( O
ROS O
) O
. O

Nine O
mycotoxins O
including O
six O
aspergillic B
acid I
group O
toxins O
, O
aluminiumneoaspergil B
( O
1 O
) O
, O
zirconiumneoaspergil B
( O
2 O
) O
, O
aspergilliamide B
( O
3 O
) O
, O
ferrineoaspergillin B
( O
5 O
) O
, O
flavacol B
( O
6 O
) O
, O
neoaspergillic B
acid I
( O
7 O
) O
, O
and O
three O
ochratoxins B
, O
ochratoxin B
A I
n I
- I
butyl I
ester I
( O
4 O
) O
, O
ochratoxin B
A I
( O
8 O
) O
, O
ochratoxin B
A I
methyl I
ester I
( O
9 O
) O
, O
were O
isolated O
from O

Nine O
mycotoxins O
including O
six O
aspergillic B
acid I
group O
toxins O
, O
aluminiumneoaspergil B
( O
1 O
) O
, O
zirconiumneoaspergil B
( O
2 O
) O
, O
aspergilliamide B
( O
3 O
) O
, O
ferrineoaspergillin B
( O
5 O
) O
, O
flavacol B
( O
6 O
) O
, O
neoaspergillic B
acid I
( O
7 O
) O
, O
and O
three O
ochratoxins B
, O
ochratoxin B
A I
n I
- I
butyl I
ester I
( O
4 O
) O
, O
ochratoxin B
A I
( O
8 O
) O
, O
ochratoxin B
A I
methyl I
ester I
( O
9 O
) O
, O
were O
isolated O
from O

Nine O
mycotoxins O
including O
six O
aspergillic B
acid I
group O
toxins O
, O
aluminiumneoaspergil B
( O
1 O
) O
, O
zirconiumneoaspergil B
( O
2 O
) O
, O
aspergilliamide B
( O
3 O
) O
, O
ferrineoaspergillin B
( O
5 O
) O
, O
flavacol B
( O
6 O
) O
, O
neoaspergillic B
acid I
( O
7 O
) O
, O
and O
three O
ochratoxins B
, O
ochratoxin B
A I
n I
- I
butyl I
ester I
( O
4 O
) O
, O
ochratoxin B
A I
( O
8 O
) O
, O
ochratoxin B
A I
methyl I
ester I
( O
9 O
) O
, O
were O
isolated O
from O

However O
, O
the O
effect O
of O
TIC B
on O
biliary O
phospholipids O
was O
not O
observed O
in O
SD O
rats O
pretreated O
with O
diethylaminoethyl B
diphenylpropylacetat I
that O
inhibits O
cytochrome O
P450s O
( O
P450 O
) O
, O
or O
in O
Eisai O
hyperbilirubinemic O
rats O
( O
EHBR O
) O
lacking O
functional O
multidrug O
resistance O
- O
associated O
protein O
2 O
( O
MRP2 O
/ O
ABCC2 O
) O
. O

Administration O
of O
TIC B
caused O
significant O
liver O
injuries O
in O
SD O
rats O
, O
with O
decreased O
biliary O
phospholipids O
, O
but O
not O
in O
EHBR O
, O
consistent O
with O
the O
in O
vitro O
observation O
that O
phospholipid O
- O
bile B
acid I
- O
mixed O
micelles O
moderated O
the O
cytotoxic O
effects O
of O
bile B
acids I
. O

Administration O
of O
TIC B
caused O
significant O
liver O
injuries O
in O
SD O
rats O
, O
with O
decreased O
biliary O
phospholipids O
, O
but O
not O
in O
EHBR O
, O
consistent O
with O
the O
in O
vitro O
observation O
that O
phospholipid O
- O
bile B
acid I
- O
mixed O
micelles O
moderated O
the O
cytotoxic O
effects O
of O
bile B
acids I
. O

Because O
the O
diminished O
biliary O
secretion O
of O
phospholipids O
with O
TIC B
administration O
was O
restored O
by O
taurocholate B
infusion O
in O
SD O
rats O
, O
the O
decreased O
biliary O
concentration O
of O
bile B
acids I
, O
due O
to O
the O
stimulation O
of O
bile B
acid I
- O
independent O
bile O
flow O
driven O
by O
TIC B
- O
SGs O
, O
might O
have O
indirectly O
attenuated O
phospholipid O
secretion O
. O

Because O
the O
diminished O
biliary O
secretion O
of O
phospholipids O
with O
TIC B
administration O
was O
restored O
by O
taurocholate B
infusion O
in O
SD O
rats O
, O
the O
decreased O
biliary O
concentration O
of O
bile B
acids I
, O
due O
to O
the O
stimulation O
of O
bile B
acid I
- O
independent O
bile O
flow O
driven O
by O
TIC B
- O
SGs O
, O
might O
have O
indirectly O
attenuated O
phospholipid O
secretion O
. O

Human O
stearoyl B
- I
CoA I
desaturase O
1 O
( O
SCD O
- O
1 O
) O
gene O
expression O
is O
negatively O
regulated O
by O
thyroid B
hormone I
without O
direct O
binding O
of O
thyroid B
hormone I
receptor O
to O
the O
gene O
promoter O
. O

Human O
stearoyl B
- I
CoA I
desaturase O
1 O
( O
SCD O
- O
1 O
) O
gene O
expression O
is O
negatively O
regulated O
by O
thyroid B
hormone I
without O
direct O
binding O
of O
thyroid B
hormone I
receptor O
to O
the O
gene O
promoter O
. O

Previous O
report O
demonstrated O
that O
thyroid B
hormone I
( O
TH O
) O
negatively O
regulates O
mouse O
SCD O
- O
1 O
gene O
promoter O
before O
SREBP O
- O
1c O
was O
revealed O
. O

Gamma O
- O
radiolysis O
- O
assisted O
cobalt B
oxide I
nanoparticle O
formation O
. O

The O
daily O
mean O
TPN O
values O
were O
1 O
. O
630 O
+ O
/ O
- O
323 O
kcal O
, O
3 O
. O
2 O
+ O
/ O
- O
0 O
. O
7 O
g O
carbohydrates B
/ O
kg O
, O
1 O
. O
26 O
+ O
/ O
- O
0 O
. O
3 O
g O
amino B
acids I
/ O
kg O
, O
and O
0 O
. O
9 O
+ O
/ O
- O
0 O
. O
2 O
g O
lipids O
/ O
kg O
. O

We O
perform O
ab O
initio O
molecular O
dynamics O
simulations O
of O
aminophenyl B
acid I
dyes O
NK1 B
and O
NK7 B
, O
differing O
by O
the O
electron O
donating O
group O
, O
in O
a O
vacuum O
and O
adsorbed O
in O
mono O
- O
and O
bi O
- O
dentate O
modes O
on O
a O
dry O
and O
a O
water O
- O
covered O
anatase B
( I
101 I
) I
surface O
of O
TiO B
( I
2 I
) I
, O
at O
300 O
and O
350 O
K O
. O

Further O
analysis O
showed O
that O
the O
larger O
enhancements O
came O
from O
coalesced O
gold O
nanotubes O
and O
detection O
of O
the O
dye O
rhodamine B
6G I
at O
concentrations O
as O
low O
as O
0 O
. O
1 O
nM O
was O
possible O
. O

Solid O
- O
phase O
parallel O
synthesis O
based O
on O
cross O
- O
linked O
polystyrene B
and O
a O
Wang O
anchor O
allowed O
the O
low O
- O
scale O
preparation O
of O
four O
small O
libraries O
based O
on O
the O
combination O
of O
two O
amino B
acid I
residues O
( O
out O
of O
Gly B
, O
Leu B
, O
Phe B
, O
Lys B
, O
phenylglycine B
, O
Tyr B
, O
Trp B
, O
His B
, O
and O
Arg B
) O
. O

Microbial O
transformation O
of O
asiatic B
acid I
. O

Asiatic B
acid I
( O
1 O
) O
, O
a O
major O
pentacyclic B
triterpene I
of O
Centella O
asiatica O
, O
was O
subjected O
to O
transformation O
by O
Penicillium O
lilacinum O
ACCC O
31890 O
, O
Fusarium O
equiseti O
CGMCC O
3 O
. O
3658 O
, O
and O
Streptomyces O
griseus O
CGMCC O
4 O
. O
18 O
strains O
. O

Asiatic B
acid I
( O
1 O
) O
, O
a O
major O
pentacyclic B
triterpene I
of O
Centella O
asiatica O
, O
was O
subjected O
to O
transformation O
by O
Penicillium O
lilacinum O
ACCC O
31890 O
, O
Fusarium O
equiseti O
CGMCC O
3 O
. O
3658 O
, O
and O
Streptomyces O
griseus O
CGMCC O
4 O
. O
18 O
strains O
. O

Incubation O
of O
asiatic B
acid I
with O
P O
. O
lilacinum O
ACCC O
31890 O
and O
F O
. O
equiseti O
CGMCC O
3 O
. O
3658 O
gave O
an O
identical O
product O
: O
2 B
alpha I
, I
3 I
beta I
, I
15 I
alpha I
, I
23 I
- I
tetrahydroxyurs I
- I
12 I
- I
en I
- I
28 I
- I
oic I
acid I
( O
2 O
) O
. O

Biotransformation O
of O
asiatic B
acid I
by O
S O
. O
griseus O
CGMCC O
4 O
. O
18 O
resulted O
in O
three O
derivatives O
: O
2 B
alpha I
, I
3 I
beta I
, I
21 I
beta I
, I
23 I
- I
tetrahydroxyurs I
- I
12 I
- I
en I
- I
28 I
- I
oic I
acid I
( O
3 O
) O
, O
2 B
alpha I
, I
3 I
beta I
, I
23 I
- I
trihydroxyurs I
- I
12 I
- I
en I
- I
28 I
, I
30 I
- I
dioic I
acid I
( O
4 O
) O
, O
and O
2 B
alpha I
, I
3 I
beta I
, I
23 I
, I
30 I
- I
tetrahydroxyurs I
- I
12 I
- I
en I
- I
28 I
- I
oic I
acid I
( O
5 O
) O
. O

One O
new O
monoterpenoid B
, O
( B
+ I
) I
- I
argutoid I
A I
( O
1 O
) O
, O
three O
new O
iridoids B
, O
( B
- I
) I
- I
incarvoid I
A I
( O
2 O
) O
, O
( B
+ I
) I
- I
incarvoid I
B I
( O
3 O
) O
, O
and O
incarvoid B
C I
( O
4 O
) O
, O
and O
five O
known O
compounds O
were O
isolated O
from O
Incarvillea O
arguta O
. O

Amino B
acid I
- O
based O
zwitterionic B
poly I
( I
serine I
methacrylate I
) I
as O
an O
antifouling O
material O
. O

This O
is O
the O
first O
work O
to O
develop O
an O
amino B
acid I
- O
based O
zwitterionic O
polymer O
as O
an O
antifouling O
material O
, O
demonstrating O
that O
pSerMA B
is O
a O
promising O
alternative O
to O
the O
traditional O
ethylene B
glycol I
- O
based O
antifouling O
materials O
. O

This O
is O
the O
first O
work O
to O
develop O
an O
amino B
acid I
- O
based O
zwitterionic O
polymer O
as O
an O
antifouling O
material O
, O
demonstrating O
that O
pSerMA B
is O
a O
promising O
alternative O
to O
the O
traditional O
ethylene B
glycol I
- O
based O
antifouling O
materials O
. O

Here O
, O
a O
novel O
bovine O
monocyte O
chemotactic O
factor O
( O
boMCF O
- O
1 O
) O
was O
isolated O
from O
commercial O
bovine O
serum O
by O
a O
four O
step O
purification O
procedure O
including O
adsorption O
to O
silicic B
acid I
, O
heparin O
affinity O
and O
cation O
- O
exchange O
chromatography O
and O
reversed O
phase O
HPLC O
. O

Homogeneous O
boMCF O
- O
1 O
was O
characterized O
as O
a O
7717Da O
protein O
by O
mass O
spectrometry O
and O
identified O
by O
Edman O
degradation O
as O
the O
predicted O
product O
of O
bovine O
macrophage O
inflammatory O
protein O
- O
1 O
alpha O
gene O
( O
boMIP O
- O
1 O
alpha O
/ O
CCL3 O
) O
isoform O
2 O
( O
lacking O
three O
NH B
2 I
- O
terminal O
amino B
acids I
) O
, O
belonging O
to O
the O
MIP O
subfamily O
of O
CC O
chemokines O
. O

Homogeneous O
boMCF O
- O
1 O
was O
characterized O
as O
a O
7717Da O
protein O
by O
mass O
spectrometry O
and O
identified O
by O
Edman O
degradation O
as O
the O
predicted O
product O
of O
bovine O
macrophage O
inflammatory O
protein O
- O
1 O
alpha O
gene O
( O
boMIP O
- O
1 O
alpha O
/ O
CCL3 O
) O
isoform O
2 O
( O
lacking O
three O
NH B
2 I
- O
terminal O
amino B
acids I
) O
, O
belonging O
to O
the O
MIP O
subfamily O
of O
CC O
chemokines O
. O

A O
photoinduced O
charge O
transfer O
composite O
of O
graphene B
oxide I
and O
ferrocene B
. O

We O
demonstrate O
the O
formation O
of O
a O
photoinduced O
charge O
transfer O
composite O
with O
graphene B
oxide I
( O
GO O
) O
and O
ferrocene B
( O
Fc O
) O
molecules O
. O

Vitamin B
K2 I
covalently O
binds O
to O
Bak O
and O
induces O
Bak O
- O
mediated O
apoptosis O
. O

Vitamin B
K2 I
( O
VK2 B
, O
menaquinone B
) O
is O
known O
to O
have O
anticancer O
activity O
in O
vitro O
and O
in O
vivo O
. O

Ethyl B
glucuronide I
( O
EtG B
) O
determination O
is O
increasingly O
used O
in O
clinical O
and O
forensic O
toxicology O
to O
document O
ethanol B
consumption O
. O

Expression O
and O
activity O
of O
nitric B
oxide I
synthase O
isoforms O
in O
methamphetamine B
- O
induced O
striatal O
dopamine B
toxicity O
. O

Nitric B
oxide I
is O
implicated O
in O
methamphetamine B
( O
METH B
) O
- O
induced O
neurotoxicity O
; O
however O
, O
the O
source O
of O
the O
nitric B
oxide I
has O
not O
been O
identified O
. O

Nitric B
oxide I
is O
implicated O
in O
methamphetamine B
( O
METH B
) O
- O
induced O
neurotoxicity O
; O
however O
, O
the O
source O
of O
the O
nitric B
oxide I
has O
not O
been O
identified O
. O

The O
current O
study O
examined O
nitric B
oxide I
synthase O
expression O
and O
activity O
and O
protein O
nitration O
in O
striata O
of O
animals O
administered O
saline O
or O
neurotoxic O
regimens O
of O
methamphetamine B
at O
postnatal O
days O
60 O
and O
/ O
or O
90 O
, O
resulting O
in O
four O
treatment O
groups O
: O
Saline O
: O
Saline O
, O
METH B
: O
Saline O
, O
Saline O
: O
METH B
, O
and O
METH B
: O
METH B
. O

Acute O
administration O
of O
methamphetamine B
on O
postnatal O
day O
90 O
( O
Saline O
: O
METH B
and O
METH B
: O
METH B
) O
increased O
nitric B
oxide I
production O
, O
as O
evidenced O
by O
increased O
protein O
nitration O
. O

Methamphetamine B
did O
not O
, O
however O
, O
change O
the O
expression O
of O
endothelial O
or O
inducible O
isoforms O
of O
nitric B
oxide I
synthase O
, O
nor O
did O
it O
change O
the O
number O
of O
cells O
positive O
for O
neuronal O
nitric B
oxide I
synthase O
mRNA O
expression O
or O
the O
amount O
of O
neuronal O
nitric B
oxide I
synthase O
mRNA O
per O
cell O
. O

Methamphetamine B
did O
not O
, O
however O
, O
change O
the O
expression O
of O
endothelial O
or O
inducible O
isoforms O
of O
nitric B
oxide I
synthase O
, O
nor O
did O
it O
change O
the O
number O
of O
cells O
positive O
for O
neuronal O
nitric B
oxide I
synthase O
mRNA O
expression O
or O
the O
amount O
of O
neuronal O
nitric B
oxide I
synthase O
mRNA O
per O
cell O
. O

Methamphetamine B
did O
not O
, O
however O
, O
change O
the O
expression O
of O
endothelial O
or O
inducible O
isoforms O
of O
nitric B
oxide I
synthase O
, O
nor O
did O
it O
change O
the O
number O
of O
cells O
positive O
for O
neuronal O
nitric B
oxide I
synthase O
mRNA O
expression O
or O
the O
amount O
of O
neuronal O
nitric B
oxide I
synthase O
mRNA O
per O
cell O
. O

However O
, O
nitric B
oxide I
synthase O
activity O
in O
striatal O
interneurons O
was O
increased O
in O
the O
Saline O
: O
METH B
and O
METH B
: O
METH B
animals O
. O

These O
data O
suggest O
that O
increased O
nitric B
oxide I
production O
after O
a O
neurotoxic O
regimen O
of O
methamphetamine B
results O
from O
increased O
nitric B
oxide I
synthase O
activity O
, O
rather O
than O
an O
induction O
of O
mRNA O
, O
and O
that O
constitutively O
expressed O
neuronal O
nitric B
oxide I
synthase O
is O
the O
most O
likely O
source O
of O
nitric B
oxide I
after O
methamphetamine B
administration O
. O

These O
data O
suggest O
that O
increased O
nitric B
oxide I
production O
after O
a O
neurotoxic O
regimen O
of O
methamphetamine B
results O
from O
increased O
nitric B
oxide I
synthase O
activity O
, O
rather O
than O
an O
induction O
of O
mRNA O
, O
and O
that O
constitutively O
expressed O
neuronal O
nitric B
oxide I
synthase O
is O
the O
most O
likely O
source O
of O
nitric B
oxide I
after O
methamphetamine B
administration O
. O

These O
data O
suggest O
that O
increased O
nitric B
oxide I
production O
after O
a O
neurotoxic O
regimen O
of O
methamphetamine B
results O
from O
increased O
nitric B
oxide I
synthase O
activity O
, O
rather O
than O
an O
induction O
of O
mRNA O
, O
and O
that O
constitutively O
expressed O
neuronal O
nitric B
oxide I
synthase O
is O
the O
most O
likely O
source O
of O
nitric B
oxide I
after O
methamphetamine B
administration O
. O

These O
data O
suggest O
that O
increased O
nitric B
oxide I
production O
after O
a O
neurotoxic O
regimen O
of O
methamphetamine B
results O
from O
increased O
nitric B
oxide I
synthase O
activity O
, O
rather O
than O
an O
induction O
of O
mRNA O
, O
and O
that O
constitutively O
expressed O
neuronal O
nitric B
oxide I
synthase O
is O
the O
most O
likely O
source O
of O
nitric B
oxide I
after O
methamphetamine B
administration O
. O

Of O
interest O
, O
animals O
rendered O
resistant O
to O
further O
methamphetamine B
- O
induced O
dopamine B
depletions O
still O
show O
equivalent O
degrees O
of O
methamphetamine B
- O
induced O
nitric B
oxide I
production O
, O
suggesting O
that O
nitric B
oxide I
production O
alone O
in O
response O
to O
methamphetamine B
is O
not O
sufficient O
to O
induce O
acute O
neurotoxic O
injury O
. O

Of O
interest O
, O
animals O
rendered O
resistant O
to O
further O
methamphetamine B
- O
induced O
dopamine B
depletions O
still O
show O
equivalent O
degrees O
of O
methamphetamine B
- O
induced O
nitric B
oxide I
production O
, O
suggesting O
that O
nitric B
oxide I
production O
alone O
in O
response O
to O
methamphetamine B
is O
not O
sufficient O
to O
induce O
acute O
neurotoxic O
injury O
. O

Surfactant O
- O
free O
microemulsion O
composed O
of O
oleic B
acid I
, O
n B
- I
propanol I
, O
and O
H2O B
. O

Herein O
, O
we O
report O
a O
surfactant O
- O
free O
microemulsion O
( O
denoted O
as O
SFME O
) O
, O
consisting O
of O
oleic B
acid I
( O
oil O
phase O
) O
, O
water O
, O
and O
n B
- I
propanol I
without O
the O
amphiphilic O
molecular O
structure O
of O
a O
traditional O
surfactant O
. O

The O
electrical O
conductivity O
measurement O
was O
employed O
to O
investigate O
the O
microregions O
of O
the O
single O
- O
phase O
microemulsion O
region O
, O
and O
three O
different O
microregions O
, O
that O
is O
, O
water O
- O
in O
- O
oleic B
acid I
( O
W O
/ O
O O
) O
, O
a O
bicontinuous O
( O
B O
. O
C O
. O
) O
region O
, O
and O
oleic B
acid I
- O
in O
- O
water O
( O
O O
/ O
W O
) O
, O
were O
identified O
, O
which O
were O
further O
confirmed O
by O
freeze O
- O
fracture O
and O
cryogenic O
transmission O
electron O
microscopy O
( O
FF O
- O
TEM O
and O
Cryo O
- O
TEM O
) O
observations O
. O

The O
electrical O
conductivity O
measurement O
was O
employed O
to O
investigate O
the O
microregions O
of O
the O
single O
- O
phase O
microemulsion O
region O
, O
and O
three O
different O
microregions O
, O
that O
is O
, O
water O
- O
in O
- O
oleic B
acid I
( O
W O
/ O
O O
) O
, O
a O
bicontinuous O
( O
B O
. O
C O
. O
) O
region O
, O
and O
oleic B
acid I
- O
in O
- O
water O
( O
O O
/ O
W O
) O
, O
were O
identified O
, O
which O
were O
further O
confirmed O
by O
freeze O
- O
fracture O
and O
cryogenic O
transmission O
electron O
microscopy O
( O
FF O
- O
TEM O
and O
Cryo O
- O
TEM O
) O
observations O
. O

The O
polarity O
and O
the O
salt O
solubility O
of O
water O
domains O
in O
the O
W O
/ O
O O
SFME O
were O
investigated O
by O
UV O
- O
visible O
spectroscopy O
using O
methyl B
orange I
and O
potassium B
ferricyanide I
as O
probes O
, O
respectively O
. O

The O
polarity O
and O
the O
salt O
solubility O
of O
water O
domains O
in O
the O
W O
/ O
O O
SFME O
were O
investigated O
by O
UV O
- O
visible O
spectroscopy O
using O
methyl B
orange I
and O
potassium B
ferricyanide I
as O
probes O
, O
respectively O
. O

We O
aim O
to O
" O
tilt O
" O
the O
stability O
of O
the O
H1 O
loop O
structure O
from O
a O
noncanonical O
conformation O
to O
a O
( O
humanized O
) O
type O
1 O
canonical O
conformation O
by O
studying O
the O
effect O
of O
selected O
mutations O
to O
the O
amino B
acid I
sequence O
of O
the O
H1 O
, O
H2 O
, O
and O
proximal O
residues O
. O

New O
iridoid B
glycoside I
and O
triterpenoid B
glycoside I
from O
Premna O
fulva O
. O

New O
iridoid B
glycoside I
and O
triterpenoid B
glycoside I
from O
Premna O
fulva O
. O

Liquid O
chromatography O
- O
photodiode O
array O
detector O
- O
mass O
spectrometry O
- O
based O
chemical O
investigation O
of O
the O
leaves O
and O
stems O
of O
Premna O
fulva O
yielded O
one O
new O
iridoid B
glycoside I
( O
1 O
) O
, O
one O
new O
triterpenoid B
glycoside I
( O
2 O
) O
along O
with O
six O
known O
compounds O
isolated O
for O
the O
first O
time O
from O
the O
genus O
. O

Liquid O
chromatography O
- O
photodiode O
array O
detector O
- O
mass O
spectrometry O
- O
based O
chemical O
investigation O
of O
the O
leaves O
and O
stems O
of O
Premna O
fulva O
yielded O
one O
new O
iridoid B
glycoside I
( O
1 O
) O
, O
one O
new O
triterpenoid B
glycoside I
( O
2 O
) O
along O
with O
six O
known O
compounds O
isolated O
for O
the O
first O
time O
from O
the O
genus O
. O

Flow O
cytometry O
with O
gal O
- O
1 O
( O
- O
/ O
- O
) O
splenocytes O
showed O
that O
6DBF7 B
and O
two O
of O
its O
more O
potent O
analogs O
( O
DB16 B
and O
DB21 B
) O
can O
fully O
inhibit O
fluorescein B
isothiocyanate I
- O
gal O
- O
1 O
binding O
. O

As O
diquat B
is O
not O
persistent O
, O
snails O
were O
exposed O
for O
short O
times O
( O
5 O
, O
24 O
, O
and O
48 O
h O
) O
to O
ecologically O
relevant O
concentrations O
( O
22 O
. O
2 O
, O
44 O
. O
4 O
, O
and O
222 O
. O
2 O
mu O
g O
l O
( O
- O
1 O
) O
) O
of O
diquat B
dibromide I
. O

Bisphenol B
A I
interferes O
with O
thyroid O
specific O
gene O
expression O
. O

Bisphenol B
A I
( O
BPA B
) O
is O
an O
endocrine O
- O
disrupting O
chemical O
that O
leads O
to O
low O
- O
dose O
human O
exposure O
due O
to O
its O
ability O
to O
leach O
from O
chemically O
derived O
products O
, O
as O
polycarbonate B
plastics O
and O
epoxy B
resin O
. O

Despite O
the O
documented O
BPA B
exposure O
outcomes O
on O
synthesis O
of O
thyroid B
hormones I
, O
there O
are O
not O
any O
data O
available O
on O
its O
actions O
on O
the O
thyroid O
follicular O
cells O
, O
site O
of O
synthesis O
of O
the O
thyroid B
hormones I
. O

Despite O
the O
documented O
BPA B
exposure O
outcomes O
on O
synthesis O
of O
thyroid B
hormones I
, O
there O
are O
not O
any O
data O
available O
on O
its O
actions O
on O
the O
thyroid O
follicular O
cells O
, O
site O
of O
synthesis O
of O
the O
thyroid B
hormones I
. O

In O
this O
study O
, O
we O
employed O
in O
vitro O
and O
in O
vivo O
( O
zebrafish O
) O
models O
to O
examine O
the O
effects O
of O
BPA B
in O
regulating O
the O
expression O
of O
genes O
involved O
in O
the O
thyroid B
hormone I
synthesis O
and O
of O
their O
transcriptional O
regulators O
at O
BPA B
doses O
as O
low O
as O
10 O
( O
- O
9 O
) O
M O
, O
a O
dose O
that O
is O
environmentally O
pertinent O
and O
far O
below O
the O
one O
detected O
in O
infants O
plasma O
. O

In O
both O
systems O
we O
could O
detect O
an O
altered O
expression O
of O
the O
genes O
involved O
in O
thyroid B
hormones I
synthesis O
and O
of O
thyroid O
specific O
transcriptional O
factors O
in O
BPA B
dose O
and O
time O
dependent O
manner O
. O

Threshold O
collision O
- O
induced O
dissociation O
of O
hydrated B
magnesium I
: O
experimental O
and O
theoretical O
investigation O
of O
the O
binding O
energies O
for O
Mg B
( I
2 I
+ I
) I
( I
H2O I
) I
x I
complexes O
( O
x O
= O
2 O
- O
10 O
) O
. O

Here O
we O
present O
boronic B
and O
borinic B
acid I
derivatives O
as O
a O
new O
class O
of O
potent O
and O
nontoxic O
APT O
inhibitors O
. O

Here O
, O
we O
develop O
an O
improved O
version O
of O
FINDSITE O
, O
FINDSITE O
( O
filt O
) O
, O
that O
filters O
out O
false O
positive O
ligands O
in O
threading O
identified O
templates O
by O
a O
better O
binding O
site O
detection O
procedure O
that O
includes O
information O
about O
the O
binding O
site O
amino B
acid I
similarity O
. O

PKAA B
exhibited O
sufficient O
buffering O
capability O
and O
endosomolytic O
activity O
due O
mainly O
to O
the O
presence O
of O
secondary B
amine I
groups O
in O
its O
backbone O
and O
rapid O
degradation O
in O
acidic O
endosomes O
, O
leading O
to O
the O
enhanced O
release O
of O
siRNA O
to O
cytoplasm O
. O

The O
obtained O
polymer O
( O
T24 O
) O
was O
then O
activated O
by O
reaction O
with O
4 B
- I
nitrophenyl I
chloroformate I
( O
NPC B
) O
in O
order O
to O
graft O
a O
cyclic O
peptide O
presenting O
an O
arginine B
- O
glycine B
- O
aspartic B
acid I
( O
RGD O
) O
motif O
. O

The O
desired O
3 B
- I
( I
arylsulfonyl I
) I
spiroimidazolidine I
- I
2 I
, I
4 I
- I
diones I
were O
synthesized O
by O
reacting O
spiroiminoimidazolid B
- I
2 I
, I
4 I
- I
dione I
with O
arylsulfonyl B
chlorides I
. O

As O
a O
mechanism O
of O
action O
, O
the O
knockdown O
of O
TLR4 O
with O
small O
interfering O
RNA O
decreased O
the O
ADP O
- O
induced O
production O
of O
nitric B
oxide I
and O
IL O
- O
12 O
by O
DCs O
, O
suggesting O
the O
membrane O
receptor O
candidate O
of O
ADP O
. O

Ion O
current O
peaks O
( O
as O
opposed O
to O
blockades O
) O
were O
produced O
by O
both O
positively O
( O
Rhodamine B
6G I
) O
and O
negatively O
( O
Alexa B
546 I
) O
charged O
molecules O
, O
showing O
that O
the O
charge O
filtering O
responsible O
for O
the O
current O
bursts O
is O
caused O
by O
the O
molecules O
themselves O
. O

Ion O
current O
peaks O
( O
as O
opposed O
to O
blockades O
) O
were O
produced O
by O
both O
positively O
( O
Rhodamine B
6G I
) O
and O
negatively O
( O
Alexa B
546 I
) O
charged O
molecules O
, O
showing O
that O
the O
charge O
filtering O
responsible O
for O
the O
current O
bursts O
is O
caused O
by O
the O
molecules O
themselves O
. O

Primary O
macrophages O
treated O
with O
lipopolysaccharide O
( O
LPS O
) O
did O
not O
produce O
C16 B
ceramide I
, O
whereas O
palmitate B
exposure O
led O
to O
a O
modest O
increase O
in O
this O
sphingolipid B
. O

Strikingly O
, O
the O
combination O
of O
LPS O
and O
palmitate B
led O
to O
a O
synergistic O
increase O
in O
C16 B
ceramide I
. O

Chemical O
Modification O
of O
Lysozyme O
, O
Glucose B
6 I
- I
Phosphate I
Dehydrogenase O
, O
and O
Bovine O
Eye O
Lens O
Proteins O
Induced O
by O
Peroxyl B
Radicals O
: O
Role O
of O
Oxidizable O
Amino B
Acid I
Residues O
. O

This O
critical O
commentary O
reviews O
scanning O
techniques O
, O
which O
employ O
natural O
and O
non O
- O
proteinogenic O
amino B
acids I
to O
facilitate O
understanding O
of O
structural O
requirements O
for O
peptide O
biological O
activity O
. O

By O
examining O
the O
relative O
effects O
of O
corticosterone B
( O
CORT B
) O
, O
arginine B
vasotocin I
( O
AVT B
, O
the O
avian O
homologue O
to O
arginine B
vasopressin I
) O
and O
corticotrophin O
- O
releasing O
factor O
( O
CRF O
) O
, O
the O
present O
study O
aimed O
to O
define O
the O
hormone O
profile O
regulating O
stress O
- O
induced O
increases O
in O
AA O
in O
the O
POM O
. O

By O
examining O
the O
relative O
effects O
of O
corticosterone B
( O
CORT B
) O
, O
arginine B
vasotocin I
( O
AVT B
, O
the O
avian O
homologue O
to O
arginine B
vasopressin I
) O
and O
corticotrophin O
- O
releasing O
factor O
( O
CRF O
) O
, O
the O
present O
study O
aimed O
to O
define O
the O
hormone O
profile O
regulating O
stress O
- O
induced O
increases O
in O
AA O
in O
the O
POM O
. O

CTLL O
- O
2 O
cells O
were O
exposed O
for O
6 O
h O
to O
two O
model O
immunotoxic O
compounds O
: O
( O
1 O
) O
the O
mycotoxin O
deoxynivalenol B
( O
DON B
, O
1 O
and O
2 O
mu O
M O
) O
, O
a O
ribotoxic O
stress O
inducer O
, O
and O
( O
2 O
) O
the O
organotin B
compound O
tributyltin B
oxide I
( O
TBTO B
, O
100 O
and O
200 O
nM O
) O
, O
an O
endoplasmic O
reticulum O
( O
ER O
) O
stress O
inducer O
. O

Formation O
and O
infrared O
absorption O
of O
protonated B
naphthalenes I
( O
1 B
- I
C10H9 I
+ I
and O
2 B
- I
C10H9 I
+ I
) O
and O
their O
neutral O
counterparts O
in O
solid O
para B
- I
hydrogen I
. O

Protonated B
naphthalene I
( O
C B
( I
10 I
) I
H I
( I
9 I
) I
( I
+ I
) I
) O
and O
its O
neutral O
counterparts O
( O
hydronaphthyl B
radicals O
, O
C B
( I
10 I
) I
H I
( I
9 I
) I
) O
are O
important O
intermediates O
in O
the O
reactions O
of O
aromatic O
compounds O
and O
in O
understanding O
the O
unidentified O
infrared O
( O
IR O
) O
emissions O
from O
interstellar O
media O
. O

In O
contrast O
, O
purified O
and O
solar B
salts I
increased O
metastasis O
in O
the O
mice O
. O

Additionally O
, O
the O
anticancer O
, O
anti O
- O
inflammatory O
, O
and O
anti O
- O
metastatic O
effects O
of O
the O
1 O
x O
and O
3 O
x O
bamboo O
salts O
were O
stronger O
than O
those O
of O
the O
purified O
and O
solar B
salts I
. O

Novel O
betulinic B
acid I
derivative O
5 B
' I
- I
chloro I
- I
2 I
, I
3 I
- I
didehydroindolo I
[ I
2 I
' I
, I
3 I
' I
: I
2 I
, I
3 I
] I
betulinic I
acid I
( O
DRF B
- I
4012 I
) O
is O
a O
new O
effective O
lupane B
type O
triterpenes B
with O
greater O
anticancer O
activity O
and O
efficacy O
than O
betulinic B
acid I
and O
currently O
under O
advanced O
preclinical O
investigation O
phase O
. O

Novel O
betulinic B
acid I
derivative O
5 B
' I
- I
chloro I
- I
2 I
, I
3 I
- I
didehydroindolo I
[ I
2 I
' I
, I
3 I
' I
: I
2 I
, I
3 I
] I
betulinic I
acid I
( O
DRF B
- I
4012 I
) O
is O
a O
new O
effective O
lupane B
type O
triterpenes B
with O
greater O
anticancer O
activity O
and O
efficacy O
than O
betulinic B
acid I
and O
currently O
under O
advanced O
preclinical O
investigation O
phase O
. O

Characterization O
of O
in O
vitro O
metabolites O
of O
luotonin B
A I
in O
human O
liver O
microsomes O
using O
electrospray O
/ O
tandem O
mass O
spectrometry O
. O

The O
pharmacological O
activity O
of O
luotonin B
A I
varies O
, O
depending O
on O
the O
type O
of O
functional O
group O
and O
the O
site O
of O
derivatization O
. O

To O
understand O
the O
in O
vivo O
efficacy O
of O
luotonin B
A I
, O
the O
in O
vitro O
metabolism O
of O
luotonin B
A I
was O
investigated O
in O
human O
liver O
microsomes O
and O
recombinant O
cDNA O
- O
expressed O
cytochromeP450 O
( O
CYP O
) O
. O

To O
understand O
the O
in O
vivo O
efficacy O
of O
luotonin B
A I
, O
the O
in O
vitro O
metabolism O
of O
luotonin B
A I
was O
investigated O
in O
human O
liver O
microsomes O
and O
recombinant O
cDNA O
- O
expressed O
cytochromeP450 O
( O
CYP O
) O
. O

Incubation O
of O
luotonin B
A I
with O
pooled O
human O
liver O
microsomes O
in O
the O
presence O
of O
NADPH B
- O
generating O
system O
resulted O
in O
the O
formation O
of O
four O
metabolites O
and O
the O
structures O
of O
each O
metabolite O
were O
tentatively O
characterized O
on O
the O
basis O
of O
electrospray O
tandem O
mass O
spectra O
. O

The O
main O
metabolic O
pathway O
of O
luotonin B
A I
in O
human O
liver O
microsomes O
was O
hydroxylation O
, O
resulting O
in O
the O
generation O
of O
two O
mono B
- I
hydroxyl I
metabolites O
( O
M1 O
and O
M2 O
) O
and O
two O
di B
- I
hydroxyl I
metabolites O
( O
M3 O
and O
M4 O
) O
. O

CYP1A2 O
was O
primarily O
involved O
in O
hydroxylation O
of O
the O
quinolone B
moiety O
( O
M1 O
andM3 O
) O
, O
while O
CYP3A4 O
was O
mainly O
responsible O
for O
hydroxylation O
of O
the O
quinazoline B
moiety O
of O
luotonin B
A I
( O
M2 O
and O
M4 O
) O
in O
human O
liver O
microsomes O
. O

Kisspeptin O
is O
a O
54 O
- O
amino B
acid I
peptide O
which O
is O
encoded O
by O
the O
KiSS O
- O
1 O
gene O
and O
activates O
the O
G O
protein O
- O
coupled O
receptor O
GPR54 O
. O

Molecular O
nonwoven O
fabrics O
in O
the O
form O
of O
ultrathin O
layer O
- O
by O
- O
layer O
( O
LbL O
) O
helical O
polymer O
films O
with O
covalent O
cross O
- O
linking O
were O
assembled O
on O
substrates O
by O
an O
alternate O
ester B
- O
amide B
exchange O
reaction O
between O
poly B
( I
gamma I
- I
methyl I
l I
- I
glutamate I
) I
( O
PMLG B
) O
and O
cross O
- O
linking O
agent O
ethylene B
diamine I
or O
4 B
, I
4 I
' I
- I
diamino I
azobenzene I
. O

The O
major O
products O
identified O
by O
FTIR O
and O
confirmed O
using O
matrix O
- O
assisted O
laser O
desorption O
/ O
ionization O
( O
MALDI O
) O
mass O
spectrometry O
were O
the O
secondary B
ozonide I
( O
SOZ B
) O
and O
a O
phospholipid O
aldehyde B
and O
carboxylic B
acid I
formed O
by O
scission O
of O
the O
double O
bond O
. O

The O
major O
products O
identified O
by O
FTIR O
and O
confirmed O
using O
matrix O
- O
assisted O
laser O
desorption O
/ O
ionization O
( O
MALDI O
) O
mass O
spectrometry O
were O
the O
secondary B
ozonide I
( O
SOZ B
) O
and O
a O
phospholipid O
aldehyde B
and O
carboxylic B
acid I
formed O
by O
scission O
of O
the O
double O
bond O
. O

The O
main O
biological O
functions O
of O
these O
173 O
genes O
include O
signaling O
by O
Nerve O
Growth O
Factor O
, O
DNA O
Repair O
, O
Integrin O
Cell O
Surface O
Interactions O
, O
Biological O
Oxidations O
, O
Apoptosis O
, O
Synaptic O
Transmission O
, O
Cell O
Cycle O
Checkpoints O
, O
and O
Arachidonic B
Acid I
Metabolism O
. O

Plants O
were O
cultivated O
outdoors O
under O
semi O
- O
controlled O
conditions O
in O
water O
solution O
containing O
Na B
selenite I
( O
20 O
mu O
g O
Se B
L O
( O
- O
1 O
) O
and O
10 O
mg O
Se B
L O
( O
- O
1 O
) O
) O
. O

The O
response O
of O
M O
. O
spicatum O
and O
C O
. O
demersum O
to O
Se B
( I
IV I
) I
regarding O
chlorophylls B
was O
variable O
, O
however O
in O
the O
majority O
of O
cases O
, O
there O
was O
a O
trend O
of O
increasing O
the O
amount O
of O
chlorophylls B
, O
while O
in O
P O
. O
perfoliatus O
the O
amount O
of O
chlorophyll B
a I
decreased O
. O

Additionally O
, O
SKN B
- O
caused O
cell O
death O
was O
reversed O
by O
a O
reactive O
oxygen B
species O
( O
ROS O
) O
scavenger O
N B
- I
acetylcysteine I
( O
NAC B
) O
whereas O
TNF O
alpha O
- O
mediated O
necrosis O
was O
successfully O
protected O
by O
butylated B
hydroxyanisole I
( O
BHA B
) O
, O
implying O
that O
ROS O
may O
be O
differentially O
derived O
from O
death O
inducing O
agents O
. O

This O
NADPH B
- O
dependent O
reduction O
of O
CBCP B
- I
one I
was O
then O
used O
to O
re O
- O
evaluate O
inhibitory O
potencies O
of O
the O
known O
inhibitors O
of O
the O
target O
AKR1C3 O
and O
the O
anti O
- O
target O
AKR1C2 O
, O
medroxyprogesterone B
acetate I
and O
ursodeoxycholic B
acid I
, O
respectively O
, O
showing O
Ki O
constants O
similar O
to O
the O
reported O
values O
. O

This O
NADPH B
- O
dependent O
reduction O
of O
CBCP B
- I
one I
was O
then O
used O
to O
re O
- O
evaluate O
inhibitory O
potencies O
of O
the O
known O
inhibitors O
of O
the O
target O
AKR1C3 O
and O
the O
anti O
- O
target O
AKR1C2 O
, O
medroxyprogesterone B
acetate I
and O
ursodeoxycholic B
acid I
, O
respectively O
, O
showing O
Ki O
constants O
similar O
to O
the O
reported O
values O
. O

Effects O
of O
p53 O
knockout O
on O
ochratoxin B
A I
- O
induced O
genotoxicity O
in O
p53 O
- O
deficient O
gpt O
delta O
mice O
. O

Ochratoxin B
A I
( O
OTA B
) O
is O
a O
mycotoxin O
produced O
by O
fungal O
species O
and O
is O
carcinogenic O
targeting O
the O
S3 O
segment O
of O
the O
renal O
proximal O
tubules O
in O
rodents O
. O

Pretreatment O
with O
the O
nitric B
oxide I
inhibitor O
N B
( I
G I
) I
- I
nitro I
- I
l I
- I
arginine I
methyl I
ester I
( O
l B
- I
NAME I
) O
reduced O
the O
locomotor O
activating O
effects O
of O
paraxanthine B
, O
but O
not O
caffeine B
. O

Phenylethanoid B
glycosides I
from O
the O
stems O
of O
Callicarpa O
peii O
( O
hemostatic O
drug O
) O
. O

Two O
new O
trisaccharide B
intermediates O
of O
phenylethanoid B
glycosides I
, O
peiioside B
A I
( I
1 I
) I
/ I
A I
( I
2 I
) I
( O
1a O
/ O
1b O
) O
and O
peiioside B
B I
( O
2 O
) O
, O
were O
isolated O
from O
the O
n B
- I
BuOH I
fraction O
of O
MeOH B
extract O
of O
the O
stems O
of O
Callicarpa O
peii O
H O
. O
T O
. O

Two O
new O
trisaccharide B
intermediates O
of O
phenylethanoid B
glycosides I
, O
peiioside B
A I
( I
1 I
) I
/ I
A I
( I
2 I
) I
( O
1a O
/ O
1b O
) O
and O
peiioside B
B I
( O
2 O
) O
, O
were O
isolated O
from O
the O
n B
- I
BuOH I
fraction O
of O
MeOH B
extract O
of O
the O
stems O
of O
Callicarpa O
peii O
H O
. O
T O
. O

On O
the O
basis O
of O
the O
isolated O
compounds O
, O
a O
presumable O
biogenetic O
pathway O
of O
the O
biologically O
interesting O
phenylethanoid B
glycosides I
about O
forsythoside B
B I
( O
3 O
) O
and O
acteoside B
( O
4 O
) O
isolated O
from O
this O
species O
was O
proposed O
. O

This O
is O
the O
first O
report O
about O
phytochemical O
research O
on O
C O
. O
peii O
and O
the O
biogenetic O
hypothesis O
of O
forsythoside B
B I
and O
acteoside B
. O

The O
twigs O
of O
Cudrania O
tricuspidata O
were O
found O
to O
show O
strong O
tyrosinase O
inhibitory O
activity O
, O
and O
further O
detailed O
component O
analysis O
resulted O
in O
the O
isolation O
of O
a O
new O
flavanol B
glucoside I
, O
( B
2S I
, I
3S I
) I
- I
2 I
, I
3 I
- I
trans I
- I
dihydromorin I
- I
7 I
- I
O I
- I
beta I
- I
d I
- I
glucoside I
( O
1 O
) O
, O
plus O
twenty O
- O
seven O
known O
compounds O
( O
2 O
- O
28 O
) O
. O

Based O
on O
the O
known O
Sap2 O
- O
substrate O
specificity O
data O
and O
X O
- O
ray O
analyses O
of O
Sap O
/ O
inhibitor O
complexes O
, O
three O
libraries O
of O
inhibitors O
were O
designed O
and O
synthesized O
by O
modifying O
the O
structure O
of O
pepstatin B
A I
, O
a O
common O
non O
- O
selective O
aspartic O
proteinase O
inhibitor O
, O
at O
the O
P3 O
, O
P2 O
, O
or O
P2 O
' O
position O
. O

Interferon O
beta O
and O
glatiramer B
acetate I
therapy O
. O

Interferon O
beta O
and O
glatiramer B
acetate I
have O
been O
mainstays O
of O
treatment O
in O
relapsingremitting O
multiple O
sclerosis O
for O
two O
decades O
. O

Finally O
, O
we O
look O
to O
the O
future O
of O
interferon O
beta O
and O
glatiramer B
acetate I
in O
the O
context O
of O
an O
ever O
growing O
armamentarium O
of O
treatments O
for O
relapsing O
remitting O
multiple O
sclerosis O
. O

Colour O
, O
cooking O
loss O
, O
myofibril O
fragmentation O
index O
( O
MFI O
) O
and O
shear O
force O
of O
duck O
breast O
and O
thigh O
meat O
postmortem O
were O
measured O
, O
and O
changes O
of O
positive O
nuclei O
were O
assessed O
with O
Terminal O
deoxynucleotidyl B
transferase O
- O
mediated O
deoxyuridine B
triphosphophate I
nick O
end O
- O
labelling O
method O
( O
TUNEL O
) O
. O

As O
determined O
by O
HPLC O
, O
hydroxycinnamic B
acids I
were O
the O
major O
phenolic B
acids I
in O
the O
red O
wines O
. O

As O
determined O
by O
HPLC O
, O
hydroxycinnamic B
acids I
were O
the O
major O
phenolic B
acids I
in O
the O
red O
wines O
. O

After O
6 O
months O
in O
the O
bottle O
, O
the O
enzyme O
- O
treated O
wines O
had O
lower O
phenolic B
acid I
concentrations O
than O
had O
the O
control O
and O
mash O
- O
heated O
wines O
, O
but O
no O
significant O
( O
p O
< O
0 O
. O
05 O
) O
differences O
were O
found O
in O
the O
concentration O
of O
total O
phenolic B
acids I
between O
the O
control O
and O
mash O
- O
heated O
wines O
. O

After O
6 O
months O
in O
the O
bottle O
, O
the O
enzyme O
- O
treated O
wines O
had O
lower O
phenolic B
acid I
concentrations O
than O
had O
the O
control O
and O
mash O
- O
heated O
wines O
, O
but O
no O
significant O
( O
p O
< O
0 O
. O
05 O
) O
differences O
were O
found O
in O
the O
concentration O
of O
total O
phenolic B
acids I
between O
the O
control O
and O
mash O
- O
heated O
wines O
. O

All O
of O
the O
phenolic B
acid I
levels O
decreased O
with O
the O
winemaking O
and O
ageing O
processes O
whereas O
only O
gallic B
acid I
increased O
. O

All O
of O
the O
phenolic B
acid I
levels O
decreased O
with O
the O
winemaking O
and O
ageing O
processes O
whereas O
only O
gallic B
acid I
increased O
. O

Identification O
of O
xyloglucan O
endotransglucosylase O
/ O
hydrolase O
genes O
( O
XTHs O
) O
and O
their O
expression O
in O
persimmon O
fruit O
as O
influenced O
by O
1 B
- I
methylcyclopropene I
and O
gibberellic B
acid I
during O
storage O
at O
ambient O
temperature O
. O

Sequence O
analysis O
showed O
that O
DKXTH1 O
and O
DKXTH2 O
contained O
a O
putative O
open O
reading O
frame O
of O
861 O
and O
876 O
bp O
encoding O
polypeptides O
of O
287 O
and O
292 O
amino B
acid I
residues O
, O
respectively O
, O
which O
contained O
the O
conserved O
DEIDFEFLG O
motif O
of O
XTH O
, O
a O
potential O
N O
- O
linked O
glycosylation O
signal O
site O
. O

1 B
- I
Methylcyclopropene I
( O
1 B
- I
MCP I
) O
and O
gibberellic B
acid I
( O
GA B
( I
3 I
) I
) O
treatments O
delayed O
the O
softening O
and O
ethylene B
peak O
of O
persimmon O
fruit O
, O
as O
well O
as O
suppressed O
the O
expression O
of O
both O
XTH O
genes O
, O
especially O
DKXTH1 O
. O

The O
effects O
of O
vanadyl B
sulphate I
on O
the O
formation O
of O
acrylamide B
have O
been O
studied O
in O
fried O
potato O
products O
, O
such O
as O
French O
fries O
and O
chips O
. O

Acrylamide B
formation O
was O
inhibited O
by O
30 O
. O
3 O
% O
, O
53 O
. O
3 O
% O
and O
89 O
. O
3 O
% O
when O
the O
sliced O
potato O
strips O
were O
soaked O
in O
0 O
. O
001 O
, O
0 O
. O
01 O
and O
0 O
. O
1 O
M O
vanadyl B
sulphate I
( O
VOSO B
( I
4 I
) I
) O
solutions O
, O
respectively O
, O
for O
60 O
min O
before O
frying O
. O

Moreover O
, O
57 O
. O
7 O
% O
, O
71 O
. O
4 O
% O
and O
92 O
. O
5 O
% O
inhibition O
of O
acrylamide B
formation O
was O
observed O
when O
chips O
were O
soaked O
in O
the O
respective O
vanadyl B
sulphate I
solution O
before O
frying O
. O

In O
a O
separate O
model O
reaction O
, O
a O
solution O
containing O
an O
equimolar O
concentration O
of O
L B
- I
asparagine I
and O
D B
- I
glucose I
showed O
a O
significant O
inhibition O
of O
acrylamide B
formation O
when O
heated O
at O
150 O
degrees O
C O
for O
30 O
min O
in O
the O
presence O
of O
vanadyl B
sulphate I
( O
VOSO B
( I
4 I
) I
) O
. O

Sugar B
- O
cane O
juice O
with O
a O
low O
amount O
of O
assimilable O
nitrogen B
( O
81 O
mg O
N O
/ O
L O
) O
, O
was O
further O
supplemented O
with O
mid O
- O
range O
or O
high O
concentrations O
of O
ammonium B
sulfate I
. O

The O
production O
of O
acetate B
esters I
was O
enhanced O
by O
mid O
- O
range O
ammonium B
supplementation O
and O
the O
production O
of O
acyl B
esters I
by O
high O
ammonium B
supplementation O
. O

The O
production O
of O
acetate B
esters I
was O
enhanced O
by O
mid O
- O
range O
ammonium B
supplementation O
and O
the O
production O
of O
acyl B
esters I
by O
high O
ammonium B
supplementation O
. O

The O
acyl B
esters I
could O
be O
correlated O
with O
expression O
of O
alcohol B
acyl B
- O
transferase O
EEB1 O
and O
the O
acyl B
esterase O
IAH1 O
. O

Described O
is O
the O
synthesis O
of O
5 B
- I
hydroxytryptamine I
- I
tetramethylrhodamine I
( O
5HT B
* O
) O
; O
an O
indole B
nitrogen I
linked O
fluorescent O
conjugate O
of O
serotonin B
. O

Discovery O
of O
nosokophic B
acid I
, O
a O
predicted O
intermediate O
of O
moenomycins B
, O
from O
nosokomycin B
- O
producing O
Streptomyces O
sp O
. O

A O
new O
actinomycete O
metabolite O
designated O
nosokophic B
acid I
was O
isolated O
from O
the O
culture O
broth O
of O
nosokomycin B
- O
producing O
Streptomyces O
sp O
. O

Nosokophic B
acid I
was O
found O
to O
be O
3 B
- I
phosphoglycosyl I
- I
2 I
- I
sesquiterpenyl I
dihydroxypropionic I
acid I
, O
a O
predicted O
biosynthetic O
intermediate O
of O
nosokomycin B
- O
related O
moenomycins B
. O

N B
- I
( I
Arylcyclopropyl I
) I
acetamides I
and O
N B
- I
( I
arylvinyl I
) I
acetamides I
or O
methyl B
ureas I
have O
been O
prepared O
as O
constrained O
analogues O
of O
melatonin B
. O

A O
small O
set O
of O
triazole B
bisphosphonates I
has O
been O
prepared O
and O
tested O
for O
the O
ability O
to O
inhibit O
geranylgeranyltransf O
II O
( O
GGTase O
II O
) O
. O

Furthermore O
, O
ganodermanondiol B
exposure O
enhanced O
the O
phosphorylation O
of O
adenosine B
monophosphate I
- O
activated O
protein O
kinase O
( O
AMPK O
) O
and O
its O
upstream O
kinase O
activators O
, O
LKB1 O
and O
Ca B
( I
2 I
+ I
) I
/ O
calmodulin O
- O
dependent O
protein O
kinase O
- O
II O
( O
CaMKII O
) O
. O

DPEP B
induced O
dose O
- O
dependent O
reduction O
of O
the O
protein O
levels O
of O
inducible O
nitric B
oxide I
synthase O
( O
iNOS O
) O
and O
cyclooxygenase O
- O
2 O
( O
COX O
- O
2 O
) O
and O
concomitant O
reduction O
in O
the O
production O
of O
NO B
and O
prostaglandin B
E I
( I
2 I
) I
( O
PGE B
( I
2 I
) I
) O
. O

The O
present O
study O
was O
designed O
to O
determine O
the O
radioprotective O
effect O
of O
two O
phytochemicals O
, O
namely O
, O
quinic B
acid I
and O
chlorogenic B
acid I
, O
against O
X O
- O
ray O
irradiation O
- O
induced O
genomic O
instability O
in O
non O
- O
tumorigenic O
human O
blood O
lymphocytes O
. O

The O
present O
study O
was O
designed O
to O
determine O
the O
radioprotective O
effect O
of O
two O
phytochemicals O
, O
namely O
, O
quinic B
acid I
and O
chlorogenic B
acid I
, O
against O
X O
- O
ray O
irradiation O
- O
induced O
genomic O
instability O
in O
non O
- O
tumorigenic O
human O
blood O
lymphocytes O
. O

The O
protective O
ability O
of O
two O
phenolic B
acids I
against O
radiation O
- O
induced O
DNA O
damage O
was O
assessed O
using O
the O
alkaline O
comet O
assay O
in O
human O
blood O
lymphocytes O
isolated O
from O
two O
healthy O
human O
donors O
. O

The O
results O
of O
the O
alkaline O
comet O
assay O
revealed O
that O
quinic B
acid I
and O
chlorogenic B
acid I
decreased O
the O
DNA O
damage O
induced O
by O
X O
- O
ray O
irradiation O
and O
provided O
a O
significant O
radioprotective O
effect O
. O

The O
results O
of O
the O
alkaline O
comet O
assay O
revealed O
that O
quinic B
acid I
and O
chlorogenic B
acid I
decreased O
the O
DNA O
damage O
induced O
by O
X O
- O
ray O
irradiation O
and O
provided O
a O
significant O
radioprotective O
effect O
. O

Quinic B
acid I
decreased O
the O
presence O
of O
irradiation O
- O
induced O
DNA O
damage O
by O
5 O
. O
99 O
- O
53 O
. O
57 O
% O
and O
chlorogenic B
acid I
by O
4 O
. O
49 O
- O
48 O
. O
15 O
% O
, O
as O
determined O
by O
the O
alkaline O
comet O
assay O
. O

Quinic B
acid I
decreased O
the O
presence O
of O
irradiation O
- O
induced O
DNA O
damage O
by O
5 O
. O
99 O
- O
53 O
. O
57 O
% O
and O
chlorogenic B
acid I
by O
4 O
. O
49 O
- O
48 O
. O
15 O
% O
, O
as O
determined O
by O
the O
alkaline O
comet O
assay O
. O

The O
results O
show O
that O
quinic B
acid I
and O
chlorogenic B
acid I
may O
act O
as O
radioprotective O
compounds O
. O

The O
results O
show O
that O
quinic B
acid I
and O
chlorogenic B
acid I
may O
act O
as O
radioprotective O
compounds O
. O

Future O
studies O
should O
focus O
on O
determining O
the O
mechanism O
by O
which O
these O
phenolic B
acids I
provide O
radioprotection O
. O

GC O
- O
MS O
analysis O
of O
lipophilic O
fraction O
revealed O
the O
presence O
of O
fatty B
acids I
and O
vitamin B
E I
as O
major O
components O
. O

GC O
- O
MS O
analysis O
of O
lipophilic O
fraction O
revealed O
the O
presence O
of O
fatty B
acids I
and O
vitamin B
E I
as O
major O
components O
. O

Dietary O
supplementation O
with O
omega B
- I
3 I
long I
chain I
fatty I
acids I
including O
docosahexaenoic B
acid I
( O
DHA B
) O
has O
increased O
in O
popularity O
in O
recent O
years O
and O
adequate O
DHA B
supplementation O
during O
pregnancy O
and O
early O
childhood O
is O
of O
clinical O
importance O
. O

All O
fungal O
isolates O
were O
fermented O
in O
liquid O
PDA O
medium O
and O
their O
extracts O
were O
preliminarily O
analyzed O
by O
antibacterial O
reactions O
, O
magnesium B
acetate I
- O
methanol B
reagent O
and O
Borntraiger O
' O
s O
reaction O
, O
and O
the O
strain O
reselection O
was O
made O
by O
thin O
- O
layer O
chromatography O
( O
TLC O
) O
, O
high O
- O
performance O
liquid O
chromatography O
( O
HPLC O
) O
and O
LC O
- O
MS O
to O
identify O
the O
fermentation O
products O
of O
the O
selected O
strains O
and O
confirmed O
through O
a O
comparison O
with O
authentic O
standards O
. O

The O
tea O
seed O
triterpene B
saponin I
( O
TS O
) O
from O
Camellia O
sinensis O
was O
found O
to O
exhibit O
better O
antitumor O
activity O
in O
vivo O
in O
S180 O
implanted O
ICR O
mice O
and O
QR O
inducing O
activity O
for O
hepa O
lclc7 O
cells O
respectively O
compared O
with O
the O
total O
tea O
seed O
saponin B
( O
TTS O
) O
, O
hydrolysate O
of O
the O
TTS O
and O
tea O
seed O
flavonoid B
glycosides I
( O
TF O
) O
. O

The O
tea O
seed O
triterpene B
saponin I
( O
TS O
) O
from O
Camellia O
sinensis O
was O
found O
to O
exhibit O
better O
antitumor O
activity O
in O
vivo O
in O
S180 O
implanted O
ICR O
mice O
and O
QR O
inducing O
activity O
for O
hepa O
lclc7 O
cells O
respectively O
compared O
with O
the O
total O
tea O
seed O
saponin B
( O
TTS O
) O
, O
hydrolysate O
of O
the O
TTS O
and O
tea O
seed O
flavonoid B
glycosides I
( O
TF O
) O
. O

By O
bioassay O
- O
guided O
isolation O
, O
the O
TS O
fraction O
was O
separated O
and O
seven O
major O
components O
were O
purified O
and O
identified O
as O
theasaponin B
E1 I
( O
1 O
) O
, O
theasaponin B
E2 I
( O
2 O
) O
, O
theasaponin B
C1 I
( O
3 O
) O
, O
assamsaponin B
C I
( O
4 O
) O
, O
theasaponin B
H1 I
( O
5 O
) O
, O
theasaponin B
A9 I
( O
6 O
) O
, O
and O
theasaponin B
A8 I
( O
7 O
) O
, O
among O
which O
compounds O
4 O
and O
5 O
were O
isolated O
from O
this O
genus O
for O
the O
first O
time O
. O

By O
bioassay O
- O
guided O
isolation O
, O
the O
TS O
fraction O
was O
separated O
and O
seven O
major O
components O
were O
purified O
and O
identified O
as O
theasaponin B
E1 I
( O
1 O
) O
, O
theasaponin B
E2 I
( O
2 O
) O
, O
theasaponin B
C1 I
( O
3 O
) O
, O
assamsaponin B
C I
( O
4 O
) O
, O
theasaponin B
H1 I
( O
5 O
) O
, O
theasaponin B
A9 I
( O
6 O
) O
, O
and O
theasaponin B
A8 I
( O
7 O
) O
, O
among O
which O
compounds O
4 O
and O
5 O
were O
isolated O
from O
this O
genus O
for O
the O
first O
time O
. O

By O
bioassay O
- O
guided O
isolation O
, O
the O
TS O
fraction O
was O
separated O
and O
seven O
major O
components O
were O
purified O
and O
identified O
as O
theasaponin B
E1 I
( O
1 O
) O
, O
theasaponin B
E2 I
( O
2 O
) O
, O
theasaponin B
C1 I
( O
3 O
) O
, O
assamsaponin B
C I
( O
4 O
) O
, O
theasaponin B
H1 I
( O
5 O
) O
, O
theasaponin B
A9 I
( O
6 O
) O
, O
and O
theasaponin B
A8 I
( O
7 O
) O
, O
among O
which O
compounds O
4 O
and O
5 O
were O
isolated O
from O
this O
genus O
for O
the O
first O
time O
. O

By O
bioassay O
- O
guided O
isolation O
, O
the O
TS O
fraction O
was O
separated O
and O
seven O
major O
components O
were O
purified O
and O
identified O
as O
theasaponin B
E1 I
( O
1 O
) O
, O
theasaponin B
E2 I
( O
2 O
) O
, O
theasaponin B
C1 I
( O
3 O
) O
, O
assamsaponin B
C I
( O
4 O
) O
, O
theasaponin B
H1 I
( O
5 O
) O
, O
theasaponin B
A9 I
( O
6 O
) O
, O
and O
theasaponin B
A8 I
( O
7 O
) O
, O
among O
which O
compounds O
4 O
and O
5 O
were O
isolated O
from O
this O
genus O
for O
the O
first O
time O
. O

By O
bioassay O
- O
guided O
isolation O
, O
the O
TS O
fraction O
was O
separated O
and O
seven O
major O
components O
were O
purified O
and O
identified O
as O
theasaponin B
E1 I
( O
1 O
) O
, O
theasaponin B
E2 I
( O
2 O
) O
, O
theasaponin B
C1 I
( O
3 O
) O
, O
assamsaponin B
C I
( O
4 O
) O
, O
theasaponin B
H1 I
( O
5 O
) O
, O
theasaponin B
A9 I
( O
6 O
) O
, O
and O
theasaponin B
A8 I
( O
7 O
) O
, O
among O
which O
compounds O
4 O
and O
5 O
were O
isolated O
from O
this O
genus O
for O
the O
first O
time O
. O

By O
bioassay O
- O
guided O
isolation O
, O
the O
TS O
fraction O
was O
separated O
and O
seven O
major O
components O
were O
purified O
and O
identified O
as O
theasaponin B
E1 I
( O
1 O
) O
, O
theasaponin B
E2 I
( O
2 O
) O
, O
theasaponin B
C1 I
( O
3 O
) O
, O
assamsaponin B
C I
( O
4 O
) O
, O
theasaponin B
H1 I
( O
5 O
) O
, O
theasaponin B
A9 I
( O
6 O
) O
, O
and O
theasaponin B
A8 I
( O
7 O
) O
, O
among O
which O
compounds O
4 O
and O
5 O
were O
isolated O
from O
this O
genus O
for O
the O
first O
time O
. O

By O
bioassay O
- O
guided O
isolation O
, O
the O
TS O
fraction O
was O
separated O
and O
seven O
major O
components O
were O
purified O
and O
identified O
as O
theasaponin B
E1 I
( O
1 O
) O
, O
theasaponin B
E2 I
( O
2 O
) O
, O
theasaponin B
C1 I
( O
3 O
) O
, O
assamsaponin B
C I
( O
4 O
) O
, O
theasaponin B
H1 I
( O
5 O
) O
, O
theasaponin B
A9 I
( O
6 O
) O
, O
and O
theasaponin B
A8 I
( O
7 O
) O
, O
among O
which O
compounds O
4 O
and O
5 O
were O
isolated O
from O
this O
genus O
for O
the O
first O
time O
. O

So O
it O
can O
be O
concluded O
that O
tea O
seed O
especially O
the O
compound O
1 O
( O
theasaponin B
E1 I
) O
could O
be O
used O
as O
an O
antitumor O
agent O
and O
a O
chemoprevention O
agent O
of O
cancer O
. O

Knockdown O
of O
HCA1 O
using O
siRNA O
resulted O
in O
an O
increase O
in O
lipid O
accumulation O
as O
assessed O
by O
quantification O
of O
Nile B
Red I
staining O
and O
TLC O
analysis O
. O

Twelve O
new O
dihydroagarofuran B
sesquiterpene I
polyol I
esters I
, O
triptersinines B
A I
- I
L I
( O
1 O
- O
12 O
) O
, O
and O
eight O
known O
sesquiterpene B
pyridine B
alkaloids I
were O
isolated O
from O
the O
leaves O
of O
Tripterygium O
wilfordii O
. O

Furthermore O
, O
in O
an O
in O
vitro O
bioassay O
, O
compounds O
1 O
, O
9 O
, O
11 O
, O
13 O
, O
14 O
, O
and O
18 O
showed O
moderate O
inhibitory O
effects O
on O
nitric B
oxide I
production O
in O
LPS O
- O
induced O
macrophages O
at O
5 O
mu O
M O
; O
all O
compounds O
were O
inactive O
when O
tested O
against O
five O
human O
cancer O
cell O
lines O
( O
IC O
( O
50 O
) O
values O
> O
1 O
mu O
M O
) O
. O

By O
using O
this O
bioassay O
- O
oriented O
approach O
five O
proanthocyanindins B
, O
including O
the O
new O
natural O
compounds O
( B
2S I
) I
- I
4 I
' I
, I
5 I
, I
7 I
- I
trihydroxyflavan I
- I
( I
4 I
beta I
- I
- I
> I
8 I
) I
- I
afzelechin I
( O
1 O
) O
and O
( B
2S I
) I
- I
4 I
' I
, I
5 I
, I
7 I
- I
trihydroxyflavan I
- I
( I
4 I
beta I
- I
- I
> I
8 I
) I
- I
epiafzelechin I
( O
2 O
) O
and O
the O
known O
geranin B
B I
( O
3 O
) O
, O
proanthocyanidin B
A2 I
( O
4 O
) O
, O
and O

By O
using O
this O
bioassay O
- O
oriented O
approach O
five O
proanthocyanindins B
, O
including O
the O
new O
natural O
compounds O
( B
2S I
) I
- I
4 I
' I
, I
5 I
, I
7 I
- I
trihydroxyflavan I
- I
( I
4 I
beta I
- I
- I
> I
8 I
) I
- I
afzelechin I
( O
1 O
) O
and O
( B
2S I
) I
- I
4 I
' I
, I
5 I
, I
7 I
- I
trihydroxyflavan I
- I
( I
4 I
beta I
- I
- I
> I
8 I
) I
- I
epiafzelechin I
( O
2 O
) O
and O
the O
known O
geranin B
B I
( O
3 O
) O
, O
proanthocyanidin B
A2 I
( O
4 O
) O
, O
and O

proanthocyanidin B
A1 I
( O
5 O
) O
, O
were O
isolated O
. O

Vanins O
are O
enzymes O
with O
pantetheinase O
activity O
and O
are O
presumed O
to O
play O
a O
role O
in O
the O
recycling O
of O
pantothenic B
acid I
( O
vitamin B
B5 I
) O
from O
pantetheine B
. O

Vanins O
are O
enzymes O
with O
pantetheinase O
activity O
and O
are O
presumed O
to O
play O
a O
role O
in O
the O
recycling O
of O
pantothenic B
acid I
( O
vitamin B
B5 I
) O
from O
pantetheine B
. O

Pantothenic B
acid I
is O
an O
essential O
nutrient O
required O
to O
synthesize O
coenzyme B
A I
, O
a O
cofactor O
involved O
in O
many O
biological O
processes O
such O
as O
fatty B
acid I
synthesis O
and O
oxidation O
of O
pyruvate B
to O
fuel O
the O
citric B
acid I
cycle O
. O

Pantothenic B
acid I
is O
an O
essential O
nutrient O
required O
to O
synthesize O
coenzyme B
A I
, O
a O
cofactor O
involved O
in O
many O
biological O
processes O
such O
as O
fatty B
acid I
synthesis O
and O
oxidation O
of O
pyruvate B
to O
fuel O
the O
citric B
acid I
cycle O
. O

Pantothenic B
acid I
is O
an O
essential O
nutrient O
required O
to O
synthesize O
coenzyme B
A I
, O
a O
cofactor O
involved O
in O
many O
biological O
processes O
such O
as O
fatty B
acid I
synthesis O
and O
oxidation O
of O
pyruvate B
to O
fuel O
the O
citric B
acid I
cycle O
. O

Pantothenic B
acid I
is O
an O
essential O
nutrient O
required O
to O
synthesize O
coenzyme B
A I
, O
a O
cofactor O
involved O
in O
many O
biological O
processes O
such O
as O
fatty B
acid I
synthesis O
and O
oxidation O
of O
pyruvate B
to O
fuel O
the O
citric B
acid I
cycle O
. O

1 B
- I
Nitro I
- I
2 I
- I
phenylethane I
is O
the O
first O
organic O
NO B
2 I
- O
containing O
molecule O
isolated O
from O
plants O
. O

The O
vasorelaxant O
effects O
of O
1 B
- I
nitro I
- I
2 I
- I
phenylethane I
did O
not O
depend O
on O
endothelial O
layer O
integrity O
, O
and O
the O
effects O
were O
refractory O
to O
L B
- I
N I
( I
G I
) I
- I
nitroarginine I
methyl I
ester I
( O
L B
- I
NAME I
) O
- O
induced O
nitric B
oxide I
synthase O
inhibition O
. O

Conversely O
, O
methylene B
blue I
- O
and O
ODQ B
- O
induced O
guanylate B
cyclase O
inhibition O
reduced O
the O
vasorelaxation O
induced O
by O
1 B
- I
nitro I
- I
2 I
- I
phenylethane I
. O

The O
effects O
of O
1 B
- I
nitro I
- I
2 I
- I
phenylethane I
were O
reversed O
by O
1H B
- I
[ I
1 I
, I
2 I
, I
4 I
] I
oxadiazolo I
[ I
4 I
, I
3 I
- I
a I
] I
quinoxalin I
- I
1 I
- I
one I
( O
ODQ B
) O
and O
comparable O
to O
the O
effects O
induced O
by O
sodium B
nitroprusside I
. O

Antidiabetic O
effect O
of O
secoisolariciresinol B
diglucoside I
in O
streptozotocin B
- O
induced O
diabetic O
rats O
. O

The O
aim O
of O
this O
study O
was O
to O
determine O
the O
antihyperglycemic O
activity O
of O
synthetic O
Secoisolariciresinol B
diglucoside I
( O
SDG B
) O
in O
streptozotocin B
( O
STZ B
) O
- O
induced O
diabetic O
rats O
. O

Specific O
conserved O
C B
- O
terminal O
amino B
acids I
of O
Caenorhabditis O
elegans O
HMP O
- O
1 O
/ O
alpha O
- O
catenin O
modulate O
F O
- O
actin O
binding O
independently O
of O
vinculin O
. O

Using O
Caenorhabditis O
elegans O
as O
a O
model O
system O
, O
we O
have O
characterized O
mutations O
in O
hmp O
- O
1 O
/ O
alpha O
- O
catenin O
that O
identify O
HMP O
- O
1 O
residues O
687 O
- O
742 O
and O
826 O
- O
927 O
, O
as O
well O
as O
amino B
acid I
802 O
, O
as O
critical O
to O
the O
localization O
of O
junctional O
proximal O
actin O
during O
epidermal O
morphogenesis O
. O

Using O
homology O
modeling O
, O
we O
show O
that O
these O
amino B
acids I
are O
positioned O
at O
key O
conserved O
sites O
within O
predicted O
alpha O
- O
helices O
in O
the O
C B
terminus O
. O

Our O
studies O
are O
the O
first O
to O
identify O
key O
conserved O
amino B
acids I
in O
the O
C B
terminus O
of O
alpha O
- O
catenin O
that O
modulate O
F O
- O
actin O
binding O
in O
living O
embryos O
of O
a O
simple O
metazoan O
. O

Previous O
work O
from O
our O
group O
has O
demonstrated O
that O
hybrid O
structures O
resulting O
from O
cinnamic B
acid I
conjugation O
with O
heterocyclic O
moieties O
from O
well O
- O
known O
antimalarials O
present O
improved O
antimalarial O
activity O
. O

Now O
, O
we O
report O
the O
synthesis O
and O
SAR O
analysis O
of O
an O
expanded O
series O
of O
cinnamic B
acid I
derivatives O
displaying O
remarkably O
high O
activities O
against O
both O
blood O
- O
and O
liver O
- O
stage O
malaria O
parasites O
. O

Both O
NaZn B
1 I
3 I
- O
and O
MgZn B
2 I
- O
type O
CoFe B
2 I
O I
4 I
- O
- O
Fe B
3 I
O I
4 I
binary O
nanocrystal O
superlattices O
have O
been O
formed O
by O
the O
liquid O
- O
air O
interfacial O
assembly O
approach O
. O

Camptothecine B
( O
Campothecin B
, O
CPT B
) O
, O
a O
quinoline B
alkaloid I
, O
is O
a O
potent O
inhibitor O
of O
eukaryotic O
topoisomerase O
I O
. O

Methanolic O
and O
ethyl B
acetate I
extracts O
of O
these O
fungal O
species O
were O
cytotoxic O
to O
colon O
and O
breast O
cancer O
cell O
lines O
. O

Bile B
acids I
in O
the O
colon O
, O
from O
healthy O
to O
cytotoxic O
molecules O
. O

Bile B
acids I
are O
natural O
detergents O
mainly O
involved O
in O
facilitating O
the O
absorption O
of O
dietary O
fat O
in O
the O
intestine O
. O

In O
addition O
to O
this O
absorptive O
function O
, O
bile B
acids I
are O
also O
essential O
in O
the O
maintenance O
of O
the O
intestinal O
epithelium O
homeostasis O
. O

To O
accomplish O
this O
regulatory O
function O
, O
bile B
acids I
may O
induce O
programmed O
cell O
death O
fostering O
the O
renewal O
of O
the O
epithelium O
. O

Bile B
acids I
may O
induce O
apoptosis O
in O
colonocytes O
through O
different O
mechanisms O
. O

In O
contrast O
to O
hepatocytes O
, O
the O
extrinsic O
apoptotic O
pathway O
seems O
to O
have O
a O
low O
relevance O
regarding O
bile B
acid I
cytotoxicity O
in O
the O
colon O
. O

In O
addition O
, O
bile B
acids I
may O
also O
act O
as O
regulatory O
molecules O
involved O
in O
different O
cell O
signaling O
pathways O
in O
colon O
cells O
. O

On O
the O
other O
hand O
, O
there O
is O
increasing O
evidence O
that O
the O
continuous O
exposure O
to O
certain O
hydrophobic O
bile B
acids I
, O
due O
to O
a O
fat O
- O
rich O
diet O
or O
pathological O
conditions O
, O
may O
induce O
oxidative O
DNA O
damage O
that O
, O
in O
turn O
, O
may O
lead O
to O
colorectal O
carcinogenesis O
as O
a O
consequence O
of O
the O
appearance O
of O
cell O
populations O
resistant O
to O
bile B
acid I
- O
induced O
apoptosis O
. O

On O
the O
other O
hand O
, O
there O
is O
increasing O
evidence O
that O
the O
continuous O
exposure O
to O
certain O
hydrophobic O
bile B
acids I
, O
due O
to O
a O
fat O
- O
rich O
diet O
or O
pathological O
conditions O
, O
may O
induce O
oxidative O
DNA O
damage O
that O
, O
in O
turn O
, O
may O
lead O
to O
colorectal O
carcinogenesis O
as O
a O
consequence O
of O
the O
appearance O
of O
cell O
populations O
resistant O
to O
bile B
acid I
- O
induced O
apoptosis O
. O

Finally O
, O
some O
bile B
acids I
, O
such O
as O
UDCA B
, O
or O
low O
concentrations O
of O
hydrophobic O
bile B
acids I
, O
can O
protect O
colon O
cells O
against O
apoptosis O
induced O
by O
high O
concentrations O
of O
cytotoxic O
bile B
acids I
, O
suggesting O
a O
dual O
behavior O
of O
these O
agents O
as O
pro O
- O
death O
or O
pro O
- O
survival O
molecules O
. O

Finally O
, O
some O
bile B
acids I
, O
such O
as O
UDCA B
, O
or O
low O
concentrations O
of O
hydrophobic O
bile B
acids I
, O
can O
protect O
colon O
cells O
against O
apoptosis O
induced O
by O
high O
concentrations O
of O
cytotoxic O
bile B
acids I
, O
suggesting O
a O
dual O
behavior O
of O
these O
agents O
as O
pro O
- O
death O
or O
pro O
- O
survival O
molecules O
. O

Finally O
, O
some O
bile B
acids I
, O
such O
as O
UDCA B
, O
or O
low O
concentrations O
of O
hydrophobic O
bile B
acids I
, O
can O
protect O
colon O
cells O
against O
apoptosis O
induced O
by O
high O
concentrations O
of O
cytotoxic O
bile B
acids I
, O
suggesting O
a O
dual O
behavior O
of O
these O
agents O
as O
pro O
- O
death O
or O
pro O
- O
survival O
molecules O
. O

One O
novel O
spirostan B
, O
named O
ophiogenin B
( O
1 O
) O
, O
together O
with O
six O
known O
spirostans B
( O
4 O
- O
8 O
, O
10 O
) O
, O
and O
one O
new O
sesquiterpene B
glycoside I
, O
named O
ophioside B
A I
( O
2 O
) O
, O
together O
with O
one O
known O
monoterpene B
glycoside I
( O
9 O
) O
were O
isolated O
from O
the O
active O
fractions O
, O
and O
the O
aglycone O
of O
compound O
2 O
that O
was O
a O
new O
natural O
compound O
was O
obtained O
from O
the O
acid O
hydrolysis O
of O
2 O
, O
named O
ophiopogonol B
( O
3 O
) O
. O

One O
novel O
spirostan B
, O
named O
ophiogenin B
( O
1 O
) O
, O
together O
with O
six O
known O
spirostans B
( O
4 O
- O
8 O
, O
10 O
) O
, O
and O
one O
new O
sesquiterpene B
glycoside I
, O
named O
ophioside B
A I
( O
2 O
) O
, O
together O
with O
one O
known O
monoterpene B
glycoside I
( O
9 O
) O
were O
isolated O
from O
the O
active O
fractions O
, O
and O
the O
aglycone O
of O
compound O
2 O
that O
was O
a O
new O
natural O
compound O
was O
obtained O
from O
the O
acid O
hydrolysis O
of O
2 O
, O
named O
ophiopogonol B
( O
3 O
) O
. O

One O
novel O
spirostan B
, O
named O
ophiogenin B
( O
1 O
) O
, O
together O
with O
six O
known O
spirostans B
( O
4 O
- O
8 O
, O
10 O
) O
, O
and O
one O
new O
sesquiterpene B
glycoside I
, O
named O
ophioside B
A I
( O
2 O
) O
, O
together O
with O
one O
known O
monoterpene B
glycoside I
( O
9 O
) O
were O
isolated O
from O
the O
active O
fractions O
, O
and O
the O
aglycone O
of O
compound O
2 O
that O
was O
a O
new O
natural O
compound O
was O
obtained O
from O
the O
acid O
hydrolysis O
of O
2 O
, O
named O
ophiopogonol B
( O
3 O
) O
. O

Besting O
vitamin B
E I
: O
sidechain O
substitution O
is O
key O
to O
the O
reactivity O
of O
naphthyridinol B
antioxidants O
in O
lipid O
bilayers O
. O

The O
activities O
of O
the O
naphthyridinols B
were O
assayed O
in O
phosphatidylcholine B
unilamellar O
liposomes O
using O
a O
recently O
developed O
high O
- O
throughput O
assay O
that O
employs O
a O
boron B
dipyrromethene I
conjugate O
of O
alpha B
- I
TOH I
( O
H O
( O
2 O
) O
B O
- O
PMHC O
) O
that O
undergoes O
fluorescence O
enhancement O
upon O
oxidation O
. O

In O
this O
context O
, O
the O
present O
study O
aimed O
to O
assess O
the O
toxicity O
of O
glyphosate B
, O
its O
by O
- O
product O
, O
aminomethylphosphoni B
acid I
( O
AMPA B
) O
and O
two O
commercial O
formulations O
, O
Roundup O
Express O
( O
( O
R O
) O
) O
( O
R O
( O
EX O
) O
) O
and O
Roundup O
All O
e O
es O
et O
Terrasses O
( O
( O
R O
) O
) O
( O
R O
( O
AT O
) O
) O
, O
containing O
glyphosate B
as O
the O
active O
ingredient O
, O
on O
the O
early O
life O
stages O
of O
the O
Pacific O
oyster O
, O
Crassostrea O
gigas O
. O

Statistical O
analyses O
of O
genome O
sequence O
- O
derived O
protein O
sequence O
data O
can O
identify O
amino B
acid I
residues O
that O
interact O
between O
proteins O
or O
between O
domains O
of O
a O
protein O
. O

These O
statistical O
methods O
are O
based O
on O
evolution O
- O
directed O
amino B
acid I
variation O
responding O
to O
structural O
and O
functional O
constraints O
in O
proteins O
. O

When O
applied O
to O
two O
- O
component O
systems O
, O
several O
research O
groups O
have O
shown O
they O
can O
be O
used O
to O
identify O
the O
amino B
acid I
interactions O
between O
response O
regulators O
and O
histidine B
kinases O
and O
the O
specificity O
therein O
. O

Recently O
, O
statistical O
studies O
between O
the O
HisKA O
and O
HATPase O
- O
ATP B
- O
binding O
domains O
of O
histidine B
kinases O
identified O
amino B
acid I
interactions O
for O
both O
the O
inactive O
and O
the O
active O
catalytic O
states O
of O
such O
kinases O
. O

Coatline B
A I
( O
1 O
) O
and O
alpha B
- I
epi I
- I
coatline I
A I
( O
4 O
) O
co O
- O
occur O
in O
the O
trunk O
extract O
of O
Andira O
coriacea O
. O

A O
combined O
theoretical O
approach O
including O
conformational O
analyses O
and O
calculation O
of O
electronic O
circular O
dichroism O
( O
ECD O
) O
spectra O
, O
in O
addition O
with O
experimental O
data O
obtained O
for O
schoepfin B
A I
( O
5 O
) O
and O
the O
new O
schoepfin B
D I
( O
6 O
) O
isolated O
from O
Senna O
quinquangulata O
, O
allowed O
the O
revision O
of O
the O
absolute O
configuration O
of O
coatlines B
A O
( O
1 O
) O
and O
B O
( O
2 O
) O
. O

A O
combined O
theoretical O
approach O
including O
conformational O
analyses O
and O
calculation O
of O
electronic O
circular O
dichroism O
( O
ECD O
) O
spectra O
, O
in O
addition O
with O
experimental O
data O
obtained O
for O
schoepfin B
A I
( O
5 O
) O
and O
the O
new O
schoepfin B
D I
( O
6 O
) O
isolated O
from O
Senna O
quinquangulata O
, O
allowed O
the O
revision O
of O
the O
absolute O
configuration O
of O
coatlines B
A O
( O
1 O
) O
and O
B O
( O
2 O
) O
. O

Photoactivable O
amino B
acid I
bioisosteres O
and O
mass O
spectrometry O
: O
snapshots O
of O
in O
vivo O
3D O
protein O
structures O
. O

Integration O
of O
biocompatible O
silica B
with O
a O
fluorescent O
polymer O
( O
PDDF O
) O
and O
superparamagnetic O
iron B
oxide I
nanoparticles O
( O
Fe3 B
O4 I
) O
to O
form O
uniform O
core O
- O
shell O
nanostructures O
has O
the O
great O
potential O
to O
form O
particles O
for O
use O
in O
multimodal O
bioimaging O
applications O
. O

Integration O
of O
biocompatible O
silica B
with O
a O
fluorescent O
polymer O
( O
PDDF O
) O
and O
superparamagnetic O
iron B
oxide I
nanoparticles O
( O
Fe3 B
O4 I
) O
to O
form O
uniform O
core O
- O
shell O
nanostructures O
has O
the O
great O
potential O
to O
form O
particles O
for O
use O
in O
multimodal O
bioimaging O
applications O
. O

Core O
- O
shell O
nanoparticles O
( O
PDDF O
/ O
Fe3 B
O4 I
@ O
SiO2 B
) O
exhibit O
fluorescent O
and O
magnetic O
properties O
that O
are O
favorable O
for O
their O
use O
in O
magnetic O
separation O
and O
guiding O
applications O
, O
as O
well O
as O
optical O
and O
magnetic O
resonance O
( O
MR O
) O
imaging O
capabilities O
. O

With O
the O
biological O
analysis O
in O
an O
in O
vitro O
intracellular O
permeation O
and O
cytotoxicity O
test O
, O
chemical O
conjugation O
of O
the O
surface O
using O
folic B
acid I
( O
FA O
) O
molecules O
can O
provide O
the O
nanoparticles O
with O
cell O
- O
targeting O
properties O
, O
localizing O
the O
nanoparticles O
to O
folate B
receptors O
( O
FRs O
) O
on O
target O
KB O
cells O
that O
over O
- O
express O
the O
FRs O
. O

The O
structure O
of O
the O
new O
brevipolide B
J I
( O
10 O
) O
was O
characterized O
through O
NMR O
and O
MS O
data O
as O
having O
the O
same O
6 B
- I
heptyl I
- I
5 I
, I
6 I
- I
dihydro I
- I
2H I
- I
pyran I
- I
2 I
- I
one I
framework O
possessing O
the O
cyclopropane B
moiety O
of O
all O
brevipolides B
but O
substituted O
by O
an O
isoferuloyl B
group O
instead O
of O
the O
p B
- I
methoxycinnamoyl I
moiety O
found O
in O
8 O
and O
9 O
. O

Here O
, O
we O
describe O
the O
design O
and O
development O
of O
multicolor O
narrow O
emissive O
Pdots O
based O
on O
different O
boron B
dipyrromethene I
( O
BODIPY B
) O
units O
. O

Cell O
adhesion O
, O
morphological O
alterations O
, O
cell O
proliferation O
, O
terminal O
deoxyuridine B
triphosphate I
nick O
- O
end O
labeling O
( O
TUNEL O
) O
and O
caspase O
- O
3 O
/ O
CPP32 O
fluorometric O
protease O
assay O
were O
important O
biomarkers O
to O
assess O
apoptosis O
in O
cells O
. O

This O
study O
aimed O
to O
evaluate O
arsenic B
- O
induced O
apoptosis O
in O
the O
hepatocytes O
of O
rat O
and O
its O
protective O
efficacy O
with O
coadministration O
of O
ascorbic B
acid I
( O
AA O
) O
and O
Pleurotus O
florida O
lectin O
( O
PFL O
) O
individually O
. O

We O
found O
that O
pigeon O
pea O
administration O
promoted O
cholesterol B
converting O
to O
bile B
acid I
in O
HFD O
- O
induced O
hamsters O
, O
thereby O
exerting O
hypolipidemic O
activity O
. O

Iodide B
- O
deficient O
conditions O
in O
both O
the O
dam O
and O
the O
pup O
were O
described O
with O
increased O
blood O
flow O
to O
the O
thyroid O
gland O
, O
TSH O
- O
mediated O
increase O
in O
thyroidal O
uptake O
of O
iodide B
and O
binding O
of O
iodide B
in O
the O
thyroid O
gland O
( O
organification O
) O
, O
and O
, O
in O
general O
, O
reduced O
thyroid B
hormone I
production O
and O
metabolism O
. O

In O
rat O
pups O
that O
were O
iodide B
deficient O
during O
gestation O
and O
lactation O
, O
these O
decreases O
in O
serum O
T4 O
levels O
were O
associated O
with O
declines O
in O
thyroid B
hormone I
in O
the O
fetal O
brain O
and O
a O
suppression O
of O
synaptic O
responses O
in O
the O
hippocampal O
region O
of O
the O
brain O
of O
the O
adult O
offspring O
( O
Gilbert O
et O
al O
. O
, O
2013 O
) O
. O

Inhibition O
of O
matrix O
metalloproteinase O
- O
9 O
expression O
by O
docosahexaenoic B
acid I
mediated O
by O
heme B
oxygenase O
1 O
in O
12 B
- I
O I
- I
tetradecanoylphorbol I
- I
13 I
- I
acetate I
- O
induced O
MCF O
- O
7 O
human O
breast O
cancer O
cells O
. O

Previous O
studies O
showed O
that O
polyunsaturated B
fatty I
acids I
exhibit O
an O
anti O
- O
cancer O
effect O
in O
various O
human O
carcinoma O
cells O
, O
but O
the O
effect O
of O
docosahexaenoic B
acid I
( O
DHA B
) O
and O
linoleic B
acid I
( O
LA O
) O
on O
metastasis O
of O
breast O
cancer O
cells O
is O
not O
fully O
clarified O
. O

Previous O
studies O
showed O
that O
polyunsaturated B
fatty I
acids I
exhibit O
an O
anti O
- O
cancer O
effect O
in O
various O
human O
carcinoma O
cells O
, O
but O
the O
effect O
of O
docosahexaenoic B
acid I
( O
DHA B
) O
and O
linoleic B
acid I
( O
LA O
) O
on O
metastasis O
of O
breast O
cancer O
cells O
is O
not O
fully O
clarified O
. O

On O
the O
azo B
/ O
hydrazo B
equilibrium O
in O
Sudan B
I I
azo B
dye O
derivatives O
. O

In O
this O
study O
, O
Raman O
, O
infrared O
, O
UV O
/ O
vis O
, O
NMR O
, O
and O
single O
crystal O
X O
- O
ray O
diffraction O
spectroscopies O
are O
used O
to O
elucidate O
the O
tautomeric O
equilibrium O
of O
azo B
dyes O
derived O
from O
1 B
- I
phenyl I
- I
azo I
- I
2 I
- I
naphthol I
( O
Sudan B
I I
) O
. O

A O
new O
crystallographic O
structure O
is O
described O
for O
Sudan B
I I
, O
revealing O
the O
presence O
of O
intramolecular O
hydrogen B
bonds O
and O
supramolecular O
interactions O
, O
such O
as O
the O
unconventional O
C B
- I
H I
. O
. O
. O
O B
hydrogen B
bond O
type O
, O
pi O
- O
stacking O
, O
and O
charge O
- O
dipole O
interactions O
. O

The O
predicted O
spectra O
are O
in O
accordance O
with O
the O
experiments O
carried O
out O
in O
the O
solid O
state O
and O
in O
solution O
of O
dichloromethane B
, O
carbon B
tetrachloride I
, O
and O
chloroform B
, O
suggesting O
the O
hydrazo B
form O
as O
the O
preferable O
tautomer O
in O
gas O
and O
condensate O
phases O
for O
Sudan B
I I
and O
its O
derivatives O
. O

The O
predicted O
spectra O
are O
in O
accordance O
with O
the O
experiments O
carried O
out O
in O
the O
solid O
state O
and O
in O
solution O
of O
dichloromethane B
, O
carbon B
tetrachloride I
, O
and O
chloroform B
, O
suggesting O
the O
hydrazo B
form O
as O
the O
preferable O
tautomer O
in O
gas O
and O
condensate O
phases O
for O
Sudan B
I I
and O
its O
derivatives O
. O

A O
small O
series O
of O
thiazolidine B
- I
2 I
, I
4 I
- I
dione I
and O
barbituric B
acid I
derivatives O
1 O
- O
4 O
was O
prepared O
using O
a O
short O
synthetic O
route O
, O
and O
all O
compounds O
were O
characterized O
by O
elemental O
analysis O
, O
mass O
spectrometry O
, O
and O
NMR O
( O
( B
1 I
) I
H I
, O
( B
13 I
) I
C I
) O
spectroscopy O
. O

Coated O
diltiazem B
hydrochloride I
- O
containing O
pellets O
were O
prepared O
using O
the O
solution O
layering O
technique O
. O

The O
coated O
pellets O
contained O
diltiazem B
hydrochloride I
both O
in O
crystalline O
and O
amorphous O
form O
. O

Crystallization O
occurs O
on O
heat O
treatment O
causing O
an O
exothermic O
peak O
on O
the O
DSC O
curves O
that O
only O
appears O
in O
pellets O
containing O
both O
diltiazem B
hydrochloride I
and O
the O
coating O
. O

Alkyl B
esters I
of O
gallic B
acid I
as O
anticancer O
agents O
: O
a O
review O
. O

Alkyl B
esters I
of O
gallic B
acid I
as O
anticancer O
agents O
: O
a O
review O
. O

The O
current O
review O
presents O
the O
antitumoral O
properties O
of O
gallic B
acid I
and O
its O
ester B
derivatives O
. O

Numerous O
studies O
have O
indicated O
that O
the O
alkyl B
esters I
are O
more O
effective O
against O
tumor O
cell O
lines O
than O
gallic B
acid I
, O
and O
that O
this O
activity O
is O
related O
to O
their O
hydrophobic O
moiety O
. O

Numerous O
studies O
have O
indicated O
that O
the O
alkyl B
esters I
are O
more O
effective O
against O
tumor O
cell O
lines O
than O
gallic B
acid I
, O
and O
that O
this O
activity O
is O
related O
to O
their O
hydrophobic O
moiety O
. O

The O
key O
amino B
acid I
residues O
in O
the O
exonuclease O
center O
of O
Chlamydophila O
pneumoniae O
DNApolI O
( O
CpDNApolI O
) O
are O
naturally O
mutated O
, O
resulting O
in O
the O
loss O
of O
3 O
' O
- O
5 O
' O
exonuclease O
. O

Nuclear O
receptor O
CAR O
specifically O
activates O
the O
two O
- O
pore O
K B
+ I
channel O
Kcnk1 O
gene O
in O
male O
mouse O
livers O
, O
which O
attenuates O
phenobarbital B
- O
induced O
hepatic O
hyperplasia O
. O

It O
was O
found O
, O
that O
in O
the O
Hyp B
* O
. O
Cyt B
* O
, O
Hyp B
. O
Thy B
* O
, O
Hyp B
. O
Hyp B
and O
Hyp B
* O
. O
Hyp B
* O
base O
pairs O
all O
H B
- O
bonds O
are O
significantly O
cooperative O
and O
mutually O
reinforce O
each O
other O
, O
while O
the O
C2H B
. O
. O
. O
O2 B
H I
- O
bond O
in O
the O
Hyp B
. O
Cyt B
base O
pair O
and O
the O
O6H B
. O
. O
. O
O4 B
H B
- O
bond O
in O
the O
Hyp B
* O
. O
Thy B
base O
pair O
behave O
anti O
- O
cooperatively O
, O
i O
. O
e O
. O
, O
they O
become O
weakened O
, O
while O
two O
others O
become O
strengthened O
. O

Our O
results O
suggest O
that O
1 B
, I
8 I
- I
naphthalimide I
derivatives O
with O
electron O
- O
donating O
- B
OCH3 I
and O
- B
N I
( I
CH3 I
) I
2 I
( O
1 O
and O
2 O
) O
, O
electron O
- O
withdrawing O
- B
CN I
and O
- B
COCH3 I
( O
3 O
and O
4 O
) O
, O
2 B
- I
( I
thiophen I
- I
2 I
- I
yl I
) I
thiophene I
( O
5 O
) O
, O
2 B
, I
3 I
- I
dihydrothieno I
[ I
3 I
, I
4 I
- I
b I
] I
[ I
1 I
, I
4 I
] I
dioxine I
( O
6 O
) O
, O
2 B
- I
phenyl I
- I
1 I
, I
3 I
, I
4 I
- I
oxadiazole I
( O
7 O
) O
, O
and O

Our O
results O
suggest O
that O
1 B
, I
8 I
- I
naphthalimide I
derivatives O
with O
electron O
- O
donating O
- B
OCH3 I
and O
- B
N I
( I
CH3 I
) I
2 I
( O
1 O
and O
2 O
) O
, O
electron O
- O
withdrawing O
- B
CN I
and O
- B
COCH3 I
( O
3 O
and O
4 O
) O
, O
2 B
- I
( I
thiophen I
- I
2 I
- I
yl I
) I
thiophene I
( O
5 O
) O
, O
2 B
, I
3 I
- I
dihydrothieno I
[ I
3 I
, I
4 I
- I
b I
] I
[ I
1 I
, I
4 I
] I
dioxine I
( O
6 O
) O
, O
2 B
- I
phenyl I
- I
1 I
, I
3 I
, I
4 I
- I
oxadiazole I
( O
7 O
) O
, O
and O

Our O
results O
suggest O
that O
1 B
, I
8 I
- I
naphthalimide I
derivatives O
with O
electron O
- O
donating O
- B
OCH3 I
and O
- B
N I
( I
CH3 I
) I
2 I
( O
1 O
and O
2 O
) O
, O
electron O
- O
withdrawing O
- B
CN I
and O
- B
COCH3 I
( O
3 O
and O
4 O
) O
, O
2 B
- I
( I
thiophen I
- I
2 I
- I
yl I
) I
thiophene I
( O
5 O
) O
, O
2 B
, I
3 I
- I
dihydrothieno I
[ I
3 I
, I
4 I
- I
b I
] I
[ I
1 I
, I
4 I
] I
dioxine I
( O
6 O
) O
, O
2 B
- I
phenyl I
- I
1 I
, I
3 I
, I
4 I
- I
oxadiazole I
( O
7 O
) O
, O
and O

Polyethylene B
Glycol I
and O
Polyethylenimine B
Dual O
- O
Functionalized O
Nano O
- O
Graphene B
Oxide I
for O
Photothermally O
Enhanced O
Gene O
Delivery O
. O

Polyethylene B
Glycol I
and O
Polyethylenimine B
Dual O
- O
Functionalized O
Nano O
- O
Graphene B
Oxide I
for O
Photothermally O
Enhanced O
Gene O
Delivery O
. O

Graphene B
oxide I
( O
GO O
) O
has O
been O
extensively O
explored O
in O
nanomedicine O
for O
its O
excellent O
physiochemical O
, O
electrical O
, O
and O
optical O
properties O
. O

Here O
, O
polyethylene B
glycol I
( O
PEG B
) O
and O
polyethylenimine B
( O
PEI B
) O
are O
covalently O
conjugated O
to O
GO O
via O
amide B
bonds O
, O
obtaining O
a O
physiologically O
stable O
dual O
- O
polymer O
- O
functionalized O
nano O
- O
GO O
conjugate O
( O
NGO O
- O
PEG B
- O
PEI B
) O
with O
ultra O
- O
small O
size O
. O

From O
the O
perspective O
of O
prevention O
, O
the O
spread O
and O
prediction O
of O
hydrochloric B
acid I
( O
HCl B
) O
that O
escaped O
from O
the O
metal O
- O
etching O
chamber O
during O
maintenance O
were O
studied O
in O
this O
article O
. O

Thermodynamic O
studies O
of O
ionic O
hydration O
and O
interactions O
for O
amino B
acid I
ionic O
liquids O
in O
aqueous O
solutions O
at O
298 O
. O
15 O
K O
. O

Amino B
acid I
ionic O
liquids O
are O
a O
special O
class O
of O
ionic O
liquids O
due O
to O
their O
unique O
acid O
- O
base O
behavior O
, O
biological O
significance O
, O
and O
applications O
in O
different O
fields O
such O
as O
templates O
in O
synthetic O
chemistry O
, O
stabilizers O
for O
biological O
macromolecules O
, O
etc O
. O

The O
physicochemical O
properties O
of O
these O
ionic O
liquids O
can O
easily O
be O
altered O
by O
making O
the O
different O
combinations O
of O
amino B
acids I
as O
anion O
along O
with O
possible O
cation O
modification O
which O
makes O
amino B
acid I
ionic O
liquids O
more O
suitable O
to O
understand O
the O
different O
kinds O
of O
molecular O
and O
ionic O
interactions O
with O
sufficient O
depth O
so O
that O
they O
can O
provide O
fruitful O
information O
for O
a O
molecular O
level O
understanding O
of O
more O
complicated O
biological O
processes O
. O

The O
physicochemical O
properties O
of O
these O
ionic O
liquids O
can O
easily O
be O
altered O
by O
making O
the O
different O
combinations O
of O
amino B
acids I
as O
anion O
along O
with O
possible O
cation O
modification O
which O
makes O
amino B
acid I
ionic O
liquids O
more O
suitable O
to O
understand O
the O
different O
kinds O
of O
molecular O
and O
ionic O
interactions O
with O
sufficient O
depth O
so O
that O
they O
can O
provide O
fruitful O
information O
for O
a O
molecular O
level O
understanding O
of O
more O
complicated O
biological O
processes O
. O

In O
this O
context O
, O
volumetric O
and O
osmotic O
coefficient O
measurements O
for O
aqueous O
solutions O
containing O
1 B
- I
ethyl I
- I
3 I
- I
methylimidazolium I
( O
[ O
Emim B
] O
) O
based O
amino B
acid I
ionic O
liquids O
of O
glycine B
, O
alanine B
, O
valine B
, O
leucine B
, O
and O
isoleucine B
are O
reported O
at O
298 O
. O
15 O
K O
. O

Analysis O
of O
the O
results O
further O
shows O
that O
the O
hydration O
of O
amino B
acid I
ionic O
liquids O
occurs O
through O
the O
cooperative O
H B
- O
bond O
formation O
with O
the O
kosmotropic O
effect O
in O
contrast O
to O
the O
usual O
inorganic O
salts O
or O
hydrophobic O
salts O
like O
tetraalkylammonium B
halides I
. O

Analysis O
of O
the O
results O
further O
shows O
that O
the O
hydration O
of O
amino B
acid I
ionic O
liquids O
occurs O
through O
the O
cooperative O
H B
- O
bond O
formation O
with O
the O
kosmotropic O
effect O
in O
contrast O
to O
the O
usual O
inorganic O
salts O
or O
hydrophobic O
salts O
like O
tetraalkylammonium B
halides I
. O

A O
safety O
study O
on O
single O
intravenous O
dose O
of O
tetrachloro B
- I
diphenyl I
glycoluril I
[ O
iodogen B
] O
dissolved O
in O
dimethyl B
sulphoxide I
( O
DMSO B
) O
. O

Iodogen B
( O
tetrachloro B
- I
diphenyl I
glycoluril I
) O
dissolved O
in O
DMSO B
( O
dimethyl B
sulphoxide I
) O
appears O
indispensable O
in O
radioiodination O
of O
hypericin B
for O
a O
new O
anticancer O
strategy O
. O

Only O
one O
crystal O
structure O
is O
currently O
available O
for O
tumor O
marker O
AKR1B10 O
, O
complexed O
with O
NADP B
( I
+ I
) I
and O
tolrestat B
, O
which O
is O
an O
aldose B
reductase O
inhibitor O
( O
ARI O
) O
of O
the O
carboxylic B
acid I
type O
. O

Here O
, O
the O
X O
- O
ray O
structure O
of O
the O
complex O
of O
the O
V301L O
substituted O
AKR1B10 O
holoenzyme O
with O
fidarestat B
, O
an O
ARI O
of O
the O
cyclic B
imide I
type O
, O
was O
obtained O
at O
1 O
. O
60 O
A O
resolution O
by O
replacement O
soaking O
of O
crystals O
containing O
tolrestat B
. O

Also O
, O
by O
performing O
multiple O
alignments O
of O
855 O
non O
- O
redundant O
amino B
acid I
sequences O
, O
we O
assessed O
the O
degree O
of O
conservation O
in O
their O
respective O
families O
of O
the O
amino B
acid I
residues O
putatively O
relevant O
for O
cation O
binding O
. O

Also O
, O
by O
performing O
multiple O
alignments O
of O
855 O
non O
- O
redundant O
amino B
acid I
sequences O
, O
we O
assessed O
the O
degree O
of O
conservation O
in O
their O
respective O
families O
of O
the O
amino B
acid I
residues O
putatively O
relevant O
for O
cation O
binding O
. O

Specific O
surface O
area O
of O
titanium B
dioxide I
( O
TiO2 B
) O
particles O
influences O
cyto O
- O
and O
photo O
- O
toxicity O
. O

The O
aim O
of O
this O
study O
is O
to O
examine O
how O
different O
specific O
surface O
areas O
of O
similar O
- O
sized O
titanium B
dioxide I
( O
TiO B
( I
2 I
) I
) O
particles O
could O
influence O
both O
cytotoxicity O
and O
phototoxicity O
. O

Lack O
of O
transient O
receptor O
potential O
melastatin O
8 O
activation O
by O
phthalate B
esters I
that O
enhance O
contact O
hypersensitivity O
in O
mice O
. O

Skin O
sensitization O
to O
fluorescein B
isothiocyanate I
( O
FITC B
) O
has O
been O
shown O
to O
be O
enhanced O
by O
several O
phthalate B
esters I
, O
including O
dibutyl B
phthalate I
( O
DBP B
) O
. O

Skin O
sensitization O
to O
fluorescein B
isothiocyanate I
( O
FITC B
) O
has O
been O
shown O
to O
be O
enhanced O
by O
several O
phthalate B
esters I
, O
including O
dibutyl B
phthalate I
( O
DBP B
) O
. O

Skin O
sensitization O
to O
fluorescein B
isothiocyanate I
( O
FITC B
) O
has O
been O
shown O
to O
be O
enhanced O
by O
several O
phthalate B
esters I
, O
including O
dibutyl B
phthalate I
( O
DBP B
) O
. O

For O
different O
types O
of O
phthalate B
esters I
, O
we O
found O
a O
correlation O
between O
the O
ability O
of O
transient O
receptor O
potential O
( O
TRP O
) O
A1 O
activation O
and O
that O
of O
enhancing O
skin O
sensitization O
. O

However O
, O
since O
phthalate B
esters I
also O
activate O
TRPV1 O
, O
phthalate B
esters I
could O
activate O
other O
types O
of O
TRP O
channels O
non O
- O
selectively O
. O

However O
, O
since O
phthalate B
esters I
also O
activate O
TRPV1 O
, O
phthalate B
esters I
could O
activate O
other O
types O
of O
TRP O
channels O
non O
- O
selectively O
. O

We O
demonstrated O
that O
phthalate B
esters I
do O
not O
activate O
TRPM8 O
. O

These O
results O
show O
that O
phthalate B
esters I
activate O
TRPA1 O
and O
TRPV1 O
with O
selectivity O
. O

The O
genotoxicity O
of O
PEI B
- O
based O
nanoparticles O
is O
reduced O
by O
acetylation O
of O
polyethylenimine B
amines I
in O
human O
primary O
cells O
. O

Herein O
, O
drug O
delivery O
carriers O
such O
as O
PEI B
- O
PLGA B
nanoparticles O
( O
PEI B
- O
NPs O
) O
and O
acetylated B
PEI I
- O
PLGA B
nanoparticles O
( O
AcPEI B
- O
NPs O
) O
were O
utilized O
to O
examine O
the O
effect O
of O
acetylation O
on O
NPs O
biocompatibility O
and O
genotoxicity O
, O
using O
human O
primary O
cells O
as O
in O
vitro O
model O
. O

Graphene B
oxide I
for O
effective O
radionuclide O
removal O
. O

Here O
we O
show O
the O
efficacy O
of O
graphene B
oxide I
( O
GO O
) O
for O
rapid O
removal O
of O
some O
of O
the O
most O
toxic O
and O
radioactive O
long O
- O
lived O
human O
- O
made O
radionuclides O
from O
contaminated O
water O
, O
even O
from O
acidic O
solutions O
( O
pH O
< O
2 O
) O
. O

Three O
cynomolgus O
monkey O
OATPs O
( O
cOATPs O
) O
, O
with O
a O
high O
degree O
of O
amino B
acid I
sequence O
identity O
( O
91 O
. O
9 O
, O
93 O
. O
5 O
, O
and O
96 O
. O
6 O
% O
for O
OATP1B1 O
, O
1B3 O
, O
and O
2B1 O
, O
respectively O
) O
to O
their O
human O
counterparts O
, O
were O
cloned O
, O
expressed O
, O
and O
characterized O
. O

This O
design O
was O
based O
on O
the O
X O
- O
ray O
co O
- O
crystal O
structure O
of O
four O
N B
- O
terminal O
amino B
acid I
residues O
( O
AVPI O
) O
of O
the O
second O
mitochondria O
- O
derived O
activator O
of O
caspase O
( O
Smac O
) O
with O
the O
X O
- O
chromosome O
- O
linked O
IAP O
( O
XIAP O
) O
protein O
. O

The O
fluorescent O
dyes O
methylene B
blue I
, O
MB O
( O
+ O
) O
, O
and O
thionine B
, O
Th O
( O
+ O
) O
, O
can O
be O
trapped O
in O
the O
pores O
of O
mesoporous O
silica B
, O
MP O
- O
SiO B
( I
2 I
) I
, O
by O
means O
of O
functional O
nanostructures O
consisting O
of O
the O
Mg B
( I
2 I
+ I
) I
- O
or O
Zn B
( I
2 I
+ I
) I
- O
dependent O
DNAzyme O
sequences O
. O

Claisen O
- O
Schmidt O
condensation O
reaction O
of O
4 B
- I
acetamidoacetophenon I
with O
aromatic B
aldehydes I
under O
ultrasonic O
irradiation O
affords O
acetylaminochalcones B
( O
yields O
: O
71 O
- O
90 O
% O
) O
which O
also O
under O
ultrasonic O
irradiation O
and O
in O
the O
presence O
of O
sodium B
acetate I
and O
acetic B
acid I
aqueous O
undergo O
facile O
and O
clean O
cyclocondensation O
with O
hydrazine B
to O
afford O
3 B
- I
( I
4 I
- I
acetamidophenyl I
) I
- I
5 I
- I
( I
aryl I
) I
- I
1 I
- I
H I
- I
pyrazolines I
. O

Claisen O
- O
Schmidt O
condensation O
reaction O
of O
4 B
- I
acetamidoacetophenon I
with O
aromatic B
aldehydes I
under O
ultrasonic O
irradiation O
affords O
acetylaminochalcones B
( O
yields O
: O
71 O
- O
90 O
% O
) O
which O
also O
under O
ultrasonic O
irradiation O
and O
in O
the O
presence O
of O
sodium B
acetate I
and O
acetic B
acid I
aqueous O
undergo O
facile O
and O
clean O
cyclocondensation O
with O
hydrazine B
to O
afford O
3 B
- I
( I
4 I
- I
acetamidophenyl I
) I
- I
5 I
- I
( I
aryl I
) I
- I
1 I
- I
H I
- I
pyrazolines I
. O

Claisen O
- O
Schmidt O
condensation O
reaction O
of O
4 B
- I
acetamidoacetophenon I
with O
aromatic B
aldehydes I
under O
ultrasonic O
irradiation O
affords O
acetylaminochalcones B
( O
yields O
: O
71 O
- O
90 O
% O
) O
which O
also O
under O
ultrasonic O
irradiation O
and O
in O
the O
presence O
of O
sodium B
acetate I
and O
acetic B
acid I
aqueous O
undergo O
facile O
and O
clean O
cyclocondensation O
with O
hydrazine B
to O
afford O
3 B
- I
( I
4 I
- I
acetamidophenyl I
) I
- I
5 I
- I
( I
aryl I
) I
- I
1 I
- I
H I
- I
pyrazolines I
. O

Kidney O
malondialdehyde B
, O
nitric B
oxide I
and O
glutathione B
contents O
and O
serum O
biochemical O
parameters O
and O
histopathological O
analysis O
were O
determined O
. O

Simultaneous O
determination O
and O
characterization O
of O
tannins B
and O
triterpene B
saponins I
from O
the O
fruits O
of O
various O
species O
of O
Terminalia O
and O
Phyllantus O
emblica O
using O
a O
UHPLC O
- O
UV O
- O
MS O
method O
: O
application O
to O
triphala O
. O

A O
simple O
UHPLC O
method O
was O
developed O
for O
the O
simultaneous O
analysis O
of O
such O
hydrolysable O
tannins B
and O
triterpene B
saponins I
from O
the O
fruit O
rinds O
of O
different O
species O
of O
Terminalia O
( O
T O
. O
chebula O
, O
T O
. O
arjuna O
, O
T O
. O
bellirica O
) O
and O
Phyllantus O
emblica O
. O

A O
separation O
by O
LC O
was O
achieved O
using O
a O
reversed O
- O
phase O
column O
and O
a O
water O
/ O
acetonitrile B
mobile O
phase O
, O
both O
containing O
formic B
acid I
, O
using O
a O
gradient O
system O
and O
a O
temperature O
of O
40 O
degrees O
C O
. O

Eight O
hydrolysable O
tannins B
( O
gallic B
acid I
, O
gallic B
acid I
methyl I
ester I
, O
corilagin B
, O
chebulagic B
acid I
, O
1 B
, I
2 I
, I
3 I
, I
6 I
- I
tetra I
- I
O I
- I
galloyl I
- I
beta I
- I
D I
- I
glucose I
, O
ellagic B
acid I
, O
chebulinic B
acid I
, O
and O
1 B
, I
2 I
, I
3 I
, I
4 I
, I
6 I
- I
penta I
- I
O I
- I
galloyl I
- I
beta I
- I
D I
- I
glucose I
) O
and O
six O
triterpene B
saponins I
( O
arjunglucoside B
- I
I I
, O
arjunglucoside B
- I
III I
, O

Eight O
hydrolysable O
tannins B
( O
gallic B
acid I
, O
gallic B
acid I
methyl I
ester I
, O
corilagin B
, O
chebulagic B
acid I
, O
1 B
, I
2 I
, I
3 I
, I
6 I
- I
tetra I
- I
O I
- I
galloyl I
- I
beta I
- I
D I
- I
glucose I
, O
ellagic B
acid I
, O
chebulinic B
acid I
, O
and O
1 B
, I
2 I
, I
3 I
, I
4 I
, I
6 I
- I
penta I
- I
O I
- I
galloyl I
- I
beta I
- I
D I
- I
glucose I
) O
and O
six O
triterpene B
saponins I
( O
arjunglucoside B
- I
I I
, O
arjunglucoside B
- I
III I
, O

Eight O
hydrolysable O
tannins B
( O
gallic B
acid I
, O
gallic B
acid I
methyl I
ester I
, O
corilagin B
, O
chebulagic B
acid I
, O
1 B
, I
2 I
, I
3 I
, I
6 I
- I
tetra I
- I
O I
- I
galloyl I
- I
beta I
- I
D I
- I
glucose I
, O
ellagic B
acid I
, O
chebulinic B
acid I
, O
and O
1 B
, I
2 I
, I
3 I
, I
4 I
, I
6 I
- I
penta I
- I
O I
- I
galloyl I
- I
beta I
- I
D I
- I
glucose I
) O
and O
six O
triterpene B
saponins I
( O
arjunglucoside B
- I
I I
, O
arjunglucoside B
- I
III I
, O

Eight O
hydrolysable O
tannins B
( O
gallic B
acid I
, O
gallic B
acid I
methyl I
ester I
, O
corilagin B
, O
chebulagic B
acid I
, O
1 B
, I
2 I
, I
3 I
, I
6 I
- I
tetra I
- I
O I
- I
galloyl I
- I
beta I
- I
D I
- I
glucose I
, O
ellagic B
acid I
, O
chebulinic B
acid I
, O
and O
1 B
, I
2 I
, I
3 I
, I
4 I
, I
6 I
- I
penta I
- I
O I
- I
galloyl I
- I
beta I
- I
D I
- I
glucose I
) O
and O
six O
triterpene B
saponins I
( O
arjunglucoside B
- I
I I
, O
arjunglucoside B
- I
III I
, O

Eight O
hydrolysable O
tannins B
( O
gallic B
acid I
, O
gallic B
acid I
methyl I
ester I
, O
corilagin B
, O
chebulagic B
acid I
, O
1 B
, I
2 I
, I
3 I
, I
6 I
- I
tetra I
- I
O I
- I
galloyl I
- I
beta I
- I
D I
- I
glucose I
, O
ellagic B
acid I
, O
chebulinic B
acid I
, O
and O
1 B
, I
2 I
, I
3 I
, I
4 I
, I
6 I
- I
penta I
- I
O I
- I
galloyl I
- I
beta I
- I
D I
- I
glucose I
) O
and O
six O
triterpene B
saponins I
( O
arjunglucoside B
- I
I I
, O
arjunglucoside B
- I
III I
, O

chebuloside B
II I
, O
bellericoside B
, O
arjunetin B
, O
and O
arjunglucoside B
- I
II I
) O
could O
be O
separated O
within O
20 O
minutes O
. O

The O
wavelength O
used O
for O
detection O
with O
the O
diode O
array O
detector O
was O
254 O
and O
275 O
nm O
for O
tannins B
and O
205 O
nm O
for O
triterpene B
saponins I
. O

The O
developed O
method O
is O
economical O
, O
fast O
, O
and O
especially O
suitable O
for O
quality O
control O
analysis O
of O
tannins B
and O
triterpene B
saponins I
in O
various O
plant O
samples O
and O
commercial O
products O
of O
Terminalia O
. O

After O
addition O
of O
fluorescein B
isothiocyanate I
- O
conjugated O
secondary O
antibodies O
, O
the O
sections O
were O
analyzed O
by O
confocal O
laser O
scanning O
microscopy O
. O

nAChR O
- O
rich O
membranes O
were O
photolabeled O
with O
[ B
( I
3 I
) I
H I
] I
AziPm I
, O
and O
labeled O
amino B
acids I
were O
identified O
by O
Edman O
degradation O
. O

[ B
( I
3 I
) I
H I
] I
AziPm I
binds O
at O
three O
sites O
within O
the O
nAChR O
transmembrane O
domain O
: O
( O
i O
) O
an O
intrasubunit O
site O
in O
the O
delta O
subunit O
helix O
bundle O
, O
photolabeling O
in O
the O
nAChR O
desensitized O
state O
( O
+ O
agonist O
) O
delta O
M2 O
- O
18 O
' O
and O
two O
residues O
in O
delta O
M1 O
( O
delta B
Phe I
- O
232 O
and O
delta B
Cys I
- O
236 O
) O
; O
( O
ii O
) O
in O
the O
ion O
channel O
, O
photolabeling O
in O
the O
nAChR O
resting O
, O
closed O
channel O
state O
( O
- O
agonist O
) O
amino B
acids I
in O
the O
M2 O

[ B
( I
3 I
) I
H I
] I
AziPm I
binds O
at O
three O
sites O
within O
the O
nAChR O
transmembrane O
domain O
: O
( O
i O
) O
an O
intrasubunit O
site O
in O
the O
delta O
subunit O
helix O
bundle O
, O
photolabeling O
in O
the O
nAChR O
desensitized O
state O
( O
+ O
agonist O
) O
delta O
M2 O
- O
18 O
' O
and O
two O
residues O
in O
delta O
M1 O
( O
delta B
Phe I
- O
232 O
and O
delta B
Cys I
- O
236 O
) O
; O
( O
ii O
) O
in O
the O
ion O
channel O
, O
photolabeling O
in O
the O
nAChR O
resting O
, O
closed O
channel O
state O
( O
- O
agonist O
) O
amino B
acids I
in O
the O
M2 O

[ B
( I
3 I
) I
H I
] I
AziPm I
binds O
at O
three O
sites O
within O
the O
nAChR O
transmembrane O
domain O
: O
( O
i O
) O
an O
intrasubunit O
site O
in O
the O
delta O
subunit O
helix O
bundle O
, O
photolabeling O
in O
the O
nAChR O
desensitized O
state O
( O
+ O
agonist O
) O
delta O
M2 O
- O
18 O
' O
and O
two O
residues O
in O
delta O
M1 O
( O
delta B
Phe I
- O
232 O
and O
delta B
Cys I
- O
236 O
) O
; O
( O
ii O
) O
in O
the O
ion O
channel O
, O
photolabeling O
in O
the O
nAChR O
resting O
, O
closed O
channel O
state O
( O
- O
agonist O
) O
amino B
acids I
in O
the O
M2 O

Amino B
acid I
grafted O
chitosan O
for O
high O
performance O
gene O
delivery O
: O
comparison O
of O
amino B
acid I
hydrophobicity O
on O
vector O
and O
polyplex O
characteristics O
. O

Amino B
acid I
grafted O
chitosan O
for O
high O
performance O
gene O
delivery O
: O
comparison O
of O
amino B
acid I
hydrophobicity O
on O
vector O
and O
polyplex O
characteristics O
. O

To O
develop O
a O
safe O
, O
effective O
, O
and O
biocompatible O
gene O
delivery O
vector O
, O
a O
series O
of O
hydrophobic O
amino B
acid I
grafted O
chitosan O
( O
AGC O
) O
derivatives O
were O
synthesized O
by O
carbodiimide B
mediated O
coupling O
reaction O
. O

Moreover O
, O
both O
cellular O
uptake O
and O
transfection O
efficiency O
improved O
with O
the O
increasing O
amino B
acid I
hydrophobicity O
. O

Hydrophobic O
amino B
acid I
substitution O
contributed O
to O
the O
enhance O
pDNA O
release O
at O
cytosolic O
pH O
. O

Improved O
self O
- O
healing O
of O
polyethylene B
/ O
carbon B
black I
nanocomposites O
by O
their O
shape O
memory O
effect O
. O

In O
this O
work O
, O
the O
improved O
self O
- O
healing O
of O
cross O
- O
linked O
polyethylene B
( O
PE O
) O
( O
cPE O
) O
/ O
carbon B
black I
( O
CB O
) O
nanocomposites O
by O
their O
shape O
memory O
effect O
( O
SME O
) O
is O
investigated O
. O

Synthesis O
of O
novel O
phosphorylated B
guanidine I
derivatives O
from O
cyanamide B
and O
their O
anti O
- O
inflammatory O
activity O
. O

2 B
- I
Aminopyridin I
- I
3 I
- I
ol I
( O
1 O
) O
was O
reacted O
with O
thiophosphoryl B
chloride I
( O
2 O
) O
to O
give O
a O
monochloride B
( O
3 O
) O
. O

It O
was O
further O
reacted O
with O
cyanamide B
to O
afford O
the O
corresponding O
cyanamine B
( O
4 O
) O
, O
which O
was O
subsequently O
reacted O
with O
different O
heterocyclic B
amines I
to O
form O
the O
title O
compounds O
( O
5a O
- O
l O
) O
. O

Two O
new O
triterpenoid B
saponins I
from O
the O
root O
of O
Platycodon O
grandiflorum O
. O

Two O
new O
triterpenoid B
saponins I
, O
named O
platycodon B
A I
( O
3 B
- I
O I
- I
beta I
- I
D I
- I
glucopyranosyl I
- I
16 I
- I
O I
- I
beta I
- I
D I
- I
glucopyranosyl I
- I
2 I
beta I
, I
3 I
beta I
, I
16 I
beta I
, I
21 I
beta I
- I
tetrahydroxyolean I
- I
12 I
- I
en I
- I
28 I
- I
oic I
acid I
) O
and O
platycodon B
B I
( O
3 B
- I
O I
- I
beta I
- I
D I
- I
glucopyranosyl I
- I
16 I
- I
O I
- I
beta I
- I
D I
- I
xylopyranosyl I
- I
2 I
beta I
, I
3 I
beta I
, I
16 I
beta I

Two O
new O
triterpenoid B
saponins I
, O
named O
platycodon B
A I
( O
3 B
- I
O I
- I
beta I
- I
D I
- I
glucopyranosyl I
- I
16 I
- I
O I
- I
beta I
- I
D I
- I
glucopyranosyl I
- I
2 I
beta I
, I
3 I
beta I
, I
16 I
beta I
, I
21 I
beta I
- I
tetrahydroxyolean I
- I
12 I
- I
en I
- I
28 I
- I
oic I
acid I
) O
and O
platycodon B
B I
( O
3 B
- I
O I
- I
beta I
- I
D I
- I
glucopyranosyl I
- I
16 I
- I
O I
- I
beta I
- I
D I
- I
xylopyranosyl I
- I
2 I
beta I
, I
3 I
beta I
, I
16 I
beta I

Two O
new O
triterpenoid B
saponins I
, O
named O
platycodon B
A I
( O
3 B
- I
O I
- I
beta I
- I
D I
- I
glucopyranosyl I
- I
16 I
- I
O I
- I
beta I
- I
D I
- I
glucopyranosyl I
- I
2 I
beta I
, I
3 I
beta I
, I
16 I
beta I
, I
21 I
beta I
- I
tetrahydroxyolean I
- I
12 I
- I
en I
- I
28 I
- I
oic I
acid I
) O
and O
platycodon B
B I
( O
3 B
- I
O I
- I
beta I
- I
D I
- I
glucopyranosyl I
- I
16 I
- I
O I
- I
beta I
- I
D I
- I
xylopyranosyl I
- I
2 I
beta I
, I
3 I
beta I
, I
16 I
beta I

The O
roles O
of O
M247 O
and O
Y261 O
, O
amino B
acids I
suggested O
by O
structural O
studies O
to O
play O
a O
role O
in O
primer O
- O
template O
unwinding O
, O
have O
been O
probed O
. O

The O
aim O
of O
this O
study O
is O
to O
compare O
the O
antiproliferative O
effects O
of O
medroxyprogesterone B
acetate I
( O
MPA B
) O
, O
and O
metformin B
in O
oopherectomized O
rat O
endometrium O
. O

Metformin B
and O
MPA B
acetate I
significantly O
reduced O
all O
parameters O
indicating O
endometrial O
hyperplasia O
, O
and O
uterotrophy O
with O
respect O
to O
the O
control O
group O
. O

The O
resulting O
photoproduct O
was O
an O
aldehyde B
that O
was O
oxidized O
under O
ambient O
conditions O
to O
its O
corresponding O
carboxylic B
acid I
, O
i O
. O
e O
. O
, O
4 B
- I
( I
1 I
, I
3 I
- I
benzoxazol I
- I
2 I
- I
yl I
) I
benzoic I
acid I
. O

Synthesis O
and O
dual O
biological O
effects O
of O
hydroxycinnamoyl B
phenylalanyl I
/ O
prolyl B
hydroxamic I
acid I
derivatives O
as O
tyrosinase O
inhibitor O
and O
antioxidant O
. O

We O
previously O
reported O
that O
caffeoyl B
- I
amino I
acidyl I
- I
hydroxamic I
acid I
( O
CA B
- I
Xaa I
- I
NHOH I
) O
acted O
as O
both O
a O
good O
antioxidant O
and O
tyrosinase O
inhibitor O
, O
in O
particular O
when O
caffeic B
acid I
was O
conjugated O
with O
proline B
or O
amino B
acids I
having O
aromatic O
ring O
like O
phenylalanine B
. O

We O
previously O
reported O
that O
caffeoyl B
- I
amino I
acidyl I
- I
hydroxamic I
acid I
( O
CA B
- I
Xaa I
- I
NHOH I
) O
acted O
as O
both O
a O
good O
antioxidant O
and O
tyrosinase O
inhibitor O
, O
in O
particular O
when O
caffeic B
acid I
was O
conjugated O
with O
proline B
or O
amino B
acids I
having O
aromatic O
ring O
like O
phenylalanine B
. O

Here O
, O
various O
hydroxycinnamic B
acid I
( O
HCA B
) O
derivatives O
were O
further O
conjugated O
with O
phenylalanyl B
hydroxamic I
acid I
and O
prolyl B
hydroxamic I
acid I
( O
HCA B
- I
Phe I
- I
NHOH I
and O
HCA B
- I
Pro I
- I
NHOH I
) O
to O
study O
the O
structure O
and O
activity O
relationship O
as O
both O
antioxidants O
and O
tyrosinase O
inhibitors O
. O

Moreover O
, O
derivatives O
of O
caffeic B
acid I
, O
ferulic B
acid I
, O
and O
sinapic B
acid I
inhibited O
lipid O
peroxidation O
more O
efficiently O
than O
vitamin B
E I
analogue O
( O
Trolox B
) O
. O

Moreover O
, O
derivatives O
of O
caffeic B
acid I
, O
ferulic B
acid I
, O
and O
sinapic B
acid I
inhibited O
lipid O
peroxidation O
more O
efficiently O
than O
vitamin B
E I
analogue O
( O
Trolox B
) O
. O

Moreover O
, O
derivatives O
of O
caffeic B
acid I
, O
ferulic B
acid I
, O
and O
sinapic B
acid I
inhibited O
lipid O
peroxidation O
more O
efficiently O
than O
vitamin B
E I
analogue O
( O
Trolox B
) O
. O

Moreover O
, O
derivatives O
of O
caffeic B
acid I
, O
ferulic B
acid I
, O
and O
sinapic B
acid I
inhibited O
lipid O
peroxidation O
more O
efficiently O
than O
vitamin B
E I
analogue O
( O
Trolox B
) O
. O

In O
addition O
, O
derivatives O
of O
caffeic B
acid I
and O
sinapic B
acid I
efficiently O
inhibited O
tyrosinase O
activity O
and O
reduced O
melanin O
content O
in O
melanocytes O
Mel O
- O
Ab O
cell O
. O

In O
addition O
, O
derivatives O
of O
caffeic B
acid I
and O
sinapic B
acid I
efficiently O
inhibited O
tyrosinase O
activity O
and O
reduced O
melanin O
content O
in O
melanocytes O
Mel O
- O
Ab O
cell O
. O

A O
similar O
signature O
is O
associated O
with O
the O
persistence O
of O
ribonucleoside B
monophosphates I
( O
rNMPs B
) O
in O
DNA O
, O
and O
it O
also O
depends O
on O
Top1 O
activity O
. O

A O
series O
of O
new O
substrate O
analogue O
inhibitors O
of O
the O
WNV O
NS2B O
- O
NS3 O
protease O
containing O
decarboxylated B
arginine I
mimetics O
at O
the O
P1 O
position O
was O
developed O
. O

The O
inhibitor O
adopts O
a O
horseshoe O
- O
like O
conformation O
, O
most O
likely O
due O
to O
a O
hydrophobic O
contact O
between O
the O
P4 O
phenyl B
ring O
and O
the O
P1 O
cyclohexyl B
group O
, O
which O
is O
further O
stabilized O
by O
an O
intramolecular O
hydrogen B
bond O
between O
the O
P1 O
guanidino B
group O
and O
the O
P4 O
carbonyl B
oxygen I
atom O
. O

melatonin B
( O
proportionally O
nine O
parts O
physiological O
serum O
+ O
one O
part O
ethyl B
alcohol I
) O
intraperitoneally O
for O
4 O
weeks O
, O
( O
2 O
) O
the O
melatonin B
group O
was O
given O
5 O
mg O
/ O
kg O
/ O
day O
melatonin B
intraperitoneally O
for O
4 O
weeks O
, O
( O
3 O
) O
the O
TCDD B
group O
was O
given O
500 O
ng O
/ O
kg O
/ O
day O
TCDD B
by O
gavage O
for O
4 O
weeks O
and O
( O
4 O
) O
the O
TCDD B
+ O
melatonin B
group O
was O
given O
TCDD B
( O
500 O
ng O
/ O
kg O
/ O
day O
) O
by O
gavage O
and O
melatonin B
( O
5 O
mg O
/ O
kg O

Progress O
in O
the O
synthesis O
of O
canthine B
alkaloids I
and O
ring O
- O
truncated O
congeners O
. O

A O
synthetic O
amino B
acid I
bearing O
a O
furan B
functionality O
was O
developed O
and O
incorporated O
into O
peptide O
sequences O
using O
solid O
phase O
synthesis O
. O

Reactions O
of O
thiol B
and O
maleimide B
PEG I
macromers O
in O
an O
off O
- O
stoichiometric O
Michael O
addition O
were O
performed O
, O
such O
that O
the O
maleimide B
moiety O
was O
in O
excess O
, O
to O
create O
hydrogel O
networks O
with O
pendant O
Diels O
- O
Alder O
compatible O
tethering O
sites O
, O
that O
is O
, O
the O
maleimide B
. O

The O
PFS B
/ O
PEI B
multilayers O
are O
effective O
for O
the O
electrochemical O
sensing O
of O
ascorbic B
acid I
and O
hydrogen B
peroxide I
and O
show O
improved O
sensing O
performance O
at O
higher O
bilayer O
numbers O
. O

The O
PFS B
/ O
PEI B
multilayers O
are O
effective O
for O
the O
electrochemical O
sensing O
of O
ascorbic B
acid I
and O
hydrogen B
peroxide I
and O
show O
improved O
sensing O
performance O
at O
higher O
bilayer O
numbers O
. O

Synthesis O
and O
antibacterial O
evaluation O
of O
a O
novel O
tricyclic B
oxaborole I
- O
fused O
fluoroquinolone B
. O

Triglyceride B
accumulation O
inhibitory O
effects O
of O
phenylpropanoid B
glycosides I
from O
Boschniakia O
rossica O
Fedtsch O
et O
Flerov O
. O

Bioassay O
- O
guided O
fractionation O
led O
to O
isolation O
of O
five O
new O
phenylpropanol B
glycosides I
, O
rossicasides B
G O
( O
1 O
) O
, O
H O
( O
2 O
) O
, O
I O
( O
3 O
) O
, O
J O
( O
4 O
) O
, O
and O
K O
( O
5 O
) O
, O
together O
with O
seven O
known O
compounds O
( O
6 O
- O
12 O
) O
from O
Boschniakia O
rossica O
. O

Anti O
- O
apoptotic O
activity O
of O
hydroxytyrosol B
and O
hydroxytyrosyl B
laurate I
. O

In O
this O
study O
we O
have O
investigated O
the O
effects O
of O
HyT B
and O
the O
corresponding O
ester O
hydroxytyrosyl B
laurate I
in O
U937 O
cells O
, O
a O
human O
monocytoid O
cell O
line O
, O
and O
in O
C2C12 O
myoblasts O
, O
a O
murine O
proliferating O
muscle O
cell O
model O
, O
after O
apoptotic O
death O
induction O
. O

Zinc B
as O
zinc B
sulphate I
was O
supplemented O
to O
rats O
at O
a O
dose O
of O
227mg O
/ O
l O
in O
drinking O
water O
. O

FXR O
- O
dependent O
and O
- O
independent O
interaction O
of O
glucocorticoids O
with O
the O
regulatory O
pathways O
involved O
in O
the O
control O
of O
bile B
acid I
handling O
by O
the O
liver O
. O

The O
ability O
of O
dexamethasone B
, O
prednisolone B
and O
budesonide B
to O
affect O
the O
liver O
handling O
of O
bile B
acids I
( O
BAs O
) O
has O
been O
investigated O
. O

Tablets O
consisting O
of O
acetaminophen B
( O
20 O
- O
30 O
% O
) O
, O
lactose B
( O
69 O
. O
07 O
- O
78 O
. O
93 O
% O
) O
and O
magnesium B
stearate I
( O
0 O
. O
93 O
- O
1 O
. O
07 O
% O
) O
were O
prepared O
in O
a O
continuous O
direct O
compression O
line O
that O
consisted O
of O
two O
loss O
- O
in O
- O
weight O
feeders O
, O
one O
for O
acetaminophen B
and O
one O
for O
premixed O
lactose B
and O
magnesium B
stearate I
, O
and O
a O
continuous O
mixer O
followed O
by O
a O
rotary O
tablet O
press O
. O

Tablets O
consisting O
of O
acetaminophen B
( O
20 O
- O
30 O
% O
) O
, O
lactose B
( O
69 O
. O
07 O
- O
78 O
. O
93 O
% O
) O
and O
magnesium B
stearate I
( O
0 O
. O
93 O
- O
1 O
. O
07 O
% O
) O
were O
prepared O
in O
a O
continuous O
direct O
compression O
line O
that O
consisted O
of O
two O
loss O
- O
in O
- O
weight O
feeders O
, O
one O
for O
acetaminophen B
and O
one O
for O
premixed O
lactose B
and O
magnesium B
stearate I
, O
and O
a O
continuous O
mixer O
followed O
by O
a O
rotary O
tablet O
press O
. O

In O
rat O
kidney O
slices O
, O
uptake O
of O
entecavir B
was O
markedly O
inhibited O
by O
p B
- I
aminohippurate I
, O
benzylpenicillin B
, O
JBP485 B
, O
and O
tetraethyl B
ammonium I
. O

Recent O
studies O
have O
demonstrated O
the O
importance O
of O
the O
nitric B
oxide I
/ O
cGMP B
/ O
cAMP B
- O
responsive O
element O
- O
binding O
protein O
( O
CREB O
) O
pathway O
to O
the O
process O
of O
learning O
and O
memory O
. O

Histidine B
dipeptides O
such O
as O
carnosine B
form O
Michael O
adducts O
with O
lipid O
- O
derived O
unsaturated B
aldehydes I
, O
and O
react O
with O
carbohydrate B
- O
derived O
oxo B
- I
and I
hydroxy I
- I
aldehydes I
forming O
products O
of O
unknown O
structure O
. O

Purification O
of O
the O
extracts O
yielded O
four O
chiral O
polyphenols B
, O
suffruticosol B
A I
( O
1 O
) O
, O
suffruticosol B
B I
( O
2 O
) O
, O
trans B
- I
epsilon I
- I
viniferin I
( O
3 O
) O
, O
and O
trans B
- I
gnetin I
H I
( O
4 O
) O
. O

Purification O
of O
the O
extracts O
yielded O
four O
chiral O
polyphenols B
, O
suffruticosol B
A I
( O
1 O
) O
, O
suffruticosol B
B I
( O
2 O
) O
, O
trans B
- I
epsilon I
- I
viniferin I
( O
3 O
) O
, O
and O
trans B
- I
gnetin I
H I
( O
4 O
) O
. O

The O
thymidine B
monophosphate I
kinase O
( O
TMPK O
) O
of O
Mycobacterium O
tuberculosis O
( O
M O
. O
tuberculosis O
) O
, O
which O
is O
an O
essential O
enzyme O
for O
the O
maintenance O
of O
the O
thymidine B
triphosphate I
pools O
, O
is O
considered O
an O
attractive O
target O
for O
the O
development O
of O
effective O
antibiotics O
against O
tuberculosis O
. O

The O
thymidine B
monophosphate I
kinase O
( O
TMPK O
) O
of O
Mycobacterium O
tuberculosis O
( O
M O
. O
tuberculosis O
) O
, O
which O
is O
an O
essential O
enzyme O
for O
the O
maintenance O
of O
the O
thymidine B
triphosphate I
pools O
, O
is O
considered O
an O
attractive O
target O
for O
the O
development O
of O
effective O
antibiotics O
against O
tuberculosis O
. O

This O
asymmetry O
is O
ascribed O
to O
the O
wetting O
properties O
of O
Pt B
on O
HOPG O
as O
influenced O
by O
the O
formation O
of O
graphene B
oxide I
. O

Thermal O
sintering O
: O
a O
novel O
technique O
used O
in O
the O
design O
, O
optimization O
and O
biopharmaceutical O
evaluation O
of O
propranolol B
HCl I
gastric O
floating O
tablets O
. O

Abstract O
The O
objective O
of O
the O
present O
investigation O
was O
to O
study O
the O
applicability O
of O
thermal O
sintering O
technique O
for O
the O
development O
of O
gastric O
floating O
tablets O
of O
propranolol B
HCl I
. O

Formulations O
were O
prepared O
using O
four O
independent O
variables O
, O
namely O
( O
i O
) O
polymer O
quantity O
, O
( O
ii O
) O
sodium B
bicarbonate I
concentration O
, O
( O
iii O
) O
sintering O
temperature O
and O
( O
iv O
) O
sintering O
time O
. O

There O
was O
a O
significant O
increase O
in O
the O
bioavailability O
of O
the O
propranolol B
HCl I
from O
PTSso O
formulation O
, O
which O
was O
evident O
from O
increased O
AUC O
levels O
and O
larger O
MRT O
values O
than O
Ciplar B
LA I
80 I
. O

A O
multivalent O
approach O
towards O
linked O
dual O
- O
pharmacology O
prostaglandin B
F I
receptor O
agonist O
/ O
carbonic O
anhydrase O
- O
II O
inhibitors O
for O
the O
treatment O
of O
glaucoma O
. O

Application O
of O
Theravance O
' O
s O
multivalent O
approach O
to O
drug O
discovery O
towards O
linked O
dual O
- O
pharmacology O
prostaglandin B
F I
receptor O
( O
FP O
) O
agonist O
/ O
carbonic O
anhydrase O
( O
CA O
) O
- O
II O
inhibitor O
compounds O
is O
described O
. O

As O
predicted O
, O
TES B
enhanced O
the O
production O
of O
both O
peroxynitrite B
precursors O
( O
i O
. O
e O
. O
, O
superoxide B
and O
nitic B
oxide I
) O
, O
and O
xanthine B
oxidase O
was O
identified O
as O
the O
likely O
source O
of O
TES B
- O
stimulated O
superoxide B
production O
. O

Peginesatide B
, O
a O
polyethylene B
glycol I
( O
PEG B
) O
ylated O
peptide O
- O
based O
erythropoiesis O
- O
stimulating O
agent O
, O
stimulates O
the O
erythropoietin O
receptor O
dimer O
that O
governs O
erythropoiesis O
. O

Although O
experimental O
evidences O
suggest O
that O
the O
intestinal O
microbiota O
is O
able O
to O
incorporate O
and O
degrade O
some O
of O
the O
available O
amino B
acids I
, O
it O
appears O
that O
the O
microbiota O
is O
also O
able O
to O
synthesize O
amino B
acids I
raising O
the O
view O
that O
amino B
acid I
exchange O
between O
the O
microbiota O
and O
host O
can O
proceed O
in O
both O
directions O
. O

Although O
experimental O
evidences O
suggest O
that O
the O
intestinal O
microbiota O
is O
able O
to O
incorporate O
and O
degrade O
some O
of O
the O
available O
amino B
acids I
, O
it O
appears O
that O
the O
microbiota O
is O
also O
able O
to O
synthesize O
amino B
acids I
raising O
the O
view O
that O
amino B
acid I
exchange O
between O
the O
microbiota O
and O
host O
can O
proceed O
in O
both O
directions O
. O

Although O
experimental O
evidences O
suggest O
that O
the O
intestinal O
microbiota O
is O
able O
to O
incorporate O
and O
degrade O
some O
of O
the O
available O
amino B
acids I
, O
it O
appears O
that O
the O
microbiota O
is O
also O
able O
to O
synthesize O
amino B
acids I
raising O
the O
view O
that O
amino B
acid I
exchange O
between O
the O
microbiota O
and O
host O
can O
proceed O
in O
both O
directions O
. O

Although O
the O
net O
result O
of O
such O
exchanges O
remains O
to O
be O
determined O
, O
it O
is O
likely O
that O
a O
significant O
part O
of O
the O
amino B
acids I
recovered O
from O
the O
alimentary O
proteins O
are O
used O
by O
the O
microbiota O
. O

In O
the O
large O
intestine O
, O
where O
the O
density O
of O
bacteria O
is O
much O
higher O
than O
in O
the O
small O
intestine O
and O
the O
transit O
time O
much O
longer O
, O
the O
residual O
undigested O
luminal O
proteins O
and O
peptides O
can O
be O
degraded O
in O
amino B
acids I
by O
the O
microbiota O
. O

These O
amino B
acids I
cannot O
be O
absorbed O
to O
a O
significant O
extent O
by O
the O
colonic O
epithelium O
, O
but O
are O
precursors O
for O
the O
synthesis O
of O
numerous O
metabolic O
end O
products O
in O
reactions O
made O
by O
the O
microbiota O
. O

Among O
these O
products O
, O
some O
like O
short O
- O
chain O
fatty B
acids I
and O
organic O
acids O
are O
energy O
substrates O
for O
the O
colonic O
mucosa O
and O
several O
peripheral O
tissues O
while O
others O
like O
sulfide B
and O
ammonia B
can O
affect O
the O
energy O
metabolism O
of O
colonic O
epithelial O
cells O
. O

With O
the O
exception O
of O
three O
residues O
, O
the O
specific O
amino B
acids I
that O
form O
the O
putative O
binding O
pocket O
for O
ICA B
in O
ERG O
are O
conserved O
in O
EAG O
. O

To O
establish O
proof O
of O
concept O
, O
microparticles O
were O
prepared O
with O
PLGA B
[ O
poly B
( I
d I
, I
l I
- I
lactide I
- I
co I
- I
glycolide I
) I
, O
50 O
: O
50 O
, O
MW O
. O
7000 O
- O
17000 O
] O
, O
hydroxypropyl B
methyl I
cellulose O
( O
HPMC O
) O
, O
and O
DXM B
by O
oil O
- O
in O
- O
water O
emulsion O
/ O
solvent O
evaporation O
technique O
. O

In O
the O
soil O
, O
the O
content O
of O
As B
extracted O
with O
acqua O
regia O
and O
that O
extracted O
with O
ammonium B
acetate I
, O
were O
analyzed O
. O

Prototypic O
substrates O
estrone B
- I
3 I
- I
sulfate I
( O
E B
- I
3 I
- I
S I
) O
and O
taurocholic B
acid I
were O
transported O
by O
the O
protein O
. O

Folic B
acid I
modified O
cationic O
gamma B
- I
cyclodextrin I
- O
oligoethylenimine B
star O
polymer O
with O
bioreducible O
disulfide B
linker O
for O
efficient O
targeted O
gene O
delivery O
. O

Herein O
, O
we O
demonstrate O
a O
design O
and O
synthesis O
of O
a O
new O
star O
- O
shaped O
cationic O
polymer O
containing O
a O
gamma B
- I
cyclodextrin I
( O
gamma B
- I
CD I
) O
core O
and O
multiple O
oligoethylenimine B
( O
OEI B
) O
arms O
with O
folic B
acid I
( O
FA O
) O
linked O
by O
a O
bioreducible O
disulfide B
bond O
for O
efficient O
targeted O
gene O
delivery O
. O

Diterpenoid B
alkaloids I
from O
Aconitum O
kirinense O
. O

A O
new O
C B
( I
18 I
) I
- I
diterpenoid I
alkaloid I
, O
kirinenine B
A I
( O
1 O
) O
, O
was O
isolated O
from O
the O
root O
of O
Aconitum O
kirinense O
, O
along O
with O
eight O
known O
diterpenoid B
alkaloids I
. O

A O
new O
C B
( I
18 I
) I
- I
diterpenoid I
alkaloid I
, O
kirinenine B
A I
( O
1 O
) O
, O
was O
isolated O
from O
the O
root O
of O
Aconitum O
kirinense O
, O
along O
with O
eight O
known O
diterpenoid B
alkaloids I
. O

A O
new O
2 B
, I
5 I
- I
diketopiperazine I
, O
( B
R I
) I
- I
2 I
- I
( I
2 I
- I
( I
furan I
- I
2 I
- I
yl I
) I
- I
oxoethyl I
) I
- I
octahydropyrrolo I
[ I
1 I
, I
2 I
- I
a I
] I
pyrazine I
- I
1 I
, I
4 I
- I
dione I
, O
and O
seven O
known O
compounds O
were O
isolated O
from O
the O
ethyl B
acetate I
extract O
of O
liquid O
fermentation O
broth O
of O
Armillaria O
mellea O
. O

The O
data O
prove O
that O
effective O
signal O
generation O
can O
be O
accomplished O
using O
a O
single O
charged O
amino B
acid I
, O
when O
appropriately O
located O
, O
providing O
a O
foundation O
to O
widely O
apply O
SWNT O
FET O
sensitivity O
to O
other O
biomolecular O
systems O
. O

New O
tetraterpene B
glycosides I
from O
the O
fruits O
of O
Lycium O
chinense O
. O

Two O
new O
compounds O
lyciumtetraterpenic B
hexaarabinoside I
( O
1 O
) O
and O
tetraterpenyl B
hexaarabinoside I
( O
2 O
) O
, O
along O
with O
two O
known O
compounds O
, O
were O
isolated O
from O
the O
methanol B
extract O
of O
the O
fruits O
of O
Lycium O
chinense O
Miller O
( O
Solanaceae O
) O
, O
and O
their O
structures O
have O
been O
elucidated O
as O
6 B
- I
( I
1 I
, I
1 I
, I
5 I
- I
trimethyl I
- I
5 I
alpha I
- I
hydroxycyclohexanyl I
) I
- I
6 I
' I
- I
( I
1 I
' I
, I
1 I
' I
, I
5 I
' I
- I
trimethyl I
- I
2 I
' I
beta I
- I

Two O
new O
compounds O
lyciumtetraterpenic B
hexaarabinoside I
( O
1 O
) O
and O
tetraterpenyl B
hexaarabinoside I
( O
2 O
) O
, O
along O
with O
two O
known O
compounds O
, O
were O
isolated O
from O
the O
methanol B
extract O
of O
the O
fruits O
of O
Lycium O
chinense O
Miller O
( O
Solanaceae O
) O
, O
and O
their O
structures O
have O
been O
elucidated O
as O
6 B
- I
( I
1 I
, I
1 I
, I
5 I
- I
trimethyl I
- I
5 I
alpha I
- I
hydroxycyclohexanyl I
) I
- I
6 I
' I
- I
( I
1 I
' I
, I
1 I
' I
, I
5 I
' I
- I
trimethyl I
- I
2 I
' I
beta I
- I

A O
series O
of O
3 B
- I
[ I
( I
4 I
- I
substituted I
- I
benzylidene I
) I
- I
amino I
] I
- I
2 I
- I
phenyl I
- I
3H I
- I
quinazolin I
- I
4 I
- I
ones I
( O
5a O
- O
k O
) O
were O
synthesized O
by O
reacting O
3 B
- I
amino I
- I
2 I
- I
phenyl I
- I
1H I
- I
quinazolin I
- I
4 I
- I
one I
with O
p B
- I
hydroxybenzaldehyde I
, O
and O
then O
further O
with O
various O
alkyl B
/ I
benzyl I
halides I
or O
substituted O
phenacyl B
bromides I
. O

Here O
, O
the O
film O
formation O
processes O
of O
three O
methyl B
methacrylate I
/ O
butyl B
acrylate I
copolymer O
latexes O
with O
high O
glass O
transition O
temperatures O
( O
T O
( O
g O
) O
) O
, O
ranging O
from O
45 O
to O
64 O
degrees O
C O
, O
have O
been O
studied O
when O
heated O
by O
infrared O
radiation O
. O

Here O
, O
the O
film O
formation O
processes O
of O
three O
methyl B
methacrylate I
/ O
butyl B
acrylate I
copolymer O
latexes O
with O
high O
glass O
transition O
temperatures O
( O
T O
( O
g O
) O
) O
, O
ranging O
from O
45 O
to O
64 O
degrees O
C O
, O
have O
been O
studied O
when O
heated O
by O
infrared O
radiation O
. O

Dibenzocyclooctadien B
lignans I
and O
norlignans B
from O
fruits O
of O
Schisandra O
wilsoniana O
. O

Seven O
new O
dibenzocyclooctadien B
lignans I
, O
marlignans B
M I
- I
S I
( O
1 O
- O
7 O
) O
, O
four O
new O
norlignans B
, O
marphenols B
C I
- I
F I
( O
8 O
- O
11 O
) O
, O
and O
21 O
known O
compounds O
( O
12 O
- O
32 O
) O
were O
isolated O
from O
the O
fruits O
of O
Schisandra O
wilsoniana O
. O

Flavonoids B
such O
as O
green O
tea O
catechins B
and O
quercetin B
glycosides I
have O
been O
shown O
to O
modulate O
the O
function O
of O
some O
OATPs O
. O

Uptake O
of O
the O
radiolabeled O
model O
substrates O
estradiol B
17 I
beta I
- I
glucuronide I
, O
estrone B
3 I
- I
sulfate I
, O
and O
dehydroepiandrostero B
sulfate I
( O
DHEAS B
) O
was O
determined O
in O
the O
absence O
and O
presence O
of O
compounds O
1 O
- O
6 O
using O
Chinese O
hamster O
ovary O
( O
CHO O
) O
cells O
stably O
expressing O
either O
OATP1B1 O
or O
OATP1B3 O
. O

IFN O
- O
alpha O
2a O
was O
incorporated O
in O
hydrogels O
composed O
of O
hyaluronic O
acid O
- O
tyramine B
( O
HA O
- O
Tyr B
) O
conjugates O
through O
the O
oxidative O
coupling O
of O
Tyr B
moieties O
with O
hydrogen B
peroxide I
( O
H2O2 B
) O
and O
horseradish O
peroxidase O
( O
HRP O
) O
. O

Although O
there O
is O
no O
pharmacological O
agent O
approved O
for O
the O
treatment O
of O
NAFLD O
, O
vitamin B
E I
( O
in O
patients O
without O
T2DM O
) O
and O
the O
thiazolidinedione O
pioglitazone B
( O
in O
patients O
with O
and O
without O
T2DM O
) O
have O
shown O
the O
most O
consistent O
results O
in O
randomized O
controlled O
trials O
. O

Extended B
- I
release I
ranolazine I
( O
ranolazine B
ER I
) O
[ O
Ranexa B
( O
( O
R O
) O
) O
] O
is O
an O
antianginal O
agent O
that O
achieves O
its O
effects O
via O
a O
novel O
mechanism O
of O
action O
( O
inhibition O
of O
the O
late O
phase O
of O
the O
inward O
sodium B
current O
) O
, O
without O
affecting O
heart O
rate O
or O
blood O
pressure O
( O
BP O
) O
. O

This O
article O
reviews O
the O
efficacy O
, O
safety O
and O
tolerability O
of O
ranolazine B
ER I
as O
add O
- O
on O
therapy O
in O
patients O
with O
chronic O
stable O
angina O
pectoris O
, O
as O
well O
as O
summarizing O
its O
pharmacological O
properties O
and O
its O
use O
in O
non O
- O
ST O
- O
elevation O
acute O
coronary O
syndromes O
. O

In O
the O
CARISA O
and O
ERICA O
trials O
, O
add O
- O
on O
therapy O
with O
ranolazine B
ER I
improved O
exercise O
tolerance O
and O
/ O
or O
reduced O
angina O
frequency O
and O
nitroglycerin B
use O
in O
patients O
with O
chronic O
stable O
angina O
; O
benefits O
were O
seen O
across O
a O
variety O
of O
patient O
subgroups O
. O

Although O
results O
of O
the O
MERLIN O
- O
TIMI O
36 O
trial O
do O
not O
support O
the O
use O
of O
ranolazine B
ER I
in O
the O
acute O
management O
of O
non O
- O
ST O
- O
elevation O
acute O
coronary O
syndromes O
, O
they O
do O
support O
its O
use O
as O
an O
antianginal O
therapy O
. O

Ranolazine B
ER I
was O
generally O
well O
tolerated O
, O
with O
the O
most O
commonly O
reported O
adverse O
events O
including O
dizziness O
, O
nausea O
, O
asthenia O
and O
constipation O
. O

Despite O
being O
associated O
with O
modest O
increases O
in O
the O
corrected O
QT O
interval O
, O
ranolazine B
ER I
demonstrated O
antiarrhythmic O
effects O
in O
the O
MERLIN O
- O
TIMI O
36 O
trial O
. O

In O
conclusion O
, O
ranolazine B
ER I
provides O
an O
important O
option O
for O
use O
as O
add O
- O
on O
therapy O
to O
reduce O
symptoms O
in O
patients O
with O
chronic O
stable O
angina O
. O

Nuclear O
receptors O
in O
bile B
acid I
metabolism O
. O

Bile B
acids I
are O
signaling O
molecules O
that O
activate O
nuclear O
receptors O
, O
such O
as O
farnesoid O
X O
receptor O
, O
pregnane B
X O
receptor O
, O
constitutive O
androstane B
receptor O
, O
and O
vitamin B
D I
receptor O
, O
and O
play O
a O
critical O
role O
in O
the O
regulation O
of O
lipid O
, O
glucose B
, O
energy O
, O
and O
drug O
metabolism O
. O

Bile B
acids I
are O
signaling O
molecules O
that O
activate O
nuclear O
receptors O
, O
such O
as O
farnesoid O
X O
receptor O
, O
pregnane B
X O
receptor O
, O
constitutive O
androstane B
receptor O
, O
and O
vitamin B
D I
receptor O
, O
and O
play O
a O
critical O
role O
in O
the O
regulation O
of O
lipid O
, O
glucose B
, O
energy O
, O
and O
drug O
metabolism O
. O

These O
xenobiotic O
/ O
endobiotic O
- O
sensing O
nuclear O
receptors O
regulate O
phase O
I O
oxidation O
, O
phase O
II O
conjugation O
, O
and O
phase O
III O
transport O
in O
bile B
acid I
and O
drug O
metabolism O
in O
the O
digestive O
system O
. O

Integration O
of O
bile B
acid I
metabolism O
with O
drug O
metabolism O
controls O
absorption O
, O
transport O
, O
and O
metabolism O
of O
nutrients O
and O
drugs O
to O
maintain O
metabolic O
homeostasis O
and O
also O
protects O
against O
liver O
injury O
, O
inflammation O
, O
and O
related O
metabolic O
diseases O
, O
such O
as O
nonalcoholic O
fatty O
liver O
disease O
, O
diabetes O
, O
and O
obesity O
. O

Electrokinetic O
charging O
of O
aqueous O
microjets O
was O
characterized O
by O
measuring O
streaming O
currents O
as O
a O
function O
of O
sodium B
iodide I
salt O
concentration O
. O

In O
the O
case O
of O
potassium B
fluoride I
no O
multipolar O
charge O
distribution O
is O
observed O
. O

This O
is O
an O
important O
discovery O
because O
this O
transition O
suggests O
a O
major O
structural O
change O
as O
a O
function O
of O
dehydrogenation O
for O
the O
stoichiometric O
B B
( I
n I
) I
H I
( I
n I
) I
( I
- I
) I
polyhedral B
boranes I
. O

Surface O
species O
were O
identified O
as O
copper B
sulfate I
and O
copper B
hydroxide I
. O

Surface O
species O
were O
identified O
as O
copper B
sulfate I
and O
copper B
hydroxide I
. O

Exercise O
training O
leads O
to O
an O
improved O
bioavailability O
of O
the O
endothelial O
nitric B
oxide I
and O
partially O
attenuates O
endothelial O
dysfunction O
. O

The O
extract O
of O
this O
plant O
showed O
, O
using O
different O
antioxidant O
assays O
( O
DPPH B
, O
ABTS B
and O
AAPH B
/ O
linoleic B
acid I
methods O
) O
and O
an O
IFN O
- O
gamma O
/ O
LPS O
induced O
RAW O
264 O
. O
7 O
murine O
macrophages O
' O
assay O
, O
the O
highest O
antioxidant O
( O
IC50 O
( O
DPPH B
assay O
) O
20 O
. O
64 O
+ O
/ O
- O
0 O
. O
84mg O
/ O
L O
) O
and O
anti O
- O
inflammatory O
( O
72 O
% O
inhibition O
at O
150mg O
/ O
L O
) O
activities O
, O
respectively O
. O

The O
analysis O
of O
the O
composition O
of O
the O
extracts O
revealed O
that O
the O
inhibitory O
activity O
against O
E O
. O
coli O
may O
be O
related O
to O
the O
presence O
of O
galloylated B
flavanols I
and O
specific O
flavonols B
, O
whereas O
the O
inhibitory O
capacity O
against O
S O
. O
aureus O
may O
be O
related O
primarily O
to O
polar O
compounds O
and O
to O
other O
flavonols B
. O

The O
pro O
- O
inflammatory O
genes O
, O
interleukin O
- O
6 O
( O
Il O
- O
6 O
) O
, O
interleukin O
- O
8 O
( O
Il O
- O
8 O
) O
and O
tumor O
necrosis O
factor O
( O
Tnf O
) O
, O
and O
two O
aromatic B
hydrocarbon I
receptor O
- O
regulated O
genes O
, O
Cyp1a1 O
and O
1b1 O
, O
were O
significantly O
up O
- O
regulated O
by O
oTRP O
. O

We O
formulated O
beta B
- I
Lap I
in O
an O
optimal O
random O
methylated B
- I
beta I
- I
cyclodextrin I
/ O
poloxamer B
407 I
mixture O
( O
i O
. O
e O
. O
, O
beta B
- I
Lap I
ternary O
system O
) O
and O
, O
using O
human O
breast O
adenocarcinoma O
MCF O
- O
7 O
cells O
and O
immunodeficient O
mice O
, O
performed O
in O
vitro O
and O
in O
vivo O
evaluation O
of O
its O
anti O
- O
tumor O
effects O
on O
proliferation O
, O
cell O
cycle O
, O
apoptosis O
, O
DNA O
damage O
, O
and O
tumor O
growth O
. O

Here O
we O
show O
that O
a O
class O
of O
ceramics O
comprising O
the O
entire O
lanthanide B
oxide I
series O
, O
ranging O
from O
ceria O
to O
lutecia O
, O
is O
intrinsically O
hydrophobic O
. O

Two O
species O
of O
mammary O
microcalcifications O
have O
been O
identified O
; O
calcium B
oxalate I
and O
hydroxyapatite B
. O

Calcium B
oxalate I
is O
mostly O
associated O
with O
benign O
lesions O
of O
the O
breast O
, O
whereas O
hydroxyapatite B
is O
associated O
with O
both O
benign O
and O
malignant O
tumors O
. O

Similar O
results O
were O
obtained O
for O
hydroxyacid B
simvastatin I
. O

Our O
test O
bed O
is O
a O
device O
- O
ready O
electrode O
architecture O
in O
which O
scalable O
, O
manufacturable O
carbon B
nanofoam O
papers O
with O
tunable O
pore O
sizes O
( O
5 O
- O
200 O
nm O
) O
and O
thickness O
( O
100 O
- O
300 O
mu O
m O
) O
are O
painted O
with O
~ O
10 O
nm O
coatings O
of O
manganese B
oxide I
( O
MnOx B
) O
. O

Fluocinolone B
acetonide I
intravitreal O
implant O
( O
Iluvien B
( O
R O
) O
) O
: O
in O
diabetic O
macular O
oedema O
. O

Fluocinolone B
acetonide I
intravitreal O
implant O
( O
Iluvien B
( O
R O
) O
) O
is O
an O
injectable O
, O
non O
- O
erodible O
, O
corticosteroid B
implant O
that O
is O
approved O
in O
several O
European O
countries O
for O
the O
treatment O
of O
chronic O
diabetic O
macular O
oedema O
( O
DMO O
) O
. O

In O
analyses O
of O
two O
multinational O
trials O
in O
patients O
with O
DMO O
previously O
treated O
with O
macular O
laser O
photocoagulation O
, O
fluocinolone B
acetonide I
intravitreal O
implant O
0 O
. O
2 O
mu O
g O
/ O
day O
was O
significantly O
more O
efficacious O
than O
sham O
injection O
in O
improving O
visual O
acuity O
. O

At O
24 O
months O
post O
injection O
, O
29 O
% O
of O
fluocinolone B
acetonide I
intravitreal O
implant O
0 O
. O
2 O
mu O
g O
/ O
day O
recipients O
had O
an O
improvement O
in O
the O
best O
- O
corrected O
visual O
acuity O
( O
BCVA O
) O
letter O
score O
of O
> O
= O
15 O
compared O
with O
16 O
% O
in O
the O
sham O
injection O
group O
( O
p O
= O
0 O
. O
002 O
) O
[ O
primary O
endpoint O
] O
. O

In O
this O
subgroup O
at O
36 O
months O
, O
34 O
% O
of O
fluocinolone B
acetonide I
intravitreal O
implant O
0 O
. O
2 O
mu O
g O
/ O
day O
recipients O
had O
an O
increase O
in O
the O
BCVA O
score O
of O
> O
= O
15 O
, O
compared O
with O
13 O
% O
of O
sham O
injection O
recipients O
( O
p O
< O
0 O
. O
001 O
) O
. O

Fluocinolone B
acetonide I
intravitreal O
implant O
recipients O
also O
had O
generally O
greater O
benefits O
than O
sham O
injection O
recipients O
on O
secondary O
endpoints O
. O

In O
patients O
who O
were O
phakic O
in O
the O
study O
eye O
at O
baseline O
, O
cataracts O
occurred O
in O
82 O
% O
of O
fluocinolone B
acetonide I
intravitreal O
implant O
0 O
. O
2 O
mu O
g O
/ O
day O
recipients O
and O
51 O
% O
of O
sham O
injection O
recipients O
. O

Overall O
, O
37 O
% O
and O
12 O
% O
of O
patients O
in O
the O
fluocinolone B
acetonide I
intravitreal O
implant O
and O
sham O
injection O
groups O
developed O
raised O
intraocular O
pressure O
( O
IOP O
) O
, O
which O
was O
generally O
controlled O
with O
IOP O
- O
lowering O
drugs O
. O

Group O
I O
mGluRs O
evoke O
K B
- O
ATP B
current O
by O
intracellular O
Ca2 B
+ I
mobilization O
in O
rat O
subthalamus O
neurons O
. O

The O
sulfonylurea B
agent O
tolbutamide B
( O
100 O
micro O
M O
) O
converted O
the O
positive O
slope O
to O
negative O
slope O
conductance O
, O
indicating O
mediation O
by O
K B
- O
ATP B
channels O
( O
ATP B
- O
sensitive O
K B
+ I
channels O
) O
. O

DHPG B
- O
evoked O
outward O
current O
was O
blocked O
by O
cyclopiazonic B
acid I
and O
thapsigargin B
and O
mimicked O
by O
caffeine B
, O
suggesting O
mediation O
by O
release O
of O
intracellular O
Ca B
( I
2 I
+ I
) I
. O

The O
nitric B
oxide I
synthase O
inhibitor O
N B
( I
G I
) I
- I
nitro I
- I
l I
- I
arginine I
methyl I
ester I
and O
inhibitors O
of O
protein O
kinase O
G O
activity O
also O
suppressed O
DHPG B
- O
induced O
outward O
current O
. O

These O
results O
show O
that O
group O
I O
mGluR O
stimulation O
generates O
K B
- O
ATP B
current O
by O
a O
nitric B
oxide I
- O
and O
protein O
kinase O
G O
- O
dependent O
process O
that O
is O
mediated O
by O
release O
of O
Ca B
( I
2 I
+ I
) I
from O
intracellular O
stores O
. O

Internalization O
Pathways O
of O
Anisotropic O
Disc O
- O
Shaped O
Zeolite B
L I
Nanocrystals O
with O
Different O
Surface O
Properties O
in O
HeLa O
Cancer O
Cells O
. O

Here O
the O
uptake O
and O
intracellular O
delivery O
of O
disc O
- O
shaped O
zeolite B
L I
nanocrystals O
as O
porous O
aminosilicates B
with O
well O
- O
defined O
crystal O
structure O
, O
uncoated O
as O
well O
as O
with O
COOH B
- I
, O
NH B
( I
2 I
) I
- I
, O
polyethyleneglycol B
( O
PEG B
) O
- O
and O
polyallylamine B
hydrochloride I
( O
PAH B
) O
surface O
coatings O
are O
reported O
. O

Here O
the O
uptake O
and O
intracellular O
delivery O
of O
disc O
- O
shaped O
zeolite B
L I
nanocrystals O
as O
porous O
aminosilicates B
with O
well O
- O
defined O
crystal O
structure O
, O
uncoated O
as O
well O
as O
with O
COOH B
- I
, O
NH B
( I
2 I
) I
- I
, O
polyethyleneglycol B
( O
PEG B
) O
- O
and O
polyallylamine B
hydrochloride I
( O
PAH B
) O
surface O
coatings O
are O
reported O
. O

Here O
the O
uptake O
and O
intracellular O
delivery O
of O
disc O
- O
shaped O
zeolite B
L I
nanocrystals O
as O
porous O
aminosilicates B
with O
well O
- O
defined O
crystal O
structure O
, O
uncoated O
as O
well O
as O
with O
COOH B
- I
, O
NH B
( I
2 I
) I
- I
, O
polyethyleneglycol B
( O
PEG B
) O
- O
and O
polyallylamine B
hydrochloride I
( O
PAH B
) O
surface O
coatings O
are O
reported O
. O

Okadaic B
acid I
( O
OKA B
) O
and O
analogues O
are O
frequent O
contaminants O
of O
coastal O
waters O
and O
seafood O
. O

To O
determine O
if O
the O
up O
- O
regulation O
of O
PDGF O
beta O
receptors O
is O
neuroprotective O
, O
primary O
hippocampal O
neurons O
were O
incubated O
with O
the O
5 O
- O
HT7 O
receptor O
agonist O
, O
LP B
12 I
, O
for O
24 O
h O
. O

Indeed O
, O
LP B
12 I
treatment O
prevented O
NMDA B
- O
induced O
neurotoxicity O
and O
this O
effect O
was O
dependent O
on O
PDGF O
beta O
receptor O
kinase O
activity O
. O

Treatment O
of O
primary O
neurons O
with O
LP B
12 I
also O
differentially O
altered O
NMDA B
receptor O
subunit O
expression O
, O
reducing O
the O
expression O
of O
NR1 O
and O
NR2B O
, O
but O
not O
NR2A O
. O

Prenatal O
exposure O
to O
bisphenol B
A I
impacts O
midbrain O
dopamine B
neurons O
and O
hippocampal O
spine O
synapses O
in O
non O
- O
human O
primates O
. O

In O
this O
study O
, O
we O
evaluated O
the O
utility O
of O
glutamate B
dehydrogenase O
( O
GLDH O
) O
, O
purine B
nucleoside I
phosphorylase O
( O
PNP O
) O
, O
malate B
dehydrogenase O
( O
MDH O
) O
, O
and O
paraxonase O
1 O
( O
PON1 O
) O
as O
indicators O
of O
liver O
injury O
in O
cohorts O
of O
human O
subjects O
, O
including O
healthy O
subjects O
across O
age O
and O
gender O
, O
subjects O
with O
a O
variety O
of O
liver O
impairments O
, O
and O
several O
cases O
of O
acetaminophen B
poisoning O
. O

Graphene B
oxide I
nanoribbons O
( O
GONRs O
) O
and O
chemically O
reduced B
graphene I
nanoribbons O
( O
crGNRs O
) O
were O
dispersed O
at O
high O
concentrations O
in O
chlorosulfonic B
acid I
to O
form O
anisotropic O
liquid O
crystal O
phases O
. O

Graphene B
oxide I
nanoribbons O
( O
GONRs O
) O
and O
chemically O
reduced B
graphene I
nanoribbons O
( O
crGNRs O
) O
were O
dispersed O
at O
high O
concentrations O
in O
chlorosulfonic B
acid I
to O
form O
anisotropic O
liquid O
crystal O
phases O
. O

Graphene B
oxide I
nanoribbons O
( O
GONRs O
) O
and O
chemically O
reduced B
graphene I
nanoribbons O
( O
crGNRs O
) O
were O
dispersed O
at O
high O
concentrations O
in O
chlorosulfonic B
acid I
to O
form O
anisotropic O
liquid O
crystal O
phases O
. O

Heat O
treatment O
of O
the O
as O
- O
spun O
GONR O
fibers O
at O
1500 O
degrees O
C O
produced O
thermally O
reduced B
graphene I
nanoribbon O
( O
trGNR O
) O
fibers O
with O
a O
tensile O
strength O
of O
378 O
MPa O
, O
Young O
' O
s O
modulus O
of O
36 O
. O
2 O
GPa O
, O
and O
electrical O
conductivity O
of O
285 O
S O
/ O
cm O
, O
which O
is O
considerably O
higher O
than O
that O
in O
other O
reported O
graphene B
- O
derived O
fibers O
. O

Sonochemical O
effects O
on O
free O
phenolic B
acids I
under O
ultrasound O
treatment O
in O
a O
model O
system O
. O

Sonochemical O
effects O
on O
seven O
free O
phenolic B
acids I
under O
ultrasound O
treatment O
in O
a O
model O
system O
have O
been O
investigated O
. O

Five O
phenolic B
acids I
( O
protocatechuic B
acid I
, O
p B
- I
hydroxybenzoic I
acid I
, O
vanillic B
acid I
, O
p B
- I
coumaric I
acid I
, O
and O
ferulic B
acid I
) O
proved O
to O
be O
stable O
, O
while O
two O
others O
( O
caffeic B
acid I
and O
sinapic B
acid I
) O
were O
degraded O
under O
ultrasound O
treatment O
. O

Five O
phenolic B
acids I
( O
protocatechuic B
acid I
, O
p B
- I
hydroxybenzoic I
acid I
, O
vanillic B
acid I
, O
p B
- I
coumaric I
acid I
, O
and O
ferulic B
acid I
) O
proved O
to O
be O
stable O
, O
while O
two O
others O
( O
caffeic B
acid I
and O
sinapic B
acid I
) O
were O
degraded O
under O
ultrasound O
treatment O
. O

Five O
phenolic B
acids I
( O
protocatechuic B
acid I
, O
p B
- I
hydroxybenzoic I
acid I
, O
vanillic B
acid I
, O
p B
- I
coumaric I
acid I
, O
and O
ferulic B
acid I
) O
proved O
to O
be O
stable O
, O
while O
two O
others O
( O
caffeic B
acid I
and O
sinapic B
acid I
) O
were O
degraded O
under O
ultrasound O
treatment O
. O

Five O
phenolic B
acids I
( O
protocatechuic B
acid I
, O
p B
- I
hydroxybenzoic I
acid I
, O
vanillic B
acid I
, O
p B
- I
coumaric I
acid I
, O
and O
ferulic B
acid I
) O
proved O
to O
be O
stable O
, O
while O
two O
others O
( O
caffeic B
acid I
and O
sinapic B
acid I
) O
were O
degraded O
under O
ultrasound O
treatment O
. O

Five O
phenolic B
acids I
( O
protocatechuic B
acid I
, O
p B
- I
hydroxybenzoic I
acid I
, O
vanillic B
acid I
, O
p B
- I
coumaric I
acid I
, O
and O
ferulic B
acid I
) O
proved O
to O
be O
stable O
, O
while O
two O
others O
( O
caffeic B
acid I
and O
sinapic B
acid I
) O
were O
degraded O
under O
ultrasound O
treatment O
. O

Five O
phenolic B
acids I
( O
protocatechuic B
acid I
, O
p B
- I
hydroxybenzoic I
acid I
, O
vanillic B
acid I
, O
p B
- I
coumaric I
acid I
, O
and O
ferulic B
acid I
) O
proved O
to O
be O
stable O
, O
while O
two O
others O
( O
caffeic B
acid I
and O
sinapic B
acid I
) O
were O
degraded O
under O
ultrasound O
treatment O
. O

The O
degradation O
rates O
of O
caffeic B
acid I
and O
sinapic B
acid I
decreased O
with O
increasing O
temperature O
. O

The O
degradation O
rates O
of O
caffeic B
acid I
and O
sinapic B
acid I
decreased O
with O
increasing O
temperature O
. O

Both O
decomposition O
and O
polymerization O
reactions O
occurred O
when O
caffeic B
acid I
and O
sinapic B
acid I
were O
subjected O
to O
ultrasound O
. O

Both O
decomposition O
and O
polymerization O
reactions O
occurred O
when O
caffeic B
acid I
and O
sinapic B
acid I
were O
subjected O
to O
ultrasound O
. O

We O
suppose O
that O
there O
are O
some O
enzymes O
responsible O
for O
converting O
intermediate O
JI B
- I
20A I
to O
3 O
' O
, O
4 O
' O
- O
bisdehydroxylated O
final O
product O
gentamicin B
C I
( O
1a O
) O
, O
while O
phosphorylation O
of O
3 B
' I
- I
OH I
is O
possibly O
the O
first O
step O
for O
C O
- O
3 O
' O
dehydroxylation O
. O

The O
resulting O
phosphotransferase O
was O
purified O
, O
and O
the O
kinetic O
parameters O
for O
Kanamycin B
A I
, O
Kanamycin B
B I
, O
Neomycin B
B I
and O
Amikacin B
were O
determined O
. O

The O
resulting O
phosphotransferase O
was O
purified O
, O
and O
the O
kinetic O
parameters O
for O
Kanamycin B
A I
, O
Kanamycin B
B I
, O
Neomycin B
B I
and O
Amikacin B
were O
determined O
. O

The O
resulting O
phosphotransferase O
was O
purified O
, O
and O
the O
kinetic O
parameters O
for O
Kanamycin B
A I
, O
Kanamycin B
B I
, O
Neomycin B
B I
and O
Amikacin B
were O
determined O
. O

A O
significant O
correlation O
between O
microscopically O
visible O
lipid O
droplets O
estimated O
by O
Nile B
Red I
staining O
and O
MR O
visible O
lipid O
signals O
was O
observed O
in O
metastatic O
lung O
carcinomas O
( O
p O
= O
0 O
. O
01 O
) O
, O
indicating O
that O
the O
proton O
MR O
visible O
lipid O
signals O
arise O
from O
cytoplasmic O
lipid O
droplets O
. O

BMI O
, O
plasma O
25 B
( I
OH I
) I
D I
, O
and O
the O
proportion O
of O
vitamin B
D I
- O
deficient O
and O
- O
insufficient O
children O
did O
not O
differ O
across O
the O
three O
groups O
. O

It O
remains O
uncertain O
if O
enhancement O
of O
the O
vitamin B
D I
status O
could O
improve O
pathophysiological O
mechanisms O
of O
prediabetes O
and O
type O
2 O
diabetes O
in O
obese O
youth O
. O

The O
prevalence O
of O
vitamin B
D I
deficiency O
( O
< O
50 O
nmol O
/ O
l O
) O
was O
39 O
. O
9 O
% O
, O
with O
34 O
. O
5 O
% O
in O
men O
and O
47 O
. O
8 O
% O
in O
women O
. O

Furthermore O
, O
participants O
with O
vitamin B
D I
sufficiency O
had O
a O
35 O
% O
lower O
risk O
of O
MetS O
than O
those O
with O
vitamin B
D I
deficiency O
( O
OR O
= O
0 O
. O
65 O
, O
95 O
% O
CI O
0 O
. O
51 O
- O
0 O
. O
84 O
, O
P O
= O
0 O
. O
0009 O
) O
. O

Furthermore O
, O
participants O
with O
vitamin B
D I
sufficiency O
had O
a O
35 O
% O
lower O
risk O
of O
MetS O
than O
those O
with O
vitamin B
D I
deficiency O
( O
OR O
= O
0 O
. O
65 O
, O
95 O
% O
CI O
0 O
. O
51 O
- O
0 O
. O
84 O
, O
P O
= O
0 O
. O
0009 O
) O
. O

Thus O
in O
this O
cohort O
of O
Chinese O
individuals O
, O
vitamin B
D I
deficiency O
is O
common O
and O
optimal O
vitamin B
D I
level O
is O
inversely O
associated O
with O
MetS O
, O
independent O
of O
several O
confounders O
and O
PTH O
level O
. O

Thus O
in O
this O
cohort O
of O
Chinese O
individuals O
, O
vitamin B
D I
deficiency O
is O
common O
and O
optimal O
vitamin B
D I
level O
is O
inversely O
associated O
with O
MetS O
, O
independent O
of O
several O
confounders O
and O
PTH O
level O
. O

Novel O
type O
II O
fatty B
acid I
biosynthesis O
( O
FAS O
II O
) O
inhibitors O
as O
multistage O
antimalarial O
agents O
. O

P O
. O
falciparum O
( O
Pf O
) O
enoyl B
acyl I
carrier O
protein O
( O
ACP O
) O
reductase O
( O
ENR O
) O
is O
a O
key O
enzyme O
of O
plasmodial O
type O
II O
fatty B
acid I
biosynthesis O
( O
FAS O
II O
) O
. O

P O
. O
falciparum O
( O
Pf O
) O
enoyl B
acyl I
carrier O
protein O
( O
ACP O
) O
reductase O
( O
ENR O
) O
is O
a O
key O
enzyme O
of O
plasmodial O
type O
II O
fatty B
acid I
biosynthesis O
( O
FAS O
II O
) O
. O

Solid O
- O
state O
NMR O
study O
reveals O
collagen O
I O
structural O
modifications O
of O
amino B
acid I
side O
chains O
upon O
fibrillogenesis O
. O

Nevertheless O
, O
only O
three O
to O
five O
rotameric O
equilibria O
are O
found O
for O
each O
amino B
acid I
residue O
, O
indicating O
a O
relatively O
low O
structural O
heterogeneity O
of O
collagen O
upon O
fibrillogenesis O
. O

Using O
side O
chain O
statistical O
data O
, O
we O
calculate O
equilibrium O
constants O
for O
a O
great O
number O
of O
amino B
acid I
residues O
. O

Our O
data O
indicate O
that O
fibril O
formation O
greatly O
affects O
hydroxyproline B
and O
proline B
prolyl I
pucker O
ring O
conformation O
. O

Finally O
, O
we O
discuss O
the O
implication O
of O
these O
structural O
data O
and O
propose O
a O
model O
in O
which O
the O
attractive O
force O
of O
fibrillogenesis O
comes O
from O
a O
structural O
reorganization O
of O
10 O
to O
15 O
% O
of O
the O
amino B
acids I
. O

An O
aqueous O
self O
- O
assembled O
micellar O
system O
( O
sodium B
dodecyl I
sulfate I
, O
SDS B
, O
decorated O
with O
various O
adhesive O
sites O
, O
cryptand B
Kryptofix B
222 I
and O
crown B
ether I
18 B
- I
Crown I
- I
6 I
molecules O
) O
has O
been O
investigated O
by O
dynamic O
light O
scattering O
( O
DLS O
) O
and O
small O
angle O
x O
- O
ray O
scattering O
( O
SAXS O
) O
to O
have O
insights O
into O
the O
micellar O
structure O
, O
the O
micellar O
interactions O
, O
and O
the O
aggregation O
properties O
of O
the O
system O
. O

An O
aqueous O
self O
- O
assembled O
micellar O
system O
( O
sodium B
dodecyl I
sulfate I
, O
SDS B
, O
decorated O
with O
various O
adhesive O
sites O
, O
cryptand B
Kryptofix B
222 I
and O
crown B
ether I
18 B
- I
Crown I
- I
6 I
molecules O
) O
has O
been O
investigated O
by O
dynamic O
light O
scattering O
( O
DLS O
) O
and O
small O
angle O
x O
- O
ray O
scattering O
( O
SAXS O
) O
to O
have O
insights O
into O
the O
micellar O
structure O
, O
the O
micellar O
interactions O
, O
and O
the O
aggregation O
properties O
of O
the O
system O
. O

Catalytic O
transformation O
of O
alcohols B
to O
carboxylic B
acid I
salts O
and O
H2 B
using O
water O
as O
the O
oxygen B
atom O
source O
. O

The O
oxidation O
of O
alcohols B
to O
carboxylic B
acids I
is O
an O
important O
industrial O
reaction O
used O
in O
the O
synthesis O
of O
bulk O
and O
fine O
chemicals O
. O

A O
homogeneous O
ruthenium B
complex O
catalyses O
the O
transformation O
of O
primary O
alcohols B
to O
carboxylic B
acid I
salts O
at O
low O
catalyst O
loadings O
( O
0 O
. O
2 O
mol O
% O
) O
in O
basic O
aqueous O
solution O
. O

A O
consequence O
of O
this O
finding O
could O
be O
a O
safer O
and O
cleaner O
process O
for O
the O
synthesis O
of O
carboxylic B
acids I
and O
their O
derivatives O
at O
both O
laboratory O
and O
industrial O
scales O
. O

A O
donor O
- O
acceptor O
type O
organic O
dye O
connected O
with O
a O
quinoidal B
thiophene I
for O
dye O
- O
sensitized O
solar O
cells O
. O

A O
donor O
- O
acceptor O
type O
organic O
dye O
connected O
with O
a O
quinoidal B
thiophene I
as O
a O
pi O
- O
conjugated O
chain O
, O
cyano B
- I
[ I
5 I
' I
- I
( I
4 I
' I
' I
- I
( I
N I
, I
N I
- I
dimethylamino I
) I
benzylidene I
) I
- I
5H I
- I
thiophen I
- I
2 I
' I
- I
ylidene I
] I
acetic I
acid I
, O
was O
synthesized O
and O
applied O
to O
dye O
- O
sensitized O
solar O
cells O
( O
DSSCs O
) O
. O

The O
absorption O
band O
of O
this O
quinoidal B
thiophene I
dye O
appeared O
at O
longer O
wavelengths O
than O
those O
of O
dyes O
with O
similar O
pi O
- O
conjugation O
length O
, O
indicating O
the O
effective O
pi O
- O
conjugation O
through O
the O
quinoidal O
structure O
. O

Although O
the O
excited O
state O
of O
the O
quinoidal B
thiophene I
dye O
is O
deactivated O
within O
several O
picoseconds O
even O
in O
solution O
, O
the O
DSSCs O
using O
the O
quinoidal B
thiophene I
dye O
showed O
incident O
photon O
to O
current O
conversion O
efficiency O
( O
IPCE O
) O
values O
of O
more O
than O
90 O
% O
, O
demonstrating O
the O
fast O
and O
efficient O
electron O
injection O
from O
the O
excited O
dye O
to O
TiO B
( I
2 I
) I
. O

Although O
the O
excited O
state O
of O
the O
quinoidal B
thiophene I
dye O
is O
deactivated O
within O
several O
picoseconds O
even O
in O
solution O
, O
the O
DSSCs O
using O
the O
quinoidal B
thiophene I
dye O
showed O
incident O
photon O
to O
current O
conversion O
efficiency O
( O
IPCE O
) O
values O
of O
more O
than O
90 O
% O
, O
demonstrating O
the O
fast O
and O
efficient O
electron O
injection O
from O
the O
excited O
dye O
to O
TiO B
( I
2 I
) I
. O

Moreover O
, O
the O
current O
study O
showed O
that O
malathion B
induced O
liver O
and O
kidney O
dysfunctions O
demonstrated O
by O
considerable O
increase O
in O
phosphatase O
alkaline O
( O
PAL O
) O
, O
aspartate B
aminotransferase O
( O
AST O
) O
and O
alanine B
aminotransferase O
( O
ALT O
) O
activities O
as O
well O
as O
total O
and O
direct O
bilirubin B
, O
creatinine B
urea B
and O
acid B
uric I
contents O
. O

Similar O
changes O
are O
also O
observed O
in O
cells O
expressing O
another O
disease O
- O
causing O
gene O
that O
triggers O
ER O
stress O
, O
as O
well O
as O
in O
cells O
treated O
with O
brefeldin B
A I
, O
which O
induces O
ER O
stress O
and O
GA O
fragmentation O
by O
inhibiting O
GA O
to O
ER O
trafficking O
. O

Isolation O
and O
synthesis O
of O
melodamide B
A I
, O
a O
new O
anti O
- O
inflammatory O
phenolic B
amide I
from O
the O
leaves O
of O
Melodorum O
fruticosum O
. O

Isolation O
and O
synthesis O
of O
melodamide B
A I
, O
a O
new O
anti O
- O
inflammatory O
phenolic B
amide I
from O
the O
leaves O
of O
Melodorum O
fruticosum O
. O

Together O
with O
twelve O
known O
compounds O
( O
2 O
- O
13 O
) O
, O
melodamide B
A I
( O
1 O
) O
, O
a O
new O
phenolic B
amide I
possessing O
p B
- I
quinol I
moiety O
, O
was O
purified O
and O
characterized O
from O
the O
methanolic O
extracts O
of O
the O
leaves O
of O
Melodorum O
fruticosum O
. O

Together O
with O
twelve O
known O
compounds O
( O
2 O
- O
13 O
) O
, O
melodamide B
A I
( O
1 O
) O
, O
a O
new O
phenolic B
amide I
possessing O
p B
- I
quinol I
moiety O
, O
was O
purified O
and O
characterized O
from O
the O
methanolic O
extracts O
of O
the O
leaves O
of O
Melodorum O
fruticosum O
. O

The O
structure O
of O
melodamide B
A I
( O
1 O
) O
was O
established O
with O
a O
combination O
of O
2D O
NMR O
experiments O
, O
HR O
- O
ESI O
- O
MS O
and O
X O
- O
ray O
analyses O
. O

Furthermore O
, O
synthesis O
and O
biological O
evaluation O
of O
melodamide B
A I
( O
1 O
) O
and O
its O
analogs O
( O
14a O
- O
p O
) O
were O
described O
. O

We O
began O
by O
studying O
the O
tetraisopropyl B
pyrophosphoramide I
adduct O
of O
BChE O
because O
this O
adduct O
has O
two O
P B
- I
N I
bonds O
. O

BChE O
inhibited O
by O
authentic O
, O
racemic B
tabun I
yielded O
both O
902 O
. O
2 O
and O
874 O
. O
2 O
m O
/ O
z O
peptides O
, O
indicating O
that O
both O
stereoisomers O
reacted O
with O
BChE O
and O
aged O
either O
by O
deamination O
or O
dealkylation O
. O

The O
effect O
of O
apricots O
on O
the O
experimental O
cataract O
model O
formed O
by O
sodium B
selenite I
. O

This O
study O
was O
designed O
in O
order O
to O
investigate O
whether O
sun O
dried O
apricots O
have O
a O
preventive O
effect O
on O
the O
experimental O
cataract O
model O
formed O
by O
sodium B
selenite I
in O
rats O
. O

Subcutaneous O
( O
30nmol O
/ O
gr O
) O
sodium B
selenite I
injection O
was O
applied O
to O
all O
the O
newborn O
rats O
except O
the O
control O
group O
( O
Group O
1 O
) O
on O
postpartum O
day O
10 O
. O

Anti O
- O
inflammatory O
activity O
of O
patchouli B
alcohol I
in O
RAW264 O
. O
7 O
and O
HT O
- O
29 O
cells O
. O

Patchouli B
alcohol I
( O
PA O
) O
is O
a O
chemical O
compound O
extracted O
from O
patchouli O
which O
belongs O
to O
the O
genus O
Pogostemon O
, O
herb O
of O
mint O
family O
. O

Gout O
, O
a O
common O
form O
of O
inflammatory O
arthritis O
, O
is O
strongly O
associated O
with O
elevated O
uric B
acid I
concentrations O
in O
the O
blood O
( O
hyperuricemia O
) O
. O

A O
recent O
study O
in O
Icelanders O
identified O
a O
rare O
missense O
single O
nucleotide B
polymorphism O
( O
SNP O
) O
in O
the O
ALDH16A1 O
gene O
, O
ALDH16A1 O
* O
2 O
, O
to O
be O
associated O
with O
gout O
and O
serum O
uric B
acid I
levels O
. O

Molecular O
modeling O
predicts O
that O
both O
the O
short O
and O
long O
forms O
of O
human O
ALDH16A1 O
protein O
would O
lack O
catalytic O
activity O
but O
may O
interact O
with O
the O
hypoxanthine B
- O
guanine B
phosphoribosyltransf O
( O
HPRT1 O
) O
protein O
, O
a O
key O
enzyme O
involved O
in O
uric B
acid I
metabolism O
and O
gout O
. O

Despite O
their O
beneficial O
anti O
- O
inflammatory O
properties O
, O
eicosapentaenoic B
acid I
( O
EPA B
) O
and O
docosahexaenoic B
acid I
( O
DHA B
) O
may O
increase O
the O
infection O
risk O
at O
high O
doses O
, O
likely O
by O
generating O
an O
immune O
- O
depressed O
state O
. O

Despite O
their O
beneficial O
anti O
- O
inflammatory O
properties O
, O
eicosapentaenoic B
acid I
( O
EPA B
) O
and O
docosahexaenoic B
acid I
( O
DHA B
) O
may O
increase O
the O
infection O
risk O
at O
high O
doses O
, O
likely O
by O
generating O
an O
immune O
- O
depressed O
state O
. O

To O
assess O
the O
contribution O
of O
different O
immune O
cell O
populations O
to O
the O
immunomodulatory O
fatty B
acid I
effect O
, O
we O
comparatively O
investigated O
several O
aspects O
of O
inflammation O
in O
human O
T O
- O
helper O
( O
Th O
) O
cells O
and O
monocytes O
. O

Both O
fatty B
acids I
, O
but O
DHA B
to O
a O
lesser O
extent O
compared O
with O
EPA B
, O
selectively O
and O
dose O
- O
dependently O
reduced O
the O
percentage O
of O
cytokine O
- O
expressing O
Th O
cells O
in O
a O
peroxisome O
proliferator O
- O
activated O
receptor O
( O
PPAR O
) O
gamma O
- O
dependent O
fashion O
, O
whereas O
the O
expression O
of O
the O
cell O
surface O
marker O
CD69 O
was O
unaltered O
on O
activated O
T O
cells O
. O

Cellular O
incorporation O
of O
EPA B
and O
DHA B
occurred O
mainly O
at O
the O
expense O
of O
arachidonic B
acid I
. O

Concomitantly O
, O
thromboxane B
B I
( B
TXB I
) I
2 I
and O
leukotriene B
B I
( B
LTB I
) I
4 I
in O
supernatants O
decreased O
, O
while O
levels O
of O
TXB3 B
and O
LTB5 B
increased O
. O

Concomitantly O
, O
thromboxane B
B I
( B
TXB I
) I
2 I
and O
leukotriene B
B I
( B
LTB I
) I
4 I
in O
supernatants O
decreased O
, O
while O
levels O
of O
TXB3 B
and O
LTB5 B
increased O
. O

Copper B
( I
I I
) I
- O
catalyzed O
borylative O
exo O
- O
cyclization O
of O
alkenyl B
halides I
containing O
unactivated O
double O
bond O
. O

A O
borylative O
exo O
- O
cyclization O
of O
alkenyl B
halides I
has O
been O
reported O
. O

One O
of O
the O
most O
popular O
models O
to O
evaluate O
the O
hepatoprotective O
potential O
of O
natural O
products O
is O
acetaminophen B
( O
APAP B
) O
- O
induced O
liver O
injury O
, O
although O
other O
hepatotoxicity O
models O
such O
as O
carbon B
tetrachloride I
, O
thioacetamide B
, O
ethanol B
and O
endotoxin O
are O
occasionally O
used O
. O

Sonhafouonic B
acid I
, O
a O
new O
cytotoxic O
and O
antifungal O
hopene B
- O
triterpenoid B
from O
Zehneria O
scabra O
camerunensis O
. O

A O
new O
hopene B
- O
type O
triterpenoid B
, O
namely O
sonhafouonic B
acid I
1a O
was O
isolated O
from O
Zehneria O
scabra O
camerunensis O
, O
together O
with O
eight O
known O
compounds O
. O

Two O
new O
isoprenylated B
chromone I
derivatives O
, O
pestaloficiols B
Q I
( I
1 I
) I
and I
R I
( O
2 O
) O
, O
and O
one O
new O
benzofuran B
derivative O
, O
pestaloficiol B
S I
( O
3 O
) O
, O
along O
with O
three O
known O
metabolites O
, O
anofinic B
acid I
( O
4 O
) O
, O
siccayne B
( O
5 O
) O
, O
and O
pyrenophorol B
( O
6 O
) O
were O
isolated O
from O
solid O
cultures O
of O
the O
plant O
endophytic O
fungus O
Pestalotiopsis O
fici O
. O

Two O
new O
isoprenylated B
chromone I
derivatives O
, O
pestaloficiols B
Q I
( I
1 I
) I
and I
R I
( O
2 O
) O
, O
and O
one O
new O
benzofuran B
derivative O
, O
pestaloficiol B
S I
( O
3 O
) O
, O
along O
with O
three O
known O
metabolites O
, O
anofinic B
acid I
( O
4 O
) O
, O
siccayne B
( O
5 O
) O
, O
and O
pyrenophorol B
( O
6 O
) O
were O
isolated O
from O
solid O
cultures O
of O
the O
plant O
endophytic O
fungus O
Pestalotiopsis O
fici O
. O

Two O
new O
isoprenylated B
chromone I
derivatives O
, O
pestaloficiols B
Q I
( I
1 I
) I
and I
R I
( O
2 O
) O
, O
and O
one O
new O
benzofuran B
derivative O
, O
pestaloficiol B
S I
( O
3 O
) O
, O
along O
with O
three O
known O
metabolites O
, O
anofinic B
acid I
( O
4 O
) O
, O
siccayne B
( O
5 O
) O
, O
and O
pyrenophorol B
( O
6 O
) O
were O
isolated O
from O
solid O
cultures O
of O
the O
plant O
endophytic O
fungus O
Pestalotiopsis O
fici O
. O

Their O
structures O
were O
elucidated O
primarily O
by O
NMR O
spectroscopy O
, O
and O
the O
absolute O
of O
the O
C O
- O
6 O
secondary B
alcohol I
in O
1 O
was O
deduced O
on O
the O
basis O
of O
circular O
dichroism O
( O
CD O
) O
data O
. O

Both O
silathio B
/ I
silasulfonyl I
acetic I
acids I
were O
efficiently O
condensed O
with O
benzohydrazides B
in O
the O
presence O
of O
phosphorus B
oxychloride I
to O
give O
sila B
- I
substituted I
1 I
, I
3 I
, I
4 I
- I
oxadiazoles I
in O
high O
yields O
. O

The O
polymer O
was O
synthesized O
by O
graft O
polymerization O
of O
methacrylic B
acid I
( O
MAA B
) O
and O
polysorbate B
80 I
( O
PS B
80 I
) O
onto O
starch O
with O
multiple O
, O
chemically O
bound O
diethylenetriaminepe B
acetic I
acid I
( O
DTPA B
) O
groups O
for O
gadolinium B
chelating O
. O

The O
polymer O
was O
synthesized O
by O
graft O
polymerization O
of O
methacrylic B
acid I
( O
MAA B
) O
and O
polysorbate B
80 I
( O
PS B
80 I
) O
onto O
starch O
with O
multiple O
, O
chemically O
bound O
diethylenetriaminepe B
acetic I
acid I
( O
DTPA B
) O
groups O
for O
gadolinium B
chelating O
. O

The O
polymer O
was O
synthesized O
by O
graft O
polymerization O
of O
methacrylic B
acid I
( O
MAA B
) O
and O
polysorbate B
80 I
( O
PS B
80 I
) O
onto O
starch O
with O
multiple O
, O
chemically O
bound O
diethylenetriaminepe B
acetic I
acid I
( O
DTPA B
) O
groups O
for O
gadolinium B
chelating O
. O

Spray O
- O
dried O
SLH O
microparticles O
comprising O
Capmul B
MCM I
( O
mono B
- I
diglycerides I
of O
C8 O
/ O
C12 O
fatty B
acids I
) O
and O
silica B
nanoparticles O
( O
Aerosil B
( O
R O
) O
380 O
) O
were O
shown O
to O
significantly O
enhance O
the O
fasted O
state O
oral O
bioavailability O
of O
celecoxib B
( O
CEL B
) O
( O
6 O
. O
5 O
fold O
, O
relative O
to O
an O
aqueous O
suspension O
and O
more O
than O
2 O
- O
fold O
higher O
relative O
to O
the O
fed O
state O
) O
after O
oral O
administration O
to O
beagle O
dogs O
. O

Spray O
- O
dried O
SLH O
microparticles O
comprising O
Capmul B
MCM I
( O
mono B
- I
diglycerides I
of O
C8 O
/ O
C12 O
fatty B
acids I
) O
and O
silica B
nanoparticles O
( O
Aerosil B
( O
R O
) O
380 O
) O
were O
shown O
to O
significantly O
enhance O
the O
fasted O
state O
oral O
bioavailability O
of O
celecoxib B
( O
CEL B
) O
( O
6 O
. O
5 O
fold O
, O
relative O
to O
an O
aqueous O
suspension O
and O
more O
than O
2 O
- O
fold O
higher O
relative O
to O
the O
fed O
state O
) O
after O
oral O
administration O
to O
beagle O
dogs O
. O

Improved O
pharmaceutical O
stability O
of O
a O
boronphenylalanine B
mannitol I
formulation O
for O
boron B
neutron O
capture O
therapy O
. O

Resolution O
of O
the O
formulation O
issues O
would O
remove O
this O
factor O
and O
therefore O
the O
stability O
of O
an O
alternative O
mannitol B
BPA I
formulation O
has O
been O
investigated O
. O

A O
mannitol B
BPA I
solution O
formulation O
was O
prepared O
and O
either O
lyophilised O
or O
stored O
as O
a O
solution O
at O
varying O
temperatures O
. O

Lyophilised O
and O
solution O
mannitol B
BPA I
formulations O
exhibited O
a O
temperature O
and O
time O
dependent O
loss O
of O
BPA B
with O
concomitant O
increases O
in O
degradation O
products O
. O

A O
solution O
or O
lyophilised O
mannitol B
BPA I
formulation O
has O
a O
shelf O
- O
life O
of O
between O
1 O
and O
4 O
years O
respectively O
, O
a O
marked O
improvement O
over O
the O
current O
fructose B
formulation O
. O

CIT B
can O
co O
- O
occur O
with O
ochratoxin B
A I
( O
OTA B
) O
, O
a O
mycotoxin O
also O
known O
for O
its O
nephrotoxicity O
, O
and O
this O
raises O
concern O
regarding O
possible O
combined O
effects O
. O

Crude O
composition O
, O
fatty B
acids I
, O
sterols B
, O
total O
phenolic O
content O
( O
TPC O
) O
, O
individual O
polyphenols B
and O
terpenic B
acids I
were O
determined O
in O
five O
wild O
edible O
mushrooms O
species O
( O
Lactarius O
deliciosus O
, O
Lactarius O
sanguifluus O
, O
Lactarius O
semisanguifluus O
, O
Russula O
delica O
, O
Suillus O
bellinii O
) O
from O
Lesvos O
Island O
, O
Greece O
. O

Crude O
composition O
, O
fatty B
acids I
, O
sterols B
, O
total O
phenolic O
content O
( O
TPC O
) O
, O
individual O
polyphenols B
and O
terpenic B
acids I
were O
determined O
in O
five O
wild O
edible O
mushrooms O
species O
( O
Lactarius O
deliciosus O
, O
Lactarius O
sanguifluus O
, O
Lactarius O
semisanguifluus O
, O
Russula O
delica O
, O
Suillus O
bellinii O
) O
from O
Lesvos O
Island O
, O
Greece O
. O

Up O
to O
19 O
simple O
polyphenols B
were O
determined O
in O
mushrooms O
extracts O
, O
the O
more O
abundant O
being O
p B
- I
OH I
- I
benzoic I
acid I
, O
p B
- I
OH I
- I
phenylacetic I
acid I
, O
o B
- I
coumaric I
acid I
, O
ferulic B
acid I
and O
chrysin B
. O

In O
addition O
, O
the O
triterpenic B
acids I
oleanolic B
and O
ursolic B
were O
detected O
for O
the O
first O
time O
in O
mushrooms O
. O

A O
new O
iridoid B
glycoside I
and O
potential O
MRB O
inhibitory O
activity O
of O
isolated O
compounds O
from O
the O
rhizomes O
of O
Cyperus O
rotundus O
L O
. O

A O
new O
iridoid B
glycoside I
, O
rotunduside B
( O
1 O
) O
, O
along O
with O
four O
known O
iridoid B
glycosides I
, O
10 B
- I
O I
- I
p I
- I
hydroxybenzoylthevir I
( O
2 O
) O
, O
10 B
- I
O I
- I
vanilloyltheviridosi I
( O
3 O
) O
, O
6 B
' I
' I
- I
O I
- I
( I
trans I
- I
p I
- I
coumaroyl I
) I
- I
procumbide I
( O
4 O
) O
and O
loganic B
acid I
( O
5 O
) O
, O
was O
isolated O
from O
the O
rhizomes O
of O
Cyperus O
rotundus O
L O
. O

A O
new O
iridoid B
glycoside I
, O
rotunduside B
( O
1 O
) O
, O
along O
with O
four O
known O
iridoid B
glycosides I
, O
10 B
- I
O I
- I
p I
- I
hydroxybenzoylthevir I
( O
2 O
) O
, O
10 B
- I
O I
- I
vanilloyltheviridosi I
( O
3 O
) O
, O
6 B
' I
' I
- I
O I
- I
( I
trans I
- I
p I
- I
coumaroyl I
) I
- I
procumbide I
( O
4 O
) O
and O
loganic B
acid I
( O
5 O
) O
, O
was O
isolated O
from O
the O
rhizomes O
of O
Cyperus O
rotundus O
L O
. O

A O
new O
iridoid B
glycoside I
, O
rotunduside B
( O
1 O
) O
, O
along O
with O
four O
known O
iridoid B
glycosides I
, O
10 B
- I
O I
- I
p I
- I
hydroxybenzoylthevir I
( O
2 O
) O
, O
10 B
- I
O I
- I
vanilloyltheviridosi I
( O
3 O
) O
, O
6 B
' I
' I
- I
O I
- I
( I
trans I
- I
p I
- I
coumaroyl I
) I
- I
procumbide I
( O
4 O
) O
and O
loganic B
acid I
( O
5 O
) O
, O
was O
isolated O
from O
the O
rhizomes O
of O
Cyperus O
rotundus O
L O
. O

Two O
new O
glycosides O
, O
2 B
- I
methyl I
pyromeconic I
acid I
3 I
- I
O I
- I
beta I
- I
d I
- I
glucopyranoside I
- I
6 I
' I
- I
( I
O I
- I
4 I
' I
' I
- I
hydroxybenzoate I
) I
( O
1 O
) O
, O
6 B
' I
- I
O I
- I
p I
- I
hydroxybenzoyl I
- I
gardoside I
( O
2 O
) O
and O
four O
known O
iridoid B
glycosides I
( O
3 O
- O
6 O
) O
were O
isolated O
from O
the O
whole O
plant O
of O
Vitex O
negundo O
. O

On O
the O
other O
hand O
, O
no O
vitamin B
E I
derivative O
was O
found O
in O
A O
. O
gemmatalis O
exuvia O
. O

This O
is O
the O
first O
report O
of O
vitamin B
E I
occurrence O
in O
the O
insect O
' O
s O
cuticle O
. O

We O
evaluated O
the O
analgesic O
- O
like O
effect O
of O
PC O
/ O
beta B
- I
CD I
and O
PC O
in O
acetic B
acid I
- O
induced O
abdominal O
writhes O
, O
hot O
- O
plate O
, O
carrageenan O
- O
induced O
paw O
edema O
and O
in O
rota O
- O
rod O
apparatus O
. O

In O
the O
present O
research O
, O
nanomaterial O
interaction O
with O
DCFH B
- I
DA I
was O
studied O
in O
relation O
to O
its O
nature O
and O
/ O
or O
assay O
conditions O
( O
cell O
- O
based O
and O
time O
exposure O
) O
by O
incubating O
Rhodamine B
( O
Rhd B
) O
- O
labeled O
25nm O
and O
50nm O
silica B
( O
SiO2 B
) O
, O
naked O
and O
oleic B
acid I
coated I
magnetite I
, O
( O
Fe3O4 B
) O
and O
maghemite B
( O
Fe2O3 B
) O
iron B
oxide I
, O
titanium B
dioxide I
( O
TiO2 B
) O
and O
poly B
( I
ethylene I
oxide I
) I
- I
poly I
( I
lactide I
/ I

In O
the O
present O
research O
, O
nanomaterial O
interaction O
with O
DCFH B
- I
DA I
was O
studied O
in O
relation O
to O
its O
nature O
and O
/ O
or O
assay O
conditions O
( O
cell O
- O
based O
and O
time O
exposure O
) O
by O
incubating O
Rhodamine B
( O
Rhd B
) O
- O
labeled O
25nm O
and O
50nm O
silica B
( O
SiO2 B
) O
, O
naked O
and O
oleic B
acid I
coated I
magnetite I
, O
( O
Fe3O4 B
) O
and O
maghemite B
( O
Fe2O3 B
) O
iron B
oxide I
, O
titanium B
dioxide I
( O
TiO2 B
) O
and O
poly B
( I
ethylene I
oxide I
) I
- I
poly I
( I
lactide I
/ I

PC2 O
and O
PC3 O
cluster O
American O
- O
and O
Virginia O
- O
blends O
, O
revealing O
inverse O
correlations O
: O
Nitrogen B
oxides I
and O
amino B
- O
or O
nitroso B
- O
aromatic O
compounds O
inversely O
correlate O
to O
either O
formaldehyde B
and O
acrolein B
, O
or O
benzo B
( I
a I
) I
pyrene I
and O
di B
- I
hydroxybenzenes I
. O

This O
model O
is O
supported O
by O
multiple O
lines O
of O
congruent O
evidence O
: O
( O
1 O
) O
mutants O
defective O
in O
amino B
acid I
signaling O
or O
transport O
are O
sensitive O
to O
dieldrin B
, O
which O
is O
reversed O
by O
the O
addition O
of O
exogenous O
leucine B
; O
( O
2 O
) O
dieldrin B
sensitivity O
of O
wild O
- O
type O
or O
mutant O
strains O
is O
dependent O
upon O
leucine B
concentration O
in O
the O
media O
; O
( O
3 O
) O
overexpression O
of O
proteins O
that O
increase O
intracellular O
leucine B
confer O
resistance O
to O
dieldrin B
; O
( O
4 O
) O
leucine B
uptake O
is O
inhibited O
in O
the O
presence O
of O
dieldrin B
; O
and O
( O
5 O
) O
dieldrin B

This O
study O
examined O
laterality O
of O
mesocorticolimbic O
monoamines B
( O
frontal O
cortex O
, O
nucleus O
accumbens O
, O
striatum O
, O
midbrain O
) O
and O
amino B
acids I
( O
frontal O
cortex O
) O
in O
male O
and O
female O
rats O
subjected O
to O
lifetime O
Pb B
exposure O
( O
0 O
or O
50 O
ppm O
in O
drinking O
water O
) O
, O
PS O
( O
restraint O
stress O
on O
gestational O
days O
16 O
- O
17 O
) O
, O
or O
the O
combination O
with O
and O
without O
repeated O
learning O
behavioral O
experience O
. O

Compounds O
1 O
- O
8 O
, O
designated O
as O
phorbaketals B
D I
- I
K I
, O
possess O
a O
spiroketal B
- O
modified O
benzopyran B
moiety O
such O
as O
phorbaketal B
A I
, O
and O
their O
structural O
variations O
are O
due O
to O
oxidation O
and O
/ O
or O
reduction O
of O
the O
tricyclic O
core O
or O
the O
side O
chain O
. O

Compound O
9 O
, O
designated O
as O
phorbin B
A I
, O
has O
a O
monocyclic O
structure O
and O
is O
proposed O
to O
be O
a O
possible O
biogenetic O
precursor O
of O
the O
phorbaketals B
. O

We O
demonstrate O
, O
using O
mass O
spectrometry O
and O
X O
- O
ray O
crystallography O
, O
that O
the O
selective O
inhibitor O
covalently O
modifies O
PI3K O
alpha O
on O
cysteine B
862 O
( O
C862 O
) O
, O
an O
amino B
acid I
unique O
to O
the O
alpha O
isoform O
, O
and O
that O
PI3K O
beta O
, O
- O
gamma O
, O
and O
- O
delta O
are O
not O
covalently O
modified O
. O

Bisphenol B
A I
activates O
the O
Nrf1 O
/ O
2 O
- O
antioxidant O
response O
element O
pathway O
in O
HEK O
293 O
cells O
. O

Bisphenol B
A I
( O
BPA B
) O
is O
used O
in O
the O
production O
of O
polycarbonate B
plastics O
and O
epoxy O
resins O
for O
baby O
bottles O
, O
liners O
of O
canned O
food O
, O
and O
many O
other O
consumer O
products O
. O

The O
arylselenium B
compounds O
benzeneselenol B
( O
PhSeH B
) O
, O
dibenzyl B
diselenide I
( O
DBDSe B
) O
, O
diphenyl B
diselenide I
( O
DPDSe B
) O
, O
and O
ebselen B
were O
capable O
of O
inducing O
extracellular O
cysteine B
accumulation O
via O
a O
cystine B
- O
and O
glucose B
- O
dependent O
process O
. O

The O
arylselenium B
compounds O
benzeneselenol B
( O
PhSeH B
) O
, O
dibenzyl B
diselenide I
( O
DBDSe B
) O
, O
diphenyl B
diselenide I
( O
DPDSe B
) O
, O
and O
ebselen B
were O
capable O
of O
inducing O
extracellular O
cysteine B
accumulation O
via O
a O
cystine B
- O
and O
glucose B
- O
dependent O
process O
. O

Sodium B
selenite I
( O
Na2SeO3 B
) O
, O
selenomethionine B
( O
SeMet B
) O
, O
seleno B
- I
l I
- I
cystine I
( O
SeCySS B
) O
, O
and O
Se B
- I
methylselenocysteine I
( O
MeSeCys B
) O
did O
not O
have O
these O
effects O
on O
macrophages O
under O
the O
same O
treatment O
conditions O
. O

CrbpI O
regulates O
mammary O
retinoic B
acid I
homeostasis O
and O
the O
mammary O
microenvironment O
. O

Cellular O
retinol B
- O
binding O
protein O
, O
type O
I O
( O
CrbpI O
) O
, O
encoded O
by O
retinol B
- O
binding O
protein O
, O
type O
1 O
( O
Rbp1 O
) O
, O
is O
a O
chaperone O
of O
vitamin B
A I
( O
retinol B
) O
that O
is O
epigenetically O
silenced O
in O
~ O
25 O
% O
of O
human O
breast O
cancers O
. O

CrbpI O
delivers O
vitamin B
A I
to O
enzymes O
for O
metabolism O
into O
an O
active O
metabolite O
, O
all B
- I
trans I
retinoic I
acid I
( O
atRA B
) O
, O
where O
atRA B
is O
essential O
to O
cell O
proliferation O
, O
apoptosis O
, O
differentiation O
, O
and O
migration O
. O

CrbpI O
regulates O
mammary O
retinoic B
acid I
homeostasis O
and O
the O
mammary O
microenvironment O
. O

Influenza O
uses O
many O
individually O
weak O
ligand O
binding O
interactions O
for O
a O
high O
avidity O
multivalent O
attachment O
to O
sialic B
acid I
- O
bearing O
cells O
. O

Polymerized O
sialic B
acid I
analogs O
can O
form O
multivalent O
interactions O
with O
influenza O
but O
are O
not O
ideal O
therapeutics O
due O
to O
solubility O
and O
toxicity O
issues O
. O

Computationally O
assisted O
assignment O
of O
kahalalide B
Y I
configuration O
using O
an O
NMR O
- O
constrained O
conformational O
search O
. O

Here O
, O
we O
report O
isolation O
of O
kahalalide B
Y I
( O
1 O
) O
from O
Bryopsis O
pennata O
for O
the O
first O
time O
; O
in O
addition O
, O
the O
application O
of O
a O
combination O
of O
molecular O
modeling O
and O
NOE O
distance O
constraint O
calculations O
was O
utilized O
to O
determine O
the O
conformation O
of O
1 O
and O
the O
absolute O
configuration O
of O
the O
final O
stereogenic O
center O
of O
1 O
. O

Surfactant O
adsorption O
and O
interfacial O
tension O
investigations O
on O
cyclopentane B
hydrate I
. O

By O
combining O
a O
revised O
cohesive O
force O
model O
with O
experimental O
data O
, O
two O
interfacial O
properties O
of O
cyclopentane B
hydrate I
were O
estimated O
: O
hydrate O
- O
water O
and O
hydrate O
- O
cyclopentane B
interfacial O
tension O
values O
at O
0 O
. O
32 O
+ O
/ O
- O
0 O
. O
05 O
mN O
/ O
m O
and O
47 O
+ O
/ O
- O
5 O
mN O
/ O
m O
, O
respectively O
. O

These O
fundamental O
physiochemical O
properties O
have O
not O
been O
estimated O
or O
measured O
for O
cyclopentane B
hydrate I
to O
date O
. O

The O
addition O
of O
surfactants O
in O
the O
cyclopentane B
phase O
significantly O
reduced O
the O
cyclopentane B
hydrate I
cohesive O
force O
; O
we O
hypothesize O
this O
behavior O
to O
be O
the O
result O
of O
surfactant O
adsorption O
on O
the O
hydrate O
- O
oil O
interface O
. O

We O
demonstrate O
a O
high O
- O
throughput O
method O
for O
synthesizing O
zinc B
selenide I
( O
ZnSe B
) O
in O
situ O
during O
fiber O
drawing O
. O

Highly O
flexible O
all O
- O
solid O
- O
state O
SCs O
were O
subsequently O
assembled O
with O
these O
novel O
HZM O
electrodes O
using O
polyvinyl B
alcohol I
/ O
LiCl B
electrolyte O
. O

Influence O
of O
chain O
length O
and O
double O
bond O
on O
the O
aqueous O
behavior O
of O
choline B
carboxylate I
soaps O
. O

In O
preceding O
studies O
, O
we O
demonstrated O
that O
choline B
carboxylates I
ChC B
( I
m I
) I
with O
alkyl B
chain O
lengths O
of O
m O
= O
12 O
- O
18 O
are O
highly O
water O
- O
soluble O
( O
for O
m O
= O
12 O
, O
soluble O
up O
to O
93 O
wt O
% O
soap O
and O
0 O
degrees O
C O
) O
. O

We O
have O
investigated O
the O
aqueous O
phase O
behavior O
of O
choline B
soaps O
with O
C B
( I
8 I
) I
and O
C B
( I
10 I
) I
chain O
- O
lengths O
( O
choline B
octanoate I
and O
choline B
decanoate I
) O
and O
with O
a O
C B
( I
18 I
) I
chain O
- O
length O
with O
a O
cis O
- O
double O
bond O
( O
choline B
oleate I
) O
. O

We O
have O
investigated O
the O
aqueous O
phase O
behavior O
of O
choline B
soaps O
with O
C B
( I
8 I
) I
and O
C B
( I
10 I
) I
chain O
- O
lengths O
( O
choline B
octanoate I
and O
choline B
decanoate I
) O
and O
with O
a O
C B
( I
18 I
) I
chain O
- O
length O
with O
a O
cis O
- O
double O
bond O
( O
choline B
oleate I
) O
. O

We O
have O
investigated O
the O
aqueous O
phase O
behavior O
of O
choline B
soaps O
with O
C B
( I
8 I
) I
and O
C B
( I
10 I
) I
chain O
- O
lengths O
( O
choline B
octanoate I
and O
choline B
decanoate I
) O
and O
with O
a O
C B
( I
18 I
) I
chain O
- O
length O
with O
a O
cis O
- O
double O
bond O
( O
choline B
oleate I
) O
. O

We O
found O
that O
choline B
decanoate I
follows O
the O
lyotropic O
phase O
behavior O
of O
the O
longer O
- O
chain O
homologues O
mentioned O
above O
. O

Choline B
octanoate I
in O
water O
shows O
no O
discontinuous O
cubic O
phases O
, O
but O
an O
extended O
, O
isotropic O
micellar O
solution O
phase O
. O

In O
addition O
, O
choline B
octanoate I
is O
at O
the O
limit O
between O
a O
surfactant O
and O
a O
hydrotrope O
. O

The O
double O
bond O
in O
choline B
oleate I
leads O
also O
to O
a O
better O
solubility O
in O
water O
and O
a O
decrease O
of O
the O
solubilization O
temperature O
. O

To O
further O
characterize O
the O
extended O
, O
isotropic O
micellar O
solution O
phase O
in O
the O
binary O
phase O
diagram O
of O
choline B
octanoate I
viscosity O
and O
conductivity O
measurements O
were O
also O
carried O
out O
. O

The O
increase O
in O
SAA O
expression O
is O
specific O
to O
ritodrine B
- O
induced O
liver O
damage O
, O
because O
SAA O
expression O
was O
not O
induced O
by O
other O
hepatotoxic O
drugs O
such O
as O
acetaminophen B
, O
valproic B
acid I
, O
or O
metformin B
. O

Impaired O
social O
behavior O
in O
chicks O
exposed O
to O
sodium B
valproate I
during O
the O
last O
week O
of O
embryogenesis O
. O

RATIONALE O
AND O
OBJECTIVES O
: O
To O
evaluate O
direct O
exposure O
to O
sodium B
valproate I
( O
VPA B
) O
during O
embryogenesis O
, O
we O
administered O
VPA B
to O
chick O
embryos O
and O
examined O
their O
social O
behaviors O
after O
hatching O
. O

Oroxylin B
A I
improves O
attention O
deficit O
hyperactivity O
disorder O
- O
like O
behaviors O
in O
the O
spontaneously O
hypertensive O
rat O
and O
inhibits O
reuptake O
of O
dopamine B
in O
vitro O
. O

In O
previous O
studies O
we O
have O
demonstrated O
that O
the O
gamma B
- I
aminobutryic I
acid I
- O
A O
( O
GABA B
- O
A O
) O
receptor O
antagonist O
oroxylin B
A I
has O
an O
awakening O
effect O
and O
it O
also O
represses O
ADHD O
- O
like O
behaviors O
( O
hyperactivity O
, O
impulsivity O
and O
inattention O
) O
in O
the O
spontaneously O
hypertensive O
rat O
( O
SHR O
) O
model O
of O
attention O
- O
deficit O
hyperactivity O
disorder O
( O
ADHD O
) O
. O

We O
hypothesized O
that O
the O
effects O
of O
oroxylin B
A I
were O
exerted O
via O
the O
GABA B
- O
A O
receptor O
given O
the O
important O
role O
of O
the O
GABAergic O
system O
in O
ADHD O
. O

However O
, O
it O
is O
possible O
that O
aside O
from O
the O
GABAergic O
system O
, O
oroxylin B
A I
may O
influence O
other O
systems O
especially O
those O
implicated O
in O
ADHD O
( O
e O
. O
g O
. O
DAergic O
, O
etc O
. O
) O
. O

To O
test O
this O
hypothesis O
, O
we O
evaluated O
the O
effects O
of O
GABA B
agonist O
, O
or O
dopamine B
( O
DA O
) O
antagonist O
in O
oroxylin B
A I
- O
induced O
alleviation O
of O
ADHD O
- O
like O
behaviors O
in O
SHR O
. O

Oroxylin B
A I
significantly O
improved O
these O
behaviors O
, O
furthermore O
, O
its O
effect O
on O
SHR O
impulsivity O
was O
attenuated O
by O
haloperidol B
, O
a O
DA O
antagonist O
, O
but O
not O
by O
baicalein B
, O
an O
agonist O
of O
the O
GABA B
- O
A O
receptor O
. O

In O
vitro O
studies O
showed O
that O
oroxylin B
A I
inhibited O
DA O
uptake O
similar O
to O
methylphenidate B
, O
a O
dopamine B
transporter O
blocker O
, O
but O
did O
not O
influence O
norepinephrine B
uptake O
unlike O
atomoxetine B
, O
a O
selective O
NE O
reuptake O
inhibitor O
. O

Collectively O
, O
the O
present O
findings O
suggest O
that O
oroxylin B
A I
improves O
ADHD O
- O
like O
behaviors O
in O
SHR O
via O
enhancement O
of O
DA O
neurotransmission O
and O
not O
modulation O
of O
GABA B
pathway O
as O
previously O
reported O
. O

Importantly O
, O
the O
present O
study O
indicates O
the O
potential O
therapeutic O
value O
of O
oroxylin B
A I
in O
the O
treatment O
of O
ADHD O
. O

The O
catalytic O
effects O
of O
perdeuterating O
the O
pyridoxal B
phosphate I
- O
dependent O
enzyme O
alanine B
racemase O
from O
Geobacillus O
stearothermophilus O
are O
reported O
. O

Vitamin B
D I
metabolism O
in O
human O
bone O
marrow O
stromal O
( O
mesenchymal O
stem O
) O
cells O
. O

Their O
in O
vitro O
differentiation O
to O
osteoblasts O
is O
stimulated O
by O
1 B
alpha I
, I
25 I
( I
OH I
) I
( I
2 I
) I
D I
, O
and O
recent O
evidence O
indicates O
that O
they O
have O
the O
capacity O
to O
metabolize O
vitamin B
D I
in O
a O
regulated O
manner O
. O

Human O
MSCs O
express O
the O
vitamin B
D I
receptor O
, O
25 O
- O
hydroxylases O
, O
1 O
alpha O
- O
hydroxylase O
, O
and O
24 O
- O
hydroxylase O
; O
stimulation O
of O
in O
vitro O
osteoblastogenesis O
by O
25 B
( I
OH I
) I
D I
depends O
on O
the O
activity O
of O
CYP27B1 O
/ O
1 O
alpha O
- O
hydroxylase O
. O

The O
finding O
that O
hMSCs O
are O
a O
both O
a O
producer O
and O
target O
of O
1 B
alpha I
, I
25 I
( I
OH I
) I
( I
2 I
) I
D I
suggests O
a O
potential O
autocrine O
/ O
paracrine O
role O
of O
vitamin B
D I
metabolism O
in O
osteoblast O
differentiation O
. O

Branched O
chain O
amino B
acids I
are O
novel O
biomarkers O
for O
discrimination O
of O
metabolic O
wellness O
. O

PCA O
- O
derived O
factors O
with O
levels O
that O
differed O
the O
most O
between O
MW O
and O
MUW O
groups O
were O
factors O
4 O
( O
branched O
chain O
amino B
acids I
[ O
BCAA O
] O
) O
[ O
p O
< O
. O
0001 O
] O
, O
8 O
( O
various O
metabolites O
) O
[ O
p O
< O
. O
0001 O
] O
, O
9 O
( O
C4 B
/ I
Ci4 I
, I
C3 I
, I
C5 I
acylcarnitines I
) O
[ O
p O
< O
. O
0001 O
] O
and O
10 O
( O
amino B
acids I
) O
[ O
p O
< O
. O
0002 O
] O
. O

PCA O
- O
derived O
factors O
with O
levels O
that O
differed O
the O
most O
between O
MW O
and O
MUW O
groups O
were O
factors O
4 O
( O
branched O
chain O
amino B
acids I
[ O
BCAA O
] O
) O
[ O
p O
< O
. O
0001 O
] O
, O
8 O
( O
various O
metabolites O
) O
[ O
p O
< O
. O
0001 O
] O
, O
9 O
( O
C4 B
/ I
Ci4 I
, I
C3 I
, I
C5 I
acylcarnitines I
) O
[ O
p O
< O
. O
0001 O
] O
and O
10 O
( O
amino B
acids I
) O
[ O
p O
< O
. O
0002 O
] O
. O

Arsenic B
induced O
neuronal O
apoptosis O
in O
guinea O
pigs O
is O
Ca2 B
+ I
dependent O
and O
abrogated O
by O
chelation O
therapy O
: O
role O
of O
voltage O
gated O
calcium B
channels O
. O

The O
phenolic B
glucoside I
gastrodin B
, O
a O
main O
constituent O
of O
a O
Chinese O
traditional O
herbal O
medicine O
, O
has O
been O
known O
to O
display O
several O
biological O
and O
pharmacological O
properties O
. O

Our O
results O
showed O
that O
gastrodin B
treatment O
strongly O
suppressed O
nuclear O
factor O
- O
kappa O
B O
( O
NF O
- O
kappa O
B O
) O
and O
mitogen O
- O
activated O
protein O
kinases O
( O
MAPKs O
) O
family O
activation O
and O
upregulation O
of O
the O
expression O
of O
inducible O
nitric B
oxide I
synthase O
( O
iNOS O
) O
, O
cyclooxygenase O
- O
2 O
( O
COX O
- O
2 O
) O
, O
tumor O
necrosis O
factor O
- O
alpha O
( O
TNF O
- O
alpha O
) O
, O
and O
interleukin O
- O
6 O
( O
IL O
- O
6 O
) O
in O
LPS O
- O
stimulated O
H9c2 O
cardiomyocytes O
. O

Nerve O
agents O
such O
as O
tabun B
, O
cyclosarin B
and O
Russian B
VX I
inhibit O
the O
essential O
enzyme O
acetylcholinesterase O
( O
AChE O
) O
by O
organophosphorylatin O
the O
catalytic O
serine B
residue O
. O

The O
oxime B
HI B
- I
6 I
shows O
a O
notably O
low O
activity O
on O
tabun B
adducts O
but O
can O
effectively O
reactivate O
adducts O
of O
cyclosarin B
and O
Russian B
VX I
. O

To O
examine O
the O
structural O
basis O
for O
the O
pronounced O
substrate O
specificity O
of O
HI B
- I
6 I
, O
we O
determined O
the O
binary O
crystal O
structures O
of O
Mus O
musculus O
AChE O
( O
mAChE O
) O
conjugated O
by O
cyclosarin B
and O
Russian B
VX I
and O
found O
a O
conformational O
mobility O
of O
the O
side O
chains O
of O
Phe338 B
and O
His447 B
. O

We O
also O
suggest O
that O
the O
conformational O
mobility O
allow O
HI B
- I
6 I
to O
reactivate O
conjugates O
of O
cyclosarin B
and O
Russian B
VX I
while O
a O
reduced O
mobility O
in O
tabun B
conjugated O
AChE O
results O
in O
steric O
hindrance O
that O
prevents O
efficient O
reactivation O
. O

Sodium B
arsenite I
induces O
cyclooxygenase O
- O
2 O
expression O
in O
human O
uroepithelial O
cells O
through O
MAPK O
pathway O
activation O
and O
reactive O
oxygen B
species O
induction O
. O

SV O
- O
HUC O
- O
1 O
cells O
were O
exposed O
to O
sodium B
arsenite I
and O
COX O
- O
2 O
expression O
, O
mitogen O
- O
activated O
protein O
kinase O
( O
MAPK O
) O
phosphorylation O
, O
glutathione B
( O
GSH B
) O
levels O
, O
ROS O
induction O
and O
Nrf2 O
expression O
were O
quantified O
. O

Lycorine B
hydrochloride I
selectively O
inhibits O
human O
ovarian O
cancer O
cell O
proliferation O
and O
tumor O
neovascularization O
with O
very O
low O
toxicity O
. O

In O
this O
study O
, O
we O
evaluated O
the O
anti O
- O
cancer O
effects O
of O
lycorine B
hydrochloride I
( O
LH O
) O
, O
a O
novel O
anti O
- O
ovarian O
cancer O
agent O
, O
using O
the O
highly O
- O
invasive O
ovarian O
cancer O
cell O
line O
, O
Hey1B O
, O
as O
a O
model O
. O

Teas O
infusions O
composition O
was O
assessed O
by O
HPLC O
in O
a O
quantitative O
assay O
for O
catechins B
, O
purine B
alkaloids I
and O
gallic B
acid I
as O
well O
as O
total O
polyphenol B
content O
. O

Teas O
infusions O
composition O
was O
assessed O
by O
HPLC O
in O
a O
quantitative O
assay O
for O
catechins B
, O
purine B
alkaloids I
and O
gallic B
acid I
as O
well O
as O
total O
polyphenol B
content O
. O

Recently O
, O
it O
has O
been O
found O
that O
the O
use O
of O
Mentha O
as O
a O
pharmaceutical O
source O
is O
based O
on O
its O
phytochemical O
constituents O
that O
have O
far O
been O
identified O
as O
tannins B
, O
saponins B
, O
phenolic B
acids I
and O
flavonoids B
. O

The O
possible O
antimutagenic O
potential O
of O
A7G B
was O
examined O
against O
mutagens O
ethyl B
methanesulfonate I
and O
acridine B
in O
an O
eukaryotic O
cell O
system O
Saccharomyces O
cerevisiae O
and O
sodium B
azide I
in O
Salmonella O
typhimurium O
TA1535 O
and O
9 B
- I
aminoacridine I
in O
S O
. O
typhimurium O
TA1537 O
. O

The O
possible O
antimutagenic O
potential O
of O
A7G B
was O
examined O
against O
mutagens O
ethyl B
methanesulfonate I
and O
acridine B
in O
an O
eukaryotic O
cell O
system O
Saccharomyces O
cerevisiae O
and O
sodium B
azide I
in O
Salmonella O
typhimurium O
TA1535 O
and O
9 B
- I
aminoacridine I
in O
S O
. O
typhimurium O
TA1537 O
. O

Moreover O
, O
the O
in O
vitro O
effects O
of O
some O
commonly O
used O
pesticides O
including O
chlorpyrifos B
, O
cypermethrin B
, O
dichlorvos B
, O
glyphosate B
isopropylamine I
and O
lambda B
cyhalomethrin I
on O
the O
enzyme O
activity O
were O
investigated O
. O

Moreover O
, O
the O
in O
vitro O
effects O
of O
some O
commonly O
used O
pesticides O
including O
chlorpyrifos B
, O
cypermethrin B
, O
dichlorvos B
, O
glyphosate B
isopropylamine I
and O
lambda B
cyhalomethrin I
on O
the O
enzyme O
activity O
were O
investigated O
. O

Of O
these O
compounds O
, O
glyphosate B
isopropylamine I
and O
dichlorvos B
showed O
an O
inhibition O
on O
CA O
- O
II O
esterase O
activity O
. O

Both O
glyphosate B
isopropylamine I
and O
dichlorvos B
inhibited O
CA O
- O
II O
isoenzyme O
in O
a O
noncompetitive O
manner O
. O

Here O
we O
show O
that O
Trim24 O
and O
Trim33 O
cooperatively O
repress O
retinoic B
acid I
receptor O
- O
dependent O
activity O
of O
VL30 O
- O
class O
endogenous O
retroviruses O
( O
ERVs O
) O
in O
liver O
. O

Association O
between O
bisphenol B
A I
and O
abnormal O
free O
thyroxine B
level O
in O
men O
. O

Bisphenol B
A I
( O
BPA B
) O
is O
a O
chemical O
that O
is O
used O
in O
a O
variety O
of O
consumer O
products O
, O
and O
exposure O
to O
BPA B
is O
widespread O
among O
the O
general O
population O
. O

Titanium B
dioxide I
nanoparticles O
increase O
inflammatory O
responses O
in O
vascular O
endothelial O
cells O
. O

Pretreatment O
with O
inhibitors O
for O
NF O
- O
kappa O
B O
( O
pyrrolidine B
dithiocarbamate I
) O
, O
oxidative O
stress O
( O
epigallocatechin B
gallate I
and O
apocynin B
) O
, O
Akt O
( O
LY294002 B
) O
, O
ERK O
( O
PD98059 B
) O
, O
JNK O
( O
SP600125 B
) O
and O
p38 O
( O
SB203580 B
) O
significantly O
attenuated O
TiO2 B
NP O
- O
induced O
MCP O
- O
1 O
and O
VCAM O
- O
1 O
gene O
expression O
. O

Pretreatment O
with O
inhibitors O
for O
NF O
- O
kappa O
B O
( O
pyrrolidine B
dithiocarbamate I
) O
, O
oxidative O
stress O
( O
epigallocatechin B
gallate I
and O
apocynin B
) O
, O
Akt O
( O
LY294002 B
) O
, O
ERK O
( O
PD98059 B
) O
, O
JNK O
( O
SP600125 B
) O
and O
p38 O
( O
SB203580 B
) O
significantly O
attenuated O
TiO2 B
NP O
- O
induced O
MCP O
- O
1 O
and O
VCAM O
- O
1 O
gene O
expression O
. O

Cinnamic B
acid I
derivatives O
as O
inhibitors O
for O
chorismatases O
and O
isochorismatases O
. O

Based O
on O
simplification O
of O
the O
physiological O
substrates O
, O
two O
cinnamic B
acid I
- O
derived O
compounds O
, O
differing O
in O
the O
saturation O
of O
the O
side O
chain O
, O
were O
developed O
. O

Carbon B
monoxide I
protects O
against O
ovariectomy O
- O
induced O
bone O
loss O
by O
inhibiting O
osteoclastogenesis O
. O

Carbon B
monoxide I
( O
CO B
) O
has O
been O
shown O
to O
have O
remarkable O
therapeutic O
value O
at O
low O
dosage O
by O
suppressing O
inflammation O
via O
inhibitory O
effects O
on O
macrophages O
, O
which O
are O
also O
precursors O
of O
osteoclasts O
( O
OC O
) O
. O

Its O
structural O
elucidation O
was O
accomplished O
using O
a O
combination O
of O
spectroscopic O
and O
chemical O
methods O
, O
including O
HRMS O
, O
extensive O
1D O
and O
2D O
NMR O
analysis O
, O
MS O
/ O
MS O
fragmentation O
, O
and O
chemical O
degradation O
and O
Marfey O
' O
s O
analysis O
of O
the O
resulting O
amino B
acid I
residues O
. O

We O
investigated O
the O
hydrolysis O
of O
anisole B
to O
phenol B
in O
high O
- O
temperature O
water O
with O
and O
without O
water O
- O
tolerant O
Lewis B
acid I
catalysis O
. O

Of O
the O
water O
- O
tolerant O
Lewis B
acid I
catalysts O
studied O
, O
In B
( I
OTf I
) I
( I
3 I
) I
offered O
the O
best O
phenol B
yield O
. O

Isolation O
of O
a O
mixed O
valence O
diiron B
hydride I
: O
evidence O
for O
a O
spectator O
hydride B
in O
hydrogen B
evolution O
catalysis O
. O

Surface O
behavior O
of O
malonic B
acid I
adsorption O
at O
the O
air O
/ O
water O
interface O
. O

Malonic B
acid I
is O
a O
small O
, O
water O
- O
soluble O
organic O
acid O
that O
is O
common O
in O
aerosols O
and O
is O
surface O
- O
active O
. O

A O
comprehensive O
investigation O
of O
the O
adsorption O
of O
malonic B
acid I
to O
the O
air O
/ O
water O
interface O
was O
accomplished O
using O
vibrational O
sum O
frequency O
spectroscopy O
( O
VSFS O
) O
and O
surface O
tension O
measurements O
as O
functions O
of O
concentration O
and O
pH O
. O

Malonic B
acid I
was O
found O
to O
be O
weakly O
solvated O
at O
the O
air O
/ O
water O
interface O
, O
and O
its O
orientation O
as O
a O
function O
of O
concentration O
was O
explored O
through O
different O
VSFS O
polarization O
schemes O
. O

Computational O
analyses O
were O
used O
to O
obtain O
depth O
- O
specific O
geometries O
of O
malonic B
acid I
at O
the O
air O
/ O
water O
interface O
that O
confirm O
and O
enrich O
the O
experimental O
results O
. O

The O
amino B
acid I
residue O
Gly106 B
is O
located O
inside O
the O
SDO O
active O
site O
cavity O
but O
does O
not O
directly O
interact O
with O
the O
substrates O
. O

NCM1 O
treatment O
did O
not O
affect O
cell O
viability O
, O
but O
increased O
cell O
size O
, O
disrupted O
cell O
membrane O
integrity O
, O
and O
decreased O
cell O
density O
, O
uptake O
of O
small O
peptides O
, O
release O
of O
endothelin O
- O
1 O
( O
ET O
- O
1 O
) O
and O
plasminogen O
activator O
inhibitor O
( O
PAI O
) O
, O
while O
causing O
no O
changes O
in O
endothelial O
nitric B
oxide I
synthase O
( O
eNOS O
) O
protein O
expression O
and O
nitric B
oxide I
( O
NO B
) O
release O
. O

NCM1 O
treatment O
did O
not O
affect O
cell O
viability O
, O
but O
increased O
cell O
size O
, O
disrupted O
cell O
membrane O
integrity O
, O
and O
decreased O
cell O
density O
, O
uptake O
of O
small O
peptides O
, O
release O
of O
endothelin O
- O
1 O
( O
ET O
- O
1 O
) O
and O
plasminogen O
activator O
inhibitor O
( O
PAI O
) O
, O
while O
causing O
no O
changes O
in O
endothelial O
nitric B
oxide I
synthase O
( O
eNOS O
) O
protein O
expression O
and O
nitric B
oxide I
( O
NO B
) O
release O
. O

Staphylococcus O
aureus O
CstR O
( O
CsoR O
- O
like O
sulfur B
transferase O
repressor O
) O
is O
a O
member O
of O
the O
CsoR O
family O
of O
transition B
metal I
sensing O
metalloregulatory O
proteins O
. O

Unlike O
CsoR O
, O
CstR O
does O
not O
form O
a O
stable O
complex O
with O
transition B
metals I
but O
instead O
reacts O
with O
sulfite B
to O
form O
a O
mixture O
of O
di B
- I
and I
trisulfide I
species O
, O
CstR2 O
( O
RS B
- I
SR I
' I
) O
and O
CstR2 O
( O
RS B
- I
S I
- I
SR I
' I
) O
n O
) O
n O
= O
1 O
or O
2 O
, O
respectively O
. O

Here O
, O
we O
investigate O
if O
CstR O
performs O
similar O
chemistry O
with O
related O
chalcogen B
oxyanions I
selenite B
and O
tellurite B
. O

We O
aimed O
at O
identifying O
novel O
genetic O
markers O
that O
would O
improve O
prediction O
of O
irinotecan B
toxicity O
and O
response O
in O
advanced O
colorectal O
cancer O
patients O
treated O
with O
folic B
acid I
( O
leucovorin B
) O
, O
fluorouracil B
( O
5 B
- I
FU I
) O
, O
and O
irinotecan B
( O
camptosar B
) O
- O
based O
regimens O
. O

Removal O
of O
molecular O
adsorbates O
on O
gold O
nanoparticles O
using O
sodium B
borohydride I
in O
water O
. O

The O
mechanism O
of O
sodium B
borohydride I
removal O
of O
organothiols B
from O
gold O
nanoparticles O
( O
AuNPs O
) O
was O
studied O
using O
an O
experimental O
investigation O
and O
computational O
modeling O
. O

A O
computational O
study O
showed O
that O
hydride B
derived O
from O
sodium B
borohydride I
has O
a O
higher O
binding O
affinity O
to O
AuNPs O
than O
organothiols B
. O

Sodium B
borohydride I
may O
be O
used O
as O
a O
hazard O
- O
free O
, O
general O
- O
purpose O
detergent O
that O
should O
find O
utility O
in O
a O
variety O
of O
AuNP O
applications O
including O
catalysis O
, O
biosensing O
, O
surface O
enhanced O
Raman O
spectroscopy O
, O
and O
AuNP O
recycle O
and O
reuse O
. O

Most O
idiosyncratic O
drug O
reactions O
are O
caused O
by O
reactive O
metabolites O
; O
12 B
- I
OH I
- I
NVP I
forms O
a O
benzylic B
sulfate I
, O
which O
was O
detected O
in O
the O
blood O
of O
animals O
treated O
with O
NVP B
or O
12 B
- I
OH I
- I
NVP I
. O

We O
designed O
and O
screened O
minimal O
peptide O
motifs O
whose O
conjugates O
with O
polyethylene B
glycol I
interact O
with O
heparin O
to O
form O
non O
- O
covalent O
hydrogels O
. O

This O
work O
represents O
the O
first O
cloning O
and O
characterization O
of O
an O
ICZ B
gene O
cluster O
isolated O
from O
a O
marine O
- O
derived O
actinomycete O
strain O
and O
would O
be O
helpful O
for O
thoroughly O
understanding O
the O
biosynthetic O
mechanism O
of O
ICZ B
glycosides I
. O

Different O
pharmacokinetics O
of O
the O
two O
structurally O
similar O
dammarane B
sapogenins I
, O
protopanaxatriol B
and O
protopanaxadiol B
, O
in O
rats O
. O

Dammarane B
Sapogenins I
( O
DS O
) O
, O
with O
main O
ingredients O
of O
protopanaxatriol B
( O
PPT B
, O
33 O
% O
) O
and O
protopanaxadiol B
( O
PPD B
, O
16 O
% O
) O
, O
is O
an O
alkaline O
hydrolyzed O
product O
of O
ginsenosides B
and O
had O
significant O
activities O
in O
improving O
learning O
and O
memory O
and O
decreasing O
chemotherapy O
- O
induced O
myelosuppression O
. O

Folic B
acid I
conjugated O
, O
doxorubicin B
- O
loaded O
nanoparticles O
showed O
enhanced O
uptake O
and O
higher O
cytotoxicity O
in O
cancer O
cells O
overexpressing O
the O
folate B
receptor O
( O
compared O
to O
the O
control O
) O
. O

Nitric B
oxide I
( O
NO B
) O
produced O
by O
the O
endothelial O
NO B
synthase O
( O
eNOS O
) O
is O
an O
antihypertensive O
, O
antithrombotic O
and O
anti O
- O
atherosclerotic O
molecule O
. O

In O
this O
study O
trisubstituted O
pyrrole B
derivatives O
with O
different O
substituents O
on O
a O
piperidinyl B
nitrogen I
were O
prepared O
. O

We O
determined O
if O
modifications O
of O
the O
piperidinyl B
nitrogen I
would O
accommodate O
a O
drug O
- O
biotin B
linking O
strategy O
for O
affinity O
purification O
of O
the O
trisubstituted O
pyrrole B
' O
s O
target O
protein O
( O
s O
) O
. O

Viscoelastic O
, O
injectable O
aggregates O
of O
micrometer O
- O
sized O
hydrogel O
particles O
made O
of O
multiarmed O
polyethylene B
glycol I
( O
starPEG O
) O
and O
heparin O
were O
prepared O
and O
tested O
for O
site O
- O
specific O
paracrine O
stimulation O
of O
tissue O
regeneration O
. O

Ozonolysis O
efficiency O
and O
safety O
evaluation O
of O
aflatoxin B
B1 I
in O
peanuts O
. O

89 O
. O
40 O
% O
of O
aflatoxin B
B1 I
( O
AFB1 B
) O
in O
peanuts O
was O
decomposed O
by O
ozone B
with O
a O
concentration O
of O
50mg O
/ O
L O
, O
flow O
rate O
of O
5L O
/ O
min O
for O
60h O
. O

Glutathione B
( O
GSH B
) O
, O
oxidized B
glutathione I
( O
GSSG B
) O
and O
total O
thiol B
( O
total O
- O
SH B
) O
content O
, O
GSH B
reductase O
( O
GR O
) O
and O
GSH B
peroxidase O
( O
GSH B
- O
Px O
) O
activities O
, O
malondialdehyde B
( O
MDA B
) O
level O
, O
as O
well O
as O
4 B
- I
hydroxynonenal I
( O
4 B
- I
HNE I
) O
and O
MDA B
modified O
proteins O
in O
homogenates O
of O
cerebral O
cortex O
were O
measured O
. O

Treatment O
of O
cells O
with O
alpha B
- I
amanitin I
or O
actinomycin B
D I
revealed O
that O
extension O
of O
B2 O
RNA O
by O
Pol O
II O
destabilizes O
the O
RNA O
. O

Steroid B
hormone I
receptors O
play O
diverse O
roles O
in O
many O
aspects O
of O
human O
physiology O
including O
cell O
division O
, O
apoptosis O
and O
homeostasis O
, O
tissue O
differentiation O
, O
sexual O
development O
and O
response O
to O
stress O
. O

Consequently O
, O
the O
foldosome O
provides O
an O
attractive O
therapeutic O
target O
in O
steroid B
hormone I
receptor O
- O
driven O
malignancies O
. O

In O
HaCaT O
cells O
, O
buthanol B
and O
ethylacetate B
fractions O
of O
80 O
% O
methanol B
C O
. O
fragile O
extract O
( O
CFB O
or O
CFE O
) O
and O
a O
single O
compound O
, O
clerosterol B
( O
CLS B
) O
isolated O
from O
CFE O
attenuated O
UVB O
( O
60mJ O
/ O
cm O
( O
2 O
) O
) O
- O
induced O
cytotoxicity O
and O
reduced O
expression O
of O
pro O
- O
inflammatory O
proteins O
including O
cyclooxygenase O
- O
2 O
( O
COX O
- O
2 O
) O
, O
inducible O
nitric B
oxide I
synthase O
( O
iNOS O
) O
, O
and O
tumor O
necrosis O
factor O
- O
alpha O
( O
TNF O

Moreover O
, O
CFB O
, O
CFE O
and O
CLS B
effectively O
suppressed O
UVB O
- O
induced O
production O
of O
pro O
- O
inflammatory O
mediators O
such O
as O
prostaglandin B
E2 I
( O
PGE2 B
) O
and O
nitric B
oxide I
( O
NO B
) O
. O

Moreover O
, O
CFB O
, O
CFE O
and O
CLS B
effectively O
suppressed O
UVB O
- O
induced O
production O
of O
pro O
- O
inflammatory O
mediators O
such O
as O
prostaglandin B
E2 I
( O
PGE2 B
) O
and O
nitric B
oxide I
( O
NO B
) O
. O

Uptake O
of O
dioscin B
by O
rat O
liver O
slices O
and O
isolated O
rat O
hepatocytes O
was O
inhibited O
significantly O
by O
Oatp O
modulators O
, O
such O
as O
ibuprofen B
( O
Oatp1a1 O
inhibitor O
) O
, O
digoxin B
( O
Oatp1a4 O
substrate O
) O
, O
and O
glycyrrhizic B
acid I
( O
Oatp1b2 O
inhibitor O
) O
, O
but O
not O
by O
TEA B
or O
p B
- I
aminohippurate I
. O

( B
- I
) I
- I
Epigallocatechin I
gallate I
, O
cyclosporin B
A I
, O
rifampicin B
, O
and O
telmisartan B
inhibited O
transport O
of O
dioscin B
in O
OATP1B3 O
- O
HEK293 O
cells O
. O

It O
is O
thus O
that O
the O
recent O
research O
and O
development O
in O
the O
field O
of O
arylamine B
organic O
dyes O
employing O
an O
iodide B
/ O
triiodide B
redox O
couple O
or O
polypyridyl B
cobalt I
redox O
shuttles O
as O
the O
electrolytes O
for O
either O
DSCs O
or O
solid O
- O
state O
DSCs O
has O
been O
summarized O
. O

Increased O
sympathetic O
nervous O
system O
activity O
contributes O
to O
deoxycorticosterone B
acetate I
( O
DOCA B
) O
- O
salt O
hypertension O
in O
rats O
. O

Time O
- O
of O
- O
flight O
secondary O
ion O
mass O
spectrometry O
( O
TOF O
- O
SIMS O
) O
and O
atomic O
force O
microscopy O
( O
AFM O
) O
are O
employed O
to O
characterize O
a O
wedge O
- O
shaped O
crater O
eroded O
by O
a O
40 O
keV O
C B
( I
60 I
) I
( I
+ I
) I
cluster O
ion O
beam O
on O
an O
organic O
thin O
film O
of O
402 O
nm O
of O
barium B
arachidate I
( O
AA O
) O
multilayers O
prepared O
by O
the O
Langmuir O
- O
Blodgett O
( O
LB O
) O
technique O
. O

The O
capacity O
of O
APLs O
to O
stimulate O
cholesterol B
efflux O
is O
suppressed O
when O
cells O
are O
incubated O
simultaneously O
with O
APLs O
and O
serum O
whilst O
the O
inhibition O
of O
cholesterol B
transport O
to O
the O
ER O
( O
measured O
in O
terms O
of O
the O
synthesis O
of O
esterified B
cholesterol I
) O
persists O
, O
indicating O
that O
both O
effects O
are O
independent O
of O
each O
other O
. O

The O
expression O
levels O
of O
10 O
of O
these O
genes O
( O
ID2 O
, O
ID3 O
, O
CCL2 O
, O
TBX3 O
, O
TGOLN2 O
, O
C1orf71 O
, O
ZNF676 O
, O
GULP1 O
, O
KLF9 O
, O
and O
ITGB5 O
) O
were O
altered O
by O
deiodinase O
- O
disrupting O
chemicals O
( O
2 B
, I
3 I
, I
7 I
, I
8 I
- I
tetrachlorodibenzo I
- I
p I
- I
dioxin I
, O
polychlorinated B
biphenyls I
, O
propylthiouracil B
, O
iodoacetic B
acid I
, O
methylmercury B
, O
beta B
- I
estradiol I

The O
expression O
levels O
of O
10 O
of O
these O
genes O
( O
ID2 O
, O
ID3 O
, O
CCL2 O
, O
TBX3 O
, O
TGOLN2 O
, O
C1orf71 O
, O
ZNF676 O
, O
GULP1 O
, O
KLF9 O
, O
and O
ITGB5 O
) O
were O
altered O
by O
deiodinase O
- O
disrupting O
chemicals O
( O
2 B
, I
3 I
, I
7 I
, I
8 I
- I
tetrachlorodibenzo I
- I
p I
- I
dioxin I
, O
polychlorinated B
biphenyls I
, O
propylthiouracil B
, O
iodoacetic B
acid I
, O
methylmercury B
, O
beta B
- I
estradiol I

, O
methimazole B
, O
3 B
- I
methylcholanthrene I
, O
aminotriazole B
, O
amiodarone B
, O
cadmium B
chloride I
, O
dimethoate B
, O
fenvalerate B
, O
octylmethoxycinnamat B
, O
iopanoic B
acid I
, O
methoxychlor B
, O
and O
4 B
- I
methylbenzylidene I
- I
camphor I
) O
. O

, O
methimazole B
, O
3 B
- I
methylcholanthrene I
, O
aminotriazole B
, O
amiodarone B
, O
cadmium B
chloride I
, O
dimethoate B
, O
fenvalerate B
, O
octylmethoxycinnamat B
, O
iopanoic B
acid I
, O
methoxychlor B
, O
and O
4 B
- I
methylbenzylidene I
- I
camphor I
) O
. O

We O
modified O
the O
nanopore O
surface O
with O
ionizable O
functional O
groups O
, O
by O
forming O
a O
monolayer O
of O
L B
- I
cysteine I
or O
by O
surface O
- O
initiated O
polymerization O
of O
methacrylic B
acid I
. O

Diffusion O
experiments O
for O
the O
cationic O
dye O
Rhodamine B
B I
through O
L B
- I
cysteine I
- O
modified O
membranes O
showed O
a O
decrease O
in O
flux O
upon O
addition O
of O
an O
acid O
due O
to O
the O
nanopore O
surface O
becoming O
positively O
charged O
. O

Effects O
of O
amlodipine B
on O
the O
oral O
bioavailability O
of O
cephalexin B
and O
cefuroxime B
axetil I
in O
healthy O
volunteers O
. O

In O
this O
study O
, O
the O
authors O
compared O
the O
effects O
of O
amlodipine B
( O
AML B
) O
on O
the O
bioavailability O
of O
cephalexin B
( O
LEX B
) O
and O
cefuroxime B
axetil I
( O
CXM B
) O
. O

Rash O
associated O
with O
dabigatran B
etexilate I
. O

Dabigatran B
etexilate I
was O
approved O
by O
the O
Food O
and O
Drug O
Administration O
in O
2010 O
as O
anticoagulant O
prophylaxis O
for O
patients O
with O
nonvalvular O
atrial O
fibrillation O
. O

The O
frequency O
of O
dermatologic O
reactions O
to O
dabigatran B
etexilate I
is O
estimated O
in O
the O
product O
labeling O
to O
be O
less O
than O
0 O
. O
1 O
% O
. O

To O
date O
, O
five O
cases O
of O
dabigatran B
etexilate I
- O
associated O
rash O
have O
reported O
, O
including O
three O
published O
cases O
. O

We O
describe O
the O
sixth O
reported O
case O
of O
dabigatran B
etexilate I
- O
associated O
rash O
, O
in O
a O
59 O
- O
year O
- O
old O
man O
with O
a O
history O
of O
atrial O
fibrillation O
who O
received O
dabigatran B
etexilate I
150 O
mg O
twice O
/ O
day O
for O
atrial O
flutter O
before O
cardioversion O
. O

We O
describe O
the O
sixth O
reported O
case O
of O
dabigatran B
etexilate I
- O
associated O
rash O
, O
in O
a O
59 O
- O
year O
- O
old O
man O
with O
a O
history O
of O
atrial O
fibrillation O
who O
received O
dabigatran B
etexilate I
150 O
mg O
twice O
/ O
day O
for O
atrial O
flutter O
before O
cardioversion O
. O

The O
patient O
had O
taken O
dabigatran B
etexilate I
for O
5 O
days O
before O
the O
rash O
was O
noted O
on O
hospital O
admission O
. O

The O
rash O
resolved O
7 O
days O
after O
the O
discontinuation O
of O
dabigatran B
etexilate I
, O
and O
the O
patient O
was O
stabilized O
on O
warfarin B
therapy O
. O

Use O
of O
the O
Naranjo O
Adverse O
Drug O
Reaction O
Probability O
Scale O
indicated O
a O
probable O
relationship O
( O
score O
of O
5 O
) O
between O
the O
patient O
' O
s O
development O
of O
the O
rash O
and O
dabigatran B
etexilate I
therapy O
. O

Clinicians O
should O
be O
aware O
of O
this O
adverse O
effect O
of O
dabigatran B
etexilate I
and O
monitor O
for O
dermatologic O
reactions O
during O
follow O
- O
up O
visits O
. O

Joining O
Copper B
Oxide I
Nanotube O
Arrays O
Driven O
by O
the O
Nanoscale O
Kirkendall O
effect O
. O

The O
results O
show O
that O
an O
appropriate O
amount O
of O
oxygen B
supply O
is O
crucial O
for O
uniform O
transformation O
from O
Cu B
NWs O
( O
average O
diameter O
~ O
50 O
nm O
) O
into O
Cu B
oxide I
nanotube O
arrays O
. O

An O
annealing O
duration O
of O
30 O
min O
at O
200 O
degrees O
C O
in O
a O
low O
vacuum O
environment O
reveals O
that O
the O
voids O
are O
not O
uniformly O
distributed O
at O
the O
Cu B
/ O
Cu B
oxide I
interface O
. O

Annealing O
above O
200 O
degrees O
C O
for O
60 O
min O
resulted O
in O
complete O
transformation O
from O
Cu B
NWs O
into O
Cu B
oxide I
nanotubes O
. O

X O
- O
ray O
photoelectron O
spectroscopy O
characterization O
indicates O
that O
the O
Cu B
oxides I
formed O
at O
200 O
degrees O
C O
and O
300 O
degrees O
C O
are O
Cu B
( I
2 I
) I
O I
and O
CuO B
, O
respectively O
. O

It O
is O
demonstrated O
that O
the O
transformation O
from O
Cu B
NW O
arrays O
into O
Cu B
oxide I
nanotube O
arrays O
can O
be O
combined O
with O
the O
joining O
of O
stacked O
Si B
chips O
in O
a O
single O
- O
process O
step O
with O
reasonable O
joint O
shear O
strength O
. O

Transmission O
electron O
microscopy O
- O
electron O
energy O
loss O
spectroscopy O
elemental O
mapping O
analysis O
reveals O
that O
the O
joint O
interface O
is O
Cu B
oxide I
. O

It O
is O
clearly O
seen O
from O
the O
optimised O
structure O
of O
the O
2 O
: O
1 O
( O
CB7 B
. O
CPT B
) O
inclusion O
complex O
that O
the O
quinoline B
nitrogen I
of O
CPT B
does O
not O
reside O
within O
either O
of O
the O
CB7 B
cavities O
, O
rather O
it O
is O
almost O
sandwiched O
between O
two O
CB7 B
rings O
, O
and O
therefore O
, O
it O
experiences O
huge O
electron O
density O
exerted O
by O
both O
carbonyl B
portals O
of O
the O
macrocycles O
. O

OATP1B1 O
- O
, O
OATP1B3 O
- O
, O
and O
OATP2B1 O
- O
mediated O
substrate O
transport O
was O
inhibited O
efficiently O
by O
silymarin O
( O
IC50 O
values O
of O
1 O
. O
3 O
, O
2 O
. O
2 O
and O
0 O
. O
3 O
micro O
M O
, O
respectively O
) O
, O
silybin B
A I
( O
IC50 O
values O
of O
9 O
. O
7 O
, O
2 O
. O
7 O
and O
4 O
. O
5 O
micro O
M O
, O
respectively O
) O
, O
silybin B
B I
( O
IC50 O
values O
of O
8 O
. O
5 O
, O
5 O
. O
0 O
and O
0 O
. O
8 O
micro O
M O
, O
respectively O
) O
, O
and O
silychristin B
( O
IC50 O
values O
of O

OATP1B1 O
- O
, O
OATP1B3 O
- O
, O
and O
OATP2B1 O
- O
mediated O
substrate O
transport O
was O
inhibited O
efficiently O
by O
silymarin O
( O
IC50 O
values O
of O
1 O
. O
3 O
, O
2 O
. O
2 O
and O
0 O
. O
3 O
micro O
M O
, O
respectively O
) O
, O
silybin B
A I
( O
IC50 O
values O
of O
9 O
. O
7 O
, O
2 O
. O
7 O
and O
4 O
. O
5 O
micro O
M O
, O
respectively O
) O
, O
silybin B
B I
( O
IC50 O
values O
of O
8 O
. O
5 O
, O
5 O
. O
0 O
and O
0 O
. O
8 O
micro O
M O
, O
respectively O
) O
, O
and O
silychristin B
( O
IC50 O
values O
of O

Furthermore O
, O
silymarin O
, O
silybin B
A I
, O
and O
silybin B
B I
( O
100 O
micro O
M O
) O
significantly O
inhibited O
OATP O
- O
mediated O
estradiol B
- I
17 I
beta I
- I
glucuronide I
and O
rosuvastatin B
uptake O
into O
human O
hepatocytes O
. O

Furthermore O
, O
silymarin O
, O
silybin B
A I
, O
and O
silybin B
B I
( O
100 O
micro O
M O
) O
significantly O
inhibited O
OATP O
- O
mediated O
estradiol B
- I
17 I
beta I
- I
glucuronide I
and O
rosuvastatin B
uptake O
into O
human O
hepatocytes O
. O

A O
low O
- O
overpotential O
potassium B
- O
oxygen B
battery O
based O
on O
potassium B
superoxide I
. O

Oxidation O
of O
tertiary B
amine I
- O
derivatized O
surfaces O
to O
control O
protein O
adhesion O
. O

Oxidation O
with O
hydrogen B
peroxide I
was O
similarly O
assessed O
, O
and O
adhesion O
of O
lysozyme O
and O
fibrinogen O
from O
phosphate B
buffered O
saline O
was O
then O
assayed O
by O
QCM O
and O
imaged O
by O
AFM O
. O

Tertiary B
amine I
- O
functionalized O
sensors O
adsorbed O
multilayers O
of O
aggregated O
lysozyme O
, O
whereas O
tertiary B
amine I
N I
- I
oxides I
and O
triethylene B
glycol I
- O
terminated O
monolayers O
are O
consistent O
with O
small O
protein O
aggregates O
. O

Tertiary B
amine I
- O
functionalized O
sensors O
adsorbed O
multilayers O
of O
aggregated O
lysozyme O
, O
whereas O
tertiary B
amine I
N I
- I
oxides I
and O
triethylene B
glycol I
- O
terminated O
monolayers O
are O
consistent O
with O
small O
protein O
aggregates O
. O

Oxidation O
of O
tertiary B
amine I
decorated O
surfaces O
therefore O
holds O
the O
potential O
for O
selective O
deposition O
of O
proteins O
and O
cells O
through O
masking O
and O
other O
patterning O
techniques O
. O

We O
previously O
demonstrated O
that O
developmental O
exposure O
to O
a O
mixture O
of O
polychlorinated B
biphenyls I
( O
PCBs B
) O
which O
was O
reconstituted O
according O
to O
the O
congener O
pattern O
found O
in O
human O
breast O
milk O
caused O
feminization O
of O
sweet O
preference O
as O
a O
sexually O
dimorphic O
behavior O
in O
adult O
male O
rats O
, O
following O
decreases O
in O
aromatase O
activity O
in O
the O
brain O
of O
newborn O
male O
pups O
. O

Neuroprotective O
effects O
of O
mercaptoethylleonuri B
and O
mercaptoethylguanidi B
analogs O
on O
hydrogen B
peroxide I
- O
induced O
apoptosis O
in O
human O
neuronal O
SH O
- O
SY5Y O
cells O
. O

We O
describe O
an O
approach O
combining O
heme B
iron B
oxidation O
with O
potassium B
ferricyanide I
and O
metabolite O
profiling O
to O
probe O
the O
mechanism O
of O
MI O
complex O
- O
based O
CYP3A4 O
inactivation O
by O
the O
secondary B
alkylamine I
drug O
lapatinib B
. O

We O
describe O
an O
approach O
combining O
heme B
iron B
oxidation O
with O
potassium B
ferricyanide I
and O
metabolite O
profiling O
to O
probe O
the O
mechanism O
of O
MI O
complex O
- O
based O
CYP3A4 O
inactivation O
by O
the O
secondary B
alkylamine I
drug O
lapatinib B
. O

Nitroso B
/ O
oxime B
metabolite O
formation O
from O
secondary O
alkylamines B
has O
been O
proposed O
to O
occur O
through O
two O
possible O
pathways O
: O
( O
1 O
) O
sequential O
N B
- O
dealkylation O
, O
N B
- O
hydroxylation O
, O
and O
dehydrogenation O
( O
primary B
hydroxylamine I
pathway O
) O
or O
( O
2 O
) O
N B
- O
hydroxylation O
with O
dehydrogenation O
to O
yield O
a O
nitrone B
followed O
by O
N B
- O
dealkylation O
( O
secondary B
hydroxylamine I
pathway O
) O
. O

Nitroso B
/ O
oxime B
metabolite O
formation O
from O
secondary O
alkylamines B
has O
been O
proposed O
to O
occur O
through O
two O
possible O
pathways O
: O
( O
1 O
) O
sequential O
N B
- O
dealkylation O
, O
N B
- O
hydroxylation O
, O
and O
dehydrogenation O
( O
primary B
hydroxylamine I
pathway O
) O
or O
( O
2 O
) O
N B
- O
hydroxylation O
with O
dehydrogenation O
to O
yield O
a O
nitrone B
followed O
by O
N B
- O
dealkylation O
( O
secondary B
hydroxylamine I
pathway O
) O
. O

All O
intermediates O
for O
the O
secondary B
hydroxylamine I
pathway O
were O
detected O
but O
the O
primary O
N B
- O
hydroxylamine B
intermediate O
of O
the O
primary B
hydroxylamine I
pathway O
was O
not O
. O

All O
intermediates O
for O
the O
secondary B
hydroxylamine I
pathway O
were O
detected O
but O
the O
primary O
N B
- O
hydroxylamine B
intermediate O
of O
the O
primary B
hydroxylamine I
pathway O
was O
not O
. O

Our O
findings O
support O
the O
mechanism O
of O
lapatinib B
CYP3A4 O
inactivation O
as O
MI O
complex O
formation O
with O
the O
nitroso B
metabolite O
formed O
through O
the O
secondary B
hydroxylamine I
and O
nitrone B
pathway O
, O
rather O
than O
by O
N B
- O
dealkylation O
to O
the O
primary B
amine I
followed O
by O
N B
- O
hydroxylation O
and O
dehydrogenation O
as O
is O
usually O
assumed O
. O

Our O
findings O
support O
the O
mechanism O
of O
lapatinib B
CYP3A4 O
inactivation O
as O
MI O
complex O
formation O
with O
the O
nitroso B
metabolite O
formed O
through O
the O
secondary B
hydroxylamine I
and O
nitrone B
pathway O
, O
rather O
than O
by O
N B
- O
dealkylation O
to O
the O
primary B
amine I
followed O
by O
N B
- O
hydroxylation O
and O
dehydrogenation O
as O
is O
usually O
assumed O
. O

Functional O
UDP B
- O
glucuronyltransferas O
2B15 O
polymorphism O
and O
bisphenol B
A I
concentrations O
in O
blood O
: O
results O
from O
physiologically O
based O
kinetic O
modelling O
. O

Bisphenol B
A I
( O
BPA B
) O
is O
a O
chemical O
in O
widespread O
use O
that O
is O
under O
scientific O
discussion O
due O
to O
its O
endocrine O
activity O
. O

The O
adsorption O
of O
the O
model O
perfumes O
phenyl B
ethanol I
, O
PE O
, O
and O
linalool B
, O
LL O
, O
at O
the O
air O
- O
solution O
interface O
by O
coadsorption O
with O
the O
anionic O
surfactant O
sodium B
dodecyl I
6 I
- I
benezene I
sulfonate I
, O
LAS B
- I
6 I
, O
has O
been O
studied O
primarily O
by O
neutron O
reflectivity O
, O
NR O
. O

In O
vitro O
polyphenolics B
erythrocyte O
model O
and O
in O
vivo O
chicken O
embryo O
model O
revealed O
gallic B
acid I
to O
be O
a O
potential O
hemorrhage O
inducer O
: O
physicochemical O
action O
mechanisms O
. O

The O
in O
vivo O
chicken O
embryo O
model O
( O
CEM O
) O
demonstrated O
that O
gallic B
acid I
( O
GA O
) O
induced O
dysvascularization O
and O
hypoxia O
. O

PEM O
revealed O
that O
the O
DO O
was O
rapidly O
depleted O
, O
leading O
to O
the O
release O
of O
a O
huge O
amount O
of O
Fe B
( I
II I
) I
ions O
and O
hydrogen B
peroxide I
( O
HPO B
) O
in O
a O
two O
- O
phase O
kinetic O
pattern O
. O

Second O
, O
the O
surface O
amino B
acids I
of O
lipase O
can O
be O
tailored O
to O
suit O
biomolecule O
conjugation O
. O

Protective O
role O
of O
L B
- I
carnitine I
and O
vitamin B
E I
on O
the O
testis O
of O
atherosclerotic O
rats O
. O

Vitamin B
E I
and O
< B
sc I
> I
l I
< I
/ I
sc I
> I
- I
carnitine I
have O
well O
- O
known O
lipid O
- O
lowering O
and O
antioxidative O
activities O
. O

The O
present O
study O
evaluates O
the O
protective O
role O
of O
vitamin B
E I
and O
< B
sc I
> I
l I
< I
/ I
sc I
> I
- I
carnitine I
on O
the O
testis O
in O
atherosclerosis O
and O
detects O
the O
most O
effective O
choice O
for O
protection O
against O
atherosclerosis O
; O
vitamin B
E I
, O
< B
sc I
> I
l I
< I
/ I
sc I
> I
- I
carnitine I
or O
a O
combination O
of O
both O
. O

The O
present O
study O
evaluates O
the O
protective O
role O
of O
vitamin B
E I
and O
< B
sc I
> I
l I
< I
/ I
sc I
> I
- I
carnitine I
on O
the O
testis O
in O
atherosclerosis O
and O
detects O
the O
most O
effective O
choice O
for O
protection O
against O
atherosclerosis O
; O
vitamin B
E I
, O
< B
sc I
> I
l I
< I
/ I
sc I
> I
- I
carnitine I
or O
a O
combination O
of O
both O
. O

A O
total O
of O
80 O
albino O
male O
rats O
were O
divided O
into O
eight O
groups O
( O
10 O
rats O
for O
each O
group O
) O
: O
control O
( O
G O
( O
1 O
) O
) O
, O
triton B
( O
G O
( O
2 O
) O
) O
, O
< B
sc I
> I
l I
< I
/ I
sc I
> I
- I
carnitine I
( O
G O
( O
3 O
) O
) O
, O
triton B
+ O
< B
sc I
> I
l I
< I
/ I
sc I
> I
- I
carnitine I
( O
G O
( O
4 O
) O
) O
, O
vitamin B
E I
( O
G O
( O
5 O
) O
) O
, O
triton B
+ O
vitamin B
E I
( O
G O
( O
6 O
) O
) O
, O
< B
sc I
> I
l I
< I
/ I
sc I
> I
- I
carnitine I
+ O
vitamin B
E I
( O
G O

A O
total O
of O
80 O
albino O
male O
rats O
were O
divided O
into O
eight O
groups O
( O
10 O
rats O
for O
each O
group O
) O
: O
control O
( O
G O
( O
1 O
) O
) O
, O
triton B
( O
G O
( O
2 O
) O
) O
, O
< B
sc I
> I
l I
< I
/ I
sc I
> I
- I
carnitine I
( O
G O
( O
3 O
) O
) O
, O
triton B
+ O
< B
sc I
> I
l I
< I
/ I
sc I
> I
- I
carnitine I
( O
G O
( O
4 O
) O
) O
, O
vitamin B
E I
( O
G O
( O
5 O
) O
) O
, O
triton B
+ O
vitamin B
E I
( O
G O
( O
6 O
) O
) O
, O
< B
sc I
> I
l I
< I
/ I
sc I
> I
- I
carnitine I
+ O
vitamin B
E I
( O
G O

A O
total O
of O
80 O
albino O
male O
rats O
were O
divided O
into O
eight O
groups O
( O
10 O
rats O
for O
each O
group O
) O
: O
control O
( O
G O
( O
1 O
) O
) O
, O
triton B
( O
G O
( O
2 O
) O
) O
, O
< B
sc I
> I
l I
< I
/ I
sc I
> I
- I
carnitine I
( O
G O
( O
3 O
) O
) O
, O
triton B
+ O
< B
sc I
> I
l I
< I
/ I
sc I
> I
- I
carnitine I
( O
G O
( O
4 O
) O
) O
, O
vitamin B
E I
( O
G O
( O
5 O
) O
) O
, O
triton B
+ O
vitamin B
E I
( O
G O
( O
6 O
) O
) O
, O
< B
sc I
> I
l I
< I
/ I
sc I
> I
- I
carnitine I
+ O
vitamin B
E I
( O
G O

( O
7 O
) O
) O
and O
triton B
+ O
< B
sc I
> I
l I
< I
/ I
sc I
> I
- I
carnitine I
+ O
vitamin B
E I
( O
G O
( O
8 O
) O
) O
. O

Treatment O
with O
< B
sc I
> I
l I
< I
/ I
sc I
> I
- I
carnitine I
or O
/ O
and O
vitamin B
E I
helps O
in O
improving O
the O
adverse O
effect O
of O
triton B
; O
also O
the O
histological O
changes O
confirm O
this O
finding O
. O

So O
the O
present O
study O
recommends O
all O
people O
to O
include O
< B
sc I
> I
l I
< I
/ I
sc I
> I
- I
carnitine I
and O
vitamin B
E I
in O
their O
diet O
to O
be O
protected O
against O
atherosclerosis O
. O

Bioactivity O
- O
guided O
fractionation O
of O
fifteen O
ethyl B
acetate I
fractions O
identified O
fraction O
2 O
to O
have O
melanogenesis O
stimulatory O
effects O
due O
to O
its O
ability O
to O
decrease O
mitogen O
- O
activated O
protein O
kinase O
phosphorylated O
extracellular O
signal O
- O
regulated O
kinases O
1 O
and O
2 O
activation O
. O

Preparative O
TLC O
of O
ethyl B
acetate I
fraction O
2 O
revealed O
the O
presence O
of O
lup B
- I
20 I
( I
29 I
) I
- I
en I
- I
3 I
- I
one I
as O
the O
major O
bioactive O
component O
. O

We O
report O
for O
the O
first O
time O
that O
E O
. O
multiflora O
ethyl B
acetate I
extract O
and O
its O
active O
compound O
lup B
- I
20 I
( I
29 I
) I
- I
en I
- I
3 I
- I
one I
stimulate O
melanogenesis O
by O
increasing O
the O
tyrosinase O
enzyme O
expression O
via O
mitogen O
- O
activated O
protein O
kinase O
phosphorylated O
extracellular O
signal O
- O
regulated O
kinases O
1 O
and O
2 O
phosphorylation O
inhibition O
, O
making O
it O
a O
possible O
treatment O
for O
hypopigmentation O
diseases O
. O

Each O
subtype O
of O
the O
Histone O
Deacetylase O
( O
HDAC O
) O
family O
perform O
a O
distinct O
role O
in O
the O
gene O
expression O
and O
cyclic O
peptides O
with O
their O
plentiful O
set O
of O
surface O
contacts O
, O
zinc B
binding O
group O
and O
macrocyclic O
cap O
, O
can O
target O
enzyme O
precisely O
through O
adequate O
modulation O
of O
the O
amino B
acid I
configurational O
and O
structural O
assortment O
. O

Index O
of O
refraction O
, O
density O
, O
and O
solubility O
of O
ammonium B
iodide I
solutions O
at O
high O
pressure O
. O

An O
asymmetric O
moissanite B
anvil O
cell O
is O
used O
to O
study O
aqueous O
solutions O
of O
ammonium B
iodide I
at O
pressures O
up O
to O
10 O
kbar O
. O

The O
propionyl B
ester I
of O
15 O
exhibited O
superior O
antimalarial O
efficacy O
. O

To O
accommodate O
these O
observations O
, O
we O
propose O
that O
in O
aqueous O
media O
at O
neutral O
to O
slightly O
alkaline O
pH O
about O
3 O
% O
of O
the O
ethephon B
is O
converted O
( O
t1 O
/ O
2 O
= O
9 O
. O
9 O
h O
at O
pH O
7 O
. O
0 O
) O
into O
a O
cyclic B
oxaphosphetane I
which O
is O
the O
actual O
BChE O
inhibitor O
forming O
the O
2 B
- I
hydroxyethylphosphon I
adduct O
on O
BChE O
at O
Ser198 B
while O
about O
97 O
% O
of O
the O
ethephon B
breaks O
down O
to O
ethylene B
( O
t1 O
/ O
2 O
= O
11 O
- O
48 O
h O
at O
pH O
7 O
. O
0 O
) O
which O
is O
responsible O
for O
plant O
growth O

NSPCs O
were O
also O
more O
resistant O
than O
neurons O
to O
mitochondrial O
cyanide B
toxicity O
, O
less O
capable O
of O
utilizing O
galactose B
as O
an O
alternative O
substrate O
to O
glucose B
, O
and O
more O
susceptible O
to O
pharmacological O
inhibition O
of O
the O
pentose B
phosphate I
pathway O
by O
6 B
- I
aminonicotinamide I
. O

DNA O
damage O
and O
oxidative O
stress O
in O
human O
B O
lymphoblastoid O
cells O
after O
combined O
exposure O
to O
hexavalent B
chromium I
and O
nickel B
compounds O
. O

In O
the O
present O
study O
, O
human O
B O
lymphoblastoid O
cells O
were O
exposed O
to O
potassium B
dichromate I
and O
/ O
or O
nickel B
chloride I
for O
24h O
or O
48h O
. O

In O
the O
present O
study O
, O
human O
B O
lymphoblastoid O
cells O
were O
exposed O
to O
potassium B
dichromate I
and O
/ O
or O
nickel B
chloride I
for O
24h O
or O
48h O
. O

Our O
results O
indicated O
that O
potassium B
dichromate I
could O
decrease O
cell O
viability O
and O
induce O
DNA O
damage O
in O
human O
B O
lymphoblastoid O
cells O
in O
a O
time O
- O
and O
concentration O
- O
dependent O
manner O
, O
but O
the O
toxicity O
of O
nickel B
chloride I
was O
not O
so O
obvious O
at O
concentrations O
used O
in O
our O
study O
. O

Our O
results O
indicated O
that O
potassium B
dichromate I
could O
decrease O
cell O
viability O
and O
induce O
DNA O
damage O
in O
human O
B O
lymphoblastoid O
cells O
in O
a O
time O
- O
and O
concentration O
- O
dependent O
manner O
, O
but O
the O
toxicity O
of O
nickel B
chloride I
was O
not O
so O
obvious O
at O
concentrations O
used O
in O
our O
study O
. O

It O
is O
suggested O
that O
synergistic O
DNA O
damage O
induced O
by O
simultaneously O
exposure O
of O
hexavalent B
chromium I
and O
nickel B
compounds O
is O
possibly O
related O
to O
oxidative O
stress O
. O

The O
docking O
results O
suggested O
that O
the O
benzene B
ring O
of O
1 B
, I
2 I
, I
3 I
, I
4 I
- I
tetrahydroquinazolin I
ring O
system O
of O
these O
molecules O
occupied O
the O
deep O
hydrophobic O
pocket O
of O
the O
protein O
and O
one O
of O
the O
NH B
along O
with O
the O
sulfonyl B
group O
participated O
in O
strong O
H B
- O
bonding O
interaction O
with O
the O
amino B
acid I
residues O
. O

Further O
, O
WOE O
also O
decreased O
the O
number O
of O
acetic B
acid I
- O
induced O
writhing O
responses O
and O
formalin B
- O
induced O
pain O
in O
the O
late O
phase O
in O
mice O
. O

LC O
- O
DAD O
- O
MS O
data O
revealed O
the O
presence O
of O
pseudohypericin B
( O
0 O
. O
135 O
- O
3 O
. O
280 O
mu O
g O
/ O
g O
) O
and O
hypericin B
( O
0 O
. O
277 O
- O
6 O
. O
634 O
mu O
g O
/ O
g O
) O
in O
all O
the O
oils O
, O
whereas O
chlorogenic B
acid I
( O
1 O
. O
063 O
mu O
g O
/ O
g O
) O
was O
detected O
only O
in O
one O
oil O
sample O
. O

Hypericin B
and O
pseudohypericin B
were O
common O
in O
the O
active O
oils O
, O
whereas O
hyperforin B
, O
adhyperforin B
, O
and O
chlorogenic B
acid I
were O
absent O
in O
these O
samples O
. O

Linoleic B
acid I
autoxidation O
inhibitions O
on O
all O
fractions O
were O
higher O
than O
that O
on O
alpha B
- I
tocopherol I
. O

All O
fractions O
diminished O
LPS O
- O
induced O
protein O
expression O
of O
inducible O
nitric B
oxide I
synthase O
( O
iNOS O
) O
and O
cyclooxygenase O
2 O
( O
COX O
- O
2 O
) O
. O

Nitric B
oxide I
( O
NO B
) O
and O
prostaglandin B
E2 I
( O
PGE B
( I
2 I
) I
) O
, O
downstream O
products O
, O
were O
also O
suppressed O
in O
dose O
- O
dependent O
manners O
, O
except O
for O
WL O
and O
WW O
. O

Nitric B
oxide I
( O
NO B
) O
and O
prostaglandin B
E2 I
( O
PGE B
( I
2 I
) I
) O
, O
downstream O
products O
, O
were O
also O
suppressed O
in O
dose O
- O
dependent O
manners O
, O
except O
for O
WL O
and O
WW O
. O

Samples O
were O
then O
analysed O
in O
SRM O
mode O
to O
detect O
nicotinic B
acid I
and O
nicotinic B
acid I
- I
d I
( I
4 I
) I
at O
m O
/ O
z O
124 O
- O
- O
> O
80 O
and O
127 O
- O
- O
> O
84 O
, O
respectively O
. O

Major O
antioxidant O
phenolic B
compounds O
identified O
in O
this O
study O
included O
proanthocyanidins B
, O
phenolic B
acids I
and O
gamma B
- I
oryzanols I
( O
ferulic B
acid I
derivatives O
) O
. O

Major O
antioxidant O
phenolic B
compounds O
identified O
in O
this O
study O
included O
proanthocyanidins B
, O
phenolic B
acids I
and O
gamma B
- I
oryzanols I
( O
ferulic B
acid I
derivatives O
) O
. O

Most O
traditional O
red O
varieties O
also O
contained O
significantly O
higher O
levels O
of O
protein O
with O
well O
balanced O
amino B
acids I
and O
higher O
contents O
of O
fat O
, O
fibre O
and O
vitamin B
E I
( O
tocopherols B
and O
tocotrienols B
) O
than O
the O
new O
- O
improved O
ones O
. O

Most O
traditional O
red O
varieties O
also O
contained O
significantly O
higher O
levels O
of O
protein O
with O
well O
balanced O
amino B
acids I
and O
higher O
contents O
of O
fat O
, O
fibre O
and O
vitamin B
E I
( O
tocopherols B
and O
tocotrienols B
) O
than O
the O
new O
- O
improved O
ones O
. O

Determination O
of O
ethyl B
carbamate I
in O
cacha O
c O
a O
produced O
from O
copper B
stills O
by O
HPLC O
. O

Ethyl B
carbamate I
( O
EC O
) O
is O
a O
common O
substance O
in O
fermented O
foods O
and O
drinks O
, O
and O
its O
quantification O
is O
important O
because O
of O
its O
carcinogenic O
nature O
and O
its O
usually O
presence O
in O
alcoholic O
beverages O
. O

CF O
had O
the O
most O
significant O
effect O
on O
the O
flavan B
- I
3 I
- I
ol I
and O
polymeric B
phenol I
( O
tannin B
) O
content O
of O
the O
wines O
compared O
to O
the O
control O
followed O
by O
G O
fining O
. O

alpha O
- O
CPP O
and O
beta O
- O
CPP O
pools O
did O
not O
improve O
ferritin O
synthesis O
, O
but O
the O
three O
specific O
CPPs O
showed O
an O
increase O
in O
ferritin O
synthesis O
in O
Caco O
- O
2 O
cells O
versus O
iron B
sulphate I
, O
beta O
- O
CN O
( O
1 O
- O
25 O
) O
4P O
being O
the O
most O
effective O
. O

However O
, O
this O
increase O
was O
of O
the O
same O
order O
as O
the O
increase O
due O
to O
the O
presence O
of O
zinc B
sulphate I
. O

Multiple O
mutations O
of O
the O
critical O
amino B
acid I
residues O
for O
the O
sweetness O
of O
the O
sweet O
- O
tasting O
protein O
, O
brazzein O
. O

Terpenic O
structure O
oxidation O
products O
accumulated O
in O
VOO O
during O
the O
autoxidation O
process O
, O
thus O
they O
may O
be O
used O
as O
early O
evaluation O
index O
of O
the O
VOO O
autoxidation O
state O
before O
fatty B
acids I
oxidation O
. O

Geraniol B
, O
geranial B
, O
and O
geranyl B
acetate I
were O
the O
most O
abundant O
compounds O
. O

For O
both O
genotypes O
and O
both O
locations O
, O
application O
of O
50 O
% O
urea B
+ O
50 O
% O
Azocompost O
increased O
levels O
of O
geraniol B
and O
geranial B
, O
and O
application O
of O
Azocompost O
alone O
increased O
levels O
of O
geranyl B
acetate I
. O

Three O
lipolysis O
- O
stimulating O
peptides O
were O
obtained O
, O
and O
the O
amino B
acid I
sequences O
were O
ILL O
, O
LLL O
and O
VHVV O
, O
respectively O
. O

The O
total O
EC O
content O
absorbed O
in O
plasma O
was O
only O
2 O
. O
54 O
+ O
/ O
- O
0 O
. O
53 O
mu O
mol O
/ O
L O
, O
indicating O
that O
the O
biological O
properties O
of O
LPOPC O
should O
be O
probably O
explained O
by O
its O
microbial O
degraded O
phenolic B
acids I
. O

A O
high O
density O
polyethylene B
( O
HDPE O
) O
/ O
calcium B
carbonate I
( O
CaCO B
( I
3 I
) I
) O
film O
containing O
TiO B
( I
2 I
) I
was O
prepared O
via O
blown O
film O
extrusion O
process O
. O

The O
photocatalytic O
properties O
of O
this O
film O
were O
evaluated O
by O
voltammetric O
, O
UV O
- O
Vis O
spectrophotometric O
and O
gas O
chromatographic O
measurements O
following O
the O
decomposition O
rate O
of O
suitably O
selected O
molecular O
probes O
, O
such O
as O
4 B
- I
hydroxybenzoic I
acid I
and O
methylene B
blue I
. O

A O
container O
consisting O
of O
a O
multilayer O
material O
, O
where O
the O
layer O
brought O
in O
contact O
with O
the O
food O
, O
made O
from O
the O
HDPE O
+ O
CaCO B
( I
3 I
) I
+ O
TiO B
( I
2 I
) I
composite O
matrix O
, O
was O
able O
to O
provide O
a O
greater O
maintenance O
of O
the O
original O
cheese O
structure O
than O
a O
rigid O
container O
currently O
used O
, O
mainly O
due O
to O
the O
inhibition O
of O
lactic B
acid I
bacteria O
and O
coliforms O
. O

Prediction O
of O
fatty B
acid I
composition O
in O
Camellia O
oleifera O
oil O
by O
near O
infrared O
transmittance O
spectroscopy O
( O
NITS O
) O
. O

By O
using O
ultrafiltration O
, O
gel O
filtration O
chromatography O
and O
reversed O
phase O
high O
performance O
liquid O
chromatography O
( O
RP O
- O
HPLC O
) O
, O
a O
novel O
antioxidant O
peptide O
( O
BNH O
- O
P7 O
) O
was O
isolated O
from O
BNH O
, O
and O
its O
amino B
acid I
sequence O
was O
identified O
as O
YPPAK O
( O
Tyr B
- I
Pro I
- I
Pro I
- I
Ala I
- I
Lys I
) O
with O
molecular O
weight O
of O
574 O
Da O
. O

BNH O
- O
P7 O
was O
also O
effectively O
against O
lipid O
peroxidation O
in O
a O
linoleic B
acid I
model O
system O
. O

The O
high O
activity O
of O
BNH O
- O
P7 O
was O
due O
to O
the O
small O
size O
and O
the O
presence O
of O
antioxidant O
and O
hydrophobic O
amino B
acid I
residues O
( O
Tyr B
and O
Pro B
) O
within O
its O
sequence O
. O

The O
results O
confirmed O
: O
( O
a O
) O
the O
effectiveness O
of O
single O
process O
indicators O
of O
roasting O
selected O
by O
the O
separative O
method O
( O
5 B
- I
methylfurfural I
, O
1 B
( I
H I
) I
- I
pyrrole I
, O
furfuryl B
alcohol I
, O
1 B
( I
H I
) I
- I
pyrrole I
- I
2 I
- I
carboxaldehyde I
, O
1 B
- I
hydroxy I
- I
2 I
- I
propanone I
, O
dihydro B
- I
2 I
( I
3H I
) I
- I
furanone I
, O
5 B
- I
methyl I
- I
( I
E I
) I
- I
2 I
- I
hepten I
- I
4 I
- I
one I
, O
acetic B
acid I
, O
pyridine B
, O
furfural B
, O

The O
results O
confirmed O
: O
( O
a O
) O
the O
effectiveness O
of O
single O
process O
indicators O
of O
roasting O
selected O
by O
the O
separative O
method O
( O
5 B
- I
methylfurfural I
, O
1 B
( I
H I
) I
- I
pyrrole I
, O
furfuryl B
alcohol I
, O
1 B
( I
H I
) I
- I
pyrrole I
- I
2 I
- I
carboxaldehyde I
, O
1 B
- I
hydroxy I
- I
2 I
- I
propanone I
, O
dihydro B
- I
2 I
( I
3H I
) I
- I
furanone I
, O
5 B
- I
methyl I
- I
( I
E I
) I
- I
2 I
- I
hepten I
- I
4 I
- I
one I
, O
acetic B
acid I
, O
pyridine B
, O
furfural B
, O

Methionine B
sulfone I
containing O
peptides O
CLs O
J O
( O
11 O
) O
and O
K O
( O
12 O
) O
may O
be O
produced O
from O
their O
reduced O
forms O
by O
oxidation O
but O
it O
is O
not O
known O
if O
these O
compounds O
occur O
in O
foods O
that O
contain O
flax O
. O

These O
compounds O
have O
been O
reported O
to O
possess O
greater O
immunosuppressive O
activity O
than O
their O
reduced O
methionine B
sulfoxide I
peptide O
forms O
4 O
and O
6 O
, O
respectively O
. O

Gamma B
- I
aminobutyric I
acid I
( O
GABA B
) O
is O
a O
non O
- O
protein O
amino B
acid I
with O
bioactive O
functions O
in O
humans O
. O

GAD O
optimal O
activity O
was O
at O
pH O
6 O
. O
0 O
at O
40 O
degrees O
C O
with O
a O
K O
( O
m O
) O
value O
for O
glutamic B
acid I
( O
Glu B
) O
of O
2 O
. O
63 O
mM O
. O

Colour O
and O
stability O
assessment O
of O
blue O
ferric B
anthocyanin I
chelates O
in O
liquid O
pectin O
- O
stabilised O
model O
systems O
. O

The O
formation O
of O
blue O
coloured O
ferric B
anthocyanin I
chelates O
and O
their O
colour O
stability O
during O
storage O
and O
thermal O
treatment O
were O
monitored O
in O
a O
pH O
range O
relevant O
to O
food O
( O
3 O
. O
6 O
- O
5 O
. O
0 O
) O
. O

The O
comprehensive O
evaluation O
of O
the O
interrelationship O
of O
pigment O
source O
, O
pH O
conditions O
and O
pectin O
type O
on O
chelate O
formation O
and O
stability O
demonstrated O
that O
ferric B
anthocyanin I
chelates O
are O
promising O
natural O
blue O
food O
colourants O
. O

To O
clarify O
the O
regulatory O
molecular O
mechanisms O
behind O
cell O
cycle O
aberrations O
related O
to O
the O
early O
stages O
of O
hepatocarcinogenesis O
, O
we O
performed O
gene O
expression O
analysis O
using O
microarrays O
and O
real O
- O
time O
reverse O
transcription O
polymerase O
chain O
reaction O
followed O
by O
immunohistochemical O
analysis O
in O
the O
livers O
of O
rats O
treated O
with O
the O
cytomegaly O
inducing O
hepatocarcinogens O
thioacetamide B
( O
TAA B
) O
, O
fenbendazole B
, O
and O
methyleugenol B
, O
the O
cytomegaly O
non O
- O
inducing O
hepatocarcinogen O
piperonyl B
butoxide I
( O

Previously O
, O
we O
found O
that O
the O
baker O
' O
s O
yeast O
cytosolic O
thioredoxin O
Trx2 O
undergoes O
cross O
- O
linking O
to O
form O
several O
protein O
- O
protein O
complexes O
in O
cells O
treated O
with O
the O
bifunctional O
electrophile O
divinyl B
sulfone I
( O
DVSF B
) O
. O

Treatment O
of O
yeast O
with O
other O
bifunctional O
electrophiles O
, O
including O
diethyl B
acetylenedicarboxyla I
( O
DAD B
) O
, O
mechlorethamine B
( O
HN2 B
) O
, O
and O
1 B
, I
2 I
, I
3 I
, I
4 I
- I
diepoxybutane I
( O
DEB B
) O
, O
resulted O
in O
the O
formation O
of O
similar O
cross O
- O
linked O
complexes O
. O

Bioanalytical O
LC O
separation O
techniques O
for O
quantitative O
analysis O
of O
free O
amino B
acids I
in O
human O
plasma O
. O

The O
quantitative O
analysis O
of O
free O
amino B
acids I
in O
human O
plasma O
has O
become O
an O
important O
and O
essential O
analysis O
parameter O
in O
different O
areas O
of O
life O
sciences O
. O

Free O
amino B
acid I
concentrations O
in O
human O
plasma O
samples O
are O
generally O
determined O
by O
means O
of O
GC O
or O
LC O
after O
chemical O
derivatization O
followed O
by O
UV O
, O
fluorescent O
or O
MS O
detection O
of O
the O
amino B
acid I
derivatives O
. O

Free O
amino B
acid I
concentrations O
in O
human O
plasma O
samples O
are O
generally O
determined O
by O
means O
of O
GC O
or O
LC O
after O
chemical O
derivatization O
followed O
by O
UV O
, O
fluorescent O
or O
MS O
detection O
of O
the O
amino B
acid I
derivatives O
. O

Derivatization O
of O
free O
amino B
acids I
is O
done O
either O
pre O
- O
or O
post O
- O
column O
, O
and O
the O
amino B
acid I
derivatives O
obtained O
posess O
improved O
chromatographic O
behavior O
, O
increased O
detection O
sensitivity O
and O
selectivity O
compared O
with O
non O
- O
derivatized O
free O
amino B
acids I
. O

Derivatization O
of O
free O
amino B
acids I
is O
done O
either O
pre O
- O
or O
post O
- O
column O
, O
and O
the O
amino B
acid I
derivatives O
obtained O
posess O
improved O
chromatographic O
behavior O
, O
increased O
detection O
sensitivity O
and O
selectivity O
compared O
with O
non O
- O
derivatized O
free O
amino B
acids I
. O

Derivatization O
of O
free O
amino B
acids I
is O
done O
either O
pre O
- O
or O
post O
- O
column O
, O
and O
the O
amino B
acid I
derivatives O
obtained O
posess O
improved O
chromatographic O
behavior O
, O
increased O
detection O
sensitivity O
and O
selectivity O
compared O
with O
non O
- O
derivatized O
free O
amino B
acids I
. O

This O
work O
gives O
an O
overview O
of O
different O
chemical O
derivatization O
methods O
applied O
and O
their O
liquid O
separation O
techniques O
in O
bioanalytical O
assays O
for O
quantitative O
free O
amino B
acid I
analysis O
in O
human O
plasma O
samples O
. O

Inflammation O
was O
assessed O
by O
evaluating O
inflammatory O
markers O
/ O
parameters O
( O
colon O
weight O
/ O
colon O
length O
ratio O
and O
myeloperoxidase O
activity O
) O
, O
by O
histological O
analysis O
and O
immunohistochemistry O
; O
interleukin O
- O
1 O
beta O
, O
interleukin O
- O
10 O
and O
interferon O
- O
gamma O
levels O
by O
ELISA O
, O
inducible O
nitric B
oxide I
synthase O
( O
iNOS O
) O
and O
cyclooxygenase O
- O
2 O
( O
COX O
- O
2 O
) O
by O
western O
blot O
and O
RT O
- O
PCR O
; O
CuZn B
- O
superoxide B
dismutase O
( O

Murine O
macrophages O
and O
intestinal O
epithelial O
cells O
were O
used O
to O
evaluate O
the O
effect O
of O
CBG O
on O
nitric B
oxide I
production O
and O
oxidative O
stress O
, O
respectively O
. O

In O
macrophages O
, O
CBG B
reduced O
nitric B
oxide I
production O
and O
iNOS O
protein O
( O
but O
not O
mRNA O
) O
expression O
. O

Rimonabant B
( O
a O
CB1 O
receptor O
antagonist O
) O
did O
not O
change O
the O
effect O
of O
CBG B
on O
nitric B
oxide I
production O
, O
while O
SR144528 B
( O
a O
CB2 O
receptor O
antagonist O
) O
further O
increased O
the O
inhibitory O
effect O
of O
CBG B
on O
nitric B
oxide I
production O
. O

Rimonabant B
( O
a O
CB1 O
receptor O
antagonist O
) O
did O
not O
change O
the O
effect O
of O
CBG B
on O
nitric B
oxide I
production O
, O
while O
SR144528 B
( O
a O
CB2 O
receptor O
antagonist O
) O
further O
increased O
the O
inhibitory O
effect O
of O
CBG B
on O
nitric B
oxide I
production O
. O

In O
conclusion O
, O
CBG B
attenuated O
murine O
colitis O
, O
reduced O
nitric B
oxide I
production O
in O
macrophages O
( O
effect O
being O
modulated O
by O
the O
CB2 O
receptor O
) O
and O
reduced O
ROS O
formation O
in O
intestinal O
epithelial O
cells O
. O

Amino B
acid I
derived O
quinazolines B
as O
Rock O
/ O
PKA O
inhibitors O
. O

SAR O
and O
lead O
optimization O
studies O
for O
Rock O
inhibitors O
based O
on O
amino B
acid I
- O
derived O
quinazolines B
are O
described O
. O

Studies O
demonstrated O
that O
these O
amino B
acid I
derived O
quinazolinones B
were O
mainly O
pan O
- O
Rock O
( O
I O
& O
II O
) O
inhibitors O
. O

This O
is O
distinct O
from O
Rock O
inhibitors O
based O
on O
non O
- O
amino B
acid I
derived O
quinazolinones B
, O
where O
high O
selectivity O
against O
PKA O
could O
be O
obtained O
. O
( O
22 O
) O
The O
inhibitors O
presented O
here O
in O
some O
cases O
possessed O
sub O
- O
nanomolar O
inhibition O
of O
Rock O
, O
nanomolar O
potency O
in O
ppMLC O
cell O
based O
assays O
, O
low O
to O
fair O
cytochrome O
P O
- O
450 O
inhibition O
, O
and O
good O
human O
microsomal O
stability O
. O

These O
results O
indicate O
that O
aza B
- I
BODIPY I
could O
serve O
as O
a O
near O
- O
IR O
probe O
for O
detecting O
conformational O
changes O
of O
A O
beta O
1 O
- O
42 O
soluble O
oligomers O
in O
vitro O
, O
and O
it O
should O
eliminate O
false O
- O
positive O
effects O
that O
are O
associated O
with O
currently O
utilized O
thioflavin B
T I
- O
based O
dyes O
. O

Cysteamine B
is O
an O
amino B
thiol I
with O
the O
chemical O
formula O
HSCH2CH2NH2 B
. O

Endogenously O
, O
cysteamine B
is O
derived O
from O
coenzyme B
A I
degradation O
, O
although O
its O
plasma O
concentrations O
are O
low O
. O

Compared O
with O
the O
high O
- O
fat O
control O
( O
HFC O
) O
group O
GMP O
supplementation O
significantly O
decreased O
adipose O
tissue O
weight O
, O
activity O
of O
fatty B
acid I
synthase O
( O
FAS O
) O
and O
glycerol B
- I
3 I
- I
phosphate I
dehydrogenase O
( O
GPDH O
) O
. O

Central O
administration O
of O
angiotensin B
IV I
rapidly O
enhances O
novel O
object O
recognition O
among O
mice O
. O

Angiotensin B
IV I
( O
Val B
( I
1 I
) I
- I
Tyr I
( I
2 I
) I
- I
Ile I
( I
3 I
) I
- I
His I
( I
4 I
) I
- I
Pro I
( I
5 I
) I
- I
Phe I
( I
6 I
) I
) O
has O
demonstrated O
potential O
cognitive O
- O
enhancing O
effects O
. O

The O
present O
investigation O
assessed O
and O
characterized O
: O
( O
1 O
) O
dose O
- O
dependency O
of O
angiotensin B
IV I
' O
s O
cognitive O
enhancement O
in O
a O
C57BL O
/ O
6J O
mouse O
model O
of O
novel O
object O
recognition O
, O
( O
2 O
) O
the O
time O
- O
course O
for O
these O
effects O
, O
( O
3 O
) O
the O
identity O
of O
residues O
in O
the O
hexapeptide B
important O
to O
these O
effects O
and O
( O
4 O
) O
the O
necessity O
of O
actions O
at O
angiotensin B
IV I
receptors O
for O
procognitive O
activity O
. O

The O
present O
investigation O
assessed O
and O
characterized O
: O
( O
1 O
) O
dose O
- O
dependency O
of O
angiotensin B
IV I
' O
s O
cognitive O
enhancement O
in O
a O
C57BL O
/ O
6J O
mouse O
model O
of O
novel O
object O
recognition O
, O
( O
2 O
) O
the O
time O
- O
course O
for O
these O
effects O
, O
( O
3 O
) O
the O
identity O
of O
residues O
in O
the O
hexapeptide B
important O
to O
these O
effects O
and O
( O
4 O
) O
the O
necessity O
of O
actions O
at O
angiotensin B
IV I
receptors O
for O
procognitive O
activity O
. O

Assessment O
of O
C57BL O
/ O
6J O
mice O
in O
a O
novel O
object O
recognition O
task O
demonstrated O
that O
prior O
administration O
of O
angiotensin B
IV I
( O
0 O
. O
1 O
, O
1 O
. O
0 O
, O
or O
10 O
. O
0 O
, O
but O
not O
0 O
. O
01 O
nmol O
, O
i O
. O
c O
. O
v O
. O
) O
significantly O
enhanced O
novel O
object O
recognition O
in O
a O
dose O
- O
dependent O
manner O
. O

These O
effects O
were O
time O
dependent O
, O
with O
improved O
novel O
object O
recognition O
observed O
when O
angiotensin B
IV I
( O
0 O
. O
1 O
nmol O
, O
i O
. O
c O
. O
v O
. O
) O
was O
administered O
10 O
or O
20 O
, O
but O
not O
30 O
min O
prior O
to O
the O
onset O
of O
the O
novel O
object O
recognition O
testing O
. O

An O
alanine B
scan O
of O
the O
angiotensin B
IV I
peptide O
revealed O
that O
replacement O
of O
the O
Val B
( O
1 O
) O
, O
Ile B
( O
3 O
) O
, O
His B
( O
4 O
) O
, O
or O
Phe B
( O
6 O
) O
residues O
with O
Ala B
attenuated O
peptide O
- O
induced O
improvements O
in O
novel O
object O
recognition O
, O
whereas O
Tyr B
( O
2 O
) O
or O
Pro B
( O
5 O
) O
replacement O
did O
not O
significantly O
affect O
performance O
. O

Administration O
of O
the O
angiotensin B
IV I
receptor O
antagonist O
, O
divalinal B
- I
Ang I
IV I
( O
20 O
nmol O
, O
i O
. O
c O
. O
v O
. O
) O
, O
reduced O
( O
but O
did O
not O
abolish O
) O
novel O
object O
recognition O
; O
however O
, O
this O
antagonist O
completely O
blocked O
the O
procognitive O
effects O
of O
angiotensin B
IV I
( O
0 O
. O
1 O
nmol O
, O
i O
. O
c O
. O
v O
. O
) O
in O
this O
task O
. O

Administration O
of O
the O
angiotensin B
IV I
receptor O
antagonist O
, O
divalinal B
- I
Ang I
IV I
( O
20 O
nmol O
, O
i O
. O
c O
. O
v O
. O
) O
, O
reduced O
( O
but O
did O
not O
abolish O
) O
novel O
object O
recognition O
; O
however O
, O
this O
antagonist O
completely O
blocked O
the O
procognitive O
effects O
of O
angiotensin B
IV I
( O
0 O
. O
1 O
nmol O
, O
i O
. O
c O
. O
v O
. O
) O
in O
this O
task O
. O

Rotorod O
testing O
demonstrated O
no O
locomotor O
effects O
with O
any O
angiotensin B
IV I
or O
divalinal B
- I
Ang I
IV I
dose O
tested O
. O

These O
data O
demonstrate O
that O
angiotensin B
IV I
produces O
a O
rapid O
enhancement O
of O
associative O
learning O
and O
memory O
performance O
in O
a O
mouse O
model O
that O
was O
dependent O
on O
the O
angiotensin B
IV I
receptor O
. O

These O
data O
demonstrate O
that O
angiotensin B
IV I
produces O
a O
rapid O
enhancement O
of O
associative O
learning O
and O
memory O
performance O
in O
a O
mouse O
model O
that O
was O
dependent O
on O
the O
angiotensin B
IV I
receptor O
. O

To O
map O
supercoiling O
, O
we O
used O
biotinylated B
trimethylpsoralen I
as O
a O
DNA O
structure O
probe O
to O
show O
that O
the O
human O
genome O
is O
organized O
into O
supercoiling O
domains O
. O

The O
effects O
of O
an O
environmentally O
relevant O
58 O
- O
congener O
polychlorinated B
biphenyl I
( O
PCB B
) O
mixture O
on O
cardiac O
development O
in O
the O
chick O
embryo O
. O

Chicken O
( O
Gallus O
domesticus O
) O
embryonic O
exposure O
in O
ovo O
to O
a O
58 O
- O
congener O
polychlorinated B
biphenyl I
( O
PCB B
) O
mixture O
resulted O
in O
teratogenic O
heart O
defects O
in O
chick O
embryos O
at O
critical O
heart O
developmental O
stages O
Hamburger O
- O
Hamilton O
( O
HH O
) O
stages O
10 O
, O
16 O
, O
and O
20 O
. O

The O
resulting O
DSSCs O
exhibit O
remarkably O
rapid O
charge O
collection O
and O
a O
DSSC O
fabricated O
with O
a O
BaSnO3 B
film O
thickness O
of O
43 O
micro O
m O
leads O
to O
a O
high O
energy O
conversion O
efficiency O
of O
5 O
. O
2 O
% O
, O
which O
is O
one O
of O
the O
highest O
reported O
for O
ternary B
oxide I
- O
based O
DSSCs O
. O

Incorporating O
Graphene B
Oxide I
and O
Gold O
Nanoclusters O
: O
A O
Synergistic O
Catalyst O
with O
Surprisingly O
High O
Peroxidase O
- O
Like O
Activity O
Over O
a O
Broad O
pH O
Range O
and O
its O
Application O
for O
Cancer O
Cell O
Detection O
. O

A O
synergistic O
graphene B
oxide I
- O
gold O
nanocluster O
( O
GO O
- O
AuNC O
) O
hybrid O
has O
been O
constructed O
as O
an O
enzyme O
mimic O
that O
is O
able O
to O
show O
high O
catalytic O
activity O
over O
a O
broad O
pH O
range O
, O
especially O
at O
neutral O
pH O
. O

Synthesis O
of O
heterocyclic B
terpenoids I
by O
promiscuous O
squalene B
- O
hopene B
cyclases O
. O

PROMISCUOUS O
ENZYMES O
: O
The O
substrate O
promiscuity O
of O
squalene B
- O
hopene B
cyclases O
has O
been O
explored O
and O
applied O
in O
the O
enzyme O
- O
catalyzed O
synthesis O
of O
heterocyclic B
terpenoids I
. O

Plasma O
samples O
of O
0 O
. O
2 O
ml O
were O
processed O
by O
liquid O
- O
liquid O
extraction O
with O
n B
- I
hexane I
/ O
ethyl B
acetate I
( O
2 O
: O
1 O
, O
v O
/ O
v O
) O
. O

Chromatographic O
separations O
were O
done O
on O
a O
Symmetry O
C O
( O
18 O
) O
column O
( O
100 O
mm O
x O
4 O
. O
6 O
mm O
, O
ID O
, O
5 O
mu O
m O
) O
at O
35 O
degrees O
C O
with O
a O
linear O
gradient O
of O
methanol B
and O
20 O
mM O
ammonium B
formate I
containing O
0 O
. O
2 O
% O
formic B
acid I
. O

Chromatographic O
separations O
were O
done O
on O
a O
Symmetry O
C O
( O
18 O
) O
column O
( O
100 O
mm O
x O
4 O
. O
6 O
mm O
, O
ID O
, O
5 O
mu O
m O
) O
at O
35 O
degrees O
C O
with O
a O
linear O
gradient O
of O
methanol B
and O
20 O
mM O
ammonium B
formate I
containing O
0 O
. O
2 O
% O
formic B
acid I
. O

A O
new O
alkaloid O
was O
isolated O
from O
the O
ethyl B
acetate I
extract O
of O
the O
culture O
of O
a O
termite O
- O
associated O
Streptomyces O
koyangensis O
BY O
- O
4 O
. O

Three O
new O
norlignans B
, O
glechomols B
A I
- I
C I
( O
1 O
- O
3 O
, O
respectively O
) O
, O
together O
with O
a O
known O
compound O
, O
4 B
- I
ethylcatechol I
( O
4 O
) O
, O
were O
isolated O
from O
the O
ethyl B
acetate I
extract O
of O
Glechoma O
longituba O
( O
NaKai O
) O
Kupr O
. O

The O
aggregation O
and O
interfacial O
behavior O
of O
mixtures O
of O
anionic O
( O
sodium B
dodecylsulfate I
, O
SDS B
) O
and O
cationic O
( O
dodecylammonium B
bromide I
, O
DTAB B
) O
surfactants O
were O
investigated O
. O

The O
aggregation O
and O
interfacial O
behavior O
of O
mixtures O
of O
anionic O
( O
sodium B
dodecylsulfate I
, O
SDS B
) O
and O
cationic O
( O
dodecylammonium B
bromide I
, O
DTAB B
) O
surfactants O
were O
investigated O
. O

Approach O
to O
distribution O
and O
accumulation O
of O
dibutyl B
phthalate I
in O
rats O
by O
immunoassay O
. O

Dibutyl B
phthalate I
( O
DBP B
) O
is O
mainly O
taken O
up O
by O
the O
general O
population O
from O
food O
intake O
. O

Uncharged O
( O
polyethylene B
glycol I
; O
PEG B
) O
, O
positively O
charged O
( O
amino B
- O
terminated O
: O
NH2 B
) O
and O
negatively O
charged O
( O
carboxyl B
- O
modified O
; O
COOH B
) O
cadmium B
selenide I
/ O
zinc B
sulfide I
quantum O
dots O
were O
used O
to O
monitor O
ingestion O
, O
uptake O
and O
depuration O
of O
nanometals O
in O
Daphnia O
magna O
and O
Ceriodaphnia O
dubia O
over O
24h O
of O
exposure O
. O

Uncharged O
( O
polyethylene B
glycol I
; O
PEG B
) O
, O
positively O
charged O
( O
amino B
- O
terminated O
: O
NH2 B
) O
and O
negatively O
charged O
( O
carboxyl B
- O
modified O
; O
COOH B
) O
cadmium B
selenide I
/ O
zinc B
sulfide I
quantum O
dots O
were O
used O
to O
monitor O
ingestion O
, O
uptake O
and O
depuration O
of O
nanometals O
in O
Daphnia O
magna O
and O
Ceriodaphnia O
dubia O
over O
24h O
of O
exposure O
. O

Uncharged O
( O
polyethylene B
glycol I
; O
PEG B
) O
, O
positively O
charged O
( O
amino B
- O
terminated O
: O
NH2 B
) O
and O
negatively O
charged O
( O
carboxyl B
- O
modified O
; O
COOH B
) O
cadmium B
selenide I
/ O
zinc B
sulfide I
quantum O
dots O
were O
used O
to O
monitor O
ingestion O
, O
uptake O
and O
depuration O
of O
nanometals O
in O
Daphnia O
magna O
and O
Ceriodaphnia O
dubia O
over O
24h O
of O
exposure O
. O

The O
optimization O
is O
done O
against O
a O
set O
of O
quantum O
chemical O
data O
for O
MgSO4 B
hydrates I
. O

The O
optimized O
force O
field O
reproduced O
the O
chemical O
structures O
, O
the O
equations O
of O
state O
, O
and O
the O
water O
binding O
curves O
of O
MgSO4 B
hydrates I
. O

The O
pharmacokinetics O
and O
conversion O
of O
the O
lactone B
to O
the O
carboxylate B
forms O
of O
ginkgolide B
B I
in O
rat O
plasma O
. O

Ginkgolide B
B I
consists O
of O
three O
lactone B
groups O
, O
which O
may O
undergo O
hydrolysis O
, O
and O
lead O
to O
the O
rings O
opening O
in O
aqueous O
solution O
with O
different O
pHs O
. O

Pharmacokinetics O
of O
lactone B
form O
( O
GB B
- I
lac I
) O
and O
the O
total O
of O
the O
lactone B
and O
carboxylate B
form O
( O
GB O
- O
tot O
) O
of O
ginkgolide B
B I
were O
investigated O
after O
intravenous O
administration O
of O
a O
dose O
of O
4 O
mg O
/ O
kg O
ginkgolide B
B I
. O

Pharmacokinetics O
of O
lactone B
form O
( O
GB B
- I
lac I
) O
and O
the O
total O
of O
the O
lactone B
and O
carboxylate B
form O
( O
GB O
- O
tot O
) O
of O
ginkgolide B
B I
were O
investigated O
after O
intravenous O
administration O
of O
a O
dose O
of O
4 O
mg O
/ O
kg O
ginkgolide B
B I
. O

After O
intravenous O
administration O
, O
ginkgolide B
B I
in O
the O
original O
form O
was O
converted O
to O
its O
carboxylate B
form O
under O
simulated O
physiological O
conditions O
. O

In O
conclusion O
, O
the O
equilibrium O
existed O
between O
lactone B
of O
ginkgolide B
B I
and O
its O
carboxylate B
form O
in O
vivo O
at O
physiological O
pH O
, O
which O
suggested O
that O
more O
attention O
should O
be O
focused O
on O
the O
original O
and O
the O
ionization O
forms O
of O
ginkgolide B
B I
and O
the O
conversion O
of O
the O
lactone B
into O
carboxylate B
in O
vivo O
. O

In O
conclusion O
, O
the O
equilibrium O
existed O
between O
lactone B
of O
ginkgolide B
B I
and O
its O
carboxylate B
form O
in O
vivo O
at O
physiological O
pH O
, O
which O
suggested O
that O
more O
attention O
should O
be O
focused O
on O
the O
original O
and O
the O
ionization O
forms O
of O
ginkgolide B
B I
and O
the O
conversion O
of O
the O
lactone B
into O
carboxylate B
in O
vivo O
. O

The O
obtained O
results O
showed O
a O
higher O
ability O
of O
oligorutin O
fractions O
to O
reduce O
the O
genotoxicity O
induced O
by O
hydrogen B
peroxide I
compared O
with O
monomeric O
rutin B
. O

In O
this O
work O
we O
report O
on O
the O
preparation O
, O
characterization O
, O
and O
properties O
of O
a O
thermally O
treated O
lignin O
- O
derived O
, O
phenolic O
- O
rich O
fraction O
( O
PRF O
) O
of O
wood O
pyrolysis O
bio O
- O
oil O
obtained O
by O
ethyl B
acetate I
extraction O
. O

In O
this O
study O
, O
we O
investigated O
the O
antinociceptive O
effect O
of O
7 B
- I
methoxyflavone I
( O
7MF B
) O
in O
mice O
using O
the O
following O
tests O
: O
acetic B
acid I
- O
induced O
writhing O
, O
glutamate B
- O
and O
formalin B
- O
induced O
nociception O
and O
hotplate O
. O

As O
a O
means O
of O
utilizing O
the O
self O
- O
assembled O
HNSs O
for O
targeting O
controlled O
drug O
delivery O
, O
folic B
acid I
( O
FA O
) O
and O
rhodamine B
6G I
( O
Rh6G B
) O
were O
grafted O
onto O
compound O
1 O
to O
yield O
the O
FA B
- I
Rh6G I
- I
1 I
complex O
. O

As O
a O
means O
of O
utilizing O
the O
self O
- O
assembled O
HNSs O
for O
targeting O
controlled O
drug O
delivery O
, O
folic B
acid I
( O
FA O
) O
and O
rhodamine B
6G I
( O
Rh6G B
) O
were O
grafted O
onto O
compound O
1 O
to O
yield O
the O
FA B
- I
Rh6G I
- I
1 I
complex O
. O

Epoxieicosatrienoic B
acids I
( O
EETs B
) O
play O
a O
protective O
role O
against O
damaging O
processes O
in O
the O
kidney O
. O

Using O
this O
method O
, O
a O
series O
of O
substituted O
enol B
esters I
containing O
the O
cyclopentenyl B
motif O
were O
prepared O
in O
moderate O
to O
high O
yields O
. O

Form O
- O
stable O
resorbable O
networks O
are O
prepared O
by O
gamma O
irradiating O
trimethylene B
carbonate I
( O
TMC B
) O
- O
and O
epsilon B
- I
caprolactone I
( O
CL O
) O
- O
based O
( O
co O
) O
polymer O
films O
. O

Furthermore O
, O
methanol B
and O
ethanol B
are O
good O
nonsolvents O
, O
whereas O
other O
nonsolvents O
such O
as O
acetone B
, O
isopropyl B
alcohol I
, O
and O
acetonitrile B
, O
result O
in O
phase O
separation O
and O
visible O
precipitates O
. O

We O
found O
that O
atorvastatin B
withdrawal O
decreased O
levels O
of O
nitric B
oxide I
and O
mitochondrial O
superoxide B
dismutase O
activity O
, O
whereas O
increased O
NADPH B
oxidase O
activity O
and O
immunoreactivity O
for O
the O
protein O
nitration O
marker O
3 B
- I
nitrotyrosine I
in O
the O
cerebral O
cortex O
. O

The O
mainstay O
of O
stent O
thrombosis O
prevention O
remains O
dual O
anti O
- O
platelet O
therapy O
with O
acetylsalicylic B
acid I
and O
a O
platelet O
ADP B
- O
receptor O
blocker O
, O
traditionally O
clopidogrel B
. O

Inhibitory O
effect O
of O
dihydroartemisinin B
against O
phorbol B
ester I
- O
induced O
cyclooxygenase O
- O
2 O
expression O
in O
macrophages O
. O

Inhibitory O
effect O
of O
dihydroartemisinin B
against O
phorbol B
ester I
- O
induced O
cyclooxygenase O
- O
2 O
expression O
in O
macrophages O
. O

Low O
- O
dose O
bisphenol B
A I
and O
estrogen B
increase O
ventricular O
arrhythmias O
following O
ischemia O
- O
reperfusion O
in O
female O
rat O
hearts O
. O

Bisphenol B
A I
( O
BPA B
) O
is O
an O
environmental O
estrogenic O
endocrine O
disruptor O
that O
may O
have O
adverse O
health O
impacts O
on O
a O
range O
of O
tissue O
/ O
systems O
. O

We O
administered O
a O
mixture O
of O
AFCAs O
( O
Eritrosin B
, O
Ponceau B
4R I
, O
Allura B
Red I
AC I
, O
Sunset B
Yellow I
FCF I
, O
Tartrazin B
, O
Amaranth B
, O
Brilliant B
Blue I
, O
Azorubin B
and O
Indigotin B
) O
to O
female O
rats O
before O
and O
during O
gestation O
. O

We O
administered O
a O
mixture O
of O
AFCAs O
( O
Eritrosin B
, O
Ponceau B
4R I
, O
Allura B
Red I
AC I
, O
Sunset B
Yellow I
FCF I
, O
Tartrazin B
, O
Amaranth B
, O
Brilliant B
Blue I
, O
Azorubin B
and O
Indigotin B
) O
to O
female O
rats O
before O
and O
during O
gestation O
. O

Metallothionein O
1A O
polymorphisms O
may O
influence O
urine O
uric B
acid I
and O
N B
- I
acetyl I
- O
beta O
- O
d O
- O
glucosaminidase O
( O
NAG O
) O
excretion O
in O
chronic O
lead O
- O
exposed O
workers O
. O

The O
aim O
of O
the O
study O
was O
to O
investigate O
the O
association O
of O
blood O
lead O
levels O
, O
urinary O
uric B
acid I
( O
UA O
) O
and O
N B
- I
acetyl I
- O
beta O
- O
d O
- O
glucosaminidase O
( O
NAG O
) O
in O
chronic O
occupational O
lead O
- O
exposed O
workers O
, O
and O
to O
study O
whether O
the O
association O
was O
influenced O
by O
MT1A O
gene O
polymorphisms O
. O

Combined O
nano O
zinc B
oxide I
and O
titanium B
dioxide I
[ O
nano O
( O
ZnO B
- O
TiO B
( I
2 I
) I
) O
] O
has O
been O
reported O
first O
time O
for O
the O
synthesis O
of O
novel O
series O
of O
4 B
, I
5 I
, I
6 I
, I
7 I
- I
tetrahydro I
- I
6 I
- I
( I
( I
5 I
- I
substituted I
- I
1 I
, I
3 I
, I
4 I
- I
oxadiazol I
- I
2 I
- I
yl I
) I
methyl I
) I
thieno I
[ I
2 I
, I
3 I
- I
c I
] I
pyridine I
. O

Combined O
nano O
zinc B
oxide I
and O
titanium B
dioxide I
[ O
nano O
( O
ZnO B
- O
TiO B
( I
2 I
) I
) O
] O
has O
been O
reported O
first O
time O
for O
the O
synthesis O
of O
novel O
series O
of O
4 B
, I
5 I
, I
6 I
, I
7 I
- I
tetrahydro I
- I
6 I
- I
( I
( I
5 I
- I
substituted I
- I
1 I
, I
3 I
, I
4 I
- I
oxadiazol I
- I
2 I
- I
yl I
) I
methyl I
) I
thieno I
[ I
2 I
, I
3 I
- I
c I
] I
pyridine I
. O

Among O
the O
synthesized O
compounds O
, O
2 B
, I
6 I
dichlorophenyl I
analogue O
( O
7f O
) O
, O
4 B
fluorophenyl I
analogue O
( O
7k O
) O
and O
2 B
, I
6 I
dichlorophenyl I
analogue O
( O
7l O
) O
shows O
promising O
antibacterial O
as O
well O
as O
antifungal O
activity O
whereas O
thiophene B
substituted O
compound O
( O
7j O
) O
shows O
promising O
antibacterial O
activity O
. O

Hepatic O
and O
renal O
Bcrp O
transporter O
expression O
in O
mice O
treated O
with O
perfluorooctanoic B
acid I
. O

The O
current O
study O
investigated O
the O
regulation O
of O
hepatic O
and O
renal O
Bcrp O
mRNA O
and O
protein O
in O
mice O
treated O
with O
the O
PPAR O
alpha O
agonist O
perfluorooctanoic B
acid I
( O
PFOA B
) O
and O
the O
ability O
of O
PFOA B
to O
alter O
human O
BCRP O
function O
in O
vitro O
. O

Oseltamivir B
shows O
dose O
linear O
kinetics O
, O
and O
oseltamivir B
carboxylate I
has O
an O
elimination O
half O
- O
life O
( O
t O
( O
1 O
/ O
2 O
) O
beta O
) O
after O
oral O
administration O
in O
healthy O
individuals O
of O
approximately O
7 O
. O
7 O
hours O
. O

Oseltamivir B
carboxylate I
is O
eliminated O
primarily O
by O
tubular O
secretion O
, O
and O
both O
clearance O
and O
tissue O
distribution O
are O
reduced O
by O
probenecid B
. O

Then O
, O
by O
a O
dip O
- O
coating O
process O
, O
an O
ordered O
polyethylene B
glycol I
( O
PEG B
) O
polymer O
- O
dot O
array O
forms O
on O
the O
HDT B
- O
patterned O
gold O
substrate O
. O

Cell O
apoptosis O
was O
evaluated O
by O
annexin O
V O
/ O
propidium B
iodide I
staining O
, O
TUNEL O
, O
and O
reactive O
oxygen B
species O
generation O
analysis O
. O

A O
concise O
synthesis O
of O
pyrazole B
analogues O
of O
combretastatin B
A1 I
as O
potent O
anti O
- O
tubulin O
agents O
. O

Combretastatin B
A1 I
( O
CA1 B
) O
binds O
to O
the O
beta O
- O
subunit O
at O
the O
colchicine B
binding O
site O
of O
tubulin O
and O
inhibits O
polymerization O
. O

It O
has O
been O
shown O
to O
be O
at O
least O
tenfold O
more O
potent O
than O
combretastatin B
A4 I
( O
CA4 B
) O
in O
terms O
of O
vascular O
shutdown O
, O
which O
correlates O
with O
its O
metabolism O
to O
reactive O
ortho B
- I
quinone I
species O
that O
are O
assumed O
to O
be O
directly O
cytotoxic O
in O
tumor O
cells O
. O

Metal O
- O
ligand O
coordination O
and O
hydrophobic O
interaction O
are O
two O
significant O
driving O
forces O
in O
the O
aggregation O
of O
mixtures O
of O
M O
( O
n O
+ O
) O
surfactants O
and O
alkyldimethylamine B
oxide I
( O
CnDMAO B
) O
in O
aqueous O
solutions O
. O

Polymer O
/ O
silica B
composite O
films O
, O
stable O
to O
calcination O
, O
were O
produced O
using O
catanionic O
surfactant O
mixtures O
( O
hexadecyltrimethylam B
bromide I
( O
CTAB B
) O
and O
sodium B
dodecyl I
sulfate I
( O
SDS B
) O
) O
and O
polymers O
( O
polyethylenimine B
( O
PEI B
) O
or O
polyacrylamide B
( O
PAAm B
) O
) O
at O
the O
air O
/ O
water O
interface O
. O

A O
critical O
role O
in O
organismal O
homeostatic O
functions O
is O
played O
by O
the O
aryl B
hydrocarbon I
receptor O
( O
AHR O
) O
complex O
, O
which O
senses O
environmental O
and O
endogenous O
compounds O
, O
influences O
metabolic O
responses O
controlling O
phase O
I O
/ O
II O
gene O
expression O
, O
and O
modulates O
vital O
phenomena O
such O
as O
development O
, O
inflammation O
and O
adaptive O
immunity O
. O

GSK2251052 B
and O
its O
major O
metabolite O
M3 O
, O
which O
resulted O
from O
oxidation O
of O
the O
propanol B
side O
chain O
to O
the O
corresponding O
carboxylic B
acid I
, O
comprised O
the O
majority O
of O
the O
plasma O
radioactivity O
, O
37 O
and O
53 O
% O
of O
the O
area O
under O
the O
plasma O
versus O
time O
concentration O
curve O
from O
time O
zero O
to O
infinity O
, O
respectively O
. O

F B
- I
Ti I
- O
MWW O
was O
post O
- O
synthesized O
by O
implanting O
fluorine B
species O
into O
a O
Ti B
- O
MWW O
framework O
through O
an O
acid O
treatment O
process O
in O
the O
presence O
of O
ammonium B
fluoride I
. O

The O
negative O
effect O
of O
SiO4 B
/ O
2F B
( I
- I
) I
units O
in O
F B
- I
Ti I
- O
MWW O
was O
eliminated O
selectively O
by O
convenient O
anion O
- O
exchange O
with O
various O
alkali B
chlorides I
. O

The O
first O
method O
analyzed O
seven O
marker O
compounds O
simultaneously O
on O
a O
reversed O
- O
phase O
column O
, O
while O
the O
second O
method O
analyzed O
a O
single O
marker O
compound O
, O
conduritol B
F I
, O
which O
exists O
only O
in O
C O
. O
wilfordii O
, O
on O
a O
Si B
- O
column O
. O

, O
sunitinib B
, O
vandetanib B
) O
and O
various O
inhibitors O
of O
other O
pathways O
and O
targets O
, O
including O
phosphatidylinositol B
3 O
' O
kinase O
( O
PI3K O
) O
/ O
AKT O
/ O
mammalian O
target O
of O
rapamycin B
( O
mTOR O
) O
, O
MET O
and O
insulin O
- O
like O
growth O
factor O
receptor O
( O
IGF O
- O
1R O
) O
. O

Serine B
qua O
non O
: O
Substitution O
of O
the O
extended O
Ser13 B
in O
the O
core O
peptide O
of O
nosiheptide B
by O
analogous O
amino B
acids I
prevented O
enamide B
dealkylation O
of O
the O
terminal O
residue O
for O
nosiheptide B
maturation O
. O

Scanning O
force O
microscopy O
, O
circular O
dichroism O
and O
thioflavin B
T I
fluorescence O
experiments O
showed O
that O
carnosine B
does O
not O
modify O
the O
conformational O
features O
of O
A O
beta O
42 O
but O
nonetheless O
inhibits O
amyloid O
growth O
. O

Oligostilbenoids O
( O
e O
. O
g O
. O
, O
ampelopsin B
F I
, O
viniferin B
, O
pallidol B
) O
result O
from O
homogeneous O
or O
heterogeneous O
coupling O
of O
monomeric O
stilbenoid B
units O
, O
leading O
to O
various O
chemical O
structures O
. O

The O
former O
appears O
more O
likely O
, O
thermodynamics O
and O
kinetics O
being O
in O
perfect O
agreement O
with O
the O
experimental O
1 O
: O
2 O
ratio O
obtained O
for O
ampelopsin B
F I
: O
pallidol B
analogues O
, O
respectively O
. O

It O
has O
been O
known O
that O
the O
addition O
of O
bile B
salts I
to O
lecithin O
organosols O
induces O
the O
formation O
of O
reverse O
wormlike O
micelles O
and O
that O
the O
worms O
are O
similar O
to O
long O
polymer O
chains O
that O
entangle O
each O
other O
to O
form O
viscoelastic O
solutions O
. O

In O
this O
study O
, O
we O
further O
investigated O
the O
effects O
of O
different O
bile B
salts I
and O
bile B
acids I
on O
the O
growth O
of O
lecithin O
reverse O
worms O
in O
cyclohexane B
and O
n B
- I
decane I
. O

In O
this O
study O
, O
we O
further O
investigated O
the O
effects O
of O
different O
bile B
salts I
and O
bile B
acids I
on O
the O
growth O
of O
lecithin O
reverse O
worms O
in O
cyclohexane B
and O
n B
- I
decane I
. O

All O
of O
the O
bile B
salts I
can O
transform O
the O
originally O
spherical O
lecithin O
reverse O
micelles O
into O
wormlike O
micelles O
and O
their O
rheological O
behaviors O
can O
be O
described O
by O
the O
single O
- O
relaxation O
- O
time O
Maxwell O
model O
. O

In O
contrast O
, O
before O
phase O
separation O
, O
bile B
acids I
can O
induce O
only O
short O
cylindrical O
micelles O
that O
are O
not O
long O
enough O
to O
impart O
viscoelasticity O
. O

Three O
conserved O
amino B
acids I
( O
Y658 O
, O
T780 O
, O
and O
S808 O
) O
and O
two O
nonconserved O
residues O
( O
P654 O
and O
A809 O
) O
were O
identified O
as O
key O
determinants O
of O
PAM O
activity O
. O

Protective O
effect O
of O
butylated B
hydroxytoluene I
on O
ferric B
nitrilotriacetate I
induced O
hepatotoxicity O
and O
oxidative O
stress O
in O
mice O
. O

Protective O
effect O
of O
butylated B
hydroxytoluene I
on O
ferric B
nitrilotriacetate I
induced O
hepatotoxicity O
and O
oxidative O
stress O
in O
mice O
. O

The O
present O
study O
was O
undertaken O
to O
evaluate O
the O
possible O
ameliorating O
effect O
of O
butylated B
hydroxyl I
toluene I
( O
BHT B
) O
, O
associated O
with O
ferric B
nitrilotriacetate I
( O
Fe B
- I
NTA I
) O
- O
induced O
oxidative O
stress O
and O
liver O
injury O
in O
mice O
. O

The O
mobile O
phase O
was O
methanol B
- O
0 O
. O
1 O
% O
phosphoric B
acid I
solution O
( O
adjusted O
pH O
to O
2 O
. O
3 O
) O
( O
80 O
: O
20 O
, O
v O
/ O
v O
) O
; O
wavelength O
of O
257nm O
and O
mobile O
phase O
flow O
rate O
of O
1 O
. O
0 O
mL O
/ O
min O
was O
utilized O
for O
the O
quantitative O
analysis O
. O

A O
C18 O
analytical O
column O
and O
mobile O
phase O
composed O
of O
acetonitrile B
and O
0 O
. O
02 O
% O
aqueous O
phosphoric B
acid I
were O
used O
for O
the O
chromatographic O
separation O
with O
DAD O
detection O
. O

In O
this O
study O
, O
the O
ethanolic O
extract O
obtained O
from O
piqui O
a O
pulp O
was O
assessed O
for O
genotoxicity O
and O
oxidative O
stress O
by O
employing O
the O
micronucleus O
test O
in O
bone O
marrow O
and O
peripheral O
blood O
cells O
in O
addition O
to O
comet O
, O
thiobarbituric B
- I
acid I
- O
reactive O
substances O
( O
TBARS O
) O
, O
and O
reduced B
glutathione I
assays O
in O
the O
liver O
, O
kidney O
, O
and O
heart O
. O

Almiramide B
C I
is O
a O
marine O
natural O
product O
with O
low O
micromolar O
activity O
against O
Leishmania O
donovani O
, O
the O
causative O
agent O
of O
leishmaniasis O
. O

We O
have O
now O
shown O
that O
almiramide B
C I
is O
also O
active O
against O
the O
related O
parasite O
Trypanosoma O
brucei O
, O
the O
causative O
agent O
of O
human O
African O
trypanosomiasis O
. O

Synthesis O
of O
new O
derivatives O
of O
pyrido B
[ I
2 I
, I
3 I
- I
d I
] I
[ I
1 I
, I
2 I
, I
4 I
] I
triazolo I
[ I
4 I
, I
3 I
- I
a I
] I
pyrimidin I
- I
5 I
- I
one I
via O
reaction O
of O
7 B
- I
( I
4 I
- I
bromophenyl I
) I
- I
1 I
, I
2 I
- I
dihydro I
- I
5 I
- I
( I
4 I
- I
fluorophenyl I
) I
- I
2 I
- I
thioxopyrido I
[ I
2 I
, I
3 I
- I
d I
] I
pyrimidin I
- I
4 I
( I
3H I
) I
- I
one I
with O
hydrazonoyl B
chlorides I
or O
reaction O
of O
2 B
- I
hydrazino I
- I

Here O
, O
we O
developed O
a O
straightforward O
, O
sensitive O
, O
and O
quantitative O
assay O
for O
the O
colorimetric O
and O
spectroscopic O
detection O
of O
various O
ROS O
and O
RNS O
such O
as O
H2O2 B
, O
. B
OH I
, O
( B
- I
) I
OCl I
, O
NO B
. I
, O
and O
O2 B
( I
- I
) I
using O
glutathione B
- O
modified O
gold O
nanoparticles O
( O
GSH B
- O
AuNPs O
) O
. O

Here O
, O
we O
developed O
a O
straightforward O
, O
sensitive O
, O
and O
quantitative O
assay O
for O
the O
colorimetric O
and O
spectroscopic O
detection O
of O
various O
ROS O
and O
RNS O
such O
as O
H2O2 B
, O
. B
OH I
, O
( B
- I
) I
OCl I
, O
NO B
. I
, O
and O
O2 B
( I
- I
) I
using O
glutathione B
- O
modified O
gold O
nanoparticles O
( O
GSH B
- O
AuNPs O
) O
. O

A O
basic O
principle O
here O
is O
that O
the O
GSHs B
on O
the O
AuNP O
surface O
can O
be O
readily O
detached O
via O
the O
formation O
of O
glutathione B
disulfides I
upon O
the O
addition O
of O
ROS O
and O
RNS O
, O
and O
destabilized O
particles O
can O
aggregate O
to O
generate O
the O
plasmonic O
couplings O
between O
plasmonic O
AuNPs O
that O
trigger O
the O
red O
shift O
in O
UV O
- O
vis O
spectrum O
and O
solution O
color O
change O
. O

Ropion B
( O
R O
) O
intravenous O
( O
flurbiprofen B
axetil I
: O
Ropion B
( O
R O
) O
) O
served O
as O
the O
model O
emulsion O
formulation O
. O

A O
binary O
mixture O
of O
Ropion B
( O
R O
) O
and O
normal O
saline O
( O
NS O
) O
, O
and O
a O
ternary O
admixture O
of O
Ropion B
( O
R O
) O
, O
NS O
, O
and O
Gaster B
( O
R O
) O
injection O
( O
famotidine B
: O
Gaster B
( O
R O
) O
) O
or O
Primperan B
( O
R O
) O
injection O
( O
metoclopramide B
hydrochloride I
: O
Primperan B
( O
R O
) O
) O
were O
prepared O
and O
the O
change O
in O
emulsion O
particle O
state O
was O
analyzed O
using O
FPIA O
under O
in O
situ O
condition O
. O

The O
effect O
of O
storage O
on O
pH O
change O
and O
the O
chemical O
stability O
of O
flurbiprofen B
axetil I
were O
also O
investigated O
. O

The O
decomposition O
of O
flurbiprofen B
axetil I
due O
to O
incompatibility O
was O
not O
observed O
in O
all O
systems O
. O

Ca2 B
+ I
- O
dependent O
protein O
kinase11 O
and O
24 O
modulate O
the O
activity O
of O
the O
inward O
rectifying O
K B
+ I
channels O
in O
Arabidopsis O
pollen O
tubes O
. O

Ca2 B
+ I
- O
dependent O
protein O
kinase11 O
and O
24 O
modulate O
the O
activity O
of O
the O
inward O
rectifying O
K B
+ I
channels O
in O
Arabidopsis O
pollen O
tubes O
. O

Herein O
we O
report O
comparative O
binding O
energy O
( O
COMBINE O
) O
analyses O
to O
derive O
quantitative O
structure O
- O
activity O
relationship O
( O
QSAR O
) O
models O
that O
help O
rationalize O
the O
determinants O
of O
binding O
affinity O
for O
inhibitors O
of O
type O
II O
dehydroquinase O
( O
DHQ2 O
) O
, O
the O
third O
enzyme O
of O
the O
shikimic B
acid I
pathway O
. O

First O
, O
a O
porous O
Si B
sample O
is O
prepared O
by O
electrochemical O
etch O
and O
then O
it O
is O
mildly O
oxidized O
, O
which O
places O
a O
thin O
layer O
of O
silicon B
oxide I
at O
the O
surface O
. O

The O
sample O
is O
then O
immersed O
in O
aqueous O
solution O
containing O
hydrogen B
fluoride I
( O
HF B
) O
, O
which O
serves O
as O
the O
reactive O
liquid O
. O

As O
a O
side O
chain O
, O
Dopa B
is O
capable O
of O
strong O
bidentate O
interactions O
with O
a O
variety O
of O
surfaces O
, O
including O
many O
minerals O
and O
metal B
oxides I
. O

In O
the O
type O
2 O
diabetic O
heart O
, O
substrate O
metabolism O
is O
shifted O
from O
glucose B
utilisation O
to O
fatty B
acid I
oxidation O
, O
resulting O
in O
metabolic O
inflexibility O
and O
cardiac O
dysfunction O
. O

The O
ischaemic O
heart O
also O
loses O
its O
metabolic O
flexibility O
and O
can O
switch O
to O
glucose B
or O
fatty B
acid I
oxidation O
as O
its O
preferential O
state O
, O
which O
may O
deteriorate O
cardiac O
function O
even O
further O
in O
case O
of O
type O
2 O
diabetes O
mellitus O
. O
Recent O
experimental O
studies O
suggest O
that O
the O
cardioprotective O
properties O
of O
volatile O
anaesthetics O
partly O
rely O
on O
changing O
myocardial O
substrate O
metabolism O
. O

Selective O
COX O
- O
2 O
inhibitors O
( O
COXib O
) O
belonging O
to O
the O
class O
of O
diaryl B
heterocycles I
( O
e O
. O
g O
. O
, O
celecoxib B
, O
rofecoxib B
, O
etc O
. O
) O
, O
are O
devoid O
of O
the O
undesirable O
effects O
due O
to O
their O
capacity O
to O
inhibit O
selectively O
inducible O
( O
COX O
- O
2 O
) O
, O
responsible O
for O
inflammatory O
effects O
but O
not O
constitutive O
cyclooxygenase O
- O
1 O
( O
COX O
- O
1 O
) O
( O
COX O
) O
; O
responsible O
for O
cytoprotective O
effects O
on O
gastric O
mucosa O
. O

Human O
diets O
contain O
sterol B
oxidation O
products O
that O
can O
induce O
cytotoxic O
effects O
, O
mainly O
caused O
by O
cholesterol B
oxides I
. O

However O
, O
phytosterol B
oxides I
effects O
have O
been O
less O
extensively O
investigated O
. O

Protein O
nitration O
promotes O
inducible O
nitric B
oxide I
synthase O
transcription O
mediated O
by O
NF O
- O
kappa O
B O
in O
high O
glucose B
- O
stimulated O
human O
lens O
epithelial O
cells O
. O

Although O
an O
important O
event O
in O
hyperglycaemia O
- O
induced O
oxidative O
stress O
is O
the O
nuclear O
factor O
- O
kappa O
b O
( O
NF O
- O
kappa O
B O
) O
- O
activated O
inducible O
nitric B
oxide I
synthase O
( O
iNOS O
) O
expression O
, O
the O
underlying O
mechanism O
is O
not O
fully O
characterized O
. O

The O
improvement O
of O
object O
recognition O
memory O
induced O
by O
NPS O
could O
be O
blocked O
by O
the O
selective O
NPSR O
antagonist O
SHA B
68 I
, O
indicating O
pharmacological O
specificity O
. O

Recently O
, O
it O
has O
been O
proposed O
to O
couple O
an O
enzymatic O
activation O
step O
based O
on O
horseradish O
peroxidase O
( O
HRP O
) O
/ O
hydrogen B
peroxide I
to O
such O
peptide O
reactivity O
assays O
. O

When O
2M4MP B
was O
incubated O
with O
HRP O
/ O
H2O2 B
in O
a O
mixture O
PBS O
( O
pH O
7 O
. O
4 O
, O
0 O
. O
1M O
) O
/ O
acetonitrile B
2 O
: O
1 O
, O
two O
main O
products O
were O
formed O
deriving O
from O
the O
formation O
of O
a O
quinone O
methide O
2M4MQ B
subsequently O
trapped O
by O
either O
H2O2 B
or O
H2O B
to O
form O
a O
benzylic B
hydroperoxide I
or O
alcohol B
, O
respectively O
. O

Our O
analysis O
suggests O
that O
fm O
is O
the O
major O
determinant O
of O
total O
drug O
M O
/ O
P O
ratio O
for O
amine B
, O
alcohol B
, O
N B
- I
and I
S I
- I
oxide I
, O
and O
carboxylic B
acid I
metabolites O
. O

In O
some O
cases O
, O
active O
transport O
plays O
an O
important O
role O
in O
this O
process O
( O
e O
. O
g O
. O
, O
carboxylic B
acid I
metabolites O
) O
. O

pH O
- O
sensitive O
nanocargo O
based O
on O
smart O
polymer O
functionalized O
graphene B
oxide I
for O
site O
- O
specific O
drug O
delivery O
. O

Graphene B
oxide I
( O
GO O
) O
was O
functionalized O
covalently O
with O
pH O
- O
sensitive O
poly B
( I
2 I
- I
( I
diethylamino I
) I
ethyl I
methacrylate I
) I
( O
PDEA B
) O
by O
surface O
- O
initiated O
in O
situ O
atom O
transfer O
radical O
polymerization O
. O

Unusual O
amino B
acids I
and O
monofluoroacetate B
from O
Dichapetalum O
michelsonii O
( O
Umutambasha O
) O
, O
a O
toxic O
plant O
from O
Rwanda O
. O

Three O
free O
unusual O
amino B
acids I
, O
named O
N B
- I
methyl I
- I
alpha I
- I
alanine I
, O
N B
- I
methyl I
- I
beta I
- I
alanine I
, O
and O
2 B
, I
7 I
- I
diaminooctan I
- I
1 I
, I
8 I
- I
dioic I
acid I
, O
described O
for O
the O
first O
time O
in O
a O
plant O
, O
and O
known O
trigonelline B
were O
also O
isolated O
from O
the O
stem O
bark O
of O
D O
. O
michelsonii O
. O

These O
unusual O
amino B
acids I
were O
detected O
by O
a O
fast O
, O
reliable O
TLC O
analysis O
in O
all O
our O
batches O
of O
Umutambasha O
, O
suggesting O
that O
they O
could O
be O
used O
for O
identification O
purposes O
in O
case O
of O
human O
or O
livestock O
intoxications O
. O

The O
synthesis O
involves O
three O
major O
steps O
: O
1 O
) O
preparation O
of O
Au B
- I
Ag I
alloyed O
nanocages O
using O
a O
galvanic O
replacement O
reaction O
between O
Ag B
nanocubes O
and O
HAuCl4 B
; O
2 O
) O
deposition O
of O
thin O
layers O
of O
pure O
Au B
onto O
the O
surfaces O
of O
the O
nanocages O
by O
reducing O
HAuCl4 B
with O
ascorbic B
acid I
, O
and O
; O
3 O
) O
formation O
of O
Au B
cubic O
nanoframes O
through O
a O
dealloying O
process O
with O
HAuCl4 B
. O

Prenatal O
bisphenol B
a I
exposure O
alters O
sex O
- O
specific O
estrogen B
receptor O
expression O
in O
the O
neonatal O
rat O
hypothalamus O
and O
amygdala O
. O

Bisphenol B
A I
( O
BPA B
) O
exposure O
is O
ubiquitous O
, O
and O
in O
laboratory O
animals O
, O
early O
- O
life O
BPA B
exposure O
has O
been O
shown O
to O
alter O
sex O
- O
specific O
neural O
organization O
, O
neuroendocrine O
physiology O
, O
and O
behavior O
. O

Sprague O
Dawley O
rats O
were O
mated O
and O
gavaged O
on O
gestational O
days O
( O
GDs O
) O
6 O
- O
21 O
with O
vehicle O
, O
2 O
. O
5 O
or O
25 O
mu O
g O
/ O
kg O
bw O
/ O
day O
BPA B
, O
or O
5 O
or O
10 O
mu O
g O
/ O
kg O
bw O
/ O
day O
ethinyl B
estradiol I
. O

Cellulose O
- O
ethylenediaminetetra B
Acid I
conjugates O
protect O
Mammalian O
cells O
from O
bacterial O
cells O
. O

Cellulose O
- O
ethylenediaminetetra B
acid I
( O
EDTA B
) O
conjugates O
were O
synthesized O
by O
the O
esterification O
of O
cellulose O
with O
ethylenediaminetetra B
dianhydride I
( O
EDTAD B
) O
. O

Cellulose O
- O
ethylenediaminetetra B
acid I
( O
EDTA B
) O
conjugates O
were O
synthesized O
by O
the O
esterification O
of O
cellulose O
with O
ethylenediaminetetra B
dianhydride I
( O
EDTAD B
) O
. O

Isolation O
of O
thermally O
stable O
cellulose O
nanocrystals O
by O
phosphoric B
Acid I
hydrolysis O
. O

It O
is O
shown O
here O
that O
on O
account O
of O
ionic O
repulsion O
between O
charged O
surface O
groups O
, O
slightly O
phosphorylated O
CNCs O
( O
P O
- O
CNCs O
, O
average O
dimensions O
31 O
+ O
/ O
- O
14 O
x O
316 O
+ O
/ O
- O
127 O
nm O
, O
surface O
charge O
density O
= O
10 O
. O
8 O
+ O
/ O
- O
2 O
. O
7 O
mmol O
/ O
kg O
cellulose O
) O
, O
prepared O
by O
controlled O
hydrolysis O
of O
cotton O
with O
phosphoric B
acid I
, O
are O
readily O
dispersible O
and O
form O
stable O
dispersions O
in O
polar O
solvents O
such O
as O
water O
, O
dimethyl B
sulfoxide I
, O
and O
dimethylformamide B
. O

It O
is O
shown O
here O
that O
on O
account O
of O
ionic O
repulsion O
between O
charged O
surface O
groups O
, O
slightly O
phosphorylated O
CNCs O
( O
P O
- O
CNCs O
, O
average O
dimensions O
31 O
+ O
/ O
- O
14 O
x O
316 O
+ O
/ O
- O
127 O
nm O
, O
surface O
charge O
density O
= O
10 O
. O
8 O
+ O
/ O
- O
2 O
. O
7 O
mmol O
/ O
kg O
cellulose O
) O
, O
prepared O
by O
controlled O
hydrolysis O
of O
cotton O
with O
phosphoric B
acid I
, O
are O
readily O
dispersible O
and O
form O
stable O
dispersions O
in O
polar O
solvents O
such O
as O
water O
, O
dimethyl B
sulfoxide I
, O
and O
dimethylformamide B
. O

Nanocomposites O
of O
an O
ethylene B
oxide I
- O
epichlorohydrin B
copolymer O
and O
H O
- O
CNCs O
, O
S O
- O
CNCs O
, O
and O
P O
- O
CNCs O
were O
prepared O
, O
and O
their O
mechanical O
properties O
were O
studied O
by O
dynamic O
mechanical O
thermal O
analysis O
. O

Electronic O
transitions O
of O
protonated O
and O
deprotonated O
amino B
acids I
in O
aqueous O
solution O
in O
the O
region O
145 O
- O
300 O
nm O
studied O
by O
attenuated O
total O
reflection O
far O
- O
ultraviolet O
spectroscopy O
. O

The O
electronic O
transitions O
of O
20 O
naturally O
occurring O
amino B
acids I
in O
aqueous O
solution O
were O
studied O
with O
attenuated O
total O
reflection O
far O
- O
ultraviolet O
( O
ATR O
- O
FUV O
) O
spectroscopy O
in O
the O
region O
from O
145 O
to O
300 O
nm O
. O

From O
the O
measured O
ATR O
spectra O
of O
sample O
solutions O
, O
the O
FUV O
absorption O
spectra O
attributed O
to O
the O
amino B
acids I
were O
separated O
from O
the O
intense O
solvent O
absorption O
by O
using O
a O
modified O
Kramers O
- O
Kronig O
transformation O
method O
. O

The O
FUV O
absorption O
spectra O
of O
the O
amino B
acids I
reflect O
the O
protonation O
states O
of O
the O
backbone O
and O
side O
- O
chain O
structures O
. O

The O
observed O
spectra O
were O
compared O
mostly O
with O
the O
electronic O
transition O
studies O
of O
the O
molecular O
fragments O
of O
the O
amino B
acids I
in O
gas O
phase O
. O

The O
FUV O
spectra O
of O
the O
amino B
acids I
exhibited O
the O
intra O
- O
and O
intermolecular O
electronic O
interactions O
of O
the O
solute O
- O
solute O
as O
well O
as O
the O
solute O
- O
solvent O
, O
and O
those O
are O
essential O
factors O
to O
elucidate O
UV O
photochemical O
processes O
of O
the O
amino B
acids I
in O
aqueous O
solution O
. O

The O
FUV O
spectra O
of O
the O
amino B
acids I
exhibited O
the O
intra O
- O
and O
intermolecular O
electronic O
interactions O
of O
the O
solute O
- O
solute O
as O
well O
as O
the O
solute O
- O
solvent O
, O
and O
those O
are O
essential O
factors O
to O
elucidate O
UV O
photochemical O
processes O
of O
the O
amino B
acids I
in O
aqueous O
solution O
. O

Studies O
of O
human O
renal O
histopathology O
and O
clinical O
diagnoses O
indicated O
that O
melamine B
- O
related O
obstructive O
nephropathy O
derives O
from O
melamine B
precipitation O
in O
the O
lower O
urinary O
tract O
, O
with O
stones O
that O
are O
thought O
to O
be O
melamine B
- O
uric B
acid I
complexes O
. O

Although O
the O
transfection O
efficiency O
is O
lower O
than O
that O
of O
the O
commercially O
available O
transfection O
agent O
Lipofectamine B
2000 I
, O
the O
R60 O
L20 O
vesicles O
are O
able O
to O
achieve O
transfection O
with O
significantly O
lower O
cytotoxicity O
and O
immunogenicity O
. O

Buffer O
- O
Stable O
Chitosan O
- O
Polyglutamic B
Acid I
Hybrid O
Nanoparticles O
for O
Biomedical O
Applications O
. O

Buffer O
stability O
is O
achieved O
by O
introducing O
polyglutamic B
acid I
to O
chitosan O
. O

Synthesis O
of O
mixed O
ceramic O
Mg B
( I
x I
) I
Zn I
( I
1 I
- I
x I
) I
O I
nanofibers O
via O
Mg2 B
+ I
doping O
using O
sol O
- O
gel O
electrospinning O
. O

Following O
an O
appropriate O
aqueous O
solution O
preparation O
of O
magnesium B
acetate I
( O
MgAc B
) O
and O
zinc B
acetate I
( O
ZnAc B
) O
with O
poly B
( I
vinyl I
alcohol I
) I
( O
PVA B
) O
, O
electrospinning O
is O
performed O
and O
then O
as O
- O
spun O
nanofibers O
are O
calcined O
in O
an O
air O
atmosphere O
at O
600 O
degrees O
C O
for O
3 O
h O
. O

Fengycin B
C I
Produced O
by O
Bacillus O
subtilis O
EA O
- O
CB0015 O
. O

The O
active O
compounds O
were O
purified O
by O
solid O
- O
phase O
extraction O
and O
HPLC O
, O
and O
their O
primary O
structures O
determined O
using O
mass O
spectrometry O
and O
amino B
acid I
analysis O
. O

A O
new O
fengycin B
isoform O
, O
fengycin B
C I
, O
with O
the O
amino B
acid I
sequence O
Glu B
- I
Orn I
- I
Tyr I
- I
Thr I
- I
Glu I
- I
Val I
- I
Pro I
- I
Gln I
- I
Thr I
- I
Ile I
was O
isolated O
. O

A O
new O
fengycin B
isoform O
, O
fengycin B
C I
, O
with O
the O
amino B
acid I
sequence O
Glu B
- I
Orn I
- I
Tyr I
- I
Thr I
- I
Glu I
- I
Val I
- I
Pro I
- I
Gln I
- I
Thr I
- I
Ile I
was O
isolated O
. O

The O
peptidic O
moiety O
differs O
from O
fengycin B
B I
at O
position O
9 O
and O
from O
fengycin B
A I
at O
positions O
6 O
and O
9 O
. O

The O
peptidic O
moiety O
differs O
from O
fengycin B
B I
at O
position O
9 O
and O
from O
fengycin B
A I
at O
positions O
6 O
and O
9 O
. O

The O
C B
- O
terminal O
residue O
of O
the O
peptidic O
moiety O
is O
linked O
to O
the O
tyrosine B
residue O
at O
position O
3 O
, O
forming O
the O
branching O
point O
of O
the O
acyl B
peptide O
and O
the O
eight O
- O
membered O
cyclic B
lactone I
. O

A O
new O
halimane B
diterpenoid I
, O
13 B
- I
hydroxy I
- I
5 I
( I
10 I
) I
, I
14 I
- I
halimadien I
- I
6 I
- I
one I
( O
1 O
) O
and O
two O
new O
labdane B
diterpenoids I
, O
6 B
alpha I
, I
7 I
alpha I
- I
diacetoxy I
- I
13 I
- I
hydroxy I
- I
8 I
( I
9 I
) I
, I
14 I
- I
labdadien I
( O
2 O
) O
and O
9 B
- I
hydroxy I
- I
13 I
( I
14 I
) I
- I
labden I
- I
15 I
, I
16 I
- I
olide I
( O
3 O
) O
, O
were O
isolated O
for O
the O
first O
time O
, O
along O
with O
fifteen O
known O
compounds O
, O
from O
the O
hexane B
soluble O
fraction O
of O
methanolic O
extract O
of O

A O
new O
halimane B
diterpenoid I
, O
13 B
- I
hydroxy I
- I
5 I
( I
10 I
) I
, I
14 I
- I
halimadien I
- I
6 I
- I
one I
( O
1 O
) O
and O
two O
new O
labdane B
diterpenoids I
, O
6 B
alpha I
, I
7 I
alpha I
- I
diacetoxy I
- I
13 I
- I
hydroxy I
- I
8 I
( I
9 I
) I
, I
14 I
- I
labdadien I
( O
2 O
) O
and O
9 B
- I
hydroxy I
- I
13 I
( I
14 I
) I
- I
labden I
- I
15 I
, I
16 I
- I
olide I
( O
3 O
) O
, O
were O
isolated O
for O
the O
first O
time O
, O
along O
with O
fifteen O
known O
compounds O
, O
from O
the O
hexane B
soluble O
fraction O
of O
methanolic O
extract O
of O

Using O
a O
recombinant O
phospholipase O
- O
D O
from O
the O
venom O
gland O
of O
L O
. O
intermedia O
( O
LiRecDT1 O
) O
in O
phospholipid O
- O
degrading O
kinetic O
experiments O
, O
we O
determined O
that O
this O
phospholipase O
- O
D O
mainly O
hydrolyzes O
synthetic O
sphingomyelin B
in O
a O
time O
- O
dependent O
manner O
, O
generating O
ceramide B
1 I
- I
phosphate I
plus O
choline B
, O
as O
well O
as O
lysophosphatidylchol B
, O
generating O
lysophosphatidic B
acid I
plus O
choline B
, O
but O
exhibits O
little O
activity O
against O

Base O
amino B
acid I
lysine B
residues O
play O
an O
important O
role O
in O
regulation O
of O
nuclear O
receptors O
[ O
e O
. O
g O
. O
, O
farnesyl B
X O
receptor O
( O
FXR O
) O
] O
, O
leading O
to O
enhanced O
or O
suppressed O
biologic O
activity O
. O

Results O
demonstrated O
that O
K122R O
, O
K210R O
, O
K339R O
, O
and O
K460R O
mutants O
of O
hFXR O
significantly O
impaired O
target O
gene O
[ O
organic O
solute O
transporter O
alpha O
/ O
beta O
and O
bile B
salt I
export O
pump O
( O
BSEP O
) O
] O
promoter O
reporter O
activity O
in O
a O
ligand O
- O
dependent O
fashion O
. O

Homocysteic B
acid I
was O
elevated O
in O
hippocampus O
and O
NAC O
by O
repeated O
MAP B
administration O
. O

Tricarboxylic B
acid I
cycle O
intermediate O
products O
, O
such O
as O
alpha B
- I
ketoglutarate I
, O
succinate B
, O
citrate B
and O
the O
methionine B
significantly O
decreased O
in O
above O
three O
brain O
regions O
after O
MAP B
administration O
; O
however O
, O
ADP B
decreased O
in O
hippocampus O
. O

In O
this O
phase O
IIb O
clinical O
trial O
, O
258 O
patients O
with O
type O
2 O
diabetes O
completed O
a O
12 O
- O
week O
protocol O
with O
50 O
, O
100 O
, O
or O
150 O
mg O
of O
MSDC B
- I
0160 I
( O
an O
mTOT O
modulator O
) O
, O
45 O
mg O
pioglitazone B
HCl I
( O
a O
PPAR O
- O
gamma O
agonist O
) O
, O
or O
a O
placebo O
. O

Subsequently O
, O
zinc B
oxide I
and O
alumina B
ALD O
precursors O
are O
shown O
to O
preferentially O
react O
with O
the O
functional O
moieties O
of O
PCDA B
, O
resulting O
in O
templated O
oxide B
nanostructures O
. O

Isolation O
of O
Ciliatamide B
D I
from O
a O
Marine O
Sponge O
Stelletta O
sp O
. O
and O
a O
Reinvestigation O
of O
the O
Configuration O
of O
Ciliatamide B
A I
. O

Isolation O
of O
Ciliatamide B
D I
from O
a O
Marine O
Sponge O
Stelletta O
sp O
. O
and O
a O
Reinvestigation O
of O
the O
Configuration O
of O
Ciliatamide B
A I
. O

A O
new O
lipopeptide O
, O
ciliatamide B
D I
( O
1 O
) O
, O
was O
isolated O
from O
a O
marine O
sponge O
Stelletta O
sp O
. O
, O
collected O
at O
Oshimashinsone O
, O
together O
with O
the O
known O
compound O
ciliatamide B
A I
( O
2 O
) O
. O

A O
new O
lipopeptide O
, O
ciliatamide B
D I
( O
1 O
) O
, O
was O
isolated O
from O
a O
marine O
sponge O
Stelletta O
sp O
. O
, O
collected O
at O
Oshimashinsone O
, O
together O
with O
the O
known O
compound O
ciliatamide B
A I
( O
2 O
) O
. O

Ciliatamide B
D I
( O
1 O
) O
is O
a O
congener O
of O
2 O
, O
in O
which O
N B
- I
Me I
- I
Phe I
is O
replaced O
by O
N B
- I
Me I
- I
Met I
( I
O I
) I
. O

Marfey O
' O
s O
analysis O
of O
the O
acid O
hydrolysate O
of O
1 O
demonstrated O
that O
the O
two O
constituent O
amino B
acids I
were O
both O
in O
the O
l O
- O
form O
. O

Based O
on O
our O
previously O
published O
work O
on O
CXCR4 O
antagonists O
, O
we O
have O
synthesized O
a O
series O
of O
aryl B
sulfonamides I
that O
inhibit O
the O
CXCR4 O
/ O
CXCL12 O
interaction O
. O

Modification O
of O
medium O
polarity O
and O
solubilization O
by O
the O
nonionic O
surfactant O
Tween B
80 I
adjusted O
the O
acid O
- O
base O
equilibria O
and O
increased O
the O
solubility O
by O
reduction O
of O
porphyrin B
aggregation O
. O

In O
this O
study O
, O
a O
novel O
technique O
was O
used O
for O
the O
reversible O
attachment O
of O
folic B
acid I
on O
the O
surface O
of O
polymeric O
micelles O
for O
a O
tumor O
- O
specific O
drug O
delivery O
system O
. O

The O
reversible O
conjugation O
is O
based O
on O
the O
interaction O
between O
phenylboronic B
acid I
( O
PBA B
) O
and O
dopamine B
to O
form O
a O
borate B
ester I
. O

The O
reversible O
conjugation O
is O
based O
on O
the O
interaction O
between O
phenylboronic B
acid I
( O
PBA B
) O
and O
dopamine B
to O
form O
a O
borate B
ester I
. O

Synthesis O
and O
relaxometric O
characterization O
of O
a O
MRI O
Gd B
- O
based O
probe O
responsive O
to O
glutamic B
acid I
decarboxylase O
enzymatic O
activity O
. O

We O
report O
here O
the O
synthesis O
and O
in O
vitro O
validation O
of O
a O
Gd B
( I
III I
) I
- O
based O
contrast O
agent O
designed O
to O
act O
as O
an O
MRI O
responsive O
probe O
for O
imaging O
the O
activity O
of O
the O
enzyme O
glutamic B
acid I
decarboxylase O
( O
GAD O
) O
present O
in O
neurons O
. O

A O
new O
sesquiterpene B
lactone I
from O
Salvia O
plebeia O
. O

Asymmetric B
Dimethylarginine I
( O
ADMA B
) O
: O
A O
Promising O
Biomarker O
for O
Cardiovascular O
Disease O
? O

Asymmetric B
Dimethylarginine I
( O
ADMA B
) O
is O
an O
endogenous O
inhibitor O
of O
nitric B
oxide I
( O
NO B
) O
production O
. O

Asymmetric B
Dimethylarginine I
( O
ADMA B
) O
is O
an O
endogenous O
inhibitor O
of O
nitric B
oxide I
( O
NO B
) O
production O
. O

Oxidative O
stress O
, O
endothelial O
nitric B
oxide I
synthase O
( O
eNOS O
) O
inhibition O
, O
eNOS O
uncoupling O
, O
inflammation O
and O
shear O
stress O
play O
a O
pivotal O
role O
in O
ADMA B
pathophysiology O
by O
managing O
PRMT O
/ O
DDAH O
expression O
and O
NO B
synthesis O
and O
leading O
to O
a O
common O
result O
- O
endothelial O
dysfunction O
. O

Chitosan O
- O
thioglycolic B
Acid I
as O
a O
versatile O
antimicrobial O
agent O
. O

As O
functionalized O
chitosans O
hold O
great O
potential O
for O
the O
development O
of O
effective O
and O
broad O
- O
spectrum O
antibiotics O
, O
representative O
chitosan O
derivatives O
were O
tested O
for O
antimicrobial O
activity O
in O
neutral O
media O
: O
trimethyl B
chitosan O
( O
TMC O
) O
, O
carboxy B
- I
methyl I
chitosan O
( O
CMC O
) O
, O
and O
chitosan O
- O
thioglycolic B
acid I
( O
TGA B
; O
medium O
molecular O
weight O
: O
MMW O
- O
TGA B
; O
low O
molecular O
weight O
: O
LMW O
- O
TGA B
) O
. O

Use O
of O
fluorescein B
isothiocyanate I
( O
FITC B
) O
- O
labeled O
chitosan O
derivates O
in O
confocal O
microscopy O
showed O
that O
LMW O
- O
TGA B
attaches O
to O
microbial O
cell O
walls O
, O
while O
transmission O
electron O
microscopy O
indicated O
that O
this O
derivative O
severely O
affects O
cell O
wall O
integrity O
and O
intracellular O
ultrastructure O
in O
all O
species O
tested O
. O

New O
surface O
- O
enhanced O
Raman O
scattering O
platforms O
: O
composite O
calcium B
carbonate I
microspheres O
coated O
with O
astralen O
and O
silver B
nanoparticles O
. O

Astralen O
has O
been O
assembled O
with O
polyallylamine B
hydrochloride I
( O
PAH B
) O
by O
the O
layer O
- O
by O
- O
layer O
manner O
followed O
by O
Ag B
nanoparticle O
formation O
by O
means O
of O
a O
silver B
mirror O
reaction O
, O
giving O
the O
final O
structure O
of O
composite O
particles O
CaCO3 B
( O
PAH B
/ O
astralen O
) O
x O
/ O
Ag B
, O
where O
x O
= O
1 O
- O
3 O
. O

Raman O
signals O
of O
commonly O
used O
scaffold O
components O
such O
as O
polylactide B
and O
polyvinyl B
alcohol I
as O
well O
as O
ECM O
component O
( O
hyaluronic O
acid O
) O
are O
significantly O
enhanced O
. O

Oroxylin B
A I
reverses O
P O
- O
glycoprotein O
- O
mediated O
multidrug O
resistance O
of O
MCF7 O
/ O
ADR O
cells O
by O
G2 O
/ O
M O
arrest O
. O

Oroxylin B
A I
is O
a O
naturally O
occurring O
monoflavonoid B
isolated O
from O
the O
root O
of O
Scutellaria O
baicalensis O
Georgi O
, O
which O
has O
been O
used O
in O
traditional O
Chinese O
medicine O
for O
its O
anti O
- O
tumor O
, O
anti O
- O
inflammatory O
and O
anti O
- O
bacterial O
properties O
. O

The O
purpose O
of O
this O
study O
is O
to O
investigate O
the O
reversal O
effect O
and O
the O
fundamental O
mechanisms O
of O
oroxylin B
A I
in O
MCF7 O
/ O
ADR O
cells O
. O

Data O
indicated O
that O
oroxylin B
A I
showed O
strong O
reversal O
potency O
in O
MCF7 O
/ O
ADR O
cells O
and O
the O
reversal O
fold O
( O
RF O
) O
reached O
4 O
. O
68 O
. O

After O
treatment O
with O
oroxylin B
A I
, O
MCF7 O
/ O
ADR O
cells O
displayed O
reduced O
functional O
activity O
and O
expression O
of O
MDR1 O
at O
both O
the O
protein O
and O
mRNA O
levels O
. O

Meanwhile O
, O
oroxylin B
A I
induced O
cells O
G2 O
/ O
M O
arrest O
in O
a O
concentration O
- O
dependent O
manner O
by O
increasing O
the O
expression O
of O
p O
- O
Chk2 O
( O
Thr68 O
) O
. O

Moreover O
, O
western O
blot O
and O
EMSA O
assays O
were O
used O
to O
reveal O
the O
inhibition O
of O
NF O
- O
kappa O
B O
in O
nucleus O
and O
the O
suppression O
of O
NF O
- O
kappa O
B O
binding O
activity O
by O
oroxylin B
A I
. O

NSC B
109555 I
ditosylate I
- O
Chk2 O
inhibitor O
partly O
dismissed O
G2 O
/ O
M O
arrest O
induced O
by O
oroxylin B
A I
, O
reversed O
the O
increased O
trend O
of O
p O
- O
Chk2 O
and O
p O
- O
P53 O
( O
Ser20 O
) O
, O
inhibited O
the O
decreasing O
effect O
of O
oroxylin B
A I
on O
the O
expression O
of O
P O
- O
gp O
and O
decreased O
the O
reversal O
fold O
of O
90 O
mu O
M O
oroxylin B
A I
from O
4 O
. O
68 O
fold O
to O
1 O
. O
73 O
fold O
. O

NSC B
109555 I
ditosylate I
- O
Chk2 O
inhibitor O
partly O
dismissed O
G2 O
/ O
M O
arrest O
induced O
by O
oroxylin B
A I
, O
reversed O
the O
increased O
trend O
of O
p O
- O
Chk2 O
and O
p O
- O
P53 O
( O
Ser20 O
) O
, O
inhibited O
the O
decreasing O
effect O
of O
oroxylin B
A I
on O
the O
expression O
of O
P O
- O
gp O
and O
decreased O
the O
reversal O
fold O
of O
90 O
mu O
M O
oroxylin B
A I
from O
4 O
. O
68 O
fold O
to O
1 O
. O
73 O
fold O
. O

NSC B
109555 I
ditosylate I
- O
Chk2 O
inhibitor O
partly O
dismissed O
G2 O
/ O
M O
arrest O
induced O
by O
oroxylin B
A I
, O
reversed O
the O
increased O
trend O
of O
p O
- O
Chk2 O
and O
p O
- O
P53 O
( O
Ser20 O
) O
, O
inhibited O
the O
decreasing O
effect O
of O
oroxylin B
A I
on O
the O
expression O
of O
P O
- O
gp O
and O
decreased O
the O
reversal O
fold O
of O
90 O
mu O
M O
oroxylin B
A I
from O
4 O
. O
68 O
fold O
to O
1 O
. O
73 O
fold O
. O

In O
conclusion O
, O
we O
suggested O
that O
oroxylin B
A I
reversed O
MDR O
by O
G2 O
/ O
M O
arrest O
and O
the O
underlying O
mechanism O
attributed O
to O
the O
suppression O
of O
P O
- O
gp O
expression O
via O
Chk2 O
/ O
P53 O
/ O
NF O
- O
kappa O
B O
signaling O
pathway O
. O

Resveratrol B
protects O
against O
arsenic B
trioxide I
- O
induced O
nephrotoxicity O
by O
facilitating O
arsenic B
metabolism O
and O
decreasing O
oxidative O
stress O
. O

Arsenic B
trioxide I
( O
As2O3 B
) O
is O
an O
environmental O
toxicant O
and O
a O
potent O
antineoplastic O
agent O
. O

In O
the O
resveratrol B
+ O
As2O3 B
- O
treated O
group O
, O
activities O
of O
glutathione B
peroxidase O
, O
catalase O
, O
and O
superoxide B
dismutase O
, O
the O
ratio O
of O
reduced O
glutathione B
to O
oxidized B
glutathione I
, O
the O
total O
arsenic B
concentrations O
, O
and O
the O
percentage O
of O
methylated B
arsenic I
in O
urine O
were O
significantly O
increased O
. O

In O
the O
resveratrol B
+ O
As2O3 B
- O
treated O
group O
, O
activities O
of O
glutathione B
peroxidase O
, O
catalase O
, O
and O
superoxide B
dismutase O
, O
the O
ratio O
of O
reduced O
glutathione B
to O
oxidized B
glutathione I
, O
the O
total O
arsenic B
concentrations O
, O
and O
the O
percentage O
of O
methylated B
arsenic I
in O
urine O
were O
significantly O
increased O
. O

Here O
, O
we O
provide O
evidence O
that O
maspin O
acts O
as O
a O
reactive O
oxygen B
species O
( O
ROS O
) O
scavenger O
through O
oxidation O
of O
three O
structurally O
exposed O
cysteine B
thiols I
to O
sulfenic B
acid I
. O

Here O
, O
we O
provide O
evidence O
that O
maspin O
acts O
as O
a O
reactive O
oxygen B
species O
( O
ROS O
) O
scavenger O
through O
oxidation O
of O
three O
structurally O
exposed O
cysteine B
thiols I
to O
sulfenic B
acid I
. O

These O
findings O
establish O
a O
novel O
mechanism O
by O
which O
maspin O
utilizes O
its O
cysteine B
thiols I
to O
inhibit O
oxidative O
stress O
and O
cell O
growth O
. O

Background O
: O
Dietary O
iodine B
intake O
is O
required O
for O
the O
production O
of O
thyroid B
hormone I
. O

When O
expressed O
at O
elevated O
levels O
in O
brown O
fat O
, O
TLE3 O
counters O
Prdm16 O
, O
suppressing O
brown O
- O
selective O
genes O
and O
inducing O
white O
- O
selective O
genes O
, O
resulting O
in O
impaired O
fatty B
acid I
oxidation O
and O
thermogenesis O
. O

PDE4 O
is O
one O
of O
eleven O
known O
cyclic B
nucleotide I
phosphodiesterase O
families O
and O
plays O
a O
pivotal O
role O
in O
mediating O
hydrolytic O
degradation O
of O
the O
important O
cyclic B
nucleotide I
second O
messenger O
, O
cyclic B
3 I
' I
5 I
' I
adenosine I
monophosphate I
( O
cAMP B
) O
. O

PDE4 O
is O
one O
of O
eleven O
known O
cyclic B
nucleotide I
phosphodiesterase O
families O
and O
plays O
a O
pivotal O
role O
in O
mediating O
hydrolytic O
degradation O
of O
the O
important O
cyclic B
nucleotide I
second O
messenger O
, O
cyclic B
3 I
' I
5 I
' I
adenosine I
monophosphate I
( O
cAMP B
) O
. O

Rp1 B
treatment O
resulted O
in O
an O
accumulation O
of O
doxorubicin B
or O
rhodamine B
123 I
by O
decreasing O
MDR O
- O
1 O
activity O
in O
doxorubicin B
- O
resistant O
cells O
. O

Rp1 B
synergistically O
induced O
cell O
death O
with O
actinomycin B
D I
in O
DXR O
cells O
. O

Moreover O
, O
Rp1 B
reversed O
resistance O
to O
actinomycin B
D I
by O
decreasing O
MDR O
- O
1 O
protein O
levels O
and O
Src O
phosphorylation O
with O
modulation O
of O
lipid O
rafts O
. O

Rp1 B
and O
actinomycin B
D I
reduced O
Src O
activity O
, O
and O
overexpression O
of O
active O
Src O
decreased O
the O
synergistic O
effect O
of O
Rp1 B
with O
actinomycin B
D I
. O

Rp1 B
and O
actinomycin B
D I
reduced O
Src O
activity O
, O
and O
overexpression O
of O
active O
Src O
decreased O
the O
synergistic O
effect O
of O
Rp1 B
with O
actinomycin B
D I
. O

We O
evaluated O
the O
effect O
of O
the O
demethylating O
agent O
5 B
- I
aza I
- I
2 I
' I
- I
deoxycytidine I
( O
5AzadC B
) O
and O
the O
histone O
deacetylase O
inhibitor O
trichostatin B
A I
( O
TSA B
) O
on O
PR O
expression O
in O
human O
astrocytoma O
cell O
lines O
U373 O
( O
grade O
III O
) O
and O
D54 O
( O
grade O
IV O
) O
by O
RT O
- O
PCR O
and O
Western O
blot O
. O

In O
this O
work O
we O
evaluated O
the O
ability O
of O
suramin B
, O
a O
polysulfonated B
naphthylurea I
derivative O
, O
to O
antagonize O
the O
cytotoxic O
and O
enzymatic O
effects O
of O
the O
crude O
venom O
of O
Apis O
mellifera O
. O

Mn B
@ O
Si14 B
+ I
: O
a O
singlet O
fullerene B
- I
like O
endohedrally O
doped O
silicon B
cluster O
. O

Mn B
@ O
Si14 B
+ I
: O
a O
singlet O
fullerene B
- I
like O
endohedrally O
doped O
silicon B
cluster O
. O

The O
endohedrally O
Mn B
- I
doped I
Si I
cationic O
cluster O
has O
a O
D3h O
fullerene B
- I
like O
structure O
featuring O
a O
closed O
- O
shell O
singlet O
ground O
state O
with O
a O
singlet O
- O
triplet O
gap O
of O
~ O
1 O
eV O
. O

The O
nanoemulsion O
used O
in O
our O
study O
was O
an O
oil O
- O
in O
- O
water O
emulsion O
droplet O
of O
average O
size O
~ O
190 O
nm O
containing O
ferrimagnetic O
iron B
oxide I
nanoparticles O
of O
average O
size O
~ O
10 O
nm O
. O

Three O
new O
19 B
- I
hydroxy I
steroidal I
glycosides I
, O
namely O
, O
junceellosides B
E I
- I
G I
( O
2 O
- O
4 O
) O
, O
were O
isolated O
together O
with O
the O
known O
analogue O
junceelloside B
C I
( O
1 O
) O
from O
the O
South O
China O
Sea O
gorgonian O
Dichotella O
gemmacea O
. O

These O
glycosides O
are O
found O
to O
have O
sugar B
moieties O
of O
both O
beta B
- I
l I
- I
and I
beta I
- I
d I
- I
arabinopyranoses I
by O
HPLC O
analysis O
of O
their O
thiocarbamoyl B
- I
thiazolidine I
derivatives O
and O
those O
of O
authentic O
d B
- I
and I
l I
- I
arabinoses I
, O
leading O
to O
the O
structure O
revision O
of O
junceelloside B
C I
( O
1 O
) O
. O

These O
copolymers O
were O
freely O
soluble O
in O
phosphate B
buffer O
but O
formed O
disulfide B
- O
cross O
- O
linked O
nanogels O
with O
defined O
sizes O
ranging O
from O
72 O
. O
5 O
to O
124 O
. O
1 O
nm O
in O
the O
presence O
of O
cystamine B
via O
ring O
- O
opening O
reaction O
with O
cyclic B
carbonate I
groups O
. O

Synonymous O
single O
nucleotide O
polymorphisms O
( O
SNPs O
) O
within O
a O
transcript O
' O
s O
coding O
region O
produce O
no O
change O
in O
the O
amino B
acid I
sequence O
of O
the O
protein O
product O
and O
are O
therefore O
intuitively O
assumed O
to O
have O
a O
neutral O
effect O
on O
protein O
function O
. O

The O
NAD B
+ I
- O
dependent O
deacetylases O
Sirt1 O
and O
Sirt2 O
mediate O
cellular O
stress O
responses O
and O
are O
highly O
expressed O
in O
vascular O
endothelial O
cells O
. O

We O
found O
that O
Sirt2 O
knock O
down O
changed O
expression O
of O
340 O
genes O
, O
which O
are O
mainly O
involved O
in O
cellular O
processes O
including O
actin O
binding O
, O
cellular O
amino B
acid I
metabolic O
process O
, O
transmembrane O
receptor O
protein O
serine B
/ O
threonine B
kinase O
signaling O
, O
ferrous B
iron I
transport O
, O
protein O
transport O
and O
localization O
, O
cell O
morphogenesis O
, O
and O
functions O
associated O
with O
endosome O
membrane O
and O
the O
trans O
- O
Golgi O
network O
. O

We O
found O
that O
Sirt2 O
knock O
down O
changed O
expression O
of O
340 O
genes O
, O
which O
are O
mainly O
involved O
in O
cellular O
processes O
including O
actin O
binding O
, O
cellular O
amino B
acid I
metabolic O
process O
, O
transmembrane O
receptor O
protein O
serine B
/ O
threonine B
kinase O
signaling O
, O
ferrous B
iron I
transport O
, O
protein O
transport O
and O
localization O
, O
cell O
morphogenesis O
, O
and O
functions O
associated O
with O
endosome O
membrane O
and O
the O
trans O
- O
Golgi O
network O
. O

These O
changes O
are O
caused O
by O
increased O
free O
fatty B
acid I
flux O
secondary O
to O
insulin O
resistance O
and O
aggravated O
by O
increased O
inflammatory O
adipokines O
. O

Although O
the O
evidence O
for O
clinical O
utility O
of O
combination O
of O
statins O
with O
fibrates B
or O
nicotinic B
acid I
in O
reducing O
cardiovascular O
events O
remains O
inconclusive O
, O
the O
preponderance O
of O
evidence O
suggests O
that O
a O
subgroup O
who O
have O
high O
triglycerides B
and O
low O
HDL O
- O
c O
levels O
may O
benefit O
from O
combination O
therapy O
of O
statins O
and O
fibrates B
. O

MD O
simulations O
of O
the O
formation O
of O
stable O
clusters O
in O
mixtures O
of O
alkaline B
salts I
and O
imidazolium B
- O
based O
ionic O
liquids O
. O

The O
presence O
of O
a O
basic O
functional O
group O
or O
a O
quaternary B
ammonium I
substituent O
on O
the O
6 B
- I
phenylnaphthalene I
was O
required O
for O
significant O
antibacterial O
activity O
. O

Layers O
of O
a O
two O
- O
dimensional O
( O
2D O
) O
zinc B
coordination O
polymer O
are O
self O
- O
assembled O
in O
the O
interlamellar O
space O
of O
a O
reverse O
microemulsion O
mesophase O
into O
stacks O
of O
nanosheets O
interleaved O
with O
cethyltrimethylammon B
bromide I
( O
CTAB B
) O
at O
regular O
intervals O
, O
thus O
giving O
rise O
to O
a O
lamellar O
hybrid O
mesostructure O
with O
a O
lattice O
period O
of O
~ O
8 O
nm O
and O
an O
underlying O
highly O
crystalline O
substructure O
. O

The O
structure O
is O
dependent O
on O
the O
metal O
center O
; O
for O
the O
early O
transition B
metals I
eta O
( O
3 O
) O
coordination O
is O
favored O
, O
whereas O
eta O
( O
2 O
) O
is O
more O
favorable O
for O
the O
later O
transition B
metals I
. O

The O
structure O
is O
dependent O
on O
the O
metal O
center O
; O
for O
the O
early O
transition B
metals I
eta O
( O
3 O
) O
coordination O
is O
favored O
, O
whereas O
eta O
( O
2 O
) O
is O
more O
favorable O
for O
the O
later O
transition B
metals I
. O

Synergistic O
interactions O
of O
epigallocatechin B
gallate I
and O
oxytetracycline B
against O
various O
drug O
resistant O
Staphylococcus O
aureus O
strains O
in O
vitro O
. O

Epigallocatechin B
gallate I
( O
EGCG B
) O
, O
the O
major O
catechin B
contained O
in O
tea O
leaves O
, O
is O
known O
to O
possess O
the O
synergistic O
anti O
- O
staphylococcal O
activity O
in O
combination O
with O
various O
beta B
- I
lactam I
antibiotics O
and O
tetracycline B
. O

The O
influence O
of O
study O
design O
and O
sex O
- O
differences O
on O
results O
from O
developmental O
neurotoxicity O
studies O
of O
bisphenol B
A I
, O
implications O
for O
toxicity O
testing O
. O

Developmental O
neurotoxicity O
( O
DNT O
) O
of O
bisphenol B
A I
( O
BPA B
) O
has O
been O
investigated O
in O
a O
large O
number O
of O
studies O
. O

A O
set O
of O
racemic B
N I
- I
phenyl I
- I
substituted I
beta I
- I
amidoamidines I
hydrochlorides I
4 O
, O
which O
are O
structurally O
related O
to O
natural O
antiviral O
agent O
amidinomycin B
( O
1 O
) O
, O
was O
synthesized O
in O
four O
steps O
starting O
from O
methacryloyl B
anilide I
( O
5 O
) O
. O

In O
patients O
who O
do O
not O
reach O
the O
LDL O
- O
C O
target O
, O
combination O
therapy O
with O
additional O
LDL O
- O
C O
lowering O
drugs O
( O
e O
. O
g O
. O
ezetimibe B
, O
bile B
acid I
sequestrants O
or O
fibrates B
) O
should O
be O
considered O
. O

SK O
- O
N O
- O
SH O
cells O
were O
treated O
with O
two O
distinct O
inhibitors O
of O
glutathione B
metabolism O
: O
L B
- I
buthionine I
- I
( I
S I
, I
R I
) I
- I
sulfoximine I
( O
BSO B
) O
and O
ethacrynic B
acid I
( O
EA O
) O
. O

Nickel B
sulfide I
/ O
nitrogen B
- I
doped I
graphene I
composites O
: O
phase O
- O
controlled O
synthesis O
and O
high O
performance O
anode O
materials O
for O
lithium B
ion O
batteries O
. O

Phase O
- O
controlled O
nickel B
sulfide I
( O
Ni3 B
S4 I
and O
NiS1 B
. I
03 I
) O
nanoparticle O
( O
NP O
) O
/ O
nitrogen B
- I
doped I
graphene I
( O
NG O
) O
composites O
are O
prepared O
through O
a O
facile O
one O
- O
pot O
hydrothermal O
process O
. O

Phase O
- O
controlled O
nickel B
sulfide I
( O
Ni3 B
S4 I
and O
NiS1 B
. I
03 I
) O
nanoparticle O
( O
NP O
) O
/ O
nitrogen B
- I
doped I
graphene I
( O
NG O
) O
composites O
are O
prepared O
through O
a O
facile O
one O
- O
pot O
hydrothermal O
process O
. O

The O
composites O
show O
ultrahigh O
capacity O
retentions O
of O
98 O
. O
87 O
% O
and O
95 O
. O
94 O
% O
for O
Ni3 B
S4 I
/ O
NG O
and O
NiS1 B
. I
03 I
/ O
NG O
electrodes O
, O
respectively O
, O
as O
anode O
materials O
for O
lithium B
ion O
batteries O
. O

Targeting O
protein O
- O
protein O
interactions O
within O
the O
cyclic B
AMP I
signaling O
system O
as O
a O
therapeutic O
strategy O
for O
cardiovascular O
disease O
. O

Pyridone B
Alkaloids I
from O
a O
Marine O
- O
Derived O
Fungus O
, O
Stagonosporopsis O
cucurbitacearum O
, O
and O
Their O
Activities O
against O
Azole B
- O
Resistant O
Candida O
albicans O
. O

Didymellamide B
A I
( O
1 O
) O
exhibited O
antifungal O
activity O
against O
azole B
- O
resistant O
Candida O
albicans O
. O

In O
enzyme O
- O
aided O
juices O
, O
the O
contents O
of O
flavonol B
glycosides I
and O
hydroxycinnamic B
acids I
were O
associated O
with O
mouth O
- O
drying O
astringency O
, O
and O
sugar B
/ O
acid O
ratio O
correlated O
with O
sweetness O
. O

In O
enzyme O
- O
aided O
juices O
, O
the O
contents O
of O
flavonol B
glycosides I
and O
hydroxycinnamic B
acids I
were O
associated O
with O
mouth O
- O
drying O
astringency O
, O
and O
sugar B
/ O
acid O
ratio O
correlated O
with O
sweetness O
. O

Most O
gap O
junction O
blockers O
also O
attenuate O
the O
function O
of O
Panx1 O
, O
including O
carbenoxolone B
, O
mefloquine B
and O
flufenamic B
acid I
. O

Steroidal B
glycosides I
from O
the O
bulbs O
of O
Fritillaria O
meleagris O
and O
their O
cytotoxic O
activities O
. O

Steroidal B
glycosides I
( O
1 O
- O
18 O
) O
, O
including O
10 O
new O
compounds O
( O
1 O
- O
10 O
) O
, O
were O
isolated O
from O
the O
bulbs O
of O
Fritillaria O
meleagris O
( O
Liliaceae O
) O
. O

Immunostaining O
for O
RUNX2 O
and O
osteocalcin O
, O
and O
also O
histochemical O
staining O
with O
picrosirius O
red O
to O
demonstrate O
collage O
type O
1 O
and O
Alizarin B
red I
to O
demonstrate O
calcium B
/ O
mineralisation O
further O
demonstrated O
osteogenic O
differentiation O
and O
revealed O
regional O
staining O
associated O
with O
the O
locations O
of O
MPs O
within O
the O
aggregates O
. O

While O
unformulated O
drug O
exhibited O
poor O
solubility O
( O
0 O
. O
22 O
mu O
g O
/ O
mL O
in O
FaSSGF O
and O
4 O
. O
31 O
mu O
g O
/ O
mL O
in O
FaSSIF O
- O
V2 B
( I
PO4 I
) I
) O
and O
dissolved O
less O
than O
2 O
% O
in O
dissolution O
tests O
, O
the O
solubility O
of O
fenofibrate B
in O
the O
presence O
of O
the O
lipid O
excipients O
increased O
dramatically O
( O
e O
. O
g O
. O
, O
to O
65 O
. O
44 O
mu O
g O
/ O
mL O
in O
the O
presence O
of O
the O
Myritol B
318 I
/ O
TPGS B
/ O
Tween B
80 I
SMEDDS O
) O
and O
there O
was O
an O

While O
unformulated O
drug O
exhibited O
poor O
solubility O
( O
0 O
. O
22 O
mu O
g O
/ O
mL O
in O
FaSSGF O
and O
4 O
. O
31 O
mu O
g O
/ O
mL O
in O
FaSSIF O
- O
V2 B
( I
PO4 I
) I
) O
and O
dissolved O
less O
than O
2 O
% O
in O
dissolution O
tests O
, O
the O
solubility O
of O
fenofibrate B
in O
the O
presence O
of O
the O
lipid O
excipients O
increased O
dramatically O
( O
e O
. O
g O
. O
, O
to O
65 O
. O
44 O
mu O
g O
/ O
mL O
in O
the O
presence O
of O
the O
Myritol B
318 I
/ O
TPGS B
/ O
Tween B
80 I
SMEDDS O
) O
and O
there O
was O
an O

attendant O
increase O
in O
the O
dissolution O
( O
over O
80 O
% O
from O
capsules O
containing O
the O
Myritol B
318 I
/ O
TPGS B
/ O
Tween B
80 I
SMEDDS O
and O
about O
20 O
% O
from O
the O
dispersion O
of O
fenofibrate B
in O
lipid O
excipients O
) O
. O

attendant O
increase O
in O
the O
dissolution O
( O
over O
80 O
% O
from O
capsules O
containing O
the O
Myritol B
318 I
/ O
TPGS B
/ O
Tween B
80 I
SMEDDS O
and O
about O
20 O
% O
from O
the O
dispersion O
of O
fenofibrate B
in O
lipid O
excipients O
) O
. O

In O
the O
in O
vitro O
assay O
, O
kinsenoside B
( O
20 O
and O
50 O
mu O
g O
/ O
mL O
) O
markedly O
inhibited O
changes O
in O
various O
biochemical O
substances O
( O
nitric B
oxide I
( O
NO B
) O
, O
lactic B
dehydrogenase O
( O
LDH O
) O
, O
superoxide B
dismutase O
( O
SOD O
) O
, O
and O
catalase O
( O
CAT O
) O
) O
in O
human O
umbilical O
vein O
endothelial O
cells O
( O
HUVECs O
) O
damaged O
by O
high O
glucose B
( O
35mM O
) O
and O
restored O
vascular O
endothelial O
structure O
by O
balancing O
the O
matrix O
metalloproteinases O
- O
the O
tissue O
inhibitors O
of O
matrix O

Bioactive O
carbazole B
alkaloids I
from O
Murraya O
koenigii O
( O
L O
. O
) O
Spreng O
. O

Four O
new O
carbazole B
alkaloids I
( O
1 O
- O
4 O
) O
and O
fourteen O
known O
carbazole B
alkaloids I
( O
5 O
- O
18 O
) O
were O
isolated O
from O
Murraya O
koenigii O
. O

Four O
new O
carbazole B
alkaloids I
( O
1 O
- O
4 O
) O
and O
fourteen O
known O
carbazole B
alkaloids I
( O
5 O
- O
18 O
) O
were O
isolated O
from O
Murraya O
koenigii O
. O

The O
enzyme O
gamma O
- O
glutamyltransferase O
( O
GGT O
) O
catalyzes O
the O
hydrolysis O
of O
the O
gamma B
- I
glutamyl I
isopeptide O
bond O
of O
glutathione B
conjugates O
( O
donor O
substrates O
) O
, O
releasing O
glutamic B
acid I
, O
or O
the O
transfer O
of O
the O
donor O
' O
s O
gamma B
- I
glutamyl I
group O
to O
an O
acceptor O
substrate O
, O
such O
as O
a O
dipeptide B
. O

Gambogic B
acid I
inhibits O
angiogenesis O
through O
inhibiting O
PHD2 O
- O
VHL O
- O
HIF O
- O
1 O
alpha O
pathway O
. O

Our O
previous O
studies O
revealed O
that O
gambogic B
acid I
( O
GA O
) O
, O
the O
major O
active O
ingredient O
of O
gamboge O
, O
possessed O
antiangiogenic O
activities O
. O

Various O
oxidative O
stress O
markers O
, O
including O
lipid O
peroxidation O
( O
LPO O
) O
, O
protein O
oxidation O
, O
DNA O
oxidation O
, O
and O
the O
ratio O
of O
reduced B
glutathione I
to O
oxidised B
glutathione I
( O
GSH B
/ O
GSSG B
) O
, O
and O
the O
activities O
of O
NADPH B
oxidase O
, O
superoxide B
dismutase O
( O
SOD O
) O
, O
catalase O
( O
CAT O
) O
, O
and O
gamma B
- I
glutamyl I
- I
cysteine I
synthetase O
( O
gamma O
- O
GCS O
) O
, O
were O
evaluated O
in O
the O
livers O
and O
kidneys O
of O
fish O
in O
the O
absence O
and O
presence O
of O

Various O
oxidative O
stress O
markers O
, O
including O
lipid O
peroxidation O
( O
LPO O
) O
, O
protein O
oxidation O
, O
DNA O
oxidation O
, O
and O
the O
ratio O
of O
reduced B
glutathione I
to O
oxidised B
glutathione I
( O
GSH B
/ O
GSSG B
) O
, O
and O
the O
activities O
of O
NADPH B
oxidase O
, O
superoxide B
dismutase O
( O
SOD O
) O
, O
catalase O
( O
CAT O
) O
, O
and O
gamma B
- I
glutamyl I
- I
cysteine I
synthetase O
( O
gamma O
- O
GCS O
) O
, O
were O
evaluated O
in O
the O
livers O
and O
kidneys O
of O
fish O
in O
the O
absence O
and O
presence O
of O

Cobalt B
chloride I
speciation O
, O
mechanisms O
of O
cytotoxicity O
on O
human O
pulmonary O
cells O
, O
and O
synergistic O
toxicity O
with O
zinc B
. O

To O
determine O
the O
most O
biologically O
deleterious O
chemistries O
of O
inflammation O
, O
we O
previously O
assessed O
products O
across O
the O
spectrum O
of O
DNA O
damage O
arising O
in O
inflamed O
tissues O
in O
the O
SJL O
mouse O
model O
nitric B
oxide I
overproduction O
( O
Pang O
et O
al O
. O
( O
2007 O
) O
Carcinogenesis O
28 O
, O
1807 O
- O
1813 O
) O
. O

However O
, O
compared O
to O
control O
mice O
, O
RcsX O
treatment O
to O
induce O
nitric B
oxide I
overproduction O
resulted O
in O
significant O
increases O
only O
in O
inosine B
and O
only O
in O
the O
spleen O
. O

Further O
, O
the O
nitric B
oxide I
synthase O
inhibitor O
, O
N B
- I
methylarginine I
, O
did O
not O
significantly O
affect O
the O
levels O
of O
inosine B
in O
control O
and O
RcsX O
- O
treated O
mice O
. O

We O
have O
recently O
shown O
that O
thermolysine O
, O
a O
protease O
enzyme O
obtained O
from O
Bacillus O
thermoproteolyticus O
rokko O
, O
can O
be O
used O
to O
trigger O
the O
gelation O
of O
FEFK O
( O
F O
, O
phenylalanine B
; O
E O
, O
glutamic B
acid I
; O
K O
, O
lysine B
) O
tetrapeptides O
through O
reverse O
hydrolysis O
and O
formation O
of O
longer O
peptide O
sequences O
, O
mainly O
octapeptides O
, O
that O
self O
- O
assemble O
readily O
. O

' O
Bacoside B
B I
' O
- O
the O
need O
remains O
for O
establishing O
identity O
. O

Subsequently O
' O
bacoside B
A I
' O
was O
identified O
as O
a O
mixture O
of O
four O
saponins B
[ O
bacoside B
A3 I
( O
1 O
) O
, O
bacopaside B
II I
( O
2 O
) O
, O
bacopasaponin B
C I
( O
3 O
) O
and O
the O
jujobogenin B
isomer O
of O
the O
latter O
( O
4 O
) O
] O
and O
was O
considered O
as O
part O
of O
major O
constituents O
of O
the O
herb O
along O
with O
bacopaside B
I I
( O
5 O
) O
. O

Subsequently O
' O
bacoside B
A I
' O
was O
identified O
as O
a O
mixture O
of O
four O
saponins B
[ O
bacoside B
A3 I
( O
1 O
) O
, O
bacopaside B
II I
( O
2 O
) O
, O
bacopasaponin B
C I
( O
3 O
) O
and O
the O
jujobogenin B
isomer O
of O
the O
latter O
( O
4 O
) O
] O
and O
was O
considered O
as O
part O
of O
major O
constituents O
of O
the O
herb O
along O
with O
bacopaside B
I I
( O
5 O
) O
. O

Subsequently O
' O
bacoside B
A I
' O
was O
identified O
as O
a O
mixture O
of O
four O
saponins B
[ O
bacoside B
A3 I
( O
1 O
) O
, O
bacopaside B
II I
( O
2 O
) O
, O
bacopasaponin B
C I
( O
3 O
) O
and O
the O
jujobogenin B
isomer O
of O
the O
latter O
( O
4 O
) O
] O
and O
was O
considered O
as O
part O
of O
major O
constituents O
of O
the O
herb O
along O
with O
bacopaside B
I I
( O
5 O
) O
. O

Subsequently O
' O
bacoside B
A I
' O
was O
identified O
as O
a O
mixture O
of O
four O
saponins B
[ O
bacoside B
A3 I
( O
1 O
) O
, O
bacopaside B
II I
( O
2 O
) O
, O
bacopasaponin B
C I
( O
3 O
) O
and O
the O
jujobogenin B
isomer O
of O
the O
latter O
( O
4 O
) O
] O
and O
was O
considered O
as O
part O
of O
major O
constituents O
of O
the O
herb O
along O
with O
bacopaside B
I I
( O
5 O
) O
. O

Subsequently O
' O
bacoside B
A I
' O
was O
identified O
as O
a O
mixture O
of O
four O
saponins B
[ O
bacoside B
A3 I
( O
1 O
) O
, O
bacopaside B
II I
( O
2 O
) O
, O
bacopasaponin B
C I
( O
3 O
) O
and O
the O
jujobogenin B
isomer O
of O
the O
latter O
( O
4 O
) O
] O
and O
was O
considered O
as O
part O
of O
major O
constituents O
of O
the O
herb O
along O
with O
bacopaside B
I I
( O
5 O
) O
. O

However O
identity O
of O
' O
bacoside B
B I
' O
still O
appears O
controversial O
with O
seemingly O
contradictory O
information O
available O
in O
the O
scientific O
literature O
. O

Relationship O
of O
Dehydroepiandrostero B
Sulfate I
with O
Overweight O
and O
Insulin O
Sensitivity O
in O
12 O
- O
16 O
- O
Year O
- O
old O
Spanish O
Children O
. O

Four O
constituents O
were O
isolated O
from O
heat O
- O
processed O
G O
. O
pentaphyllum O
using O
resin O
HP O
- O
20 O
, O
silica B
gel I
and O
reversed O
ODS O
column O
chromatography O
. O

They O
were O
identified O
by O
mass O
and O
NMR O
spectra O
as O
damulin B
A I
and O
damulin B
B I
, O
gypenoside B
L I
and O
gypenoside B
LI I
, O
respectively O
. O

They O
were O
identified O
by O
mass O
and O
NMR O
spectra O
as O
damulin B
A I
and O
damulin B
B I
, O
gypenoside B
L I
and O
gypenoside B
LI I
, O
respectively O
. O

They O
were O
identified O
by O
mass O
and O
NMR O
spectra O
as O
damulin B
A I
and O
damulin B
B I
, O
gypenoside B
L I
and O
gypenoside B
LI I
, O
respectively O
. O

They O
were O
identified O
by O
mass O
and O
NMR O
spectra O
as O
damulin B
A I
and O
damulin B
B I
, O
gypenoside B
L I
and O
gypenoside B
LI I
, O
respectively O
. O

Two O
new O
tirucallane B
triterpenoids I
from O
the O
leaves O
of O
Aquilaria O
sinensis O
. O

Two O
new O
tirucallane B
triterpenoids I
, O
aquilacallanes B
A I
- I
B I
( O
1 O
- O
2 O
) O
, O
together O
with O
15 O
known O
compounds O
( O
3 O
- O
17 O
) O
were O
isolated O
from O
the O
leaves O
of O
Aquilaria O
sinensis O
. O

The O
known O
compounds O
, O
ursolic B
acid I
( O
7 O
) O
and O
5 B
, I
7 I
, I
4 I
' I
- I
trimethoxyflavone I
( O
14 O
) O
, O
exhibited O
weak O
cytotoxic O
activity O
against O
some O
cells O
. O

The O
ETTAG O
was O
histologically O
indistinguishable O
from O
normal O
orthotopic O
thyroid O
tissue O
, O
and O
its O
follicular O
nature O
was O
confirmed O
by O
immunohistochemical O
positivity O
for O
thyroglobulin O
, O
thyroperoxidase O
, O
thyroid O
transcription O
factor O
- O
1 O
( O
TTF O
- O
1 O
/ O
Titf O
- O
1 O
/ O
Nkx2 O
. O
1 O
) O
, O
cytokeratin O
( O
CK O
) O
AE1 O
/ O
AE3 O
, O
CK O
7 O
, O
pendrin O
, O
human O
sodium B
iodide I
symporter O
( O
hNIS O
) O
, O
paired O
box O
gene O

To O
study O
this O
, O
steroid B
hormone I
profiles O
in O
urine O
were O
assessed O
in O
male O
subjects O
suffering O
from O
functional O
mutations O
in O
ATP B
binding O
cassette O
transporter O
A1 O
( O
ABCA1 O
) O
( O
n O
= O
24 O
) O
, O
lecithin O
: O
cholesterol B
acyltransferase O
( O
LCAT O
) O
( O
n O
= O
40 O
) O
, O
as O
well O
as O
in O
11 O
subjects O
with O
low O
HDL O
cholesterol B
( O
HDL O
- O
C O
) O
without O
ABCA1 O
/ O
LCAT O
mutations O
. O

A O
study O
of O
secondary O
metabolites O
from O
the O
bark O
of O
Alnus O
glutinosa O
led O
to O
the O
isolation O
of O
fourteen O
diarylheptanoids B
: O
oregonin B
( O
1 O
) O
, O
platyphylloside B
( O
2 O
) O
, O
rubranoside B
A I
( O
3 O
) O
, O
rubranoside B
B I
( O
4 O
) O
, O
hirsutanonol B
( O
5 O
) O
, O
hirsutenone B
( O
6 O
) O
, O
hirsutanonol B
- I
5 I
- I
O I
- I
beta I
- I
D I
- I
glucopyranoside I
( O
7 O
) O
, O
platyphyllonol B
- I
5 I
- I
O I
- I
beta I
- I
D I
- I
xylopyranoside I
( O
8 O

A O
study O
of O
secondary O
metabolites O
from O
the O
bark O
of O
Alnus O
glutinosa O
led O
to O
the O
isolation O
of O
fourteen O
diarylheptanoids B
: O
oregonin B
( O
1 O
) O
, O
platyphylloside B
( O
2 O
) O
, O
rubranoside B
A I
( O
3 O
) O
, O
rubranoside B
B I
( O
4 O
) O
, O
hirsutanonol B
( O
5 O
) O
, O
hirsutenone B
( O
6 O
) O
, O
hirsutanonol B
- I
5 I
- I
O I
- I
beta I
- I
D I
- I
glucopyranoside I
( O
7 O
) O
, O
platyphyllonol B
- I
5 I
- I
O I
- I
beta I
- I
D I
- I
xylopyranoside I
( O
8 O

) O
, O
aceroside B
VII I
( O
9 O
) O
, O
alnuside B
A I
( O
10 O
) O
, O
alnuside B
B I
( O
11 O
) O
, O
1 B
, I
7 I
- I
bis I
- I
( I
3 I
, I
4 I
- I
dihydoxyphenyl I
) I
- I
5 I
- I
hydroxy I
- I
heptane I
- I
3 I
- I
O I
- I
beta I
- I
D I
- I
xylopyranoside I
( O
12 O
) O
, O
( B
5S I
) I
- I
1 I
- I
( I
4 I
- I
hydroxyphenyl I
) I
- I
7 I
- I
( I
3 I
, I
4 I
- I
dihydroxyphenyl I
) I
- I
5 I
- I
O I
- I
beta I
- I
D I
- I
glucopyranosyl I
- I

) O
, O
aceroside B
VII I
( O
9 O
) O
, O
alnuside B
A I
( O
10 O
) O
, O
alnuside B
B I
( O
11 O
) O
, O
1 B
, I
7 I
- I
bis I
- I
( I
3 I
, I
4 I
- I
dihydoxyphenyl I
) I
- I
5 I
- I
hydroxy I
- I
heptane I
- I
3 I
- I
O I
- I
beta I
- I
D I
- I
xylopyranoside I
( O
12 O
) O
, O
( B
5S I
) I
- I
1 I
- I
( I
4 I
- I
hydroxyphenyl I
) I
- I
7 I
- I
( I
3 I
, I
4 I
- I
dihydroxyphenyl I
) I
- I
5 I
- I
O I
- I
beta I
- I
D I
- I
glucopyranosyl I
- I

) O
, O
aceroside B
VII I
( O
9 O
) O
, O
alnuside B
A I
( O
10 O
) O
, O
alnuside B
B I
( O
11 O
) O
, O
1 B
, I
7 I
- I
bis I
- I
( I
3 I
, I
4 I
- I
dihydoxyphenyl I
) I
- I
5 I
- I
hydroxy I
- I
heptane I
- I
3 I
- I
O I
- I
beta I
- I
D I
- I
xylopyranoside I
( O
12 O
) O
, O
( B
5S I
) I
- I
1 I
- I
( I
4 I
- I
hydroxyphenyl I
) I
- I
7 I
- I
( I
3 I
, I
4 I
- I
dihydroxyphenyl I
) I
- I
5 I
- I
O I
- I
beta I
- I
D I
- I
glucopyranosyl I
- I

Edge O
- O
to O
- O
Edge O
Assembled O
Graphene B
Oxide I
Aerogels O
with O
Outstanding O
Mechanical O
Performance O
and O
Superhigh O
Chemical O
Activity O
. O

Herein O
, O
chemically O
crosslinked O
graphene B
oxide I
( O
GO O
) O
3D O
aerogels O
with O
large O
specific O
surface O
areas O
( O
up O
to O
850 O
m O
( O
2 O
) O
g O
( O
- O
1 O
) O
) O
, O
outstanding O
mechanical O
performance O
( O
up O
to O
20 O
MPa O
Young O
' O
s O
modulus O
, O
1 O
MPa O
yield O
strength O
and O
45 O
J O
g O
( O
- O
1 O
) O
specific O
energy O
adsorption O
) O
, O
and O
superhigh O
chemical O
activity O
( O
toward O
some O
reducing O
gases O
such O
as O
H2 B
S I
, O
HI B
, O
and O
SO2 B
) O
, O
are O
fabricated O
by O
assembling O
2D O
GO O
sheets O
edge O
- O
to O
- O
edge O
into O
uniform O
, O
3D O
hydrogel O
networks O
with O
subsequent O

Herein O
, O
chemically O
crosslinked O
graphene B
oxide I
( O
GO O
) O
3D O
aerogels O
with O
large O
specific O
surface O
areas O
( O
up O
to O
850 O
m O
( O
2 O
) O
g O
( O
- O
1 O
) O
) O
, O
outstanding O
mechanical O
performance O
( O
up O
to O
20 O
MPa O
Young O
' O
s O
modulus O
, O
1 O
MPa O
yield O
strength O
and O
45 O
J O
g O
( O
- O
1 O
) O
specific O
energy O
adsorption O
) O
, O
and O
superhigh O
chemical O
activity O
( O
toward O
some O
reducing O
gases O
such O
as O
H2 B
S I
, O
HI B
, O
and O
SO2 B
) O
, O
are O
fabricated O
by O
assembling O
2D O
GO O
sheets O
edge O
- O
to O
- O
edge O
into O
uniform O
, O
3D O
hydrogel O
networks O
with O
subsequent O

D O
. O
magna O
21 O
day O
studies O
were O
conducted O
with O
model O
stressors O
of O
sodium B
chloride I
and O
dissolved O
silver B
. O

Significant O
differences O
in O
neonate O
phototactic O
behavior O
were O
observed O
among O
treatment O
level O
broods O
, O
suggesting O
that O
maternal O
exposure O
to O
sublethal O
levels O
of O
NaCl B
and O
Ag B
+ I
impacted O
offspring O
. O

In O
fact O
, O
progeny O
phototactic O
response O
was O
significantly O
affected O
at O
or O
below O
21 O
- O
day O
LOEC O
thresholds O
for O
fecundity O
in O
broods O
2 O
, O
3 O
, O
5 O
and O
6 O
of O
the O
NaCl B
experiment O
and O
in O
broods O
2 O
, O
4 O
, O
5 O
and O
6 O
of O
the O
dissolved O
Ag B
+ I
study O
. O

Aim O
of O
this O
study O
was O
to O
elucidate O
lutein B
oxidation O
products O
mediated O
through O
peroxyl B
radical O
inducer O
2 B
, I
2 I
' I
- I
Azobis I
( I
2 I
- I
methylpropionamidine I
) I
dihydrochloride I
( O
AAPH B
) O
and O
to O
study O
antioxidant O
and O
cytotoxic O
effects O
of O
oxidized B
lutein I
using O
liposome O
and O
HeLa O
cells O
. O

Lutein B
( O
20 O
mu O
mol O
) O
with O
AAPH B
( O
5mM O
) O
in O
liposome O
' O
s O
was O
incubated O
at O
37 O
degrees O
C O
in O
dark O
for O
3h O
, O
oxidized B
lutein I
products O
were O
characterized O
by O
LC O
- O
MS O
( O
APCI O
( O
+ O
) O
) O
and O
studied O
for O
their O
free O
radical O
scavenging O
activity O
and O
cytotoxic O
effects O
in O
terms O
of O
cell O
viability O
, O
cellular O
glutathione B
, O
and O
malondialdehyde B
levels O
. O

Free O
radical O
scavenging O
activity O
of O
oxidized B
lutein I
was O
higher O
by O
32 O
. O
7 O
% O
( O
IC50 O
, O
2 O
. O
64 O
mu O
g O
) O
than O
lutein B
( O
IC50 O
, O
5 O
. O
28 O
mu O
g O
) O
. O

Oxidized B
lutein I
lowered O
the O
lipid O
peroxidation O
( O
21 O
% O
) O
, O
HeLa O
cells O
viability O
( O
22 O
% O
) O
and O
glutathione B
levels O
( O
32 O
% O
) O
than O
lutein B
. O

To O
conclude O
, O
the O
oxidized B
lutein I
may O
be O
highly O
reactive O
, O
since O
oxidation O
by O
AAPH B
results O
in O
peroxyl B
radical O
ions O
, O
which O
can O
react O
with O
conjugated O
polyene B
chain O
of O
lutein B
that O
could O
lead O
to O
higher O
antioxidant O
and O
cytotoxic O
effects O
on O
HeLa O
cells O
. O

Tricyclic B
thiazoles I
are O
a O
new O
class O
of O
angiogenesis O
inhibitors O
. O

Tricyclic B
thiazoleamine I
derivatives O
that O
were O
identified O
as O
hits O
in O
a O
screen O
against O
human O
umbilical O
vein O
endothelial O
cell O
proliferation O
were O
subjected O
to O
a O
structure O
- O
activity O
relationship O
study O
. O

A O
total O
of O
42 O
pre O
- O
migrating O
( O
silver O
) O
female O
eels O
from O
lowly O
, O
highly O
and O
extremely O
polluted O
environments O
in O
Belgium O
and O
, O
for O
comparative O
purposes O
, O
a O
lowly O
polluted O
habitat O
in O
Italy O
were O
measured O
for O
polychlorinated B
biphenyls I
( O
PCBs B
) O
, O
organochlorine B
pesticides O
( O
OCPs O
) O
and O
brominated O
flame O
retardants O
( O
BFRs O
) O
. O

This O
method O
is O
demonstrated O
using O
zinc B
phosphide I
( O
Zn3P2 B
) O
and O
zinc B
antimonide I
( O
beta O
- O
Zn4Sb3 B
) O
nanowires O
as O
example O
systems O
. O

This O
method O
is O
demonstrated O
using O
zinc B
phosphide I
( O
Zn3P2 B
) O
and O
zinc B
antimonide I
( O
beta O
- O
Zn4Sb3 B
) O
nanowires O
as O
example O
systems O
. O

Predictive O
factors O
of O
sensitivity O
to O
elisidepsin B
, O
a O
novel O
kahalalide B
f I
- O
derived O
marine O
compound O
. O

Elisidepsin B
( O
PM02734 B
, O
Irvalec B
( O
R O
) O
) O
is O
a O
synthetic O
marine O
- O
derived O
cyclic O
peptide O
of O
the O
Kahalalide B
F I
family O
currently O
in O
phase O
II O
clinical O
development O
. O

We O
show O
here O
that O
treatment O
of O
prostate O
cancer O
PPC O
- O
1 O
cells O
with O
the O
superoxide B
generators O
menadione B
, O
paraquat B
, O
or O
buthionine B
sulfoximine I
down O
- O
regulates O
c O
- O
FLIP O
long O
( O
c O
- O
FLIPL O
) O
protein O
levels O
, O
which O
is O
prevented O
by O
the O
proteasome O
inhibitor O
MG132 B
. O

Additionally O
, O
the O
increased O
levels O
of O
mRNA O
and O
protein O
in O
adipocyte O
- O
specific O
fatty B
acid I
binding O
protein O
4 O
and O
fatty B
acid I
synthase O
induced O
by O
RGZ B
in O
3T3 O
- O
L1 O
cells O
were O
decreased O
upon O
treatment O
with O
6 B
- I
gingerol I
. O

Additionally O
, O
the O
increased O
levels O
of O
mRNA O
and O
protein O
in O
adipocyte O
- O
specific O
fatty B
acid I
binding O
protein O
4 O
and O
fatty B
acid I
synthase O
induced O
by O
RGZ B
in O
3T3 O
- O
L1 O
cells O
were O
decreased O
upon O
treatment O
with O
6 B
- I
gingerol I
. O

A O
new O
compound O
1 O
( O
named O
botryosphaerin B
F I
) O
, O
along O
with O
other O
three O
known O
compounds O
2 O
( O
13 B
, I
14 I
, I
15 I
, I
16 I
- I
tetranorlabd I
- I
7 I
- I
ene I
- I
19 I
, I
6b I
: I
12 I
, I
17 I
- I
diolide I
) O
, O
3 O
( O
botryosphaerin B
B I
) O
and O
4 O
( O
LL B
- I
Z1271 I
beta I
) O
, O
has O
been O
isolated O
from O
the O
mangrove O
fungus O
Aspergillus O
terreus O
( O
No O
. O
GX7 O
- O
3B O
) O
. O

A O
new O
compound O
1 O
( O
named O
botryosphaerin B
F I
) O
, O
along O
with O
other O
three O
known O
compounds O
2 O
( O
13 B
, I
14 I
, I
15 I
, I
16 I
- I
tetranorlabd I
- I
7 I
- I
ene I
- I
19 I
, I
6b I
: I
12 I
, I
17 I
- I
diolide I
) O
, O
3 O
( O
botryosphaerin B
B I
) O
and O
4 O
( O
LL B
- I
Z1271 I
beta I
) O
, O
has O
been O
isolated O
from O
the O
mangrove O
fungus O
Aspergillus O
terreus O
( O
No O
. O
GX7 O
- O
3B O
) O
. O

Baeckein B
E I
, O
a O
new O
bioactive O
C B
- I
methylated I
biflavonoid I
from O
the O
roots O
of O
Baeckea O
frutescens O
. O

A O
phytochemical O
study O
of O
Baeckea O
frutescens O
afforded O
a O
new O
biflavonoid B
named O
as O
baeckein B
E I
( O
1 O
) O
, O
along O
with O
four O
known O
C B
- I
methylated I
flavonols I
, O
baeckeins B
A I
( O
2 O
) O
and O
B O
( O
3 O
) O
, O
6 B
- I
methylquercetin I
( O
6 O
) O
and O
6 B
- I
methylquercetin I
- I
4 I
' I
- I
O I
- I
beta I
- I
d I
- I
glucopyranoside I
( O
7 O
) O
, O
and O
two O
known O
biflavonoids O
baeckeins B
C I
( O
4 O
) O
and O
D O
( O
5 O
) O
. O

A O
phytochemical O
study O
of O
Baeckea O
frutescens O
afforded O
a O
new O
biflavonoid B
named O
as O
baeckein B
E I
( O
1 O
) O
, O
along O
with O
four O
known O
C B
- I
methylated I
flavonols I
, O
baeckeins B
A I
( O
2 O
) O
and O
B O
( O
3 O
) O
, O
6 B
- I
methylquercetin I
( O
6 O
) O
and O
6 B
- I
methylquercetin I
- I
4 I
' I
- I
O I
- I
beta I
- I
d I
- I
glucopyranoside I
( O
7 O
) O
, O
and O
two O
known O
biflavonoids O
baeckeins B
C I
( O
4 O
) O
and O
D O
( O
5 O
) O
. O

A O
phytochemical O
study O
of O
Baeckea O
frutescens O
afforded O
a O
new O
biflavonoid B
named O
as O
baeckein B
E I
( O
1 O
) O
, O
along O
with O
four O
known O
C B
- I
methylated I
flavonols I
, O
baeckeins B
A I
( O
2 O
) O
and O
B O
( O
3 O
) O
, O
6 B
- I
methylquercetin I
( O
6 O
) O
and O
6 B
- I
methylquercetin I
- I
4 I
' I
- I
O I
- I
beta I
- I
d I
- I
glucopyranoside I
( O
7 O
) O
, O
and O
two O
known O
biflavonoids O
baeckeins B
C I
( O
4 O
) O
and O
D O
( O
5 O
) O
. O

Their O
amino B
acid I
sequences O
were O
related O
to O
Martentoxin O
, O
which O
has O
been O
characterized O
from O
the O
Chinese O
scorpion O
Buthus O
martenzi O
Karch O
and O
described O
as O
both O
a O
BKCa O
and O
Kv1 O
. O
3 O
blocker O
. O

Towards O
the O
bioequivalence O
of O
pressurised O
metered O
dose O
inhalers O
1 O
: O
Design O
and O
characterisation O
of O
aerodynamically O
equivalent O
beclomethasone B
dipropionate I
inhalers O
with O
and O
without O
glycerol B
as O
a O
non O
- O
volatile O
excipient O
. O

Both O
inhaler O
formulations O
contained O
the O
drug O
, O
beclomethasone B
dipropionate I
( O
BDP B
) O
, O
a O
volatile O
mixture O
of O
ethanol B
co O
- O
solvent O
and O
propellant O
( O
hydrofluoroalkane B
- O
HFA B
) O
. O

In O
conclusion O
, O
fisetin B
supplementation O
displayed O
hypocholesterolemic O
effects O
by O
modulating O
the O
expression O
of O
genes O
associated O
with O
cholesterol B
and O
bile B
acid I
metabolism O
. O

The O
HPLC O
- O
DAD O
- O
ESI O
/ O
MS O
( O
n O
) O
analysis O
revealed O
the O
presence O
of O
four O
dicaffeoyl B
acid I
derivatives O
and O
nine O
flavonoids B
, O
comprising O
quercetin B
, O
kaempferol B
and O
isorhamnetin B
derivatives O
. O

Aqueous O
extract O
is O
richer O
in O
dicaffeoyl B
acid I
derivatives O
. O

MDL B
11939 I
( O
1 O
. O
0 O
mg O
/ O
kg O
) O
, O
a O
5HT2A O
receptor O
antagonist O
, O
fully O
reversed O
the O
changes O
induced O
by O
DOI B
on O
HFO O
but O
only O
partially O
for O
the O
low O
gamma O
band O
. O

Equivalent O
increases O
in O
HFO O
power O
were O
observed O
after O
TCB B
- I
2 I
( O
5HT2A O
receptor O
agonist O
, O
0 O
. O
1 O
- O
1 O
. O
5 O
mg O
/ O
kg O
) O
, O
but O
not O
CP B
809101 I
( O
5H2C O
receptor O
agonist O
, O
0 O
. O
1 O
- O
3 O
mg O
/ O
kg O
) O
. O

Synthesis O
of O
indolyl B
- I
3 I
- I
acetonitrile I
derivatives O
and O
their O
inhibitory O
effects O
on O
nitric B
oxide I
and O
PGE2 B
productions O
in O
LPS O
- O
induced O
RAW O
264 O
. O
7 O
cells O
. O

RESULTS O
: O
Our O
findings O
summarized O
novel O
anti O
- O
inflammatory O
mechanisms O
for O
Atropa O
acuminata O
based O
on O
dual O
in O
vitro O
cyclooxygenase O
1 O
/ O
2 O
/ O
and O
5 O
- O
Lipoxygenase O
inhibitory O
activities O
and O
also O
significant O
downregulation O
of O
nitric B
oxide I
( O
NO B
) O
and O
pro O
- O
inflammatory O
cytokin O
( O
TNF O
- O
alpha O
and O
Il O
- O
1 O
beta O
) O
release O
in O
LPS O
- O
stimulated O
RAW O
246 O
. O
7 O
macrophage O
cell O
line O
. O

Two O
new O
saponins B
of O
20 B
, I
26 I
- I
epoxy I
derivatives O
of O
pseudojujubogenin B
, O
hoduloside B
XI I
( O
1 O
) O
and O
hoduloside B
XII I
( O
2 O
) O
were O
isolated O
from O
the O
seeds O
of O
Hovenia O
trichocarpa O
. O

Two O
new O
saponins B
of O
20 B
, I
26 I
- I
epoxy I
derivatives O
of O
pseudojujubogenin B
, O
hoduloside B
XI I
( O
1 O
) O
and O
hoduloside B
XII I
( O
2 O
) O
were O
isolated O
from O
the O
seeds O
of O
Hovenia O
trichocarpa O
. O

Hoduloside B
XI I
was O
confirmed O
to O
be O
3 B
- I
O I
- I
{ I
beta I
- I
d I
- I
glucopyranosyl I
( I
1 I
- I
- I
> I
3 I
) I
- I
[ I
beta I
- I
d I
- I
xylopyranosyl I
( I
1 I
- I
- I
> I
2 I
) I
] I
- I
alpha I
- I
l I
- I
arabinopyranosyl I
} I
- I
20 I
, I
26 I
- I
epoxypseudojujubogen I
. O

Hoduloside B
XII I
was O
identified O
as O
3 B
- I
O I
- I
{ I
beta I
- I
d I
- I
xylopyranose I
( I
1 I
- I
- I
> I
2 I
) I
glucopyranosyl I
( I
1 I
- I
- I
> I
3 I
) I
[ I
rhamnopyranose I
( I
1 I
- I
- I
> I
2 I
) I
] I
beta I
- I
d I
- I
glucopyranosyl I
} I
- I
20 I
, I
26 I
- I
epoxypseudojujubogen I
. O

The O
effect O
of O
sodium B
selenite I
on O
lead O
induced O
cognitive O
dysfunction O
. O

Lactating O
Sprague O
- O
Dawley O
rats O
( O
SD O
rats O
) O
were O
randomly O
divided O
to O
four O
groups O
: O
0ppm O
lead B
acetate I
( O
Pb B
) O
; O
0ppm O
Pb B
and O
0 O
. O
2ppm O
sodium B
selenite I
( O
Se B
) O
; O
100ppm O
Pb B
; O
100ppm O
Pb B
and O
0 O
. O
2ppm O
Se B
. O

Lactating O
Sprague O
- O
Dawley O
rats O
( O
SD O
rats O
) O
were O
randomly O
divided O
to O
four O
groups O
: O
0ppm O
lead B
acetate I
( O
Pb B
) O
; O
0ppm O
Pb B
and O
0 O
. O
2ppm O
sodium B
selenite I
( O
Se B
) O
; O
100ppm O
Pb B
; O
100ppm O
Pb B
and O
0 O
. O
2ppm O
Se B
. O

Pooled O
sensitivity O
and O
specificity O
of O
( B
99m I
) I
Tc I
- I
MIBI I
scan O
in O
detecting O
malignant O
thyroid O
nodules O
were O
85 O
. O
1 O
% O
[ O
95 O
% O
confidence O
interval O
( O
95 O
% O
CI O
) O
: O
81 O
. O
1 O
- O
88 O
. O
5 O
% O
] O
and O
45 O
. O
7 O
% O
( O
95 O
% O
CI O
: O
42 O
. O
7 O
- O
48 O
. O
7 O
% O
) O
, O
respectively O
, O
on O
a O
per O
lesion O
- O
based O
analysis O
, O
irrespective O
of O
eventual O
results O
of O
previous O
technetium B
pertechnetate I
( O
( B
99m I
) I
TcO4 I
) O
or O
iodine B
- I
123 I
( O
( B
123 I
) I
I I
) O
scan O
. O

HISTONE O
DEACETYLASE O
INHIBITION O
AFFECTS O
SODIUM B
IODIDE I
SYMPORTER O
( O
NIS O
) O
EXPRESSION O
AND O
INDUCES O
( B
1 I
) I
( I
3 I
) I
( I
1 I
) I
I I
CYTOTOXICITY O
IN O
ANAPLASTIC O
THYROID O
CANCER O
CELLS O
. O

The O
resistance O
of O
anaplastic O
thyroid O
cancer O
to O
radioiodine B
treatment O
is O
principally O
due O
to O
the O
absence O
of O
expression O
of O
the O
sodium B
iodide I
symporter O
( O
NIS O
) O
, O
mainly O
due O
to O
epigenetic O
silencing O
. O

Using O
whole O
mount O
in O
situ O
hybridization O
to O
examine O
thyroid B
hormone I
deiodinase O
expression O
in O
embryonic O
and O
larval O
zebrafish O
: O
A O
tool O
for O
examining O
OH B
- I
BDE I
toxicity O
to O
early O
life O
stages O
. O

Polybrominated B
diphenyl I
ethers I
( O
PBDEs B
) O
and O
their O
oxidative O
metabolites O
( O
hydroxylated B
PBDEs I
; O
OH B
- I
BDEs I
) O
are O
known O
endocrine O
disrupting O
contaminants O
that O
have O
been O
shown O
to O
disrupt O
thyroid B
hormone I
regulation O
both O
in O
mammals O
and O
in O
fish O
. O

Polybrominated B
diphenyl I
ethers I
( O
PBDEs B
) O
and O
their O
oxidative O
metabolites O
( O
hydroxylated B
PBDEs I
; O
OH B
- I
BDEs I
) O
are O
known O
endocrine O
disrupting O
contaminants O
that O
have O
been O
shown O
to O
disrupt O
thyroid B
hormone I
regulation O
both O
in O
mammals O
and O
in O
fish O
. O

The O
purpose O
of O
this O
study O
was O
to O
determine O
the O
precise O
organ O
and O
tissue O
locations O
that O
express O
genes O
critical O
to O
thyroid B
hormone I
regulation O
in O
developing O
zebrafish O
( O
Danio O
rerio O
) O
, O
and O
to O
determine O
the O
effects O
of O
an O
OH B
- I
BDE I
on O
their O
expression O
. O

While O
PBDEs B
and O
OH B
- I
BDEs I
have O
been O
shown O
to O
inhibit O
the O
activity O
and O
expression O
of O
deiodionases O
, O
a O
family O
of O
enzymes O
that O
regulate O
thyroid B
hormone I
concentrations O
intracellularly O
, O
it O
is O
unclear O
whether O
or O
not O
they O
can O
affect O
regional O
expression O
of O
the O
different O
isoforms O
during O
early O
development O
. O

These O
variants O
are O
expected O
to O
encode O
either O
a O
full O
length O
( O
OATP2B1 O
- O
FL O
) O
or O
shortened O
protein O
lacking O
22 O
N B
- O
terminus O
amino B
acids I
( O
OATP2B O
- O
Short O
) O
. O

Using O
a O
transient O
heterologous O
cell O
expression O
system O
, O
we O
find O
that O
the O
transport O
activities O
of O
the O
short O
OATP2B1 O
variant O
towards O
substrates O
estrone B
sulfate I
and O
rosuvastatin B
are O
similar O
to O
the O
well O
- O
characterized O
full O
length O
variant O
. O

The O
analyses O
have O
been O
performed O
in O
comparison O
to O
acetylsalicylic B
acid I
( O
ASA B
) O
and O
diclofenac B
( O
Diclo B
) O
, O
which O
are O
well O
- O
known O
to O
reduce O
colon O
carcinoma O
risk O
. O

Cajaninstilbene B
acid I
( O
CSA B
) O
exerts O
cytoprotective O
effects O
against O
oxidative O
stress O
through O
the O
Nrf2 O
- O
dependent O
antioxidant O
pathway O
. O

Cajaninstilbene B
acid I
( O
CSA B
) O
, O
an O
active O
compound O
separated O
from O
pigeon O
pea O
leaves O
, O
possesses O
the O
highly O
efficient O
antioxidant O
activities O
. O

Ca B
( I
2 I
+ I
) I
binding O
induced O
a O
large O
IR O
spectrum O
, O
with O
prominent O
amide B
I O
/ O
II O
polypeptide O
changes O
, O
bandshifts O
assigned O
to O
carboxylate B
and O
an O
arginine B
, O
and O
a O
number O
of O
bandshifts O
of O
heme B
a I
. O

The O
Na B
( I
+ I
) I
- O
induced O
binding O
spectrum O
showed O
much O
weaker O
amide B
I O
/ O
II O
and O
heme B
a I
changes O
but O
had O
similar O
shifts O
assignable O
to O
carboxylate B
and O
arginine B
residues O
. O

Amino B
acids I
as O
co O
- O
amorphous O
stabilizers O
for O
poorly O
water O
soluble O
drugs O
- O
Part O
1 O
: O
Preparation O
, O
stability O
and O
dissolution O
enhancement O
. O

In O
this O
study O
, O
we O
investigated O
a O
fundamentally O
different O
approach O
to O
stabilize O
the O
amorphous O
form O
of O
drugs O
, O
namely O
the O
use O
of O
amino B
acids I
as O
small O
molecular O
weight O
excipients O
that O
form O
specific O
molecular O
interactions O
with O
the O
drug O
resulting O
in O
co O
- O
amorphous O
forms O
. O

The O
two O
poorly O
water O
soluble O
drugs O
carbamazepine B
and O
indomethacin B
were O
combined O
with O
amino B
acids I
from O
the O
binding O
sites O
of O
the O
biological O
receptors O
of O
these O
drugs O
. O

Mixtures O
of O
drug O
and O
the O
amino B
acids I
arginine B
, O
phenylalanine B
, O
tryptophan B
and O
tyrosine B
were O
prepared O
by O
vibrational O
ball O
milling O
. O

The O
dissolution O
rate O
of O
all O
co O
- O
amorphous O
drug O
- O
amino B
acid I
mixtures O
was O
significantly O
increased O
over O
that O
of O
the O
respective O
crystalline O
and O
amorphous O
pure O
drugs O
. O

Amino B
acids I
thus O
appear O
as O
promising O
excipients O
to O
solve O
challenges O
connected O
with O
the O
stability O
and O
dissolution O
of O
amorphous O
drugs O
. O

The O
involvement O
of O
heme B
oxygenase O
1 O
but O
not O
nitric B
oxide I
synthase O
2 O
in O
a O
hepatoprotective O
action O
of O
quercetin B
in O
lipopolysaccharide O
- O
induced O
hepatotoxicity O
of O
d B
- I
galactosamine I
sensitized O
rats O
. O

Experiment O
2 O
: O
1 O
) O
C O
containing O
carbonyl B
iron I
( O
average O
; O
22 O
. O
4mg O
/ O
day O
; O
6 O
weeks O
) O
; O
CI O
2 O
) O
CI O
plus O
ezetimibe B
; O
CIE O
3 O
) O
H O
containing O
carbonyl B
iron I
; O
HI O
4 O
) O
HI O
plus O
ezetimibe B
; O
HIE O
. O

Experiment O
2 O
: O
1 O
) O
C O
containing O
carbonyl B
iron I
( O
average O
; O
22 O
. O
4mg O
/ O
day O
; O
6 O
weeks O
) O
; O
CI O
2 O
) O
CI O
plus O
ezetimibe B
; O
CIE O
3 O
) O
H O
containing O
carbonyl B
iron I
; O
HI O
4 O
) O
HI O
plus O
ezetimibe B
; O
HIE O
. O

Astaxanthin B
Suppresses O
MPP B
+ I
- O
Induced O
Oxidative O
Damage O
in O
PC12 O
Cells O
through O
a O
Sp1 O
/ O
NR1 O
Signaling O
Pathway O
. O

Objective O
: O
To O
investigate O
astaxanthin B
( O
ATX B
) O
neuroprotection O
, O
and O
its O
mechanism O
, O
on O
a O
1 B
- I
methyl I
- I
4 I
- I
phenyl I
- I
pyridine I
ion O
( O
MPP B
+ I
) O
- O
induced O
cell O
model O
of O
Parkinson O
' O
s O
disease O
. O

Methods O
: O
Mature O
, O
differentiated O
PC12 O
cells O
treated O
with O
MPP B
+ I
were O
used O
as O
an O
in O
vitro O
cell O
model O
. O

Results O
: O
PC12 O
cell O
viability O
was O
significantly O
reduced O
by O
MPP B
+ I
treatment O
. O

Following O
co O
- O
treatment O
with O
ATX B
and O
MPP B
+ I
, O
cell O
viability O
was O
significantly O
increased O
, O
and O
Sp1 O
and O
NR1 O
mRNA O
and O
protein O
were O
decreased O
, O
compared O
with O
the O
MPP B
+ I
groups O
( O
p O
< O
0 O
. O
01 O
) O
. O

Following O
co O
- O
treatment O
with O
ATX B
and O
MPP B
+ I
, O
cell O
viability O
was O
significantly O
increased O
, O
and O
Sp1 O
and O
NR1 O
mRNA O
and O
protein O
were O
decreased O
, O
compared O
with O
the O
MPP B
+ I
groups O
( O
p O
< O
0 O
. O
01 O
) O
. O

In O
addition O
, O
mithracycin B
A I
protected O
PC12 O
cells O
from O
oxidative O
stress O
caused O
by O
MPP B
+ I
by O
specifically O
inhibiting O
the O
expression O
of O
Sp1 O
. O

In O
addition O
, O
mithracycin B
A I
protected O
PC12 O
cells O
from O
oxidative O
stress O
caused O
by O
MPP B
+ I
by O
specifically O
inhibiting O
the O
expression O
of O
Sp1 O
. O

Conclusion O
: O
ATX B
inhibited O
oxidative O
stress O
induced O
by O
MPP B
+ I
in O
PC12 O
cells O
, O
via O
the O
SP1 O
/ O
NR1 O
signaling O
pathway O
. O

The O
reaction O
proceeds O
with O
high O
site O
- O
and O
diastereoselectivity O
to O
provide O
aryl B
pyrroloindoline I
products O
in O
one O
step O
from O
simple O
starting O
materials O
. O

Recently O
we O
demonstrated O
the O
ability O
of O
mercuric B
chloride I
( O
Hg B
( I
2 I
+ I
) I
) O
in O
human O
hepatoma O
HepG2 O
cells O
to O
significantly O
decrease O
the O
TCDD B
- O
mediated O
induction O
of O
Cytochrome O
P450 O
1A1 O
( O
CYP1A1 O
) O
mRNA O
, O
protein O
, O
and O
catalytic O
activity O
levels O
. O

Importantly O
, O
this O
inhibition O
was O
specific O
to O
CYP1A1and O
was O
not O
radiated O
to O
other O
aryl B
hydrocarbon I
receptor O
( O
AhR O
) O
- O
regulated O
genes O
, O
as O
MeHg B
induced O
NAD B
( I
P I
) I
H I
: O
quinone B
oxidoreductase O
1 O
mRNA O
and O
protein O
levels O
. O

Furthermore O
, O
the O
inhibition O
of O
HO O
- O
1 O
activity O
, O
by O
tin B
mesoporphyrin I
, O
caused O
a O
complete O
restoration O
of O
MeHg B
- O
mediated O
inhibition O
of O
CYP1A1 O
activity O
, O
induced O
by O
TCDD B
. O

Second O
, O
the O
bioactive O
compounds O
identified O
( O
epimedin B
A I
, O
epimedin B
B I
, O
epimedin B
C I
and O
icariin B
) O
were O
fished O
and O
knocked O
out O
using O
high O
- O
speed O
counter O
- O
current O
chromatography O
and O
preparative O
HPLC O
. O

Second O
, O
the O
bioactive O
compounds O
identified O
( O
epimedin B
A I
, O
epimedin B
B I
, O
epimedin B
C I
and O
icariin B
) O
were O
fished O
and O
knocked O
out O
using O
high O
- O
speed O
counter O
- O
current O
chromatography O
and O
preparative O
HPLC O
. O

Second O
, O
the O
bioactive O
compounds O
identified O
( O
epimedin B
A I
, O
epimedin B
B I
, O
epimedin B
C I
and O
icariin B
) O
were O
fished O
and O
knocked O
out O
using O
high O
- O
speed O
counter O
- O
current O
chromatography O
and O
preparative O
HPLC O
. O

MATERIALS O
AND O
METHODS O
: O
The O
plant O
ethanolic O
extracts O
were O
initially O
tested O
against O
lipopolysaccharide O
( O
LPS O
) O
- O
induced O
prostaglandin B
E2 I
( O
PGE2 B
) O
production O
in O
RAW264 O
. O
7 O
mouse O
macrophages O
, O
and O
interleukin O
6 O
( O
IL O
- O
6 O
) O
and O
tumor O
necrosis O
factor O
( O
TNF O
) O
production O
in O
human O
U937 O
monocytes O
. O

An O
intermediate O
GTX2 B
, I
3 I
- I
aldehyde I
was O
first O
synthesized O
by O
activating O
the O
NH2 B
group O
of O
the O
2nd O
and O
8th O
amino B
acid I
residues O
with O
three O
different O
aldehydes B
and O
two O
artificial O
complete O
antigens O
GTX2 B
, I
3 I
- I
aldehyde I
- O
bovine O
serum O
albumin O
( O
BSA O
) O
and O
GTX2 B
, I
3 I
- I
aldehyde I
- O
keyhole O
limpet O
hemocyanin O
( O
KLH O
) O
were O
then O
prepared O
by O
cross O
- O
linking O
the O
intermediate O
with O
BSA O
or O
KLH O
. O

All O
women O
who O
attended O
the O
infertility O
clinic O
during O
this O
period O
were O
screened O
for O
hyperprolactinemia O
and O
only O
women O
with O
hyperprolactinemia O
and O
infertility O
were O
further O
studied O
for O
the O
presence O
of O
macroprolactin O
by O
polyethylene B
glycol I
precipitation O
assay O
. O

Nickel B
and O
Cobalt B
- O
Catalyzed O
Coupling O
of O
Alkyl B
Halides I
with O
Alkenes B
via O
Heck O
Reactions O
and O
Radical O
Conjugate O
Addition O
. O

Cross O
- O
coupling O
of O
alkyl B
halides I
with O
alkenes B
leading O
to O
Heck O
- O
type O
and O
addition O
products O
is O
summarized O
. O

The O
development O
of O
Heck O
reaction O
with O
aliphatic B
halides I
although O
has O
made O
significant O
progress O
in O
the O
past O
decade O
and O
particularly O
recently O
, O
it O
was O
much O
less O
explored O
in O
comparison O
with O
the O
aryl B
halides I
. O

The O
development O
of O
Heck O
reaction O
with O
aliphatic B
halides I
although O
has O
made O
significant O
progress O
in O
the O
past O
decade O
and O
particularly O
recently O
, O
it O
was O
much O
less O
explored O
in O
comparison O
with O
the O
aryl B
halides I
. O

The O
use O
of O
Ni B
- O
and O
Co B
- O
catalyzed O
protocols O
allowed O
efficient O
Heck O
coupling O
of O
activated O
and O
unactivated O
alkenes B
with O
1 O
( O
o O
) O
, O
2 O
( O
o O
) O
and O
3 O
( O
o O
) O
alkyl B
halides I
. O

The O
recent O
development O
of O
Ni B
- O
and O
Co B
- O
catalyzed O
addition O
of O
alkyl B
halides I
to O
alkenes B
displays O
much O
improved O
reactivity O
and O
functional O
group O
tolerance O
. O

In O
this O
mini O
- O
review O
, O
we O
also O
attempt O
to O
overview O
the O
mechanisms O
that O
are O
proposed O
in O
the O
reactions O
, O
aiming O
at O
providing O
insight O
into O
the O
nickel B
and O
cobalt B
- O
catalyzed O
coupling O
of O
alkyl B
halides I
with O
alkenes B
. O

Chlorpyrifos B
( O
CPF B
) O
is O
an O
organophosphate B
( O
OP O
) O
insecticide O
that O
is O
metabolically O
activated O
to O
the O
highly O
toxic O
chlorpyrifos B
oxon I
. O

Estimated O
CLint O
for O
phthalic B
acid I
production O
by O
hCYP3A4 O
was O
24 O
. O
5 O
mu O
LnmolCYP O
( O
- O
1 O
) O
min O
( O
- O
1 O
) O
while O
it O
was O
continuously O
produced O
by O
rCYP2C6 O
and O
3A2 O
via O
passive O
mechanism O
. O

Five O
times O
per O
day O
, O
subjects O
received O
a O
food O
supplement O
consisting O
of O
eicosapentaenoic B
acid I
( O
EPA B
) O
and O
docosahexaenoic B
acid I
( O
DHA B
) O
( O
3 O
g O
per O
day O
, O
944 O
mg O
EPA B
, O
and O
2 O
, O
088 O
mg O
DHA B
) O
. O

Five O
times O
per O
day O
, O
subjects O
received O
a O
food O
supplement O
consisting O
of O
eicosapentaenoic B
acid I
( O
EPA B
) O
and O
docosahexaenoic B
acid I
( O
DHA B
) O
( O
3 O
g O
per O
day O
, O
944 O
mg O
EPA B
, O
and O
2 O
, O
088 O
mg O
DHA B
) O
. O

Fatty B
acid I
supplementation O
/ O
n3 B
PUFA I
supplementation O
was O
associated O
with O
a O
downregulated O
expression O
of O
the O
genes O
encoding O
PPAR O
gamma O
and O
PGC O
- O
1 O
alpha O
( O
P O
< O
0 O
. O
001 O
) O
, O
and O
an O
upregulated O
expression O
of O
the O
genes O
encoding O
PPAR O
alpha O
( O
P O
< O
0 O
. O
007 O
) O
and O
SREBP1 O
( O
P O
< O
0 O
. O
021 O
) O
. O

Fatty B
acid I
supplementation O
/ O
n3 B
PUFA I
supplementation O
was O
associated O
with O
a O
downregulated O
expression O
of O
the O
genes O
encoding O
PPAR O
gamma O
and O
PGC O
- O
1 O
alpha O
( O
P O
< O
0 O
. O
001 O
) O
, O
and O
an O
upregulated O
expression O
of O
the O
genes O
encoding O
PPAR O
alpha O
( O
P O
< O
0 O
. O
007 O
) O
and O
SREBP1 O
( O
P O
< O
0 O
. O
021 O
) O
. O

FixK2 O
belongs O
to O
the O
cyclic B
AMP I
receptor O
protein O
( O
CRP O
) O
superfamily O
. O

Therefore O
, O
we O
propose O
a O
mechanism O
whereby O
the O
oxo B
- I
acids I
generated O
after O
oxidation O
of O
the O
cysteine B
thiol I
cause O
an O
electrostatic O
repulsion O
, O
thus O
preventing O
specific O
DNA O
binding O
. O

The O
neoclerodane B
diterpene I
salvinorin B
A I
is O
the O
major O
active O
component O
of O
the O
hallucinogenic O
mint O
plant O
Salvia O
divinorum O
Epling O
and O
J O
a O
tiva O
( O
Lamiaceae O
) O
. O

The O
neoclerodane B
diterpene I
salvinorin B
A I
is O
the O
major O
active O
component O
of O
the O
hallucinogenic O
mint O
plant O
Salvia O
divinorum O
Epling O
and O
J O
a O
tiva O
( O
Lamiaceae O
) O
. O

Since O
the O
finding O
that O
salvinorin B
A I
exerts O
its O
potent O
psychotropic O
actions O
through O
the O
activation O
of O
opioid O
receptors O
, O
the O
site O
of O
action O
of O
morphine B
and O
related O
analogues O
, O
there O
has O
been O
much O
interest O
in O
elucidating O
the O
underlying O
mechanisms O
behind O
its O
effects O
. O

These O
effects O
are O
particularly O
remarkable O
because O
( O
1 O
) O
salvinorin B
A I
is O
the O
first O
reported O
non O
- O
nitrogenous O
opioid O
receptor O
agonist O
and O
( O
2 O
) O
its O
effects O
are O
not O
mediated O
through O
the O
previously O
investigated O
targets O
of O
psychotomimetics O
. O

Pristine O
LiP O
showed O
a O
lag O
period O
in O
veratryl B
alcohol I
( O
VA O
) O
oxidation O
. O

Moreover O
, O
a O
significant O
decrease O
in O
hypothalamic O
anti O
- O
inflammatory O
IL O
- O
10 O
- O
expression O
and O
an O
increase O
in O
inflammatory O
microsomal O
prostaglandin B
E I
synthase O
( O
mPGES O
) O
mRNA O
- O
expression O
8 O
h O
after O
LPS O
- O
injection O
was O
revealed O
in O
AG490 B
pre O
- O
treated O
animals O
compared O
to O
solvent O
- O
treated O
LPS O
- O
controls O
. O

In O
addition O
to O
the O
anti O
- O
inflammatory O
lipid O
, O
lipoxin B
A4 I
, O
several O
other O
endogenous O
agonists O
also O
bind O
FPR2 O
, O
including O
serum O
amyloid O
A O
, O
glucocorticoid O
- O
induced O
annexin O
1 O
, O
urokinase O
and O
its O
receptor O
, O
suggesting O
that O
the O
activation O
of O
FPR2 O
may O
result O
in O
potent O
pro O
- O
or O
anti O
- O
inflammatory O
responses O
. O

Three O
new O
dolastane B
diterpenes I
( O
1 O
- O
3 O
) O
and O
five O
previously O
reported O
perhydroazulenes B
were O
isolated O
from O
the O
organic O
extracts O
of O
the O
brown O
alga O
Dilophus O
spiralis O
. O

Specific O
control O
of O
group O
IVA O
cytosolic O
phospholipase O
A2 O
( O
cPLA2 O
alpha O
or O
PLA2G4A O
) O
expression O
modulates O
arachidonic B
acid I
production O
, O
thus O
tightly O
regulating O
the O
downstream O
effects O
of O
pro O
- O
and O
anti O
- O
inflammatory O
eicosanoids B
. O

A O
reliable O
nanocasting O
method O
has O
been O
developed O
to O
synthesize O
mesoporous O
hybrids O
of O
platinum B
( O
Pt B
) O
nanoparticles O
decorating O
tungsten B
trioxide I
( O
WO3 B
) O
. O

The O
synthetic O
strategy O
can O
be O
easily O
extended O
to O
prepare O
other O
mesoporous O
nanohybrids O
with O
metal B
oxide I
loaded O
precious O
metal O
composites O
. O

When O
photoirradiation O
was O
conducted O
in O
the O
presence O
of O
a O
lipid O
( O
methyl B
linoleate I
) O
, O
BaP B
metabolites O
, O
BPDE B
, O
and O
three O
related O
PAHs B
, O
pyrene B
, O
7 B
, I
8 I
, I
9 I
, I
10 I
- I
tetrahydro I
- I
BaP I
trans I
- I
7 I
, I
8 I
- I
diol I
, O
and O
7 B
, I
8 I
, I
9 I
, I
10 I
- I
tetrahydro I
- I
BaP I
trans I
- I
9 I
, I
10 I
- I
diol I
, O
all O
induced O
lipid O
peroxidation O
. O

The O
formation O
of O
lipid O
peroxides O
by O
BaP B
t I
- I
7 I
, I
8 I
- I
diol I
was O
inhibited O
by O
NaN3 B
and O
enhanced O
by O
deuterated B
methanol I
, O
which O
suggests O
that O
singlet O
oxygen B
may O
be O
involved O
in O
the O
generation O
of O
lipid O
peroxides O
. O

The O
phosphate B
- O
terminated O
branch O
of O
PEG B
was O
synthesized O
via O
a O
substitution O
reaction O
of O
the O
hydroxyl B
end O
groups O
using O
phosphoryl B
chloride I
. O

Blockade O
of O
autophagy O
with O
bafilomycin B
A1 I
or O
3 B
- I
methyladenine I
sensitized O
the O
A549 O
and O
H1299 O
cells O
to O
apoptosis O
. O

Inspired O
by O
Pearson O
' O
s O
hard O
and O
soft O
acid O
- O
base O
( O
HSAB O
) O
principle O
, O
uniform O
amorphous O
Ni B
( I
OH I
) I
2 I
nanoboxes O
with O
intact O
shell O
structures O
and O
various O
sizes O
are O
quickly O
fabricated O
by O
deliberately O
selecting O
S2 B
O3 I
( I
2 I
- I
) I
as O
the O
coordinating O
etchant O
toward O
Cu2 B
O I
templates O
and O
optimizing O
the O
reaction O
conditions O
. O

Pressor O
and O
renal O
regional O
hemodynamic O
effects O
of O
urotensin B
II I
in O
neonatal O
pigs O
. O

Renal O
expression O
of O
the O
peptide O
hormone O
urotensin B
II I
( O
UII B
) O
and O
its O
receptor O
( O
UTR O
) O
are O
dependent O
on O
kidney O
maturation O
and O
anatomical O
regions O
. O

Dose O
- O
dependent O
pharmacokinetics O
of O
bulleyaconitine B
A I
in O
rats O
. O

This O
study O
was O
conducted O
to O
determine O
the O
pharmacokinetic O
characteristics O
of O
bulleyaconitine B
A I
( O
BLA B
) O
after O
oral O
gavage O
and O
intravenous O
administration O
of O
BLA B
at O
a O
single O
dose O
of O
0 O
. O
04 O
, O
0 O
. O
12 O
, O
0 O
. O
36 O
mg O
/ O
kg O
( O
oral O
) O
or O
0 O
. O
02 O
mg O
/ O
kg O
( O
i O
. O
v O
. O
) O
in O
male O
Sprague O
- O
Dawley O
rats O
. O

Anticancer O
activity O
of O
the O
liposome O
- O
encapsulated O
cyclic B
dipeptides I
, O
cyclo B
( I
His I
- I
Gly I
) I
and O
cyclo B
( I
His I
- I
Ala I
) I
. O

Cyclic B
dipeptides I
have O
been O
well O
characterized O
for O
their O
biological O
activity O
, O
including O
antimicrobial O
and O
anticancer O
activities O
. O

However O
, O
modification O
of O
the O
polyethylene B
glycol I
with O
folic B
acid I
to O
target O
folate O
receptors O
significantly O
decreased O
the O
IC50 O
values O
recorded O
in O
all O
cells O
lines O
tested O
, O
particularly O
HeLa O
cells O
cultured O
in O
media O
containing O
physiological O
concentrations O
of O
folic B
acid I
with O
the O
lowest O
IC50 O
being O
recorded O
as O
0 O
. O
0962 O
mM O
for O
folate B
- O
targeted O
cyclo B
( I
His I
- I
Ala I
) I
. O

However O
, O
modification O
of O
the O
polyethylene B
glycol I
with O
folic B
acid I
to O
target O
folate O
receptors O
significantly O
decreased O
the O
IC50 O
values O
recorded O
in O
all O
cells O
lines O
tested O
, O
particularly O
HeLa O
cells O
cultured O
in O
media O
containing O
physiological O
concentrations O
of O
folic B
acid I
with O
the O
lowest O
IC50 O
being O
recorded O
as O
0 O
. O
0962 O
mM O
for O
folate B
- O
targeted O
cyclo B
( I
His I
- I
Ala I
) I
. O

However O
, O
modification O
of O
the O
polyethylene B
glycol I
with O
folic B
acid I
to O
target O
folate O
receptors O
significantly O
decreased O
the O
IC50 O
values O
recorded O
in O
all O
cells O
lines O
tested O
, O
particularly O
HeLa O
cells O
cultured O
in O
media O
containing O
physiological O
concentrations O
of O
folic B
acid I
with O
the O
lowest O
IC50 O
being O
recorded O
as O
0 O
. O
0962 O
mM O
for O
folate B
- O
targeted O
cyclo B
( I
His I
- I
Ala I
) I
. O

Therefore O
, O
hydrophilic O
cyclic B
dipeptides I
are O
ideal O
candidates O
for O
inclusion O
into O
targeted O
drug O
delivery O
systems O
such O
as O
liposomes O
. O

The O
antioxidant O
capacities O
of O
the O
extract O
were O
evaluated O
using O
1 B
, I
1 I
- I
diphenyl I
- I
2 I
- I
picrylhydrazyl I
radical O
, O
beta B
- I
carotene I
/ O
linoleic B
acid I
and O
reducing O
power O
and O
metal O
chelating O
activity O
assays O
. O

Development O
of O
solid O
lipid O
nanoparticles O
based O
controlled O
release O
system O
for O
topical O
delivery O
of O
terbinafine B
hydrochloride I
. O

The O
study O
describes O
the O
development O
and O
evaluation O
of O
solid O
lipid O
nanoparticles O
( O
SLNs O
) O
of O
terbinafine B
hydrochloride I
( O
TH O
) O
for O
sustained O
release O
and O
skin O
targeting O
. O

Finally O
, O
cyclosporine B
A I
( O
CsA B
) O
was O
used O
as O
an O
illustrative O
case O
to O
support O
applicability O
of O
ZFE O
in O
hepatotoxicity O
testing O
by O
comparing O
CsA B
- O
induced O
gene O
expression O
between O
ZFE O
, O
in O
vivo O
mouse O
liver O
and O
HepaRG O
cells O
on O
the O
levels O
of O
single O
genes O
, O
pathways O
and O
transcription O
factors O
. O

Modeling O
the O
Conformational O
Preference O
of O
the O
Carbon B
- O
Bonded O
Covalent O
Adduct O
Formed O
upon O
Exposure O
of O
2 B
' I
- I
Deoxyguanosine I
to O
Ochratoxin B
A I
. O

The O
conformational O
flexibility O
of O
the O
C8 O
- O
linked O
guanine B
adduct O
formed O
from O
attachment O
of O
ochratoxin B
A I
( O
OTA B
) O
was O
analyzed O
using O
a O
systematic O
computational O
approach O
and O
models O
ranging O
from O
the O
nucleobase B
to O
the O
adducted O
DNA O
helix O
. O

Although O
OTA B
is O
twisted O
with O
respect O
to O
the O
base O
in O
the O
nucleobase B
model O
, O
addition O
of O
the O
deoxyribose B
sugar I
induces O
a O
further O
twist O
and O
restricts O
rotation O
about O
the O
C B
- I
C I
linkage O
due O
to O
close O
contacts O
between O
OTA B
and O
the O
sugar O
. O

Two O
novel O
reddish O
- O
orange O
alkaloids O
, O
mycoleptodiscin B
A I
( O
1 O
) O
and O
mycoleptodiscin B
B I
( O
2 O
) O
, O
were O
isolated O
from O
liquid O
cultures O
of O
the O
endophytic O
fungus O
Mycoleptodiscus O
sp O
. O
that O
had O
been O
isolated O
from O
Desmotes O
incomparabilis O
in O
Panama O
. O

Two O
novel O
reddish O
- O
orange O
alkaloids O
, O
mycoleptodiscin B
A I
( O
1 O
) O
and O
mycoleptodiscin B
B I
( O
2 O
) O
, O
were O
isolated O
from O
liquid O
cultures O
of O
the O
endophytic O
fungus O
Mycoleptodiscus O
sp O
. O
that O
had O
been O
isolated O
from O
Desmotes O
incomparabilis O
in O
Panama O
. O

Mycoleptodiscin B
B I
( O
2 O
) O
was O
active O
in O
inhibiting O
the O
growth O
of O
cancer O
cell O
lines O
with O
IC50 O
values O
in O
the O
range O
0 O
. O
60 O
- O
0 O
. O
78 O
mu O
M O
. O

Molecularly O
imprinted O
polymers O
( O
MIPs O
) O
for O
selective O
adsorption O
of O
ractopamine B
hydrochloride I
( O
RAC B
) O
were O
synthesised O
by O
an O
in O
situ O
method O
, O
in O
which O
salbutamol B
( O
SAL B
) O
was O
used O
as O
the O
dummy O
- O
template O
to O
avoid O
the O
template O
leakage O
. O

The O
production O
from O
glycerol B
of O
succinic B
, I
acetic I
, I
citric I
, I
malic I
and I
oxalic I
acids I
from O
C O
. O
oleophila O
and O
W O
. O
anomalus O
, O
and O
that O
of O
succinic B
, I
oxalic I
and I
acetic I
acids I
by O
P O
. O
fermentans O
is O
reported O
for O
the O
first O
time O
in O
this O
work O
, O
as O
is O
the O
production O
of O
oxalic B
acid I
from O
glycerol B
in O
yeasts O
. O

Cocoa O
extract O
and O
the O
fraction O
obtained O
after O
in O
vitro O
gastrointestinal O
digestion O
presented O
antioxidant O
activity O
against O
oxidative O
stress O
induced O
by O
hydrogen B
peroxide I
in O
Caco O
- O
2 O
cells O
. O

Antioxidant O
activity O
( O
AA O
% O
) O
of O
free O
and O
bound O
phenolic B
compounds O
was O
measured O
using O
the O
linoleic B
acid I
/ O
beta B
- I
carotene I
assay O
. O

Maqui O
berry O
( O
Aristotelia O
chilensis O
) O
and O
the O
constituent O
delphinidin B
glycoside I
inhibit O
photoreceptor O
cell O
death O
induced O
by O
visible O
light O
. O

Viability O
of O
661W O
after O
light O
treatment O
for O
24h O
, O
assessed O
by O
the O
tetrazolium B
salt O
( O
WST O
- O
8 O
) O
assay O
and O
Hoechst B
33342 I
nuclear O
staining O
, O
was O
improved O
by O
addition O
of O
MBE O
, O
D3G5G B
, O
and O
D3S5G B
. O

The O
pH O
of O
both O
samples O
decreased O
during O
storage O
due O
to O
lactic B
acid I
production O
( O
post O
acidification O
) O
. O

The O
presence O
of O
chloride B
ions O
produced O
an O
equilibrium O
of O
stable O
silver B
chloride I
complexes O
which O
were O
void O
of O
antimicrobial O
efficacy O
. O

Changes O
in O
urocanic B
acid I
, O
histamine B
, O
putrescine B
and O
cadaverine B
levels O
in O
Indian O
mackerel O
( O
Rastrelliger O
kanagurta O
) O
during O
storage O
at O
different O
temperatures O
. O

( O
Euphorbiaceae O
) O
stem O
bark O
essential O
oil O
as O
possible O
mutagen O
- O
protective O
food O
ingredient O
against O
heterocyclic B
amines I
from O
cooked O
food O
. O

The O
Amazonian O
Croton O
lechleri O
stem O
bark O
essential O
oil O
was O
tested O
for O
its O
anti O
- O
mutagenic O
potential O
by O
performing O
the O
Ames O
test O
against O
heterocyclic B
amines I
( O
HCAs B
) O
, O
in O
continuing O
research O
on O
applicative O
functional O
profile O
of O
this O
phytocomplex O
as O
food O
ingredient O
( O
Rossi O
et O
al O
. O
, O
2011 O
) O
. O

The O
dimer O
fraction O
was O
separated O
by O
size O
- O
exclusion O
chromatography O
( O
SEC O
) O
after O
pre O
- O
fractionation O
on O
silica B
gel I
. O

Applied O
analytical O
techniques O
also O
confirmed O
presence O
of O
dimers O
with O
different O
configuration O
than O
disteryl B
ethers I
. O

Six O
pomelo O
cultivars O
had O
antihyperlipidemic O
activities O
including O
the O
inhibition O
of O
pancreatic O
lipase O
and O
cholesterol B
esterase O
, O
as O
well O
as O
cholesterol B
micelle O
formation O
and O
bile B
acid I
binding O
. O

In O
" O
pinking O
" O
of O
onion O
, O
E B
- I
( I
+ I
) I
- I
S I
- I
( I
1 I
- I
propenyl I
) I
- I
l I
- I
cysteine I
sulfoxide I
is O
first O
cleaved O
by O
alliinase O
to O
yield O
colour O
developers O
( O
CDs O
) O
, O
which O
react O
with O
amino B
acids I
, O
such O
as O
valine B
, O
to O
form O
pigment O
precursors O
( O
PPs O
) O
. O

The O
honey O
from O
B O
. O
pilosa O
also O
had O
significantly O
greater O
scavenging O
activities O
for O
1 B
, I
1 I
- I
diphenyl I
- I
2 I
- I
picrylhydrazyl I
( O
DPPH B
. I
) O
and O
hydroxyl B
radical O
, O
and O
substantially O
more O
reducing O
power O
. O

Fatty B
acid I
profiling O
of O
the O
seed O
oils O
of O
some O
varieties O
of O
field O
peas O
( O
Pisum O
sativum O
) O
by O
RP O
- O
LC O
/ O
ESI O
- O
MS O
/ O
MS O
: O
Towards O
the O
development O
of O
an O
oilseed O
pea O
. O

Reversed O
- O
phase O
liquid O
chromatography O
coupled O
to O
negative O
- O
ion O
electrospray O
tandem O
mass O
spectrometry O
( O
RP O
- O
LC O
/ O
ESI O
- O
MS O
/ O
MS O
) O
was O
used O
to O
study O
the O
fatty B
acid I
profile O
from O
the O
oil O
of O
harvested O
field O
pea O
( O
Pisum O
sativum O
) O
varieties O
as O
part O
of O
a O
research O
project O
to O
develop O
this O
legume O
as O
a O
commercial O
oilseed O
for O
Canada O
. O

Small O
percentages O
of O
other O
long O
chain O
fatty B
acids I
were O
also O
detected O
. O

Fatty B
acid I
extracts O
did O
not O
require O
further O
manipulation O
before O
final O
analysis O
by O
RP O
- O
LC O
/ O
ESI O
- O
MS O
/ O
MS O
, O
indicating O
the O
utility O
and O
relative O
simplicity O
of O
this O
technique O
for O
future O
screening O
studies O
. O

Clean O
- O
up O
of O
extracts O
was O
performed O
by O
solid O
- O
phase O
extraction O
using O
C18 O
and O
glass O
columns O
containing O
silica B
gel I
and O
florisil B
for O
USAE O
or O
only O
C18 O
for O
USAEME O
. O

We O
suggest O
that O
the O
concentration O
- O
dependent O
protection O
by O
sugars B
resulted O
from O
a O
combination O
of O
mechanisms O
, O
including O
: O
( O
1 O
) O
reduced O
aqueous O
O2 B
solubility O
, O
( O
2 O
) O
scavenging O
of O
reactive O
oxygen B
species O
, O
and O
( O
3 O
) O
chelation O
of O
traces O
of O
transition B
metal I
ions O
, O
which O
is O
suggested O
to O
be O
the O
main O
reason O
for O
the O
differences O
among O
the O
sugars B
. O

All O
A O
. O
nomius O
and O
A O
. O
parasiticus O
isolates O
produced O
aflatoxins B
B I
and I
G I
, O
but O
not O
cyclopiazonic B
acid I
( O
CPA B
) O
. O

These O
melons O
contain O
almost O
twice O
the O
amount O
of O
citric B
acid I
compared O
to O
standard O
melons O
and O
are O
described O
as O
' O
zesty O
and O
fresh O
' O
. O

Ostreol B
A I
: O
A O
new O
cytotoxic O
compound O
isolated O
from O
the O
epiphytic O
dinoflagellate O
Ostreopsis O
cf O
. O
ovata O
from O
the O
coastal O
waters O
of O
Jeju O
Island O
, O
Korea O
. O

Ostreol B
A I
was O
isolated O
from O
cultures O
of O
the O
epiphytic O
dinoflagellate O
Ostreopsis O
cf O
. O
ovata O
from O
the O
coastal O
waters O
of O
Jeju O
Island O
, O
Korea O
. O

The O
compound O
, O
a O
non O
- O
palytoxin O
derivative O
, O
has O
a O
polyhydroxy B
chain O
ending O
with O
the O
primary B
amino I
group O
and O
contains O
an O
amide B
bond O
, O
along O
with O
two O
tetrahydropyran B
rings O
in O
the O
chain O
. O

Arylsulfonamide B
pyrimidines I
as O
VLA O
- O
4 O
antagonists O
. O

TRP O
and O
ASIC O
channels O
mediate O
the O
antinociceptive O
effect O
of O
citronellyl B
acetate I
. O

Background O
Citronellyl B
acetate I
( O
CAT B
) O
, O
a O
monoterpene B
product O
of O
the O
secondary O
metabolism O
of O
plants O
, O
has O
been O
shown O
in O
the O
literature O
to O
possess O
several O
different O
biological O
activities O
. O

Methods O
The O
acetic B
acid I
- O
induced O
writhing O
test O
and O
the O
paw O
- O
licking O
test O
, O
in O
which O
paw O
licking O
was O
induced O
by O
glutamate B
and O
formalin B
, O
were O
performed O
to O
evaluate O
the O
antinociceptive O
action O
of O
CAT B
and O
to O
determine O
the O
involvement O
of O
PKC O
, O
PKA O
, O
TRPV1 O
, O
TRPA1 O
, O
TRPM8 O
and O
ASIC O
in O
its O
antinociceptive O
mechanism O
. O

Results O
CAT B
was O
administered O
intragastrically O
( O
25 O
, O
50 O
, O
75 O
, O
100 O
and O
200mg O
/ O
kg O
) O
, O
and O
the O
two O
higher O
doses O
caused O
antinociceptive O
effects O
in O
the O
acetic B
acid I
model O
; O
the O
highest O
dose O
reduced O
pain O
for O
4h O
after O
it O
was O
administered O
( O
200mg O
/ O
kg O
) O
. O

In O
an O
investigation O
into O
the O
participation O
of O
TRP O
channels O
and O
ASICs O
in O
CAT B
' O
s O
antinociceptive O
mechanism O
, O
we O
used O
capsaicin B
( O
2 O
. O
2 O
mu O
g O
/ O
paw O
) O
, O
cinnamaldehyde B
( O
10mmol O
/ O
paw O
) O
, O
menthol B
( O
1 O
. O
2mmol O
/ O
paw O
) O
and O
acidified O
saline O
( O
2 O
% O
acetic B
acid I
, O
pH O
1 O
. O
98 O
) O
. O

Anti O
- O
inflammatory O
activity O
of O
hexane B
extracts O
from O
bones O
and O
internal O
organs O
of O
Anguilla O
japonica O
suppresses O
cyclooxygenase O
- O
2 O
- O
dependent O
prostaglandin B
D2 I
generation O
in O
mast O
cells O
and O
anaphylaxis O
in O
mice O
. O

The O
purpose O
of O
this O
study O
is O
to O
investigate O
the O
effects O
of O
n B
- I
hexane I
extracts O
from O
bones O
and O
internal O
organs O
of O
Japanese O
eel O
, O
Anguilla O
japonica O
( O
HEE O
) O
, O
on O
cyclooxygenase O
- O
2 O
( O
COX O
- O
2 O
) O
- O
dependent O
prostaglandin B
D2 I
( O
PGD2 B
) O
generation O
in O
stem O
cell O
factor O
( O
SCF O
) O
, O
IL O
- O
10 O
, O
plus O
LPS O
- O
induced O
mouse O
bone O
marrow O
- O
derived O
mast O
cells O
( O
BMMCs O
) O
and O
on O
passive O
cutaneous O
anaphylaxis O
( O
PCA O
) O
in O
mice O
. O

Combinatorial O
Treatment O
of O
Tart O
Cherry O
Extract O
and O
Essential O
Fatty B
Acids I
Reduces O
Cognitive O
Impairments O
and O
Inflammation O
in O
the O
mu O
- O
p75 O
Saporin O
- O
Induced O
Mouse O
Model O
of O
Alzheimer O
' O
s O
Disease O
. O

The O
current O
study O
tested O
a O
combinatorial O
treatment O
of O
antioxidants O
from O
tart O
cherry O
extract O
and O
essential O
fatty B
acids I
from O
Nordic O
fish O
and O
emu O
oils O
for O
reducing O
cognitive O
deficits O
in O
the O
mu O
- O
p75 O
saporin O
( O
SAP O
) O
- O
induced O
mouse O
model O
of O
AD O
. O

Since O
metabolic O
derangements O
found O
in O
metabolic O
syndrome O
, O
such O
as O
high O
serum O
levels O
of O
glucose B
, O
insulin O
and O
free B
fatty I
acids I
( O
FFAs B
) O
, O
are O
major O
risk O
factors O
promoting O
atherosclerosis O
, O
we O
investigated O
whether O
PLIN3 O
expression O
is O
affected O
by O
glucose B
, O
insulin O
and O
oleic B
acid I
( O
OA O
) O
using O
RAW264 O
. O
7 O
cells O
. O

The O
peaks O
71 O
, O
93 O
, O
150 O
are O
likely O
representing O
sappanone B
A I
, O
protosappanin B
E I
and O
neoprotosappanin B
, O
respectively O
. O

The O
peaks O
71 O
, O
93 O
, O
150 O
are O
likely O
representing O
sappanone B
A I
, O
protosappanin B
E I
and O
neoprotosappanin B
, O
respectively O
. O

CONCLUSION O
: O
This O
is O
the O
first O
report O
that O
sappanone B
A I
, O
protosappanin B
E I
, O
neoprotosappanin B
and O
two O
unidentified O
compounds O
can O
be O
considered O
as O
possible O
active O
compounds O
that O
might O
inhibit O
IL O
- O
6 O
production O
. O

CONCLUSION O
: O
This O
is O
the O
first O
report O
that O
sappanone B
A I
, O
protosappanin B
E I
, O
neoprotosappanin B
and O
two O
unidentified O
compounds O
can O
be O
considered O
as O
possible O
active O
compounds O
that O
might O
inhibit O
IL O
- O
6 O
production O
. O

Ndonya O
, O
as O
it O
is O
colloquially O
known O
, O
refers O
to O
two O
products O
which O
look O
identical O
to O
the O
untrained O
eye O
- O
one O
is O
dyed O
table O
salt B
and O
the O
other O
is O
hexavalent B
chromium I
. O

A O
further O
product O
used O
medicinally O
, O
although O
not O
widely O
available O
, O
was O
identified O
as O
iron B
chromite I
ore O
. O

Uptake O
of O
radiolabeled B
gabapentin I
into O
cells O
in O
the O
presence O
of O
chemical O
inhibitors O
, O
siRNA O
or O
overexpressed O
drug O
transporters O
of O
interest O
was O
investigated O
. O

Light O
- O
Emitting O
Field O
- O
Effect O
Transistors O
Having O
Combined O
Organic O
Semiconductor O
and O
Metal B
Oxide I
Layers O
. O

A O
new O
organic O
light O
- O
emitting O
field O
- O
effect O
transistor O
characterized O
by O
a O
metal B
oxide I
layer O
inserted O
between O
the O
organic O
layer O
and O
the O
gate O
insulator O
is O
proposed O
. O

The O
metal B
oxide I
is O
indirectly O
connected O
with O
source O
and O
drain O
electrodes O
through O
the O
organic O
layer O
. O

Interestingly O
, O
physical O
mixture O
containing O
furosemide B
, O
PVP B
K12 I
and O
SDS B
produced O
a O
similar O
level O
of O
oral O
exposure O
as O
the O
SNDs O
, O
albeit O
with O
a O
longer O
Tmax O
than O
the O
SND O
formulation O
. O

The O
results O
suggest O
that O
PVP B
K12 I
and O
SDS B
were O
able O
to O
increase O
the O
furosemide B
free O
fraction O
available O
for O
oral O
absorption O
. O

Polyhydroxy B
pregnane I
glycoside I
( O
PPG B
) O
, O
a O
steroidal B
glycoside I
was O
isolated O
from O
Wattakaka O
volubilis O
Linn O
. O

PPG B
had O
a O
more O
effective O
response O
than O
the O
reference O
drug O
diclofenac B
sodium I
in O
both O
the O
models O
of O
inflammation O
. O

Wattakaka O
volubilis O
steroidal B
glycoside I
mixture O
( O
WVSM O
) O
and O
PPG B
( O
1 O
- O
50 O
mu O
M O
) O
significantly O
inhibited O
the O
COX O
- O
2 O
and O
iNOS O
enzymes O
resulting O
in O
low O
levels O
of O
PGE2 O
and O
NO O
in O
LPS O
- O
induced O
RAW O
264 O
. O
7 O
macrophage O
cells O
. O

A O
total O
of O
19 O
metabolites O
were O
identified O
in O
human O
urine O
collected O
from O
patients O
with O
hepatobiliary O
diseases O
after O
an O
intravenous O
drip O
infusion O
of O
500 O
mg O
of O
racemic B
ornidazole I
. O

Chemical O
inhibition O
study O
with O
niflumic B
acid I
and O
flurbiprofen B
supported O
these O
findings O
. O

Using O
temperature O
block O
, O
Brefeldin B
A I
, O
and O
recovery O
from O
each O
, O
we O
found O
that O
the O
cytoplasmic O
tail O
of O
M6PR O
causes O
the O
recruitment O
of O
AP O
- O
1 O
and O
GGAs O
to O
recycling O
endosomes O
and O
not O
at O
the O
Golgi O
, O
as O
predicted O
by O
steady O
state O
staining O
profiles O
. O

Oxidation O
of O
CO B
by O
Nickel B
Oxide I
Clusters O
Revealed O
by O
Post O
Heating O
. O

Reactions O
of O
nickel B
oxide I
cluster O
ions O
, O
NinOn B
+ I
x I
( I
+ I
) I
( O
n O
= O
4 O
- O
10 O
, O
x O
= O
- O
1 O
~ O
+ O
3 O
) O
, O
with O
CO B
in O
a O
He B
buffer O
gas O
were O
investigated O
using O
mass O
spectrometry O
. O

A O
Platform O
for O
Large O
- O
Scale O
Graphene B
Electronics O
- O
CVD O
Growth O
of O
Single O
- O
Layer O
Graphene B
on O
CVD O
- O
Grown O
Hexagonal O
Boron B
Nitride I
. O

Direct O
chemical O
vapor O
deposition O
( O
CVD O
) O
growth O
of O
single O
- O
layer O
graphene B
on O
CVD O
- O
grown O
hexagonal O
boron B
nitride I
( O
h O
- O
BN B
) O
film O
can O
suggest O
a O
large O
- O
scale O
and O
high O
- O
quality O
graphene B
/ O
h O
- O
BN B
film O
hybrid O
structure O
with O
a O
defect O
- O
free O
interface O
. O

In O
PC O
, O
this O
moiety O
might O
provide O
a O
sufficient O
handle O
to O
bind O
to O
peripheral O
proteins O
via O
a O
cation O
- O
pi O
cage O
, O
where O
the O
pi O
systems O
of O
two O
or O
more O
aromatic O
residues O
are O
within O
4 O
- O
5 O
A O
of O
the O
quaternary B
amine I
. O

Theoretical O
Investigation O
of O
Generator O
- O
Collector O
Microwell O
Arrays O
for O
Improving O
Electroanalytical O
Selectivity O
: O
Application O
to O
Selective O
Dopamine B
Detection O
in O
the O
Presence O
of O
Ascorbic B
Acid I
. O

Recessed O
generator O
- O
collector O
assemblies O
consisting O
of O
an O
array O
of O
recessed O
disks O
( O
generator O
electrodes O
) O
with O
a O
gold O
layer O
( O
collector O
electrode O
) O
deposited O
over O
the O
top O
- O
plane O
insulator O
reportedly O
allow O
increased O
selectivity O
and O
sensitivity O
during O
electrochemical O
detection O
of O
dopamine B
( O
DA O
) O
in O
the O
presence O
of O
ascorbic B
acid I
( O
AA O
) O
, O
a O
situation O
which O
is O
frequently O
encountered O
. O

The O
ozone B
- O
oxidized B
graphene I
is O
not O
removed O
but O
is O
gradually O
transformed O
to O
graphene B
oxide I
( O
GO O
) O
. O

The O
ozone B
- O
oxidized B
graphene I
is O
not O
removed O
but O
is O
gradually O
transformed O
to O
graphene B
oxide I
( O
GO O
) O
. O

Asymmetric B
dimethylarginine I
predicts O
decline O
of O
glucose B
tolerance O
in O
men O
with O
stable O
coronary O
artery O
disease O
: O
a O
4 O
. O
5 O
- O
year O
follow O
- O
up O
study O
. O

BACKGROUND O
: O
Endothelial O
dysfunction O
, O
largely O
dependent O
on O
impaired O
nitric B
oxide I
bioavailability O
, O
has O
been O
reportedly O
associated O
with O
incident O
type O
2 O
diabetes O
. O

Our O
aim O
was O
to O
test O
the O
hypothesis O
that O
asymmetric B
dimethylarginine I
( O
ADMA B
) O
, O
an O
endogenous O
inhibitor O
of O
nitric B
oxide I
formation O
, O
might O
be O
linked O
to O
future O
deterioration O
in O
glucose B
tolerance O
in O
stable O
coronary O
artery O
disease O
( O
CAD O
) O
. O

Our O
aim O
was O
to O
test O
the O
hypothesis O
that O
asymmetric B
dimethylarginine I
( O
ADMA B
) O
, O
an O
endogenous O
inhibitor O
of O
nitric B
oxide I
formation O
, O
might O
be O
linked O
to O
future O
deterioration O
in O
glucose B
tolerance O
in O
stable O
coronary O
artery O
disease O
( O
CAD O
) O
. O

Plasma O
ADMA B
and O
its O
structural O
isomer O
symmetric B
dimethylarginine I
( O
SDMA B
) O
were O
measured O
prior O
to O
coronary O
angiography O
. O

Sodium B
fluoride I
induces O
apoptosis O
in O
odontoblasts O
via O
a O
JNK O
- O
dependent O
mechanism O
. O

Sodium B
fluoride I
( O
NaF B
) O
is O
widely O
used O
for O
the O
treatment O
of O
dental O
caries O
and O
dentin O
hypersensitivity O
. O

Perinatal O
exposure O
to O
BDE B
- I
99 I
causes O
learning O
disorders O
and O
decreases O
serum O
thyroid B
hormone I
levels O
and O
BDNF O
gene O
expression O
in O
hippocampus O
in O
rat O
offspring O
. O

When O
pups O
were O
weaning O
, O
cortex O
and O
hippocampal O
gene O
expressions O
of O
brain O
- O
derived O
neurotrophic O
factor O
( O
BDNF O
) O
of O
the O
different O
isoforms O
of O
the O
thyroid B
hormone I
( O
TH O
) O
receptors O
( O
TRs O
) O
were O
evaluated O
. O

In O
this O
study O
, O
submerged O
macrophyte O
Ceratophyllum O
demersum O
( O
C O
. O
demersum O
) O
was O
adopted O
to O
examine O
the O
effects O
of O
anatoxin B
- I
a I
on O
morphological O
( O
growth O
) O
, O
physiological O
( O
photosynthetic O
pigment O
contents O
) O
and O
biochemical O
( O
hydrogen B
peroxide I
level O
, O
biotransformation O
and O
antioxidative O
enzymes O
) O
responses O
in O
the O
aquatic O
plant O
at O
environmentally O
relevant O
concentrations O
( O
0 O
. O
005 O
, O
0 O
. O
05 O
, O
0 O
. O
5 O
, O
5 O
and O
50 O
mu O
g O
/ O
L O
) O
. O

The O
significant O
elevation O
of O
antioxidative O
enzymes O
in O
parallel O
with O
increased O
formation O
of O
hydrogen B
peroxide I
appeared O
from O
0 O
. O
5 O
mu O
g O
/ O
L O
of O
anatoxin B
- I
a I
. O

In O
the O
measurement O
of O
photosynthetic O
pigments O
, O
the O
decrease O
in O
chlorophyll B
a I
content O
was O
detected O
at O
5 O
and O
50 O
mu O
g O
/ O
L O
, O
whereas O
the O
increase O
in O
carotenoids O
/ O
total O
chlorophyll B
was O
observed O
from O
0 O
. O
05 O
mu O
g O
/ O
L O
. O

Results O
showed O
that O
oral O
administration O
of O
plant O
stanyl B
hemisuccinate I
( O
2 O
x O
, O
5 O
x O
) O
and O
plant O
stanyl B
sorbitol I
succinate I
( O
2 O
x O
, O
5 O
x O
) O
effectively O
attenuated O
the O
serum O
total O
cholesterol B
and O
low O
density O
lipoprotein O
cholesterol B
levels O
, O
while O
had O
no O
effect O
on O
the O
serum O
triacylglycerol B
and O
high O
density O
lipoprotein O
cholesterol B
. O

Meanwhile O
, O
both O
plant O
stanyl B
hemisuccinate I
and O
plant O
stanyl B
sorbitol I
succinate I
could O
remarkably O
promote O
liver O
X O
receptor O
alpha O
( O
LXR O
alpha O
) O
expression O
, O
and O
increased O
cholesterol B
7 O
alpha O
- O
hydroxylase O
( O
CYP7A1 O
) O
expression O
and O
faecal O
total O
bile B
acid I
output O
to O
varying O
degrees O
. O

Meanwhile O
, O
both O
plant O
stanyl B
hemisuccinate I
and O
plant O
stanyl B
sorbitol I
succinate I
could O
remarkably O
promote O
liver O
X O
receptor O
alpha O
( O
LXR O
alpha O
) O
expression O
, O
and O
increased O
cholesterol B
7 O
alpha O
- O
hydroxylase O
( O
CYP7A1 O
) O
expression O
and O
faecal O
total O
bile B
acid I
output O
to O
varying O
degrees O
. O

These O
results O
suggested O
two O
novel O
plant O
stanol B
derivatives O
possessed O
hypocholesterolemic O
effect O
, O
and O
the O
cholesterol B
- O
lowering O
action O
of O
plant O
stanol B
derivatives O
may O
be O
through O
activating O
the O
potential O
LXR O
alpha O
- O
CYP7A1 O
- O
bile B
acid I
excretion O
pathway O
. O

Wines O
stored O
at O
5 O
degrees O
C O
for O
6months O
did O
not O
show O
significant O
changes O
in O
flavor O
; O
otherwise O
, O
the O
samples O
stored O
at O
15 O
and O
25 O
degrees O
C O
, O
showed O
a O
significant O
decrease O
in O
linalool B
, O
beta B
- I
damascenone I
, O
ethyl B
hexanoate I
, O
and O
ethyl B
octanoate I
levels O
. O

Wines O
stored O
at O
5 O
degrees O
C O
for O
6months O
did O
not O
show O
significant O
changes O
in O
flavor O
; O
otherwise O
, O
the O
samples O
stored O
at O
15 O
and O
25 O
degrees O
C O
, O
showed O
a O
significant O
decrease O
in O
linalool B
, O
beta B
- I
damascenone I
, O
ethyl B
hexanoate I
, O
and O
ethyl B
octanoate I
levels O
. O

In O
these O
last O
samples O
, O
alpha B
- I
terpineol I
, O
hotrienol B
, O
nerol B
oxide I
, O
furanic B
linalool I
oxides I
A I
/ I
B I
and O
rose B
oxide I
concentrations O
significantly O
increased O
. O

In O
these O
last O
samples O
, O
alpha B
- I
terpineol I
, O
hotrienol B
, O
nerol B
oxide I
, O
furanic B
linalool I
oxides I
A I
/ I
B I
and O
rose B
oxide I
concentrations O
significantly O
increased O
. O

Similarly O
, O
the O
total O
phenolic B
, O
flavonoids B
and O
tartaric B
esters I
content O
and O
the O
composition O
of O
organic O
acids O
did O
not O
show O
significant O
differences O
( O
p O
< O
0 O
. O
05 O
) O
during O
the O
process O
. O

It O
is O
known O
that O
oxidised B
phenols I
can O
bind O
proteins O
. O

A O
new O
method O
for O
the O
detection O
of O
alternariol B
( O
AOH B
) O
, O
alternariol B
monomethyl I
ether I
( O
AME B
) O
, O
altenuene B
( O
ALT B
) O
, O
tentoxin B
( O
TEN B
) O
, O
and O
tenuazonic B
acid I
( O
TeA B
) O
, O
five O
alternaria O
toxins O
( O
ATs O
) O
was O
developed O
by O
liquid O
chromatography O
- O
triple O
quadrupole O
mass O
spectrometry O
equipped O
with O
atmospheric O
pressure O
chemical O
ionisation O
( O
APCI O
) O
. O

Flavonol B
glycosides I
with O
lipid O
accumulation O
inhibitory O
activity O
and O
simultaneous O
quantitative O
analysis O
of O
15 O
polyphenols B
and O
caffeine B
in O
the O
flower O
buds O
of O
Camellia O
sinensis O
from O
different O
regions O
by O
LCMS O
. O

A O
new O
flavonol B
glycoside I
, O
chakaflavonoside B
B I
( O
17 O
) O
, O
which O
was O
isolated O
in O
the O
course O
of O
this O
analytical O
study O
, O
was O
found O
to O
show O
oleic B
acid I
- O
albumin O
- O
induced O
lipid O
accumulation O
inhibitory O
activity O
. O

A O
new O
flavonol B
glycoside I
, O
chakaflavonoside B
B I
( O
17 O
) O
, O
which O
was O
isolated O
in O
the O
course O
of O
this O
analytical O
study O
, O
was O
found O
to O
show O
oleic B
acid I
- O
albumin O
- O
induced O
lipid O
accumulation O
inhibitory O
activity O
. O

Residues O
and O
dissipation O
of O
kresoxim B
methyl I
in O
apple O
under O
field O
condition O
. O

The O
dissipation O
and O
residual O
levels O
of O
kresoxim B
methyl I
in O
apple O
under O
field O
condition O
were O
determined O
by O
using O
HPLC O
- O
DAD O
with O
QuEChERS O
method O
. O

The O
dissipation O
rates O
of O
kresoxim B
methyl I
were O
described O
by O
using O
first O
- O
order O
kinetics O
and O
its O
half O
- O
life O
, O
as O
they O
are O
ranged O
from O
4 O
. O
58 O
to O
4 O
. O
77days O
in O
apple O
. O

The O
terminal O
residues O
of O
kresoxim B
methyl I
were O
below O
the O
FAO O
/ O
WHO O
maximum O
residue O
limit O
( O
MRL O
, O
0 O
. O
2mgkg O
( O
- O
1 O
) O
) O
in O
apple O
when O
measured O
14days O
after O
the O
final O
application O
, O
which O
suggested O
that O
the O
use O
of O
this O
fungicide O
was O
safe O
for O
humans O
. O

This O
study O
would O
help O
in O
providing O
the O
basic O
information O
for O
developing O
regulation O
to O
guard O
a O
safe O
use O
of O
kresoxim B
methyl I
in O
apple O
orchard O
and O
to O
prevent O
health O
problem O
from O
consumers O
. O

Instead O
, O
a O
lower O
relative O
content O
of O
methyl B
esters I
, O
such O
as O
methyl B
hexanoate I
and O
methyl B
octanoate I
, O
known O
to O
act O
as O
medfly O
pheromone O
and O
attractant O
respectively O
, O
was O
found O
in O
the O
least O
susceptible O
cvs O
. O

Instead O
, O
a O
lower O
relative O
content O
of O
methyl B
esters I
, O
such O
as O
methyl B
hexanoate I
and O
methyl B
octanoate I
, O
known O
to O
act O
as O
medfly O
pheromone O
and O
attractant O
respectively O
, O
was O
found O
in O
the O
least O
susceptible O
cvs O
. O

Instead O
, O
a O
lower O
relative O
content O
of O
methyl B
esters I
, O
such O
as O
methyl B
hexanoate I
and O
methyl B
octanoate I
, O
known O
to O
act O
as O
medfly O
pheromone O
and O
attractant O
respectively O
, O
was O
found O
in O
the O
least O
susceptible O
cvs O
. O

In O
the O
present O
study O
, O
the O
cytotoxic O
effects O
of O
a O
non O
- O
modified O
clay O
( O
Cloisite B
( O
R O
) O
Na B
+ I
) O
and O
an O
organoclay O
( O
Cloisite B
( O
R O
) O
30B O
) O
have O
been O
investigated O
in O
the O
hepatic O
cell O
line O
HepG2 O
. O

Nitric B
oxide I
could O
be O
involved O
in O
the O
acquisition O
and O
maintenance O
of O
behavioral O
cocaine B
effects O
, O
probably O
by O
activation O
of O
neuronal O
nitric B
oxide I
synthase O
( O
nNOS O
) O
/ O
NO B
/ O
soluble O
guanylyl B
cyclase O
( O
sGC O
) O
/ O
cyclic B
guanosine I
monophosphate I
( O
cGMP B
) O
signaling O
pathway O
, O
since O
inhibition O
of O
the O
nNOS O
enzyme O
attenuates O
development O
of O
sensitization O
in O
rats O
. O

Nitric B
oxide I
could O
be O
involved O
in O
the O
acquisition O
and O
maintenance O
of O
behavioral O
cocaine B
effects O
, O
probably O
by O
activation O
of O
neuronal O
nitric B
oxide I
synthase O
( O
nNOS O
) O
/ O
NO B
/ O
soluble O
guanylyl B
cyclase O
( O
sGC O
) O
/ O
cyclic B
guanosine I
monophosphate I
( O
cGMP B
) O
signaling O
pathway O
, O
since O
inhibition O
of O
the O
nNOS O
enzyme O
attenuates O
development O
of O
sensitization O
in O
rats O
. O

The O
statistical O
approach O
is O
based O
on O
the O
percolation O
theory O
with O
Monte O
Carlo O
methods O
and O
is O
examined O
by O
applying O
it O
to O
the O
experimental O
results O
of O
three O
solid O
samples O
having O
unique O
hydrogen B
arrangement O
for O
1 O
- O
3 O
dimensions O
: O
the O
n B
- I
alkane I
/ O
d B
- I
urea I
inclusion O
complex O
as O
a O
one O
- O
dimensional O
( O
1D O
) O
system O
, O
whose O
( B
1 I
) I
H I
nuclei O
align O
approximately O
in O
1D O
, O
and O
magnesium B
hydroxide I
and O
adamantane B
as O
a O
two O
- O
dimensional O
( O
2D O
) O
and O
a O
three O
- O
dimensional O
( O
3D O
) O
system O
, O
respectively O
. O

Optoelectronic O
Processes O
in O
Squaraine B
Dye I
- O
Doped O
OLEDs O
for O
Emission O
in O
the O
Near O
- O
Infrared O
. O

In O
particular O
, O
the O
compound O
labeled O
NSC130813 B
was O
shown O
to O
act O
synergistically O
with O
cisplatin B
and O
mitomycin B
C I
, O
to O
increase O
UVC O
mediated O
cytotoxicity O
, O
to O
modify O
DNA O
repair O
as O
indicated O
by O
the O
staining O
of O
phosphorylated O
H2AX O
and O
to O
disrupt O
interaction O
between O
ERCC1 O
and O
XPF O
in O
cells O
. O

Due O
to O
its O
production O
of O
potent O
antimicrobial O
oxidants O
including O
hypochlorous B
acid I
, O
human O
myeloperoxidase O
( O
MPO O
) O
plays O
a O
critical O
role O
in O
innate O
immunity O
and O
inflammatory O
diseases O
. O

Sacchathridine B
A I
, O
a O
Prostaglandin B
Release O
Inhibitor O
from O
Saccharothrix O
sp O
. O

Sacchathridine B
A I
( O
1 O
) O
was O
isolated O
from O
the O
fermentation O
broth O
of O
strain O
Saccharothrix O
sp O
. O

Compound O
1 O
showed O
inhibitory O
activity O
of O
prostaglandin B
E2 I
release O
in O
a O
concentration O
- O
dependent O
manner O
from O
human O
synovial O
sarcoma O
cells O
, O
SW982 O
, O
with O
an O
IC50 O
value O
of O
1 O
. O
0 O
mu O
M O
, O
but O
had O
no O
effect O
on O
cell O
growth O
up O
to O
30 O
mu O
M O
. O

In O
our O
previous O
study O
we O
developed O
a O
novel O
series O
of O
tetrahydroisoquinoli B
- O
based O
hydroxamic B
acid I
derivatives O
as O
histone O
deacetylase O
( O
HDAC O
) O
inhibitors O
( O
Bioorg O
. O
Med O
. O
Chem O
. O
, O
2010 O
, O
18 O
, O
1761 O
- O
1772 O
. O
, O
J O
. O
Med O
. O
Chem O
. O
, O
2011 O
, O
54 O
, O
2823 O
- O
2838 O
. O
) O
, O
among O
which O
compound O
ZYJ B
- I
34c I
( O
1 O
) O
was O
identified O
and O
validated O
as O
the O
most O
potent O
one O
with O
marked O
in O
vitro O
and O
in O
vivo O
antitumor O
potency O
( O
J O
. O
Med O
. O

Metabolism O
of O
2 B
, I
2 I
' I
, I
3 I
, I
3 I
' I
, I
6 I
, I
6 I
' I
- I
hexachlorobiphenyl I
( O
PCB B
136 I
) O
atropisomers O
in O
tissue O
slices O
from O
phenobarbital B
or O
dexamethasone B
- O
induced O
rats O
is O
sex O
- O
dependent O
. O

Chiral O
polychlorinated B
biphenyls I
( O
PCBs B
) O
such O
as O
PCB B
136 I
enantioselectively O
sensitize O
the O
ryanodine B
receptor O
( O
RyR O
) O
. O

Chiral O
polychlorinated B
biphenyls I
( O
PCBs B
) O
such O
as O
PCB B
136 I
enantioselectively O
sensitize O
the O
ryanodine B
receptor O
( O
RyR O
) O
. O

The O
effect O
of O
sex O
and O
cytochrome O
P450 O
( O
P450 O
) O
enzyme O
induction O
on O
the O
enantioselective O
metabolism O
of O
PCB B
136 I
was O
studied O
using O
liver O
tissue O
slices O
prepared O
from O
na O
i O
ve O
control O
( O
CTL O
) O
, O
phenobarbital B
( O
PB O
; O
CYP2B O
inducer O
) O
or O
dexamethasone B
( O
DEX B
; O
CYP3A O
inducer O
) O
pretreated O
adult O
Sprague O
- O
Dawley O
rats O
. O

PCB B
136 I
metabolism O
was O
also O
examined O
in O
hippocampal O
slices O
derived O
from O
untreated O
rat O
pups O
. O

In O
liver O
tissue O
slices O
, O
hydroxylated B
PCB I
( O
OH B
- I
PCB I
) O
profiles O
depended O
on O
sex O
and O
inducer O
pretreatment O
, O
and O
OH B
- I
PCB I
levels O
followed O
the O
rank O
orders O
male O
> O
female O
and O
PB O
> O
DEX B
> O
CTL O
. O

In O
contrast O
, O
the O
enantiomeric O
enrichment O
of O
PCB B
136 I
and O
its O
metabolites O
was O
independent O
of O
sex O
and O
inducer O
pretreatment O
. O

Only O
small O
amounts O
of O
PCB B
136 I
partitioned O
into O
hippocampal O
tissue O
slices O
and O
no O
OH B
- I
PCB I
metabolites O
were O
detected O
. O

Two O
monomers O
that O
undergo O
different O
click O
reactions O
, O
pentafluorophenyl B
acrylate I
( O
PFPA B
) O
and O
4 B
- I
( I
trimethylsilyl I
) I
ethynylstyrene I
( O
TMSES B
) O
, O
were O
sequentially O
polymerized O
from O
a O
silicon B
surface O
in O
the O
presence O
of O
a O
shadowmask O
with O
UV O
light O
, O
generating O
12 O
. O
5 O
and O
62 O
mu O
m O
pitch O
patterns O
. O

Novel O
racemic O
tetrahydrocurcuminoi B
dihydropyrimidinone I
analogues O
as O
potent O
acetylcholinesterase O
inhibitors O
. O

The O
synthesis O
of O
racemic O
tetrahydrocurcumin B
- O
( O
THC B
- O
) O
, O
tetrahydrodemethoxyc B
- O
( O
THDC B
- O
) O
and O
tetrahydrobisdemetho B
- O
( O
THBDC B
- O
) O
dihydropyrimidinone B
( O
DHPM B
) O
analogues O
was O
achieved O
by O
utilizing O
the O
multi O
- O
component O
Biginelli O
reaction O
in O
the O
presence O
of O
copper B
sulphate I
as O
a O
catalyst O
. O

We O
conjugated O
either O
ester B
or O
amide B
- O
linker O
modified O
MTX B
to O
dendrimer O
scaffolds O
with O
or O
without O
folic B
acid I
( O
FA O
) O
. O

MPG O
leaf O
hydromethanolic O
extract O
contained O
tryptophan B
and O
flavonoids B
, O
including O
quercetin B
glycosides I
. O

Our O
objective O
was O
to O
improve O
the O
assessment O
of O
these O
compounds O
in O
human O
blood O
using O
GC O
with O
flame O
ionization O
detection O
. O
Methods O
: O
An O
amount O
of O
50 O
micro O
l O
of O
blood O
was O
diluted O
with O
300 O
micro O
l O
of O
sterile O
water O
, O
40 O
micro O
l O
of O
10 O
% O
sodium B
tungstate I
, O
and O
20 O
micro O
l O
of O
1 O
% O
sulphuric B
acid I
. O

Our O
objective O
was O
to O
improve O
the O
assessment O
of O
these O
compounds O
in O
human O
blood O
using O
GC O
with O
flame O
ionization O
detection O
. O
Methods O
: O
An O
amount O
of O
50 O
micro O
l O
of O
blood O
was O
diluted O
with O
300 O
micro O
l O
of O
sterile O
water O
, O
40 O
micro O
l O
of O
10 O
% O
sodium B
tungstate I
, O
and O
20 O
micro O
l O
of O
1 O
% O
sulphuric B
acid I
. O

Proteasomal O
cleavage O
site O
prediction O
of O
protein O
antigen O
using O
BP O
neural O
network O
based O
on O
a O
new O
set O
of O
amino B
acid I
descriptor O
. O

Thus O
, O
models O
based O
on O
the O
properties O
of O
amino B
acids I
can O
be O
highly O
reliable O
and O
reflect O
the O
structural O
features O
of O
interactions O
between O
proteasomes O
and O
peptide O
sequences O
. O

The O
aim O
of O
the O
present O
study O
was O
to O
elucidate O
the O
influences O
of O
body O
iron B
status O
and O
three O
dietary O
factors O
( O
green O
tea O
extract O
, O
ascorbic B
acid I
, O
and O
calcium B
) O
on O
the O
pharmacokinetics O
of O
hemin B
using O
stable O
isotope O
labeling O
methods O
followed O
by O
ICP O
- O
MS O
measurement O
. O

On O
the O
other O
hand O
, O
ascorbic B
acid I
significantly O
affected O
hemin B
iron B
absorption O
only O
in O
iron B
- O
deficient O
rats O
, O
in O
which O
C O
max O
showed O
a O
significant O
increase O
. O

Thyroid B
hormone I
directly O
affects O
serum O
creatinine B
in O
muscle O
and O
low O
thyroid O
function O
might O
exert O
a O
similar O
direct O
effect O
in O
the O
kidney O
. O

The O
[ O
17 O
. O
8 O
] O
0 O
( O
+ O
) O
- O
X O
( O
1 O
) O
Sigma O
( O
+ O
) O
( O
0 O
, O
0 O
) O
band O
of O
gold B
monofluoride I
, O
AuF B
, O
has O
been O
recorded O
at O
a O
resolution O
of O
40 O
MHz O
both O
field O
free O
and O
in O
the O
presence O
of O
a O
static O
electric O
and O
magnetic O
field O
. O

Although O
PKCs O
may O
inhibit O
insulin O
signal O
transduction O
, O
these O
enzymes O
are O
not O
merely O
downstream O
effectors O
of O
lipid O
accumulation O
, O
but O
in O
fact O
control O
the O
fate O
of O
fatty B
acids I
, O
thus O
the O
tail O
wags O
the O
dog O
. O

Kappa O
- O
opioid O
receptor O
- O
selective O
dicarboxylic B
ester I
- O
derived O
salvinorin B
A I
ligands O
. O

Kappa O
- O
opioid O
receptor O
- O
selective O
dicarboxylic B
ester I
- O
derived O
salvinorin B
A I
ligands O
. O

Salvinorin B
A I
, O
the O
active O
ingredient O
of O
the O
hallucinogenic O
plant O
Salvia O
divinorum O
is O
the O
most O
potent O
known O
naturally O
occurring O
hallucinogen O
and O
is O
a O
selective O
kappa O
- O
opioid O
receptor O
agonist O
. O

To O
better O
understand O
the O
ligand O
- O
receptor O
interactions O
, O
a O
series O
of O
dicarboxylic B
ester I
- O
type O
of O
salvinorin B
A I
derivatives O
were O
synthesized O
and O
evaluated O
for O
their O
binding O
affinity O
at O
kappa O
- O
, O
delta O
- O
and O
mu O
- O
opioid O
receptors O
. O

To O
better O
understand O
the O
ligand O
- O
receptor O
interactions O
, O
a O
series O
of O
dicarboxylic B
ester I
- O
type O
of O
salvinorin B
A I
derivatives O
were O
synthesized O
and O
evaluated O
for O
their O
binding O
affinity O
at O
kappa O
- O
, O
delta O
- O
and O
mu O
- O
opioid O
receptors O
. O

Methyl B
malonyl I
derivative O
4 O
shows O
the O
highest O
binding O
affinity O
( O
Ki O
= O
2nM O
) O
, O
analogues O
5 O
, O
7 O
, O
and O
14 O
exhibit O
significant O
affinity O
for O
the O
kappa O
- O
receptor O
( O
Ki O
= O
21 O
, O
36 O
and O
39nM O
) O
. O

Structure O
- O
activity O
relationships O
of O
hybrid O
annonaceous B
acetogenins I
: O
Powerful O
growth O
inhibitory O
effects O
of O
their O
connecting O
groups O
between O
heterocycle O
and O
hydrophobic O
carbon B
chain O
bearing O
THF B
ring O
on O
human O
cancer O
cell O
lines O
. O

Five O
novel O
hybrid O
molecules O
of O
annonaceous B
acetogenins I
and O
insecticides O
targeting O
mitochondrial O
complex O
I O
were O
synthesized O
and O
their O
growth O
inhibitory O
activities O
against O
39 O
human O
cancer O
cell O
lines O
were O
investigated O
. O

The O
bile B
salt I
export O
pump O
( O
BSEP O
or O
ABCB11 O
) O
prevents O
accumulation O
of O
toxic O
bile B
salt I
concentrations O
in O
hepatocytes O
, O
and O
BSEP O
inhibition O
or O
deficiency O
may O
cause O
cholestasis O
and O
liver O
injury O
. O

The O
bile B
salt I
export O
pump O
( O
BSEP O
or O
ABCB11 O
) O
prevents O
accumulation O
of O
toxic O
bile B
salt I
concentrations O
in O
hepatocytes O
, O
and O
BSEP O
inhibition O
or O
deficiency O
may O
cause O
cholestasis O
and O
liver O
injury O
. O

The O
self O
- O
assembly O
of O
short O
amino B
acid I
chains O
appears O
to O
be O
one O
of O
the O
most O
promising O
strategies O
for O
the O
fabrication O
of O
nanostructures O
. O

PURPOSE O
: O
Recent O
studies O
in O
patients O
with O
inflammatory O
bowel O
diseases O
( O
IBD O
) O
on O
thiopurine B
therapy O
suggest O
that O
too O
low O
6 B
- I
thioguanine I
nucleotide I
concentrations O
( O
6 B
- I
TGN I
) O
and O
too O
high O
methylmercaptopurine B
nucleotide I
concentrations O
( O
MMPN B
) O
can O
be O
reversed O
by O
a O
combination O
therapy O
of O
allopurinol B
and O
low O
- O
dose O
thiopurines B
. O

Modulation O
of O
carbon B
tetrachloride I
- O
induced O
nephrotoxicity O
in O
rats O
by O
n B
- I
hexane I
extract O
of O
Sonchus O
asper O
. O

In O
the O
present O
study O
, O
protective O
effects O
of O
S O
. O
asper O
against O
carbon B
tetrachloride I
( O
CCl4 B
) O
- O
induced O
nephrotoxicity O
of O
rats O
were O
determined O
. O

Group O
I O
( O
control O
group O
) O
was O
given O
saline O
( O
1 O
ml O
/ O
kg O
body O
weight O
( O
b O
. O
w O
. O
) O
, O
0 O
. O
85 O
% O
NaCl B
) O
and O
dimethyl B
sulfoxide I
( O
1 O
ml O
/ O
kg O
b O
. O
w O
. O
) O
; O
group O
II O
was O
treated O
with O
CCl4 B
( O
1 O
ml O
/ O
kg O
b O
. O
w O
. O
intraperitoneally O
) O
; O
groups O
III O
and O
IV O
were O
administered O
with O
CCl4 B
and O
after O
48 O
h O
with O
S O
. O
asper O
n B
- I
hexane I
extract O
( O
SHE O
; O
100 O
and O
200 O
mg O
/ O
kg O
b O
. O
w O
. O
) O
. O

The O
results O
revealed O
that O
CCl4 B
- O
induced O
oxidative O
stress O
as O
evidenced O
by O
the O
significant O
depletion O
of O
antioxidant O
enzymes O
, O
namely O
, O
superoxide B
dismutase O
, O
catalase O
, O
peroxidase O
, O
glutathione B
- O
S B
- O
transferase O
, O
glutathione B
peroxidase O
, O
glutathione B
reductase O
, O
and O
glutathione B
contents O
, O
while O
increased O
lipid O
peroxidation O
( O
thiobarbituric B
acid I
- O
reactive O
substances O
contents O
) O
. O

Our O
calculated O
results O
show O
that O
the O
four O
reaction O
channels O
forming O
1 B
- I
buten I
- I
2 I
- I
ol I
+ O
H B
y I
O2 I
radical O
( O
R5 O
) O
, O
2 B
- I
buten I
- I
2 I
- I
ol I
+ O
H B
y I
O2 I
radical O
( O
R10 O
) O
, O
acetic B
acid I
+ O
ethylene B
+ O
y O
O B
H I
radical O
( O
R13 O
) O
, O
2 B
- I
methyl I
- I
2 I
- I
oxetanol I
+ O
y O
OH B
radical O
( O
R15 O
) O
are O
the O
dominant O
channels O
. O

Our O
calculated O
results O
show O
that O
the O
four O
reaction O
channels O
forming O
1 B
- I
buten I
- I
2 I
- I
ol I
+ O
H B
y I
O2 I
radical O
( O
R5 O
) O
, O
2 B
- I
buten I
- I
2 I
- I
ol I
+ O
H B
y I
O2 I
radical O
( O
R10 O
) O
, O
acetic B
acid I
+ O
ethylene B
+ O
y O
O B
H I
radical O
( O
R13 O
) O
, O
2 B
- I
methyl I
- I
2 I
- I
oxetanol I
+ O
y O
OH B
radical O
( O
R15 O
) O
are O
the O
dominant O
channels O
. O

When O
the O
temperature O
is O
below O
1000 O
K O
, O
the O
reaction O
R15 O
forming O
the O
cyclic B
ether I
, O
2 B
- I
methyl I
- I
2 I
- I
oxetanol I
, O
is O
dominant O
; O
while O
the O
reaction O
R13 O
forming O
acetic B
acid I
+ O
ethylene B
+ O
y O
OH B
radical O
becomes O
increasingly O
dominant O
at O
temperatures O
above O
1000 O
K O
. O

When O
the O
temperature O
is O
below O
1000 O
K O
, O
the O
reaction O
R15 O
forming O
the O
cyclic B
ether I
, O
2 B
- I
methyl I
- I
2 I
- I
oxetanol I
, O
is O
dominant O
; O
while O
the O
reaction O
R13 O
forming O
acetic B
acid I
+ O
ethylene B
+ O
y O
OH B
radical O
becomes O
increasingly O
dominant O
at O
temperatures O
above O
1000 O
K O
. O

No O
pressure O
dependence O
has O
been O
found O
for O
the O
reaction O
channels O
forming O
2 B
- I
methyl I
- I
2 I
- I
oxetanol I
+ O
OH B
radical O
and O
acetic B
acid I
+ O
ethylene B
+ O
OH B
radical O
. O

Synthesis O
and O
cytotoxic O
evaluation O
of O
novel O
pyrimidine B
deoxyapiothionucleos I
. O

The O
synthesis O
of O
novel O
pyrimidine B
deoxyapiothionucleos I
of O
d O
- O
and O
l O
- O
series O
was O
realized O
following O
application O
of O
a O
versatile O
and O
high O
- O
yielding O
scheme O
, O
which O
utilized O
inexpensive O
l B
- I
and I
d I
- I
arabinose I
as O
starting O
materials O
, O
respectively O
, O
and O
which O
makes O
use O
of O
a O
regio O
- O
and O
stereo O
- O
selective O
Pummerer O
rearrangement O
reaction O
for O
the O
coupling O
of O
the O
nucleobase B
with O
the O
thiosugar B
moiety O
. O

A O
Surgical O
Model O
in O
Male O
Obese O
Rats O
Uncovers O
Protective O
Effects O
of O
Bile B
Acids I
Post O
- O
Bariatric O
Surgery O
. O

Bariatric O
surgery O
elevates O
serum O
bile B
acids I
. O

Conjugated O
bile B
acid I
administration O
, O
such O
as O
tauroursodeoxycholic B
acid I
( O
TUDCA B
) O
, O
improves O
insulin O
sensitivity O
, O
while O
short O
- O
circuiting O
bile B
acid I
circulation O
through O
ileal O
interposition O
surgery O
in O
rats O
raises O
TUDCA B
levels O
. O

Conjugated O
bile B
acid I
administration O
, O
such O
as O
tauroursodeoxycholic B
acid I
( O
TUDCA B
) O
, O
improves O
insulin O
sensitivity O
, O
while O
short O
- O
circuiting O
bile B
acid I
circulation O
through O
ileal O
interposition O
surgery O
in O
rats O
raises O
TUDCA B
levels O
. O

Conjugated O
bile B
acid I
administration O
, O
such O
as O
tauroursodeoxycholic B
acid I
( O
TUDCA B
) O
, O
improves O
insulin O
sensitivity O
, O
while O
short O
- O
circuiting O
bile B
acid I
circulation O
through O
ileal O
interposition O
surgery O
in O
rats O
raises O
TUDCA B
levels O
. O

BD O
rats O
had O
improved O
glucose B
tolerance O
, O
increased O
higher O
post O
- O
prandial O
GLP O
- O
1 O
response O
and O
serum O
bile B
acids I
but O
less O
liver O
steatosis O
. O

Serum O
bile B
acid I
levels O
including O
TUDCA B
concentrations O
were O
higher O
in O
BD O
compared O
to O
SH O
pair O
- O
fed O
rats O
. O

Fecal O
bile B
acid I
levels O
were O
not O
different O
. O

Bile B
acid I
gavage O
( O
TUDCA B
/ O
UDCA B
) O
in O
diet O
- O
induced O
obese O
rats O
, O
elevated O
serum O
TUDCA B
and O
concomitantly O
reduced O
hepatic O
steatosis O
and O
ER O
stress O
( O
CHOP O
mRNA O
) O
. O

These O
data O
demonstrate O
the O
ability O
of O
alterations O
in O
bile B
acids I
to O
recapitulate O
important O
metabolic O
improvements O
seen O
after O
bariatric O
surgery O
. O

Further O
, O
our O
work O
establishes O
a O
model O
for O
focused O
study O
of O
bile B
acids I
in O
the O
context O
of O
bariatric O
surgery O
that O
may O
lead O
to O
the O
identification O
of O
therapeutics O
for O
metabolic O
disease O
. O

Abstract O
Objectives O
: O
Silver B
nanoparticles O
( O
AgNPs O
) O
with O
a O
size O
ranging O
from O
7 O
to O
70 O
nm O
were O
synthesized O
using O
the O
ascorbic B
acid I
- O
citrate B
seed O
- O
mediated O
growth O
approach O
at O
room O
temperature O
. O

Methods O
: O
The O
8 O
nm O
silver B
particles O
were O
prepared O
using O
gallic B
acid I
in O
alkaline O
conditions O
and O
used O
as O
seed O
to O
prepare O
AgNPs O
. O

Results O
: O
The O
presence O
of O
ascorbic B
acid I
and O
citrate B
allows O
the O
regulation O
of O
size O
and O
size O
distribution O
of O
the O
nanoparticles O
. O

Gas O
Chromatography O
- O
Electron O
Impact O
Mass O
Spectrometry O
analyses O
of O
the O
three O
EOs O
showed O
that O
H O
. O
suaveolens O
EO O
was O
dominated O
by O
monoterpene B
and O
sesquiterpene B
hydrocarbons I
. O

Oxygenated B
monoterpenes I
were O
the O
main O
chemical O
class O
in O
R O
. O
officinalis O
and O
L O
. O
angustifolia O
EOs O
. O

Additionally O
, O
selected O
( O
co O
) O
- O
pyrolyses O
between O
the O
chlorinated B
ethylenes I
, O
CH2Cl2 B
, O
C4Cl4 B
, O
C4Cl6 B
, O
and O
C2H2 B
have O
been O
performed O
to O
explicitly O
probe O
the O
roles O
of O
2C3 B
and O
C4 B
/ O
C2 B
reaction O
pairs O
in O
aromatic O
growth O
. O

The O
reactions O
of O
perchlorinated B
C4 I
species O
C4Cl5 B
, O
C4Cl3 B
, O
and O
C4Cl4 B
with O
C2Cl2 B
were O
subsequently O
explored O
through O
extensive O
kinetic O
simulations O
of O
the O
possible O
reaction O
pathways O
based O
on O
previous O
kinetic O
models O
and O
the O
exhaustive O
quantum O
chemical O
investigations O
of O
our O
preceding O
work O
. O

The O
experimental O
and O
theoretical O
results O
strongly O
suggest O
that O
, O
at O
moderate O
temperatures O
, O
aromatic O
ring O
formation O
from O
chlorinated B
ethylenes I
normally O
follows O
a O
Diels O
- O
Alder O
coupling O
of O
C4 B
and O
C2 B
molecular O
units O
followed O
by O
internal O
shifts O
; O
the O
one O
exception O
is O
the O
C4Cl4 B
+ O
C2Cl2 B
system O
, O
where O
steric O
factors O
lead O
to O
the O
formation O
of O
non O
- O
aromatic O
products O
. O

Wool O
was O
dissolved O
in O
sodium B
hydroxide I
solution O
, O
the O
pH O
value O
of O
the O
solution O
was O
adjusted O
to O
5 O
. O
55 O
and O
the O
precipitate O
was O
harvested O
as O
wool O
polypeptide O
. O

Abstract O
Aim O
: O
In O
order O
to O
avoid O
gastric O
irritation O
caused O
by O
tolmetin B
sodium I
( O
TS O
) O
, O
gastro O
resistant O
Eudragit B
( O
R O
) O
S O
100 O
microsphere O
formulations O
were O
prepared O
with O
the O
emulsion O
/ O
solvent O
diffusion O
method O
. O

Materials O
and O
methods O
: O
With O
bovine O
albumin O
- O
fluorescein B
isothiocyanate I
conjugate O
( O
FITC B
- O
BSA O
) O
as O
a O
vaccine O
model O
, O
formulations O
were O
selected O
with O
the O
construction O
of O
pseudo O
- O
ternary O
phase O
diagrams O
and O
a O
short O
- O
term O
stability O
study O
. O

Two O
new O
isoflavone B
glycosides I
, O
ammopiptanosides B
A I
and I
B I
, O
have O
been O
isolated O
from O
the O
95 O
% O
EtOH B
extract O
of O
the O
twigs O
of O
Ammopiptanthus O
nanus O
( O
M O
. O
Pop O
. O
) O
Cheng O
f O
. O
, O
together O
with O
six O
known O
compounds O
, O
and O
their O
structures O
were O
characterized O
by O
spectroscopic O
methods O
and O
compared O
with O
the O
data O
in O
the O
literature O
. O

Sulfonated B
Polyaniline I
- O
Based O
Organic O
Electrodes O
for O
Controlled O
Electrical O
Stimulation O
of O
Human O
Osteosarcoma O
Cells O
. O

Here O
we O
report O
a O
facile O
fabrication O
method O
of O
self O
- O
doped O
sulfonated B
polyaniline I
( O
SPAN B
) O
- O
based O
interdigitated O
electrodes O
( O
IDEs O
) O
for O
controlled O
electrical O
stimulation O
of O
human O
osteosarcoma O
( O
HOS O
) O
cells O
. O

Three O
new O
triterpene B
glycosides I
from O
Ilex O
asprella O
. O

Design O
, O
Synthesis O
and O
biological O
evaluation O
of O
catecholamine B
vehicle O
for O
studying O
dopaminergic O
system O
. O

Molecular O
docking O
studies O
were O
performed O
with O
Human O
Serum O
Albumin O
( O
HSA O
: O
PDB O
1E78 O
) O
, O
showing O
binding O
pattern O
with O
amino B
acid I
residues O
Arg218 B
, O
Arg222 B
and O
Lys444 B
, O
identifies O
the O
ligand O
- O
HSA O
interaction O
for O
the O
transportation O
affinity O
of O
the O
ligand O
at O
the O
specific O
site O
of O
the O
target O
. O

Health O
benefits O
of O
seafood O
; O
Is O
it O
just O
the O
fatty B
acids I
? O

The O
results O
showed O
that O
Phyllanthus O
emblica O
L O
. O
exhibited O
the O
highest O
levels O
of O
vitamin B
C I
( O
575 O
+ O
/ O
- O
452mg O
/ O
100g O
) O
, O
total O
phenolics B
( O
TP O
) O
( O
3703 O
+ O
/ O
- O
1244mGAE O
/ O
100g O
) O
, O
and O
antioxidant O
activities O
, O
as O
measured O
by O
DPPH B
, O
FRAP O
and O
ORAC O
assays O
. O

Effect O
of O
different O
maize O
meal O
diets O
on O
growth O
and O
vitamin B
A I
: O
Case O
- O
study O
on O
chickens O
. O

However O
, O
it O
was O
reported O
, O
in O
2008 O
, O
that O
vitamin B
A I
deficiency O
increased O
despite O
the O
mandatory O
fortification O
programme O
. O

This O
motivates O
an O
investigation O
into O
the O
absorption O
of O
vitamin B
A I
as O
fortificant O
in O
the O
maize O
meal O
. O

Relative O
absorption O
, O
in O
chickens O
as O
the O
biological O
model O
, O
was O
determined O
by O
evaluating O
growth O
and O
vitamin B
A I
status O
. O

The O
fortified O
white O
maize O
meal O
diet O
was O
able O
to O
maintain O
the O
vitamin B
A I
status O
of O
the O
chickens O
. O

Poor O
absorption O
of O
the O
fortificant O
vitamin B
A I
is O
therefore O
not O
a O
constraint O
in O
combating O
vitamin B
A I
deficiency O
. O

Poor O
absorption O
of O
the O
fortificant O
vitamin B
A I
is O
therefore O
not O
a O
constraint O
in O
combating O
vitamin B
A I
deficiency O
. O

Voluntary O
food O
fortification O
with O
folic B
acid I
in O
Spain O
: O
Predicted O
contribution O
to O
children O
' O
s O
dietary O
intakes O
as O
assessed O
with O
new O
food O
folate B
composition O
data O
. O

The O
Spanish O
market O
offers O
a O
significant O
number O
of O
folic B
acid I
( O
FA O
) O
voluntarily O
fortified O
foods O
. O

Although O
more O
expensive O
, O
it O
is O
considered O
more O
accurate O
to O
base O
protein O
content O
of O
foods O
on O
amino B
acid I
data O
( O
Greenfield O
& O
Southgate O
, O
2003 O
) O
. O

For O
all O
cuts O
, O
the O
correlation O
coefficient O
of O
total O
amino B
acids I
to O
protein O
( O
N O
x O
6 O
. O
25 O
) O
was O
0 O
. O
635 O
. O

This O
indicates O
a O
poor O
correlation O
for O
predicting O
actual O
protein O
content O
( O
as O
determined O
by O
total O
amino B
acid I
count O
) O
, O
based O
on O
the O
nitrogen B
factor O
of O
6 O
. O
25 O
. O

On O
average O
, O
the O
sum O
of O
amino B
acids I
per O
cut O
amounted O
to O
91 O
% O
of O
total O
determined O
protein O
( O
N O
x O
6 O
. O
25 O
) O
for O
the O
same O
cut O
. O

RESULTS O
: O
The O
ethanol B
extract O
( O
30 O
and O
100mg O
/ O
kg O
, O
P O
< O
0 O
. O
001 O
) O
, O
given O
orally O
, O
produced O
dose O
dependent O
inhibition O
of O
acetic B
acid I
- O
induced O
visceral O
pain O
. O

In O
addition O
, O
three O
phenolic B
acids I
were O
detected O
in O
Jom O
only O
( O
5765 O
mu O
g O
/ O
g O
extract O
) O
, O
and O
protocatechuic B
acid I
was O
the O
most O
abundant O
one O
. O

In O
addition O
, O
three O
phenolic B
acids I
were O
detected O
in O
Jom O
only O
( O
5765 O
mu O
g O
/ O
g O
extract O
) O
, O
and O
protocatechuic B
acid I
was O
the O
most O
abundant O
one O
. O

The O
synthetic O
approach O
used O
for O
preparation O
of O
isomeric O
amidino B
substituted I
- I
phenylene I
- I
bis I
- I
benzothyazoles I
3a O
- O
3f O
was O
achieved O
by O
condensation O
reaction O
of O
isophthaloyl B
dichloride I
1a O
and O
terephthaloyl B
dichloride I
1b O
or O
with O
phthalic B
acid I
1c O
with O
5 B
- I
amidinium I
- I
2 I
- I
aminobenzothiolate I
2a O
and O
5 B
- I
( I
imidazolinium I
- I
2 I
- I
yl I
) I
- I
2 I
- I
aminobenzothiolate I
2b O
in O
good O
yields O
. O

The O
synthetic O
approach O
used O
for O
preparation O
of O
isomeric O
amidino B
substituted I
- I
phenylene I
- I
bis I
- I
benzothyazoles I
3a O
- O
3f O
was O
achieved O
by O
condensation O
reaction O
of O
isophthaloyl B
dichloride I
1a O
and O
terephthaloyl B
dichloride I
1b O
or O
with O
phthalic B
acid I
1c O
with O
5 B
- I
amidinium I
- I
2 I
- I
aminobenzothiolate I
2a O
and O
5 B
- I
( I
imidazolinium I
- I
2 I
- I
yl I
) I
- I
2 I
- I
aminobenzothiolate I
2b O
in O
good O
yields O
. O

The O
synthetic O
approach O
used O
for O
preparation O
of O
isomeric O
amidino B
substituted I
- I
phenylene I
- I
bis I
- I
benzothyazoles I
3a O
- O
3f O
was O
achieved O
by O
condensation O
reaction O
of O
isophthaloyl B
dichloride I
1a O
and O
terephthaloyl B
dichloride I
1b O
or O
with O
phthalic B
acid I
1c O
with O
5 B
- I
amidinium I
- I
2 I
- I
aminobenzothiolate I
2a O
and O
5 B
- I
( I
imidazolinium I
- I
2 I
- I
yl I
) I
- I
2 I
- I
aminobenzothiolate I
2b O
in O
good O
yields O
. O

The O
targeted O
compounds O
were O
converted O
in O
the O
desired O
water O
soluble O
dihydrochloride B
salts O
by O
reaction O
of O
appropriate O
free O
base O
with O
concd O
HCl B
in O
ethanol B
or O
acetic B
acid I
. O

The O
petal O
- O
like O
and O
tree O
- O
like O
graphene B
networks O
grown O
by O
a O
plasma O
enhanced O
CVD O
process O
on O
a O
thin O
( O
500 O
nm O
) O
silicon B
oxide I
layer O
supported O
by O
a O
silicon B
wafer O
demonstrate O
a O
significant O
difference O
in O
the O
resistance O
- O
magnetic O
field O
dependencies O
at O
temperatures O
ranging O
from O
2 O
to O
200 O
K O
. O

Sparstolonin B
B I
suppresses O
lipopolysaccharide O
- O
induced O
inflammation O
in O
human O
umbilical O
vein O
endothelial O
cells O
. O

Sparstolonin B
B I
( O
SsnB B
) O
is O
an O
isocoumarin B
compound O
isolated O
from O
the O
tubers O
of O
both O
Sparganium O
stoloniferum O
and O
Scirpus O
yagara O
. O

Adding O
ethylene B
glycol I
( O
EG O
) O
to O
poly B
( I
3 I
, I
4 I
- I
ethylenedioxythiophe I
) I
: O
poly B
( I
styrenesulfonate I
) I
( O
PEDOT B
: O
PSS B
) O
solution O
improves O
the O
crystallinity O
of O
the O
PEDOT B
and O
the O
ordering O
of O
the O
PEDOT B
nanocrystals O
in O
solid O
films O
. O

3D O
Graphene B
Foams O
Cross O
- O
linked O
with O
Pre O
- O
encapsulated O
Fe3 B
O4 I
Nanospheres O
for O
Enhanced O
Lithium B
Storage O
. O

Electrostatic O
assembly O
between O
Fe3 B
O4 I
nanospheres O
and O
graphene B
oxide I
, O
and O
subsequent O
hydrothermal O
assembly O
with O
additional O
graphene B
sheets O
, O
leads O
to O
Fe3 B
O4 I
nanospheres O
encapsulated O
in O
the O
graphene B
shells O
and O
interconnected O
by O
the O
graphene B
networks O
. O

Electrostatic O
assembly O
between O
Fe3 B
O4 I
nanospheres O
and O
graphene B
oxide I
, O
and O
subsequent O
hydrothermal O
assembly O
with O
additional O
graphene B
sheets O
, O
leads O
to O
Fe3 B
O4 I
nanospheres O
encapsulated O
in O
the O
graphene B
shells O
and O
interconnected O
by O
the O
graphene B
networks O
. O

Electrostatic O
assembly O
between O
Fe3 B
O4 I
nanospheres O
and O
graphene B
oxide I
, O
and O
subsequent O
hydrothermal O
assembly O
with O
additional O
graphene B
sheets O
, O
leads O
to O
Fe3 B
O4 I
nanospheres O
encapsulated O
in O
the O
graphene B
shells O
and O
interconnected O
by O
the O
graphene B
networks O
. O

Such O
3D O
Fe3 B
O4 I
/ O
graphene B
foams O
exhibit O
enhanced O
lithium B
storage O
with O
excellent O
cycling O
performance O
and O
rate O
capability O
. O

Prolonged O
- O
release O
fampridine B
( O
fampridine B
PR I
) O
is O
a O
potassium B
channel O
blocker O
that O
improves O
conductivity O
of O
signal O
on O
demyelinated O
axons O
in O
central O
nervous O
system O
. O

Fampridine B
PR I
has O
been O
approved O
to O
improve O
speed O
of O
walking O
in O
patients O
with O
multiple O
sclerosis O
. O

This O
statement O
provides O
a O
brief O
summary O
of O
data O
on O
fampridine B
PR I
and O
recommendations O
on O
practical O
use O
of O
the O
medication O
in O
clinical O
practice O
, O
prediction O
, O
and O
evaluation O
of O
response O
to O
treatment O
and O
patient O
management O
. O

In O
the O
present O
study O
, O
we O
chemically O
synthesized O
novel O
17 B
- I
fluorinated I
steroids I
and O
evaluated O
the O
cytotoxicity O
profiles O
of O
these O
compounds O
in O
T47D O
breast O
cancer O
cells O
compared O
to O
the O
activity O
of O
known O
antiprogestins B
, O
including O
ZK230 B
211 I
, O
RU B
- I
486 I
, O
CDB2914 B
, O
CDB4124 B
and O
ORG33628 B
. O

Glucose B
- O
induced O
insulin O
secretion O
from O
pancreatic O
beta O
- O
cells O
depends O
critically O
on O
activity O
of O
ATP B
- O
sensitive O
K B
+ I
channels O
( O
KATP O
channel O
) O
. O

Pre O
- O
treatment O
of O
a O
muscarine O
receptor O
antagonist O
, O
atropine B
methyl B
nitrate I
, O
which O
does O
not O
cross O
the O
blood O
- O
brain O
barrier O
, O
almost O
completely O
blocked O
insulin O
secretion O
induced O
by O
voluntary O
feeding O
of O
standard O
chow O
or O
carbohydrate B
in O
Kir6 O
. O
2 O
- O
/ O
- O
mice O
. O

For O
the O
Ar19Kr B
n I
Xe19 I
, O
Ar19Kr19Xe B
n I
, O
and O
Ar B
n I
Kr19Xe19 I
( O
n O
= O
0 O
- O
17 O
) O
clusters O
investigated O
, O
the O
results O
show O
that O
only O
two O
minimum O
energy O
configurations O
exist O
, O
i O
. O
e O
. O
, O
polytetrahedron O
and O
six O
- O
fold O
pancake O
. O

A O
focused O
library O
based O
on O
the O
marine O
natural O
products O
polyandrocarpamines B
A I
( O
1 O
) O
and O
B O
( O
2 O
) O
has O
been O
designed O
and O
synthesised O
using O
parallel O
solution O
- O
phase O
chemistry O
. O

Stability O
studies O
were O
conducted O
on O
two O
nonaqueous O
topical O
formulations O
: O
a O
polyethylene B
glycol I
( O
PEG B
) O
ointment O
base O
and O
an O
organic O
oleaginous O
base O
. O

Here O
, O
we O
study O
distribution O
of O
carbon B
nanotubes O
( O
CNTs O
) O
in O
two O
immiscible O
aqueous O
phases O
formed O
by O
the O
addition O
of O
polyethylene B
glycol I
( O
PEG B
) O
and O
dextran O
. O

Over O
the O
last O
decade O
, O
selective O
phosphopeptide O
enrichment O
methods O
including O
IMAC O
and O
metal B
oxides I
( O
TiO2 B
and O
ZrO2 B
) O
have O
been O
developed O
and O
greatly O
facilitate O
large O
scale O
phosphoproteome O
analysis O
of O
various O
cells O
, O
tissues O
and O
living O
organisms O
, O
in O
combination O
with O
modern O
mass O
spectrometers O
featuring O
high O
mass O
accuracy O
and O
high O
mass O
resolution O
. O

We O
describe O
common O
strategies O
for O
mass O
spectrometric O
analysis O
of O
stable O
isotope O
labeled O
samples O
, O
as O
well O
as O
two O
widely O
applied O
phosphopeptide O
enrichment O
methods O
based O
on O
IMAC O
( O
NTA B
- I
Fe I
( I
3 I
+ I
) I
) O
and O
metal B
oxide I
( O
ZrO2 B
) O
. O

As O
an O
abundant O
ingredient O
in O
Huangqin O
, O
wogonoside B
is O
a O
flavonoid B
glycoside I
. O

The O
inhibition O
of O
wogonoside B
against O
nitric B
oxide I
( O
NO B
) O
, O
prostaglandin B
E2 I
( O
PGE2 B
) O
, O
tumor O
necrosis O
factor O
- O
alpha O
( O
TNF O
- O
alpha O
) O
and O
interleukin O
- O
6 O
( O
IL O
- O
6 O
) O
in O
LPS O
- O
induced O
RAW264 O
. O
7 O
cells O
were O
measured O
. O

The O
inhibition O
of O
wogonoside B
against O
nitric B
oxide I
( O
NO B
) O
, O
prostaglandin B
E2 I
( O
PGE2 B
) O
, O
tumor O
necrosis O
factor O
- O
alpha O
( O
TNF O
- O
alpha O
) O
and O
interleukin O
- O
6 O
( O
IL O
- O
6 O
) O
in O
LPS O
- O
induced O
RAW264 O
. O
7 O
cells O
were O
measured O
. O

Additionally O
, O
the O
effects O
of O
wogonoside B
on O
mRNA O
expression O
of O
inducible O
nitric B
oxide I
synthase O
( O
iNOS O
) O
, O
cyclooxygenase O
2 O
( O
COX2 O
) O
, O
TNF O
- O
alpha O
and O
IL O
- O
6 O
were O
also O
investigated O
. O

In O
view O
of O
this O
, O
the O
present O
study O
investigates O
the O
protective O
effect O
of O
FXO O
on O
lead B
acetate I
( O
PbAc B
) O
- O
induced O
renal O
damage O
. O

Rats O
were O
pre O
- O
fed O
normal O
diet O
and O
the O
diet O
rich O
in O
FXO O
for O
14 O
days O
, O
and O
then O
, O
four O
doses O
of O
lead B
acetate I
( O
25 O
mg O
/ O
kg O
body O
weight O
) O
were O
administered O
intraperitoneally O
while O
still O
on O
diet O
. O

Aromatic B
glycosides I
from O
the O
flower O
buds O
of O
Lonicera O
japonica O
. O

Results O
showed O
that O
exposure O
to O
VOCs O
( O
IAQS O
dose O
) O
resulted O
in O
oxidative O
damages O
of O
lung O
, O
which O
were O
supported O
by O
the O
significant O
changes O
on O
reactive O
oxygen B
species O
, O
reduced B
glutathione I
( O
GSH B
) O
, O
GSH B
S B
- O
transferase O
, O
total O
antioxidative O
capacity O
, O
malondialdehyde B
, O
protein O
carbonyl B
and O
nitric B
oxide I
( O
NO B
) O
. O

Results O
showed O
that O
exposure O
to O
VOCs O
( O
IAQS O
dose O
) O
resulted O
in O
oxidative O
damages O
of O
lung O
, O
which O
were O
supported O
by O
the O
significant O
changes O
on O
reactive O
oxygen B
species O
, O
reduced B
glutathione I
( O
GSH B
) O
, O
GSH B
S B
- O
transferase O
, O
total O
antioxidative O
capacity O
, O
malondialdehyde B
, O
protein O
carbonyl B
and O
nitric B
oxide I
( O
NO B
) O
. O

A O
highly O
effective O
drug O
carrier O
is O
constructed O
by O
coating O
folic B
acid I
- O
terminated O
poly B
( I
ethylene I
glycol I
) I
( O
PEG B
- O
FA O
) O
on O
single O
walled O
carbon B
nanotubes O
( O
SWNTs O
) O
in O
a O
facile O
non O
- O
covalent O
method O
. O

Hybrid O
Molecule O
from O
O B
( I
2 I
) I
- I
( I
2 I
, I
4 I
- I
Dinitrophenyl I
) I
diazeniumdiolate I
and O
Oleanolic B
Acid I
: O
a O
GST O
pi O
Activated O
Nitric B
Oxide I
Prodrug O
with O
Selective O
Anti O
- O
human O
Hepatocellular O
Carcinoma O
Activity O
and O
Improved O
Stability O
. O

Hybrid O
Molecule O
from O
O B
( I
2 I
) I
- I
( I
2 I
, I
4 I
- I
Dinitrophenyl I
) I
diazeniumdiolate I
and O
Oleanolic B
Acid I
: O
a O
GST O
pi O
Activated O
Nitric B
Oxide I
Prodrug O
with O
Selective O
Anti O
- O
human O
Hepatocellular O
Carcinoma O
Activity O
and O
Improved O
Stability O
. O

A O
series O
of O
hybrids O
from O
O B
( I
2 I
) I
- I
( I
2 I
, I
4 I
- I
dinitrophenyl I
) I
diazeniumdiolate I
and O
oleanolic B
acid I
( O
OA O
) O
were O
designed O
, O
synthesized O
, O
and O
biologically O
evaluated O
as O
novel O
nitric B
oxide I
( O
NO B
) O
releasing O
prodrugs O
which O
could O
be O
activated O
by O
glutathione B
S O
- O
transferase O
pi O
( O
GST O
pi O
) O
overexpressed O
in O
a O
number O
of O
cancer O
cells O
. O

A O
series O
of O
hybrids O
from O
O B
( I
2 I
) I
- I
( I
2 I
, I
4 I
- I
dinitrophenyl I
) I
diazeniumdiolate I
and O
oleanolic B
acid I
( O
OA O
) O
were O
designed O
, O
synthesized O
, O
and O
biologically O
evaluated O
as O
novel O
nitric B
oxide I
( O
NO B
) O
releasing O
prodrugs O
which O
could O
be O
activated O
by O
glutathione B
S O
- O
transferase O
pi O
( O
GST O
pi O
) O
overexpressed O
in O
a O
number O
of O
cancer O
cells O
. O

Exposure O
to O
DEHP B
decreased O
four O
fatty B
acid I
levels O
in O
plasma O
of O
prepartum O
mice O
. O

To O
identify O
the O
fatty B
acid I
( O
FA O
) O
species O
involved O
and O
to O
understand O
the O
underlying O
mechanisms O
, O
pregnant O
Sv O
/ O
129 O
wild O
- O
type O
( O
mPPAR O
alpha O
) O
, O
peroxisome O
proliferator O
- O
activated O
receptor O
alpha O
- O
null O
( O
Ppar O
alpha O
- O
null O
) O
and O
humanized O
PPAR O
alpha O
( O
hPPAR O
alpha O
) O
mice O
were O
treated O
with O
diets O
containing O
0 O
% O
, O
0 O
. O
01 O
% O
, O
0 O
. O
05 O
% O
or O
0 O
. O
1 O
% O
DEHP B
. O

The O
plasma O
levels O
of O
linoleic B
acid I
, O
alpha B
- I
linolenic I
acid I
, O
palmitic B
acid I
and O
oleic B
acid I
were O
higher O
in O
the O
pregnant O
control O
mPPARa O
mice O
than O
in O
Ppara O
- O
null O
and O
hPPARa O
mice O
. O

The O
plasma O
levels O
of O
linoleic B
acid I
, O
alpha B
- I
linolenic I
acid I
, O
palmitic B
acid I
and O
oleic B
acid I
were O
higher O
in O
the O
pregnant O
control O
mPPARa O
mice O
than O
in O
Ppara O
- O
null O
and O
hPPARa O
mice O
. O

The O
plasma O
levels O
of O
linoleic B
acid I
, O
alpha B
- I
linolenic I
acid I
, O
palmitic B
acid I
and O
oleic B
acid I
were O
higher O
in O
the O
pregnant O
control O
mPPARa O
mice O
than O
in O
Ppara O
- O
null O
and O
hPPARa O
mice O
. O

DEHP B
exposure O
slightly O
increased O
hepatic O
arachidonic B
acid I
, O
alpha B
- I
linolenic I
acid I
, O
palmitoleic B
acid I
and O
oleic B
acid I
in O
fetuses O
, O
but O
not O
in O
pups O
. O

DEHP B
exposure O
slightly O
increased O
hepatic O
arachidonic B
acid I
, O
alpha B
- I
linolenic I
acid I
, O
palmitoleic B
acid I
and O
oleic B
acid I
in O
fetuses O
, O
but O
not O
in O
pups O
. O

DEHP B
exposure O
slightly O
increased O
hepatic O
arachidonic B
acid I
, O
alpha B
- I
linolenic I
acid I
, O
palmitoleic B
acid I
and O
oleic B
acid I
in O
fetuses O
, O
but O
not O
in O
pups O
. O

The O
National O
Institute O
for O
Health O
and O
Clinical O
Excellence O
( O
NICE O
) O
invited O
the O
manufacturer O
of O
dabigatran B
etexilate I
( O
Boehringer O
Ingelheim O
Ltd O
, O
UK O
) O
to O
submit O
evidence O
for O
the O
clinical O
and O
cost O
- O
effectiveness O
of O
this O
drug O
for O
the O
prevention O
of O
stroke O
and O
systemic O
embolism O
in O
patients O
with O
non O
- O
valvular O
atrial O
fibrillation O
( O
AF O
) O
as O
part O
of O
the O
NICE O
single O
technology O
appraisal O
process O
. O

For O
comparison O
, O
zinc B
chloride I
combined O
with O
different O
potassium B
carboxylate I
salts O
and O
ligands O
were O
also O
tested O
for O
catalytic O
hydrosilylation O
reactions O
. O

For O
comparison O
, O
zinc B
chloride I
combined O
with O
different O
potassium B
carboxylate I
salts O
and O
ligands O
were O
also O
tested O
for O
catalytic O
hydrosilylation O
reactions O
. O

Here O
, O
we O
probe O
the O
cellular O
uptake O
of O
streptavidin O
using O
biotinylated B
guanidinoneomycin I
( O
biotinGNeo B
) O
, O
a O
low O
molecular O
weight O
guanidinium B
- O
rich O
molecular O
transporter O
. O

Because O
guanidinylated B
neomycin I
was O
previously O
found O
to O
exclusively O
bind O
to O
heparan O
sulfate O
, O
our O
observations O
suggest O
that O
heparan O
sulfate O
proteoglycan O
aggregation O
is O
a O
pivotal O
step O
for O
endocytic O
entry O
into O
cells O
by O
guanidinoglycosides B
. O

Each O
peptide O
differs O
in O
a O
single O
amino B
acid I
at O
its O
C B
- O
terminus O
, O
which O
minimizes O
the O
effects O
of O
peptide O
sequences O
and O
serves O
as O
a O
model O
molecule O
to O
create O
positive O
, O
neutral O
and O
negative O
charges O
on O
the O
surface O
of O
the O
NPs O
at O
pH O
4 O
- O
10 O
. O

) O
, O
2 B
- I
hydroxy I
- I
3 I
- I
methyl I
- I
1 I
- I
methoxyanthraquinone I
( O
7 O
) O
, O
oleanolic B
acid I
( O
8 O
) O
, O
ursolic B
acid I
( O
9 O
) O
, O
stigmasterol B
( O
10 O
) O
and O
docosanoic B
acid I
( O
11 O
) O
, O
were O
isolated O
and O
identified O
. O

) O
, O
2 B
- I
hydroxy I
- I
3 I
- I
methyl I
- I
1 I
- I
methoxyanthraquinone I
( O
7 O
) O
, O
oleanolic B
acid I
( O
8 O
) O
, O
ursolic B
acid I
( O
9 O
) O
, O
stigmasterol B
( O
10 O
) O
and O
docosanoic B
acid I
( O
11 O
) O
, O
were O
isolated O
and O
identified O
. O

) O
, O
2 B
- I
hydroxy I
- I
3 I
- I
methyl I
- I
1 I
- I
methoxyanthraquinone I
( O
7 O
) O
, O
oleanolic B
acid I
( O
8 O
) O
, O
ursolic B
acid I
( O
9 O
) O
, O
stigmasterol B
( O
10 O
) O
and O
docosanoic B
acid I
( O
11 O
) O
, O
were O
isolated O
and O
identified O
. O

A O
significant O
decrease O
in O
blood O
glutathione B
( O
16 O
. O
7 O
% O
) O
, O
total O
antioxidant O
activity O
( O
45 O
. O
4 O
% O
) O
and O
vitamin B
E I
( O
40 O
. O
8 O
% O
) O
was O
observed O
and O
no O
significant O
effect O
was O
found O
on O
blood O
selenium B
levels O
. O

Sciadopitysin B
also O
decreased O
the O
production O
of O
tumor O
necrosis O
factor O
- O
a O
( O
TNF O
- O
alpha O
) O
induced O
by O
antimycin B
A I
, O
a O
mitochondrial O
electron O
transport O
inhibitor O
. O

We O
investigated O
the O
protective O
effects O
of O
sciadopitysin B
on O
antimycin B
A I
- O
induced O
toxicity O
in O
osteoblastic O
MC3T3 O
- O
E1 O
cells O
. O

Exposure O
of O
MC3T3 O
- O
E1 O
cells O
to O
antimycin B
A I
caused O
a O
significant O
reduction O
in O
osteoblast O
dysfunction O
. O

However O
, O
pretreatment O
with O
sciadopitysin B
prior O
to O
antimycin B
A I
exposure O
significantly O
reduced O
antimycin B
A I
- O
induced O
cell O
damage O
by O
preventing O
mitochondrial O
membrane O
potential O
dissipation O
, O
adenosine B
triphosphate I
( O
ATP B
) O
loss O
, O
reactive O
oxygen B
species O
( O
ROS O
) O
release O
, O
and O
nitrotyrosine B
increase O
, O
suggesting O
that O
sciadopitysin B
may O
be O
useful O
for O
protecting O
mitochondria O
against O
a O
burst O
of O
oxidative O
stress O
. O

However O
, O
pretreatment O
with O
sciadopitysin B
prior O
to O
antimycin B
A I
exposure O
significantly O
reduced O
antimycin B
A I
- O
induced O
cell O
damage O
by O
preventing O
mitochondrial O
membrane O
potential O
dissipation O
, O
adenosine B
triphosphate I
( O
ATP B
) O
loss O
, O
reactive O
oxygen B
species O
( O
ROS O
) O
release O
, O
and O
nitrotyrosine B
increase O
, O
suggesting O
that O
sciadopitysin B
may O
be O
useful O
for O
protecting O
mitochondria O
against O
a O
burst O
of O
oxidative O
stress O
. O

However O
, O
pretreatment O
with O
sciadopitysin B
prior O
to O
antimycin B
A I
exposure O
significantly O
reduced O
antimycin B
A I
- O
induced O
cell O
damage O
by O
preventing O
mitochondrial O
membrane O
potential O
dissipation O
, O
adenosine B
triphosphate I
( O
ATP B
) O
loss O
, O
reactive O
oxygen B
species O
( O
ROS O
) O
release O
, O
and O
nitrotyrosine B
increase O
, O
suggesting O
that O
sciadopitysin B
may O
be O
useful O
for O
protecting O
mitochondria O
against O
a O
burst O
of O
oxidative O
stress O
. O

Moreover O
, O
sciadopitysin B
increased O
phosphorylation O
of O
cAMP B
- O
response O
element O
- O
binding O
protein O
( O
CREB O
) O
inhibited O
by O
antimycin B
A I
. O

It O
evidenced O
antinociceptive O
activity O
on O
the O
acetic B
acid I
- O
induced O
nociception O
, O
hot O
plate O
and O
formalin B
tests O
( O
at O
10 O
mg O
/ O
kg O
and O
30 O
mg O
/ O
kg O
) O
. O

Multiple O
Site O
- O
Selective O
Insertions O
of O
Noncanonical O
Amino B
Acids I
into O
Sequence O
- O
Repetitive O
Polypeptides O
. O

A O
simple O
and O
efficient O
method O
is O
described O
for O
the O
introduction O
of O
noncanonical O
amino B
acids I
at O
multiple O
, O
defined O
sites O
within O
recombinant O
polypeptide O
sequences O
. O

Escherichia O
coli O
MRA30 O
, O
a O
bacterial O
host O
strain O
with O
attenuated O
activity O
of O
release O
factor O
1 O
( O
RF1 O
) O
, O
was O
assessed O
for O
its O
ability O
to O
support O
incorporation O
of O
a O
diverse O
range O
of O
noncanonical O
amino B
acids I
in O
response O
to O
multiple O
encoded O
amber O
( O
TAG O
) O
codons O
within O
genes O
derived O
from O
superfolder O
GFP O
and O
an O
elastin O
- O
mimetic O
protein O
polymer O
. O

Suppression O
efficiency O
and O
protein O
yield O
depended O
on O
the O
identity O
of O
the O
orthogonal O
aminoacyl B
- O
tRNA O
synthetase O
/ O
tRNA O
( O
CUA O
) O
pair O
and O
the O
noncanonical O
amino B
acid I
. O

Elastin O
- O
mimetic O
protein O
polymers O
were O
prepared O
in O
which O
noncanonical O
amino B
acid I
derivatives O
were O
incorporated O
at O
up O
to O
22 O
specific O
sites O
within O
the O
polypeptide O
sequence O
with O
high O
substitution O
efficiency O
. O

The O
crude O
extract O
of O
T O
. O
stocksianum O
( O
Ts O
. O
Cr O
) O
and O
its O
subsequent O
organic O
fractions O
: O
n B
- I
hexane I
( O
Ts O
. O
Hex B
) O
, O
chloroform B
( O
Ts O
. O
CHCl3 B
) O
and O
ethyl B
acetate I
( O
Ts O
. O
EtAc B
) O
exhibited O
1 B
, I
1 I
- I
diphenyl I
, I
2 I
- I
picrylhydrazyl I
free O
radical O
scavenging O
activity O
with O
different O
potencies O
. O

AIM O
OF O
THE O
STUDY O
: O
The O
present O
study O
was O
aimed O
to O
establish O
a O
scientific O
evidence O
for O
anti O
obesity O
efficiency O
of O
ethyl B
acetate I
extract O
of O
Tecomella O
undulata O
bark O
( O
EATUB O
) O
. O

The O
bioactive O
fraction O
( O
F1 O
) O
was O
determined O
to O
possess O
4 O
. O
95 O
% O
of O
ferulic B
acid I
. O

Ferulic B
acid I
and O
rutin B
are O
being O
reported O
and O
quantified O
for O
the O
first O
time O
from O
the O
bark O
of O
Tecomella O
undulata O
. O

Examples O
of O
the O
function O
of O
[ B
S3 I
] I
. I
( I
- I
) I
in O
materials O
science O
, O
electrochemistry O
, O
analytical O
chemistry O
and O
geochemistry O
are O
used O
to O
illustrate O
the O
widespread O
influence O
of O
this O
fundamentally O
important O
triatomic B
sulfur I
species O
. O

In O
this O
method O
, O
superparamagnetic O
magnetite B
nanoparticles O
are O
first O
synthesized O
by O
coprecipitation O
using O
ferrous B
chloride I
and O
ferric B
chloride I
. O

In O
this O
method O
, O
superparamagnetic O
magnetite B
nanoparticles O
are O
first O
synthesized O
by O
coprecipitation O
using O
ferrous B
chloride I
and O
ferric B
chloride I
. O

Immediately O
following O
the O
synthesis O
, O
carbonate B
- O
substituted O
( O
B O
- O
type O
) O
hydroxyapatite B
particles O
are O
mechanochemically O
synthesized O
by O
wet O
milling O
dicalcium B
phosphate I
dihydrate I
and O
calcium B
carbonate I
in O
a O
dispersed O
suspension O
of O
magnetite B
nanoparticles O
, O
during O
which O
the O
magnetite B
nanoparticles O
are O
incorporated O
into O
the O
hydroxyapatite B
matrix O
. O

The O
preferential O
adsorption O
of O
Cs B
+ I
to O
the O
silica B
surface O
is O
traced O
to O
the O
weak O
hydration O
of O
neutral O
silanols B
and O
the O
resulting O
hydrophobic O
expulsion O
of O
weakly O
hydrated O
ions O
from O
bulk O
solution O
to O
the O
interface O
. O

The O
same O
interactions O
keep O
the O
strongly O
hydrated O
Li B
+ I
and O
Na B
+ I
in O
solution O
. O

The O
same O
interactions O
keep O
the O
strongly O
hydrated O
Li B
+ I
and O
Na B
+ I
in O
solution O
. O

Cs B
+ I
is O
correspondingly O
expelled O
from O
the O
surface O
and O
adsorption O
of O
small O
ions O
is O
encouraged O
. O

A O
sedonan B
A I
( O
1 O
) O
/ O
ent B
- I
sandwicensin I
( O
8 O
) O
combination O
exhibited O
synergistic O
growth O
inhibition O
. O

We O
argue O
that O
CP29 O
proteins O
previously O
studied O
by O
HB O
spectroscopy O
lacked O
at O
least O
one O
Chl B
a I
molecule O
( O
i O
. O
e O
. O
, O
a615 O
or O
a611 O
) O
, O
which O
along O
with O
Chl O
a612 O
contribute O
to O
the O
lowest O
energy O
state O
in O
more O
intact O
CP29 O
, O
and O
one O
Chl B
b I
( O
most O
likely O
b607 O
) O
. O

We O
argue O
that O
CP29 O
proteins O
previously O
studied O
by O
HB O
spectroscopy O
lacked O
at O
least O
one O
Chl B
a I
molecule O
( O
i O
. O
e O
. O
, O
a615 O
or O
a611 O
) O
, O
which O
along O
with O
Chl O
a612 O
contribute O
to O
the O
lowest O
energy O
state O
in O
more O
intact O
CP29 O
, O
and O
one O
Chl B
b I
( O
most O
likely O
b607 O
) O
. O

[ O
Photochem O
. O
Photobiol O
. O
2000 O
, O
71 O
, O
574 O
] O
were O
blueshifted O
by O
~ O
1 O
nm O
, O
the O
low O
- O
energy O
state O
appeared O
to O
be O
highly O
localized O
on O
a O
single O
Chl B
a I
molecule O
, O
and O
the O
position O
of O
the O
low O
- O
energy O
state O
was O
independent O
of O
burning O
fluence O
. O

Zero O
- O
phonon O
hole O
widths O
obtained O
for O
the O
Chl B
b I
band O
at O
638 O
. O
5 O
nm O
( O
5 O
K O
) O
revealed O
two O
independent O
Chl B
b I
- O
- O
> O
Chl B
a I
EET O
times O
, O
i O
. O
e O
. O
, O
4 O
+ O
/ O
- O
0 O
. O
5 O
ps O
and O
0 O
. O
4 O
+ O
/ O
- O
0 O
. O
1 O
ps O
. O

Zero O
- O
phonon O
hole O
widths O
obtained O
for O
the O
Chl B
b I
band O
at O
638 O
. O
5 O
nm O
( O
5 O
K O
) O
revealed O
two O
independent O
Chl B
b I
- O
- O
> O
Chl B
a I
EET O
times O
, O
i O
. O
e O
. O
, O
4 O
+ O
/ O
- O
0 O
. O
5 O
ps O
and O
0 O
. O
4 O
+ O
/ O
- O
0 O
. O
1 O
ps O
. O

Zero O
- O
phonon O
hole O
widths O
obtained O
for O
the O
Chl B
b I
band O
at O
638 O
. O
5 O
nm O
( O
5 O
K O
) O
revealed O
two O
independent O
Chl B
b I
- O
- O
> O
Chl B
a I
EET O
times O
, O
i O
. O
e O
. O
, O
4 O
+ O
/ O
- O
0 O
. O
5 O
ps O
and O
0 O
. O
4 O
+ O
/ O
- O
0 O
. O
1 O
ps O
. O

EET O
time O
from O
650 O
nm O
Chl B
b I
- O
- O
> O
Chl B
a I
and O
downward O
EET O
from O
Chl O
( O
s O
) O
a O
state O
( O
s O
) O
at O
665 O
nm O
occurs O
in O
4 O
. O
9 O
+ O
/ O
- O
0 O
. O
7 O
ps O
. O

EET O
time O
from O
650 O
nm O
Chl B
b I
- O
- O
> O
Chl B
a I
and O
downward O
EET O
from O
Chl O
( O
s O
) O
a O
state O
( O
s O
) O
at O
665 O
nm O
occurs O
in O
4 O
. O
9 O
+ O
/ O
- O
0 O
. O
7 O
ps O
. O

Considerable O
differences O
were O
noticed O
in O
mitochondrial O
membrane O
lipid O
composition O
, O
namely O
in O
terms O
of O
fatty B
acyl I
chains O
and O
relative O
proportions O
of O
phospholipid O
classes O
, O
the O
modified O
diet O
inducing O
a O
decrease O
in O
the O
saturated O
to O
unsaturated O
molar O
ratio O
and O
an O
increase O
in O
the O
phosphatidylcholine B
to O
phosphatidylethanola B
molar O
ratio O
. O

Mass O
spectrometry O
lipid O
analysis O
showed O
significant O
differences O
in O
the O
major O
species O
of O
cardiolipin B
, O
with O
an O
apparent O
increased O
incorporation O
of O
oleic B
acid I
as O
a O
result O
of O
exposure O
to O
the O
modified O
diet O
. O

Rapeseed O
oil O
- O
enriched O
diet O
also O
appeared O
to O
promote O
a O
decrease O
in O
hydroperoxide B
production O
by O
the O
respiratory O
chain O
, O
although O
a O
simultaneous O
decrease O
in O
vitamin B
E I
content O
was O
detected O
. O

Four O
new O
glycosylated B
flavonoids I
were O
isolated O
and O
their O
structures O
were O
elucidated O
on O
the O
basis O
of O
1D O
, O
2D O
NMR O
and O
MS O
spectra O
as O
3 B
' I
, I
5 I
' I
- I
dimethoxymyricetin I
- I
3 I
- I
O I
- I
beta I
- I
d I
- I
xylopyranosyl I
- I
7 I
- I
O I
- I
fucopyranosyl I
- I
( I
1 I
- I
- I
> I
3 I
) I
- I
beta I
- I
d I
- I
glucopyranoside I
( O
1 O
) O
, O
3 B
' I
- I
methoxyquercetin I
- I
7 I
- I
O I
- I
beta I
- I
d I
- I
fucopyranosyl I
- I
( I
1 I
- I
- I

LC O
- O
MS O
( O
n O
) O
analysis O
on O
the O
extract O
revealed O
the O
presence O
of O
other O
myricetin B
, O
quercetin B
, O
isorhamnetin B
glycosides I
, O
simple O
phenolic B
acids I
and O
esters B
. O

LC O
- O
MS O
( O
n O
) O
analysis O
on O
the O
extract O
revealed O
the O
presence O
of O
other O
myricetin B
, O
quercetin B
, O
isorhamnetin B
glycosides I
, O
simple O
phenolic B
acids I
and O
esters B
. O

Here O
, O
the O
extracts O
were O
evaluated O
by O
their O
cytotoxic O
activity O
against O
tumor O
( O
Hep O
- O
2 O
, O
HeLa O
) O
and O
non O
tumor O
( O
MRC O
- O
5 O
) O
cell O
lines O
, O
presenting O
significant O
inhibitory O
activity O
of O
cell O
growth O
in O
all O
extracts O
analyzed O
, O
chloroform B
, O
ethyl B
acetate I
, O
hexane B
, O
ethanol B
, O
which O
is O
related O
to O
its O
chemical O
composition O
. O

The O
increased O
triglyceride B
, O
total O
cholesterol B
, O
non O
- O
esterified O
fatty B
acid I
, O
high O
- O
density O
lipoprotein O
cholesterol B
, O
and O
very O
low O
- O
density O
lipoprotein O
cholesterol B
/ O
low O
- O
density O
lipoprotein O
cholesterol B
levels O
in O
serum O
, O
and O
triglyceride B
and O
total O
cholesterol B
contents O
in O
the O
kidney O
of O
nephrectomized O
rats O
were O
significantly O
decreased O
by O
Hachimi O
- O
jio O
- O
gan O
and O
Bakumi O
- O
jio O
- O
gan O
administration O
. O

On O
the O
contrary O
, O
the O
increased O
reactive O
oxygen B
species O
and O
thiobarbituric B
acid I
- O
reactive O
substance O
were O
decreased O
, O
while O
superoxide B
dismutase O
and O
the O
reduced B
glutathione I
/ O
oxidized B
glutathione I
ratio O
were O
augmented O
by O
Hachimi O
- O
jio O
- O
gan O
rather O
than O
Bakumi O
- O
jio O
- O
gan O
. O

On O
the O
contrary O
, O
the O
increased O
reactive O
oxygen B
species O
and O
thiobarbituric B
acid I
- O
reactive O
substance O
were O
decreased O
, O
while O
superoxide B
dismutase O
and O
the O
reduced B
glutathione I
/ O
oxidized B
glutathione I
ratio O
were O
augmented O
by O
Hachimi O
- O
jio O
- O
gan O
rather O
than O
Bakumi O
- O
jio O
- O
gan O
. O

On O
the O
contrary O
, O
the O
increased O
reactive O
oxygen B
species O
and O
thiobarbituric B
acid I
- O
reactive O
substance O
were O
decreased O
, O
while O
superoxide B
dismutase O
and O
the O
reduced B
glutathione I
/ O
oxidized B
glutathione I
ratio O
were O
augmented O
by O
Hachimi O
- O
jio O
- O
gan O
rather O
than O
Bakumi O
- O
jio O
- O
gan O
. O

The O
improvement O
of O
nuclear O
factor O
- O
kappa O
Bp65 O
, O
cyclooxygenase O
- O
2 O
, O
inducible O
nitric B
oxide I
synthase O
, O
NF O
- O
E2 O
- O
related O
factor O
2 O
, O
and O
heme B
oxygenase O
- O
1 O
was O
marked O
in O
the O
group O
administered O
Bakumi O
- O
jio O
- O
gan O
. O

Fusidic B
acid I
and O
rifampicin B
co O
- O
loaded O
PLGA B
nanofibers O
for O
the O
prevention O
of O
orthopedic O
implant O
associated O
infections O
. O

Here O
we O
report O
the O
development O
of O
a O
biodegradable O
localized O
delivery O
system O
using O
poly B
( I
D I
, I
L I
- I
lactic I
acid I
- I
co I
- I
glycolic I
acid I
) I
( O
PLGA B
) O
for O
the O
combinatorial O
release O
of O
fusidic B
acid I
( O
FA O
) O
( O
or O
its O
sodium B
salt O
; O
SF O
) O
and O
rifampicin B
( O
RIF B
) O
using O
electrospinning O
. O

Synthesis O
of O
some O
novel O
biologically O
active O
piperidin B
- I
4 I
- I
one I
oxime I
carbonates I
from O
1 B
- I
methyl I
- I
3alkyl I
- I
2 I
, I
6 I
- I
diphenylpiperidin I
- I
4 I
- I
one I
oximes I
and O
substituted O
chloroformates B
was O
carried O
out O
in O
the O
presence O
of O
potassium B
carbonate I
as O
base O
and O
tetrabutylammonium B
bromide I
( O
TBAB B
) O
as O
catalyst O
. O

Synthesis O
of O
some O
novel O
biologically O
active O
piperidin B
- I
4 I
- I
one I
oxime I
carbonates I
from O
1 B
- I
methyl I
- I
3alkyl I
- I
2 I
, I
6 I
- I
diphenylpiperidin I
- I
4 I
- I
one I
oximes I
and O
substituted O
chloroformates B
was O
carried O
out O
in O
the O
presence O
of O
potassium B
carbonate I
as O
base O
and O
tetrabutylammonium B
bromide I
( O
TBAB B
) O
as O
catalyst O
. O

For O
all O
the O
synthesized O
compounds O
( O
5a O
- O
5l O
) O
antimicrobial O
activity O
has O
been O
tested O
against O
bacterial O
and O
fungal O
strains O
using O
Streptomycin B
and O
Amphotericin B
B I
as O
standards O
. O

Linoleic B
acid I
( O
LA O
) O
was O
used O
as O
a O
representative O
free B
fatty I
acid I
. O

Apoptosis O
was O
evaluated O
using O
various O
methods O
including O
a O
terminal O
deoxyribonucleotide B
transferase O
- O
mediated O
deoxyuridine B
triphosphate I
nick O
- O
end O
labeling O
analysis O
kit O
and O
Western O
blotting O
for O
cleaved O
caspase O
3 O
, O
cleaved O
poly B
( I
ADP I
- I
ribose I
) I
polymerase O
and O
Bcl O
- O
xL O
. O

The O
phosphorylations O
of O
Akt O
and O
endothelial O
nitric B
oxide I
synthase O
( O
eNOS O
) O
as O
well O
as O
the O
level O
of O
NO B
were O
measured O
to O
confirm O
the O
effect O
of O
ucOC O
on O
insulin O
signaling O
pathway O
. O

Treatment O
of O
ucOC O
( O
ranged O
from O
0 O
. O
3 O
to O
30ng O
/ O
ml O
) O
significantly O
increased O
the O
phosphorylation O
of O
Akt O
and O
eNOS O
and O
nitric B
oxide I
secretion O
from O
endothelial O
cells O
in O
a O
PI3 O
- O
kinase O
dependent O
manner O
. O

The O
induction O
of O
IGFBP O
- O
4 O
protein O
was O
dependent O
on O
a O
functional O
aryl B
hydrocarbon I
receptor O
and O
was O
preceded O
by O
a O
rapid O
increase O
in O
the O
level O
of O
IGFBP O
- O
4 O
mRNA O
indicating O
that O
IGFBP O
- O
4 O
is O
a O
previously O
unknown O
transcriptional O
target O
of O
TCDD B
in O
5L O
cells O
. O

Pyrazole B
derivatives O
as O
inhibitors O
of O
arachidonic B
acid I
- O
induced O
platelet O
aggregation O
. O

Analogs O
from O
this O
series O
demonstrated O
potent O
anti O
- O
aggregatory O
activities O
against O
arachidonic B
acid I
- O
induced O
platelet O
aggregation O
, O
as O
measured O
by O
turbidimetric O
method O
of O
Born O
. O

In O
HEK293 O
cells O
stably O
expressing O
human O
GPR55 O
( O
HEK O
- O
GPR55 O
) O
, O
the O
compound O
behaved O
as O
an O
antagonist O
on O
LPI B
- O
mediated O
Ca2 B
+ I
release O
and O
extracellular O
signal O
- O
regulated O
kinases O
( O
ERK1 O
/ O
2 O
) O
activation O
, O
but O
not O
in O
HEK293 O
cells O
expressing O
cannabinoid O
receptor O
1 O
or O
2 O
( O
CB1 O
or O
CB2 O
) O
. O

Prostaglandin B
E2 I
acts O
via O
bone O
marrow O
macrophages O
to O
block O
PTH O
- O
stimulated O
osteoblast O
differentiation O
in O
vitro O
. O

PTH O
also O
induces O
cyclooxygenase O
- O
2 O
( O
COX O
- O
2 O
) O
, O
producing O
prostaglandin B
E2 I
( O
PGE2 B
) O
, O
that O
can O
act O
on O
both O
OBs O
and O
osteoclasts O
( O
OCs O
) O
. O

NUCLEOSIDE B
REVERSE O
TRANSCRIPTASE O
INHIBITORS O
INDUCE O
A O
MITOPHAGY O
- O
ASSOCIATED O
ENDOTHELIAL O
DYSFUNCTION O
THAT O
IS O
REVERSED O
BY O
COENZYME B
Q10 I
CO O
- O
TREATMENT O
. O

To O
test O
whether O
rescue O
of O
mitochondrial O
electron O
transport O
attenuated O
NRTI O
- O
induced O
endothelial O
dysfunction O
, O
in O
some O
cases O
, O
cells O
were O
co O
- O
treated O
with O
the O
electron O
transport O
cofactor O
coenzyme B
Q10 I
( O
Q10 B
) O
. O

Moreover O
, O
nitric B
oxide I
levels O
were O
decreased O
, O
while O
endothelin O
- O
1 O
release O
was O
increased O
. O

Copolymerization O
of O
2 B
- I
methylene I
- I
1 I
, I
3 I
- I
dioxepane I
and O
glycidyl B
methacrylate I
, O
a O
well O
- O
defined O
and O
efficient O
process O
for O
achieving O
functionalized O
polyesters B
for O
covalent O
binding O
of O
bioactive O
molecules O
. O

We O
have O
in O
a O
one O
- O
pot O
reaction O
synthesized O
a O
series O
of O
amorphous O
and O
degradable O
polyester B
- O
based O
copolymers O
with O
active O
functional O
groups O
by O
copolymerization O
of O
2 B
- I
methylene I
- I
1 I
, I
3 I
- I
dioxepane I
and O
glycidyl B
methacrylate I
. O

The O
presence O
of O
heparin O
was O
verified O
by O
toluidine B
blue I
staining O
and O
all O
the O
films O
tested O
showed O
positive O
signals O
for O
heparin O
. O

Out O
of O
the O
tested O
compounds O
, O
three O
benzophenanthridine B
alkaloids I
( O
1 O
, O
4 O
, O
and O
7 O
) O
, O
a O
dibenzyl B
butyrolactone I
lignan I
( O
10 O
) O
, O
and O
two O
2 B
- I
arylbenzofuran I
neolignans I
( O
12 O
and O
13 O
) O
displayed O
significant O
cytotoxicity O
to O
HCT116 O
cells O
, O
confirmed O
by O
the O
Guava O
ViaCount O
viability O
assay O
. O

These O
results O
suggested O
that O
specific O
benzophenanthridine B
alkaloids I
and O
2 B
- I
arylbenzofuran I
neolignans I
isolated O
from O
Zanthoxylum O
capense O
show O
strong O
anticancer O
activity O
in O
HCT116 O
colon O
carcinoma O
cells O
. O

Nordihydroguaiaretic B
acid I
induces O
Nrf2 O
nuclear O
translocation O
in O
vivo O
and O
attenuates O
renal O
damage O
and O
apoptosis O
in O
the O
ischemia O
and O
reperfusion O
model O
. O

It O
has O
been O
shown O
that O
the O
pretreatment O
with O
nordihydroguaiaretic B
acid I
( O
NDGA B
) O
, O
a O
lignan O
with O
direct O
and O
indirect O
antioxidant O
properties O
, O
protects O
against O
the O
ischemia O
- O
reperfusion O
( O
I O
/ O
R O
) O
- O
induced O
renal O
oxidant O
damage O
. O

Chromatographic O
separation O
was O
accomplished O
on O
an O
Agilent O
TC O
- O
C18 O
column O
( O
4 O
. O
6mm O
x O
250mm O
, O
5 O
mu O
m O
) O
, O
with O
gradient O
elution O
by O
using O
a O
mixture O
of O
methanoic B
acid I
( O
A O
) O
and O
acetonitrile B
( O
B O
) O
as O
the O
mobile O
phase O
at O
a O
flow O
rate O
of O
0 O
. O
8mL O
/ O
min O
. O

While O
citronellyl B
nitrile I
, O
3 B
- I
methyl I
- I
5 I
- I
phenylpentanenitrile I
, O
cinnamyl B
nitrile I
, O
and O
3 B
- I
methyl I
- I
5 I
- I
phenylpent I
- I
2 I
- I
enenitrile I
revealed O
positive O
results O
in O
the O
in O
- O
vitro O
tests O
, O
but O
confirmatory O
in O
- O
vivo O
tests O
determined O
these O
nitriles B
to O
be O
negative O
in O
the O
in O
- O
vivo O
micronucleus O
assay O
. O

While O
citronellyl B
nitrile I
, O
3 B
- I
methyl I
- I
5 I
- I
phenylpentanenitrile I
, O
cinnamyl B
nitrile I
, O
and O
3 B
- I
methyl I
- I
5 I
- I
phenylpent I
- I
2 I
- I
enenitrile I
revealed O
positive O
results O
in O
the O
in O
- O
vitro O
tests O
, O
but O
confirmatory O
in O
- O
vivo O
tests O
determined O
these O
nitriles B
to O
be O
negative O
in O
the O
in O
- O
vivo O
micronucleus O
assay O
. O

Whole O
blood O
collagen O
- O
induced O
platelet O
aggregation O
and O
calcium B
- O
induced O
thromboxane B
B2 I
( O
TxB2 B
) O
, O
aortic O
6 B
- I
keto I
- I
prostaglandin I
F1 I
alpha I
( O
6 B
- I
keto I
- I
PGF1 I
alpha I
) O
and O
nitrites B
+ O
nitrates B
, O
plasma O
concentration O
of O
lipid O
peroxides B
( O
TBARS O
) O
and O
red O
blood O
cell O
content O
of O
reduced B
glutathione I
( O
GSH B
) O
were O
measured O
. O

Whole O
blood O
collagen O
- O
induced O
platelet O
aggregation O
and O
calcium B
- O
induced O
thromboxane B
B2 I
( O
TxB2 B
) O
, O
aortic O
6 B
- I
keto I
- I
prostaglandin I
F1 I
alpha I
( O
6 B
- I
keto I
- I
PGF1 I
alpha I
) O
and O
nitrites B
+ O
nitrates B
, O
plasma O
concentration O
of O
lipid O
peroxides B
( O
TBARS O
) O
and O
red O
blood O
cell O
content O
of O
reduced B
glutathione I
( O
GSH B
) O
were O
measured O
. O

Recognizing O
the O
functionality O
of O
the O
pentacyclic B
steroidal I
derivative O
7a O
as O
important O
synthon O
to O
obtain O
new O
brassinosteroid B
analogs O
, O
we O
have O
accomplished O
the O
derivatization O
of O
hecogenin B
, O
a O
sapogenin O
from O
the O
25R O
serie O
containing O
a O
carbonyl B
group O
at O
C O
- O
12 O
, O
to O
a O
22 B
, I
23 I
- I
dioxocholestanic I
chain O
derivative O
. O

Starting O
from O
hecogenin B
acetate I
( O
5a O
) O
or O
hecogenin B
tosylate I
( O
5b O
) O
, O
we O
obtained O
two O
pentacyclic O
derivatives O
( O
7a O
and O
7b O
) O
which O
were O
subjected O
to O
an O
oxidation O
reaction O
on O
the O
double O
bond O
at O
C O
- O
12 O
( O
23 O
) O
to O
obtain O
a O
22 B
, I
23 I
- I
dioxocholestanic I
chain O
, O
with O
the O
regeneration O
of O
the O
carbonyl B
group O
at O
C O
- O
12 O
. O

Starting O
from O
hecogenin B
acetate I
( O
5a O
) O
or O
hecogenin B
tosylate I
( O
5b O
) O
, O
we O
obtained O
two O
pentacyclic O
derivatives O
( O
7a O
and O
7b O
) O
which O
were O
subjected O
to O
an O
oxidation O
reaction O
on O
the O
double O
bond O
at O
C O
- O
12 O
( O
23 O
) O
to O
obtain O
a O
22 B
, I
23 I
- I
dioxocholestanic I
chain O
, O
with O
the O
regeneration O
of O
the O
carbonyl B
group O
at O
C O
- O
12 O
. O

Designing O
, O
structural O
elucidation O
, O
comparison O
of O
DNA O
binding O
, O
cleavage O
, O
radical O
scavenging O
activity O
and O
anticancer O
activity O
of O
copper B
( I
I I
) I
complex O
with O
5 B
- I
dimethyl I
- I
2 I
- I
phenyl I
- I
4 I
- I
[ I
( I
pyridin I
- I
2 I
- I
ylmethylene I
) I
- I
amino I
] I
- I
1 I
, I
2 I
- I
dihydro I
- I
pyrazol I
- I
3 I
- I
one I
Schiff B
base I
ligand O
. O

Nitroimidazolyl B
hydrazones I
are O
better O
amoebicides O
than O
their O
cyclized O
1 B
, I
3 I
, I
4 I
- I
oxadiazoline I
analogues O
: O
In O
vitro O
studies O
and O
Lipophilic O
efficiency O
analysis O
. O

The O
Cd B
- O
treated O
group O
was O
injected O
subcutaneously O
with O
cadmium B
chloride I
( O
CdCl2 B
) O
dissolved O
in O
saline O
at O
a O
dose O
of O
2 O
ml O
/ O
kg O
/ O
day O
for O
30 O
days O
, O
resulting O
in O
a O
dosage O
of O
1 O
mg O
/ O
kg O
Cd B
. O

We O
isolated O
five O
phenolic B
glycosides I
( O
acteoside B
, O
eutigoside B
B I
, O
isoacteoside B
, O
rutin B
and O
cornoside B
) O
from O
Abeliophyllum O
distichum O
leaves O
by O
high O
- O
speed O
counter O
current O
chromatography O
( O
HSCCC O
) O
using O
a O
solvent O
system O
of O
ethyl B
acetate I
: O
n B
- I
butanol I
: O
water O
( O
8 O
: O
0 O
. O
7 O
: O
5 O
) O
. O

We O
isolated O
five O
phenolic B
glycosides I
( O
acteoside B
, O
eutigoside B
B I
, O
isoacteoside B
, O
rutin B
and O
cornoside B
) O
from O
Abeliophyllum O
distichum O
leaves O
by O
high O
- O
speed O
counter O
current O
chromatography O
( O
HSCCC O
) O
using O
a O
solvent O
system O
of O
ethyl B
acetate I
: O
n B
- I
butanol I
: O
water O
( O
8 O
: O
0 O
. O
7 O
: O
5 O
) O
. O

We O
isolated O
five O
phenolic B
glycosides I
( O
acteoside B
, O
eutigoside B
B I
, O
isoacteoside B
, O
rutin B
and O
cornoside B
) O
from O
Abeliophyllum O
distichum O
leaves O
by O
high O
- O
speed O
counter O
current O
chromatography O
( O
HSCCC O
) O
using O
a O
solvent O
system O
of O
ethyl B
acetate I
: O
n B
- I
butanol I
: O
water O
( O
8 O
: O
0 O
. O
7 O
: O
5 O
) O
. O

